PMID-sentid	Pub_year	Sent_text	comp_official_name	comp_offset	protein_name	organism	prot_offset
2479425-4	1989	G-CSF-induced neutrophils exhibited an increased O2- radical production, and serum levels of enzymes related to granulocyte turnover, including lysozyme and elastase, were markedly elevated during therapy.	o2- radical	49-60	colony stimulating factor 3	Homo sapiens	0-5
2481663-5	1989	G-CSF significantly enhanced the RA-induced granulocytic differentiation of APL cells in vitro.	Tretinoin	33-35	colony stimulating factor 3	Homo sapiens	0-5
2480603-1	1989	Cell proliferation in the bone marrow and blood of two patients with metastatic breast cancer who were treated with granulocyte colony-stimulating factor was studied by using [3H]thymidine labeling and autoradiography.	Tritium	176-178	colony stimulating factor 3	Homo sapiens	116-153
2480603-1	1989	Cell proliferation in the bone marrow and blood of two patients with metastatic breast cancer who were treated with granulocyte colony-stimulating factor was studied by using [3H]thymidine labeling and autoradiography.	Thymidine	179-188	colony stimulating factor 3	Homo sapiens	116-153
2480603-2	1989	Additionally, the fate of neutrophils labeled with 99mTc-hexamethylpropyleneamineoxime was observed following granulocyte colony-stimulating factor infusion.	99mtc-hexamethylpropyleneamineoxime	51-86	colony stimulating factor 3	Homo sapiens	110-147
2553162-1	1989	Recombinant human granulocyte colony-stimulating factor (rhG-CSF) enhanced superoxide release and membrane depolarization in parallel in human granulocytes stimulated by the receptor-mediated agonists, N-formyl-methionyl-leucyl-phenylalanine and wheat germ agglutinin, but not by the Ca2+ ionophore ionomycin and phorbol myristate acetate, which bypass the receptors to stimulate the cells.	Superoxides	75-85	colony stimulating factor 3	Homo sapiens	18-55
2553162-1	1989	Recombinant human granulocyte colony-stimulating factor (rhG-CSF) enhanced superoxide release and membrane depolarization in parallel in human granulocytes stimulated by the receptor-mediated agonists, N-formyl-methionyl-leucyl-phenylalanine and wheat germ agglutinin, but not by the Ca2+ ionophore ionomycin and phorbol myristate acetate, which bypass the receptors to stimulate the cells.	Ionomycin	299-308	colony stimulating factor 3	Homo sapiens	18-55
2553162-1	1989	Recombinant human granulocyte colony-stimulating factor (rhG-CSF) enhanced superoxide release and membrane depolarization in parallel in human granulocytes stimulated by the receptor-mediated agonists, N-formyl-methionyl-leucyl-phenylalanine and wheat germ agglutinin, but not by the Ca2+ ionophore ionomycin and phorbol myristate acetate, which bypass the receptors to stimulate the cells.	Tetradecanoylphorbol Acetate	313-338	colony stimulating factor 3	Homo sapiens	18-55
2476027-5	1989	The percentages and absolute numbers of large granular lymphocytes were increased in the rh-GCSF group compared with the control group.	Rhodium	89-91	colony stimulating factor 3	Homo sapiens	92-96
2672934-0	1989	Methimazole-induced agranulocytosis and granulocyte-colony stimulating factor.	Methimazole	0-11	colony stimulating factor 3	Homo sapiens	40-77
2769251-9	1989	Only a single significant relationship was demonstrated for the DA metabolites, with CSF 3-MT correlating with plasma HVA (r = 0.301, p less than 0.025).	Homovanillic Acid	118-121	colony stimulating factor 3	Homo sapiens	85-90
2789274-1	1989	In patients who have not received extensive prior chemotherapy or radiotherapy, it has been previously demonstrated that granulocyte colony-stimulating factor (G-CSF) abrogated the leukopenia following administration of melphalan (25 mg/m2).	Melphalan	220-229	colony stimulating factor 3	Homo sapiens	121-158
2789274-1	1989	In patients who have not received extensive prior chemotherapy or radiotherapy, it has been previously demonstrated that granulocyte colony-stimulating factor (G-CSF) abrogated the leukopenia following administration of melphalan (25 mg/m2).	Melphalan	220-229	colony stimulating factor 3	Homo sapiens	160-165
2789274-6	1989	G-CSF produced a rapid and sustained elevation in neutrophil levels within 24 hours even when started 8 days after melphalan.	Melphalan	115-124	colony stimulating factor 3	Homo sapiens	0-5
2789274-10	1989	G-CSF was well tolerated, although mild bone pain occurred and was reduced with acetaminophen.	Acetaminophen	80-93	colony stimulating factor 3	Homo sapiens	0-5
2789274-12	1989	We conclude that after melphalan chemotherapy, G-CSF may need to be given for only a short period to prevent chemotherapy-induced neutropenia, and that G-CSF induces a rapid rise in neutrophil levels even when started 8 days after melphalan administration.	Melphalan	231-240	colony stimulating factor 3	Homo sapiens	152-157
2475185-4	1989	When a continuous infusion of G-CSF was administered after melphalan, serum G-CSF levels remained constant for a longer period of time but did decrease during the second phase of a biphasic neutrophil response.	Melphalan	59-68	colony stimulating factor 3	Homo sapiens	30-35
2473792-3	1989	Cultures of unseparated bone marrow, harvested from patients four to six days after administration of 5-fluorouracil (5-FU), resulted in additive GM colony formation with GM-CSF plus G-CSF, GM-CSF plus IL-3, and G-CSF plus IL-3.	Fluorouracil	118-122	colony stimulating factor 3	Homo sapiens	212-217
2475185-4	1989	When a continuous infusion of G-CSF was administered after melphalan, serum G-CSF levels remained constant for a longer period of time but did decrease during the second phase of a biphasic neutrophil response.	Melphalan	59-68	colony stimulating factor 3	Homo sapiens	76-81
2665868-6	1989	In duplicate experiments, 0.7% and 3.5% (day 7) or 3.6% and 3.9% (day 14) of My-10-positive PD-MMCs formed GM colonies in response to hrGM-CSF and 5.1% and 6.0% (day 7) of My-10-positive PD-MMCs formed GM colonies in response to G-CSF.	pd-mmcs	92-99	colony stimulating factor 3	Homo sapiens	229-234
2665868-6	1989	In duplicate experiments, 0.7% and 3.5% (day 7) or 3.6% and 3.9% (day 14) of My-10-positive PD-MMCs formed GM colonies in response to hrGM-CSF and 5.1% and 6.0% (day 7) of My-10-positive PD-MMCs formed GM colonies in response to G-CSF.	my-10	77-82	colony stimulating factor 3	Homo sapiens	229-234
2665868-8	1989	Also observed was a synergistic effect on GM colony formation in which more My-10-positive PD-MMCs stimulated by hrGM-CSF and G-CSF could form GM colonies than the sum of those stimulated by each separately.	gm	42-44	colony stimulating factor 3	Homo sapiens	126-131
2472117-0	1989	Disulfide structures of human interleukin-6 are similar to those of human granulocyte colony stimulating factor.	Disulfides	0-9	colony stimulating factor 3	Homo sapiens	74-111
2472117-2	1989	The relative positions of four half-cystines in human interleukin-6 (IL-6) match four of the five in human granulocyte colony stimulating factor.	half-	31-36	colony stimulating factor 3	Homo sapiens	107-144
2472117-2	1989	The relative positions of four half-cystines in human interleukin-6 (IL-6) match four of the five in human granulocyte colony stimulating factor.	Cystine	36-44	colony stimulating factor 3	Homo sapiens	107-144
2478178-3	1989	G-CSF administration resulted in a return of the absolute neutrophil count to normal or above normal levels within 12-14 days at all dose levels of doxorubicin used and allowed the administration of up to three cycles of high dose chemotherapy at 14 day intervals.	Doxorubicin	148-159	colony stimulating factor 3	Homo sapiens	0-5
2478178-7	1989	Two months after doxorubicin-G-CSF therapy there was a pronounced improvement of symptoms compared with before treatment.	Doxorubicin	17-28	colony stimulating factor 3	Homo sapiens	29-34
2465167-7	1989	Using specific immunologic assays, IL-1- as well as poly(rI).poly(rC)-inducible production of granulocyte colony-stimulating factor (G-CSF), granulocyte-macrophage CSF, and macrophage CSF was found.	Poly C	61-69	colony stimulating factor 3	Homo sapiens	94-131
2471275-2	1989	Our studies suggest that 10 micrograms/kg/day of G-CSF administered as a continuous subcutaneous infusion abrogates the neutropenia associated with a standard dose of melphalan.	Melphalan	167-176	colony stimulating factor 3	Homo sapiens	49-54
2649140-5	1989	The 3H-thymidine (3H-TdR) uptake studies revealed that IL-3, GM-CSF, G-CSF and M-CSF were efficient stimulators of DNA synthesis of AML cells in 19, 15, 13 and four of those cases, respectively.	3h-thymidine	4-16	colony stimulating factor 3	Homo sapiens	69-74
2649140-5	1989	The 3H-thymidine (3H-TdR) uptake studies revealed that IL-3, GM-CSF, G-CSF and M-CSF were efficient stimulators of DNA synthesis of AML cells in 19, 15, 13 and four of those cases, respectively.	Tritium	4-6	colony stimulating factor 3	Homo sapiens	69-74
2647723-3	1989	Treatment of monocytes with phorbol myristic acid or cycloheximide induces both genes, while lipopolysaccharide selectively and transiently induces G-CSF transcripts.	phorbol-12-myristate	28-49	colony stimulating factor 3	Homo sapiens	148-153
2465167-7	1989	Using specific immunologic assays, IL-1- as well as poly(rI).poly(rC)-inducible production of granulocyte colony-stimulating factor (G-CSF), granulocyte-macrophage CSF, and macrophage CSF was found.	Poly C	61-69	colony stimulating factor 3	Homo sapiens	133-138
2465168-0	1989	Modulation by retinoids and interferons of alkaline phosphatase activity in granulocytes induced by granulocyte colony-stimulating factor.	Retinoids	14-23	colony stimulating factor 3	Homo sapiens	100-137
2465168-3	1989	In this study we examined whether NAP activity inducible with G-CSF could be modulated by other factors that are present in vivo or those that are known to induce differentiation of hemopoietic cells.	nap	34-37	colony stimulating factor 3	Homo sapiens	62-67
2465168-6	1989	IFN-gamma was a potent inhibitor of G-CSF stimulation: IFN-gamma at 100 U/ml inhibited by greater than 90% the induction of NAP by G-CSF.	nap	124-127	colony stimulating factor 3	Homo sapiens	36-41
2465168-6	1989	IFN-gamma was a potent inhibitor of G-CSF stimulation: IFN-gamma at 100 U/ml inhibited by greater than 90% the induction of NAP by G-CSF.	nap	124-127	colony stimulating factor 3	Homo sapiens	131-136
2465168-8	1989	Furthermore, the simultaneous addition of 10(-6) M retinol partially reversed the inhibitory action of IFN-gamma on the NAP induction by G-CSF.	Vitamin A	51-58	colony stimulating factor 3	Homo sapiens	137-142
2463792-0	1989	Disulfide and secondary structures of recombinant human granulocyte colony stimulating factor.	Disulfides	0-9	colony stimulating factor 3	Homo sapiens	56-93
2463930-1	1989	[3H]thymidine uptake by NFS-60 cells in microcultures was found to increase in a linear fashion with the increasing doses of purified recombinant human granulocyte colony-stimulating factor (rhG-CSF).	Tritium	1-3	colony stimulating factor 3	Homo sapiens	152-189
2463930-1	1989	[3H]thymidine uptake by NFS-60 cells in microcultures was found to increase in a linear fashion with the increasing doses of purified recombinant human granulocyte colony-stimulating factor (rhG-CSF).	Thymidine	4-13	colony stimulating factor 3	Homo sapiens	152-189
2467651-4	1988	G-CSF was also administered to patients following melphalan and this resulted in a reduction in the duration of the neutropenia that invariably follows melphalan.	Melphalan	50-59	colony stimulating factor 3	Homo sapiens	0-5
2459064-4	1988	Recombinant human granulocyte colony-stimulating factor hastened the recovery of peripheral neutrophil counts in animals made leukopenic by prior treatment with cyclophosphamide.	Cyclophosphamide	161-177	colony stimulating factor 3	Homo sapiens	18-55
2467644-5	1988	In both, cyclophosphamide and busulfan induced myelosuppression, G-CSF in doses between 10 and 30 micrograms/kg/d was able to significantly shorten the time of neutropenia.	Cyclophosphamide	9-25	colony stimulating factor 3	Homo sapiens	65-70
2783371-3	1989	The presence of H-7 or staurosporine led to an inhibition of colony formation stimulated by crude colony-stimulating factor (CSF), interleukin-3 (IL-3), granulocyte-macrophage CSF (GM-CSF), granulocyte CSF (G-CSF), or macrophage CSF (M-CSF) in a dose-dependent manner.	1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine	16-19	colony stimulating factor 3	Homo sapiens	207-212
2783371-3	1989	The presence of H-7 or staurosporine led to an inhibition of colony formation stimulated by crude colony-stimulating factor (CSF), interleukin-3 (IL-3), granulocyte-macrophage CSF (GM-CSF), granulocyte CSF (G-CSF), or macrophage CSF (M-CSF) in a dose-dependent manner.	Staurosporine	23-36	colony stimulating factor 3	Homo sapiens	207-212
2462357-5	1988	Dexamethasone and gamma-interferon inhibit the magnitude of G-CSF-induced neutrophilia, suggesting that endogenous glucocorticosteroids and gamma-interferon, both which are released along with G-CSF in vivo during endotoxemia, may play a negative feedback role in the endogenous regulation of granulopoiesis.	Dexamethasone	0-13	colony stimulating factor 3	Homo sapiens	60-65
2462357-5	1988	Dexamethasone and gamma-interferon inhibit the magnitude of G-CSF-induced neutrophilia, suggesting that endogenous glucocorticosteroids and gamma-interferon, both which are released along with G-CSF in vivo during endotoxemia, may play a negative feedback role in the endogenous regulation of granulopoiesis.	Dexamethasone	0-13	colony stimulating factor 3	Homo sapiens	193-198
2462357-5	1988	Dexamethasone and gamma-interferon inhibit the magnitude of G-CSF-induced neutrophilia, suggesting that endogenous glucocorticosteroids and gamma-interferon, both which are released along with G-CSF in vivo during endotoxemia, may play a negative feedback role in the endogenous regulation of granulopoiesis.	glucocorticosteroids	115-135	colony stimulating factor 3	Homo sapiens	60-65
2462357-5	1988	Dexamethasone and gamma-interferon inhibit the magnitude of G-CSF-induced neutrophilia, suggesting that endogenous glucocorticosteroids and gamma-interferon, both which are released along with G-CSF in vivo during endotoxemia, may play a negative feedback role in the endogenous regulation of granulopoiesis.	glucocorticosteroids	115-135	colony stimulating factor 3	Homo sapiens	193-198
3264194-3	1988	The 3H-thymidine uptake data revealed that IL-3, GM-CSF, G-CSF, and M-CSF were stimulators of AML proliferation in 19, 15, 13, and 4 cases, respectively.	Tritium	4-6	colony stimulating factor 3	Homo sapiens	57-62
3264194-3	1988	The 3H-thymidine uptake data revealed that IL-3, GM-CSF, G-CSF, and M-CSF were stimulators of AML proliferation in 19, 15, 13, and 4 cases, respectively.	Thymidine	7-16	colony stimulating factor 3	Homo sapiens	57-62
3264194-6	1988	On the other hand, in six cases, G-CSF enhanced the IL-3- or GM-CSF-stimulated thymidine uptake.	Thymidine	79-88	colony stimulating factor 3	Homo sapiens	33-38
2461375-5	1988	The induction of NAP by G-CSF was detectable at 0.4 ng/ml and became maximal between 10 and 20 ng/ml.	nap	17-20	colony stimulating factor 3	Homo sapiens	24-29
2461375-6	1988	Anti-G-CSF serum incubated with either NAP-IF or rG-CSF inhibited induction of NAP.	nap	39-42	colony stimulating factor 3	Homo sapiens	5-10
2456345-8	1988	In Northern blot analysis of enriched RNA, synthetic oligonucleotide probes complementary to human G-CSF and M-CSF coding sequence each hybridized with a single RNA species of 1.7 and 4.4 kb, respectively.	Oligonucleotides	53-68	colony stimulating factor 3	Homo sapiens	99-104
2467651-4	1988	G-CSF was also administered to patients following melphalan and this resulted in a reduction in the duration of the neutropenia that invariably follows melphalan.	Melphalan	152-161	colony stimulating factor 3	Homo sapiens	0-5
2455710-0	1988	Structures of the sugar chains of recombinant human granulocyte-colony-stimulating factor produced by Chinese hamster ovary cells.	Sugars	18-23	colony stimulating factor 3	Homo sapiens	52-89
2456256-6	1988	The N-terminal sequence of the recombinant G-CSF from the pL system was Met-Thr-Pro-Leu-Gly-Pro-.	Threonine	76-79	colony stimulating factor 3	Homo sapiens	43-48
2456256-8	1988	Deletion of the threonine codon at the beginning of the coding region for the mature G-CSF resulted in efficient removal of the N-terminal methionine residue during expression in E. coli.	Threonine	16-25	colony stimulating factor 3	Homo sapiens	85-90
2456256-8	1988	Deletion of the threonine codon at the beginning of the coding region for the mature G-CSF resulted in efficient removal of the N-terminal methionine residue during expression in E. coli.	Methionine	139-149	colony stimulating factor 3	Homo sapiens	85-90
3284887-6	1988	Since the independent addition of PF-382-CM or of M-CM1 is devoid of stimulatory function, we suggest that the PF-382 derived BFU-E growth inducer, which differs from IL-1, IL-3, IL-4, GM and G-CSF, exerts its activity "via" a synergistic mechanism with a monokine.	1-(5-bromo-pyridin-2-yl)-3-[2-(6-fluoro-2-hydroxy-3-propionyl-phenyl)-cyclopropyl]-urea	126-129	colony stimulating factor 3	Homo sapiens	192-197
2895212-6	1988	G-CSF administration following melphalan reduced the period of neutropenia caused by melphalan.	Melphalan	31-40	colony stimulating factor 3	Homo sapiens	0-5
2448161-6	1988	Separation of G-CSF from GM-CSF was accomplished by the addition of trifluoroacetic acid to the mobile phase at the reverse-phase HPLC step.	Trifluoroacetic Acid	68-88	colony stimulating factor 3	Homo sapiens	14-19
2455710-2	1988	The recombinant human G-CSF was treated with alkaline borohydride and the oligosaccharide-alditols liberated were fractioned by gel filtration on a Bio-Gel P-4 column, followed by high-performance liquid chromatography by use of a strong anion exchanger.	alkaline borohydride	45-65	colony stimulating factor 3	Homo sapiens	22-27
2455710-2	1988	The recombinant human G-CSF was treated with alkaline borohydride and the oligosaccharide-alditols liberated were fractioned by gel filtration on a Bio-Gel P-4 column, followed by high-performance liquid chromatography by use of a strong anion exchanger.	oligosaccharide-alditols	74-98	colony stimulating factor 3	Homo sapiens	22-27
2451772-2	1988	The phosphorylation of 22 kD, pI 6.0 and 5.8 proteins (pp22) in HL-60 cells or myeloid leukemic cells from patients, was enhanced by treatment with granuloid inducers such as retinoic acid, dimethyl sulfoxide or G-CSF, in common with prostaglandin E2 and theophylline, or dibutyryl c-AMP, which increased intracellular c-AMP.	granuloid	148-157	colony stimulating factor 3	Homo sapiens	212-217
2451772-2	1988	The phosphorylation of 22 kD, pI 6.0 and 5.8 proteins (pp22) in HL-60 cells or myeloid leukemic cells from patients, was enhanced by treatment with granuloid inducers such as retinoic acid, dimethyl sulfoxide or G-CSF, in common with prostaglandin E2 and theophylline, or dibutyryl c-AMP, which increased intracellular c-AMP.	Tretinoin	175-188	colony stimulating factor 3	Homo sapiens	212-217
3077558-4	1988	GM-CSF and G-CSF act on mature cells at the site of inflammation, increasing their functional capacity by concentration-dependent effects on chemotaxis, increased phagocytosis, enhanced superoxide production, and increased antibody-dependent cellular cytotoxicity (Vadas et al., 1983a, b; Gasson et al., 1984; Weisbart et al., 1985).	Superoxides	186-196	colony stimulating factor 3	Homo sapiens	11-16
3260000-0	1988	Effects of recombinant G-CSF and GM-CSF on the growth in methylcellulose and suspension of the blast cells in acute myeloblastic leukemia.	Methylcellulose	57-72	colony stimulating factor 3	Homo sapiens	23-28
2447047-1	1987	Human granulocyte colony-stimulating factor (hG-CSF) cDNA was cloned, by using a synthetic oligonucleotide probe, from an Okayama-Berg cDNA library of lipopolysaccharide-stimulated human peripheral blood macrophages.	Oligonucleotides	91-106	colony stimulating factor 3	Homo sapiens	6-43
2444540-3	1987	When mice were injected subcutaneously once a day with 2.5 micrograms of hG-CSF beginning on the day after CPA injection, the reduction was prevented markedly, even 4 days later.	Cyclophosphamide	107-110	colony stimulating factor 3	Homo sapiens	73-79
2447047-1	1987	Human granulocyte colony-stimulating factor (hG-CSF) cDNA was cloned, by using a synthetic oligonucleotide probe, from an Okayama-Berg cDNA library of lipopolysaccharide-stimulated human peripheral blood macrophages.	Oligonucleotides	91-106	colony stimulating factor 3	Homo sapiens	45-51
3491641-0	1987	Effect of human recombinant granulocyte colony-stimulating factor on hematopoietic injury in mice induced by 5-fluorouracil.	Fluorouracil	109-123	colony stimulating factor 3	Homo sapiens	28-65
3499607-3	1987	When bone marrow cells from 5-fluorouracil-treated mice were cultured in suspension for 7 days with recombinant human IL-1 alpha and/or G-CSF, it was found that the two factors synergized to enhance recovery of myelopoietic cells and colony-forming cells of both high and low proliferative potential.	Fluorouracil	28-42	colony stimulating factor 3	Homo sapiens	136-141
3499607-6	1987	Daily administration of recombinant human G-CSF or recombinant human IL-1 alpha accelerated recovery of stem cells, progenitor cells, and blood neutrophils by up to 4 days in 5-fluorouracil-treated C3H/HeJ and B6D2F1 mice.	Fluorouracil	175-189	colony stimulating factor 3	Homo sapiens	42-47
2453015-2	1987	An oligonucleotide encoding the amino acids -11 to -4 of G-CSF detected a single abundant G-CSF mRNA of 1.6 kilobases (Kb) produced by U87 MG cells.	Oligonucleotides	3-18	colony stimulating factor 3	Homo sapiens	57-62
2453015-2	1987	An oligonucleotide encoding the amino acids -11 to -4 of G-CSF detected a single abundant G-CSF mRNA of 1.6 kilobases (Kb) produced by U87 MG cells.	Oligonucleotides	3-18	colony stimulating factor 3	Homo sapiens	90-95
2453015-5	1987	Only a single base substitution was observed at the third position of the codon for leu 152 indicating that G-CSF is highly conserved in cells of widely different origin.	Leucine	84-87	colony stimulating factor 3	Homo sapiens	108-113
3034272-0	1987	Recombinant human granulocyte colony-stimulating factor enhances superoxide release in human granulocytes stimulated by the chemotactic peptide.	Superoxides	65-75	colony stimulating factor 3	Homo sapiens	18-55
3034599-4	1987	The purified recombinant G-CSF runs as a single band with an apparent Mr of 19,000 on a polyacrylamide gel electrophoresis in the presence of sodium dodecyl sulfate.	polyacrylamide	88-102	colony stimulating factor 3	Homo sapiens	25-30
3034599-4	1987	The purified recombinant G-CSF runs as a single band with an apparent Mr of 19,000 on a polyacrylamide gel electrophoresis in the presence of sodium dodecyl sulfate.	Sodium Dodecyl Sulfate	142-164	colony stimulating factor 3	Homo sapiens	25-30
3484706-5	1986	Newly produced G-CSF had an approximate molecular weight of 24,000 daltons as judged by chromatography on Sephadex G-150.	sephadex	106-120	colony stimulating factor 3	Homo sapiens	15-20
3491168-4	1986	Thus, "pluripoietin"-containing media provide a large-scale source of BPA similar in its biological activity to standard sources used for studying human hematopoiesis in vitro.	bisphenol A	70-73	colony stimulating factor 3	Homo sapiens	7-19
33146835-0	2021	Febrile neutropenia and role of prophylactic granulocyte colony-stimulating factor in docetaxel and cyclophosphamide chemotherapy for breast cancer.	Docetaxel	86-95	colony stimulating factor 3	Homo sapiens	45-82
2988760-8	1985	A simple, rapid assay for a new human CSA with pluripotent hematopoietic stimulating activity (pluripoietin) is described based on stimulation of [3H]glucosamine incorporation.	Cyclosporine	38-41	colony stimulating factor 3	Homo sapiens	95-107
2988760-8	1985	A simple, rapid assay for a new human CSA with pluripotent hematopoietic stimulating activity (pluripoietin) is described based on stimulation of [3H]glucosamine incorporation.	Tritium	147-149	colony stimulating factor 3	Homo sapiens	95-107
2988760-8	1985	A simple, rapid assay for a new human CSA with pluripotent hematopoietic stimulating activity (pluripoietin) is described based on stimulation of [3H]glucosamine incorporation.	Glucosamine	150-161	colony stimulating factor 3	Homo sapiens	95-107
6609780-2	1984	The G-CSF had an apparent molecular weight of 33,000 as determined by high speed gel permeation chromatography, but its molecular weight was decreased to 15,000 by 0.1% sodium dodecyl sulfate.	Sodium Dodecyl Sulfate	169-191	colony stimulating factor 3	Homo sapiens	4-9
6609780-6	1984	The G-CSF was stable against 5 mM dithiothreitol, whereas the M-CSF was slowly inactivated.	Dithiothreitol	34-48	colony stimulating factor 3	Homo sapiens	4-9
33146835-14	2021	Primary prophylactic G-CSF is an effective therapy for preventing FN during TC chemotherapy.	Technetium	76-78	colony stimulating factor 3	Homo sapiens	21-26
33146835-0	2021	Febrile neutropenia and role of prophylactic granulocyte colony-stimulating factor in docetaxel and cyclophosphamide chemotherapy for breast cancer.	Cyclophosphamide	100-116	colony stimulating factor 3	Homo sapiens	45-82
34010932-1	2022	PURPOSE: Pegteograstim (Neulapeg) is a recombinant human granulocyte colony-stimulating factor conjugated with methoxy-maleimide-polyethylene glycol.	methoxy-maleimide-polyethylene glycol	111-148	colony stimulating factor 3	Homo sapiens	57-94
33868473-7	2021	Further detection of immune-associated cytokines and cells suggested that beta-asarone might be involved in the antitumor immune response by stimulating granulocyte-colony stimulating factor and increasing the number of macrophage cells in the spleen.	asarone	74-86	colony stimulating factor 3	Homo sapiens	153-190
33483893-4	2021	The ncIBs were easily dissolved in 0.2% N-lauroylsarcosine solution and then directly applied to a Ni-NTA affinity chromatography column to get G-CSF with high purity (> 90%).	ni-nta	99-105	colony stimulating factor 3	Homo sapiens	144-149
34021462-3	2021	In addition to our cases, we identified 30 previous reports of G-CSF-producing tumors on which 18F-fluorodeoxyglucose positron emission tomography (FDG-PET)/CT, bone scintigraphy, or evaluation of bone marrow MR findings was performed.	Fluorodeoxyglucose F18	95-117	colony stimulating factor 3	Homo sapiens	63-68
34021462-5	2021	G-CSF-producing tumors presented large necrotic masses (mean diameter 83.2 mm, range 17-195 mm) with marked FDG uptake (mean maximum standardized uptake value: 20.09).	Fluorodeoxyglucose F18	108-111	colony stimulating factor 3	Homo sapiens	0-5
34040446-0	2021	A Community Hospital-Based Study: A Prespecified Neutrophil Count with Adjuvant mFOLFOX6 Associated with Increased Delays, Increased G-CSF Use, and Reduced Dose Intensity.	mfolfox6	80-88	colony stimulating factor 3	Homo sapiens	133-138
34040446-10	2021	There was an inverse relationship between the frequency of G-CSF use and the RDI of continuous infusion 5FU, r=-0.26 (p<0.001).	Fluorouracil	104-107	colony stimulating factor 3	Homo sapiens	59-64
33998705-9	2021	Amygdalin analogue treatment leads to reduced expression of local pro-inflammatory cytokines, but systemic pro-inflammatory cytokines that are highly expressed in psoriasis patients such as IL-17A, IL-6, or G-CSF, are also decreased.	Amygdalin	0-9	colony stimulating factor 3	Homo sapiens	207-212
33617894-0	2021	Bortezomib enhances G-CSF-induced hematopoietic stem cell mobilization by decreasing CXCL12 levels and increasing vascular permeability.	Bortezomib	0-10	colony stimulating factor 3	Homo sapiens	20-25
33999634-4	2021	Here, a computational approach is proposed to clarify the role of beta-cyclodextrin (betaCD) and 2-hydroxypropyl-beta-cyclodextrin (HPbetaCD) against granulocyte colony-stimulating (GCSF) factor denaturation at the air-water and ice-water interfaces, and also in bulk water at 300 or 260 K. Both traditional molecular dynamics (MD) simulations and enhanced sampling techniques (metadynamics, MetaD) are used to shed light on the underlying molecular mechanisms.	betadex	66-83	colony stimulating factor 3	Homo sapiens	182-186
33999634-4	2021	Here, a computational approach is proposed to clarify the role of beta-cyclodextrin (betaCD) and 2-hydroxypropyl-beta-cyclodextrin (HPbetaCD) against granulocyte colony-stimulating (GCSF) factor denaturation at the air-water and ice-water interfaces, and also in bulk water at 300 or 260 K. Both traditional molecular dynamics (MD) simulations and enhanced sampling techniques (metadynamics, MetaD) are used to shed light on the underlying molecular mechanisms.	betadex	85-91	colony stimulating factor 3	Homo sapiens	182-186
33999634-4	2021	Here, a computational approach is proposed to clarify the role of beta-cyclodextrin (betaCD) and 2-hydroxypropyl-beta-cyclodextrin (HPbetaCD) against granulocyte colony-stimulating (GCSF) factor denaturation at the air-water and ice-water interfaces, and also in bulk water at 300 or 260 K. Both traditional molecular dynamics (MD) simulations and enhanced sampling techniques (metadynamics, MetaD) are used to shed light on the underlying molecular mechanisms.	2-Hydroxypropyl-beta-cyclodextrin	97-130	colony stimulating factor 3	Homo sapiens	182-186
33999634-4	2021	Here, a computational approach is proposed to clarify the role of beta-cyclodextrin (betaCD) and 2-hydroxypropyl-beta-cyclodextrin (HPbetaCD) against granulocyte colony-stimulating (GCSF) factor denaturation at the air-water and ice-water interfaces, and also in bulk water at 300 or 260 K. Both traditional molecular dynamics (MD) simulations and enhanced sampling techniques (metadynamics, MetaD) are used to shed light on the underlying molecular mechanisms.	2-Hydroxypropyl-beta-cyclodextrin	132-140	colony stimulating factor 3	Homo sapiens	182-186
33999634-5	2021	Bulk simulations revealed that CDs were preferentially included within the surface hydration layer of GCSF, and even included some peptide residues in their hydrophobic cavity.	Cyclodextrins	31-34	colony stimulating factor 3	Homo sapiens	102-106
33617894-7	2021	These results suggest that the pro-mobilization effect of BTZ could involve (1) the dissociation of HSPCs from BMSCs triggered by G-CSF, (2) vascular hyperpermeability elicited by BTZ, and (3) downregulation of CXCL12 concomitantly induced by G-CSF and BTZ.	Bortezomib	58-61	colony stimulating factor 3	Homo sapiens	243-248
33617894-1	2021	Bortezomib (BTZ) is known to enhance the mobilization of hematopoietic stem and progenitor cells (HSPCs) induced by granulocyte colony-stimulating factor (G-CSF).	Bortezomib	0-10	colony stimulating factor 3	Homo sapiens	116-153
33617894-1	2021	Bortezomib (BTZ) is known to enhance the mobilization of hematopoietic stem and progenitor cells (HSPCs) induced by granulocyte colony-stimulating factor (G-CSF).	Bortezomib	0-10	colony stimulating factor 3	Homo sapiens	155-160
33617894-1	2021	Bortezomib (BTZ) is known to enhance the mobilization of hematopoietic stem and progenitor cells (HSPCs) induced by granulocyte colony-stimulating factor (G-CSF).	Bortezomib	12-15	colony stimulating factor 3	Homo sapiens	116-153
33617894-1	2021	Bortezomib (BTZ) is known to enhance the mobilization of hematopoietic stem and progenitor cells (HSPCs) induced by granulocyte colony-stimulating factor (G-CSF).	Bortezomib	12-15	colony stimulating factor 3	Homo sapiens	155-160
33617894-5	2021	Next, in terms of the mechanism of action, G-CSF, but not BTZ, downregulated the expression of very late antigen-4 on HSPCs and vascular cell adhesion molecule-1 on bone marrow (BM) stromal cells; however, intriguingly, both G-CSF and BTZ downregulated CXCL12 chemokine expression in BM.	Bortezomib	235-238	colony stimulating factor 3	Homo sapiens	43-48
33617894-7	2021	These results suggest that the pro-mobilization effect of BTZ could involve (1) the dissociation of HSPCs from BMSCs triggered by G-CSF, (2) vascular hyperpermeability elicited by BTZ, and (3) downregulation of CXCL12 concomitantly induced by G-CSF and BTZ.	Bortezomib	58-61	colony stimulating factor 3	Homo sapiens	130-135
33965236-2	2021	An FDA-IND for sequential Kasai-GCSF treatment in biliary atresia BA was approved.	fda-ind	3-10	colony stimulating factor 3	Homo sapiens	32-36
33787864-2	2021	We recently reported the results of treating children with AML with a combination of low-dose cytarabine and mitoxantrone or omacetaxine mepesuccinate with concurrent granulocyte colony-stimulating factor (G-CSF) (low-dose chemotherapy [LDC]) for remission induction followed by standard postremission strategies.	Cytarabine	94-104	colony stimulating factor 3	Homo sapiens	206-211
33914350-12	2021	Neutropenia and thrombocytopenia after lurbinectedin administration to cancer patients are noncumulative, reversible, short lasting, and clinically manageable with secondary prophylaxis of G-CSF or platelet transfusion and, if needed, dose reductions.	PM 01183	39-52	colony stimulating factor 3	Homo sapiens	189-194
33880064-2	2021	In this study, we aimed to evaluate the efficacy of polyethylene glycol recombinant granulocyte colony-stimulating factor (PEG-rhG-CSF) compared with short-acting rhG-CSF in the dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin (DA-EPOCH) regimen.	Polyethylene Glycols	52-71	colony stimulating factor 3	Homo sapiens	84-121
33880064-2	2021	In this study, we aimed to evaluate the efficacy of polyethylene glycol recombinant granulocyte colony-stimulating factor (PEG-rhG-CSF) compared with short-acting rhG-CSF in the dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin (DA-EPOCH) regimen.	Etoposide	192-201	colony stimulating factor 3	Homo sapiens	84-121
33880064-2	2021	In this study, we aimed to evaluate the efficacy of polyethylene glycol recombinant granulocyte colony-stimulating factor (PEG-rhG-CSF) compared with short-acting rhG-CSF in the dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin (DA-EPOCH) regimen.	Prednisone	203-213	colony stimulating factor 3	Homo sapiens	84-121
33880064-2	2021	In this study, we aimed to evaluate the efficacy of polyethylene glycol recombinant granulocyte colony-stimulating factor (PEG-rhG-CSF) compared with short-acting rhG-CSF in the dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin (DA-EPOCH) regimen.	Vincristine	215-226	colony stimulating factor 3	Homo sapiens	84-121
33880064-2	2021	In this study, we aimed to evaluate the efficacy of polyethylene glycol recombinant granulocyte colony-stimulating factor (PEG-rhG-CSF) compared with short-acting rhG-CSF in the dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin (DA-EPOCH) regimen.	Cyclophosphamide	228-244	colony stimulating factor 3	Homo sapiens	84-121
33880064-2	2021	In this study, we aimed to evaluate the efficacy of polyethylene glycol recombinant granulocyte colony-stimulating factor (PEG-rhG-CSF) compared with short-acting rhG-CSF in the dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin (DA-EPOCH) regimen.	Doxorubicin	250-261	colony stimulating factor 3	Homo sapiens	84-121
33880064-2	2021	In this study, we aimed to evaluate the efficacy of polyethylene glycol recombinant granulocyte colony-stimulating factor (PEG-rhG-CSF) compared with short-acting rhG-CSF in the dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin (DA-EPOCH) regimen.	EPOCH protocol	263-271	colony stimulating factor 3	Homo sapiens	84-121
33965236-10	2021	HSC count increased 12-fold and 17.5-fold for the 5 mug/kg and10 ug/kg dose respectively; with respective median total bilirubin levels for GCSF vs no-GCSF groups of 55 vs 91 muM at 1 month, p = 0.05; 15 vs 37 muM at 3 months, p = 0.24); and the 6-months cholangitis frequency of 40% vs 90%, p = 0.077.	Bilirubin	119-128	colony stimulating factor 3	Homo sapiens	140-144
33470903-7	2021	Our results showed that GCSF administration significantly increased serum triglyceride (TG) levels in patients.	Triglycerides	74-86	colony stimulating factor 3	Homo sapiens	24-28
33470903-7	2021	Our results showed that GCSF administration significantly increased serum triglyceride (TG) levels in patients.	Triglycerides	88-90	colony stimulating factor 3	Homo sapiens	24-28
33483284-4	2021	Plerixafor was administered subcutaneously to 30 HRDs at a median dose of 0.24 mg/Kg (interquartile range (IQR): 0.23-0.25) because mobilization failure after using mobilization with G-CSF (mobilization failure was defined as collection of <4.0 x 106 CD34+ cells/Kg recipient).	plerixafor	0-10	colony stimulating factor 3	Homo sapiens	183-188
33860642-0	2021	Prevention of docetaxel-associated febrile neutropenia with primary granulocyte colony-stimulating factor in Chinese metastatic hormone-sensitive and castration-resistant prostate cancer patients.	Docetaxel	14-23	colony stimulating factor 3	Homo sapiens	68-105
33860642-4	2021	Primary GCSF prophylaxis was defined as administration within 5 days of starting docetaxel.	Docetaxel	81-90	colony stimulating factor 3	Homo sapiens	8-12
33860642-11	2021	CONCLUSIONS: To alleviate the risk of docetaxel-related FN, primary GCSF prophylaxis is suggested for Asian mCRPC and mHSPC patients, particularly those with poor performance status.	Docetaxel	38-47	colony stimulating factor 3	Homo sapiens	68-72
33472913-13	2021	CONCLUSIONS: The guadecitabine RP2D was 20 mg/m2, days 1-5, in combination with GC and requires GCSF prophylaxis.	guadecitabine	17-30	colony stimulating factor 3	Homo sapiens	96-100
33976061-3	2021	After completion of 1 course of CAG therapy(cytarabine, aclarubicin, G-CSF), his white blood cell count increased sufficiently, so he underwent a robot-assisted Hartmann operation in October.	GUANOSINE 5'-TRIPHOSPHATE P3-[1-(2-NITROPHENYL)ETHYL ESTER]	32-35	colony stimulating factor 3	Homo sapiens	69-74
33483284-10	2021	In conclusion, addition of plerixafor after G-CSF mobilization failure in HRDs allowed collecting higher number of CD34+ cells in comparison with steady-state mobilization.	plerixafor	27-37	colony stimulating factor 3	Homo sapiens	44-49
33582555-3	2021	C/EBPbeta is a leucine-zipper transcription factor that regulates expression of a variety of inflammatory cytokines or chemokines, such as IL-8, G-CSF (granulocyte colony stimulating factor), and GM-CSF (granulocyte macrophage colony stimulating factor) which induce neutrophil infiltration and differentiation.	Leucine	15-22	colony stimulating factor 3	Homo sapiens	145-150
33582555-3	2021	C/EBPbeta is a leucine-zipper transcription factor that regulates expression of a variety of inflammatory cytokines or chemokines, such as IL-8, G-CSF (granulocyte colony stimulating factor), and GM-CSF (granulocyte macrophage colony stimulating factor) which induce neutrophil infiltration and differentiation.	Leucine	15-22	colony stimulating factor 3	Homo sapiens	152-189
33753907-1	2021	Given the availability and efficacy of the mobilizing agent plerixafor in augmenting hematopoietic progenitor cell mobilization with granulocyte colony-stimulating factor (G-CSF), there is a strong case for comparing the cost-effectiveness of mobilization with G-CSF + cyclophosphamide versus G-CSF alone.	plerixafor	60-70	colony stimulating factor 3	Homo sapiens	133-170
33753907-1	2021	Given the availability and efficacy of the mobilizing agent plerixafor in augmenting hematopoietic progenitor cell mobilization with granulocyte colony-stimulating factor (G-CSF), there is a strong case for comparing the cost-effectiveness of mobilization with G-CSF + cyclophosphamide versus G-CSF alone.	plerixafor	60-70	colony stimulating factor 3	Homo sapiens	172-177
33753907-6	2021	The CEA model showed that G-CSF alone was strongly dominant versus cyclophosphamide + G-CSF ( +- on-demand plerixafor), with incremental savings of $1198.59 and an incremental probability of a successful 4 million-CD34+ apheresis (+0.052).	plerixafor	107-117	colony stimulating factor 3	Homo sapiens	26-31
33753907-6	2021	The CEA model showed that G-CSF alone was strongly dominant versus cyclophosphamide + G-CSF ( +- on-demand plerixafor), with incremental savings of $1198.59 and an incremental probability of a successful 4 million-CD34+ apheresis (+0.052).	plerixafor	107-117	colony stimulating factor 3	Homo sapiens	86-91
33710672-1	2021	Administration of plerixafor with granulocyte-colony stimulating factor (G-CSF) mobilizes CD34+ cells much more effectively than G-CSF alone, but cost generally limits plerixafor use to patients at high risk of insufficient CD34+ cell collection based on low peripheral blood (PB) CD34+ counts following 4 days of G-CSF.	plerixafor	18-28	colony stimulating factor 3	Homo sapiens	34-71
33710672-1	2021	Administration of plerixafor with granulocyte-colony stimulating factor (G-CSF) mobilizes CD34+ cells much more effectively than G-CSF alone, but cost generally limits plerixafor use to patients at high risk of insufficient CD34+ cell collection based on low peripheral blood (PB) CD34+ counts following 4 days of G-CSF.	plerixafor	18-28	colony stimulating factor 3	Homo sapiens	73-78
32747325-7	2021	Prophylactic granulocyte-colony stimulating factor is recommended for intensive regimens such as DA-EPOCH-R, R-DHAP, or R-ICE.	da-epoch-r	97-107	colony stimulating factor 3	Homo sapiens	13-50
33682959-0	2021	Plerixafor added to G-CSF allows mobilization of a sufficient number of hematopoietic progenitors without impacting the efficacy of TCR-alpha/beta depletion in pediatric haploidentical and genoidentical donors failing to mobilize with G-CSF alone.	plerixafor	0-10	colony stimulating factor 3	Homo sapiens	235-240
32747325-7	2021	Prophylactic granulocyte-colony stimulating factor is recommended for intensive regimens such as DA-EPOCH-R, R-DHAP, or R-ICE.	r-dhap	109-115	colony stimulating factor 3	Homo sapiens	13-50
33647545-0	2021	Usefulness of 18F-fluorodeoxyglucose positron emission tomography for assessment of tumorviability after resection of granulocyte-colony-stimulating-factor -Producing cholangiocarcinoma-a case report.	Fluorodeoxyglucose F18	14-36	colony stimulating factor 3	Homo sapiens	118-155
33028987-1	2021	We conducted a prospective clinical trial to investigate the safety and efficacy of plerixafor (P) in allogeneic peripheral blood stem cells (PBSC) donors with poor mobilization response to standard-dose granulocyte colony-stimulating factor (G-CSF), defined by <2 x 106 CD34 + cells/kg recipient body-weight (CD34+/kg RBW) after 1st apheresis.	plerixafor	84-94	colony stimulating factor 3	Homo sapiens	204-241
33647545-15	2021	FDG uptake in the bone marrow is characteristic in G-CSF producing tumor.	Fluorodeoxyglucose F18	0-3	colony stimulating factor 3	Homo sapiens	51-56
33781522-9	2021	The "on demand" use of plerixafor was higher in the G-CSF group (76%) compared with the LD-Cy group (19%) and the HD-Cy group (6%).	plerixafor	23-33	colony stimulating factor 3	Homo sapiens	52-57
33737338-6	2021	We then hypothesized that the mobilization of immune cells by G-CSF may increase the antitumor efficacy of Celyvir treatment by increasing the immune infiltration into the tumors.	celyvir	107-114	colony stimulating factor 3	Homo sapiens	62-67
33361463-0	2021	Granulocyte-Colony Stimulating Factor reduces cocaine-seeking and downregulates glutamatergic synaptic proteins in medial prefrontal cortex.	Cocaine	46-53	colony stimulating factor 3	Homo sapiens	0-37
33361463-3	2021	Previous work from our group has identified granulocyte-colony stimulating factor (G-CSF) as a neuroactive cytokine that alters behavioral response to cocaine, increases synaptic dopamine release, and enhances cognitive flexibility.	Cocaine	151-158	colony stimulating factor 3	Homo sapiens	44-81
33361463-3	2021	Previous work from our group has identified granulocyte-colony stimulating factor (G-CSF) as a neuroactive cytokine that alters behavioral response to cocaine, increases synaptic dopamine release, and enhances cognitive flexibility.	Cocaine	151-158	colony stimulating factor 3	Homo sapiens	83-88
33361463-3	2021	Previous work from our group has identified granulocyte-colony stimulating factor (G-CSF) as a neuroactive cytokine that alters behavioral response to cocaine, increases synaptic dopamine release, and enhances cognitive flexibility.	Dopamine	179-187	colony stimulating factor 3	Homo sapiens	44-81
33361463-3	2021	Previous work from our group has identified granulocyte-colony stimulating factor (G-CSF) as a neuroactive cytokine that alters behavioral response to cocaine, increases synaptic dopamine release, and enhances cognitive flexibility.	Dopamine	179-187	colony stimulating factor 3	Homo sapiens	83-88
33361463-4	2021	Here, we investigate the role of G-CSF in affecting extinction and reinstatement of cocaine-seeking and perform detailed characterization of its proteomic effects in multiple limbic substructures.	Cocaine	84-91	colony stimulating factor 3	Homo sapiens	33-38
33361463-13	2021	Emerging evidence suggests that targeting the immune system may be a viable translational research strategy; preclinical studies have found that the neuroactive cytokine granulocyte-colony stimulating factor (G-CSF) alters cocaine reward and reinforcement and can enhance cognitive flexibility.	Cocaine	223-230	colony stimulating factor 3	Homo sapiens	170-207
33585350-0	2021	Clinical utilization of long-acting granulocyte colony-stimulating factor (pegfilgrastim) prophylaxis in breast cancer patients with adjuvant docetaxel-cyclophosphamide chemotherapy.	Docetaxel	142-151	colony stimulating factor 3	Homo sapiens	36-73
33643294-7	2020	We postulate that G-CSF-mobilized MPPs might become a valuable cellular therapy to expand donor Tregs in vivo and prevent GVHD, thereby making allo-HSCT safer for the treatment of leukemia patients.	tregs	96-101	colony stimulating factor 3	Homo sapiens	18-23
33147611-0	2021	A management of neutropenia using granulocyte colony stimulating factor support for chemotherapy consisted of docetaxel, cisplatin and 5-fluorouracil in patients with oesophageal squamous cell carcinoma.	Docetaxel	110-119	colony stimulating factor 3	Homo sapiens	34-71
33147611-0	2021	A management of neutropenia using granulocyte colony stimulating factor support for chemotherapy consisted of docetaxel, cisplatin and 5-fluorouracil in patients with oesophageal squamous cell carcinoma.	Cisplatin	121-130	colony stimulating factor 3	Homo sapiens	34-71
33147611-0	2021	A management of neutropenia using granulocyte colony stimulating factor support for chemotherapy consisted of docetaxel, cisplatin and 5-fluorouracil in patients with oesophageal squamous cell carcinoma.	Fluorouracil	135-149	colony stimulating factor 3	Homo sapiens	34-71
33147611-1	2021	BACKGROUND: An exploratory study was designed to evaluate the efficacy of granulocyte colony stimulating factor support for chemotherapy consisting of docetaxel, cisplatin and 5-fluorouracil chemotherapy in patients with oesophageal cancer.	Docetaxel	151-160	colony stimulating factor 3	Homo sapiens	74-111
33147611-1	2021	BACKGROUND: An exploratory study was designed to evaluate the efficacy of granulocyte colony stimulating factor support for chemotherapy consisting of docetaxel, cisplatin and 5-fluorouracil chemotherapy in patients with oesophageal cancer.	Cisplatin	162-171	colony stimulating factor 3	Homo sapiens	74-111
33147611-1	2021	BACKGROUND: An exploratory study was designed to evaluate the efficacy of granulocyte colony stimulating factor support for chemotherapy consisting of docetaxel, cisplatin and 5-fluorouracil chemotherapy in patients with oesophageal cancer.	Fluorouracil	176-190	colony stimulating factor 3	Homo sapiens	74-111
33147611-12	2021	CONCLUSIONS: Granulocyte colony stimulating factor support including secondary prophylactic usage may be feasible for maintaining the intensity of docetaxel, cisplatin and 5-fluorouracil chemotherapy in patients with oesophageal cancer.	Docetaxel	147-156	colony stimulating factor 3	Homo sapiens	13-50
33147611-12	2021	CONCLUSIONS: Granulocyte colony stimulating factor support including secondary prophylactic usage may be feasible for maintaining the intensity of docetaxel, cisplatin and 5-fluorouracil chemotherapy in patients with oesophageal cancer.	Cisplatin	158-167	colony stimulating factor 3	Homo sapiens	13-50
33147611-12	2021	CONCLUSIONS: Granulocyte colony stimulating factor support including secondary prophylactic usage may be feasible for maintaining the intensity of docetaxel, cisplatin and 5-fluorouracil chemotherapy in patients with oesophageal cancer.	Fluorouracil	172-186	colony stimulating factor 3	Homo sapiens	13-50
33181139-10	2021	Differences in Pthrp, Il-6, Il-1alpha and beta, and G-csf gene expression in vitro correlated with differences in in vivo plasma calcium levels, tumor growth, metastasis, and neutrophilic inflammation.	Calcium	129-136	colony stimulating factor 3	Homo sapiens	52-57
33585350-0	2021	Clinical utilization of long-acting granulocyte colony-stimulating factor (pegfilgrastim) prophylaxis in breast cancer patients with adjuvant docetaxel-cyclophosphamide chemotherapy.	Cyclophosphamide	152-168	colony stimulating factor 3	Homo sapiens	36-73
33500424-7	2021	In vitro and in vivo experiments revealed that tumor-derived granulocyte colony-stimulating factor (G-CSF) was involved in the underlying causative mechanism of increased BM FDG-uptake, and that immune suppression mediated by G-CSF-induced myeloid-derived suppressor cells (MDSCs) is responsible for the poor prognosis of this type of cancer.	Fluorodeoxyglucose F18	174-177	colony stimulating factor 3	Homo sapiens	61-98
32827162-0	2021	Justification for a Fixed Dose of Eflapegrastim, a Long-Acting G-CSF, in Patients Receiving Docetaxel-Cyclophosphamide Chemotherapy.	eflapegrastim	34-47	colony stimulating factor 3	Homo sapiens	63-68
32827162-1	2021	Eflapegrastim (Rolontis) is a long-acting granulocyte colony-stimulating factor (G-CSF) produced by conjugating a human G-CSF analogue and a human immunoglobulin G4 Fc fragment, linked via a polyethylene glycol linker.	eflapegrastim	0-13	colony stimulating factor 3	Homo sapiens	42-79
32827162-1	2021	Eflapegrastim (Rolontis) is a long-acting granulocyte colony-stimulating factor (G-CSF) produced by conjugating a human G-CSF analogue and a human immunoglobulin G4 Fc fragment, linked via a polyethylene glycol linker.	eflapegrastim	0-13	colony stimulating factor 3	Homo sapiens	81-86
32827162-1	2021	Eflapegrastim (Rolontis) is a long-acting granulocyte colony-stimulating factor (G-CSF) produced by conjugating a human G-CSF analogue and a human immunoglobulin G4 Fc fragment, linked via a polyethylene glycol linker.	eflapegrastim	0-13	colony stimulating factor 3	Homo sapiens	120-125
32827162-1	2021	Eflapegrastim (Rolontis) is a long-acting granulocyte colony-stimulating factor (G-CSF) produced by conjugating a human G-CSF analogue and a human immunoglobulin G4 Fc fragment, linked via a polyethylene glycol linker.	rolontis	15-23	colony stimulating factor 3	Homo sapiens	42-79
32827162-1	2021	Eflapegrastim (Rolontis) is a long-acting granulocyte colony-stimulating factor (G-CSF) produced by conjugating a human G-CSF analogue and a human immunoglobulin G4 Fc fragment, linked via a polyethylene glycol linker.	rolontis	15-23	colony stimulating factor 3	Homo sapiens	81-86
32827162-1	2021	Eflapegrastim (Rolontis) is a long-acting granulocyte colony-stimulating factor (G-CSF) produced by conjugating a human G-CSF analogue and a human immunoglobulin G4 Fc fragment, linked via a polyethylene glycol linker.	rolontis	15-23	colony stimulating factor 3	Homo sapiens	120-125
32827162-1	2021	Eflapegrastim (Rolontis) is a long-acting granulocyte colony-stimulating factor (G-CSF) produced by conjugating a human G-CSF analogue and a human immunoglobulin G4 Fc fragment, linked via a polyethylene glycol linker.	Polyethylene Glycols	191-210	colony stimulating factor 3	Homo sapiens	42-79
32827162-1	2021	Eflapegrastim (Rolontis) is a long-acting granulocyte colony-stimulating factor (G-CSF) produced by conjugating a human G-CSF analogue and a human immunoglobulin G4 Fc fragment, linked via a polyethylene glycol linker.	Polyethylene Glycols	191-210	colony stimulating factor 3	Homo sapiens	81-86
32827162-3	2021	Based on these results, a fixed dose of 13.2 mg eflapegrastim (3.6 mg G-CSF) was compared with pegfilgrastim (6 mg G-CSF) in 2 phase 3 studies and in a pharmacokinetic single-arm multicenter study.	eflapegrastim	48-61	colony stimulating factor 3	Homo sapiens	70-75
32827162-7	2021	Eflapegrastim elicited a greater effect on ANC than pegfilgrastim in patients at ~60% of the G-CSF dose.	eflapegrastim	0-13	colony stimulating factor 3	Homo sapiens	93-98
32827162-9	2021	The results from 2 phase 3 studies demonstrate that eflapegrastim at a fixed dose of 13.2 mg (3.6 mg G-CSF) administered once per chemotherapy cycle is effective in prophylactic treatment of chemotherapy-induced neutropenia.	eflapegrastim	52-65	colony stimulating factor 3	Homo sapiens	101-106
32363436-6	2021	In addition, CMBL5-LO inhibited several chemo-attractants, including interleukin (IL)-6, macrophage inflammatory protein (MIP)-2, chemokine (C-C motif) ligand 5 (CCL5), granulocyte colony-stimulating factor (GCSF), and monocyte chemoattractant protein-1 (MCP-1) expression.	cmbl5-lo	13-21	colony stimulating factor 3	Homo sapiens	169-206
32363436-6	2021	In addition, CMBL5-LO inhibited several chemo-attractants, including interleukin (IL)-6, macrophage inflammatory protein (MIP)-2, chemokine (C-C motif) ligand 5 (CCL5), granulocyte colony-stimulating factor (GCSF), and monocyte chemoattractant protein-1 (MCP-1) expression.	cmbl5-lo	13-21	colony stimulating factor 3	Homo sapiens	208-212
33471934-0	2021	Nicotinamide (vitamin B3) treatment improves response to G-CSF in severe congenital neutropenia patients.	Niacinamide	0-12	colony stimulating factor 3	Homo sapiens	57-62
33471934-0	2021	Nicotinamide (vitamin B3) treatment improves response to G-CSF in severe congenital neutropenia patients.	Niacinamide	14-24	colony stimulating factor 3	Homo sapiens	57-62
33500424-7	2021	In vitro and in vivo experiments revealed that tumor-derived granulocyte colony-stimulating factor (G-CSF) was involved in the underlying causative mechanism of increased BM FDG-uptake, and that immune suppression mediated by G-CSF-induced myeloid-derived suppressor cells (MDSCs) is responsible for the poor prognosis of this type of cancer.	Fluorodeoxyglucose F18	174-177	colony stimulating factor 3	Homo sapiens	100-105
33467957-2	2021	We hypothesized G-CSF and plerixafor may enhance sensitivity to azacitidine in MDS.	Azacitidine	64-75	colony stimulating factor 3	Homo sapiens	16-21
33551833-13	2020	Two antiviral drugs (Elbasvir and Ritonavir) were included; Elbasvir and Ritonavir formed van der Waals (VDW) interactions with surrounding residues to bind with CSF3, and Elbasvir and Ritonavir significantly inhibited CSF3 protein expression.	2-(pyrrolidin-2-yl)-5-(2-(4-(5-(pyrrolidin-2-yl)-1H-imidazol-2-yl)phenyl)benzofuran-5-yl)-1H-imidazole	60-68	colony stimulating factor 3	Homo sapiens	162-166
33551833-13	2020	Two antiviral drugs (Elbasvir and Ritonavir) were included; Elbasvir and Ritonavir formed van der Waals (VDW) interactions with surrounding residues to bind with CSF3, and Elbasvir and Ritonavir significantly inhibited CSF3 protein expression.	2-(pyrrolidin-2-yl)-5-(2-(4-(5-(pyrrolidin-2-yl)-1H-imidazol-2-yl)phenyl)benzofuran-5-yl)-1H-imidazole	60-68	colony stimulating factor 3	Homo sapiens	219-223
33551833-13	2020	Two antiviral drugs (Elbasvir and Ritonavir) were included; Elbasvir and Ritonavir formed van der Waals (VDW) interactions with surrounding residues to bind with CSF3, and Elbasvir and Ritonavir significantly inhibited CSF3 protein expression.	Ritonavir	73-82	colony stimulating factor 3	Homo sapiens	162-166
33551833-13	2020	Two antiviral drugs (Elbasvir and Ritonavir) were included; Elbasvir and Ritonavir formed van der Waals (VDW) interactions with surrounding residues to bind with CSF3, and Elbasvir and Ritonavir significantly inhibited CSF3 protein expression.	Ritonavir	73-82	colony stimulating factor 3	Homo sapiens	219-223
33551833-13	2020	Two antiviral drugs (Elbasvir and Ritonavir) were included; Elbasvir and Ritonavir formed van der Waals (VDW) interactions with surrounding residues to bind with CSF3, and Elbasvir and Ritonavir significantly inhibited CSF3 protein expression.	2-(pyrrolidin-2-yl)-5-(2-(4-(5-(pyrrolidin-2-yl)-1H-imidazol-2-yl)phenyl)benzofuran-5-yl)-1H-imidazole	60-68	colony stimulating factor 3	Homo sapiens	162-166
33551833-13	2020	Two antiviral drugs (Elbasvir and Ritonavir) were included; Elbasvir and Ritonavir formed van der Waals (VDW) interactions with surrounding residues to bind with CSF3, and Elbasvir and Ritonavir significantly inhibited CSF3 protein expression.	2-(pyrrolidin-2-yl)-5-(2-(4-(5-(pyrrolidin-2-yl)-1H-imidazol-2-yl)phenyl)benzofuran-5-yl)-1H-imidazole	60-68	colony stimulating factor 3	Homo sapiens	219-223
33551833-13	2020	Two antiviral drugs (Elbasvir and Ritonavir) were included; Elbasvir and Ritonavir formed van der Waals (VDW) interactions with surrounding residues to bind with CSF3, and Elbasvir and Ritonavir significantly inhibited CSF3 protein expression.	Ritonavir	73-82	colony stimulating factor 3	Homo sapiens	162-166
33551833-13	2020	Two antiviral drugs (Elbasvir and Ritonavir) were included; Elbasvir and Ritonavir formed van der Waals (VDW) interactions with surrounding residues to bind with CSF3, and Elbasvir and Ritonavir significantly inhibited CSF3 protein expression.	Ritonavir	73-82	colony stimulating factor 3	Homo sapiens	219-223
33447858-11	2021	CONCLUSIONS: We encountered a rare case of G-CSF-producing malignant phyllodes tumor of the breast.	phyllodes	69-78	colony stimulating factor 3	Homo sapiens	43-48
33039551-8	2021	The system was demonstrated for four common deviations in the PEGylation process, namely: delayed quenching time, wrong concentration of reducing agent added, wrong PEG to G-CSF ratio, and wrong sequence of addition of reactants.	Polyethylene Glycols	62-65	colony stimulating factor 3	Homo sapiens	172-177
33443626-0	2021	Successful treatment of G-CSF-related aortitis with prednisolone during preoperative chemotherapy for breast cancer: a case report.	Prednisolone	52-64	colony stimulating factor 3	Homo sapiens	24-29
33425313-0	2020	Disseminated focal 18F-fluoro-deoxyglucose uptake upon granulocyte colony-stimulating factor therapy mimicking malignant bone infiltration: case report of a patient with very severe aplastic anemia.	Fluorodeoxyglucose F18	19-42	colony stimulating factor 3	Homo sapiens	55-92
33610484-2	2021	This study evaluated the effectiveness of granulocyte colony-stimulating factor (G-CSF) plus ciprofloxacin as prophylaxis in post-docetaxel patients with mCRPC treated with cabazitaxel and at high risk for neutropenia.	Docetaxel	130-139	colony stimulating factor 3	Homo sapiens	42-79
33610484-2	2021	This study evaluated the effectiveness of granulocyte colony-stimulating factor (G-CSF) plus ciprofloxacin as prophylaxis in post-docetaxel patients with mCRPC treated with cabazitaxel and at high risk for neutropenia.	Docetaxel	130-139	colony stimulating factor 3	Homo sapiens	81-86
33610484-2	2021	This study evaluated the effectiveness of granulocyte colony-stimulating factor (G-CSF) plus ciprofloxacin as prophylaxis in post-docetaxel patients with mCRPC treated with cabazitaxel and at high risk for neutropenia.	cabazitaxel	173-184	colony stimulating factor 3	Homo sapiens	42-79
33610484-12	2021	CONCLUSIONS: Prophylactic G-CSF was effective in preventing neutropenia grade >= 3 and other hematologic complications during treatment with cabazitaxel 25 mg/m2 in post-docetaxel patients with mCRPC at high risk for neutropenia.	cabazitaxel	141-152	colony stimulating factor 3	Homo sapiens	26-31
33610484-12	2021	CONCLUSIONS: Prophylactic G-CSF was effective in preventing neutropenia grade >= 3 and other hematologic complications during treatment with cabazitaxel 25 mg/m2 in post-docetaxel patients with mCRPC at high risk for neutropenia.	Docetaxel	170-179	colony stimulating factor 3	Homo sapiens	26-31
33128745-3	2021	Efficient resolubilization of the interfacial precipitate offers a way to improve the recovery as well as selectivity of ATPS systems.In this protocol, we describe a method for aqueous two-phase-assisted precipitation and resolubilization of the recombinant human Granulocyte Colony Stimulating Factor (GCSF) for its selective isolation from E. coli host cell proteins as well as nucleic acids.	atps	121-125	colony stimulating factor 3	Homo sapiens	264-301
33128745-3	2021	Efficient resolubilization of the interfacial precipitate offers a way to improve the recovery as well as selectivity of ATPS systems.In this protocol, we describe a method for aqueous two-phase-assisted precipitation and resolubilization of the recombinant human Granulocyte Colony Stimulating Factor (GCSF) for its selective isolation from E. coli host cell proteins as well as nucleic acids.	atps	121-125	colony stimulating factor 3	Homo sapiens	303-307
33585342-8	2021	LEARNING POINTS: Ceftriaxone-induced agranulocytosis is rare but may occur in patients with high cumulative doses.Prompt recognition, drug withdrawal and administration of recombinant human granulocyte colony-stimulating factor (rhG-CSF) are the mainstay approach.	Ceftriaxone	17-28	colony stimulating factor 3	Homo sapiens	190-227
33551430-5	2021	The median length of hospitalization after starting chemotherapy in the second-cycle DA-EPOCH-R was significantly shorter with PEG-G-CSF group (n=9) of 9 (7-13) days compared with G-CSF group (n=6) of 18 (15-22) days (P<0.001).	-epoch-r	87-95	colony stimulating factor 3	Homo sapiens	131-136
33415106-0	2020	Vitamin D Promotes Trophoblast Cell Induced Separation of Vascular Smooth Muscle Cells in Vascular Remodeling via Induction of G-CSF.	Vitamin D	0-9	colony stimulating factor 3	Homo sapiens	127-132
33415106-5	2020	We demonstrate that 1,25(OH)2D can enhance the ability of PEx to induce SpA remodeling, via a mechanism associated with increased secretion of granulocyte-colony stimulating factor (G-CSF).	1,25(oh)2d	20-30	colony stimulating factor 3	Homo sapiens	143-180
33415106-5	2020	We demonstrate that 1,25(OH)2D can enhance the ability of PEx to induce SpA remodeling, via a mechanism associated with increased secretion of granulocyte-colony stimulating factor (G-CSF).	1,25(oh)2d	20-30	colony stimulating factor 3	Homo sapiens	182-187
33425313-13	2020	Interpretation of [18F]FDG-PET/CT in patients with aplastic anemia may be complicated by the frequent therapeutic use of G-CSF.	Fluorodeoxyglucose F18	23-26	colony stimulating factor 3	Homo sapiens	121-126
33425313-14	2020	With G-CSF, islets of residual bone marrow activity can be visualized on [18F]FDG-PET/CT images that might be misinterpreted as malignant bone infiltration.	Fluorodeoxyglucose F18	78-81	colony stimulating factor 3	Homo sapiens	5-10
33112626-3	2020	We have taken a combined approach of in silico molecular docking and hydrogen deuterium exchange-mass spectrometry (HDX-MS) to characterize the interactions between granulocyte colony-stimulating factor (G-CSF), and some common excipients.	Hydrogen	69-77	colony stimulating factor 3	Homo sapiens	165-202
33112626-3	2020	We have taken a combined approach of in silico molecular docking and hydrogen deuterium exchange-mass spectrometry (HDX-MS) to characterize the interactions between granulocyte colony-stimulating factor (G-CSF), and some common excipients.	Hydrogen	69-77	colony stimulating factor 3	Homo sapiens	204-209
33277285-4	2020	METHODS AND ANALYSIS: This is a multicentre, open-label, randomised phase III study that aimed to compare G-CSF+CA/CY/TBI as a conditioning regimen for CBT with CA/CY/TBI.	N,N-BIS(4-CHLOROBENZYL)-1H-1,2,3,4-TETRAAZOL-5-AMINE	152-155	colony stimulating factor 3	Homo sapiens	106-111
32876851-6	2020	Target CD34 cells yield of 5 x 106/kg was achieved with single apheresis in 58.6% of patients after B-Cy-GCSF mobilization as compared to 44.3% in Cy-GCSF group (p = 0.07).	Cysteine	102-104	colony stimulating factor 3	Homo sapiens	105-109
33277285-2	2020	To minimise graft failure and relapse after CBT, intensification of conditioning by the addition of high-dose cytosine arabinoside (CA) and concomitant continuous use of granulocyte-colony stimulating factor (G-CSF) are reported to convey a significantly better survival after CBT in some retrospective studies.	N,N-BIS(4-CHLOROBENZYL)-1H-1,2,3,4-TETRAAZOL-5-AMINE	277-280	colony stimulating factor 3	Homo sapiens	170-207
32386071-0	2020	Impact of G-CSF on FOLFIRINOX-induced neutropenia prevention: a population PK/PD approach.	folfirinox	19-29	colony stimulating factor 3	Homo sapiens	10-15
32386071-1	2020	AIM: Granulocyte colony-stimulating factor (G-CSF) is frequently prescribed to prevent chemotherapy-induced neutropenia, but the administration schedule remains empirical in case of bi-monthly chemotherapy such as FOLFIRINOX regimen.	folfirinox	214-224	colony stimulating factor 3	Homo sapiens	5-42
32386071-2	2020	This pharmacokinetic/pharmacodynamic (PK/PD) study was performed to determine effect of different G-CSF regimens on the incidence and duration of neutropenia following FOLFIRINOX administration in order to propose an optimal G-CSF dosing schedule.	folfirinox	168-178	colony stimulating factor 3	Homo sapiens	98-103
32386071-12	2020	Simulations showed pegylated-G-CSF administration 24 hours after the end of chemotherapy seems to be the optimal schedule to reduce FOLFIRINOX-induced neutropenia.	folfirinox	132-142	colony stimulating factor 3	Homo sapiens	29-34
32876851-6	2020	Target CD34 cells yield of 5 x 106/kg was achieved with single apheresis in 58.6% of patients after B-Cy-GCSF mobilization as compared to 44.3% in Cy-GCSF group (p = 0.07).	b-cy	100-104	colony stimulating factor 3	Homo sapiens	105-109
32876851-8	2020	Addition of bortezomib to Cy-GCSF mobilization showed a trend towards increased CD34 collection and reduced need for apheresis sessions.	Bortezomib	12-22	colony stimulating factor 3	Homo sapiens	29-33
32876851-5	2020	In B-Cy-GCSF group, median CD34 cells collected were 9.21 x 106/kg (range 4.95-17.1) while in the Cy-GCSF cohort, the median CD34 cell yield was 8.2 x 106/kg (0.4-24.2).	Boron	3-4	colony stimulating factor 3	Homo sapiens	8-12
32876851-5	2020	In B-Cy-GCSF group, median CD34 cells collected were 9.21 x 106/kg (range 4.95-17.1) while in the Cy-GCSF cohort, the median CD34 cell yield was 8.2 x 106/kg (0.4-24.2).	Cysteine	5-7	colony stimulating factor 3	Homo sapiens	8-12
32876851-8	2020	Addition of bortezomib to Cy-GCSF mobilization showed a trend towards increased CD34 collection and reduced need for apheresis sessions.	Cysteine	26-28	colony stimulating factor 3	Homo sapiens	29-33
32876851-5	2020	In B-Cy-GCSF group, median CD34 cells collected were 9.21 x 106/kg (range 4.95-17.1) while in the Cy-GCSF cohort, the median CD34 cell yield was 8.2 x 106/kg (0.4-24.2).	Cysteine	98-100	colony stimulating factor 3	Homo sapiens	101-105
32859502-4	2020	METHODS: In this single-center, prospective, observational, real world study, GTDS plus dexamethasone was administered to MM patients receiving chemo-mobilization based on CY 2 g/m2 plus G-CSF in an outpatient setting.	Granisetron	78-82	colony stimulating factor 3	Homo sapiens	187-192
32842815-0	2020	Primary prophylaxis with G-CSF may improve outcomes in patients with newly diagnosed stage III/IV Hodgkin lymphoma treated with brentuximab vedotin plus chemotherapy.	SGN-30 monoclonal antibody	128-139	colony stimulating factor 3	Homo sapiens	25-30
32842815-0	2020	Primary prophylaxis with G-CSF may improve outcomes in patients with newly diagnosed stage III/IV Hodgkin lymphoma treated with brentuximab vedotin plus chemotherapy.	vedotin	140-147	colony stimulating factor 3	Homo sapiens	25-30
32859502-4	2020	METHODS: In this single-center, prospective, observational, real world study, GTDS plus dexamethasone was administered to MM patients receiving chemo-mobilization based on CY 2 g/m2 plus G-CSF in an outpatient setting.	Dexamethasone	88-101	colony stimulating factor 3	Homo sapiens	187-192
33203399-9	2020	Grade 3/4 haematological toxicities were lower with docetaxel-sunitinib (18.2% vs 34.3%, p = 0.132), attributed to greater discretionary use of prophylactic G-CSF (90.9% vs 63.0%, p = 0.024).	Docetaxel	52-61	colony stimulating factor 3	Homo sapiens	157-162
32822472-5	2020	Mechanistically, dnTCF4 progenitors exhibited downregulation of the Csf3r gene, reduced G-CSF receptor levels, attenuation of downstream Stat3 phosphorylation after G-CSF treatment, and impaired G-CSF-mediated differentiation.	dntcf4	17-23	colony stimulating factor 3	Homo sapiens	88-93
32822472-5	2020	Mechanistically, dnTCF4 progenitors exhibited downregulation of the Csf3r gene, reduced G-CSF receptor levels, attenuation of downstream Stat3 phosphorylation after G-CSF treatment, and impaired G-CSF-mediated differentiation.	dntcf4	17-23	colony stimulating factor 3	Homo sapiens	165-170
33330413-2	2020	Although huG-CSF has been used as a drug for more than 20 years, it has three significant drawbacks: (i) it relies on PEG aldehyde for PEGylation of the alpha-amino group of the first amino acid, and this leads to non-specific PEGylation of the epsilon amino group of lysine residues within the G-CSF; (ii) longer-acting G-CSF variants are desirable to reduce the risk of chemotherapy-associated neutropenia; and (iii) G-CSF cannot be administered on the day of chemotherapy.	peg aldehyde	118-130	colony stimulating factor 3	Homo sapiens	11-16
33330413-2	2020	Although huG-CSF has been used as a drug for more than 20 years, it has three significant drawbacks: (i) it relies on PEG aldehyde for PEGylation of the alpha-amino group of the first amino acid, and this leads to non-specific PEGylation of the epsilon amino group of lysine residues within the G-CSF; (ii) longer-acting G-CSF variants are desirable to reduce the risk of chemotherapy-associated neutropenia; and (iii) G-CSF cannot be administered on the day of chemotherapy.	Lysine	268-274	colony stimulating factor 3	Homo sapiens	11-16
33330413-3	2020	In an attempt to overcome the above drawbacks, we engineered cysteine variants of G-CSF to facilitate the maleimide PEG-based site-specific PEGylation that leads to a highly homogenous PEGylated product.	Cysteine	61-69	colony stimulating factor 3	Homo sapiens	82-87
33330413-3	2020	In an attempt to overcome the above drawbacks, we engineered cysteine variants of G-CSF to facilitate the maleimide PEG-based site-specific PEGylation that leads to a highly homogenous PEGylated product.	maleimide	106-115	colony stimulating factor 3	Homo sapiens	82-87
33330413-3	2020	In an attempt to overcome the above drawbacks, we engineered cysteine variants of G-CSF to facilitate the maleimide PEG-based site-specific PEGylation that leads to a highly homogenous PEGylated product.	Polyethylene Glycols	116-119	colony stimulating factor 3	Homo sapiens	82-87
33203399-9	2020	Grade 3/4 haematological toxicities were lower with docetaxel-sunitinib (18.2% vs 34.3%, p = 0.132), attributed to greater discretionary use of prophylactic G-CSF (90.9% vs 63.0%, p = 0.024).	Sunitinib	62-71	colony stimulating factor 3	Homo sapiens	157-162
32975550-5	2020	When HUCPV were cultured with degradable Mg, a moderate inflammation (e.g., lower secretions of pro-inflammatory interleukin 1 beta and IL2, and tumour necrosis factor alpha, interferon gamma, anti-inflammatory interleukins 4, 5, 10, 13, and 1 receptor antagonists and granulocyte colony stimulating factor), and an increased pro-healing M2 macrophage phenotype were observed.	hucpv	5-10	colony stimulating factor 3	Homo sapiens	269-306
33245731-8	2020	TMPRSS2, inflammatory cytokines G-CSF, M-CSF, IL-1alpha, IL-6 and MCP-1 are suppressed by MEKi alone or with remdesivir.	remdesivir	109-119	colony stimulating factor 3	Homo sapiens	32-37
32975550-5	2020	When HUCPV were cultured with degradable Mg, a moderate inflammation (e.g., lower secretions of pro-inflammatory interleukin 1 beta and IL2, and tumour necrosis factor alpha, interferon gamma, anti-inflammatory interleukins 4, 5, 10, 13, and 1 receptor antagonists and granulocyte colony stimulating factor), and an increased pro-healing M2 macrophage phenotype were observed.	Magnesium	41-43	colony stimulating factor 3	Homo sapiens	269-306
32945902-0	2020	Combinatorial ethanol treatment increases the overall productivity of recombinant hG-CSF in E. coli: a comparative study.	Ethanol	14-21	colony stimulating factor 3	Homo sapiens	82-88
32945902-2	2020	In the present study, we report the feasibility of inducing recombinant hG-CSF expression (rhG-CSF) in a pET vector system by combinatorial induction using low-concentration ethanol, IPTG, and lactose and auto-induction media (AIM).	Ethanol	174-181	colony stimulating factor 3	Homo sapiens	72-78
32945902-2	2020	In the present study, we report the feasibility of inducing recombinant hG-CSF expression (rhG-CSF) in a pET vector system by combinatorial induction using low-concentration ethanol, IPTG, and lactose and auto-induction media (AIM).	Isopropyl Thiogalactoside	183-187	colony stimulating factor 3	Homo sapiens	72-78
32945902-2	2020	In the present study, we report the feasibility of inducing recombinant hG-CSF expression (rhG-CSF) in a pET vector system by combinatorial induction using low-concentration ethanol, IPTG, and lactose and auto-induction media (AIM).	Lactose	193-200	colony stimulating factor 3	Homo sapiens	72-78
32845551-0	2020	Cladribine with Granulocyte Colony-Stimulating Factor, Cytarabine, and Aclarubicin Regimen in Refractory/Relapsed Acute Myeloid Leukemia: A Phase II Multicenter Study.	Cladribine	0-10	colony stimulating factor 3	Homo sapiens	16-53
33204611-0	2020	Plerixafor on-demand in association with low-dose cyclophosphamide and G-CSF in the mobilization of patients with multiple myeloma: High effectiveness, low toxicity, and affordable cost.	plerixafor	0-10	colony stimulating factor 3	Homo sapiens	71-76
33120908-0	2020	Primary Granulocyte Colony-Stimulating Factor Prophylaxis in Metastatic Pancreatic Cancer Patients Treated with FOLFIRINOX as the First-Line Treatment.	folfirinox	112-122	colony stimulating factor 3	Homo sapiens	8-45
33120908-9	2020	When administering FOLFIRINOX for MPC, primary G-CSF prophylaxis could be rationalized to reduced AEs and improve survival; more prospective studies are needed.	folfirinox	19-29	colony stimulating factor 3	Homo sapiens	47-52
33092501-0	2021	Evaluation of the Cardioprotective Effect of Granulocyte Colony Stimulating Factor in Patients with Carbon Monoxide Poisoning.	Carbon Monoxide	100-115	colony stimulating factor 3	Homo sapiens	45-82
33092501-12	2021	CONCLUSION: GCSF could probably reduce CO-induced cardiac ischemia in patients with acute CO poisoning.	Carbon Monoxide	0-2	colony stimulating factor 3	Homo sapiens	12-16
32755990-11	2020	DHT pre-treatment significantly decreased IFNgamma-induced expression of HLA-DR, mRNA expression of iNOS, COX2 and MCP1, and secretion of IL1, IL2, IL5, IL6, MCP1 and GCSF.	Dihydrotestosterone	0-3	colony stimulating factor 3	Homo sapiens	167-171
32687956-10	2020	In combination with our previously established GCSF manufacturing train, the end-to-end continuous manufacturing process starting from inclusion bodies to unformulated PEG-GCSF drug substance was successfully run for 12 h. All attributes were found to be consistent over the period of operation with product purity > 99 % and high molecular weight impurities < 0.5 %.	Polyethylene Glycols	168-171	colony stimulating factor 3	Homo sapiens	47-51
31564240-12	2020	In addition, recombinant human granulocyte colony-stimulating factor + stromal cell-derived factor-1 promoted greater angiogenesis than atorvastatin or recombinant human granulocyte colony-stimulating factor alone and increased the expression of growth-associated protein-43, neuroglobin, and glial cell-derived neurotrophic factor, while decreasing the levels of cleaved caspase 3 in the brain after ischemic stroke.	atorvastatin	136-148	colony stimulating factor 3	Homo sapiens	31-68
31564240-13	2020	CONCLUSIONS: Combination therapy with recombinant human granulocyte colony-stimulating factor and stromal cell-derived factor-1 is more effective than atorvastatin or recombinant human granulocyte colony-stimulating factor alone in protecting against stroke-induced damage and could be an optimal therapeutic strategy for stroke.	atorvastatin	151-163	colony stimulating factor 3	Homo sapiens	56-93
33023630-9	2020	As previously reported, DEX or IgG alone significantly suppressed TNF-alpha-induced production of IL-6 and G-CSF and mRNA expression, but induction of those cytokines by IL-1 s (IL-1alpha and IL-1beta) was resistant to high-dose IgG.	Dexamethasone	24-27	colony stimulating factor 3	Homo sapiens	107-112
32761893-16	2020	Observed rates of FN >20% in TC and TCH in routine clinical practice should guide primary GCSF use in accordance with international guidelines.	thiocarbohydrazide	36-39	colony stimulating factor 3	Homo sapiens	90-94
33053936-6	2020	Besides aggressive nutrition, granulocyte colony stimulating factor, fecal microbiota transplantation, and plasma exchange appear promising therapies and provide a hope for steroid ineligible or steroid non-responsive patients.	Steroids	173-180	colony stimulating factor 3	Homo sapiens	30-67
32586769-2	2020	Although granulocyte colony-stimulating factor (G-CSF) supported cyclophosphamide (CY) is used as the pre-ASCT mobilization regimen, there is no consensus on the optimal dosage of CY.	Cyclophosphamide	65-81	colony stimulating factor 3	Homo sapiens	9-46
32499108-7	2020	RESULTS: Mobilization with ID - cyclophosphamide and G-CSF resulted in a significantly higher CD34+ peak mean on day 1 yield (119 CD34+ muL vs 67.3; p = 0.06) and in total average CD34+ yield (mean collection 10.6 x 106/kg vs 5.8 x 106/kg; p = 0.004) compared to patients mobilized with G-CSF and plerixafor.	Cyclophosphamide	32-48	colony stimulating factor 3	Homo sapiens	287-292
32586769-2	2020	Although granulocyte colony-stimulating factor (G-CSF) supported cyclophosphamide (CY) is used as the pre-ASCT mobilization regimen, there is no consensus on the optimal dosage of CY.	Cyclophosphamide	65-81	colony stimulating factor 3	Homo sapiens	48-53
32499108-7	2020	RESULTS: Mobilization with ID - cyclophosphamide and G-CSF resulted in a significantly higher CD34+ peak mean on day 1 yield (119 CD34+ muL vs 67.3; p = 0.06) and in total average CD34+ yield (mean collection 10.6 x 106/kg vs 5.8 x 106/kg; p = 0.004) compared to patients mobilized with G-CSF and plerixafor.	plerixafor	297-307	colony stimulating factor 3	Homo sapiens	53-58
32499108-12	2020	CONCLUSIONS: Our data demonstrate that in patients with multiple myeloma eligible for ASCT, a chemo-free mobilization with G-CSF and plerixafor on demand is associated with efficacy in PBSC collection and optimal safety profile with similar average costs when compared to a chemo-mobilization with ID - cyclophosphamide.	id - cyclophosphamide	298-319	colony stimulating factor 3	Homo sapiens	123-128
32996003-1	2020	PURPOSE: To understand the impact of methionine oxidation in GCSF on efficacy (neutrophil production/activation) and safety (biochemical and histopathological changes).	Methionine	37-47	colony stimulating factor 3	Homo sapiens	61-65
32996003-3	2020	Oxidation in GCSF was induced by H2O2 treatment and four samples were prepared: wtGCSF (no oxidation), MetO (1138), MetO (1,138,127) and MetO (1138,127,122).	Hydrogen Peroxide	33-37	colony stimulating factor 3	Homo sapiens	13-17
32996003-5	2020	In vivo pharmacodynamics examined changes in neutrophil production upon GCSF methionine oxidation, with the outcome correlated with the differential expression of genes implicated in the GCSF mediated neutrophil activation/ maturation.	Methionine	77-87	colony stimulating factor 3	Homo sapiens	72-76
32996003-9	2020	Role of Asp 110 in GCSF as the critical residue having adverse impact on efficacy in context of methionine oxidation has been elucidated.	Aspartic Acid	8-11	colony stimulating factor 3	Homo sapiens	19-23
32996003-9	2020	Role of Asp 110 in GCSF as the critical residue having adverse impact on efficacy in context of methionine oxidation has been elucidated.	Methionine	96-106	colony stimulating factor 3	Homo sapiens	19-23
32996003-11	2020	CONCLUSION: The data from the present study suggests that methionine oxidation in GCSF is a critical quality attribute that needs careful monitoring and control during commercial manufacturing and subsequent supply chain stages.	Methionine	58-68	colony stimulating factor 3	Homo sapiens	82-86
32973999-0	2020	G-CSF mediated neutrophil augmentation in a unique case of comorbid idiopathic Parkinson"s disease and treatment-resistant schizophrenia on clozapine.	Clozapine	140-149	colony stimulating factor 3	Homo sapiens	0-5
32973999-6	2020	Two doses of G-CSF led to a sustained increase in the neutrophil count, allowing the continuation of clozapine therapy in the 1 year of follow up.	Clozapine	101-110	colony stimulating factor 3	Homo sapiens	13-18
32938976-0	2020	Honey isomaltose contributes to the induction of granulocyte-colony stimulating factor (G-CSF) secretion in the intestinal epithelial cells following honey heating.	Isomaltose	6-16	colony stimulating factor 3	Homo sapiens	49-86
32973999-7	2020	This illustrates the potential for G-CSF to be used to facilitate clozapine use in a patient population not described previously.	Clozapine	66-75	colony stimulating factor 3	Homo sapiens	35-40
32938976-0	2020	Honey isomaltose contributes to the induction of granulocyte-colony stimulating factor (G-CSF) secretion in the intestinal epithelial cells following honey heating.	Isomaltose	6-16	colony stimulating factor 3	Homo sapiens	88-93
32973999-9	2020	We suggest that G-CSF might be considered as a treatment option in other cases where clozapine-associated neutropenia obstructs its use.	Clozapine	85-94	colony stimulating factor 3	Homo sapiens	16-21
32938976-12	2020	Since G-CSF is clinically used for cancer patients to accelerate their recovery from neutropenia following chemotherapy or accompanied with aplastic anemia, these findings indicate that honey which contains high level of isomaltose could improve immunosuppressive conditions when honey is heated, and that heated isomaltose might be of potential therapeutic use in patients with compromised immunity caused by chemotherapeutic agents.	Isomaltose	221-231	colony stimulating factor 3	Homo sapiens	6-11
32938976-12	2020	Since G-CSF is clinically used for cancer patients to accelerate their recovery from neutropenia following chemotherapy or accompanied with aplastic anemia, these findings indicate that honey which contains high level of isomaltose could improve immunosuppressive conditions when honey is heated, and that heated isomaltose might be of potential therapeutic use in patients with compromised immunity caused by chemotherapeutic agents.	Isomaltose	313-323	colony stimulating factor 3	Homo sapiens	6-11
32717620-0	2020	Review of conditioning regimens for haplo-identical donor transplants using post-transplant cyclophosphamide in recipients of G-CSF mobilised peripheral stem cell.	Cyclophosphamide	92-108	colony stimulating factor 3	Homo sapiens	126-131
32687266-1	2020	Eflapegrastim (Rolontis  ) is a novel, long-acting hematopoietic growth factor consisting of a recombinant human granulocyte-colony stimulating factor (rhG-CSF) analog conjugated to a human IgG4 Fc fragment via a short polyethylene glycol linker.	eflapegrastim	0-13	colony stimulating factor 3	Homo sapiens	113-150
32687266-1	2020	Eflapegrastim (Rolontis  ) is a novel, long-acting hematopoietic growth factor consisting of a recombinant human granulocyte-colony stimulating factor (rhG-CSF) analog conjugated to a human IgG4 Fc fragment via a short polyethylene glycol linker.	rolontis	15-23	colony stimulating factor 3	Homo sapiens	113-150
32437087-1	2020	Granulocyte colony-stimulating factor (G-CSF) stimulation of myeloid cells induced tyrosine-phosphorylation of cellular proteins.	Tyrosine	83-91	colony stimulating factor 3	Homo sapiens	0-37
32437087-1	2020	Granulocyte colony-stimulating factor (G-CSF) stimulation of myeloid cells induced tyrosine-phosphorylation of cellular proteins.	Tyrosine	83-91	colony stimulating factor 3	Homo sapiens	39-44
32437087-4	2020	In Gab3-overexpressed cells, the level of tyrosine phosphorylation of endogenous Gab2 by G-CSF stimulation was markedly down-regulated, while the phosphorylation of Gab3 was significantly enhanced.	Tyrosine	42-50	colony stimulating factor 3	Homo sapiens	89-94
32437087-6	2020	The G-CSF stimulation-dependent tyrosine phosphorylation of Gab3, the association of SHP2 to Gab3 and the following MAPK activation were prolonged in the Gab3-overexpressed cells, compared to the parental cells, where the binding of SHP2 to Gab2 protein and thereby the activation of MAPK were not sustained after G-CSF stimulation.	Tyrosine	32-40	colony stimulating factor 3	Homo sapiens	4-9
32687266-10	2020	The results demonstrate noninferior efficacy and comparable safety for eflapegrastim, at a lower G-CSF dose, vs pegfilgrastim.	eflapegrastim	71-84	colony stimulating factor 3	Homo sapiens	97-102
32871908-15	2020	OUTCOMES: DIP relapsed when the regimen of aclacinomycin + cytarabine + G-CSF + dasatinib regimen (G-CSF (400ug/day, day 1 to 15), cytarabine (30 mg/day, day 2 to 15), aclacinomycin (20 mg/day, day 2 to 5)and dasatinib (140 mg/day, continuously)) was given, and was recovered after treatment for AP was performed.	dip	10-13	colony stimulating factor 3	Homo sapiens	72-77
32871908-15	2020	OUTCOMES: DIP relapsed when the regimen of aclacinomycin + cytarabine + G-CSF + dasatinib regimen (G-CSF (400ug/day, day 1 to 15), cytarabine (30 mg/day, day 2 to 15), aclacinomycin (20 mg/day, day 2 to 5)and dasatinib (140 mg/day, continuously)) was given, and was recovered after treatment for AP was performed.	dip	10-13	colony stimulating factor 3	Homo sapiens	99-104
32294159-3	2020	Off-label use of empagliflozin in four GSD-Ib patients with incomplete response to granulocyte colony stimulating factor (GCSF) treatment decreased serum 1,5-anhydroglucitol and neutrophil 1,5-anhydroglucitol-6-phosphate levels within one month.	empagliflozin	17-30	colony stimulating factor 3	Homo sapiens	83-120
32294159-3	2020	Off-label use of empagliflozin in four GSD-Ib patients with incomplete response to granulocyte colony stimulating factor (GCSF) treatment decreased serum 1,5-anhydroglucitol and neutrophil 1,5-anhydroglucitol-6-phosphate levels within one month.	empagliflozin	17-30	colony stimulating factor 3	Homo sapiens	122-126
32294159-3	2020	Off-label use of empagliflozin in four GSD-Ib patients with incomplete response to granulocyte colony stimulating factor (GCSF) treatment decreased serum 1,5-anhydroglucitol and neutrophil 1,5-anhydroglucitol-6-phosphate levels within one month.	1,5-anhydroglucitol	154-173	colony stimulating factor 3	Homo sapiens	83-120
32838757-6	2020	Treatment with 20 mg empagliflozin per day resulted in normalisation of the neutrophil count and neutrophil function even after termination of G-CSF.	empagliflozin	21-34	colony stimulating factor 3	Homo sapiens	143-148
32294159-3	2020	Off-label use of empagliflozin in four GSD-Ib patients with incomplete response to granulocyte colony stimulating factor (GCSF) treatment decreased serum 1,5-anhydroglucitol and neutrophil 1,5-anhydroglucitol-6-phosphate levels within one month.	1,5-anhydroglucitol	154-173	colony stimulating factor 3	Homo sapiens	122-126
32294159-3	2020	Off-label use of empagliflozin in four GSD-Ib patients with incomplete response to granulocyte colony stimulating factor (GCSF) treatment decreased serum 1,5-anhydroglucitol and neutrophil 1,5-anhydroglucitol-6-phosphate levels within one month.	1,5-anhydroglucitol-6-phosphate	189-220	colony stimulating factor 3	Homo sapiens	83-120
32294159-3	2020	Off-label use of empagliflozin in four GSD-Ib patients with incomplete response to granulocyte colony stimulating factor (GCSF) treatment decreased serum 1,5-anhydroglucitol and neutrophil 1,5-anhydroglucitol-6-phosphate levels within one month.	1,5-anhydroglucitol-6-phosphate	189-220	colony stimulating factor 3	Homo sapiens	122-126
32855992-0	2020	A Case of Steroid-Responsive, COVID-19 Immune Reconstitution Inflammatory Syndrome Following the Use of Granulocyte Colony-Stimulating Factor.	Steroids	10-17	colony stimulating factor 3	Homo sapiens	104-141
32817981-8	2020	When controlling for neutropenia, G-CSF administration was associated with increased need for high oxygen supplementation and death (HR: 2.97, 95% CI: 1.06-8.28, P value: 0.038).	Oxygen	99-105	colony stimulating factor 3	Homo sapiens	34-39
32413454-1	2020	Poly(L-glutamic acid)-co-poly(ethylene glycol) block copolymers (PLE-PEG) are here investigated as polymers for conjugation to therapeutic proteins such as granulocyte colony stimulating factor (G-CSF) and human growth hormone (hGH).	poly(l-glutamic acid)-co-poly(ethylene glycol) block copolymers	0-63	colony stimulating factor 3	Homo sapiens	156-193
32413454-1	2020	Poly(L-glutamic acid)-co-poly(ethylene glycol) block copolymers (PLE-PEG) are here investigated as polymers for conjugation to therapeutic proteins such as granulocyte colony stimulating factor (G-CSF) and human growth hormone (hGH).	poly(l-glutamic acid)-co-poly(ethylene glycol) block copolymers	0-63	colony stimulating factor 3	Homo sapiens	195-200
32413454-1	2020	Poly(L-glutamic acid)-co-poly(ethylene glycol) block copolymers (PLE-PEG) are here investigated as polymers for conjugation to therapeutic proteins such as granulocyte colony stimulating factor (G-CSF) and human growth hormone (hGH).	ple-peg	65-72	colony stimulating factor 3	Homo sapiens	156-193
32413454-1	2020	Poly(L-glutamic acid)-co-poly(ethylene glycol) block copolymers (PLE-PEG) are here investigated as polymers for conjugation to therapeutic proteins such as granulocyte colony stimulating factor (G-CSF) and human growth hormone (hGH).	ple-peg	65-72	colony stimulating factor 3	Homo sapiens	195-200
32413454-3	2020	When PLE-PEG copolymers are selectively tethered to the N-terminus of G-CSF and hGH, they yield homogeneous monoconjugates that preserve the protein"s secondary structure.	ple-peg copolymers	5-23	colony stimulating factor 3	Homo sapiens	70-75
32476162-0	2020	Eflapegrastim, a Long-Acting Granulocyte-Colony Stimulating Factor for the Management of Chemotherapy-Induced Neutropenia: Results of a Phase III Trial.	eflapegrastim	0-13	colony stimulating factor 3	Homo sapiens	29-66
32793908-8	2020	TMPRSS2, inflammatory cytokines G-CSF, M- CSF, IL-1a, IL-6 and MCP-1 are suppressed by MEKi alone or in combination with remdesivir.	remdesivir	121-131	colony stimulating factor 3	Homo sapiens	32-37
32832175-6	2020	The cumulative dose of ritodrine hydrochloride was 2,610 mg. Ritodrine therapy was immediately stopped, and she was given an intravenous injection of antibiotics and granulocyte colony-stimulating factor.	Ritodrine	23-46	colony stimulating factor 3	Homo sapiens	166-203
32476162-1	2020	BACKGROUND: Eflapegrastim, a novel, long-acting recombinant human granulocyte-colony stimulating factor (rhG-CSF), consists of a rhG-CSF analog conjugated to a human immuglobulin G4 Fc fragment via a short polyethylene glycol linker.	eflapegrastim	12-25	colony stimulating factor 3	Homo sapiens	66-103
32476162-1	2020	BACKGROUND: Eflapegrastim, a novel, long-acting recombinant human granulocyte-colony stimulating factor (rhG-CSF), consists of a rhG-CSF analog conjugated to a human immuglobulin G4 Fc fragment via a short polyethylene glycol linker.	Polyethylene Glycols	206-225	colony stimulating factor 3	Homo sapiens	66-103
32476162-10	2020	CONCLUSION: These results demonstrate noninferiority and comparable safety for eflapegrastim at a lower G-CSF dose versus pegfilgrastim.	eflapegrastim	79-92	colony stimulating factor 3	Homo sapiens	104-109
32615949-10	2020	CONCLUSION: Collectively, the unique mechanism of etoposide with G-CSF-induced mobilization is associated with IL-8 secretion from the BMSCs, which is responsible for the enhanced proliferation and mobilization of HSCs in the bone marrow; this was not observed with mobilization using cyclophosphamide with G-CSF or G-CSF alone.	Etoposide	50-59	colony stimulating factor 3	Homo sapiens	65-70
32660451-11	2020	CONCLUSIONS: Clinicians should consider the patient"s risk of clinically significant ADRs and prophylactic granulocyte colony stimulating factor when selecting the starting dose of cabazitaxel for CRPC.	cabazitaxel	181-192	colony stimulating factor 3	Homo sapiens	107-144
32615949-5	2020	RESULTS: Retrospective analysis of the clinical data revealed that the etoposide with G-CSF mobilization group showed the highest yield of CD34+ cells and the lowest change in white blood cell counts during mobilization.	Etoposide	71-80	colony stimulating factor 3	Homo sapiens	86-91
32615949-9	2020	In animal studies, the etoposide with G-CSF mobilization group presented higher IL-8-related cytokine and MMP9 expression and lower SDF-1 expression in the BM, compared to the groups not treated with etoposide.	Etoposide	23-32	colony stimulating factor 3	Homo sapiens	38-43
32695401-1	2020	Advanced granulocyte colony-stimulating factor (G-CSF)-producing lung tumours are generally refractory to platinum-based chemotherapy and are associated with poor prognosis.	Platinum	106-114	colony stimulating factor 3	Homo sapiens	9-46
32695401-1	2020	Advanced granulocyte colony-stimulating factor (G-CSF)-producing lung tumours are generally refractory to platinum-based chemotherapy and are associated with poor prognosis.	Platinum	106-114	colony stimulating factor 3	Homo sapiens	48-53
32664488-2	2020	GCSF itself is also a multipotent cytokine that can modulate microribonucleic acid (microRNA) expression profiles in vitro.	microribonucleic acid	61-82	colony stimulating factor 3	Homo sapiens	0-4
32615949-9	2020	In animal studies, the etoposide with G-CSF mobilization group presented higher IL-8-related cytokine and MMP9 expression and lower SDF-1 expression in the BM, compared to the groups not treated with etoposide.	Etoposide	200-209	colony stimulating factor 3	Homo sapiens	38-43
32615949-10	2020	CONCLUSION: Collectively, the unique mechanism of etoposide with G-CSF-induced mobilization is associated with IL-8 secretion from the BMSCs, which is responsible for the enhanced proliferation and mobilization of HSCs in the bone marrow; this was not observed with mobilization using cyclophosphamide with G-CSF or G-CSF alone.	Etoposide	50-59	colony stimulating factor 3	Homo sapiens	307-312
32615949-10	2020	CONCLUSION: Collectively, the unique mechanism of etoposide with G-CSF-induced mobilization is associated with IL-8 secretion from the BMSCs, which is responsible for the enhanced proliferation and mobilization of HSCs in the bone marrow; this was not observed with mobilization using cyclophosphamide with G-CSF or G-CSF alone.	Etoposide	50-59	colony stimulating factor 3	Homo sapiens	307-312
32615949-10	2020	CONCLUSION: Collectively, the unique mechanism of etoposide with G-CSF-induced mobilization is associated with IL-8 secretion from the BMSCs, which is responsible for the enhanced proliferation and mobilization of HSCs in the bone marrow; this was not observed with mobilization using cyclophosphamide with G-CSF or G-CSF alone.	Cyclophosphamide	285-301	colony stimulating factor 3	Homo sapiens	65-70
32376372-1	2020	Pegfilgrastimis a recombinant PEGylated human granulocyte colony-stimulating factor (G-CSF) analog filgrastim (trade names Neulasta  or G-Lasta ) that stimulates the production of white blood cells (neutrophils).	pegfilgrastimis	0-15	colony stimulating factor 3	Homo sapiens	46-83
32345753-8	2020	In diabetic patients under pioglitazone therapy, HSPC mobilization after G-CSF was partially rescued.	Pioglitazone	27-39	colony stimulating factor 3	Homo sapiens	73-78
32376372-1	2020	Pegfilgrastimis a recombinant PEGylated human granulocyte colony-stimulating factor (G-CSF) analog filgrastim (trade names Neulasta  or G-Lasta ) that stimulates the production of white blood cells (neutrophils).	pegfilgrastimis	0-15	colony stimulating factor 3	Homo sapiens	85-90
32376372-1	2020	Pegfilgrastimis a recombinant PEGylated human granulocyte colony-stimulating factor (G-CSF) analog filgrastim (trade names Neulasta  or G-Lasta ) that stimulates the production of white blood cells (neutrophils).	g-lasta	136-143	colony stimulating factor 3	Homo sapiens	85-90
32324593-3	2020	Targeting tumor glutamine metabolism led to a decrease in CSF3 and hence recruitment of MDSCs as well immunogenic cell death leading to an increase in inflammatory tumor-associated macrophages (TAMs).	Glutamine	16-25	colony stimulating factor 3	Homo sapiens	58-62
31751735-7	2020	Based on these findings, intraperitoneally administered Fuchp may accelerate the recovery of white blood cells and neutrophils, in which its activity exceeded that of recombinant human granulocyte colony-stimulating factor (rhG-CSF).	fuchp	56-61	colony stimulating factor 3	Homo sapiens	185-222
32432145-0	2020	Granulocyte colony-stimulating factor-producing squamous cell carcinoma of the tongue exhibiting characteristic fluorine-18 deoxyglucose accumulation on positron emission tomography-computed tomography: A case report.	Fluorine	112-120	colony stimulating factor 3	Homo sapiens	0-37
31742349-8	2020	Furthermore, we show that the granulocyte colony-stimulating factor (G-CSF)/phosphatidylinositol 3-kinase (PI3K)/protein kinase B (Akt) pathway plays an important role in protecting granulosa cells from cisplatin-induced apoptosis.	Phosphatidylinositols	76-96	colony stimulating factor 3	Homo sapiens	30-67
31742349-8	2020	Furthermore, we show that the granulocyte colony-stimulating factor (G-CSF)/phosphatidylinositol 3-kinase (PI3K)/protein kinase B (Akt) pathway plays an important role in protecting granulosa cells from cisplatin-induced apoptosis.	Phosphatidylinositols	76-96	colony stimulating factor 3	Homo sapiens	69-74
31742349-8	2020	Furthermore, we show that the granulocyte colony-stimulating factor (G-CSF)/phosphatidylinositol 3-kinase (PI3K)/protein kinase B (Akt) pathway plays an important role in protecting granulosa cells from cisplatin-induced apoptosis.	Cisplatin	203-212	colony stimulating factor 3	Homo sapiens	30-67
31742349-8	2020	Furthermore, we show that the granulocyte colony-stimulating factor (G-CSF)/phosphatidylinositol 3-kinase (PI3K)/protein kinase B (Akt) pathway plays an important role in protecting granulosa cells from cisplatin-induced apoptosis.	Cisplatin	203-212	colony stimulating factor 3	Homo sapiens	69-74
32014363-7	2020	In G-CSF + cyclophosphamide method median PFS was 15.4 +- 4.9 months wheras it was only 4 months in G-CSF + plerixafor method.	plerixafor	108-118	colony stimulating factor 3	Homo sapiens	3-8
32432145-0	2020	Granulocyte colony-stimulating factor-producing squamous cell carcinoma of the tongue exhibiting characteristic fluorine-18 deoxyglucose accumulation on positron emission tomography-computed tomography: A case report.	Deoxyglucose	124-136	colony stimulating factor 3	Homo sapiens	0-37
32432145-2	2020	We report a rare case of aggressive G-CSF-producing squamous cell carcinoma of the tongue exhibiting fluorine-18 deoxyglucose (FDG) accumulation in primary lesion, metastatic lymph nodes, spleen, and bone marrow on positron emission tomography-computed tomography (PET/CT).	fluorine-18 deoxyglucose	101-125	colony stimulating factor 3	Homo sapiens	36-41
32432145-2	2020	We report a rare case of aggressive G-CSF-producing squamous cell carcinoma of the tongue exhibiting fluorine-18 deoxyglucose (FDG) accumulation in primary lesion, metastatic lymph nodes, spleen, and bone marrow on positron emission tomography-computed tomography (PET/CT).	fluorescein-digalactoside	127-130	colony stimulating factor 3	Homo sapiens	36-41
32432145-8	2020	This is a rare case of G-CSF producing tongue carcinoma with elevated FDG accumulation in the spleen and bone marrow.	fluorescein-digalactoside	70-73	colony stimulating factor 3	Homo sapiens	23-28
32432145-9	2020	CONCLUSION: In patients with the tongue cancer and hyperleukocytosis, where FDG accumulations in the spleen and bone marrow are observed using PET/CT and when these accumulations are not caused by metastasis, G-CSF-producing tumors, with associated poor prognosis, should be considered.	fluorescein-digalactoside	76-79	colony stimulating factor 3	Homo sapiens	209-214
32276997-3	2020	We present a case of an atraumatic idiopathic splenic rupture in University Hospital, Ayr in a patient who received G-CSF treatment for chemotherapy-induced (methotrexate) pancytopenia and was successfully managed by laparoscopic splenectomy.	Methotrexate	158-170	colony stimulating factor 3	Homo sapiens	116-121
31896762-3	2020	Higher DMPA levels were associated with reduced CVL concentrations of GCSF, MCSF, IL-16, CTACK, LIF, IL-1alpha, and SCGF-beta in adjusted linear mixed models.	N,N-dimethyl-4-anisidine	7-11	colony stimulating factor 3	Homo sapiens	70-74
32411715-5	2020	However, we found that G-CSF does not prime PMNs toward NETs formation, but increases the serum concentration of cell-free DNA, proteases like neutrophils elastase and myeloperoxidase, and reactive oxygen species.	Oxygen	198-204	colony stimulating factor 3	Homo sapiens	23-28
31837586-8	2020	In these assays, impairment in ATM-related DNA damage response following acetaminophen toxicity was ameliorated by selected growth factors, including fibroblast growth factors, granulocyte colony stimulating factor and vascular endothelial growth factor.	Acetaminophen	73-86	colony stimulating factor 3	Homo sapiens	177-214
32292576-6	2020	Injection of Mobilan induced signs of self-resolving inflammation not present in placebo-injected patients, including transient elevation of PSA and cytokine (G-CSF, IL-6) levels, and increased lymphoid infiltration in prostate tissue.	Indomethacin	13-20	colony stimulating factor 3	Homo sapiens	159-164
32227252-4	2020	G-CSF was expressed by E. coli BL21 (DE3) through IPTG induction, followed by its purification using pH optimization on a chitin column.	Isopropyl Thiogalactoside	50-54	colony stimulating factor 3	Homo sapiens	0-5
32463914-0	2020	Severe clozapine-induced agranulocytosis: successful treatment with G-CSF and rechallenge of clozapine plus D2 potentiation therapy (amisulpride).	Clozapine	7-16	colony stimulating factor 3	Homo sapiens	68-73
32189927-16	2020	Conclusion: Survival in DC was shorter than what was expected in the natural history of the disease after GCSF use.	Deoxycytidine	24-26	colony stimulating factor 3	Homo sapiens	106-110
31836387-5	2020	Eukaryotic transcriptome sequencing and western blot analysis demonstrated that 1,3-DCQA binds to 14-3-3tau to prevent breast cancer proliferation and metastasis via Jak/PI3K/Akt and Raf/ERK pathway, which promote IL6 and CSF3 expression raised by CREB (CREBBP, CREB5) and induced cell apoptosis via Bad/Bax/caspase 9 signaling pathway.	3,5-dicaffeoylquinic acid	80-88	colony stimulating factor 3	Homo sapiens	222-226
32020764-2	2020	Pegylated recombinant human granulocyte colony-stimulating factor (PEG-rhG-CSF) is widely used for primary or secondary prophylaxis of febrile neutropenia (FN) in chemotherapy.	pentaerythritol poly(ethylene glycol) ether tetrasuccinimidyl glutarate	67-70	colony stimulating factor 3	Homo sapiens	28-65
32051346-2	2020	Through RNA sequencing analysis of transcriptomes of human airway smooth muscle cells treated with IL-17A, dexamethasone (DEX, a synthetic glucocorticoid drug), alone or in combination, we identified a group of genes that are synergistically induced by IL-17A and DEX, including the neutrophil-promoting cytokine CSF3.	Dexamethasone	107-120	colony stimulating factor 3	Homo sapiens	313-317
32051346-2	2020	Through RNA sequencing analysis of transcriptomes of human airway smooth muscle cells treated with IL-17A, dexamethasone (DEX, a synthetic glucocorticoid drug), alone or in combination, we identified a group of genes that are synergistically induced by IL-17A and DEX, including the neutrophil-promoting cytokine CSF3.	Dexamethasone	122-125	colony stimulating factor 3	Homo sapiens	313-317
32051346-2	2020	Through RNA sequencing analysis of transcriptomes of human airway smooth muscle cells treated with IL-17A, dexamethasone (DEX, a synthetic glucocorticoid drug), alone or in combination, we identified a group of genes that are synergistically induced by IL-17A and DEX, including the neutrophil-promoting cytokine CSF3.	Dexamethasone	264-267	colony stimulating factor 3	Homo sapiens	313-317
32051346-3	2020	In type-17 (Th17/IL-17Ahi) preclinical models of neutrophilic severe asthma (acute and chronic) and COPD, although DEX treatment was able to reduce the expression of neutrophil-mobilizing CXCL1 and CXCL2 in lung tissue, CSF3 expression was upregulated by DEX treatment.	Dexamethasone	115-118	colony stimulating factor 3	Homo sapiens	220-224
32051346-5	2020	Disruption of the IL-17A/DEX synergy by IL-17A inhibition with anti-IL-17A mAb or cyanidin-3-glucoside (C3G, a small-molecule IL-17A blocker) or depletion of CSF3 effectively rendered DEX sensitivity in type-17 preclinical models of neutrophilic airway diseases.	Dexamethasone	25-28	colony stimulating factor 3	Homo sapiens	158-162
30314715-0	2020	Continuing clozapine despite recurrent neutropenia: A 8 year follow-up case report with granulocyte-colony stimulating factor as-required use.	Clozapine	11-20	colony stimulating factor 3	Homo sapiens	88-125
32148519-6	2020	Herein, microarray-based transcriptomic analysis shows that G-CSF stimulation in vitro results in modulation of various signaling pathways including ones related with the metabolism of hyaluronan (HA), conferring a profile of cell mobilization to ADSCs, mediated in a cell-intrinsic fashion in part by reducing CD44 expression and HA synthesis-related genes.	Hyaluronic Acid	185-195	colony stimulating factor 3	Homo sapiens	60-65
31836387-5	2020	Eukaryotic transcriptome sequencing and western blot analysis demonstrated that 1,3-DCQA binds to 14-3-3tau to prevent breast cancer proliferation and metastasis via Jak/PI3K/Akt and Raf/ERK pathway, which promote IL6 and CSF3 expression raised by CREB (CREBBP, CREB5) and induced cell apoptosis via Bad/Bax/caspase 9 signaling pathway.	interferon tau	98-107	colony stimulating factor 3	Homo sapiens	222-226
31814585-0	2019	Chemotherapy-induced febrile neutropenia: primary G-CSF prophylaxis indicated during docetaxel cycles.	Docetaxel	85-94	colony stimulating factor 3	Homo sapiens	50-55
31982939-9	2020	In contrast, human neutrophils strongly responded to G-CSF stimulation resulting also in a higher response to PMA + G-CSF stimulation.	Tetradecanoylphorbol Acetate	110-113	colony stimulating factor 3	Homo sapiens	53-58
31982939-9	2020	In contrast, human neutrophils strongly responded to G-CSF stimulation resulting also in a higher response to PMA + G-CSF stimulation.	Tetradecanoylphorbol Acetate	110-113	colony stimulating factor 3	Homo sapiens	116-121
32879214-5	2020	In this study, we found that Pegfilgrastim (PEG-G-CSF, the PEGylated form of the recombinant human granulocyte colony-stimulating factor) induced anti-PEG IgM in mice when administered via either intravenous or subcutaneous administration.	Polyethylene Glycols	44-47	colony stimulating factor 3	Homo sapiens	48-53
32879214-5	2020	In this study, we found that Pegfilgrastim (PEG-G-CSF, the PEGylated form of the recombinant human granulocyte colony-stimulating factor) induced anti-PEG IgM in mice when administered via either intravenous or subcutaneous administration.	Polyethylene Glycols	44-47	colony stimulating factor 3	Homo sapiens	99-136
31906232-5	2019	RESULTS: G-CSF treatment increased the concentration of cells expressing Foxp3, specific marker for Tregs, in the decidua, whereas in no treated RPL a reduction of these cells was found when compared to controls.	tregs	100-105	colony stimulating factor 3	Homo sapiens	9-14
30648524-9	2020	CCL20, CSF3, and WNT16 increased after celecoxib (by 7%, 9% and 9%, respectively, P<0.05), but these serum proteins were no longer statistically significant after controlling for multiple testing.	Celecoxib	39-48	colony stimulating factor 3	Homo sapiens	7-11
31376324-11	2020	Also, purification conditions (DTT and existence of extra cysteine) had a significant effect on the stability and functionality of the produced G-CSF.	Dithiothreitol	31-34	colony stimulating factor 3	Homo sapiens	144-149
31376324-11	2020	Also, purification conditions (DTT and existence of extra cysteine) had a significant effect on the stability and functionality of the produced G-CSF.	Cysteine	58-66	colony stimulating factor 3	Homo sapiens	144-149
31566813-2	2019	Plerixafor, a strong inducer and mobilizer of HPCs, can be used as an adjunct to G-CSF to improve mobilization efficiency.	plerixafor	0-10	colony stimulating factor 3	Homo sapiens	81-86
31814585-9	2019	CONCLUSIONS: In breast cancer treatment, compared to other frequently-used agents, monotherapy with docetaxel (100 mg/m2) renders a substantial risk of FN (20.9%), thereby justifying the use of primary G-CSF according to international guidelines.	Docetaxel	100-109	colony stimulating factor 3	Homo sapiens	202-207
31814588-0	2019	Primary G-CSF prophylaxis following docetaxel treatment.	docetaxel	36-45	colony stimulating factor 3	Homo sapiens	8-13
31607567-5	2019	We found that a rapid, 2-h regimen of a single oral dose of Viagra (sildenafil citrate) combined with a single injection of the CXCR4 antagonist AMD3100 leads to efficient HSC mobilization at levels rivaling the standard-of-care 5-day regimen of granulocyte-colony stimulating factor (G-CSF/Filgrastim/Neupogen).	sildenafil	68-86	colony stimulating factor 3	Homo sapiens	246-283
31827384-11	2019	A significant but temporal decrease was detected in basic FGF, G-CSF, and GM-CSF at week four of fluoxetine administration.	Fluoxetine	97-107	colony stimulating factor 3	Homo sapiens	63-68
31607567-5	2019	We found that a rapid, 2-h regimen of a single oral dose of Viagra (sildenafil citrate) combined with a single injection of the CXCR4 antagonist AMD3100 leads to efficient HSC mobilization at levels rivaling the standard-of-care 5-day regimen of granulocyte-colony stimulating factor (G-CSF/Filgrastim/Neupogen).	sildenafil	68-86	colony stimulating factor 3	Homo sapiens	285-290
31502114-0	2019	Prophylactic administration of granulocyte colony-stimulating factor in epirubicin and cyclophosphamide chemotherapy for Japanese breast cancer patients: a retrospective study.	Epirubicin	72-82	colony stimulating factor 3	Homo sapiens	31-68
31502114-0	2019	Prophylactic administration of granulocyte colony-stimulating factor in epirubicin and cyclophosphamide chemotherapy for Japanese breast cancer patients: a retrospective study.	Cyclophosphamide	87-103	colony stimulating factor 3	Homo sapiens	31-68
31505087-12	2019	This analysis revealed important amrubicin pharmacokinetic-pharmacodynamic covariates and provided useful information to predict patients who would require prophylactic granulocyte colony stimulating factor.	amrubicin	33-42	colony stimulating factor 3	Homo sapiens	169-206
31377467-10	2019	Minocycline inhibited IL-6 and granulocyte colony-stimulating factor (G-CSF) in plasma and TNF in the cerebellum.	Minocycline	0-11	colony stimulating factor 3	Homo sapiens	31-68
31377467-10	2019	Minocycline inhibited IL-6 and granulocyte colony-stimulating factor (G-CSF) in plasma and TNF in the cerebellum.	Minocycline	0-11	colony stimulating factor 3	Homo sapiens	70-75
31410140-11	2019	Compared with sequential treatment with azithromycin alone, pidotimod combined with azithromycin significantly reduced the expression levels of IL-10 and G-CSF in serum of children with mycoplasma pneumonia, improved the curative effect and reduced the occurrence of adverse reactions, which has high application value in clinic.	Azithromycin	84-96	colony stimulating factor 3	Homo sapiens	154-159
31358485-2	2019	We hypothesized that administration of BTZ at peak G-CSF mobilization in patients with multiple myeloma (MM) would be safe, augment mobilization, and have an in vivo purging effect on circulating myeloma cells.	Bortezomib	39-42	colony stimulating factor 3	Homo sapiens	51-56
31358485-11	2019	Median peripheral blood CD34+ cells at day 4 before BTZ administration was 16 per microliter and 15 hours later was 32 per microliter suggesting that administration of BTZ at peak G-CSF mobilization augments the mobilization effect of G-CSF.	Bortezomib	168-171	colony stimulating factor 3	Homo sapiens	180-185
31358485-11	2019	Median peripheral blood CD34+ cells at day 4 before BTZ administration was 16 per microliter and 15 hours later was 32 per microliter suggesting that administration of BTZ at peak G-CSF mobilization augments the mobilization effect of G-CSF.	Bortezomib	168-171	colony stimulating factor 3	Homo sapiens	235-240
31358485-14	2019	CONCLUSION: Administration of 1 dose of BTZ at peak G-CSF mobilization was safe and well tolerated, enhanced stem cell mobilization, and did not affect graft viability.	Bortezomib	40-43	colony stimulating factor 3	Homo sapiens	52-57
31358485-15	2019	The mobilization effect of BTZ at peak G-CSF mobilization shown in this phase I study needs to be confirmed in a larger randomized trial.	Bortezomib	27-30	colony stimulating factor 3	Homo sapiens	39-44
31481121-3	2019	METHODS: We extended our prospective study in patients treated with low-dose PTCy (14.5 mg/kg on days 3 and 4) in ATG/granulocyte colony-stimulating factor (G-CSF)-based regimen and compared the results to the contemporary cohort of patients without low-dose PTCy (ATG cohort).	ptcy	77-81	colony stimulating factor 3	Homo sapiens	114-155
31481121-3	2019	METHODS: We extended our prospective study in patients treated with low-dose PTCy (14.5 mg/kg on days 3 and 4) in ATG/granulocyte colony-stimulating factor (G-CSF)-based regimen and compared the results to the contemporary cohort of patients without low-dose PTCy (ATG cohort).	ptcy	77-81	colony stimulating factor 3	Homo sapiens	157-162
31090035-8	2019	In conclusion, although the number of reported cases is limited, there appears to be an association between arteritis and the administration of G-CSF, and steroids are an effective therapeutic option.	Steroids	155-163	colony stimulating factor 3	Homo sapiens	144-149
30664267-0	2019	Efficacy of Granulocyte Colony-stimulating Factor in the Management of Steroid-Nonresponsive Severe Alcoholic Hepatitis: A Double-Blind Randomized Controlled Trial.	Steroids	71-78	colony stimulating factor 3	Homo sapiens	12-49
30664267-3	2019	We assessed the efficacy and safety of granulocyte colony-stimulating factor (G-CSF) in steroid nonresponders.	Steroids	88-95	colony stimulating factor 3	Homo sapiens	39-76
30664267-3	2019	We assessed the efficacy and safety of granulocyte colony-stimulating factor (G-CSF) in steroid nonresponders.	Steroids	88-95	colony stimulating factor 3	Homo sapiens	78-83
31522450-9	2019	The purity of G-CSF isoforms was confirmed by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) and they were clearly detected in western blot analysis using anti-G-CSF polyclonal antibody.	Sodium Dodecyl Sulfate	46-68	colony stimulating factor 3	Homo sapiens	14-19
31567972-7	2019	Combined therapy with 5-ASA + Adalimumab led to the strongest changes in marker modulation: IL-4, IL-5, IL-15, and PDGF-BB, were upregulated (P &lt; .05).Elevated serum levels of G-CSF, IL-1Ra, and PDGF-BB were associated with IBD endoscopic activity, and of IP-10 with extraintestinal manifestations of IBD.	Mesalamine	22-27	colony stimulating factor 3	Homo sapiens	179-184
31507324-0	2019	Decitabine-containing G-CSF priming regimen overcomes resistance of primary mediastinal neoplasm from early T-cell precursors to conventional chemotherapy: a case report.	Decitabine	0-10	colony stimulating factor 3	Homo sapiens	22-27
31522450-9	2019	The purity of G-CSF isoforms was confirmed by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) and they were clearly detected in western blot analysis using anti-G-CSF polyclonal antibody.	polyacrylamide	69-83	colony stimulating factor 3	Homo sapiens	14-19
31522450-9	2019	The purity of G-CSF isoforms was confirmed by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) and they were clearly detected in western blot analysis using anti-G-CSF polyclonal antibody.	Sodium Dodecyl Sulfate	105-108	colony stimulating factor 3	Homo sapiens	14-19
31269977-12	2019	CONCLUSIONS: Chronic MTX poisoning is more serious than acute toxicity and accompanies higher dermatologic, hematologic, and hepatic complications necessitating more aggressive treatments including administration of higher doses of leucovorin or bone marrow stimulants such as G-CSF.	Methotrexate	21-24	colony stimulating factor 3	Homo sapiens	277-282
31363366-1	2019	Plerixafor in combination granulocyte-colony stimulating factor (G-CSF) has been used for the mobilization of hematopoietic stem cells (HSCs) to the peripheral blood for collection and subsequent autologous transplantation in patients with non-Hodgkin lymphoma (NHL) and multiple myeloma (MM).	plerixafor	0-10	colony stimulating factor 3	Homo sapiens	65-70
30547304-9	2019	Additionally, the therapeutic use of granulocyte-colony stimulating factor was 6.3% (5/80) of cases in the GRNX group and 17.9% (10/56) of cases in the MFLX group (P = 0.0498).	Moxifloxacin	152-156	colony stimulating factor 3	Homo sapiens	37-74
31138020-8	2019	Indexed late gadolinium enhancement significantly decreased in G-CSF group only (P=0.04).	Gadolinium	13-23	colony stimulating factor 3	Homo sapiens	63-68
31115604-2	2019	Herein, we aimed to improve the effect of CAG [Ara-C, ACR, and G-CSF (granulocyte colony-stimulating factor)] regimen for acute monocytic leukemia by replacing G-CSF with GM-CSF.	GUANOSINE 5'-TRIPHOSPHATE P3-[1-(2-NITROPHENYL)ETHYL ESTER]	42-45	colony stimulating factor 3	Homo sapiens	63-68
31115604-2	2019	Herein, we aimed to improve the effect of CAG [Ara-C, ACR, and G-CSF (granulocyte colony-stimulating factor)] regimen for acute monocytic leukemia by replacing G-CSF with GM-CSF.	GUANOSINE 5'-TRIPHOSPHATE P3-[1-(2-NITROPHENYL)ETHYL ESTER]	42-45	colony stimulating factor 3	Homo sapiens	70-107
31115604-2	2019	Herein, we aimed to improve the effect of CAG [Ara-C, ACR, and G-CSF (granulocyte colony-stimulating factor)] regimen for acute monocytic leukemia by replacing G-CSF with GM-CSF.	GUANOSINE 5'-TRIPHOSPHATE P3-[1-(2-NITROPHENYL)ETHYL ESTER]	42-45	colony stimulating factor 3	Homo sapiens	160-165
30996164-0	2019	Clinical Safety and Efficacy of Secondary Prophylactic Pegylated G-CSF in Advanced Pancreatic Cancer Patients Treated with mFOLFIRINOX: A Single-center Retrospective Study.	mfolfirinox	123-134	colony stimulating factor 3	Homo sapiens	65-70
31137171-11	2019	With G-CSF support, epirubicin 85-90 mg/m(2) is appropriate tolerance dose for Chinese early breast cancer patients with high recurrence risk.	Epirubicin	20-30	colony stimulating factor 3	Homo sapiens	5-10
30989487-0	2019	Successful hematopoietic stem-cell mobilization with plerixafor plus granulocyte-colony stimulating factor in multiple myeloma patients treated with pomalidomide.	pomalidomide	149-161	colony stimulating factor 3	Homo sapiens	69-106
30989487-4	2019	Here, we report the two cases in which hematopoietic stem cells were mobilized using plerixafor plus granulocyte-colony stimulating factor after exposure to lenalidomide and pomalidomide.	Lenalidomide	157-169	colony stimulating factor 3	Homo sapiens	101-138
30989487-4	2019	Here, we report the two cases in which hematopoietic stem cells were mobilized using plerixafor plus granulocyte-colony stimulating factor after exposure to lenalidomide and pomalidomide.	pomalidomide	174-186	colony stimulating factor 3	Homo sapiens	101-138
31303761-1	2019	Purpose: The chemotherapeutic regimen DCAG (decitabine with cytarabine, aclarubicin hydrochloride, and granulocyte colony-stimulating factor) is effective for elderly patients with acute myeloid leukemia, but recommendations for young patients remain controversial.	dcag	38-42	colony stimulating factor 3	Homo sapiens	103-140
30871977-2	2019	The median peak CD34+ values after etoposide + G-CSF +- plerixafor was 54.07 CD34+/muL compared with 9.6 CD34+/muL after previous mobilization attempts (P < .001).	plerixafor	56-66	colony stimulating factor 3	Homo sapiens	47-52
30871977-6	2019	The most common grades 3 to 4 adverse events of etoposide + G-CSF +- plerixafor were febrile neutropenia (69.35%), mucositis (51.62%), and bacteremia (20.97%).	plerixafor	69-79	colony stimulating factor 3	Homo sapiens	60-65
31068249-7	2019	However, knockdown of cGAS and STING suppressed 29-kDa FN-f-induced expression of GM-CSF, G-CSF, and IFN-alpha together with the decreased activation of TANK-binding kinase 1 (TBK1), interferon regulatory factor 3 (IRF3), and inhibitor protein kappaBalpha (IkappaBalpha).	Fenofibrate	55-59	colony stimulating factor 3	Homo sapiens	90-95
30811242-0	2019	Oral loratadine in the management of G-CSF-induced bone pain: a pilot study.	Loratadine	5-15	colony stimulating factor 3	Homo sapiens	37-42
30998754-2	2019	In docetaxel (DOC)-based chemotherapy, the frequency of febrile neutropenia (FN) and the G-CSF dose administered varied greatly between studies.	Docetaxel	3-12	colony stimulating factor 3	Homo sapiens	89-94
30998754-2	2019	In docetaxel (DOC)-based chemotherapy, the frequency of febrile neutropenia (FN) and the G-CSF dose administered varied greatly between studies.	Docetaxel	14-17	colony stimulating factor 3	Homo sapiens	89-94
30450616-8	2019	In this study, microCols were used for improving the purification achieved for granulocyte colony stimulating factor (G-CSF) expressed using a cell-free CHO in vitro translation (IVT) system and were compared to a conventional 1 ml IMAC column.	CAV protocol	153-156	colony stimulating factor 3	Homo sapiens	118-123
30725360-0	2019	Phase II study of FLAGM (fludarabine + high-dose cytarabine + granulocyte colony-stimulating factor + mitoxantrone) for relapsed or refractory acute myeloid leukemia.	flagm	18-23	colony stimulating factor 3	Homo sapiens	62-99
30277120-8	2019	BPT occurred more often in patients receiving G-CSF (p = .03), particularly the poly-ethylenglycol-bound molecule.	bpt	0-3	colony stimulating factor 3	Homo sapiens	46-51
30277120-8	2019	BPT occurred more often in patients receiving G-CSF (p = .03), particularly the poly-ethylenglycol-bound molecule.	poly-ethylenglycol	80-98	colony stimulating factor 3	Homo sapiens	46-51
30979482-0	2019	Significance of Granulocyte Colony-Stimulating Factor-Combined High-Dose Cytarabine, Cyclophosphamide, and Total Body Irradiation in Allogeneic Hematopoietic Cell Transplantation for Myeloid Malignant Neoplasms.	Cytarabine	73-83	colony stimulating factor 3	Homo sapiens	16-53
30979482-9	2019	CONCLUSION: A G-CSF-combined HDCA/CY/TBI regimen is a promising conditioning in patients with myeloid malignant neoplasms who undergo not only CBT but also BMT or PBSCT.	Thioacetazone	37-40	colony stimulating factor 3	Homo sapiens	14-19
30811374-0	2019	Extended Requirement of Granulocyte Colony-Stimulating Factor for Clozapine-Associated Neutropenia.	Clozapine	66-75	colony stimulating factor 3	Homo sapiens	24-61
31149552-4	2019	Here, we present a case of a 77-year-old woman who underwent adjuvant chemotherapy (combined paclitaxel and carboplatin) for ovarian cancer, and then developed acute arteritis after receiving G-CSF.	Paclitaxel	93-103	colony stimulating factor 3	Homo sapiens	192-197
30633255-11	2019	As PA had the most stable fibre formation, it was chosen as a template to further incorporate stromal cell-derived factor-1 (SDF-1) and granulocyte colony-stimulating factor (G-CSF), and stimulate higher hMSC infiltration.	Protactinium	3-5	colony stimulating factor 3	Homo sapiens	136-173
30633255-11	2019	As PA had the most stable fibre formation, it was chosen as a template to further incorporate stromal cell-derived factor-1 (SDF-1) and granulocyte colony-stimulating factor (G-CSF), and stimulate higher hMSC infiltration.	Protactinium	3-5	colony stimulating factor 3	Homo sapiens	175-180
31149552-4	2019	Here, we present a case of a 77-year-old woman who underwent adjuvant chemotherapy (combined paclitaxel and carboplatin) for ovarian cancer, and then developed acute arteritis after receiving G-CSF.	Carboplatin	108-119	colony stimulating factor 3	Homo sapiens	192-197
29977015-3	2019	Here, we used a quantitative phospho-tyrosine analysis to generate a comprehensive signaling map of G-CSF induced tyrosine phosphorylation in the normal versus mutated (proximal: T618I and truncated: Q741x) G-CSFRs.	Tyrosine	37-45	colony stimulating factor 3	Homo sapiens	100-105
30428338-1	2019	Granulocyte colony-stimulating factor (G-CSF)-stimulated peripheral blood progenitor cells (G-PBs) from either a related or unrelated donor continue to be the preferred donor source for most allogeneic hematopoietic cell transplantation (HCT).	glycerol phenylbutyrate	92-97	colony stimulating factor 3	Homo sapiens	0-37
30428338-1	2019	Granulocyte colony-stimulating factor (G-CSF)-stimulated peripheral blood progenitor cells (G-PBs) from either a related or unrelated donor continue to be the preferred donor source for most allogeneic hematopoietic cell transplantation (HCT).	glycerol phenylbutyrate	92-97	colony stimulating factor 3	Homo sapiens	39-44
30428338-7	2019	We suggest that, based on the experience of the two Phase II clinical trials and the unique biology of plerixafor-mobilized donor product, it should be evaluated in Phase III trials as an approach to replacing G-CSF mobilization for allogeneic HCT.	plerixafor	103-113	colony stimulating factor 3	Homo sapiens	210-215
30565075-6	2019	The aim of this work was to design and produce DT-GCSF immunotoxin using truncated DT fused to G-CSF.	Thymidine	47-49	colony stimulating factor 3	Homo sapiens	50-54
30565075-6	2019	The aim of this work was to design and produce DT-GCSF immunotoxin using truncated DT fused to G-CSF.	Thymidine	47-49	colony stimulating factor 3	Homo sapiens	95-100
30565075-6	2019	The aim of this work was to design and produce DT-GCSF immunotoxin using truncated DT fused to G-CSF.	Thymidine	83-85	colony stimulating factor 3	Homo sapiens	50-54
30642286-9	2019	CONCLUSION: In conclusion, an intermediate dose of VP-16 with G-CSF appears to be an effective and tolerable chemo-mobilization method compared to CY and G-CSF, particularly in cases where use plerixafor in MM is difficult.	plerixafor	193-203	colony stimulating factor 3	Homo sapiens	62-67
31112940-3	2019	G-CSF/plerixafor and G-CSF/plerixafor/Bu+Flu modulated distinct signaling networks in AML blasts of patients undergoing conditioning with active disease compared to nonleukemic PB cells of patients in remission.	plerixafor	6-16	colony stimulating factor 3	Homo sapiens	0-5
31112940-3	2019	G-CSF/plerixafor and G-CSF/plerixafor/Bu+Flu modulated distinct signaling networks in AML blasts of patients undergoing conditioning with active disease compared to nonleukemic PB cells of patients in remission.	plerixafor	27-37	colony stimulating factor 3	Homo sapiens	21-26
30705914-0	2019	False Negativity of Tc-99m Labeled Sodium Phytate Bone Marrow Imaging Under the Effect of G-CSF Prescription in Aplastic Anemia: A Case Report.	tc-99	20-25	colony stimulating factor 3	Homo sapiens	90-95
30705914-0	2019	False Negativity of Tc-99m Labeled Sodium Phytate Bone Marrow Imaging Under the Effect of G-CSF Prescription in Aplastic Anemia: A Case Report.	Phytic Acid	35-49	colony stimulating factor 3	Homo sapiens	90-95
30705914-2	2019	We report a severe aplastic anemia (SAA) patient with false-negative 99mTc sodium phytate bone marrow imaging findings under concurrent G-CSF therapy.	saa	36-39	colony stimulating factor 3	Homo sapiens	136-141
30705914-2	2019	We report a severe aplastic anemia (SAA) patient with false-negative 99mTc sodium phytate bone marrow imaging findings under concurrent G-CSF therapy.	Phytic Acid	75-89	colony stimulating factor 3	Homo sapiens	136-141
30705914-8	2019	Consequently, it should be kept in mind that a 99mTc sodium phytate bone marrow scintigraphy during the concurrent administration of G-CSF may lead to the achievement of false negative results because it induces changes in bone marrow mimicking a normal marrow scan in patients with AA.	Phytic Acid	53-67	colony stimulating factor 3	Homo sapiens	133-138
30378501-4	2019	Granulocyte Colony-Stimulating Factor (G-CSF), is a hematopoietic cytokine that promotes proliferation and differentiation of neutrophils and is involved in cardiac repair after MI.	2-methyl-4-isothiazolin-3-one	178-180	colony stimulating factor 3	Homo sapiens	0-37
30378501-4	2019	Granulocyte Colony-Stimulating Factor (G-CSF), is a hematopoietic cytokine that promotes proliferation and differentiation of neutrophils and is involved in cardiac repair after MI.	2-methyl-4-isothiazolin-3-one	178-180	colony stimulating factor 3	Homo sapiens	39-44
30446275-13	2019	CONCLUSION: Non-pegylated liposomal doxorubicin-carboplatin combination exhibits an acceptable safety profile, with GCSF prophylaxis.	doxorubicin-carboplatin	36-59	colony stimulating factor 3	Homo sapiens	116-120
30266677-10	2019	ID-AraC with G-CSF should be the preferred chemomobilization protocol for patients with MM scheduled to undergo tandem autoSCT.	Cytarabine	3-7	colony stimulating factor 3	Homo sapiens	13-18
30679689-6	2019	In this study we investigated the role of ceramides in G-CSF signaling.	Ceramides	42-51	colony stimulating factor 3	Homo sapiens	55-60
30679689-8	2019	G-CSF also induces downregulation of ceramides in WT and CerS2 null BMCs, as well as upregulation of very long chain lactosylceramides.	Ceramides	37-46	colony stimulating factor 3	Homo sapiens	0-5
30679689-8	2019	G-CSF also induces downregulation of ceramides in WT and CerS2 null BMCs, as well as upregulation of very long chain lactosylceramides.	Lactosylceramides	117-134	colony stimulating factor 3	Homo sapiens	0-5
30679689-11	2019	In conclusion, very long chain ceramides are important for G-CSF signaling and translocation of G-CSF-R into DRMs.	Ceramides	31-40	colony stimulating factor 3	Homo sapiens	59-64
30661042-12	2019	At least in this case, the target of the clozapine injury appears to be the CFU-GM, explaining the rapid and full response to GM-CSF after lack of response to G-CSF.	Clozapine	41-50	colony stimulating factor 3	Homo sapiens	159-164
30451720-15	2019	In conjunction with other therapies (salicylates, mesalamine sulfasalazine and prednisone), G-CSF ameliorates inflammatory bowel symptoms, but doses must be limited because it increases spleen size associated with abdominal pain.	Salicylates	37-48	colony stimulating factor 3	Homo sapiens	92-97
30451720-15	2019	In conjunction with other therapies (salicylates, mesalamine sulfasalazine and prednisone), G-CSF ameliorates inflammatory bowel symptoms, but doses must be limited because it increases spleen size associated with abdominal pain.	mesalamine sulfasalazine	50-74	colony stimulating factor 3	Homo sapiens	92-97
30451720-15	2019	In conjunction with other therapies (salicylates, mesalamine sulfasalazine and prednisone), G-CSF ameliorates inflammatory bowel symptoms, but doses must be limited because it increases spleen size associated with abdominal pain.	Prednisone	79-89	colony stimulating factor 3	Homo sapiens	92-97
30828151-3	2019	Plerixafor is a potent mobilizer when used with G-CSF.	plerixafor	0-10	colony stimulating factor 3	Homo sapiens	48-53
29977015-3	2019	Here, we used a quantitative phospho-tyrosine analysis to generate a comprehensive signaling map of G-CSF induced tyrosine phosphorylation in the normal versus mutated (proximal: T618I and truncated: Q741x) G-CSFRs.	Tyrosine	114-122	colony stimulating factor 3	Homo sapiens	100-105
30859156-8	2018	The urinary free deoxypyridinoline level significantly increased on day 3 of G-CSF treatment (25.6+-6.5 nmol/mmol Cr) and significantly decreased after 7 days of G-CSF therapy (22.6+-6.4 nmol/mmol Cr) (p&lt;0.001 and p&lt;0.001, respectively), which was still significantly higher than the values recorded before G-CSF therapy (p&lt;0.001).	deoxypyridinoline	17-34	colony stimulating factor 3	Homo sapiens	77-82
31068511-4	2019	The use of plerixafor was determined according to the CD34+ cell count in the peripheral blood (PB CD34+) on day 4 of G-CSF administration and patients" backgrounds.	plerixafor	11-21	colony stimulating factor 3	Homo sapiens	118-123
30444537-8	2019	RESULTS: For the granulocyte-colony-stimulating factor plus dexamethasone (G-CSF/Dex)-stimulated group, both the granulocyte and the lymphocyte counts decreased 6.51 x 109 /L (-23.1%, p &lt; 0.001) and 0.21 x 109 /L (-20.4%, p &lt; 0.001), respectively, between Donation 1 and Donation 20.	Dexamethasone	60-73	colony stimulating factor 3	Homo sapiens	75-84
30577864-0	2018	Efficacy of granulocyte colony stimulating factor in patients with severe alcoholic hepatitis with partial or null response to steroid (GRACIAH trial): study protocol for a randomized controlled trial.	Steroids	127-134	colony stimulating factor 3	Homo sapiens	12-49
30859156-8	2018	The urinary free deoxypyridinoline level significantly increased on day 3 of G-CSF treatment (25.6+-6.5 nmol/mmol Cr) and significantly decreased after 7 days of G-CSF therapy (22.6+-6.4 nmol/mmol Cr) (p&lt;0.001 and p&lt;0.001, respectively), which was still significantly higher than the values recorded before G-CSF therapy (p&lt;0.001).	deoxypyridinoline	17-34	colony stimulating factor 3	Homo sapiens	162-167
30859156-8	2018	The urinary free deoxypyridinoline level significantly increased on day 3 of G-CSF treatment (25.6+-6.5 nmol/mmol Cr) and significantly decreased after 7 days of G-CSF therapy (22.6+-6.4 nmol/mmol Cr) (p&lt;0.001 and p&lt;0.001, respectively), which was still significantly higher than the values recorded before G-CSF therapy (p&lt;0.001).	deoxypyridinoline	17-34	colony stimulating factor 3	Homo sapiens	162-167
30859156-8	2018	The urinary free deoxypyridinoline level significantly increased on day 3 of G-CSF treatment (25.6+-6.5 nmol/mmol Cr) and significantly decreased after 7 days of G-CSF therapy (22.6+-6.4 nmol/mmol Cr) (p&lt;0.001 and p&lt;0.001, respectively), which was still significantly higher than the values recorded before G-CSF therapy (p&lt;0.001).	Chromium	114-116	colony stimulating factor 3	Homo sapiens	77-82
30343510-4	2018	Granulocyte-colony stimulating factor (G-CSF) is given to stimulate neutrophil proliferation after melphalan administration.	Melphalan	99-108	colony stimulating factor 3	Homo sapiens	0-37
29948238-1	2018	BACKGROUND: The efficacy of primary prophylactic granulocyte colony-stimulating factor (G-CSF) in preventing febrile neutropenia (FN) in patients treated with docetaxel, cisplatin, and 5-fluorouracil (TPF) chemotherapy remains controversial.	Docetaxel	159-168	colony stimulating factor 3	Homo sapiens	49-86
29948238-1	2018	BACKGROUND: The efficacy of primary prophylactic granulocyte colony-stimulating factor (G-CSF) in preventing febrile neutropenia (FN) in patients treated with docetaxel, cisplatin, and 5-fluorouracil (TPF) chemotherapy remains controversial.	Docetaxel	159-168	colony stimulating factor 3	Homo sapiens	88-93
29948238-1	2018	BACKGROUND: The efficacy of primary prophylactic granulocyte colony-stimulating factor (G-CSF) in preventing febrile neutropenia (FN) in patients treated with docetaxel, cisplatin, and 5-fluorouracil (TPF) chemotherapy remains controversial.	Cisplatin	170-179	colony stimulating factor 3	Homo sapiens	49-86
29948238-1	2018	BACKGROUND: The efficacy of primary prophylactic granulocyte colony-stimulating factor (G-CSF) in preventing febrile neutropenia (FN) in patients treated with docetaxel, cisplatin, and 5-fluorouracil (TPF) chemotherapy remains controversial.	Cisplatin	170-179	colony stimulating factor 3	Homo sapiens	88-93
29948238-1	2018	BACKGROUND: The efficacy of primary prophylactic granulocyte colony-stimulating factor (G-CSF) in preventing febrile neutropenia (FN) in patients treated with docetaxel, cisplatin, and 5-fluorouracil (TPF) chemotherapy remains controversial.	Fluorouracil	185-199	colony stimulating factor 3	Homo sapiens	49-86
29948238-1	2018	BACKGROUND: The efficacy of primary prophylactic granulocyte colony-stimulating factor (G-CSF) in preventing febrile neutropenia (FN) in patients treated with docetaxel, cisplatin, and 5-fluorouracil (TPF) chemotherapy remains controversial.	Fluorouracil	185-199	colony stimulating factor 3	Homo sapiens	88-93
29948238-1	2018	BACKGROUND: The efficacy of primary prophylactic granulocyte colony-stimulating factor (G-CSF) in preventing febrile neutropenia (FN) in patients treated with docetaxel, cisplatin, and 5-fluorouracil (TPF) chemotherapy remains controversial.	TPF	201-204	colony stimulating factor 3	Homo sapiens	49-86
29948238-1	2018	BACKGROUND: The efficacy of primary prophylactic granulocyte colony-stimulating factor (G-CSF) in preventing febrile neutropenia (FN) in patients treated with docetaxel, cisplatin, and 5-fluorouracil (TPF) chemotherapy remains controversial.	TPF	201-204	colony stimulating factor 3	Homo sapiens	88-93
30501709-3	2018	The patients in CTG group received treatment with Ara-C, THP and G-CSF; the patients received the treatment with decitabine plus CTG.	ctg	16-19	colony stimulating factor 3	Homo sapiens	65-70
29948957-5	2018	Neoadjuvant DDCT (adriamycin plus cyclophosphamide or epirubicin plus cyclophosphamide followed by paclitaxel) was administrated every 2 weeks with G-CSF support.	ddct	12-16	colony stimulating factor 3	Homo sapiens	148-153
30206044-0	2018	Docetaxel Plus RAmucirumab With Primary Prophylactic Pegylated Granulocyte-ColONy Stimulating Factor Support for Elderly Patients With Advanced Non-small-cell Lung Cancer: A Multicenter Prospective Single Arm Phase II Trial: DRAGON Study (WJOG9416L).	Docetaxel	0-9	colony stimulating factor 3	Homo sapiens	63-100
29706650-12	2018	Hence, G-CSF avoidance and corticosteroid"s prophylaxis decrease morbidity in patients undergoing PBSCT with MM treated with bortezomib/IMiDs.	Bortezomib	125-135	colony stimulating factor 3	Homo sapiens	7-12
29706650-12	2018	Hence, G-CSF avoidance and corticosteroid"s prophylaxis decrease morbidity in patients undergoing PBSCT with MM treated with bortezomib/IMiDs.	imids	136-141	colony stimulating factor 3	Homo sapiens	7-12
30410568-0	2018	Transient co-expression with three O-glycosylation enzymes allows production of GalNAc-O-glycosylated Granulocyte-Colony Stimulating Factor in N. benthamiana.	N-acetylgalactosaminuronic acid	80-86	colony stimulating factor 3	Homo sapiens	102-139
30343510-4	2018	Granulocyte-colony stimulating factor (G-CSF) is given to stimulate neutrophil proliferation after melphalan administration.	Melphalan	99-108	colony stimulating factor 3	Homo sapiens	39-44
30406037-8	2018	However, the levels of interleukins [IL-6, IL-10, granulocyte colony stimulating factor (GCSF), and transforming growth factor beta1 (TGFbeta1)] were higher in patients with AP-ALA, whereas in patients with R-ALA, higher levels of interferon gamma (IFNgamma) were detected.	ap-ala	174-180	colony stimulating factor 3	Homo sapiens	89-93
30322928-7	2018	Cytokine profiling of CRPC tumor grafts exposed to GSNO revealed a significant decrease in expression of G-CSF and M-CSF compared with grafts not exposed to GSNO.	S-Nitrosoglutathione	51-55	colony stimulating factor 3	Homo sapiens	105-110
29392707-1	2018	The aim of the study was to evaluate the quantitative relationship between duration of severe neutropenia (DSN, the efficacy endpoint) and area under effect curve of absolute neutrophil counts (ANC-AUEC, the pharmacodynamic endpoint), based on data from filgrastim products, a human granulocyte colony-stimulating factor (G-CSF).	D-serine	107-110	colony stimulating factor 3	Homo sapiens	283-320
30333315-12	2018	The ketoprofen recipients demonstrated reduced skin thickness, as well as improved composite measures of histopathology and decreased plasma granulocyte CSF (G-CSF) expression.	Ketoprofen	4-14	colony stimulating factor 3	Homo sapiens	153-163
30043207-1	2018	PURPOSE: To explore the efficacy and safety of daily administration of recombinant human granulocyte colony-stimulating factor (rhG-CSF), and a single subcutaneous injection of polyethylene glycol recombinant human granulocyte colony-stimulating factor (PEG-rhG-CSF, a sustained-duration rhG-CSF) in neutropenia induced after chemotherapy.	Polyethylene Glycols	177-196	colony stimulating factor 3	Homo sapiens	215-252
30017795-7	2018	In addition, patients with G-CSF application showed a significantly greater increase in CA27.29 levels after chemotherapy compared with patients without any G-CSF application during chemotherapy (Mann-Whitney U test; Z = -7.81, P &lt; .001).	ca27	88-92	colony stimulating factor 3	Homo sapiens	27-32
29392707-1	2018	The aim of the study was to evaluate the quantitative relationship between duration of severe neutropenia (DSN, the efficacy endpoint) and area under effect curve of absolute neutrophil counts (ANC-AUEC, the pharmacodynamic endpoint), based on data from filgrastim products, a human granulocyte colony-stimulating factor (G-CSF).	D-serine	107-110	colony stimulating factor 3	Homo sapiens	322-327
29983334-5	2018	Here, we show that primary human monocytes stimulated with Shiga toxin 1a (Stx1a) through the glycolipid receptor globotriaosylceramide released larger amounts of proinflammatory molecules (IL-1beta, TNFalpha, IL-6, G-CSF, CXCL8, CCL2, CCL4) than Stx1a-treated neutrophils.	globotriaosylceramide	114-135	colony stimulating factor 3	Homo sapiens	216-221
29572761-9	2018	A frequency of treatment delay greater than 7 and 14 days, G-CSF support, blood transfusion, and dose reduction or regimen change were also significantly reduced in the W-TC group.	w-tc	169-173	colony stimulating factor 3	Homo sapiens	59-64
30288389-12	2018	Conclusion: GM-CSF and G-CSF expression in the tumor lesions obtained by initial transurethral resection are independent predictors of poor outcome in MIBC after RC.	4-METHYL-2-PENTANOL	151-155	colony stimulating factor 3	Homo sapiens	23-28
30473962-0	2018	Temozolomide-induced Aplastic Anemia Treated with Eltrombopag and Granulocyte Colony Stimulating Factor: A Report of a Rare Complication.	Temozolomide	0-12	colony stimulating factor 3	Homo sapiens	66-103
30220167-1	2018	Objectives: To investigate the efficacy and safety of prophylactic use of pegylated recombinant human granulocyte colony-stimulating factor(PEG-rhG-CSF) in breast cancer receiving docetaxel as adjuvant chemotherapy.	Docetaxel	180-189	colony stimulating factor 3	Homo sapiens	102-151
30147373-3	2018	The aim of the present study was to investigate the expression and prognostic value of G-CSF in patients with PDAC.	pdac	110-114	colony stimulating factor 3	Homo sapiens	87-92
30147373-11	2018	Specifically, adjuvant chemotherapy consisting of gemcitabine prolongs survival of patients with high G-CSF expression (median survival time 14 months vs 7.5 months).	gemcitabine	50-61	colony stimulating factor 3	Homo sapiens	102-107
30127892-1	2018	The low-dose cytarabine, aclarubicin and granulocyte-colony stimulating factor (G-CSF) (CAG) priming regimen is an effective treatment for patients with relapsed or refractory acute myeloid leukemia (AML) and advanced myelodysplastic syndrome (MDS).	Cytarabine	13-23	colony stimulating factor 3	Homo sapiens	80-85
29963237-0	2018	Docetaxel plus ramucirumab with primary prophylactic pegylated-granulocyte-colony stimulating factor for pretreated non-small cell lung cancer.	Docetaxel	0-9	colony stimulating factor 3	Homo sapiens	63-100
29970577-6	2018	RESULTS: Serum G-CSF concentrations peaked in the second week of ddAC cases and in the ninth week of TC cases.	didecyldimethylammonium	65-69	colony stimulating factor 3	Homo sapiens	15-20
29970577-6	2018	RESULTS: Serum G-CSF concentrations peaked in the second week of ddAC cases and in the ninth week of TC cases.	Technetium	101-103	colony stimulating factor 3	Homo sapiens	15-20
30568355-5	2018	Patients in the intervention group received intrauterine perfusion of 300 mug (0.5 ml) of G-CSF on the day of ovulation trigger.	intrauterine	44-56	colony stimulating factor 3	Homo sapiens	90-95
30069023-4	2018	Using a elegant co-culture cellular system, we were able to prove that nutrients and oxygen deprivation activated non-malignant stromal fibroblasts, which in turn established with tumor cells a paracrine loop mediated by Interleukine-6 (IL-6), Activin-A and Granulocyte colony-stimulating factor (G-CSF), that drove subsequent tumor formation and cellular dedifferentiation.	Oxygen	85-91	colony stimulating factor 3	Homo sapiens	258-295
30069023-4	2018	Using a elegant co-culture cellular system, we were able to prove that nutrients and oxygen deprivation activated non-malignant stromal fibroblasts, which in turn established with tumor cells a paracrine loop mediated by Interleukine-6 (IL-6), Activin-A and Granulocyte colony-stimulating factor (G-CSF), that drove subsequent tumor formation and cellular dedifferentiation.	Oxygen	85-91	colony stimulating factor 3	Homo sapiens	297-302
29877199-9	2018	CONCLUSIONS: In this first randomized, large-scale clinical trial of G-CSF-mobilized PBMNC transplantation, the cell therapy was tolerated by a variety of PAD patients.	pbmnc	85-90	colony stimulating factor 3	Homo sapiens	69-74
29709093-7	2018	Magnesium sulfate administered 1-hour post-LPS inhibited FM secretion of IL-1beta, IL-6, G-CSF, RANTES, and TNFalpha.	Magnesium Sulfate	0-17	colony stimulating factor 3	Homo sapiens	89-94
29655274-0	2018	Granulocyte colony-stimulating factor-producing melanoma treated with the combination of dabrafenib and trametinib.	dabrafenib	89-99	colony stimulating factor 3	Homo sapiens	0-37
29655274-0	2018	Granulocyte colony-stimulating factor-producing melanoma treated with the combination of dabrafenib and trametinib.	trametinib	104-114	colony stimulating factor 3	Homo sapiens	0-37
29963237-1	2018	Purpose: The aim of our study was to evaluate the efficacy and safety of docetaxel plus ramucirumab with primary prophylactic pegylated (PEG)-granulocyte-colony stimulating factor (G-CSF) for pretreated non-small cell lung cancer (NSCLC).	Docetaxel	73-82	colony stimulating factor 3	Homo sapiens	142-179
29963237-1	2018	Purpose: The aim of our study was to evaluate the efficacy and safety of docetaxel plus ramucirumab with primary prophylactic pegylated (PEG)-granulocyte-colony stimulating factor (G-CSF) for pretreated non-small cell lung cancer (NSCLC).	Docetaxel	73-82	colony stimulating factor 3	Homo sapiens	181-186
29963237-1	2018	Purpose: The aim of our study was to evaluate the efficacy and safety of docetaxel plus ramucirumab with primary prophylactic pegylated (PEG)-granulocyte-colony stimulating factor (G-CSF) for pretreated non-small cell lung cancer (NSCLC).	Polyethylene Glycols	137-140	colony stimulating factor 3	Homo sapiens	142-179
29963237-1	2018	Purpose: The aim of our study was to evaluate the efficacy and safety of docetaxel plus ramucirumab with primary prophylactic pegylated (PEG)-granulocyte-colony stimulating factor (G-CSF) for pretreated non-small cell lung cancer (NSCLC).	Polyethylene Glycols	137-140	colony stimulating factor 3	Homo sapiens	181-186
29963237-13	2018	Conclusions: Our study demonstrated the efficacy and safety of docetaxel plus ramucirumab with PEG-G-CSF in clinical practice.	Docetaxel	63-72	colony stimulating factor 3	Homo sapiens	99-104
29963237-13	2018	Conclusions: Our study demonstrated the efficacy and safety of docetaxel plus ramucirumab with PEG-G-CSF in clinical practice.	Polyethylene Glycols	95-98	colony stimulating factor 3	Homo sapiens	99-104
29567938-11	2018	Higher G-CSF expression was associated with later tumor stages and higher tumor VEGF-A and serum CA724 levels, whereas higher G-CSFR expression was associated with lymph node metastasis.	ca724	97-102	colony stimulating factor 3	Homo sapiens	7-12
31149526-6	2018	Diffuse fluorodeoxyglucose uptake in the long bones and marked leukocytosis suggested that the G-CSF was produced by the primary tumor, which showed upregulated G-CSF mRNA and protein levels.	Fluorodeoxyglucose F18	8-26	colony stimulating factor 3	Homo sapiens	95-100
29392425-2	2018	The Programa Espanol de Tratamientos en Hematologia (PETHEMA) group designed a phase I-II trial using FLAG-Ida (fludarabine, idarubicin, cytarabine, and G-CSF) plus high-dose intravenous plerixafor, a molecule inducing mobilization of blasts through the SDF-1alpha-CXCR4 axis blockade and potentially leading to chemosensitization of the leukemic cells.	programa espanol	4-20	colony stimulating factor 3	Homo sapiens	153-158
29721176-7	2018	Conclusions: On the basis of our results, we recommend primary prophylactic use of granulocyte colony-stimulating factor and/or antibiotics selectively for patients predicted to be at high risk for TPF chemotherapy-induced FN.	TPF	198-201	colony stimulating factor 3	Homo sapiens	83-120
29232311-8	2018	During lithium therapy, granulocyte-colony stimulating factor, CD34+ hematopoietic stem/progenitor cells, and neutrophil elastase enter the circulation with activated neutrophils to promote the extravascular migration of activated neutrophils and enhance tissue inflammation.	Lithium	7-14	colony stimulating factor 3	Homo sapiens	24-61
29535105-10	2018	We found that Filgrastim (granulocyte colony-stimulating factor [G-CSF]) exposure highly increased neutrophil-mediated ATG cytotoxicity (by 40-fold [0.5 vs 20%; P = .002]), which explained the enhanced T-cell clearance after CBT.	N,N-BIS(4-CHLOROBENZYL)-1H-1,2,3,4-TETRAAZOL-5-AMINE	225-228	colony stimulating factor 3	Homo sapiens	65-70
29191663-1	2018	We conducted a prospective study on T and natural killer (NK) cell subset composition of graft and transplant outcomes in T cell-replete haploidentical transplantation with a single dose of subcutaneous plerixafor (Px) added to granulocyte colony-stimulating factor (G-CSF)-based mobilization in allogeneic donors to collect 10 x 106/kg CD34+ hematopoietic stem cells (HSCs) at single apheresis.	plerixafor	203-213	colony stimulating factor 3	Homo sapiens	267-272
29339724-0	2018	Granulocyte-colony stimulating factor controls neural and behavioral plasticity in response to cocaine.	Cocaine	95-102	colony stimulating factor 3	Homo sapiens	0-37
29086459-9	2018	EGF increased G-CSF receptor (G-CSFR) expression following 5-FU.	Fluorouracil	59-63	colony stimulating factor 3	Homo sapiens	14-19
29339724-3	2018	Through a broad screen of innate immune mediators, we identify granulocyte-colony stimulating factor (G-CSF) as a potent mediator of cocaine-induced adaptations.	Cocaine	133-140	colony stimulating factor 3	Homo sapiens	63-100
29339724-3	2018	Through a broad screen of innate immune mediators, we identify granulocyte-colony stimulating factor (G-CSF) as a potent mediator of cocaine-induced adaptations.	Cocaine	133-140	colony stimulating factor 3	Homo sapiens	102-107
29339724-4	2018	Here we report that G-CSF potentiates cocaine-induced increases in neural activity in the nucleus accumbens (NAc) and prefrontal cortex.	Cocaine	38-45	colony stimulating factor 3	Homo sapiens	20-25
29339724-5	2018	In addition, G-CSF injections potentiate cocaine place preference and enhance motivation to self-administer cocaine, while not affecting responses to natural rewards.	Cocaine	41-48	colony stimulating factor 3	Homo sapiens	13-18
29339724-5	2018	In addition, G-CSF injections potentiate cocaine place preference and enhance motivation to self-administer cocaine, while not affecting responses to natural rewards.	Cocaine	108-115	colony stimulating factor 3	Homo sapiens	13-18
29339724-6	2018	Infusion of G-CSF neutralizing antibody into NAc blocks the ability of G-CSF to modulate cocaine"s behavioral effects, providing a direct link between central G-CSF action in NAc and cocaine reward.	Cocaine	89-96	colony stimulating factor 3	Homo sapiens	12-17
29339724-6	2018	Infusion of G-CSF neutralizing antibody into NAc blocks the ability of G-CSF to modulate cocaine"s behavioral effects, providing a direct link between central G-CSF action in NAc and cocaine reward.	Cocaine	89-96	colony stimulating factor 3	Homo sapiens	71-76
29339724-6	2018	Infusion of G-CSF neutralizing antibody into NAc blocks the ability of G-CSF to modulate cocaine"s behavioral effects, providing a direct link between central G-CSF action in NAc and cocaine reward.	Cocaine	89-96	colony stimulating factor 3	Homo sapiens	71-76
29339724-7	2018	These results demonstrate that manipulating G-CSF is sufficient to alter the motivation for cocaine, but not natural rewards, providing a pharmacotherapeutic avenue to manipulate addictive behaviors without abuse potential.	Cocaine	92-99	colony stimulating factor 3	Homo sapiens	44-49
29030083-7	2018	2-AG levels are significantly higher in PB of the G-CSF-treated group compared with BM plasma.	glyceryl 2-arachidonate	0-4	colony stimulating factor 3	Homo sapiens	50-55
29107446-1	2018	We describe the characterisation of a novel monoPEGylated recombinant human granulocyte colony-stimulating factor analogue, pegteograstim (Neulapeg), prepared by site-specific 20 kDa maleimide-PEG conjugation.	KDA	179-182	colony stimulating factor 3	Homo sapiens	76-113
29107446-1	2018	We describe the characterisation of a novel monoPEGylated recombinant human granulocyte colony-stimulating factor analogue, pegteograstim (Neulapeg), prepared by site-specific 20 kDa maleimide-PEG conjugation.	maleimide-peg	183-196	colony stimulating factor 3	Homo sapiens	76-113
28870643-6	2017	Baseline characteristics between peg-GCSF and GCSF groups were similar.	Polyethylene Glycols	33-36	colony stimulating factor 3	Homo sapiens	37-41
28929372-4	2018	The recombinant human granulocyte colony-stimulating factor (G-CSF) biosimilar EP2006/Zarxio  (filgrastim-sdnz) became the first FDA-approved biosimilar in 2015.	filgrastim-sdnz	95-110	colony stimulating factor 3	Homo sapiens	22-59
28929372-4	2018	The recombinant human granulocyte colony-stimulating factor (G-CSF) biosimilar EP2006/Zarxio  (filgrastim-sdnz) became the first FDA-approved biosimilar in 2015.	filgrastim-sdnz	95-110	colony stimulating factor 3	Homo sapiens	61-66
29257093-6	2017	), enhance vascularization and protect the cerebrovasculature (e.g., coumarin derivate IMM-H004 and granulocyte-colony stimulating factor (G-CSF)), and exert their effects through other modes of action (e.g., oxygen transporters, ascorbic acid, etc.).	coumarin	69-77	colony stimulating factor 3	Homo sapiens	100-137
29257093-6	2017	), enhance vascularization and protect the cerebrovasculature (e.g., coumarin derivate IMM-H004 and granulocyte-colony stimulating factor (G-CSF)), and exert their effects through other modes of action (e.g., oxygen transporters, ascorbic acid, etc.).	coumarin	69-77	colony stimulating factor 3	Homo sapiens	139-145
29296907-7	2017	Substrate-based drug design led to the discovery of GSK3277329, which stimulated the release of G-CSF in activated THP-1 cells, peripheral blood mononuclear cells, and human umbilical vein endothelial cells.	gsk3277329	52-62	colony stimulating factor 3	Homo sapiens	96-101
29296907-8	2017	When administered subcutaneously to cynomolgus monkeys (Macaca fascicularis), GSK3277329 caused systemic elevation of G-CSF and interleukin-6 (IL-6), but not IL-1beta or tumor necrosis factor alpha, indicating a selective cytokine-stimulation profile.	gsk3277329	78-88	colony stimulating factor 3	Homo sapiens	118-123
29035393-1	2017	Donor-lymphocyte infusion (DLI) for relapse following haploidentical hematopoietic cell transplantation (haploHCT) with post-transplant cyclophosphamide (PTCy) has been described in recipients of bone marrow grafts, but not recipients of G-CSF mobilized peripheral blood (PB) grafts.	ptcy	154-158	colony stimulating factor 3	Homo sapiens	238-243
28870643-9	2017	CONCLUSION: We suggest routine use of peg-GCSF is an acceptable alternative to daily GCSF, for patients in whom da-EPOCH-R is selected as first-line treatment for aggressive B-NHL.	Polyethylene Glycols	38-41	colony stimulating factor 3	Homo sapiens	42-46
28660351-7	2017	The two groups displayed slight heterogeneity: patients receiving moxifloxacin were approximately 10 years younger (54 vs. 64 years, p = 0.01), more likely to receive granulocyte colony stimulating factor (GCSF) (45 vs. 19%, p = 0.001), and neutropenic for a longer duration (23 vs. 19 days, p = 0.009).	Moxifloxacin	66-78	colony stimulating factor 3	Homo sapiens	167-204
29390394-5	2017	No platelet engraftment delay (&gt;21 days) was observed among patients in the TPO group, while 3 patients in the non-TPO group displayed delayed platelet engraftment.Adding rhTPO to the ID-CTX chemotherapy plus G-CSF regimen improved treatment efficacy in mobilizing PBSCs for autologous hematopoietic stem cell transplantation.	rhtpo	174-179	colony stimulating factor 3	Homo sapiens	212-217
28660351-7	2017	The two groups displayed slight heterogeneity: patients receiving moxifloxacin were approximately 10 years younger (54 vs. 64 years, p = 0.01), more likely to receive granulocyte colony stimulating factor (GCSF) (45 vs. 19%, p = 0.001), and neutropenic for a longer duration (23 vs. 19 days, p = 0.009).	Moxifloxacin	66-78	colony stimulating factor 3	Homo sapiens	206-210
29181135-0	2017	Graves" Disease Thyrotoxicosis and Propylthiouracil Related Agranulocytosis Successfully Treated with Therapeutic Plasma Exchange and G-CSF Followed by Total Thyroidectomy.	Propylthiouracil	35-51	colony stimulating factor 3	Homo sapiens	134-139
29153350-6	2017	In recent years, main (yet largely ineffective) approach was to increase G-CSF dose and add SCF, but novel and promising pathways have been opened up by the synergistic impact of a reversible inhibitor of CXCR4, plerixafor, with G-CSF.	plerixafor	212-222	colony stimulating factor 3	Homo sapiens	229-234
28875358-4	2017	Cell assay data revealed that the cys-64-cys74 disulfide bond in reduced GCSF imparts stabilization in absence of the cys-36-cys42 bond.	Cysteine	34-37	colony stimulating factor 3	Homo sapiens	73-77
28875358-4	2017	Cell assay data revealed that the cys-64-cys74 disulfide bond in reduced GCSF imparts stabilization in absence of the cys-36-cys42 bond.	Disulfides	47-56	colony stimulating factor 3	Homo sapiens	73-77
28875358-4	2017	Cell assay data revealed that the cys-64-cys74 disulfide bond in reduced GCSF imparts stabilization in absence of the cys-36-cys42 bond.	Cysteine	41-44	colony stimulating factor 3	Homo sapiens	73-77
28973394-0	2017	Synthesis and characterization of heparosan-granulocyte-colony stimulating factor conjugates: a natural sugar-based drug delivery system to treat neutropenia.	Sugars	104-109	colony stimulating factor 3	Homo sapiens	44-81
29162833-0	2017	The combination of CHK1 inhibitor with G-CSF overrides cytarabine resistance in human acute myeloid leukemia.	Cytarabine	55-65	colony stimulating factor 3	Homo sapiens	39-44
29158911-14	2017	Specifically gemcitabine/carboplatin had a greater incidence (85%) of grade 2 or greater leukopenia, thrombocytopenia, and neutropenia compared to gemcitabine/cisplatin (19%) However, there was no significant difference in dose reductions, treatment delays, or granulocyte-colony stimulating factor (G-CSF) administration between regimens.	gemcitabine	13-24	colony stimulating factor 3	Homo sapiens	261-298
29158911-14	2017	Specifically gemcitabine/carboplatin had a greater incidence (85%) of grade 2 or greater leukopenia, thrombocytopenia, and neutropenia compared to gemcitabine/cisplatin (19%) However, there was no significant difference in dose reductions, treatment delays, or granulocyte-colony stimulating factor (G-CSF) administration between regimens.	gemcitabine	13-24	colony stimulating factor 3	Homo sapiens	300-305
29158911-14	2017	Specifically gemcitabine/carboplatin had a greater incidence (85%) of grade 2 or greater leukopenia, thrombocytopenia, and neutropenia compared to gemcitabine/cisplatin (19%) However, there was no significant difference in dose reductions, treatment delays, or granulocyte-colony stimulating factor (G-CSF) administration between regimens.	Carboplatin	25-36	colony stimulating factor 3	Homo sapiens	261-298
29158911-14	2017	Specifically gemcitabine/carboplatin had a greater incidence (85%) of grade 2 or greater leukopenia, thrombocytopenia, and neutropenia compared to gemcitabine/cisplatin (19%) However, there was no significant difference in dose reductions, treatment delays, or granulocyte-colony stimulating factor (G-CSF) administration between regimens.	Carboplatin	25-36	colony stimulating factor 3	Homo sapiens	300-305
28846166-0	2017	Cortisol inhibits CSF2 and CSF3 via DNA methylation and inhibits invasion in first-trimester trophoblast cells.	Hydrocortisone	0-8	colony stimulating factor 3	Homo sapiens	27-31
28846166-6	2017	RESULTS: Cortisol inhibited expression of CSF2 (GM-CSF) and CSF3 (G-CSF) in trophoblast cells.	Hydrocortisone	9-17	colony stimulating factor 3	Homo sapiens	60-64
28846166-6	2017	RESULTS: Cortisol inhibited expression of CSF2 (GM-CSF) and CSF3 (G-CSF) in trophoblast cells.	Hydrocortisone	9-17	colony stimulating factor 3	Homo sapiens	66-71
28840583-8	2017	Child-Turcotte-Pugh (CTP) and Model for End-Stage Liver Disease (MELD), disease severity scores improved in patients treated with G-CSF, with significant difference only for the CTP score at 90 days follow-up.	Cytidine Triphosphate	21-24	colony stimulating factor 3	Homo sapiens	130-135
28840583-8	2017	Child-Turcotte-Pugh (CTP) and Model for End-Stage Liver Disease (MELD), disease severity scores improved in patients treated with G-CSF, with significant difference only for the CTP score at 90 days follow-up.	Cytidine Triphosphate	178-181	colony stimulating factor 3	Homo sapiens	130-135
28775207-4	2017	Elevated concentrations of G-CSF in PDAC promoted differentiation of Ly6G+ cells from progenitors, stimulated IL10 secretion from myeloid cells, and decreased T-cell proliferation via upregulation of Arg, iNOS, VEGF, IL6, and IL1b from CD11b+ cells.	Arginine	200-203	colony stimulating factor 3	Homo sapiens	27-32
28675459-10	2017	The combination of desipramine and G-CSF is safe and signals improved mobilization over G-CSF alone, providing a possible alternative means of mobilization that needs further investigation.	Desipramine	19-30	colony stimulating factor 3	Homo sapiens	88-93
28747065-0	2017	Use of granulocyte-colony stimulating factor to prevent recurrent clozapine-induced neutropenia on drug rechallenge: A systematic review of the literature and clinical recommendations.	Clozapine	66-75	colony stimulating factor 3	Homo sapiens	7-44
28747065-2	2017	Co-prescription of granulocyte-colony stimulating factor may prevent recurrent neutropenia and allow continuation or rechallenge of clozapine.	Clozapine	132-141	colony stimulating factor 3	Homo sapiens	19-56
28747065-3	2017	OBJECTIVE AND METHODS: Systematic review of literature reporting the use of granulocyte-colony stimulating factor to allow rechallenge or continuation of clozapine in people with previous episodes of clozapine-induced neutropenia.	Clozapine	154-163	colony stimulating factor 3	Homo sapiens	76-113
28589686-2	2017	In this study, recombinant human granulocyte colony-stimulating factor (G-CSF)-loaded chitosan nanoparticles were incorporated in Poly(epsilon-caprolactone) (PCL) nanofibers, followed by surface coating with collagen type I.	polycaprolactone	130-156	colony stimulating factor 3	Homo sapiens	33-70
28589686-2	2017	In this study, recombinant human granulocyte colony-stimulating factor (G-CSF)-loaded chitosan nanoparticles were incorporated in Poly(epsilon-caprolactone) (PCL) nanofibers, followed by surface coating with collagen type I.	polycaprolactone	130-156	colony stimulating factor 3	Homo sapiens	72-77
29469718-2	2017	We present a patient who developed ESS after induction of CLAG chemotherapy [2-Chlorodeoxyadenosine (2-CdA) with cytarabine (Ara-C) and (granulocyte-colony stimulating factor) G-CSF] for management of the blast crisis of his chronic myelogenous leukemia (CML).	ESS	35-38	colony stimulating factor 3	Homo sapiens	137-174
29469718-2	2017	We present a patient who developed ESS after induction of CLAG chemotherapy [2-Chlorodeoxyadenosine (2-CdA) with cytarabine (Ara-C) and (granulocyte-colony stimulating factor) G-CSF] for management of the blast crisis of his chronic myelogenous leukemia (CML).	ESS	35-38	colony stimulating factor 3	Homo sapiens	176-181
29026576-0	2017	Use of granulocyte colony-stimulating factor in the treatment of methimazole-induced agranulocytosis: a case report.	Methimazole	65-76	colony stimulating factor 3	Homo sapiens	7-44
28943331-0	2017	Impact of Granulocyte-colony Stimulating Factor on Bleomycin-induced Pneumonitis in Chemotherapy-treated Germ Cell Tumors.	Bleomycin	51-60	colony stimulating factor 3	Homo sapiens	10-47
28943331-1	2017	OBJECTIVE: To examine the impact of granulocyte-colony stimulating factor (G-CSF) use on the incidence and severity of bleomycin-induced pneumonitis (BIP) in patients with germ cell tumor (GCT) receiving first-line chemotherapy.	Bleomycin	119-128	colony stimulating factor 3	Homo sapiens	36-73
28943331-1	2017	OBJECTIVE: To examine the impact of granulocyte-colony stimulating factor (G-CSF) use on the incidence and severity of bleomycin-induced pneumonitis (BIP) in patients with germ cell tumor (GCT) receiving first-line chemotherapy.	Bleomycin	119-128	colony stimulating factor 3	Homo sapiens	75-80
28747065-3	2017	OBJECTIVE AND METHODS: Systematic review of literature reporting the use of granulocyte-colony stimulating factor to allow rechallenge or continuation of clozapine in people with previous episodes of clozapine-induced neutropenia.	Clozapine	200-209	colony stimulating factor 3	Homo sapiens	76-113
28747065-5	2017	RESULTS: A total of 17 articles were identified that reported on clozapine rechallenge with granulocyte-colony stimulating factor support.	Clozapine	65-74	colony stimulating factor 3	Homo sapiens	92-129
28747065-13	2017	CONCLUSION: Preliminary data suggest granulocyte-colony stimulating factor is safe and effective in facilitating rechallenge with clozapine.	Clozapine	130-139	colony stimulating factor 3	Homo sapiens	37-74
29340124-14	2017	We recommend G-CSF use in HL patients receiving bleomycin when needed to maintain dose intensity.	Bleomycin	48-57	colony stimulating factor 3	Homo sapiens	13-18
28817489-0	2017	The Use of Granulocyte Colony-Stimulating Factor in Clozapine Rechallenge: A Systematic Review.	Clozapine	52-61	colony stimulating factor 3	Homo sapiens	11-48
28817489-2	2017	Granulocyte colony-stimulating factor (G-CSF) has been used to support clozapine rechallenge after neutropenia with the aim of maintaining the neutrophil count.	Clozapine	71-80	colony stimulating factor 3	Homo sapiens	0-37
28817489-2	2017	Granulocyte colony-stimulating factor (G-CSF) has been used to support clozapine rechallenge after neutropenia with the aim of maintaining the neutrophil count.	Clozapine	71-80	colony stimulating factor 3	Homo sapiens	39-44
28817489-4	2017	METHODS/PROCEDURES: We conducted a systematic review to identify all studies investigating or describing G-CSF as a prophylaxis to enable continued clozapine treatment during a rechallenge.	Clozapine	148-157	colony stimulating factor 3	Homo sapiens	105-110
28817489-5	2017	FINDINGS/RESULTS: We identified 32 reports of patients who received G-CSF either regularly (n = 23) or as required (n = 9) to support clozapine rechallenge after an episode of neutropenia necessitating discontinuation of clozapine.	Clozapine	134-143	colony stimulating factor 3	Homo sapiens	68-73
28817489-5	2017	FINDINGS/RESULTS: We identified 32 reports of patients who received G-CSF either regularly (n = 23) or as required (n = 9) to support clozapine rechallenge after an episode of neutropenia necessitating discontinuation of clozapine.	Clozapine	221-230	colony stimulating factor 3	Homo sapiens	68-73
28817489-7	2017	Seventy percent (n = 16) of patients in receipt of continual prophylactic G-CSF were successfully maintained on clozapine.	Clozapine	112-121	colony stimulating factor 3	Homo sapiens	74-79
28817489-9	2017	IMPLICATIONS/CONCLUSIONS: Our findings suggest that G-CSF can sometimes be safely used to support the maintenance of normal neutrophil counts and clozapine use after neutropenia.	Clozapine	146-155	colony stimulating factor 3	Homo sapiens	52-57
28721592-2	2017	PEGylation, the covalent modification of G-CSF with polyethylene glycol (PEG), has a beneficial effect on drug properties, but there are concerns connected to the immunogenicity of PEGylated compounds and bioaccumulation of the synthetic polymer.	Polyethylene Glycols	52-71	colony stimulating factor 3	Homo sapiens	41-46
28721592-2	2017	PEGylation, the covalent modification of G-CSF with polyethylene glycol (PEG), has a beneficial effect on drug properties, but there are concerns connected to the immunogenicity of PEGylated compounds and bioaccumulation of the synthetic polymer.	Polyethylene Glycols	0-3	colony stimulating factor 3	Homo sapiens	41-46
28721592-2	2017	PEGylation, the covalent modification of G-CSF with polyethylene glycol (PEG), has a beneficial effect on drug properties, but there are concerns connected to the immunogenicity of PEGylated compounds and bioaccumulation of the synthetic polymer.	Polymers	238-245	colony stimulating factor 3	Homo sapiens	41-46
29469718-2	2017	We present a patient who developed ESS after induction of CLAG chemotherapy [2-Chlorodeoxyadenosine (2-CdA) with cytarabine (Ara-C) and (granulocyte-colony stimulating factor) G-CSF] for management of the blast crisis of his chronic myelogenous leukemia (CML).	clag	58-62	colony stimulating factor 3	Homo sapiens	137-174
29469718-2	2017	We present a patient who developed ESS after induction of CLAG chemotherapy [2-Chlorodeoxyadenosine (2-CdA) with cytarabine (Ara-C) and (granulocyte-colony stimulating factor) G-CSF] for management of the blast crisis of his chronic myelogenous leukemia (CML).	clag	58-62	colony stimulating factor 3	Homo sapiens	176-181
28775207-6	2017	Anti-G-CSF treatment in combination with the DNA synthesis inhibitor gemcitabine reduced tumor size, increased the number of infiltrating T cells, and decreased the number of Ly6G+ cells more effectively than gemcitabine alone.	gemcitabine	209-220	colony stimulating factor 3	Homo sapiens	5-10
28922288-0	2017	Addition of Filgrastim (Neupogen) for Clozapine Rechallenge in the Case of Parkinson Disease Patient.	Clozapine	38-47	colony stimulating factor 3	Homo sapiens	12-22
28781303-5	2017	High-dose methylprednisolone therapy should thus be considered for patients demonstrating ANA-positive agranulocytosis with an unknown etiology that is refractory to G-CSF treatment.	Methylprednisolone	10-28	colony stimulating factor 3	Homo sapiens	166-171
28508228-5	2017	In addition, an increase in blasts after G-CSF priming had a significant negative impact on CR rate in untreated patients.	Chromium	92-94	colony stimulating factor 3	Homo sapiens	41-46
28437295-2	2017	Granulocyte colony-stimulating factor (G-CSF) and granulocyte-macrophage colony-stimulating factor (GM-CSF) have been used to reduce the frequency and duration of clozapine-associated neutropenia.	Clozapine	163-172	colony stimulating factor 3	Homo sapiens	0-37
29245915-10	2017	Multiplex analyses of plasma taken after drug exposure at animal nadir indicated that the levels of M-CSF, CXCL-9, PDGF and G-CSF were significantly increased by [curcumin + sildenafil] and that expression of CXCL1 and CCL5 were significantly reduced.	Curcumin	163-171	colony stimulating factor 3	Homo sapiens	124-129
29245915-10	2017	Multiplex analyses of plasma taken after drug exposure at animal nadir indicated that the levels of M-CSF, CXCL-9, PDGF and G-CSF were significantly increased by [curcumin + sildenafil] and that expression of CXCL1 and CCL5 were significantly reduced.	Sildenafil Citrate	174-184	colony stimulating factor 3	Homo sapiens	124-129
28476490-1	2017	Plerixafor, given subcutaneously with granulocyte colony-stimulating factor (G-CSF), improves autologous stem cell collection in patients with lymphoma and multiple myeloma.	plerixafor	0-10	colony stimulating factor 3	Homo sapiens	38-75
28476490-1	2017	Plerixafor, given subcutaneously with granulocyte colony-stimulating factor (G-CSF), improves autologous stem cell collection in patients with lymphoma and multiple myeloma.	plerixafor	0-10	colony stimulating factor 3	Homo sapiens	77-82
27578390-2	2017	The purpose of this study was to evaluate efficacy and safety of plerixafor in an immediate rescue approach, administrated subsequently to G-CSF alone or chemotherapy and G-CSF in patients at risk for mobilization failure.	plerixafor	65-75	colony stimulating factor 3	Homo sapiens	171-176
27578390-4	2017	Primary endpoint was the efficacy of the immediate rescue approach of plerixafor to achieve &gt;=2.0 x 106 CD34+ cells/kg for a single or &gt;=5 x 106 CD34+ cells/kg for a double transplantation and potential differences between G-CSF and chemotherapy-based mobilization.	plerixafor	70-80	colony stimulating factor 3	Homo sapiens	229-234
27578390-10	2017	The addition of plerixafor in an immediate rescue model is efficient and safe after both, G-CSF and chemomobilization and results in extremely high success rates.	plerixafor	16-26	colony stimulating factor 3	Homo sapiens	90-95
27958690-5	2017	RESULTS: After 3 months, patients receiving G-CSF reported increased subjective relief of symptoms and showed increased transcutaneous oxygen tension (TcPO2).	Oxygen	135-141	colony stimulating factor 3	Homo sapiens	44-49
28437295-0	2017	Clozapine-Associated Agranulocytosis Treatment With Granulocyte Colony-Stimulating Factor/Granulocyte-Macrophage Colony-Stimulating Factor: A Systematic Review.	Clozapine	0-9	colony stimulating factor 3	Homo sapiens	52-89
28437295-2	2017	Granulocyte colony-stimulating factor (G-CSF) and granulocyte-macrophage colony-stimulating factor (GM-CSF) have been used to reduce the frequency and duration of clozapine-associated neutropenia.	Clozapine	163-172	colony stimulating factor 3	Homo sapiens	39-44
28437295-4	2017	METHODS/PROCEDURES: We conducted a systematic review of published interventional and observational studies, case series, and case reports where G-CSF/GM-CSF was used to treat clozapine-associated agranulocytosis.	Clozapine	175-184	colony stimulating factor 3	Homo sapiens	144-149
28437295-8	2017	IMPLICATIONS/CONCLUSIONS: Our findings indicate that G-CSF/GM-CSF use is well tolerated and suggest that G-CSF can sometimes be safely used to reduce the duration of neutropenia associated with clozapine use.	Clozapine	194-203	colony stimulating factor 3	Homo sapiens	53-58
28437295-8	2017	IMPLICATIONS/CONCLUSIONS: Our findings indicate that G-CSF/GM-CSF use is well tolerated and suggest that G-CSF can sometimes be safely used to reduce the duration of neutropenia associated with clozapine use.	Clozapine	194-203	colony stimulating factor 3	Homo sapiens	105-110
28097942-7	2017	A regimen of low-dose cytarabine and aclarubicin combined with granulocyte-colony-stimulating factor (CAG) led to higher CR rates in the CD25-positive AML patients than intensive chemotherapies.	Chromium	121-123	colony stimulating factor 3	Homo sapiens	63-100
28515226-6	2017	CSL324 was effective in controlling G-CSF-mediated neutrophilia when administered either before or after G-CSF.	csl324	0-6	colony stimulating factor 3	Homo sapiens	36-41
28515226-6	2017	CSL324 was effective in controlling G-CSF-mediated neutrophilia when administered either before or after G-CSF.	csl324	0-6	colony stimulating factor 3	Homo sapiens	105-110
28097942-7	2017	A regimen of low-dose cytarabine and aclarubicin combined with granulocyte-colony-stimulating factor (CAG) led to higher CR rates in the CD25-positive AML patients than intensive chemotherapies.	Chromium	121-123	colony stimulating factor 3	Homo sapiens	102-105
28231491-0	2017	Effect of granulocyte colony-stimulating factor on outcomes in patients with non-M3 acute myelogenous leukemia treated with anthracycline-based induction (7+3 regimen) chemotherapies.	Anthracyclines	124-137	colony stimulating factor 3	Homo sapiens	10-47
28685085-0	2017	Diffuse fluorodeoxyglucose-positron uptake in the bone marrow of a patient with granulocyte colony-stimulating factor-producing pleomorphic carcinoma of the lung: A case report.	Fluorodeoxyglucose F18	8-26	colony stimulating factor 3	Homo sapiens	80-117
28231491-1	2017	We analyzed the effects of granulocyte colony-stimulating factor (G-CSF) on outcomes in 315 anthracycline-based induction chemotherapy-treated patients with non-M3 acute myelogenous leukemia (AML).	Anthracyclines	92-105	colony stimulating factor 3	Homo sapiens	66-71
28032635-14	2017	CONCLUSION: Dexamethasone increases granulocyte yield upon coadministration with G-CSF by extending G-CSF half-life.	Dexamethasone	12-25	colony stimulating factor 3	Homo sapiens	81-86
29108384-6	2017	With administration of PEG-G-CSF, all of the 40 patients completed 8 cycles of ddEC-P +- trastuzumab regimen without dose reductions or treatment delays.	Polyethylene Glycols	23-26	colony stimulating factor 3	Homo sapiens	27-32
29108384-10	2017	More importantly, the proper dose of PEG-G-CSF for high risk Chinese breast cancer patients during ddEC-P chemotherapy may be 6 mg for ddEC treatment and 3 mg for ddP treatment.	Polyethylene Glycols	37-40	colony stimulating factor 3	Homo sapiens	41-46
28459367-0	2017	Glioblastoma-synthesized G-CSF and GM-CSF contribute to growth and immunosuppression: Potential therapeutic benefit from dapsone, fenofibrate, and ribavirin.	Dapsone	121-128	colony stimulating factor 3	Homo sapiens	25-30
28459367-0	2017	Glioblastoma-synthesized G-CSF and GM-CSF contribute to growth and immunosuppression: Potential therapeutic benefit from dapsone, fenofibrate, and ribavirin.	Fenofibrate	130-141	colony stimulating factor 3	Homo sapiens	25-30
28459367-0	2017	Glioblastoma-synthesized G-CSF and GM-CSF contribute to growth and immunosuppression: Potential therapeutic benefit from dapsone, fenofibrate, and ribavirin.	Ribavirin	147-156	colony stimulating factor 3	Homo sapiens	25-30
28150167-4	2017	METHODS: In this study, we utilized metal-catalyzed oxidizing conditions to generate carbonylation in recombinant human serum albumin (HSA) and granulocyte-colony stimulating factor (G-CSF), two proteins with distinct metal-binding abilities.	Metals	36-41	colony stimulating factor 3	Homo sapiens	144-181
28150167-4	2017	METHODS: In this study, we utilized metal-catalyzed oxidizing conditions to generate carbonylation in recombinant human serum albumin (HSA) and granulocyte-colony stimulating factor (G-CSF), two proteins with distinct metal-binding abilities.	Metals	36-41	colony stimulating factor 3	Homo sapiens	183-188
28150167-4	2017	METHODS: In this study, we utilized metal-catalyzed oxidizing conditions to generate carbonylation in recombinant human serum albumin (HSA) and granulocyte-colony stimulating factor (G-CSF), two proteins with distinct metal-binding abilities.	Metals	218-223	colony stimulating factor 3	Homo sapiens	144-181
28150167-4	2017	METHODS: In this study, we utilized metal-catalyzed oxidizing conditions to generate carbonylation in recombinant human serum albumin (HSA) and granulocyte-colony stimulating factor (G-CSF), two proteins with distinct metal-binding abilities.	Metals	218-223	colony stimulating factor 3	Homo sapiens	183-188
28150167-10	2017	We also detected a previously unreported, oxidation-induced cleavage site in G-CSF between His44 and Pro45, which might be attributed to a presence of a potential metal-binding site near residue Pro45.	Metals	163-168	colony stimulating factor 3	Homo sapiens	77-82
27817104-0	2017	Prevention of granulocyte-colony stimulating factor (G-CSF) induced bone pain using double histamine blockade.	Histamine	91-100	colony stimulating factor 3	Homo sapiens	14-51
27817104-0	2017	Prevention of granulocyte-colony stimulating factor (G-CSF) induced bone pain using double histamine blockade.	Histamine	91-100	colony stimulating factor 3	Homo sapiens	53-58
27817104-8	2017	The primary endpoint was to determine the analgesic effects of double histamine blockade for G-CSF induced bone pain.	Histamine	70-79	colony stimulating factor 3	Homo sapiens	93-98
27817104-13	2017	CONCLUSION: The use of a double histamine blockade is an inexpensive, safe, and effective way to alleviate bone pain symptoms secondary to G-CSF agents.	Histamine	32-41	colony stimulating factor 3	Homo sapiens	139-144
28542361-6	2017	The addition of anti-G-CSF antibodies enabled dexamethasone to decrease airway G-CSF, neutrophils, and lung injury scores.	Dexamethasone	46-59	colony stimulating factor 3	Homo sapiens	21-26
28542361-6	2017	The addition of anti-G-CSF antibodies enabled dexamethasone to decrease airway G-CSF, neutrophils, and lung injury scores.	Dexamethasone	46-59	colony stimulating factor 3	Homo sapiens	79-84
28542361-8	2017	In vitro using BEAS 2B bronchial epithelial cells, A549 lung epithelial cells, human monocyte-derived macrophages, and human neutrophils, we found that dexamethasone and proinflammatory cytokines synergistically induced G-CSF.	Dexamethasone	152-165	colony stimulating factor 3	Homo sapiens	220-225
28542361-10	2017	These data support that G-CSF plays a role in upregulation of airway neutrophil numbers by dexamethasone in the LPS-induced acute lung injury model.	Dexamethasone	91-104	colony stimulating factor 3	Homo sapiens	24-29
28881590-10	2017	Collectively, our study suggested that miR-125b induced by G-CSF plays a promoting role in the metastasis of CRC by targeting MCL1, which may serve as a novel therapeutic target for CRC metastasis.	mir-125b	39-47	colony stimulating factor 3	Homo sapiens	59-64
28034992-0	2017	Plerixafor and G-CSF combination mobilizes hematopoietic stem and progenitors cells with a distinct transcriptional profile and a reduced in vivo homing capacity compared to plerixafor alone.	plerixafor	174-184	colony stimulating factor 3	Homo sapiens	15-20
28264648-7	2017	Patients receiving docetaxel could be administered primary prophylactic granulocyte-colony stimulating factor according to standard guidelines.	Docetaxel	19-28	colony stimulating factor 3	Homo sapiens	72-109
28082237-6	2017	The FF G-CSF showed a trend toward negative relationship with TG and TC; TNF-alpha concentration was positively associated with TG.	Triglycerides	62-64	colony stimulating factor 3	Homo sapiens	7-12
28082237-6	2017	The FF G-CSF showed a trend toward negative relationship with TG and TC; TNF-alpha concentration was positively associated with TG.	Technetium	69-71	colony stimulating factor 3	Homo sapiens	7-12
28032635-0	2017	Dexamethasone promotes granulocyte mobilization by prolonging the half-life of granulocyte-colony-stimulating factor in healthy donors for granulocyte transfusions.	Dexamethasone	0-13	colony stimulating factor 3	Homo sapiens	79-116
28032635-13	2017	Compared with coadministration of dexamethasone, administration of G-CSF alone to the same GTX donors led to a faster decline in circulating G-CSF levels, whereas dexamethasone itself did not induce any G-CSF, demonstrating a role for dexamethasone in increasing G-CSF half-life.	hexylglutathione	91-94	colony stimulating factor 3	Homo sapiens	67-72
28032635-13	2017	Compared with coadministration of dexamethasone, administration of G-CSF alone to the same GTX donors led to a faster decline in circulating G-CSF levels, whereas dexamethasone itself did not induce any G-CSF, demonstrating a role for dexamethasone in increasing G-CSF half-life.	hexylglutathione	91-94	colony stimulating factor 3	Homo sapiens	141-146
28032635-13	2017	Compared with coadministration of dexamethasone, administration of G-CSF alone to the same GTX donors led to a faster decline in circulating G-CSF levels, whereas dexamethasone itself did not induce any G-CSF, demonstrating a role for dexamethasone in increasing G-CSF half-life.	hexylglutathione	91-94	colony stimulating factor 3	Homo sapiens	141-146
28032635-13	2017	Compared with coadministration of dexamethasone, administration of G-CSF alone to the same GTX donors led to a faster decline in circulating G-CSF levels, whereas dexamethasone itself did not induce any G-CSF, demonstrating a role for dexamethasone in increasing G-CSF half-life.	hexylglutathione	91-94	colony stimulating factor 3	Homo sapiens	141-146
28032635-14	2017	CONCLUSION: Dexamethasone increases granulocyte yield upon coadministration with G-CSF by extending G-CSF half-life.	Dexamethasone	12-25	colony stimulating factor 3	Homo sapiens	100-105
27340768-7	2017	The results showed that keratinocyte-releasable G-CSF-stimulating factors remain stable at 56 C and upon 50% ammonium sulfate precipitation.	Ammonium Sulfate	109-125	colony stimulating factor 3	Homo sapiens	48-53
28178994-11	2017	RESULTS: Doxycycline decreased plasma lysophosphatidate concentrations, delayed tumor growth and decreased the concentrations of several cytokines/chemokines (IL-1beta, IL-6, IL-9, CCL2, CCL11, CXCL1, CXCL2, CXCL9, G-CSF, LIF, VEGF) in the tumor.	Doxycycline	9-20	colony stimulating factor 3	Homo sapiens	215-220
27749622-5	2017	Plerixafor in combination with granulocyte-colony stimulating factor showed its efficacy in mobilizing 6x10 CD34+/kg HSCs able to rescue two HDC cycles of carboplatin-etoposide, leading to stable hematopoietic engraftment.	Carboplatin	155-166	colony stimulating factor 3	Homo sapiens	31-68
27749622-5	2017	Plerixafor in combination with granulocyte-colony stimulating factor showed its efficacy in mobilizing 6x10 CD34+/kg HSCs able to rescue two HDC cycles of carboplatin-etoposide, leading to stable hematopoietic engraftment.	Etoposide	167-176	colony stimulating factor 3	Homo sapiens	31-68
28137309-6	2017	ROS have been implicated in IR-induced EMT, via activation of several EMT transcription factors-including Snail, HIF-1, ZEB1, and STAT3-that are activated by signalling pathways, including those of TGF-beta, Wnt, Hedgehog, Notch, G-CSF, EGFR/PI3K/Akt, and MAPK.	Reactive Oxygen Species	0-3	colony stimulating factor 3	Homo sapiens	230-235
27751704-5	2017	: This case suggests that loratadine may be an easy to implement, safe, and effective therapy in the emergency department management of intractable bone pain caused by G-CSF use.	Loratadine	26-36	colony stimulating factor 3	Homo sapiens	168-173
27751704-6	2017	Emergency physicians should be aware that loratadine may successfully relieve otherwise intractable G-CSF-induced bone pain and allow for discharge home.	Loratadine	42-52	colony stimulating factor 3	Homo sapiens	100-105
28079370-7	2017	These degradable polymers were then employed as excipients for the stabilization of the therapeutic protein granulocyte colony-stimulating factor (G-CSF) against storage at 4  C and shipping temperatures of 60  C. The best stabilization was observed using the trehalose- and zwitterion- substituted polyesters.	Polymers	17-25	colony stimulating factor 3	Homo sapiens	108-145
28079370-7	2017	These degradable polymers were then employed as excipients for the stabilization of the therapeutic protein granulocyte colony-stimulating factor (G-CSF) against storage at 4  C and shipping temperatures of 60  C. The best stabilization was observed using the trehalose- and zwitterion- substituted polyesters.	Polymers	17-25	colony stimulating factor 3	Homo sapiens	147-152
28079370-7	2017	These degradable polymers were then employed as excipients for the stabilization of the therapeutic protein granulocyte colony-stimulating factor (G-CSF) against storage at 4  C and shipping temperatures of 60  C. The best stabilization was observed using the trehalose- and zwitterion- substituted polyesters.	Trehalose	260-269	colony stimulating factor 3	Homo sapiens	108-145
28079370-7	2017	These degradable polymers were then employed as excipients for the stabilization of the therapeutic protein granulocyte colony-stimulating factor (G-CSF) against storage at 4  C and shipping temperatures of 60  C. The best stabilization was observed using the trehalose- and zwitterion- substituted polyesters.	Trehalose	260-269	colony stimulating factor 3	Homo sapiens	147-152
28079370-10	2017	This work provides potential biocompatible polymers for stabilization of the important therapeutic G-CSF, as well as a general platform for the future discovery of new polymeric protein stabilizers.	Polymers	43-51	colony stimulating factor 3	Homo sapiens	99-104
27980502-7	2017	The major changes of the metabolite profiles following G-CSF administration included alteration of several fatty acids, including increased levels of several medium and long-chain fatty acids, as well as polyunsaturated fatty acids; while there were lower levels of other lipid metabolites such as phospholipids, lysolipids, sphingolipids.	Fatty Acids	107-118	colony stimulating factor 3	Homo sapiens	55-60
28093087-11	2017	On univariate analysis, cisplatin based chemotherapy, presence of central venous catheter, female gender, poor performance status, high risk stratification according to the Khorana model and use of granulocyte colony stimulating factor were all significantly associated with the development of VTE.	Cisplatin	24-33	colony stimulating factor 3	Homo sapiens	198-235
28011495-8	2017	Granulocyte colony-stimulating factor (G-CSF) in serum was elevated at 5.6 pg/ml, which further raised to 43 pg/ml one week after FOLFIRINOX chemotherapy (oxaliplatin, irinotecan, 5-fluorouracil), while WBC decreased from 103.3 G/l to 59.3 G/l.	folfirinox	130-140	colony stimulating factor 3	Homo sapiens	0-37
28011495-8	2017	Granulocyte colony-stimulating factor (G-CSF) in serum was elevated at 5.6 pg/ml, which further raised to 43 pg/ml one week after FOLFIRINOX chemotherapy (oxaliplatin, irinotecan, 5-fluorouracil), while WBC decreased from 103.3 G/l to 59.3 G/l.	folfirinox	130-140	colony stimulating factor 3	Homo sapiens	39-44
28011495-8	2017	Granulocyte colony-stimulating factor (G-CSF) in serum was elevated at 5.6 pg/ml, which further raised to 43 pg/ml one week after FOLFIRINOX chemotherapy (oxaliplatin, irinotecan, 5-fluorouracil), while WBC decreased from 103.3 G/l to 59.3 G/l.	Oxaliplatin	155-166	colony stimulating factor 3	Homo sapiens	0-37
28011495-8	2017	Granulocyte colony-stimulating factor (G-CSF) in serum was elevated at 5.6 pg/ml, which further raised to 43 pg/ml one week after FOLFIRINOX chemotherapy (oxaliplatin, irinotecan, 5-fluorouracil), while WBC decreased from 103.3 G/l to 59.3 G/l.	Oxaliplatin	155-166	colony stimulating factor 3	Homo sapiens	39-44
28011495-8	2017	Granulocyte colony-stimulating factor (G-CSF) in serum was elevated at 5.6 pg/ml, which further raised to 43 pg/ml one week after FOLFIRINOX chemotherapy (oxaliplatin, irinotecan, 5-fluorouracil), while WBC decreased from 103.3 G/l to 59.3 G/l.	Irinotecan	168-178	colony stimulating factor 3	Homo sapiens	0-37
28011495-8	2017	Granulocyte colony-stimulating factor (G-CSF) in serum was elevated at 5.6 pg/ml, which further raised to 43 pg/ml one week after FOLFIRINOX chemotherapy (oxaliplatin, irinotecan, 5-fluorouracil), while WBC decreased from 103.3 G/l to 59.3 G/l.	Irinotecan	168-178	colony stimulating factor 3	Homo sapiens	39-44
28011495-8	2017	Granulocyte colony-stimulating factor (G-CSF) in serum was elevated at 5.6 pg/ml, which further raised to 43 pg/ml one week after FOLFIRINOX chemotherapy (oxaliplatin, irinotecan, 5-fluorouracil), while WBC decreased from 103.3 G/l to 59.3 G/l.	Fluorouracil	180-194	colony stimulating factor 3	Homo sapiens	0-37
28011495-8	2017	Granulocyte colony-stimulating factor (G-CSF) in serum was elevated at 5.6 pg/ml, which further raised to 43 pg/ml one week after FOLFIRINOX chemotherapy (oxaliplatin, irinotecan, 5-fluorouracil), while WBC decreased from 103.3 G/l to 59.3 G/l.	Fluorouracil	180-194	colony stimulating factor 3	Homo sapiens	39-44
27980502-7	2017	The major changes of the metabolite profiles following G-CSF administration included alteration of several fatty acids, including increased levels of several medium and long-chain fatty acids, as well as polyunsaturated fatty acids; while there were lower levels of other lipid metabolites such as phospholipids, lysolipids, sphingolipids.	long-chain fatty acids	169-191	colony stimulating factor 3	Homo sapiens	55-60
27980502-7	2017	The major changes of the metabolite profiles following G-CSF administration included alteration of several fatty acids, including increased levels of several medium and long-chain fatty acids, as well as polyunsaturated fatty acids; while there were lower levels of other lipid metabolites such as phospholipids, lysolipids, sphingolipids.	Fatty Acids, Unsaturated	204-231	colony stimulating factor 3	Homo sapiens	55-60
27980502-7	2017	The major changes of the metabolite profiles following G-CSF administration included alteration of several fatty acids, including increased levels of several medium and long-chain fatty acids, as well as polyunsaturated fatty acids; while there were lower levels of other lipid metabolites such as phospholipids, lysolipids, sphingolipids.	Phospholipids	298-311	colony stimulating factor 3	Homo sapiens	55-60
27980502-7	2017	The major changes of the metabolite profiles following G-CSF administration included alteration of several fatty acids, including increased levels of several medium and long-chain fatty acids, as well as polyunsaturated fatty acids; while there were lower levels of other lipid metabolites such as phospholipids, lysolipids, sphingolipids.	lysolipids	313-323	colony stimulating factor 3	Homo sapiens	55-60
27980502-7	2017	The major changes of the metabolite profiles following G-CSF administration included alteration of several fatty acids, including increased levels of several medium and long-chain fatty acids, as well as polyunsaturated fatty acids; while there were lower levels of other lipid metabolites such as phospholipids, lysolipids, sphingolipids.	Sphingolipids	325-338	colony stimulating factor 3	Homo sapiens	55-60
27980502-9	2017	Lastly, the levels of several nucleotides and nucleotide metabolites (guanosine, adenosine, inosine) were also decreased after G-CSF administration, while methylated products were increased.	Guanosine	70-79	colony stimulating factor 3	Homo sapiens	127-132
27980502-9	2017	Lastly, the levels of several nucleotides and nucleotide metabolites (guanosine, adenosine, inosine) were also decreased after G-CSF administration, while methylated products were increased.	Adenosine	81-90	colony stimulating factor 3	Homo sapiens	127-132
27980502-9	2017	Lastly, the levels of several nucleotides and nucleotide metabolites (guanosine, adenosine, inosine) were also decreased after G-CSF administration, while methylated products were increased.	Inosine	92-99	colony stimulating factor 3	Homo sapiens	127-132
28109298-14	2017	CONCLUSIONS: Neurodevelopmental improvement was seen in response to intravenous G-CSF followed by mPBMC reinfusion, particularly to the G-CSF alone even without mPBMC reinfusion.	mpbmc	98-103	colony stimulating factor 3	Homo sapiens	136-141
28109298-14	2017	CONCLUSIONS: Neurodevelopmental improvement was seen in response to intravenous G-CSF followed by mPBMC reinfusion, particularly to the G-CSF alone even without mPBMC reinfusion.	mpbmc	161-166	colony stimulating factor 3	Homo sapiens	80-85
29237905-0	2017	A clinical study of polyethylene glycol recombinant human granulocyte colony-stimulating factor prevention neutropenia syndrome in patients with esophageal carcinoma and lung cancer after concurrent chemoradiotherapy.	Polyethylene Glycols	20-39	colony stimulating factor 3	Homo sapiens	58-95
29237905-1	2017	OBJECTIVE: To compare the efficacy and safety of PEG-rhG-CSF and recombinant human G-CSF (rhG-CSF) for the prevention and delayed application in febrile neutropenia, hospitalization rate in concurrent chemoradiotherapy of tumors.	Polyethylene Glycols	49-52	colony stimulating factor 3	Homo sapiens	55-60
27980502-7	2017	The major changes of the metabolite profiles following G-CSF administration included alteration of several fatty acids, including increased levels of several medium and long-chain fatty acids, as well as polyunsaturated fatty acids; while there were lower levels of other lipid metabolites such as phospholipids, lysolipids, sphingolipids.	medium and	158-168	colony stimulating factor 3	Homo sapiens	55-60
28679984-0	2017	A case of a patient with granulocyte-colony stimulating factor-producing pancreatic cancer who responded to nab-paclitaxel plus gemcitabine.	gemcitabine	128-139	colony stimulating factor 3	Homo sapiens	25-62
28679984-4	2017	The patient did not respond to FOLFIRINOX therapy (leucovorin, fluorouracil, irinotecan, and oxaliplatin), but nab-paclitaxel plus gemcitabine treatment was effective, resulting in tumor shrinkage and reduced G-CSF levels.	Paclitaxel	115-125	colony stimulating factor 3	Homo sapiens	209-214
28679984-4	2017	The patient did not respond to FOLFIRINOX therapy (leucovorin, fluorouracil, irinotecan, and oxaliplatin), but nab-paclitaxel plus gemcitabine treatment was effective, resulting in tumor shrinkage and reduced G-CSF levels.	gemcitabine	131-142	colony stimulating factor 3	Homo sapiens	209-214
27859332-1	2017	BACKGROUND: Plerixafor is predominantly used for patients mobilizing inadequate stem cell numbers for autologous transplantation after stimulation with granulocyte-colony-stimulating factor (G-CSF).	plerixafor	12-22	colony stimulating factor 3	Homo sapiens	152-189
28243353-7	2017	Furthermore, aspalatone also prevented VEGF-induced release of inflammatory markers such as Angiopoietin-2, Leptin, EGF, G-CSF, HB-EGF, and HGF in HAECs.	aspalatone	13-23	colony stimulating factor 3	Homo sapiens	121-126
27568305-0	2017	Recombinant granulocyte colony-stimulating factor (rG-CSF) in the management of neutropenia induced by anthracyclines and ifosfamide in patients with soft tissue sarcomas (NEUSAR).	Anthracyclines	103-117	colony stimulating factor 3	Homo sapiens	12-49
27568305-0	2017	Recombinant granulocyte colony-stimulating factor (rG-CSF) in the management of neutropenia induced by anthracyclines and ifosfamide in patients with soft tissue sarcomas (NEUSAR).	Ifosfamide	122-132	colony stimulating factor 3	Homo sapiens	12-49
27859332-1	2017	BACKGROUND: Plerixafor is predominantly used for patients mobilizing inadequate stem cell numbers for autologous transplantation after stimulation with granulocyte-colony-stimulating factor (G-CSF).	plerixafor	12-22	colony stimulating factor 3	Homo sapiens	191-196
27859332-2	2017	STUDY DESIGN AND METHODS: We here report on 300 patients undergoing stem cell mobilization with G-CSF, among them 36 poor mobilizers (CD34+ cell counts &lt; 50 x 106 /L blood) receiving G-CSF alone and 49 receiving G-CSF in combination with plerixafor for rescue intervention.	plerixafor	241-251	colony stimulating factor 3	Homo sapiens	96-101
27859332-10	2017	CONCLUSION: Our data demonstrate that plerixafor is highly effective as rescue measurement after mobilization failure with G-CSF alone and short-term clinical outcome after stem cell transplantation is comparable.	plerixafor	38-48	colony stimulating factor 3	Homo sapiens	123-128
28066833-6	2016	G-CSF 300microg/1ml was administered at the day of oocyte puncture or day of progesterone administration of FET cycle.	Progesterone	77-89	colony stimulating factor 3	Homo sapiens	0-5
27721193-0	2016	Variation in the use of granulocyte-colony stimulating factor for dose dense paclitaxel: A single institution retrospective study.	Paclitaxel	77-87	colony stimulating factor 3	Homo sapiens	24-61
27721193-1	2016	INTRODUCTION: The necessity of using granulocyte-colony stimulating factor (G-CSF) during dose-dense (DD) paclitaxel (T) after doxorubicin and cyclophosphamide (AC) is unclear.	Paclitaxel	106-116	colony stimulating factor 3	Homo sapiens	76-81
27470289-0	2016	Improved Outcome of Refractory/Relapsed Acute Myeloid Leukemia after Post-Transplantation Cyclophosphamide-Based Haploidentical Transplantation with Myeloablative Conditioning and Early Prophylactic Granulocyte Colony-Stimulating Factor-Mobilized Donor Lymphocyte Infusions.	Cyclophosphamide	90-106	colony stimulating factor 3	Homo sapiens	199-236
26939585-11	2016	Comparison with a historical control group of 70 MM and lymphoma patients, who were mobilized with G-CSF, showed significantly higher CD 34+ cells/kg collected in the bortezomib mobilization study group.	Bortezomib	167-177	colony stimulating factor 3	Homo sapiens	99-104
28039406-9	2016	Across groups, circulating G-CSF was elevated from PRE at IP (P &lt; 0.001), 1H (P = 0.011), and 5H (P = 0.025), while GM-CSF was elevated at IP (P &lt; 0.001) and 1H (P = 0.007).	Hydrogen	77-79	colony stimulating factor 3	Homo sapiens	27-32
28039406-9	2016	Across groups, circulating G-CSF was elevated from PRE at IP (P &lt; 0.001), 1H (P = 0.011), and 5H (P = 0.025), while GM-CSF was elevated at IP (P &lt; 0.001) and 1H (P = 0.007).	5h	97-99	colony stimulating factor 3	Homo sapiens	27-32
28039406-9	2016	Across groups, circulating G-CSF was elevated from PRE at IP (P &lt; 0.001), 1H (P = 0.011), and 5H (P = 0.025), while GM-CSF was elevated at IP (P &lt; 0.001) and 1H (P = 0.007).	Hydrogen	164-166	colony stimulating factor 3	Homo sapiens	27-32
27588816-8	2016	However, when combining IL-1ss, IL-6 and G-CSF in the patients with CD, the cytokine levels were significantly lower in the AndoSanTM - versus the placebo group, visit 3.	andosantm	124-133	colony stimulating factor 3	Homo sapiens	41-46
26832782-10	2016	A correlation was found in the expression of Il-1RA, Il-8, G-CSF, MIP-1beta, and TNF-alpha at zirconia implants and teeth.	zirconium oxide	94-102	colony stimulating factor 3	Homo sapiens	59-64
27981253-4	2016	MATERIALS AND METHODS: 0.5 ml (300 microg/ml) GCSF was infused intrauterine in intervention group.	intrauterine	63-75	colony stimulating factor 3	Homo sapiens	46-50
27424082-4	2016	To demonstrate the versatility of this catechol chemoselective reaction, we used four proteins (lysozyme, basic-fibroblast growth factor (bFGF), granulocyte-colony stimulating factor (G-CSF), insulin, and erythropoietin (EPO)) as well as two peptides (hinge-3 and laminin-derived peptide (LDP)).	catechol	39-47	colony stimulating factor 3	Homo sapiens	184-189
27815970-3	2016	In this study, we investigated the effects of G-CSF treatment on the Th1/Th2 cells and the underlying mechanisms in patients with ITP in vitro.	Inosine Triphosphate	130-133	colony stimulating factor 3	Homo sapiens	46-51
27815970-8	2016	The results showed that G-CSF could significantly reduce the Th1/Th2 ratio in PBMCs from patients with ITP in vitro.	Inosine Triphosphate	103-106	colony stimulating factor 3	Homo sapiens	24-29
27646945-10	2016	Conclusion Primary G-CSF prophylaxis was associated with low-to-modest benefit in lowering neutropenia-related hospitalization in patients with breast cancer who received TC and TCH regimens.	Technetium	171-173	colony stimulating factor 3	Homo sapiens	19-24
27646945-10	2016	Conclusion Primary G-CSF prophylaxis was associated with low-to-modest benefit in lowering neutropenia-related hospitalization in patients with breast cancer who received TC and TCH regimens.	thiocarbohydrazide	178-181	colony stimulating factor 3	Homo sapiens	19-24
27651638-4	2016	INTERVENTIONS: Intrauterine infusion of GCSF (300 mcg/1 ml) was done in patients with thin endometrium on day 14 of FET cycles, and their endometrial thicknesses were measured after 48 h of infusion.	intrauterine	15-27	colony stimulating factor 3	Homo sapiens	40-44
26750985-1	2016	The maximum tolerated dose (MTD) of idarubicin should be reevaluated in the treatment of acute myeloid leukemia (AML) in the era of granulocyte colony-stimulating factor and better supportive care.	Idarubicin	36-46	colony stimulating factor 3	Homo sapiens	132-169
27018002-0	2016	9- and 13-Hydroxy-octadecadienoic acids (9+13 HODE) are inversely related to granulocyte colony stimulating factor and IL-6 in runners after 2h running.	9- and 13-hydroxy-octadecadienoic acids	0-39	colony stimulating factor 3	Homo sapiens	77-114
27751427-0	2016	Successful treatment with granulocyte-colony stimulating factor for ritodrine-induced neutropenia in a twin pregnancy.	Ritodrine	68-77	colony stimulating factor 3	Homo sapiens	26-63
27751427-9	2016	CONCLUSION: Based on prior case reports and the clinical presentation of our case, G-CSF may be a useful treatment for pregnant women with ritodrine-induced neutropenia.	Ritodrine	139-148	colony stimulating factor 3	Homo sapiens	83-88
27374031-2	2016	Plerixafor, a reversible inhibitor of the binding of stromal cell-derived factor 1 to its cognate receptor CXCR4, has demonstrated a higher capacity for the mobilization of peripheral blood stem cells in combination with granulocyte colony stimulating factor (G-CSF) compared with G-CSF alone.	plerixafor	0-10	colony stimulating factor 3	Homo sapiens	221-258
27374031-2	2016	Plerixafor, a reversible inhibitor of the binding of stromal cell-derived factor 1 to its cognate receptor CXCR4, has demonstrated a higher capacity for the mobilization of peripheral blood stem cells in combination with granulocyte colony stimulating factor (G-CSF) compared with G-CSF alone.	plerixafor	0-10	colony stimulating factor 3	Homo sapiens	260-265
27374031-2	2016	Plerixafor, a reversible inhibitor of the binding of stromal cell-derived factor 1 to its cognate receptor CXCR4, has demonstrated a higher capacity for the mobilization of peripheral blood stem cells in combination with granulocyte colony stimulating factor (G-CSF) compared with G-CSF alone.	plerixafor	0-10	colony stimulating factor 3	Homo sapiens	281-286
27374031-8	2016	RESULTS AND CONCLUSIONS: After a review of the literature, the expert consensus recommended the administration of pre-emptive plerixafor for multiple myeloma or lymphoma patients with a CD34+ cell count lower than 10 cells/muL in peripheral blood (measured in the morning of day 4 of mobilization with G-CSF or after haematopietic recovery in the case of mobilization with chemotherapy plus G-CSF).	plerixafor	126-136	colony stimulating factor 3	Homo sapiens	302-307
27374031-8	2016	RESULTS AND CONCLUSIONS: After a review of the literature, the expert consensus recommended the administration of pre-emptive plerixafor for multiple myeloma or lymphoma patients with a CD34+ cell count lower than 10 cells/muL in peripheral blood (measured in the morning of day 4 of mobilization with G-CSF or after haematopietic recovery in the case of mobilization with chemotherapy plus G-CSF).	plerixafor	126-136	colony stimulating factor 3	Homo sapiens	391-396
27568360-6	2016	Trifluridine/tipiracil was associated with an acceptable tolerability profile, with adverse events generally being managed with dose reductions, temporary interruptions in treatment or administration of granulocyte-colony stimulating factor.	Trifluridine	0-12	colony stimulating factor 3	Homo sapiens	203-240
27018002-0	2016	9- and 13-Hydroxy-octadecadienoic acids (9+13 HODE) are inversely related to granulocyte colony stimulating factor and IL-6 in runners after 2h running.	Deuterium	141-143	colony stimulating factor 3	Homo sapiens	77-114
27355397-2	2016	Plerixafor is used for mobilization of CD34(+) cells with G-CSF in non-Hodgkin lymphoma (NHL) and myeloma (MM) patients.	plerixafor	0-10	colony stimulating factor 3	Homo sapiens	58-63
27109327-10	2016	RESULTS: These past years, clozapine have been rechallenged successfully after neutropenia thanks to different procedures, the different options being simple rechallenge, rechallenge with lithium and/or rechallenge with G-CSF.	Clozapine	27-36	colony stimulating factor 3	Homo sapiens	220-225
27109327-11	2016	Lithium as G-CSF are used to increase neutrophil blood rate and prevent neutropenia recurrence after clozapine rechallenge.	Lithium	0-7	colony stimulating factor 3	Homo sapiens	11-16
27109327-11	2016	Lithium as G-CSF are used to increase neutrophil blood rate and prevent neutropenia recurrence after clozapine rechallenge.	Clozapine	101-110	colony stimulating factor 3	Homo sapiens	11-16
27109327-12	2016	G-CSF was first used within the context of chemotherapy and extends now to clozapine-induced neutropenia.	Clozapine	75-84	colony stimulating factor 3	Homo sapiens	0-5
27109327-26	2016	Lithium as G-CSF may have other adverse effects which need to be considered.	Lithium	0-7	colony stimulating factor 3	Homo sapiens	11-16
27131268-1	2016	BACKGROUND: Autologous progenitor cell therapy comprising granulocyte-colony stimulating factor (G-CSF) for mobilization of bone-marrow derived progenitor cells (BMPCs) into peripheral blood and inhibition of dipeptidylpeptidase-IV by sitagliptin for enhanced myocardial recruitment of circulating BMPCs has been shown to improve survival after acute myocardial infarction (MI) in preclinical studies.	Sitagliptin Phosphate	235-246	colony stimulating factor 3	Homo sapiens	58-95
26758765-0	2016	Granulocyte colony-stimulating factor in secondary prophylaxis for advanced-stage Hodgkin lymphoma treated with ABVD chemotherapy: a cost-effectiveness analysis.	ABVD protocol	112-116	colony stimulating factor 3	Homo sapiens	0-37
27429863-5	2015	Subsequently, the action and synergy of plerixafor with Granulocyte-colony stimulating factor (G-CSF) led to the clinical approval of plerixafor as the first compound for mobilization of HSPCs.	plerixafor	134-144	colony stimulating factor 3	Homo sapiens	56-93
27429863-5	2015	Subsequently, the action and synergy of plerixafor with Granulocyte-colony stimulating factor (G-CSF) led to the clinical approval of plerixafor as the first compound for mobilization of HSPCs.	plerixafor	134-144	colony stimulating factor 3	Homo sapiens	95-100
27131268-1	2016	BACKGROUND: Autologous progenitor cell therapy comprising granulocyte-colony stimulating factor (G-CSF) for mobilization of bone-marrow derived progenitor cells (BMPCs) into peripheral blood and inhibition of dipeptidylpeptidase-IV by sitagliptin for enhanced myocardial recruitment of circulating BMPCs has been shown to improve survival after acute myocardial infarction (MI) in preclinical studies.	Sitagliptin Phosphate	235-246	colony stimulating factor 3	Homo sapiens	97-102
27245311-5	2016	Plerixafor was generally used for rescue after suboptimal granulocyte-colony stimulating factor (G-CSF) mobilization ("just in time") or for remobilization after an unsuccessful attempt with chemotherapy plus G-CSF.	plerixafor	0-10	colony stimulating factor 3	Homo sapiens	58-95
27270316-9	2016	By inducing the production of G-CSF/IL-6 in vivo, 14,15-EET induced the enhancement of STAT3 activation in neutrophils to increase MMP-9 expression and decrease TRAIL expression.	14,15-epoxy-5,8,11-eicosatrienoic acid	50-59	colony stimulating factor 3	Homo sapiens	30-35
27282562-0	2016	AMD3100 and G-CSF disrupt the cross-talk between leukemia cells and the endosteal niche and enhance their sensitivity to chemotherapeutic drugs in biomimetic polystyrene scaffolds.	Polystyrenes	158-169	colony stimulating factor 3	Homo sapiens	12-17
27282562-10	2016	The combination of G-CSF and AMD3100 had stronger effects on killing the leukemia cells induced by Ara-C.	Cytarabine	99-104	colony stimulating factor 3	Homo sapiens	19-24
27245311-5	2016	Plerixafor was generally used for rescue after suboptimal granulocyte-colony stimulating factor (G-CSF) mobilization ("just in time") or for remobilization after an unsuccessful attempt with chemotherapy plus G-CSF.	plerixafor	0-10	colony stimulating factor 3	Homo sapiens	97-102
27245311-5	2016	Plerixafor was generally used for rescue after suboptimal granulocyte-colony stimulating factor (G-CSF) mobilization ("just in time") or for remobilization after an unsuccessful attempt with chemotherapy plus G-CSF.	plerixafor	0-10	colony stimulating factor 3	Homo sapiens	209-214
27347068-1	2016	Combining cytarabine, aclarubicin and granulocyte colony-stimulating factor (G-CSF) has demonstrated marked efficacy in the treatment of elderly and relapsed/refractory patients with acute myeloid leukemia (AML); however, the role of G-CSF remains poorly understood.	Cytarabine	10-20	colony stimulating factor 3	Homo sapiens	77-82
27347068-1	2016	Combining cytarabine, aclarubicin and granulocyte colony-stimulating factor (G-CSF) has demonstrated marked efficacy in the treatment of elderly and relapsed/refractory patients with acute myeloid leukemia (AML); however, the role of G-CSF remains poorly understood.	Cytarabine	10-20	colony stimulating factor 3	Homo sapiens	234-239
27347068-1	2016	Combining cytarabine, aclarubicin and granulocyte colony-stimulating factor (G-CSF) has demonstrated marked efficacy in the treatment of elderly and relapsed/refractory patients with acute myeloid leukemia (AML); however, the role of G-CSF remains poorly understood.	Aclarubicin	22-33	colony stimulating factor 3	Homo sapiens	234-239
27245191-0	2016	G-CSF Dosing to Prevent Recurrent Clozapine-Induced Agranulocytosis.	Clozapine	34-43	colony stimulating factor 3	Homo sapiens	0-5
26939922-0	2016	Impact of an electronic tool in prescribing primary prophylaxis with ciprofloxacin or granulocyte colony-stimulating factor for breast cancer patients receiving TC chemotherapy.	Technetium	161-163	colony stimulating factor 3	Homo sapiens	86-123
26939922-1	2016	BACKGROUND: The US Oncology Trial 9735 (doxorubicin and cyclophosphamide (AC) versus docetaxel and cyclophosphamide (TC)) reported febrile neutropenia (FN) in 5 % of patients receiving TC chemotherapy, in the absence of routine primary prophylaxis with granulocyte colony-stimulating factor (G-CSF) or antibiotics.	Charcoal	1-3	colony stimulating factor 3	Homo sapiens	253-290
26939922-1	2016	BACKGROUND: The US Oncology Trial 9735 (doxorubicin and cyclophosphamide (AC) versus docetaxel and cyclophosphamide (TC)) reported febrile neutropenia (FN) in 5 % of patients receiving TC chemotherapy, in the absence of routine primary prophylaxis with granulocyte colony-stimulating factor (G-CSF) or antibiotics.	Charcoal	1-3	colony stimulating factor 3	Homo sapiens	292-297
26939922-1	2016	BACKGROUND: The US Oncology Trial 9735 (doxorubicin and cyclophosphamide (AC) versus docetaxel and cyclophosphamide (TC)) reported febrile neutropenia (FN) in 5 % of patients receiving TC chemotherapy, in the absence of routine primary prophylaxis with granulocyte colony-stimulating factor (G-CSF) or antibiotics.	Technetium	117-119	colony stimulating factor 3	Homo sapiens	253-290
26939922-1	2016	BACKGROUND: The US Oncology Trial 9735 (doxorubicin and cyclophosphamide (AC) versus docetaxel and cyclophosphamide (TC)) reported febrile neutropenia (FN) in 5 % of patients receiving TC chemotherapy, in the absence of routine primary prophylaxis with granulocyte colony-stimulating factor (G-CSF) or antibiotics.	Technetium	117-119	colony stimulating factor 3	Homo sapiens	292-297
27350939-7	2016	Significant amelioration of prothrombin time and total bilirubin in LF patients was attributed to G-CSF therapy (OR, -0.064; 95% CI,-0.481 to 0.353; p&lt; 0.001; and OR, -0.803; 95% CI, -1.177 to -0.430; p = 0.000, respectively).	Bilirubin	55-64	colony stimulating factor 3	Homo sapiens	98-103
27068251-0	2016	Alteration in the concentrations of Interleukin-7 (IL-7), Interleukin-10 (IL-10) and Granulocyte Colony Stimulating Factor (G-CSF) in alcohol-dependent individuals without liver disease, during detoxification therapy.	Alcohols	134-141	colony stimulating factor 3	Homo sapiens	85-122
27094941-7	2016	in Clin Drug Investig 29:821-825, 2009).We describe a case of a 55-year-old male, with peripheral vascular disease who after receiving Neupogen (G-CSF) developed a latent case of IAA.	indoleacetic acid	179-182	colony stimulating factor 3	Homo sapiens	145-150
27068251-0	2016	Alteration in the concentrations of Interleukin-7 (IL-7), Interleukin-10 (IL-10) and Granulocyte Colony Stimulating Factor (G-CSF) in alcohol-dependent individuals without liver disease, during detoxification therapy.	Alcohols	134-141	colony stimulating factor 3	Homo sapiens	124-129
27068251-1	2016	BACKGROUND: The course of Interleukin-7 (IL-7), Interleukin-10 (IL-10) and Granulocyte Colony Stimulating Factor (G-CSF) was investigated in alcohol-dependent individuals without liver disease in order to ascertain the use of these cytokines as markers for the follow-up testing and the outcome of the detoxification treatment.	Alcohols	141-148	colony stimulating factor 3	Homo sapiens	114-119
26294015-1	2016	Vinorelbine chemotherapy with granulocyte-colony stimulating factor (G-CSF) stimulation is a widely applied non-myelosuppressive mobilization regimen in Switzerland for myeloma patients, but its neurotoxic potential limits its use in patients with bortezomib-induced polyneuropathy.	Vinorelbine	0-11	colony stimulating factor 3	Homo sapiens	30-67
27408395-0	2016	Methimazole Induced Total Myeloid Aplasia with Delayed Recovery Despite Granulocyte Colony Stimulating Factor (G-CSF): Marrow Progenitor Recovery Kinetics.	Methimazole	0-11	colony stimulating factor 3	Homo sapiens	72-109
27408395-0	2016	Methimazole Induced Total Myeloid Aplasia with Delayed Recovery Despite Granulocyte Colony Stimulating Factor (G-CSF): Marrow Progenitor Recovery Kinetics.	Methimazole	0-11	colony stimulating factor 3	Homo sapiens	111-116
26802050-5	2016	G-CSF/dexamethasone-mobilized neutrophils efficiently inhibited A. fumigatus germination and killed Aspergillus and Candida hyphae, but the killing of C. albicans yeasts was distinctly impaired.	Dexamethasone	6-19	colony stimulating factor 3	Homo sapiens	0-5
26802050-8	2016	Together, these findings indicate that G-CSF/dexamethasone-mobilized neutrophils for transfusion purposes have a selectively impaired capacity to kill Candida yeasts, as a consequence of an altered neutrophil granular content.	Dexamethasone	45-58	colony stimulating factor 3	Homo sapiens	39-44
27188901-9	2016	HMB ingestion was also very likely (92%-95% Likelihood) to lower granulocyte colony-stimulating factor and interleukin 10 compared to PL.	beta-hydroxyisovaleric acid	0-3	colony stimulating factor 3	Homo sapiens	65-102
27121434-0	2016	Late Onset Agranulocytosis with Clozapine Associated with HLA DR4 Responding to Treatment with Granulocyte Colony-stimulating Factor: A Case Report and Review of Literature.	Clozapine	32-41	colony stimulating factor 3	Homo sapiens	95-132
27239063-7	2016	With FEC-DG significantly more G-CSF support in cycles 4 to 6 (FEC-DG: 57.8 %, FEC-D: 36.3 %, p &lt; 0.001) was provided.	fec-dg	5-11	colony stimulating factor 3	Homo sapiens	31-36
26294015-1	2016	Vinorelbine chemotherapy with granulocyte-colony stimulating factor (G-CSF) stimulation is a widely applied non-myelosuppressive mobilization regimen in Switzerland for myeloma patients, but its neurotoxic potential limits its use in patients with bortezomib-induced polyneuropathy.	Vinorelbine	0-11	colony stimulating factor 3	Homo sapiens	69-74
26294015-1	2016	Vinorelbine chemotherapy with granulocyte-colony stimulating factor (G-CSF) stimulation is a widely applied non-myelosuppressive mobilization regimen in Switzerland for myeloma patients, but its neurotoxic potential limits its use in patients with bortezomib-induced polyneuropathy.	Bortezomib	248-258	colony stimulating factor 3	Homo sapiens	69-74
27055795-6	2016	The results of protein chip showed that the expression of granulocyte colony-stimulating factor (G-CSF) in the hydrocortisone group decreased compared with the control group, meanwhile the expression of IL-4 increased.	Hydrocortisone	111-125	colony stimulating factor 3	Homo sapiens	58-95
27015562-3	2016	Multiplex assays performed on tumor material that survived and re-grew after [pemetrexed + sorafenib] exposure showed increased phosphorylation of ERBB1 and of NFkappaB and IkappaB; with reduced IkappaB and elevated G-CSF and KC protein levels.	Pemetrexed	78-88	colony stimulating factor 3	Homo sapiens	216-221
27015562-3	2016	Multiplex assays performed on tumor material that survived and re-grew after [pemetrexed + sorafenib] exposure showed increased phosphorylation of ERBB1 and of NFkappaB and IkappaB; with reduced IkappaB and elevated G-CSF and KC protein levels.	Sorafenib	91-100	colony stimulating factor 3	Homo sapiens	216-221
27099434-6	2016	Modification of gut microbiota composition and their products, such as lipopolysaccharide, nutritional interventions, immune modulation, increasing steroid sensitivity, genetic polymorphism and epigenetic modification of alcohol induced liver damage, augmenting hepatic regeneration using GCSF are potential therapeutic avenues in steroid non-responsive/ineligible patients.	Alcohols	221-228	colony stimulating factor 3	Homo sapiens	289-293
27055795-6	2016	The results of protein chip showed that the expression of granulocyte colony-stimulating factor (G-CSF) in the hydrocortisone group decreased compared with the control group, meanwhile the expression of IL-4 increased.	Hydrocortisone	111-125	colony stimulating factor 3	Homo sapiens	97-102
27055795-7	2016	The expression of G-CSF in the icariin+ hydrocortisone groups increased compared with the hydrocortisone group, meanwhile the expression of IL-4 decreased.No appreciable change was found in the expression of apoptotic factors.	icariin	31-38	colony stimulating factor 3	Homo sapiens	18-23
27055795-7	2016	The expression of G-CSF in the icariin+ hydrocortisone groups increased compared with the hydrocortisone group, meanwhile the expression of IL-4 decreased.No appreciable change was found in the expression of apoptotic factors.	Hydrocortisone	40-54	colony stimulating factor 3	Homo sapiens	18-23
27055795-7	2016	The expression of G-CSF in the icariin+ hydrocortisone groups increased compared with the hydrocortisone group, meanwhile the expression of IL-4 decreased.No appreciable change was found in the expression of apoptotic factors.	Hydrocortisone	90-104	colony stimulating factor 3	Homo sapiens	18-23
27103979-5	2016	VP-16 + G-CSF resulted in successful mobilization in 95.55% of the patients (on one patient stem cell collection with plerixafor was applied), including 76 patients (83.52%) whose stem cells were collected successfully in a single day.	plerixafor	118-128	colony stimulating factor 3	Homo sapiens	8-13
26859277-0	2016	Successful Use of Single Doses of Granulocyte-Colony Stimulating Factor (G-CSF) in the Treatment of Late-Onset Agranulocytosis Associated With Clozapine in a Patient With Treatment-Resistant Schizophrenia: A Case Report.	Clozapine	143-152	colony stimulating factor 3	Homo sapiens	34-71
26859277-0	2016	Successful Use of Single Doses of Granulocyte-Colony Stimulating Factor (G-CSF) in the Treatment of Late-Onset Agranulocytosis Associated With Clozapine in a Patient With Treatment-Resistant Schizophrenia: A Case Report.	Clozapine	143-152	colony stimulating factor 3	Homo sapiens	73-78
26538529-0	2016	Role of G-CSF in monophosphoryl lipid A-mediated augmentation of neutrophil functions after burn injury.	Lipid A	32-39	colony stimulating factor 3	Homo sapiens	8-13
26538529-9	2016	Neutralization of G-CSF before monophosphoryl lipid A administration blocked monophosphoryl lipid A-induced expansion of bone marrow myeloid progenitors and mobilization of neutrophils into the blood and their recruitment to the site of infection.	monophosphoryl	77-91	colony stimulating factor 3	Homo sapiens	18-23
26538529-9	2016	Neutralization of G-CSF before monophosphoryl lipid A administration blocked monophosphoryl lipid A-induced expansion of bone marrow myeloid progenitors and mobilization of neutrophils into the blood and their recruitment to the site of infection.	Lipid A	92-99	colony stimulating factor 3	Homo sapiens	18-23
26538529-11	2016	Our findings provide convincing evidence that monophosphoryl lipid A-induced G-CSF facilitates early expansion, mobilization, and recruitment of neutrophils to the site of infection after burn injury, allowing for a robust immune response to infection.	Lipid A	61-68	colony stimulating factor 3	Homo sapiens	77-82
26586169-1	2016	We describe two cases of polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, and skin changes (POEMS) syndrome patients with deteriorated extravascular volume overload without increased levels of vascular endothelial growth factor after the administration of cyclophosphamide + granulocyte colony-stimulating factor for stem cell mobilization.	Cyclophosphamide	273-289	colony stimulating factor 3	Homo sapiens	292-329
26726942-1	2016	Cyclophosphamide plus G-CSF (C+G-CSF) is one of the most widely used stem cell (SC) mobilization regimens for patients with multiple myeloma (MM).	Cyclophosphamide	0-16	colony stimulating factor 3	Homo sapiens	29-36
26726942-2	2016	Plerixafor plus G-CSF (P+G-CSF) has demonstrated superior SC mobilization efficacy when compared with G-CSF alone and has been shown to rescue patients who fail mobilization with G-CSF or C+G-CSF.	plerixafor	0-10	colony stimulating factor 3	Homo sapiens	25-30
26726942-2	2016	Plerixafor plus G-CSF (P+G-CSF) has demonstrated superior SC mobilization efficacy when compared with G-CSF alone and has been shown to rescue patients who fail mobilization with G-CSF or C+G-CSF.	plerixafor	0-10	colony stimulating factor 3	Homo sapiens	25-30
26726942-2	2016	Plerixafor plus G-CSF (P+G-CSF) has demonstrated superior SC mobilization efficacy when compared with G-CSF alone and has been shown to rescue patients who fail mobilization with G-CSF or C+G-CSF.	plerixafor	0-10	colony stimulating factor 3	Homo sapiens	25-30
26726942-2	2016	Plerixafor plus G-CSF (P+G-CSF) has demonstrated superior SC mobilization efficacy when compared with G-CSF alone and has been shown to rescue patients who fail mobilization with G-CSF or C+G-CSF.	plerixafor	0-10	colony stimulating factor 3	Homo sapiens	188-195
26726942-6	2016	The use of P+G-CSF was associated with a higher success rate of SC collection defined as &gt;=5 x 10(6) CD34+ cells/kg (94 versus 83%, P=0.013) and less toxicities.	Aminoglutethimide	86-92	colony stimulating factor 3	Homo sapiens	13-18
27073670-13	2016	Patients who require the administration of long- term G-CSF are at risk of unplanned re-hospitalization, and treating them with polyethylene glycol G-CSF to reduce the number of required injections should be considered as an option.	Polyethylene Glycols	128-147	colony stimulating factor 3	Homo sapiens	148-153
26764356-2	2016	We hypothesized that high-dose cyclophosphamide given after G-CSF-mobilized blood cell transplantation would reduce the cumulative 1-year incidence of chronic GVHD to 15% or less.	Cyclophosphamide	31-47	colony stimulating factor 3	Homo sapiens	60-65
27069870-0	2016	Granulocyte colony-stimulating factor (G-CSF): A saturated fatty acid-induced myokine with insulin-desensitizing properties in humans.	Fatty Acids	49-69	colony stimulating factor 3	Homo sapiens	0-37
26500236-9	2016	After lenvatinib treatment, the number of circulating endothelial and c-Kit(+) cells decreased and the levels of interleukin (IL)-6, IL10, granulocyte-colony stimulating factor, and vascular endothelial growth factor increased (P &lt; 0.05).	lenvatinib	6-16	colony stimulating factor 3	Homo sapiens	139-176
26437056-8	2016	Although CY-based mobilization was more effective, G-CSF alone was successful in a great majority of patients to reach the defined collection target after three cycles of lenalidomide-based induction.	Lenalidomide	171-183	colony stimulating factor 3	Homo sapiens	51-56
27069870-0	2016	Granulocyte colony-stimulating factor (G-CSF): A saturated fatty acid-induced myokine with insulin-desensitizing properties in humans.	Fatty Acids	49-69	colony stimulating factor 3	Homo sapiens	39-44
27069870-4	2016	In human skeletal muscle cells differentiated in vitro (myotubes), we have shown in previous studies that the expression of CSF3, the gene encoding granulocyte colony-stimulating factor (G-CSF), is markedly induced upon FFA treatment and exercise.	Fatty Acids, Nonesterified	220-223	colony stimulating factor 3	Homo sapiens	124-128
27069870-4	2016	In human skeletal muscle cells differentiated in vitro (myotubes), we have shown in previous studies that the expression of CSF3, the gene encoding granulocyte colony-stimulating factor (G-CSF), is markedly induced upon FFA treatment and exercise.	Fatty Acids, Nonesterified	220-223	colony stimulating factor 3	Homo sapiens	148-185
27069870-4	2016	In human skeletal muscle cells differentiated in vitro (myotubes), we have shown in previous studies that the expression of CSF3, the gene encoding granulocyte colony-stimulating factor (G-CSF), is markedly induced upon FFA treatment and exercise.	Fatty Acids, Nonesterified	220-223	colony stimulating factor 3	Homo sapiens	187-192
27069870-7	2016	In line with this, a functional polymorphism in the CSF3 gene affects adipose tissue- and whole-body insulin sensitivity and glucose tolerance in human subjects with elevated plasma FFA concentrations.	Glucose	125-132	colony stimulating factor 3	Homo sapiens	52-56
26721307-6	2016	In general, EtOH decreased secretion of IP-10, IL-6, eotaxin, GCSF, and MCP-1.	Ethanol	12-16	colony stimulating factor 3	Homo sapiens	62-66
26549378-0	2016	Functional characterization of recombinant human granulocyte colony stimulating factor (hGMCSF) immobilized onto silica nanoparticles.	Silicon Dioxide	113-119	colony stimulating factor 3	Homo sapiens	49-86
26838248-2	2016	METHOD: A consecutive cohort of patients with advanced cancers and CIM were treated with mouth-rinse G-CSF.	cim	67-70	colony stimulating factor 3	Homo sapiens	101-106
26382274-0	2016	D-CAG (decitabine followed by cytarabine, aclarubicin, and G-CSF) for relapsed acute myeloid leukemia after hematopoietic cell transplantation.	d-cag	0-5	colony stimulating factor 3	Homo sapiens	59-64
27007532-8	2016	Negative correlations between copper and G-CSF and GM-CSF were also shown.	Copper	30-36	colony stimulating factor 3	Homo sapiens	41-46
27007532-10	2016	In the Zn-H group, levels of G-CSF and MCP-1 were significantly higher by 70% and 145%, respectively, compared to the Zn-L group.	zn-h	7-11	colony stimulating factor 3	Homo sapiens	29-34
26838248-4	2016	The mouth-rinse with G-CSF at a dose of 150-300ug plus 100ml-500ml normal saline was started from the time of oral mucositis was confirmed and continuously used for at least 7 days as one course.	Sodium Chloride	74-80	colony stimulating factor 3	Homo sapiens	21-26
26925666-8	2016	Granulocyte colony-stimulating factor (G-CSF) was given with docetaxel to 41.8% of women and 20.6% of women receiving prophylactic antibiotics.	Docetaxel	61-70	colony stimulating factor 3	Homo sapiens	0-37
26838248-11	2016	Regarding CIM, the median response time to mouth rinse of G-CSF was 2 (1-5) days, and all patients with CIM demonstrated a positive response.	cim	10-13	colony stimulating factor 3	Homo sapiens	58-63
26925666-8	2016	Granulocyte colony-stimulating factor (G-CSF) was given with docetaxel to 41.8% of women and 20.6% of women receiving prophylactic antibiotics.	Docetaxel	61-70	colony stimulating factor 3	Homo sapiens	39-44
26969772-7	2016	This analysis showed that the addition of plerixafor to granulocyte colony stimulating factor is well tolerated and results in a greater proportion of patients with non-Hodgkin lymphomas or multiple myeloma reaching optimal CD34(+) cell collections with a smaller number of apheresis compared the use of granulocyte colony stimulating factor alone.	plerixafor	42-52	colony stimulating factor 3	Homo sapiens	304-341
26122627-7	2016	In seven patients G-CSF requirement decreased and the dose was reduced after the end of the study.In conclusion, our study demonstrated the efficacy of vitamin E supplementation.	Vitamin E	152-161	colony stimulating factor 3	Homo sapiens	18-23
26969772-5	2016	The association of plerixafor, a C-X-C Chemokine receptor type 4 (CXCR4) inhibitor, to granulocyte colony stimulating factor generates rapid mobilization of hematopoietic progenitor cells.	plerixafor	19-29	colony stimulating factor 3	Homo sapiens	87-124
26397697-1	2016	Decitabine and CHG regimen (low-dose cytarabine and homoharringtonine with G-CSF) have been used for treating higher risk myelodysplastic syndrome (MDS).	Decitabine	0-10	colony stimulating factor 3	Homo sapiens	75-80
27720385-0	2016	Use of Granulocyte Colony-Stimulating Factor in a Neutropenic HIV-Infected Patient on Clozapine.	Clozapine	86-95	colony stimulating factor 3	Homo sapiens	7-44
27863757-3	2016	Combining other treatments to granulocyte-colony stimulating factor, such as cyclophosphamide, could overcome the mobilization limitation.	Cyclophosphamide	77-93	colony stimulating factor 3	Homo sapiens	30-67
26668716-7	2015	Stimulation with Poly(I:C) resulted in a significant increased secretion of IL-4, IL-6, RANTES, IP-10, MIP-1beta, VEGF, FGF, IL-1RA, IL-2R and G-CSF.	Poly I-C	17-25	colony stimulating factor 3	Homo sapiens	143-148
26666576-7	2015	The depletion of MDSC via splenectomy or the administration of anti-Gr-1 antibody sensitized G-CSF-producing cervical cancer to cisplatin.	Cisplatin	128-137	colony stimulating factor 3	Homo sapiens	93-98
26152744-6	2015	RESULTS: In late-stage cancer patients, plasma levels of multiple biomarkers, including IL6, G-CSF, MCP-1, and MIP1-beta, increased with increasing motolimod dose.	VTX-2337	148-157	colony stimulating factor 3	Homo sapiens	93-98
26597475-0	2015	[Granulocyte- colony stimulating factor (G-CSF) use in clinical practice in patients receiving chemotherapy for breast cancer: The Opaline Study].	ceric oxide	131-138	colony stimulating factor 3	Homo sapiens	0-39
26597475-0	2015	[Granulocyte- colony stimulating factor (G-CSF) use in clinical practice in patients receiving chemotherapy for breast cancer: The Opaline Study].	ceric oxide	131-138	colony stimulating factor 3	Homo sapiens	41-46
26432074-0	2015	Increasing aclarubicin dosage of the conventional CAG (low-dose cytarabine and aclarubicin in combination with granulocyte colony-stimulating factor) regimen is more efficacious as a salvage therapy than CAG for relapsed/refractory acute myeloid leukemia.	Aclarubicin	11-22	colony stimulating factor 3	Homo sapiens	111-148
26293782-4	2015	In vitro, EGCG divergently affected HMGB1-mediated production of several chemokines: reducing CXCL15 and RANTES/CCL5, but elevating G-CSF and MIP-1alpha/CCL3 production by peritoneal macrophages.	epigallocatechin gallate	10-14	colony stimulating factor 3	Homo sapiens	132-137
26293782-0	2015	EGCG induces G-CSF expression and neutrophilia in experimental sepsis.	epigallocatechin gallate	0-4	colony stimulating factor 3	Homo sapiens	13-18
26293782-2	2015	Here, we provide evidence to support EGCG"s capacities in stimulating G-CSF production and neutrophilia in vivo.	epigallocatechin gallate	37-41	colony stimulating factor 3	Homo sapiens	70-75
26293782-3	2015	In an animal model of sepsis, EGCG significantly elevated peritoneal levels of G-CSF and several chemokines (e.g., MCP-1/CCL2 and MIP-1gamma/CCL9), and consequently increased peritoneal neutrophil numbers (neutrophilia) at a late stage.	epigallocatechin gallate	30-34	colony stimulating factor 3	Homo sapiens	79-84
26553325-3	2015	The aim of this study was to determine the influence of PDT with aminolevulinic acid (ALA-PDT) in a hypoxic-like microenvironment on the secretion of growth factors: GM-CSF (granulocyte and macrophage colony stimulating factor), G-CSF (granulocyte colony-stimulating factor) and FGF (fibroblast growth factor) by experimental models of colon cancer cells in vitro.	Aminolevulinic Acid	65-84	colony stimulating factor 3	Homo sapiens	229-234
26553325-3	2015	The aim of this study was to determine the influence of PDT with aminolevulinic acid (ALA-PDT) in a hypoxic-like microenvironment on the secretion of growth factors: GM-CSF (granulocyte and macrophage colony stimulating factor), G-CSF (granulocyte colony-stimulating factor) and FGF (fibroblast growth factor) by experimental models of colon cancer cells in vitro.	Aminolevulinic Acid	65-84	colony stimulating factor 3	Homo sapiens	236-273
26553325-3	2015	The aim of this study was to determine the influence of PDT with aminolevulinic acid (ALA-PDT) in a hypoxic-like microenvironment on the secretion of growth factors: GM-CSF (granulocyte and macrophage colony stimulating factor), G-CSF (granulocyte colony-stimulating factor) and FGF (fibroblast growth factor) by experimental models of colon cancer cells in vitro.	Alanine	86-89	colony stimulating factor 3	Homo sapiens	229-234
26553325-3	2015	The aim of this study was to determine the influence of PDT with aminolevulinic acid (ALA-PDT) in a hypoxic-like microenvironment on the secretion of growth factors: GM-CSF (granulocyte and macrophage colony stimulating factor), G-CSF (granulocyte colony-stimulating factor) and FGF (fibroblast growth factor) by experimental models of colon cancer cells in vitro.	Alanine	86-89	colony stimulating factor 3	Homo sapiens	236-273
26553339-5	2015	In hypoxia and serum-deprived culture conditions, LPA induces CD34(+) cell proliferation without maintaining the their undifferentiating state, and enhances IL-8, IL-6 and G-CSF secretion during the first 12 h compared to non-treated cells.	lysophosphatidic acid	50-53	colony stimulating factor 3	Homo sapiens	172-177
26337685-0	2015	The risk of febrile neutropenia and need for G-CSF primary prophylaxis with the docetaxel and cyclophosphamide regimen in early-stage breast cancer patients: a meta-analysis.	Docetaxel	80-89	colony stimulating factor 3	Homo sapiens	45-50
26265462-5	2015	The analyses of cytokines in the G-BM- and U-BM-derived MSCs supernatants revealed that PGE2 levels were significantly lower in the G-CSF-primed samples.	Dinoprostone	88-92	colony stimulating factor 3	Homo sapiens	132-137
26805233-10	2015	Combination therapy using TS-1 plus CDDP plus trastuzumab resulted in a good response, and the leukocytosis and elevated serum G-CSF gradually improved.	cddp	36-40	colony stimulating factor 3	Homo sapiens	127-132
26646037-9	2015	This group was successfully rechallenged following careful consideration of the risks and benefits, and lithium and G-CSF contributed to allowing continued clozapine therapy.	Clozapine	156-165	colony stimulating factor 3	Homo sapiens	116-121
26401918-0	2015	Fully Synthetic Granulocyte Colony-Stimulating Factor Enabled by Isonitrile-Mediated Coupling of Large, Side-Chain-Unprotected Peptides.	Cyanides	65-75	colony stimulating factor 3	Homo sapiens	16-53
26401918-4	2015	In light of this, we have developed a synthetic platform to prepare G-CSF aglycone with the goal of enabling access to native and designed glycoforms with site-selectivity and glycan homogeneity.	Polysaccharides	176-182	colony stimulating factor 3	Homo sapiens	68-73
25985920-1	2015	Granulocyte colony-stimulating factor (G-CSF) increases the susceptibility of dormant malignant or nonmalignant hematopoietic cells to cytarabine arabinoside (Ara-C) through the induction of cell cycle entry.	cytarabine arabinoside	135-157	colony stimulating factor 3	Homo sapiens	39-44
26418032-6	2015	Inhibition of the TLR3, TLR/TIR-domain-containing adaptor-inducing interferon beta (TRIF), NF-kappaB, and IRF3 pathways decreased the polyI:C- and IL-17A/polyI:C-induced G-CSF and IL-8 mRNA expression.	Poly I	134-139	colony stimulating factor 3	Homo sapiens	170-175
26418032-6	2015	Inhibition of the TLR3, TLR/TIR-domain-containing adaptor-inducing interferon beta (TRIF), NF-kappaB, and IRF3 pathways decreased the polyI:C- and IL-17A/polyI:C-induced G-CSF and IL-8 mRNA expression.	Poly I	154-159	colony stimulating factor 3	Homo sapiens	170-175
26308166-2	2015	Here, we present site assignment and absolute quantification of oxidation variants of pegfilgrastim, a poly(ethylene glycol) modified recombinant human granulocyte-colony stimulating factor.	Polyethylene Glycols	103-124	colony stimulating factor 3	Homo sapiens	152-189
26366074-11	2015	Our results show that ellagic acid encapsulated in metalla-prisms inhibited cancer cells via the modulation of mRNA induction and protein expression levels of the granulocyte-colony stimulating factor and regulated on activation normal T cell expressed and secreted protein in macrophages.	Ellagic Acid	22-34	colony stimulating factor 3	Homo sapiens	163-200
26418032-3	2015	In this study, we demonstrated that IL-17A and polyI:C, the ligand of TLR3, synergistically induced the expression of proinflammatory cytokines and chemokines (G-CSF, IL-8, CXCL1, CXCL5, IL-1F9), but not type I interferon (IFN-alpha1, -beta) in primary culture of normal human bronchial epithelial cells.	Poly I-C	47-54	colony stimulating factor 3	Homo sapiens	160-165
25985920-1	2015	Granulocyte colony-stimulating factor (G-CSF) increases the susceptibility of dormant malignant or nonmalignant hematopoietic cells to cytarabine arabinoside (Ara-C) through the induction of cell cycle entry.	cytarabine arabinoside	135-157	colony stimulating factor 3	Homo sapiens	0-37
25985920-1	2015	Granulocyte colony-stimulating factor (G-CSF) increases the susceptibility of dormant malignant or nonmalignant hematopoietic cells to cytarabine arabinoside (Ara-C) through the induction of cell cycle entry.	Cytarabine	159-164	colony stimulating factor 3	Homo sapiens	0-37
25985920-1	2015	Granulocyte colony-stimulating factor (G-CSF) increases the susceptibility of dormant malignant or nonmalignant hematopoietic cells to cytarabine arabinoside (Ara-C) through the induction of cell cycle entry.	Cytarabine	159-164	colony stimulating factor 3	Homo sapiens	39-44
25985920-4	2015	The TBI &gt;= 8 Gy + Ara-C/G-CSF + CY regimen showed significantly higher incidence of neutrophil engraftment (hazard ratio, 1.52; 95% confidence interval [CI], 1.10 to 2.08; P = .009) and lower overall mortality (hazard ratio, .46; 95% CI, .26 to .82; P = .008) rates compared with those without a G-CSF regimen.	Cytarabine	21-26	colony stimulating factor 3	Homo sapiens	299-304
25985920-4	2015	The TBI &gt;= 8 Gy + Ara-C/G-CSF + CY regimen showed significantly higher incidence of neutrophil engraftment (hazard ratio, 1.52; 95% confidence interval [CI], 1.10 to 2.08; P = .009) and lower overall mortality (hazard ratio, .46; 95% CI, .26 to .82; P = .008) rates compared with those without a G-CSF regimen.	Cyclophosphamide	35-37	colony stimulating factor 3	Homo sapiens	299-304
26057332-6	2015	Second, the regulation of G-CSF and its receptor was measured following eccentric exercise-induced muscle damage and the expression levels we investigated for redox sensitivity by administering the antioxidant N-acetylcysteine (NAC).	Acetylcysteine	210-226	colony stimulating factor 3	Homo sapiens	26-31
25517250-8	2015	Epinephrine and G-CSF-induced up-regulation of CXCR4 mRNA is dependent on beta receptors, so incubation of HSCs with propranolol led to inhibition of such increased expression.	Propranolol	117-128	colony stimulating factor 3	Homo sapiens	16-21
26021434-1	2015	We treated 60 relapsed/refractory mixed-phenotype acute leukemia patients (MPAL-1) with increasing the aclarubicin dose in CAG regimen (HD-CAG, cytarabine (10 mg/m(2)/12 h, days 1-14), aclarubicin (5-7 mg/m(2)/day, days 1-14), granulocyte colony-stimulating factor (200 mug/m(2)/day, days 1-14).	Aclarubicin	103-114	colony stimulating factor 3	Homo sapiens	227-264
26254266-3	2015	A polyethylene glycol-modified form of G-CSF is approved for the treatment of neutropenias.	Polyethylene Glycols	2-21	colony stimulating factor 3	Homo sapiens	39-44
25854308-0	2015	Sulfasalazine-induced DRESS and severe agranulocytosis successfully treated by granulocyte colony-stimulating factor.	Sulfasalazine	0-13	colony stimulating factor 3	Homo sapiens	79-116
25529330-0	2015	Arecoline increases basic fibroblast growth factor but reduces expression of IL-1, IL-6, G-CSF and GM-CSF in human umbilical vein endothelium.	Arecoline	0-9	colony stimulating factor 3	Homo sapiens	89-94
26049123-14	2015	CONCLUSION: Weekly paclitaxel/carboplatin with G-CSF is an effective treatment with acceptable toxicity in patients with platinum-resistant or platinum-refractory OC, advanced or recurrent EC and CC.	Paclitaxel	19-29	colony stimulating factor 3	Homo sapiens	47-52
26049123-14	2015	CONCLUSION: Weekly paclitaxel/carboplatin with G-CSF is an effective treatment with acceptable toxicity in patients with platinum-resistant or platinum-refractory OC, advanced or recurrent EC and CC.	Carboplatin	30-41	colony stimulating factor 3	Homo sapiens	47-52
26049123-14	2015	CONCLUSION: Weekly paclitaxel/carboplatin with G-CSF is an effective treatment with acceptable toxicity in patients with platinum-resistant or platinum-refractory OC, advanced or recurrent EC and CC.	Platinum	121-129	colony stimulating factor 3	Homo sapiens	47-52
25772027-7	2015	The use of tacrolimus-based immunosuppression and granulocyte colony-stimulating factor were associated with decreased PGF risk.	Prostaglandins F	119-122	colony stimulating factor 3	Homo sapiens	50-87
26178004-0	2015	Hyperleucocytosis following G-CSF treatment for sulfasalazine-induced agranulocytosis.	Sulfasalazine	48-61	colony stimulating factor 3	Homo sapiens	28-33
25721167-3	2015	Plerixafor (PL) is a chemokine receptor CXC Type 4-stromal-derived factor 1 inhibitor; its HSC-mobilizing properties are synergistic with G-CSF in poor mobilizing patients.	plerixafor	0-10	colony stimulating factor 3	Homo sapiens	138-143
26086621-7	2015	95% sequence coverage was obtained by reducing human granulocyte-colony stimulating factor (G-CSF) prior to MS/MS and MS(3) analysis to specifically target the residues between the disulfide bonds.	Disulfides	181-190	colony stimulating factor 3	Homo sapiens	53-90
26086621-7	2015	95% sequence coverage was obtained by reducing human granulocyte-colony stimulating factor (G-CSF) prior to MS/MS and MS(3) analysis to specifically target the residues between the disulfide bonds.	Disulfides	181-190	colony stimulating factor 3	Homo sapiens	92-97
26176698-4	2015	We evaluated if prolonged inflammation driven by low dose G-CSF-mobilized human PBMCs (G-hPBMCs) would lead to cGvHD following cyclophosphamide (CTX) administration and total body irradiation (TBI) in NSG mice.	Cyclophosphamide	127-143	colony stimulating factor 3	Homo sapiens	58-63
26039405-1	2015	D5h star-like CsF5 , formally isoelectronic with known XeF5 (-) ion, is computed to be a local minimum on the potential energy surface of CsF5 , surrounded by reasonably large activation energies for its exothermic decomposition to CsF+2 F2 , or to CsF3  (three isomeric forms)+F2 , or for rearrangement to a significantly more stable isomer, a classical Cs(+) complex of F5 (-) .	vidofludimus	0-3	colony stimulating factor 3	Homo sapiens	249-253
26039405-1	2015	D5h star-like CsF5 , formally isoelectronic with known XeF5 (-) ion, is computed to be a local minimum on the potential energy surface of CsF5 , surrounded by reasonably large activation energies for its exothermic decomposition to CsF+2 F2 , or to CsF3  (three isomeric forms)+F2 , or for rearrangement to a significantly more stable isomer, a classical Cs(+) complex of F5 (-) .	Cesium	14-16	colony stimulating factor 3	Homo sapiens	249-253
25751646-4	2015	All patients in the plerixafor group (n=27) received G-CSF and plerixafor preemptively based on an established algorithm.	plerixafor	20-30	colony stimulating factor 3	Homo sapiens	53-58
25891070-1	2015	Vinorelbine chemotherapy with G-CSF stimulation is the standard mobilization regimen in Switzerland for multiple myeloma patients.	Vinorelbine	0-11	colony stimulating factor 3	Homo sapiens	30-35
25851633-10	2015	In the meta-analysis of placebo-controlled studies comparing G-CSF primary prophylaxis with placebo in the as-treated analysis sets, the HR (95% CI) for OS was 0.77 (0.58-1.03).	Arsenic	107-109	colony stimulating factor 3	Homo sapiens	61-66
25851633-10	2015	In the meta-analysis of placebo-controlled studies comparing G-CSF primary prophylaxis with placebo in the as-treated analysis sets, the HR (95% CI) for OS was 0.77 (0.58-1.03).	Osmium	153-155	colony stimulating factor 3	Homo sapiens	61-66
26114754-4	2015	In this study, we showed that U0126, a MEK1/2 inhibitor, decreases lipopolysaccharide (LPS)-stimulated G-CSF promoter activity, mRNA expression and protein secretion.	U 0126	30-35	colony stimulating factor 3	Homo sapiens	103-108
26114754-7	2015	Further chromatin immunoprecipitation (ChIP) assays revealed that U0126 inhibits LPS-induced binding of NF-kappaB (p50/p65) and C/EBPbeta to the G-CSF promoter, but not their nuclear protein levels.	U 0126	66-71	colony stimulating factor 3	Homo sapiens	145-150
25578474-2	2015	Plerixafor, a specific antagonist of the chemokine receptor CXCR4, can rescue some but not all patients who failed to mobilize with G-CSF alone.	plerixafor	0-10	colony stimulating factor 3	Homo sapiens	132-137
25293363-7	2015	Mobilization-related toxicity was also, however, augmented by Cy; 14% of Cy+G-CSF patients were hospitalized because of complications versus none receiving G-CSF (P &lt; 0.0001).	Cyclophosphamide	62-64	colony stimulating factor 3	Homo sapiens	73-81
25293363-7	2015	Mobilization-related toxicity was also, however, augmented by Cy; 14% of Cy+G-CSF patients were hospitalized because of complications versus none receiving G-CSF (P &lt; 0.0001).	Cyclophosphamide	62-64	colony stimulating factor 3	Homo sapiens	76-81
25689616-0	2015	G-CSF treatment can attenuate dexamethasone-induced reduction in C2C12 myotube protein synthesis.	Dexamethasone	30-43	colony stimulating factor 3	Homo sapiens	0-5
25888304-1	2015	Dormant leukemia cells, which might escape the cytotoxic effect of conditioning before hematopoietic stem cell transplantation (HSCT), could be induced to enter the cell cycle by granulocyte colony-stimulating factor (G-CSF) and become more susceptible to the cell-cycle-specific agent cytarabine arabinoside (Ara-C).	cytarabine arabinoside	286-308	colony stimulating factor 3	Homo sapiens	218-223
25888304-1	2015	Dormant leukemia cells, which might escape the cytotoxic effect of conditioning before hematopoietic stem cell transplantation (HSCT), could be induced to enter the cell cycle by granulocyte colony-stimulating factor (G-CSF) and become more susceptible to the cell-cycle-specific agent cytarabine arabinoside (Ara-C).	Cytarabine	310-315	colony stimulating factor 3	Homo sapiens	218-223
25888304-2	2015	Based on this effect, we have utilized G-CSF-combined high-dose Ara-C in myeloablative conditioning for allogeneic bone marrow or peripheral blood stem cell transplantation from HLA-identical family donors since 1988.	Cytarabine	64-69	colony stimulating factor 3	Homo sapiens	39-44
25888304-3	2015	We report on the long-term outcomes of allogeneic HSCT using a conditioning regimen of 12Gy total body irradiation and G-CSF-combined high-dose Ara-C in 89 adult patients with acute myeloid leukemia, chronic myelogenous leukemia, or myelodysplastic syndrome.	Cytarabine	144-149	colony stimulating factor 3	Homo sapiens	119-124
31149423-10	2016	As the third line chemotherapy, the combination consisting of doxorubicin and ifosfamide was administered and showed a good therapeutic effect and normalized white blood cell count and serum G-CSF level.	Doxorubicin	62-73	colony stimulating factor 3	Homo sapiens	191-196
31149423-10	2016	As the third line chemotherapy, the combination consisting of doxorubicin and ifosfamide was administered and showed a good therapeutic effect and normalized white blood cell count and serum G-CSF level.	Ifosfamide	78-88	colony stimulating factor 3	Homo sapiens	191-196
25791363-2	2015	METHODS: In this open-label phase 1 study, docetaxel (60 or 75 mg/m(2); 1-h intravenous infusion) was given on day 1 of a 21-day cycle in combination with escalating doses of trabectedin (0.4-1.3 mg/m(2) by 3-h intravenous infusion, 1 h after docetaxel) and prophylactic granulocyte colony-stimulating factor (G-CSF).	Docetaxel	43-52	colony stimulating factor 3	Homo sapiens	271-308
25791363-2	2015	METHODS: In this open-label phase 1 study, docetaxel (60 or 75 mg/m(2); 1-h intravenous infusion) was given on day 1 of a 21-day cycle in combination with escalating doses of trabectedin (0.4-1.3 mg/m(2) by 3-h intravenous infusion, 1 h after docetaxel) and prophylactic granulocyte colony-stimulating factor (G-CSF).	Docetaxel	43-52	colony stimulating factor 3	Homo sapiens	310-315
25791363-11	2015	CONCLUSION: In patients with previously treated, advanced malignancies, the combination of therapeutic doses of trabectedin and docetaxel showed clinical activity and was tolerable with prophylactic G-CSF, with no evidence of clinically important drug interactions.	Trabectedin	112-123	colony stimulating factor 3	Homo sapiens	199-204
25791363-11	2015	CONCLUSION: In patients with previously treated, advanced malignancies, the combination of therapeutic doses of trabectedin and docetaxel showed clinical activity and was tolerable with prophylactic G-CSF, with no evidence of clinically important drug interactions.	Docetaxel	128-137	colony stimulating factor 3	Homo sapiens	199-204
25689616-6	2015	Here we show for the first time that treatment with moderate doses (4 and 40ng/ml) of G-CSF attenuates the effects of dexamethasone in reducing protein synthesis in C2C12 myotubes.	Dexamethasone	118-131	colony stimulating factor 3	Homo sapiens	86-91
25689616-7	2015	However, a higher dose (100ng/ml) of G-CSF exacerbates the dexamethasone-induced reduction in protein synthesis.	Dexamethasone	59-72	colony stimulating factor 3	Homo sapiens	37-42
25892894-3	2015	In this study, we report the development of t-acute promyelocytic leukemia in a cT4N1M0 gastric cancer patient after an approximate 44 mo latency period following treatment with 4 cycles of oxaliplatin (OXP) (85 mg/m(2) on day 1) plus capecitabine (1250 mg/m(2) orally twice daily on days 1-14) in combination with recombinant human granulocyte-colony stimulating factor treatment.	Oxaliplatin	190-201	colony stimulating factor 3	Homo sapiens	333-370
25693946-0	2015	Effects of sucrose and benzyl alcohol on GCSF conformational dynamics revealed by hydrogen deuterium exchange mass spectrometry.	Sucrose	11-18	colony stimulating factor 3	Homo sapiens	41-45
25693946-0	2015	Effects of sucrose and benzyl alcohol on GCSF conformational dynamics revealed by hydrogen deuterium exchange mass spectrometry.	Benzyl Alcohol	23-37	colony stimulating factor 3	Homo sapiens	41-45
25693946-0	2015	Effects of sucrose and benzyl alcohol on GCSF conformational dynamics revealed by hydrogen deuterium exchange mass spectrometry.	Hydrogen	82-90	colony stimulating factor 3	Homo sapiens	41-45
25693946-0	2015	Effects of sucrose and benzyl alcohol on GCSF conformational dynamics revealed by hydrogen deuterium exchange mass spectrometry.	Deuterium	91-100	colony stimulating factor 3	Homo sapiens	41-45
25693946-4	2015	In this study, we examined the roles of the excipients, sucrose and benzyl alcohol, on the conformational dynamics of recombinant human granulocyte colony stimulating factor using hydrogen/deuterium exchange coupled with mass spectrometry (HDX-MS).	Sucrose	56-63	colony stimulating factor 3	Homo sapiens	136-173
25693946-4	2015	In this study, we examined the roles of the excipients, sucrose and benzyl alcohol, on the conformational dynamics of recombinant human granulocyte colony stimulating factor using hydrogen/deuterium exchange coupled with mass spectrometry (HDX-MS).	Benzyl Alcohol	68-82	colony stimulating factor 3	Homo sapiens	136-173
25693946-4	2015	In this study, we examined the roles of the excipients, sucrose and benzyl alcohol, on the conformational dynamics of recombinant human granulocyte colony stimulating factor using hydrogen/deuterium exchange coupled with mass spectrometry (HDX-MS).	Hydrogen	180-188	colony stimulating factor 3	Homo sapiens	136-173
25693946-4	2015	In this study, we examined the roles of the excipients, sucrose and benzyl alcohol, on the conformational dynamics of recombinant human granulocyte colony stimulating factor using hydrogen/deuterium exchange coupled with mass spectrometry (HDX-MS).	Deuterium	189-198	colony stimulating factor 3	Homo sapiens	136-173
25763784-6	2015	Systemic levels of IFN-alpha and cervicovaginal fluid levels of IFN-alpha, CXCL10, monocyte chemotactic protein-1, and granulocyte-colony stimulating factor were significantly lower in DMPA users compared to control volunteers not using hormonal contraception.	Medroxyprogesterone Acetate	185-189	colony stimulating factor 3	Homo sapiens	119-156
25981661-2	2015	In this study, we report 2 cases of pancreatic cancer treated with FOLFIRINOX and G-CSF prophylaxis at the standard therapeutic dose, after treatment with gemcitabine and S-1 chemotherapy failed.	gemcitabine	155-166	colony stimulating factor 3	Homo sapiens	82-87
25641128-1	2015	BACKGROUND: Plerixafor in combination with granulocyte-colony-stimulating factor (G-CSF) is approved for the use of stem cell collection in patients who fail to mobilize on G-CSF.	plerixafor	12-22	colony stimulating factor 3	Homo sapiens	173-178
25892894-3	2015	In this study, we report the development of t-acute promyelocytic leukemia in a cT4N1M0 gastric cancer patient after an approximate 44 mo latency period following treatment with 4 cycles of oxaliplatin (OXP) (85 mg/m(2) on day 1) plus capecitabine (1250 mg/m(2) orally twice daily on days 1-14) in combination with recombinant human granulocyte-colony stimulating factor treatment.	Oxaliplatin	203-206	colony stimulating factor 3	Homo sapiens	333-370
25849550-0	2015	G-CSF protects human brain vascular endothelial cells injury induced by high glucose, free fatty acids and hypoxia through MAPK and Akt signaling.	Glucose	77-84	colony stimulating factor 3	Homo sapiens	0-5
25849550-0	2015	G-CSF protects human brain vascular endothelial cells injury induced by high glucose, free fatty acids and hypoxia through MAPK and Akt signaling.	Fatty Acids, Nonesterified	86-102	colony stimulating factor 3	Homo sapiens	0-5
25849550-5	2015	We observed that pretreatment of the cultured human brain vascular endothelial cells (HBVECs) with G-CSF largely prevented cell death induced by the combination stimulus with high glucose, free fatty acids (FFA) and hypoxia by increasing cell viability, decreasing apoptosis and caspase-3 activity.	Glucose	180-187	colony stimulating factor 3	Homo sapiens	99-104
25849550-5	2015	We observed that pretreatment of the cultured human brain vascular endothelial cells (HBVECs) with G-CSF largely prevented cell death induced by the combination stimulus with high glucose, free fatty acids (FFA) and hypoxia by increasing cell viability, decreasing apoptosis and caspase-3 activity.	Fatty Acids, Nonesterified	189-205	colony stimulating factor 3	Homo sapiens	99-104
25849550-5	2015	We observed that pretreatment of the cultured human brain vascular endothelial cells (HBVECs) with G-CSF largely prevented cell death induced by the combination stimulus with high glucose, free fatty acids (FFA) and hypoxia by increasing cell viability, decreasing apoptosis and caspase-3 activity.	Fatty Acids, Nonesterified	207-210	colony stimulating factor 3	Homo sapiens	99-104
25849550-7	2015	The results from fluorescent probe Fluo-3/AM showed that G-CSF greatly suppressed the levels of intracellular calcium ions under combination stimulus.	Fluo-3	35-41	colony stimulating factor 3	Homo sapiens	57-62
25849550-7	2015	The results from fluorescent probe Fluo-3/AM showed that G-CSF greatly suppressed the levels of intracellular calcium ions under combination stimulus.	Calcium	110-117	colony stimulating factor 3	Homo sapiens	57-62
25849550-10	2015	Overall, G-CSF is capable of alleviating HBVECs injury triggered by the combination administration with high glucose, FFA and hypoxia involving the mitogen-activated protein kinases (MAPK) and Akt signaling cascades.	Glucose	109-116	colony stimulating factor 3	Homo sapiens	9-14
25595138-8	2015	Improvements in ACQ and/or AQLQ scores with atorvastatin and ICS were associated with decreases in G-CSF, IL-7, CCL2 and CXCL8.	acenaphthenequinone	16-19	colony stimulating factor 3	Homo sapiens	99-104
25394884-5	2015	RESULTS: Increasing concentrations of glucose significantly increased trophoblast secretion of the inflammatory cytokines/chemokines: IL-1beta, IL-6, IL-8, GRO-alpha, RANTES, and G-CSF; significantly increased trophoblast secretion of the anti-angiogenic factors sFlt-1 and sEndoglin; and significantly decreased trophoblast migration.	Glucose	38-45	colony stimulating factor 3	Homo sapiens	179-184
25595138-8	2015	Improvements in ACQ and/or AQLQ scores with atorvastatin and ICS were associated with decreases in G-CSF, IL-7, CCL2 and CXCL8.	aqlq	27-31	colony stimulating factor 3	Homo sapiens	99-104
25595138-7	2015	Atorvastatin significantly reduced sputum concentrations of CCL7, IL-12p70, sCD40L, FGF-2, CCL4, TGF-alpha and MMP-8 compared with placebo and, when combined with inhaled beclometasone, reduced sputum concentrations of MMP-8, IL-1beta, IL-10, MMP-9, sCD40L, FGF-2, IL-7, G-CSF and CCL7 compared to ICS alone.	Atorvastatin	0-12	colony stimulating factor 3	Homo sapiens	271-276
25595138-8	2015	Improvements in ACQ and/or AQLQ scores with atorvastatin and ICS were associated with decreases in G-CSF, IL-7, CCL2 and CXCL8.	Atorvastatin	44-56	colony stimulating factor 3	Homo sapiens	99-104
25805962-14	2015	These results suggest G-CSF activates STAT5 through the JAK pathway in combination with ATRA, resulting in myeloid differentiation in HT93A cells.	Tretinoin	88-92	colony stimulating factor 3	Homo sapiens	22-27
25354577-3	2015	STUDY DESIGN AND METHODS: We report on 33 patients diagnosed with lymphoma who had at least one prior mobilization failure and received cytarabine at a dose of 400 mg/m(2) /day intravenously x 3 days plus granulocyte-colony-stimulating factor (G-CSF) 10 to 12 mug/kg/day as mobilization regimen.	Cytarabine	136-146	colony stimulating factor 3	Homo sapiens	205-242
25354577-3	2015	STUDY DESIGN AND METHODS: We report on 33 patients diagnosed with lymphoma who had at least one prior mobilization failure and received cytarabine at a dose of 400 mg/m(2) /day intravenously x 3 days plus granulocyte-colony-stimulating factor (G-CSF) 10 to 12 mug/kg/day as mobilization regimen.	Cytarabine	136-146	colony stimulating factor 3	Homo sapiens	244-249
25805962-0	2015	Granulocyte colony-stimulating factor potentiates all-trans retinoic acid-induced granulocytic differentiation in acute promyelocytic leukemia cell line HT93A.	Tretinoin	60-73	colony stimulating factor 3	Homo sapiens	0-37
25663885-2	2015	The present study describes a case of complete remission in an elderly patient with AML transformed from chronic myelomonocytic leukemia (CMML) and the treatment of the case with decitabine in combination with cytarabine, aclarubicin and granulocyte colony-stimulating factor (CAG).	Decitabine	179-189	colony stimulating factor 3	Homo sapiens	238-275
25805962-7	2015	RESULTS: ATRA (100 nM) induced granulocytic differentiation (upregulation of CD11b and downregulation of CD34) and the effect was potentiated by addition of G-CSF, while G-CSF alone had no effect on HT93A cells.	Tretinoin	9-13	colony stimulating factor 3	Homo sapiens	157-162
25805962-7	2015	RESULTS: ATRA (100 nM) induced granulocytic differentiation (upregulation of CD11b and downregulation of CD34) and the effect was potentiated by addition of G-CSF, while G-CSF alone had no effect on HT93A cells.	Tretinoin	9-13	colony stimulating factor 3	Homo sapiens	170-175
25805962-13	2015	Janus kinase (JAK) inhibitor ruxolitinib (320 nM) had little or no effect on ATRA-induced differentiation, but eliminated the enhancing effect of G-CSF, as evidenced by the levels of CD11b and CD34 expression.	ruxolitinib	29-40	colony stimulating factor 3	Homo sapiens	146-151
24884311-5	2015	We observed that intravenously administered plerixafor can be safely combined with vinorelbine/G-CSF.	plerixafor	44-54	colony stimulating factor 3	Homo sapiens	95-100
24884311-8	2015	Plerixafor can be safely added to G-CSF and/or vinorelbine chemotherapy.	plerixafor	0-10	colony stimulating factor 3	Homo sapiens	34-39
25174614-6	2015	In toxicokinetic studies, the serum concentration of GW003 after the eighth injection was much lower than it was after the first injection, and a neutralizing antibody against G-CSF was found to have a dose-dependent effect upon the treatment groups.	gw003	53-58	colony stimulating factor 3	Homo sapiens	176-181
24738975-0	2015	Intermittent granulocyte colony-stimulating factor for neutropenia management in patients with relapsed or refractory multiple myeloma treated with lenalidomide plus dexamethasone.	Lenalidomide	148-160	colony stimulating factor 3	Homo sapiens	13-50
25174614-0	2015	The induction of prolonged myelopoietic effects in monkeys by GW003, a recombinant human granulocyte colony-stimulating factor genetically fused to recombinant human albumin.	gw003	62-67	colony stimulating factor 3	Homo sapiens	89-126
25407640-6	2015	Peg-GCSF was filled in an EtO sterilized delivery device and incubated at accelerated stress conditions.	Polyethylene Glycols	0-3	colony stimulating factor 3	Homo sapiens	4-8
25407640-7	2015	Glu-C peptide mapping and LC-MS analyses revealed residual EtO reacted with Peg-GCSF and resulted in EtO modifications at two methionine residues (Met-127 and Met-138).	Ethylene Oxide	59-62	colony stimulating factor 3	Homo sapiens	80-84
25407640-7	2015	Glu-C peptide mapping and LC-MS analyses revealed residual EtO reacted with Peg-GCSF and resulted in EtO modifications at two methionine residues (Met-127 and Met-138).	Polyethylene Glycols	76-79	colony stimulating factor 3	Homo sapiens	80-84
24738975-0	2015	Intermittent granulocyte colony-stimulating factor for neutropenia management in patients with relapsed or refractory multiple myeloma treated with lenalidomide plus dexamethasone.	Dexamethasone	166-179	colony stimulating factor 3	Homo sapiens	13-50
24738975-7	2015	Intermittent G-CSF may be an effective approach for lenalidomide dose-preservation, which may lead to improved outcomes, although it does not prevent infections or thrombocytopenia-related dose limitations.	Lenalidomide	52-64	colony stimulating factor 3	Homo sapiens	13-18
26732055-4	2015	The main action of G-CSF - G-CSFR linkage is stimulation of the production, mobilization, survival and chemotaxis of neutrophils, but there are many other G-CSF effects: growth and migration of endothelial cells, decrease of norepinephrine reuptake, increase in osteoclastic activity and decrease in osteoblast activity.	Norepinephrine	225-239	colony stimulating factor 3	Homo sapiens	19-24
25665603-0	2015	[Unfractionated heparin inhibits lipopolysaccharide-induced expression of granulocyte colony-stimulating factor in human endothelial cells through Toll-like receptor 4 signaling pathway].	Heparin	16-23	colony stimulating factor 3	Homo sapiens	74-111
25494484-3	2015	Human erythropoietin (hEPO) or granulocyte colony-stimulating factor (hGCSF) was independently fused into CDR3H, CDR2H, or CDR3L of Herceptin using an engineered "stalk" motif.	cdr3h	106-111	colony stimulating factor 3	Homo sapiens	31-68
25494484-3	2015	Human erythropoietin (hEPO) or granulocyte colony-stimulating factor (hGCSF) was independently fused into CDR3H, CDR2H, or CDR3L of Herceptin using an engineered "stalk" motif.	cdr3h	106-111	colony stimulating factor 3	Homo sapiens	70-75
25494484-3	2015	Human erythropoietin (hEPO) or granulocyte colony-stimulating factor (hGCSF) was independently fused into CDR3H, CDR2H, or CDR3L of Herceptin using an engineered "stalk" motif.	cdr2h	113-118	colony stimulating factor 3	Homo sapiens	70-75
25494484-3	2015	Human erythropoietin (hEPO) or granulocyte colony-stimulating factor (hGCSF) was independently fused into CDR3H, CDR2H, or CDR3L of Herceptin using an engineered "stalk" motif.	cdr3l	123-128	colony stimulating factor 3	Homo sapiens	70-75
25640368-0	2015	Clinical study on safety and efficacy of JiSaiXin (recombinant human granulocyte colony stimulating factor injection manufactured in China) for Chinese undergoing chemotherapy.	jisaixin	41-49	colony stimulating factor 3	Homo sapiens	69-106
25461798-3	2015	Here, hydrogen/deuterium exchange mass spectrometry (HDX-MS) was used to study the effects of arginine on recombinant human granulocyte colony-stimulating factor (rhG-CSF) refolding at the scale of peptide mapping.	Arginine	94-102	colony stimulating factor 3	Homo sapiens	124-161
25186439-2	2015	Our objectives were to establish model-based decision rules from early absolute neutrophil counts (ANC) to anticipate prolonged high grade neutropenia at cycle 1 and to prevent it through delayed granulocyte colony stimulating factor (G-CSF) administration in carboplatin-treated patients.	Carboplatin	260-271	colony stimulating factor 3	Homo sapiens	196-233
25665603-1	2015	OBJECTIVE: To determine the effect of unfractionated heparin (UFH) on lipopolysaccharide (LPS)-induced expression of granulocyte colony-stimulating factor (G-CSF), and the role of Toll-like receptor 4 (TLR4) signaling pathway in this process.	Heparin	53-60	colony stimulating factor 3	Homo sapiens	117-154
25665603-1	2015	OBJECTIVE: To determine the effect of unfractionated heparin (UFH) on lipopolysaccharide (LPS)-induced expression of granulocyte colony-stimulating factor (G-CSF), and the role of Toll-like receptor 4 (TLR4) signaling pathway in this process.	Heparin	53-60	colony stimulating factor 3	Homo sapiens	156-161
25665603-1	2015	OBJECTIVE: To determine the effect of unfractionated heparin (UFH) on lipopolysaccharide (LPS)-induced expression of granulocyte colony-stimulating factor (G-CSF), and the role of Toll-like receptor 4 (TLR4) signaling pathway in this process.	Heparin	62-65	colony stimulating factor 3	Homo sapiens	117-154
25665603-1	2015	OBJECTIVE: To determine the effect of unfractionated heparin (UFH) on lipopolysaccharide (LPS)-induced expression of granulocyte colony-stimulating factor (G-CSF), and the role of Toll-like receptor 4 (TLR4) signaling pathway in this process.	Heparin	62-65	colony stimulating factor 3	Homo sapiens	156-161
25640368-1	2015	OBJECTIVES: To assess safety and efficacy of JiSaiXin (Recombinant Human Granulocyte Colony Stimulating Factor Injection manufactured in China, G-CSF) 150ug per day for three days and whether this regimen could reduce the incidence of febrile neutropenia caused by chemotherapy.	jisaixin	45-53	colony stimulating factor 3	Homo sapiens	73-110
25458084-7	2015	HHT was given in combination with cytarabine, daunorubicin, idarubicin, aclacinomycin, mitoxantrone, or granulocyte colony-stimulating factor.	Homoharringtonine	0-3	colony stimulating factor 3	Homo sapiens	104-141
26732055-4	2015	The main action of G-CSF - G-CSFR linkage is stimulation of the production, mobilization, survival and chemotaxis of neutrophils, but there are many other G-CSF effects: growth and migration of endothelial cells, decrease of norepinephrine reuptake, increase in osteoclastic activity and decrease in osteoblast activity.	Norepinephrine	225-239	colony stimulating factor 3	Homo sapiens	27-33
26732055-4	2015	The main action of G-CSF - G-CSFR linkage is stimulation of the production, mobilization, survival and chemotaxis of neutrophils, but there are many other G-CSF effects: growth and migration of endothelial cells, decrease of norepinephrine reuptake, increase in osteoclastic activity and decrease in osteoblast activity.	Norepinephrine	225-239	colony stimulating factor 3	Homo sapiens	27-32
25450254-1	2015	We assessed the feasibility of developing a suitable international reference standard for determination of in vitro biological activity of human sequence recombinant PEG-G-CSF products with a 20kD linear PEG linked to the N-terminal methionyl residue of G-CSF (INN Filgrastim), produced using a conjugation process and coupling chemistry similar to that employed for the lead PEGfilgrastim product.	Polyethylene Glycols	166-169	colony stimulating factor 3	Homo sapiens	170-175
24964172-0	2015	The efficiency of granulocyte colony-stimulating factor in hemorrhagic mucositis and febrile neutropenia resulted from methotrexate toxicity.	Methotrexate	119-131	colony stimulating factor 3	Homo sapiens	18-55
24964172-10	2015	Here, we presented a case of hemorrhagic mucositis and febrile neutropenia resulted from high-dose MTX that responded very well to granulocyte colony-stimulating factor treatment and we reviewed the literature.	Methotrexate	99-102	colony stimulating factor 3	Homo sapiens	131-168
26631878-0	2015	Efficacy of Prophylactic G-CSF in Patients Receiving FOLFIRINOX: A Preliminary Retrospective Study.	folfirinox	53-63	colony stimulating factor 3	Homo sapiens	25-30
26631878-3	2015	The aim of this retrospective study was to investigate the incidence of FN or severe neutropenia induced by full-dose FOLFIRINOX administration with G-CSF prophylaxis during the first cycle of treatment.	folfirinox	118-128	colony stimulating factor 3	Homo sapiens	149-154
26631878-4	2015	METHODS: Patients with advanced pancreatic cancer who received FOLFIRINOX with G-CSF prophylaxis during the first cycle of treatment from January 2014 to August 2014 were investigated and the frequency of adverse events during the first cycle was measured.	folfirinox	63-73	colony stimulating factor 3	Homo sapiens	79-84
26631878-10	2015	CONCLUSION: Although the present study was retrospective and small, the simultaneous administration of G-CSF might be effective for the prevention of severe neutropenia and FN in patients treated with FOLFIRINOX.	folfirinox	201-211	colony stimulating factor 3	Homo sapiens	103-108
25450254-4	2015	Results indicated that on the basis of parallelism, the current WHO 2nd IS for G-CSF or any of the PEG-G-CSF samples could be used as the international standard for PEG-G-CSF preparations.	Polyethylene Glycols	99-102	colony stimulating factor 3	Homo sapiens	103-108
25450254-4	2015	Results indicated that on the basis of parallelism, the current WHO 2nd IS for G-CSF or any of the PEG-G-CSF samples could be used as the international standard for PEG-G-CSF preparations.	Polyethylene Glycols	99-102	colony stimulating factor 3	Homo sapiens	103-108
25450254-5	2015	However, because of the variability in potency estimates seen when PEG-G-CSF preparations were compared with the current WHO 2nd IS for G-CSF, a candidate PEG-G-CSF was suitable as the WHO IS.	Polyethylene Glycols	67-70	colony stimulating factor 3	Homo sapiens	71-76
25439845-1	2015	OBJECTIVE: To determine whether granulocyte colony-stimulating factor (G-CSF) could prevent loss of spermatogenesis induced by busulfan chemotherapy via protection of undifferentiated spermatogonia, which might serve as an adjuvant approach to preserving male fertility among cancer patients.	Busulfan	127-135	colony stimulating factor 3	Homo sapiens	32-69
25439845-1	2015	OBJECTIVE: To determine whether granulocyte colony-stimulating factor (G-CSF) could prevent loss of spermatogenesis induced by busulfan chemotherapy via protection of undifferentiated spermatogonia, which might serve as an adjuvant approach to preserving male fertility among cancer patients.	Busulfan	127-135	colony stimulating factor 3	Homo sapiens	71-76
24806275-2	2015	The goal of this study was to investigate the potential for Mn(2+), via its pro-oxidative properties, to activate production of pro-inflammatory cytokines/chemokines IL-1beta, IL-6, IL-8, IFNgamma, TNFalpha, and G-CSF by human monocyte-derived macrophages in vitro.	Manganese(2+)	60-66	colony stimulating factor 3	Homo sapiens	212-217
24806275-6	2015	In the case of LPS and MnCl2 combinations, the observed increases in production of IL-1beta, IL-6, IL-8, IFNgamma, and G-CSF were greater than those seen with cells exposed to the individual agents.	manganese chloride	23-28	colony stimulating factor 3	Homo sapiens	119-124
25450254-2	2015	Based on initial data which showed that the current WHO 2nd international standard, IS for G-CSF (09/136) or alternatively, a PEG-G-CSF standard with a unitage traceable to the G-CSF IS may potentially serve as the IS for PEG-G-CSF products, two candidate preparations of PEG-G-CSF were formulated and lyophilized at NIBSC.	Polyethylene Glycols	126-129	colony stimulating factor 3	Homo sapiens	130-135
25450254-2	2015	Based on initial data which showed that the current WHO 2nd international standard, IS for G-CSF (09/136) or alternatively, a PEG-G-CSF standard with a unitage traceable to the G-CSF IS may potentially serve as the IS for PEG-G-CSF products, two candidate preparations of PEG-G-CSF were formulated and lyophilized at NIBSC.	Polyethylene Glycols	126-129	colony stimulating factor 3	Homo sapiens	130-135
25450254-2	2015	Based on initial data which showed that the current WHO 2nd international standard, IS for G-CSF (09/136) or alternatively, a PEG-G-CSF standard with a unitage traceable to the G-CSF IS may potentially serve as the IS for PEG-G-CSF products, two candidate preparations of PEG-G-CSF were formulated and lyophilized at NIBSC.	Polyethylene Glycols	126-129	colony stimulating factor 3	Homo sapiens	130-135
25450254-2	2015	Based on initial data which showed that the current WHO 2nd international standard, IS for G-CSF (09/136) or alternatively, a PEG-G-CSF standard with a unitage traceable to the G-CSF IS may potentially serve as the IS for PEG-G-CSF products, two candidate preparations of PEG-G-CSF were formulated and lyophilized at NIBSC.	Polyethylene Glycols	126-129	colony stimulating factor 3	Homo sapiens	130-135
25665464-0	2015	The addition of granulocyte-colony stimulating factor shifts the dose limiting toxicity and markedly increases the maximum tolerated dose and activity of the kinesin spindle protein inhibitor SB-743921 in patients with relapsed or refractory lymphoma: results of an international, multicenter phase I/II study.	SB 743921	192-201	colony stimulating factor 3	Homo sapiens	16-53
25373509-4	2015	After stimulation with G-CSF, STAT5 but not STAT3 was significantly phosphorylated in both nilotinib-treated and untreated cells.	nilotinib	91-100	colony stimulating factor 3	Homo sapiens	23-28
26366343-3	2015	We encountered a patient with a G-CSF-induced pancreatic cancer who was treated by surgical resection, followed by steroid treatment and chemotherapy.	Steroids	115-122	colony stimulating factor 3	Homo sapiens	32-37
26228581-6	2015	One-hundred and twenty-nine patients (68%) received cyclophosphamide-recombinant human granulocyte colony-stimulating factor for stem cell mobilization.	Cyclophosphamide	52-68	colony stimulating factor 3	Homo sapiens	87-124
26146654-8	2015	Inhibition of NO synthesis by L-N(G)-Nitroarginine Methyl Ester (L-NAME) significantly reduced the effects of G-CSF on rCBF, NO surge, infarct volume, and neurological deficits.	l-n(g)-nitroarginine methyl ester	30-63	colony stimulating factor 3	Homo sapiens	110-115
26146654-8	2015	Inhibition of NO synthesis by L-N(G)-Nitroarginine Methyl Ester (L-NAME) significantly reduced the effects of G-CSF on rCBF, NO surge, infarct volume, and neurological deficits.	NG-Nitroarginine Methyl Ester	65-71	colony stimulating factor 3	Homo sapiens	110-115
26366343-18	2015	To our knowledge, this patient was the first with a G-CSF producing anaplastic carcinoma of the pancreas to be treated by surgical resection, steroid and adjuvant chemotherapy.	Steroids	142-149	colony stimulating factor 3	Homo sapiens	52-57
25709889-0	2015	Progressive transfusion and growth factor independence with adjuvant sertraline in low risk myelodysplastic syndrome treated with an erythropoiesis stimulating agent and granulocyte-colony stimulating factor.	Sertraline	69-79	colony stimulating factor 3	Homo sapiens	170-207
25489479-5	2014	METHOD: We report details about a patient with treatment-resistant schizophrenia who was given chemotherapy (fludarabine, cyclophosphamide and rituximab) for CLL in the course of concomitant treatment with clozapine and granulocyte-colony stimulating factor (G-CSFs).	fludarabine	109-120	colony stimulating factor 3	Homo sapiens	220-257
25435725-5	2014	G-CSF (PDgrastim) was administered at 300 mug/day subcutaneously on days 4-6 and 11-13. pre- and post-hydration was given according to our hospital protocol.	pdgrastim	7-16	colony stimulating factor 3	Homo sapiens	0-5
25489479-5	2014	METHOD: We report details about a patient with treatment-resistant schizophrenia who was given chemotherapy (fludarabine, cyclophosphamide and rituximab) for CLL in the course of concomitant treatment with clozapine and granulocyte-colony stimulating factor (G-CSFs).	Cyclophosphamide	122-138	colony stimulating factor 3	Homo sapiens	220-257
25489479-5	2014	METHOD: We report details about a patient with treatment-resistant schizophrenia who was given chemotherapy (fludarabine, cyclophosphamide and rituximab) for CLL in the course of concomitant treatment with clozapine and granulocyte-colony stimulating factor (G-CSFs).	Clozapine	206-215	colony stimulating factor 3	Homo sapiens	220-257
25489479-9	2014	CONCLUSION: Continuing with clozapine in the course of chemotherapy may be relatively safer for patients who responded well to clozapine concomitant with G-CSF treatment.	Clozapine	28-37	colony stimulating factor 3	Homo sapiens	154-159
25431865-1	2014	BACKGROUND: According to the results of the international study Relapsed AML 2001/01 response was better after re-induction with L-DNR/FLAG (liposomal daunorubicin, fludarabine, cytarabine, G-CSF) compared to FLAG only but survival rate was not improved.	l-dnr/flag	129-139	colony stimulating factor 3	Homo sapiens	190-195
23371824-1	2014	BACKGROUND: The aim of this study was to evaluate the toxicity and quality of life (QoL) of breast cancer patients treated with a docetaxel-containing chemotherapeutic regimen and to compare adriamycin and cyclophosphamide (AC) for four cycles followed by docetaxel (D) for four cycles with docetaxel, adriamycin, and cyclophosphamide (TAC) for six cycles without primary granulocyte colony-stimulating factor (G-CSF) prophylaxis.	Docetaxel	130-139	colony stimulating factor 3	Homo sapiens	372-409
23371824-1	2014	BACKGROUND: The aim of this study was to evaluate the toxicity and quality of life (QoL) of breast cancer patients treated with a docetaxel-containing chemotherapeutic regimen and to compare adriamycin and cyclophosphamide (AC) for four cycles followed by docetaxel (D) for four cycles with docetaxel, adriamycin, and cyclophosphamide (TAC) for six cycles without primary granulocyte colony-stimulating factor (G-CSF) prophylaxis.	Docetaxel	130-139	colony stimulating factor 3	Homo sapiens	411-416
25330205-0	2014	Adjuvant Docetaxel and Cyclophosphamide (DC) with prophylactic granulocyte colony-stimulating factor (G-CSF) on days 8 &amp;12 in breast cancer patients: a retrospective analysis.	Cyclophosphamide	23-39	colony stimulating factor 3	Homo sapiens	63-100
25130876-7	2014	Among plerixafor-treated patient group, 9 of 11 poor mobilizers who received second-cycle plerixafor mobilization were able to collect higher number of CD34+ cells than that of CD34+ cells during the G-CSF-based first mobilization.	plerixafor	6-16	colony stimulating factor 3	Homo sapiens	200-205
25130876-7	2014	Among plerixafor-treated patient group, 9 of 11 poor mobilizers who received second-cycle plerixafor mobilization were able to collect higher number of CD34+ cells than that of CD34+ cells during the G-CSF-based first mobilization.	plerixafor	90-100	colony stimulating factor 3	Homo sapiens	200-205
25330205-0	2014	Adjuvant Docetaxel and Cyclophosphamide (DC) with prophylactic granulocyte colony-stimulating factor (G-CSF) on days 8 &amp;12 in breast cancer patients: a retrospective analysis.	Cyclophosphamide	23-39	colony stimulating factor 3	Homo sapiens	102-107
25330205-0	2014	Adjuvant Docetaxel and Cyclophosphamide (DC) with prophylactic granulocyte colony-stimulating factor (G-CSF) on days 8 &amp;12 in breast cancer patients: a retrospective analysis.	Deoxycytidine	41-43	colony stimulating factor 3	Homo sapiens	63-100
25330205-0	2014	Adjuvant Docetaxel and Cyclophosphamide (DC) with prophylactic granulocyte colony-stimulating factor (G-CSF) on days 8 &amp;12 in breast cancer patients: a retrospective analysis.	Adenosine Monophosphate	120-123	colony stimulating factor 3	Homo sapiens	63-100
25330205-0	2014	Adjuvant Docetaxel and Cyclophosphamide (DC) with prophylactic granulocyte colony-stimulating factor (G-CSF) on days 8 &amp;12 in breast cancer patients: a retrospective analysis.	Adenosine Monophosphate	120-123	colony stimulating factor 3	Homo sapiens	102-107
25144791-3	2014	In the present investigation, recombinant human granulocyte colony stimulating factor (rhGCSF) was used to explore this relationship since it was previously shown to rapidly undergo non-native aggregation/precipitation under physiological conditions in a reaction attenuated by the addition of sucrose [Krishnan, S.; et al.	Sucrose	294-301	colony stimulating factor 3	Homo sapiens	48-85
25338585-1	2014	This study was purposed to compare the clinical efficacy and adverse reactions of low-dose decitabine combined with CAG regimen (aclarubicin, Ara-C, and G-CSF) and CAG regimen alone in intermediate to high-risk myelodysplastic syndromes (MDS), and evaluate the validity and efficacy of the former regimen as new treatment method of intermediate to high-risk myelodysplastic syndromes.	Decitabine	91-101	colony stimulating factor 3	Homo sapiens	153-158
25070584-0	2014	Characterization of stress-exposed granulocyte colony stimulating factor using ELISA and hydrogen/deuterium exchange mass spectrometry.	Hydrogen	89-97	colony stimulating factor 3	Homo sapiens	35-72
25070584-0	2014	Characterization of stress-exposed granulocyte colony stimulating factor using ELISA and hydrogen/deuterium exchange mass spectrometry.	Deuterium	98-107	colony stimulating factor 3	Homo sapiens	35-72
24821366-0	2014	Efficacy and safety of early G-CSF administration in patients with head and neck cancer treated by docetaxel-cisplatin and 5-fluorouracil (DCF protocol): a retrospective study.	Docetaxel	99-108	colony stimulating factor 3	Homo sapiens	29-34
24821366-0	2014	Efficacy and safety of early G-CSF administration in patients with head and neck cancer treated by docetaxel-cisplatin and 5-fluorouracil (DCF protocol): a retrospective study.	Cisplatin	109-118	colony stimulating factor 3	Homo sapiens	29-34
24821366-0	2014	Efficacy and safety of early G-CSF administration in patients with head and neck cancer treated by docetaxel-cisplatin and 5-fluorouracil (DCF protocol): a retrospective study.	Fluorouracil	123-137	colony stimulating factor 3	Homo sapiens	29-34
24821366-0	2014	Efficacy and safety of early G-CSF administration in patients with head and neck cancer treated by docetaxel-cisplatin and 5-fluorouracil (DCF protocol): a retrospective study.	dcf	139-142	colony stimulating factor 3	Homo sapiens	29-34
24862637-2	2014	We report 41 patients with PGF, treated with granulocyte colony-stimulating factor-mobilized CD34 selected cells, at a median interval from transplant of 140 days, without conditioning and without GVHD prophylaxis.	Prostaglandins F	27-30	colony stimulating factor 3	Homo sapiens	45-82
24845752-8	2014	Total soluble protein containing hG-CSF isolated from positive calli showed proliferative potential when tested on HL-60 cell lines by MTT assay.	monooxyethylene trimethylolpropane tristearate	135-138	colony stimulating factor 3	Homo sapiens	33-39
27708892-4	2014	The patient needed monthly doses of G-CSF for nearly 6 months, and his steroid dose was increased.	Steroids	71-78	colony stimulating factor 3	Homo sapiens	36-41
24532305-0	2014	Retrospective analysis of the use of G-CSF and its impact on dose response for anthracycline plus taxane-based schedules in early breast cancer.	Anthracyclines	79-92	colony stimulating factor 3	Homo sapiens	37-42
24532305-0	2014	Retrospective analysis of the use of G-CSF and its impact on dose response for anthracycline plus taxane-based schedules in early breast cancer.	taxane	98-104	colony stimulating factor 3	Homo sapiens	37-42
24532305-8	2014	CONCLUSIONS: With a wide use of G-CSF in patients treated with adjuvant anthracyclines plus taxane-based schedules, 98 % of patients received a RDI &gt;=85 %.	Anthracyclines	72-86	colony stimulating factor 3	Homo sapiens	32-37
24532305-8	2014	CONCLUSIONS: With a wide use of G-CSF in patients treated with adjuvant anthracyclines plus taxane-based schedules, 98 % of patients received a RDI &gt;=85 %.	taxane	92-98	colony stimulating factor 3	Homo sapiens	32-37
24595405-2	2014	PURPOSE: Primary prophylaxis with granulocyte colony-stimulating factor (G-CSF) is used in many institutions across the UK due to unacceptable febrile neutropenia (FN) rates with FEC-D (fluorouracil, epirubicin, cyclophosphamide-docetaxel).	Fluorouracil	186-198	colony stimulating factor 3	Homo sapiens	34-71
24945073-5	2014	Even after CysQ was removed, the solubility of hFTN-L and hG-CSF, the secondary structure of hG-CSF, and self-assembly activity of hFTN-L were successfully maintained.	cysq	11-15	colony stimulating factor 3	Homo sapiens	93-99
24797182-2	2014	In such situations, plerixafor is commonly added to improve PBSC collection yields along with cytokine (G-CSF alone) or chemomobilization (chemotherapy+G-CSF).	plerixafor	20-30	colony stimulating factor 3	Homo sapiens	152-157
24797182-8	2014	Our experience highlights the safety and effectiveness of chemomobilization with plerixafor after G-CSF plus plerixafor (G+P) failure and suggests this is a viable salvage strategy after initial failed G+P mobilization.	plerixafor	81-91	colony stimulating factor 3	Homo sapiens	98-103
24945073-5	2014	Even after CysQ was removed, the solubility of hFTN-L and hG-CSF, the secondary structure of hG-CSF, and self-assembly activity of hFTN-L were successfully maintained.	cysq	11-15	colony stimulating factor 3	Homo sapiens	58-64
24625457-0	2014	Plerixafor added to G-CSF-supported paclitaxel-ifosfamide-cisplatin salvage chemotherapy enhances mobilization of adequate numbers of hematopoietic stem cells for subsequent autografting in hard-to-mobilize patients with relapsed/refractory germ-cell tumors: a single-center experience.	plerixafor	0-10	colony stimulating factor 3	Homo sapiens	20-25
24625457-0	2014	Plerixafor added to G-CSF-supported paclitaxel-ifosfamide-cisplatin salvage chemotherapy enhances mobilization of adequate numbers of hematopoietic stem cells for subsequent autografting in hard-to-mobilize patients with relapsed/refractory germ-cell tumors: a single-center experience.	Paclitaxel	36-46	colony stimulating factor 3	Homo sapiens	20-25
24625457-0	2014	Plerixafor added to G-CSF-supported paclitaxel-ifosfamide-cisplatin salvage chemotherapy enhances mobilization of adequate numbers of hematopoietic stem cells for subsequent autografting in hard-to-mobilize patients with relapsed/refractory germ-cell tumors: a single-center experience.	Ifosfamide	47-57	colony stimulating factor 3	Homo sapiens	20-25
24625457-0	2014	Plerixafor added to G-CSF-supported paclitaxel-ifosfamide-cisplatin salvage chemotherapy enhances mobilization of adequate numbers of hematopoietic stem cells for subsequent autografting in hard-to-mobilize patients with relapsed/refractory germ-cell tumors: a single-center experience.	Cisplatin	58-67	colony stimulating factor 3	Homo sapiens	20-25
24595405-2	2014	PURPOSE: Primary prophylaxis with granulocyte colony-stimulating factor (G-CSF) is used in many institutions across the UK due to unacceptable febrile neutropenia (FN) rates with FEC-D (fluorouracil, epirubicin, cyclophosphamide-docetaxel).	Fluorouracil	186-198	colony stimulating factor 3	Homo sapiens	73-78
24595405-2	2014	PURPOSE: Primary prophylaxis with granulocyte colony-stimulating factor (G-CSF) is used in many institutions across the UK due to unacceptable febrile neutropenia (FN) rates with FEC-D (fluorouracil, epirubicin, cyclophosphamide-docetaxel).	Epirubicin	200-210	colony stimulating factor 3	Homo sapiens	34-71
24595405-2	2014	PURPOSE: Primary prophylaxis with granulocyte colony-stimulating factor (G-CSF) is used in many institutions across the UK due to unacceptable febrile neutropenia (FN) rates with FEC-D (fluorouracil, epirubicin, cyclophosphamide-docetaxel).	Epirubicin	200-210	colony stimulating factor 3	Homo sapiens	73-78
24595405-2	2014	PURPOSE: Primary prophylaxis with granulocyte colony-stimulating factor (G-CSF) is used in many institutions across the UK due to unacceptable febrile neutropenia (FN) rates with FEC-D (fluorouracil, epirubicin, cyclophosphamide-docetaxel).	Cyclophosphamide	212-228	colony stimulating factor 3	Homo sapiens	34-71
24660786-1	2014	BACKGROUND: Plerixafor is a Food and Drug Administration-approved agent for improving peripheral blood stem cell (PBSC) mobilization in filgrastim (granulocyte-colony-stimulating factor [G-CSF])-stimulated patients with multiple myeloma and non-Hodgkin"s lymphoma.	plerixafor	12-22	colony stimulating factor 3	Homo sapiens	187-192
24595405-2	2014	PURPOSE: Primary prophylaxis with granulocyte colony-stimulating factor (G-CSF) is used in many institutions across the UK due to unacceptable febrile neutropenia (FN) rates with FEC-D (fluorouracil, epirubicin, cyclophosphamide-docetaxel).	Cyclophosphamide	212-228	colony stimulating factor 3	Homo sapiens	73-78
24595405-2	2014	PURPOSE: Primary prophylaxis with granulocyte colony-stimulating factor (G-CSF) is used in many institutions across the UK due to unacceptable febrile neutropenia (FN) rates with FEC-D (fluorouracil, epirubicin, cyclophosphamide-docetaxel).	Docetaxel	229-238	colony stimulating factor 3	Homo sapiens	34-71
24595405-2	2014	PURPOSE: Primary prophylaxis with granulocyte colony-stimulating factor (G-CSF) is used in many institutions across the UK due to unacceptable febrile neutropenia (FN) rates with FEC-D (fluorouracil, epirubicin, cyclophosphamide-docetaxel).	Docetaxel	229-238	colony stimulating factor 3	Homo sapiens	73-78
25002508-7	2014	In vitro biochemical studies show that G-CSF programs MPO-EL expression on human blood leukocytes and marrow myeloid cells via induction of N-linked sialofucosylations on MPO, with concomitant cell surface display of the molecule.	Nitrogen	140-141	colony stimulating factor 3	Homo sapiens	39-44
24977755-15	2014	The use of propranolol blunts early tachycardia, reduces HPC mobilization, and results in a faster return to baseline of the G-CSF peak seen after injury.	Propranolol	11-22	colony stimulating factor 3	Homo sapiens	125-130
24968143-10	2014	Taken together, these data indicate that clozapine stimulates the bone marrow to produce more neutrophils in a manner that is characteristic of endogenous G-CSF stimulation, and it is consistent with the inflammatory response observed in patients treated with clozapine.	Clozapine	41-50	colony stimulating factor 3	Homo sapiens	155-160
24968143-10	2014	Taken together, these data indicate that clozapine stimulates the bone marrow to produce more neutrophils in a manner that is characteristic of endogenous G-CSF stimulation, and it is consistent with the inflammatory response observed in patients treated with clozapine.	Clozapine	260-269	colony stimulating factor 3	Homo sapiens	155-160
24752449-15	2014	CONCLUSIONS: The recommended dose of LY2523355 with therapeutic G-CSF use for further studies was determined to be 5 mg/m2/day in Japanese patients with advanced solid tumors.	litronesib	37-46	colony stimulating factor 3	Homo sapiens	64-69
24117899-3	2014	Plerixafor is a novel CXCR4 antagonist, licensed for autologous PBSC harvest (PBSCH) in patients who failed mobilization with granulocyte-colony-stimulating factor (G-CSF) alone.	plerixafor	0-10	colony stimulating factor 3	Homo sapiens	126-163
24128272-4	2014	STUDY DESIGN AND METHODS: In 11 patients with MM or NHL, 240 mug/kg plerixafor was administered at 5 p.m. on Day 4 of granulocyte-colony-stimulating factor (G-CSF) mobilization.	plerixafor	68-78	colony stimulating factor 3	Homo sapiens	118-155
24597960-1	2014	INTRODUCTION: Peg-filgrastim (PEG-FIL), a polyethylene glycol-conjugated form of granulocyte colony-stimulating factor (G-CSF), has been introduced in clinical practice and is effective in shortening the time of neutropenia after cytotoxic chemotherapy.	Polyethylene Glycols	42-61	colony stimulating factor 3	Homo sapiens	81-118
24597960-1	2014	INTRODUCTION: Peg-filgrastim (PEG-FIL), a polyethylene glycol-conjugated form of granulocyte colony-stimulating factor (G-CSF), has been introduced in clinical practice and is effective in shortening the time of neutropenia after cytotoxic chemotherapy.	Polyethylene Glycols	42-61	colony stimulating factor 3	Homo sapiens	120-125
24623048-4	2014	When cultured with dMAT, adipocytes showed decreased lipolysis and adipokine secretion and increased expression/production of cytokines (IL-6, G-CSF) and fibrotic mediators (LOXL2 and the matricellular proteins THSB2 and CTGF).	2-dimethylamino-4,5,6,7-tetrabromo-1H-benzimidazole	19-23	colony stimulating factor 3	Homo sapiens	143-148
24128272-4	2014	STUDY DESIGN AND METHODS: In 11 patients with MM or NHL, 240 mug/kg plerixafor was administered at 5 p.m. on Day 4 of granulocyte-colony-stimulating factor (G-CSF) mobilization.	plerixafor	68-78	colony stimulating factor 3	Homo sapiens	157-162
24117899-3	2014	Plerixafor is a novel CXCR4 antagonist, licensed for autologous PBSC harvest (PBSCH) in patients who failed mobilization with granulocyte-colony-stimulating factor (G-CSF) alone.	plerixafor	0-10	colony stimulating factor 3	Homo sapiens	165-170
24117899-4	2014	Experience using plerixafor in healthy allogeneic donors failing G-CSF mobilization is scarce.	plerixafor	17-27	colony stimulating factor 3	Homo sapiens	65-70
24117899-8	2014	PBSCH was planned on Day -1 after 4 days of 10 mug/kg G-CSF.	pbsch	0-5	colony stimulating factor 3	Homo sapiens	54-59
23944772-8	2014	CONCLUSION: We have presented six cases with different causes leading to insufficient G-CSF mobilization in allogeneic donors and in which the administration of plerixafor just-in-time ensured a proper graft for transplantation.	plerixafor	161-171	colony stimulating factor 3	Homo sapiens	86-91
24485664-13	2014	Prophylactic use of G-CSF, especially at cycle 1 and in men aged &gt; or =75 years, is important and improves tolerability in senior adults treated with cabazitaxel.	cabazitaxel	153-164	colony stimulating factor 3	Homo sapiens	20-25
24394665-8	2014	The proteasome inhibitor bortezomib reversed the defective G-CSF-triggered granulocytic differentiation of CD34(+) cells from CN patients in vitro, an effect that was accompanied by restoration of LEF-1 protein levels and LEF-1 messenger RNA autoregulation.	Bortezomib	25-35	colony stimulating factor 3	Homo sapiens	59-64
24329418-4	2014	RESULTS: EtOH exposure inhibited activation-induced production of growth factors hepatocyte growth factor (HGF), granulocyte colony-stimulating factor (G-CSF), and vascular-endothelial growth factor (VEGF) by peripheral blood mononuclear cells (PBMC).	Ethanol	9-13	colony stimulating factor 3	Homo sapiens	113-150
24329418-4	2014	RESULTS: EtOH exposure inhibited activation-induced production of growth factors hepatocyte growth factor (HGF), granulocyte colony-stimulating factor (G-CSF), and vascular-endothelial growth factor (VEGF) by peripheral blood mononuclear cells (PBMC).	Ethanol	9-13	colony stimulating factor 3	Homo sapiens	152-157
24317848-11	2014	Patients of Indian ethnicity and those who underwent gemcitabine-containing chemotherapy were less likely to receive adjunctive G-CSF treatment.	gemcitabine	53-64	colony stimulating factor 3	Homo sapiens	128-133
24333750-6	2014	These data demonstrate that CBT after G-CSF-combined myeloablative conditioning is a promising curative option for patients with myeloid malignancies not in remission.	N,N-BIS(4-CHLOROBENZYL)-1H-1,2,3,4-TETRAAZOL-5-AMINE	28-31	colony stimulating factor 3	Homo sapiens	38-43
24763003-10	2014	G-CSF did not affect phagocytosis and normalized ROS generation in all of the patient.	Reactive Oxygen Species	49-52	colony stimulating factor 3	Homo sapiens	0-5
24505406-4	2014	RESULTS: All SAA patients with severe infections were treated with granulocyte transfusions combined with G-CSF.	saa	13-16	colony stimulating factor 3	Homo sapiens	106-111
24512007-0	2014	Metamizole-induced bicytopenia reversed by G-CSF and IVIG treatment in a child.	Dipyrone	0-10	colony stimulating factor 3	Homo sapiens	43-48
24317127-0	2014	Plerixafor "on demand": results of a strategy based on peripheral blood CD34+ cells in lymphoma patients at first or subsequent mobilization with chemotherapy+G-CSF.	plerixafor	0-10	colony stimulating factor 3	Homo sapiens	159-164
24474639-1	2014	Pegfilgrastim is produced by binding a 20,000-dalton polyethylene glycol molecule to granulocyte colony-stimulating factor (G-CSF), increasing the mass of the compound, and resulting in a longer-lasting form of G-CSF.	Polyethylene Glycols	53-72	colony stimulating factor 3	Homo sapiens	85-122
24474639-1	2014	Pegfilgrastim is produced by binding a 20,000-dalton polyethylene glycol molecule to granulocyte colony-stimulating factor (G-CSF), increasing the mass of the compound, and resulting in a longer-lasting form of G-CSF.	Polyethylene Glycols	53-72	colony stimulating factor 3	Homo sapiens	124-129
23927398-0	2014	Algorithms for early identification of poor mobilization and for on-demand use of plerixafor in patients mobilized by chemotherapy and granulocyte-colony stimulating factor.	plerixafor	82-92	colony stimulating factor 3	Homo sapiens	135-172
24444783-12	2014	RESULTS: Administration of G-CSF induced a significant increase in WBC, both in the placebo and the pentoxifylline group (p&lt;0.01 for both groups).	Pentoxifylline	100-114	colony stimulating factor 3	Homo sapiens	27-32
23800093-9	2014	CONCLUSIONS: This preliminary result warrants further investigation of high-dose MTX and cytarabine plus G-CSF as a means to remobilize stem cells in those with prior failure to mobilize stem cells with chemotherapy and G-CSF.	Methotrexate	81-84	colony stimulating factor 3	Homo sapiens	220-225
23800093-9	2014	CONCLUSIONS: This preliminary result warrants further investigation of high-dose MTX and cytarabine plus G-CSF as a means to remobilize stem cells in those with prior failure to mobilize stem cells with chemotherapy and G-CSF.	Cytarabine	89-99	colony stimulating factor 3	Homo sapiens	220-225
24505406-13	2014	CONCLUSION: Granulocyte transfusions combined with G-CSF could be an adjunctive therapy for treating severe infections of patients with SAA.	saa	136-139	colony stimulating factor 3	Homo sapiens	51-56
23978944-3	2014	CR rates with G-CSF priming and G-CSF post-chemotherapy were comparable (57 vs. 67 %, p = 0.153), with overall survival (OS) probabilities of 14 vs. 17 % at 10 years.	Chromium	0-2	colony stimulating factor 3	Homo sapiens	14-19
23978944-3	2014	CR rates with G-CSF priming and G-CSF post-chemotherapy were comparable (57 vs. 67 %, p = 0.153), with overall survival (OS) probabilities of 14 vs. 17 % at 10 years.	Chromium	0-2	colony stimulating factor 3	Homo sapiens	32-37
23781769-1	2014	BACKGROUND: Although the efficacy of plerixafor in peripheral blood stem cell (PBSC) mobilization has been explored in several studies, factors associated with successful plerixafor mobilization after administration of granulocyte-colony-stimulating factor (G-CSF), with or without chemotherapy, have not been investigated.	plerixafor	171-181	colony stimulating factor 3	Homo sapiens	219-256
23656194-1	2014	Plerixafor "on demand" after chemotherapy plus granulocyte-colony-stimulating factor (G-CSF) is efficient in peripheral stem cell mobilization, but the timing of administration and criteria for patient selection are under investigation.	plerixafor	0-10	colony stimulating factor 3	Homo sapiens	86-91
23781769-7	2014	CONCLUSION: This large, prospective, nationwide study confirmed plerixafor efficacy for mobilizing PBSCs when added to G-CSF with or without chemotherapy.	plerixafor	64-74	colony stimulating factor 3	Homo sapiens	119-124
24315970-3	2014	In this study, granulocyte colony stimulating factor (G-CSF) was dissolved in neat dimethyl sulfoxide (DMSO) and was PEGylated.	Dimethyl Sulfoxide	83-101	colony stimulating factor 3	Homo sapiens	15-52
24505236-10	2014	In summary, the efficacy of biosimilar G-CSFs in terms of PBSC yield as well as their toxicity profile are equivalent to historical data with the reference G-CSF.	pbsc	58-62	colony stimulating factor 3	Homo sapiens	39-44
24315970-3	2014	In this study, granulocyte colony stimulating factor (G-CSF) was dissolved in neat dimethyl sulfoxide (DMSO) and was PEGylated.	Dimethyl Sulfoxide	83-101	colony stimulating factor 3	Homo sapiens	54-59
24315970-3	2014	In this study, granulocyte colony stimulating factor (G-CSF) was dissolved in neat dimethyl sulfoxide (DMSO) and was PEGylated.	Dimethyl Sulfoxide	103-107	colony stimulating factor 3	Homo sapiens	15-52
24315970-3	2014	In this study, granulocyte colony stimulating factor (G-CSF) was dissolved in neat dimethyl sulfoxide (DMSO) and was PEGylated.	Dimethyl Sulfoxide	103-107	colony stimulating factor 3	Homo sapiens	54-59
24315970-5	2014	Structure analysis revealed that the protein was unfolded in DMSO, which could make the PEGylated sites of G-CSF easily accessible.	Dimethyl Sulfoxide	61-65	colony stimulating factor 3	Homo sapiens	107-112
24315970-8	2014	Stopped-flow demonstrated that the conjugation speed of G-CSF by MAL-PEG and SC-PEG in DMSO were 1.6x10(4) and 2x10(2) times faster than those in aqueous solution.	mal-peg	65-72	colony stimulating factor 3	Homo sapiens	56-61
24315970-8	2014	Stopped-flow demonstrated that the conjugation speed of G-CSF by MAL-PEG and SC-PEG in DMSO were 1.6x10(4) and 2x10(2) times faster than those in aqueous solution.	sc-peg	77-83	colony stimulating factor 3	Homo sapiens	56-61
24315970-8	2014	Stopped-flow demonstrated that the conjugation speed of G-CSF by MAL-PEG and SC-PEG in DMSO were 1.6x10(4) and 2x10(2) times faster than those in aqueous solution.	Dimethyl Sulfoxide	87-91	colony stimulating factor 3	Homo sapiens	56-61
25134304-1	2014	PURPOSE: To determine if the treatment with uterine infusion of granulocyte colony-stimulating factor (G-CSF) can improve endometrial thickness in an infertile woman with a double uterus, who consistently showed a thin endometrium in the late proliferative phase either in controlled ovarian hyperstimulation (COH) IVF-ET cycles or with graduated estrogen/sildenafil protocols for frozen embryo transfer (ET).	Sildenafil Citrate	356-366	colony stimulating factor 3	Homo sapiens	64-101
24334224-4	2014	Our results demonstrated that Thr134, the equivalent O-linked glycosylation site found on endogenous human G-CSF, is the only site modified with a single mannose, allowing glycoengineered P. pastoris to be used as a viable production platform for therapeutic rhG-CSF.	Mannose	154-161	colony stimulating factor 3	Homo sapiens	107-112
24308604-1	2014	The characterization of proteins modified with poly(ethylene glycol) (PEG), such as recombinant human granulocyte-colony stimulating factor (PEGylated rhG-CSF or pegfilgrastim), by electrospray ionization-mass spectrometry (ESI-MS) constitutes a challenge due to the overlapping protein charge state pattern and PEG polydispersity.	Polyethylene Glycols	47-68	colony stimulating factor 3	Homo sapiens	102-139
24308604-1	2014	The characterization of proteins modified with poly(ethylene glycol) (PEG), such as recombinant human granulocyte-colony stimulating factor (PEGylated rhG-CSF or pegfilgrastim), by electrospray ionization-mass spectrometry (ESI-MS) constitutes a challenge due to the overlapping protein charge state pattern and PEG polydispersity.	Polyethylene Glycols	70-73	colony stimulating factor 3	Homo sapiens	102-139
24308604-1	2014	The characterization of proteins modified with poly(ethylene glycol) (PEG), such as recombinant human granulocyte-colony stimulating factor (PEGylated rhG-CSF or pegfilgrastim), by electrospray ionization-mass spectrometry (ESI-MS) constitutes a challenge due to the overlapping protein charge state pattern and PEG polydispersity.	Polyethylene Glycols	141-144	colony stimulating factor 3	Homo sapiens	102-139
23944933-5	2014	Both IL-17C and polyI:C increased the expression of antimicrobial peptides and proinflammatory cytokines, such as human beta-defensin (hBD) 2, colony-stimulating factor 3 (CSF3), and S100A12 in NHBE cells.	Poly I-C	16-23	colony stimulating factor 3	Homo sapiens	143-170
23944933-5	2014	Both IL-17C and polyI:C increased the expression of antimicrobial peptides and proinflammatory cytokines, such as human beta-defensin (hBD) 2, colony-stimulating factor 3 (CSF3), and S100A12 in NHBE cells.	Poly I-C	16-23	colony stimulating factor 3	Homo sapiens	172-176
23944933-6	2014	Knockdown of IL-17 receptor (IL-17R) E, the specific receptor for IL-17C, using IL-17RE small interfering RNA, attenuated polyI:C-induced hBD2, CSF3, and S100A12 expression, without any reduction of polyI:C-induced IL-17C expression, which suggest that IL-17C enhances hBD2, CSF, and S100A12 expression in an autocrine/paracrine manner in NHBE cells.	Poly I	122-127	colony stimulating factor 3	Homo sapiens	144-148
23944933-7	2014	Knockdown of IL-17C also decreased polyI:C-induced hBD2, CSF3, and S100A12 expression.	Poly I	35-40	colony stimulating factor 3	Homo sapiens	57-61
23944933-7	2014	Knockdown of IL-17C also decreased polyI:C-induced hBD2, CSF3, and S100A12 expression.	Carbon	18-19	colony stimulating factor 3	Homo sapiens	57-61
24138497-2	2014	We present an interim analysis of the first prospective study in which Plerixafor was administered on-demand in patients affected by multiple myeloma and lymphoma who received high dose cyclophosphamide or DHAP (dexamethasone, cytarabine, cisplatin) plus G-CSF to mobilize peripheral blood stem cells (PBSC).	plerixafor	71-81	colony stimulating factor 3	Homo sapiens	255-260
24138497-9	2014	When in combination with cyclophosphamide or DHAP plus G-CSF, the "on-demand" use of Plerixafor showed, in comparison to conventionally treated patients, a significant improvement in mobilization of PBSC with no increase in overall cost.	plerixafor	85-95	colony stimulating factor 3	Homo sapiens	55-60
26155135-3	2014	The results showed that both DEX and CsA dose-dependently inhibited the production of eleven cytokines: interleukin (IL)-2, IL-4, IL-5, IL-6, IL-13, IL-17, interferon gamma (IFN-gamma), tumor necrosis factor alpha (TNF-alpha), granulocyte-macrophage colony-stimulating factor (GM-CSF) and granulocyte colony-stimulating factor (G-CSF).	Dexamethasone	29-32	colony stimulating factor 3	Homo sapiens	289-326
26155135-3	2014	The results showed that both DEX and CsA dose-dependently inhibited the production of eleven cytokines: interleukin (IL)-2, IL-4, IL-5, IL-6, IL-13, IL-17, interferon gamma (IFN-gamma), tumor necrosis factor alpha (TNF-alpha), granulocyte-macrophage colony-stimulating factor (GM-CSF) and granulocyte colony-stimulating factor (G-CSF).	Dexamethasone	29-32	colony stimulating factor 3	Homo sapiens	328-333
26155135-3	2014	The results showed that both DEX and CsA dose-dependently inhibited the production of eleven cytokines: interleukin (IL)-2, IL-4, IL-5, IL-6, IL-13, IL-17, interferon gamma (IFN-gamma), tumor necrosis factor alpha (TNF-alpha), granulocyte-macrophage colony-stimulating factor (GM-CSF) and granulocyte colony-stimulating factor (G-CSF).	Cyclosporine	37-40	colony stimulating factor 3	Homo sapiens	289-326
26155135-3	2014	The results showed that both DEX and CsA dose-dependently inhibited the production of eleven cytokines: interleukin (IL)-2, IL-4, IL-5, IL-6, IL-13, IL-17, interferon gamma (IFN-gamma), tumor necrosis factor alpha (TNF-alpha), granulocyte-macrophage colony-stimulating factor (GM-CSF) and granulocyte colony-stimulating factor (G-CSF).	Cyclosporine	37-40	colony stimulating factor 3	Homo sapiens	328-333
25134304-1	2014	PURPOSE: To determine if the treatment with uterine infusion of granulocyte colony-stimulating factor (G-CSF) can improve endometrial thickness in an infertile woman with a double uterus, who consistently showed a thin endometrium in the late proliferative phase either in controlled ovarian hyperstimulation (COH) IVF-ET cycles or with graduated estrogen/sildenafil protocols for frozen embryo transfer (ET).	Sildenafil Citrate	356-366	colony stimulating factor 3	Homo sapiens	103-108
25134304-2	2014	MATERIALS AND METHODS: A single uterine infusion of G-CSF was performed in the late proliferative phase in a woman who only attained a five-mm thickness despite a high dose vaginal and oral estradiol regimen plus sildenafil.	Estradiol	190-199	colony stimulating factor 3	Homo sapiens	52-57
25134304-2	2014	MATERIALS AND METHODS: A single uterine infusion of G-CSF was performed in the late proliferative phase in a woman who only attained a five-mm thickness despite a high dose vaginal and oral estradiol regimen plus sildenafil.	Sildenafil Citrate	213-223	colony stimulating factor 3	Homo sapiens	52-57
24483859-12	2014	GCSF was used for a patient treated with TLV.	telaprevir	41-44	colony stimulating factor 3	Homo sapiens	0-4
25784842-2	2014	The aim of this part of the project was to assess the knowledge of oncologists on indications for granulocyte colony-stimulating factor (G-CSF) secondary prophylaxis (SP) of febrile neutropenia (FN) and FN management based on current therapeutic guidelines (Polish Society of Clinical Oncology [PTOK] and European Organisation for Research and Treatment of Cancer [EORTC]).	sp	167-169	colony stimulating factor 3	Homo sapiens	98-135
25784842-2	2014	The aim of this part of the project was to assess the knowledge of oncologists on indications for granulocyte colony-stimulating factor (G-CSF) secondary prophylaxis (SP) of febrile neutropenia (FN) and FN management based on current therapeutic guidelines (Polish Society of Clinical Oncology [PTOK] and European Organisation for Research and Treatment of Cancer [EORTC]).	sp	167-169	colony stimulating factor 3	Homo sapiens	137-142
25784842-7	2014	RESULTS AND CONCLUSIONS: Indications for G-CSF SP were generally well recognized: in nearly 90% of responses, oncologists assessed correctly indications/lack of indications for secondary prophylaxis, in accordance with guideline recommendations and Experts" opinion.	sp	47-49	colony stimulating factor 3	Homo sapiens	41-46
24041627-8	2014	The only randomized clinical trial conducted for the prevention and treatment of G-CSF induced bone pain showed the efficacy of naproxen in reducing the incidence, the severity and the duration of bone pain induced by the administration of pegfilgrastim.	Naproxen	128-136	colony stimulating factor 3	Homo sapiens	81-86
24659680-6	2014	Regarding G-CSF stimulation the G-CSF receptor CSF2RB (1.1-fold) was linked via STAT3 to erythroid-specific ALAS2 (2.9-fold) and GATA2 (1.3-fold) factors, all upregulated in mPB-derived erythroid progenitors, coupled to common upregulated NUDC gene involved in the proliferation of erythroid cells.	alas2	108-113	colony stimulating factor 3	Homo sapiens	10-15
24038146-2	2014	In this study, we explored the role of the Ca(2+)i signaling transduction pathway in the commitment of hematopoietic stem/progenitor cells to either the monocytic or granulocytic lineage in response to macrophage colony-stimulating factor (M-CSF) and granulocyte colony-stimulating factor (G-CSF).	ca(2+)i	43-50	colony stimulating factor 3	Homo sapiens	251-288
24659680-6	2014	Regarding G-CSF stimulation the G-CSF receptor CSF2RB (1.1-fold) was linked via STAT3 to erythroid-specific ALAS2 (2.9-fold) and GATA2 (1.3-fold) factors, all upregulated in mPB-derived erythroid progenitors, coupled to common upregulated NUDC gene involved in the proliferation of erythroid cells.	alas2	108-113	colony stimulating factor 3	Homo sapiens	32-37
24038146-2	2014	In this study, we explored the role of the Ca(2+)i signaling transduction pathway in the commitment of hematopoietic stem/progenitor cells to either the monocytic or granulocytic lineage in response to macrophage colony-stimulating factor (M-CSF) and granulocyte colony-stimulating factor (G-CSF).	ca(2+)i	43-50	colony stimulating factor 3	Homo sapiens	290-295
25510103-1	2013	Transgenic poultry with a gene of human granulocyte colony-stimulating factor (gcsf) was developed by arti- ficial insemination with the transfected sperm using the "Lipofectamin 2000" reagent.	lipofectamin 2000" reagent	166-192	colony stimulating factor 3	Homo sapiens	40-77
25648659-0	2014	Comparison of Therapeutic G-CSF Cycles and Prophylactic G-CSF Cycles in Patients Receiving Paclitaxel and Carboplatin Combination Chemotherapy for Ovarian Cancer: A Retrospective Study Report.	Carboplatin	106-117	colony stimulating factor 3	Homo sapiens	56-61
25648659-1	2014	OBJECTIVE: The aim of the present study was to investigate the differences between therapeutic granulocyte-colony stimulating factor (G-CSF) cycles and prophylactic G-CSF cycles in patients receiving paclitaxel and carboplatin combination chemotherapy for ovarian cancer.	Paclitaxel	200-210	colony stimulating factor 3	Homo sapiens	95-132
25648659-1	2014	OBJECTIVE: The aim of the present study was to investigate the differences between therapeutic granulocyte-colony stimulating factor (G-CSF) cycles and prophylactic G-CSF cycles in patients receiving paclitaxel and carboplatin combination chemotherapy for ovarian cancer.	Paclitaxel	200-210	colony stimulating factor 3	Homo sapiens	134-139
25648659-1	2014	OBJECTIVE: The aim of the present study was to investigate the differences between therapeutic granulocyte-colony stimulating factor (G-CSF) cycles and prophylactic G-CSF cycles in patients receiving paclitaxel and carboplatin combination chemotherapy for ovarian cancer.	Paclitaxel	200-210	colony stimulating factor 3	Homo sapiens	165-170
25648659-1	2014	OBJECTIVE: The aim of the present study was to investigate the differences between therapeutic granulocyte-colony stimulating factor (G-CSF) cycles and prophylactic G-CSF cycles in patients receiving paclitaxel and carboplatin combination chemotherapy for ovarian cancer.	Carboplatin	215-226	colony stimulating factor 3	Homo sapiens	95-132
25648659-1	2014	OBJECTIVE: The aim of the present study was to investigate the differences between therapeutic granulocyte-colony stimulating factor (G-CSF) cycles and prophylactic G-CSF cycles in patients receiving paclitaxel and carboplatin combination chemotherapy for ovarian cancer.	Carboplatin	215-226	colony stimulating factor 3	Homo sapiens	165-170
23597142-0	2014	Granulocyte colony-stimulating factor as secondary prophylaxis of febrile neutropenia in the management of advanced-stage Hodgkin lymphoma treated with adriamycin, bleomycin, vinblastine and dacarbazine chemotherapy: a decision analysis.	Doxorubicin	152-162	colony stimulating factor 3	Homo sapiens	0-37
23597142-0	2014	Granulocyte colony-stimulating factor as secondary prophylaxis of febrile neutropenia in the management of advanced-stage Hodgkin lymphoma treated with adriamycin, bleomycin, vinblastine and dacarbazine chemotherapy: a decision analysis.	Bleomycin	164-173	colony stimulating factor 3	Homo sapiens	0-37
23597142-0	2014	Granulocyte colony-stimulating factor as secondary prophylaxis of febrile neutropenia in the management of advanced-stage Hodgkin lymphoma treated with adriamycin, bleomycin, vinblastine and dacarbazine chemotherapy: a decision analysis.	Vinblastine	175-186	colony stimulating factor 3	Homo sapiens	0-37
23597142-0	2014	Granulocyte colony-stimulating factor as secondary prophylaxis of febrile neutropenia in the management of advanced-stage Hodgkin lymphoma treated with adriamycin, bleomycin, vinblastine and dacarbazine chemotherapy: a decision analysis.	Dacarbazine	191-202	colony stimulating factor 3	Homo sapiens	0-37
25104881-0	2014	Production of the growth factors GM-CSF, G-CSF, and VEGF by human peripheral blood cells induced with metal complexes of human serum gamma -globulin formed with copper or zinc ions.	Metals	102-107	colony stimulating factor 3	Homo sapiens	41-46
25104881-0	2014	Production of the growth factors GM-CSF, G-CSF, and VEGF by human peripheral blood cells induced with metal complexes of human serum gamma -globulin formed with copper or zinc ions.	Copper	161-167	colony stimulating factor 3	Homo sapiens	41-46
25104881-3	2014	The gamma-globulin metal complexes formed with both copper and zinc ions were found to similarly reduce production of GM-CSF, G-CSF, and VEGF induced in normal human PBC cultures by the control gamma-globulins or by copper and zinc ions used alone.	Metals	19-24	colony stimulating factor 3	Homo sapiens	126-131
25104881-3	2014	The gamma-globulin metal complexes formed with both copper and zinc ions were found to similarly reduce production of GM-CSF, G-CSF, and VEGF induced in normal human PBC cultures by the control gamma-globulins or by copper and zinc ions used alone.	Copper	52-58	colony stimulating factor 3	Homo sapiens	126-131
24312369-6	2013	RESULTS: We observed lower baseline levels of IL-6 (p = 0.041), GCSF (p = 0.036) and LBP (p = 0.016) in TB-IRIS patients.	Terbium	104-106	colony stimulating factor 3	Homo sapiens	64-68
24083590-0	2013	Safety of polyethylene glycol recombinant human granulocyte colony-stimulating factor in treating non-small cell lung cancer patients at I b stage.	Polyethylene Glycols	10-29	colony stimulating factor 3	Homo sapiens	48-85
23801085-0	2013	Model-based approach to describe G-CSF effects in carboplatin-treated cancer patients.	Carboplatin	50-61	colony stimulating factor 3	Homo sapiens	33-38
24081949-4	2013	G-CSF directly induces neutrophil mobilization from the bone marrow (BM) into the blood, but the mechanisms underlying plerixafor-induced neutrophilia remain poorly defined.	plerixafor	119-129	colony stimulating factor 3	Homo sapiens	0-5
24155641-8	2013	Hematologic toxicity is common and should be monitored, and granulocyte colony-stimulating factor should be considered when gemcitabine plus docetaxel is used.	gemcitabine	124-135	colony stimulating factor 3	Homo sapiens	60-97
24155641-8	2013	Hematologic toxicity is common and should be monitored, and granulocyte colony-stimulating factor should be considered when gemcitabine plus docetaxel is used.	Docetaxel	141-150	colony stimulating factor 3	Homo sapiens	60-97
24167701-0	2013	Continuing clozapine with granulocyte colony-stimulating factor in patients with neutropenia.	Clozapine	11-20	colony stimulating factor 3	Homo sapiens	26-63
23749720-1	2013	Plerixafor, a recently approved peripheral blood progenitor cell mobilizing agent, is often added to granulocyte-colony stimulating factor (G-CSF) to mobilize peripheral blood progenitor cells in patients with lymphoma or myeloma who cannot mobilize enough CD34+ cells with G-CSF alone to undergo autologous stem cell transplantation.	plerixafor	0-10	colony stimulating factor 3	Homo sapiens	274-279
23764455-1	2013	Plerixafor with granulocyte colony-stimulating factor (G-CSF) is effective for hematopoietic stem cell (HSC) mobilization in patients with non-Hodgkin Lymphoma and myeloma; however, labeling requires dosing 11 hours before apheresis.	plerixafor	0-10	colony stimulating factor 3	Homo sapiens	16-53
23764455-1	2013	Plerixafor with granulocyte colony-stimulating factor (G-CSF) is effective for hematopoietic stem cell (HSC) mobilization in patients with non-Hodgkin Lymphoma and myeloma; however, labeling requires dosing 11 hours before apheresis.	plerixafor	0-10	colony stimulating factor 3	Homo sapiens	55-60
26202037-2	2013	Administration of granulocyte colony-stimulating factor (G-CSF) induces the circulation of BMCs in the peripheral blood.	bmcs	91-95	colony stimulating factor 3	Homo sapiens	18-55
26202037-2	2013	Administration of granulocyte colony-stimulating factor (G-CSF) induces the circulation of BMCs in the peripheral blood.	bmcs	91-95	colony stimulating factor 3	Homo sapiens	57-62
26202037-3	2013	A phase II prospective trial was carried out for evaluation of BMC mobilization induced by multiple courses of G-CSF in cirrhotic patients.	bmc	63-66	colony stimulating factor 3	Homo sapiens	111-116
23686402-1	2013	PURPOSE: As the result of a recent national shortage in paclitaxel, some patients who were receiving or scheduled to receive weekly paclitaxel were converted to every 3-week (q3w) docetaxel with granulocyte colony-stimulating factor support.	Paclitaxel	56-66	colony stimulating factor 3	Homo sapiens	195-232
23686402-1	2013	PURPOSE: As the result of a recent national shortage in paclitaxel, some patients who were receiving or scheduled to receive weekly paclitaxel were converted to every 3-week (q3w) docetaxel with granulocyte colony-stimulating factor support.	Docetaxel	180-189	colony stimulating factor 3	Homo sapiens	195-232
24156441-0	2013	[Effect of dexamethasone on G-CSF mobilization of peripheral blood stem cells in healthy donors and hematopoietic reconstruction in the recipients].	Dexamethasone	11-24	colony stimulating factor 3	Homo sapiens	28-33
23395419-1	2013	Granulocyte colony-stimulating factor agents such as filgrastim can be administered in order to reduce the duration of clozapine-induced agranulocytosis.	Clozapine	119-128	colony stimulating factor 3	Homo sapiens	0-37
25510103-1	2013	Transgenic poultry with a gene of human granulocyte colony-stimulating factor (gcsf) was developed by arti- ficial insemination with the transfected sperm using the "Lipofectamin 2000" reagent.	lipofectamin 2000" reagent	166-192	colony stimulating factor 3	Homo sapiens	79-83
24314160-1	2013	OBJECTIVE: To assess the efficacy and safety of recombinant human granulocyte colony stimulating factor (rhG-CSF) primed donor peripheral blood stem cell (PBSC) on the treatment of poor graft function (PGF) after allogeneic stem cell transplantation(allo-HSCT).	Prostaglandins F	202-205	colony stimulating factor 3	Homo sapiens	66-103
25509351-4	2013	In the present study, we aimed to find out whether CD271 enrichment can help isolation of MSCs from G-CSF-mobilized PB.	Lead	116-118	colony stimulating factor 3	Homo sapiens	100-105
25509351-5	2013	Five G-CSF-mobilized PB samples were collected from the remnant parts of the bags used for BM transplantation.	Lead	21-23	colony stimulating factor 3	Homo sapiens	5-10
25509351-10	2013	Although the percentage of CD271+ cells showed no difference between BM-MNCs and G-CSF-mobilized PB-MNCs, hematopoietic markers such as CD45, CD34 and CD133 composed a higher percentage of CD271-positive cells in the G-CSF-mobilized PB group.	Lead	97-99	colony stimulating factor 3	Homo sapiens	81-86
23991206-0	2013	LDL cholesterol modulates human CD34+ HSPCs through effects on proliferation and the IL-17 G-CSF axis.	Cholesterol	4-15	colony stimulating factor 3	Homo sapiens	91-96
23991206-14	2013	Finally, the HSPC mobilizing cytokine G-CSF (r(2)=0.0683, p &lt; 0.05), and its upstream regulator IL-17 (r(2)=0.0891, p &lt; 0.05) both correlated positively with LDL cholesterol, while SDF-1 levels were not significantly affected.	Cholesterol	168-179	colony stimulating factor 3	Homo sapiens	38-43
23991206-15	2013	CONCLUSIONS: Our findings support a model where LDL cholesterol levels positively correlate with CD34+ HSPC levels in humans through effects on the levels of G-CSF via IL-17 promoting mobilization of HSPCs, and by direct effects of LDL cholesterol on HSPC proliferation.	Cholesterol	52-63	colony stimulating factor 3	Homo sapiens	158-163
23991206-15	2013	CONCLUSIONS: Our findings support a model where LDL cholesterol levels positively correlate with CD34+ HSPC levels in humans through effects on the levels of G-CSF via IL-17 promoting mobilization of HSPCs, and by direct effects of LDL cholesterol on HSPC proliferation.	Cholesterol	236-247	colony stimulating factor 3	Homo sapiens	158-163
23945326-0	2013	[A case of bladder cancer producing granulocyte colony-stimulating factor and interleukin-6 causing respiratory failure treated with neoadjuvant systemic chemotherapy along with sivelestat].	sivelestat	178-188	colony stimulating factor 3	Homo sapiens	36-73
23334269-7	2013	The data support the current International Multiple Myeloma Working Group guidelines recommending the use of cyclophosphamide and G-CSF based mobilization for patients previously exposed to lenalidomide.	Lenalidomide	190-202	colony stimulating factor 3	Homo sapiens	130-135
23772882-5	2013	TNF-alpha, IFN-gamma, IL-4, IL-5, and G-CSF levels were significantly higher (p values &lt; 0.05 for all) in plasma with EDTA, whereas the levels of IL-6, IL-8, IL-10, IL-17, MIP-1beta, GM-CSF and MCP-1 were found to be significantly higher (p values &lt; 0.05 for all) in plasma with heparin.	Edetic Acid	121-125	colony stimulating factor 3	Homo sapiens	38-43
23674093-10	2013	Treatment with U0126 (a mitogen-activated protein kinase inhibitor) drastically reduced basal levels of G-CSF and TNF-alpha-induced G-CSF in aggressive cancer cells.	U 0126	15-20	colony stimulating factor 3	Homo sapiens	104-109
23674093-10	2013	Treatment with U0126 (a mitogen-activated protein kinase inhibitor) drastically reduced basal levels of G-CSF and TNF-alpha-induced G-CSF in aggressive cancer cells.	U 0126	15-20	colony stimulating factor 3	Homo sapiens	132-137
23557674-9	2013	Then, a 4th clozapine treatment was decided under cover of filgrastim (G-CSF), the role of which is to limit the risk of a new neutropenia.	Clozapine	12-21	colony stimulating factor 3	Homo sapiens	71-76
23737687-2	2013	In the present study, we examined clinical practice patterns and the impact of pp-g-csf on fn incidence in women with early-stage breast cancer (ebc) treated with modern adjuvant chemotherapy (act).	NSC638702	145-148	colony stimulating factor 3	Homo sapiens	82-87
23737687-8	2013	Among women receiving pp-g-csf, higher fn rates were associated with an age of 65 years or older, taxane-based chemotherapy, and prophylaxis with filgrastim.	taxane	98-104	colony stimulating factor 3	Homo sapiens	25-30
23737687-10	2013	The observed high fn risk despite pp-g-csf was linked to older age, taxane-based chemotherapy, and filgrastim.	taxane	68-74	colony stimulating factor 3	Homo sapiens	37-42
23548906-2	2013	RESULTS: Transcriptional regulation of CSF-2 and CSF-3 in concanavalin A-activated MSCs requires MT1-MMP signaling and is inhibited by EGCG.	epigallocatechin gallate	135-139	colony stimulating factor 3	Homo sapiens	49-54
23548906-8	2013	EGCG antagonized the ConA-induced CSF-2 and CSF-3 gene expression, and this process required an MT1-MMP-mediated sequential activation of the Src and JAK/STAT pathways.	epigallocatechin gallate	0-4	colony stimulating factor 3	Homo sapiens	44-49
23548906-10	2013	Given that MSCs are recruited within vascularizing tumors and are believed to contribute to tumor angiogenesis, possibly through secretion of CSF-2 and CSF-3, our study suggests that diet-derived polyphenols such as EGCG may exert chemopreventive action through pharmacological targeting of the MT1-MMP intracellular signaling.	Polyphenols	196-207	colony stimulating factor 3	Homo sapiens	152-157
23548906-10	2013	Given that MSCs are recruited within vascularizing tumors and are believed to contribute to tumor angiogenesis, possibly through secretion of CSF-2 and CSF-3, our study suggests that diet-derived polyphenols such as EGCG may exert chemopreventive action through pharmacological targeting of the MT1-MMP intracellular signaling.	epigallocatechin gallate	216-220	colony stimulating factor 3	Homo sapiens	152-157
23059755-3	2013	OBJECTIVE: To report a case on the use of granulocyte colony-stimulating factor (G-CSF) in conjunction with clozapine and chemotherapy.	Clozapine	108-117	colony stimulating factor 3	Homo sapiens	42-79
23059755-3	2013	OBJECTIVE: To report a case on the use of granulocyte colony-stimulating factor (G-CSF) in conjunction with clozapine and chemotherapy.	Clozapine	108-117	colony stimulating factor 3	Homo sapiens	81-86
23059755-4	2013	METHODS: We searched PubMed for any available information on the use of granulocyte G-CSF with clozapine and chemotherapy.	Clozapine	95-104	colony stimulating factor 3	Homo sapiens	84-89
23059755-8	2013	We found case reports and a case series on the use of G-CSF in clozapine rechallenge with clozapine-induced agranulocytosis with mixed results.	Clozapine	63-72	colony stimulating factor 3	Homo sapiens	54-59
23059755-8	2013	We found case reports and a case series on the use of G-CSF in clozapine rechallenge with clozapine-induced agranulocytosis with mixed results.	Clozapine	90-99	colony stimulating factor 3	Homo sapiens	54-59
23059755-10	2013	CONCLUSIONS: With risks of psychosis relapse and exacerbation with discontinuing clozapine, the addition of G-CSF could be a useful aid in replenishing white cell counts lost to chemotherapy whilst continuing clozapine.	Clozapine	209-218	colony stimulating factor 3	Homo sapiens	108-113
23749899-8	2013	Under treatment with low concentrations of 5-fluorouracil and cisplatin, all examined cell lines showed an increasing secretion of the cytokines IL-6 and G-CSF.	Fluorouracil	43-57	colony stimulating factor 3	Homo sapiens	154-159
23749899-8	2013	Under treatment with low concentrations of 5-fluorouracil and cisplatin, all examined cell lines showed an increasing secretion of the cytokines IL-6 and G-CSF.	Cisplatin	62-71	colony stimulating factor 3	Homo sapiens	154-159
23592195-0	2013	Characterization of disulfide linkages in recombinant human granulocyte-colony stimulating factor.	Disulfides	20-29	colony stimulating factor 3	Homo sapiens	60-97
23592195-1	2013	RATIONALE: Recombinant human G granulocyte-colony stimulating factor (rhG-CSF) produced in Escherichia coli is a non-glycosylated polypeptide containing five cysteine residues.	Cysteine	158-166	colony stimulating factor 3	Homo sapiens	31-68
23592195-2	2013	The reported major disulfide (S-S) linkages in mature human G-CSF are C36 -C42 and C64 -C74 , leaving C17 as a free cysteine, which could potentially result in S-S scrambling.	Disulfides	19-28	colony stimulating factor 3	Homo sapiens	60-65
23592195-2	2013	The reported major disulfide (S-S) linkages in mature human G-CSF are C36 -C42 and C64 -C74 , leaving C17 as a free cysteine, which could potentially result in S-S scrambling.	Sulfur	30-31	colony stimulating factor 3	Homo sapiens	60-65
23592195-2	2013	The reported major disulfide (S-S) linkages in mature human G-CSF are C36 -C42 and C64 -C74 , leaving C17 as a free cysteine, which could potentially result in S-S scrambling.	Sulfur	32-33	colony stimulating factor 3	Homo sapiens	60-65
23592195-2	2013	The reported major disulfide (S-S) linkages in mature human G-CSF are C36 -C42 and C64 -C74 , leaving C17 as a free cysteine, which could potentially result in S-S scrambling.	Cysteine	116-124	colony stimulating factor 3	Homo sapiens	60-65
23557674-22	2013	This confirms the role of hematopoietic cytokines (mainly G-CSF) in neutropenia episodes induced by clozapine.	Clozapine	100-109	colony stimulating factor 3	Homo sapiens	58-63
23557674-26	2013	We also noticed a "biased notoriety of the clozapine", with the association with other hematotoxic molecules, the existence of a circadian rhythm of neutrophils or G-CSF, along with transitional or ethnical neutropenia.	Clozapine	43-52	colony stimulating factor 3	Homo sapiens	164-169
23809830-0	2013	Use of Plerixafor in patients that show failure of peripheral blood stem cell mobilization with G-CSF.	plerixafor	7-17	colony stimulating factor 3	Homo sapiens	96-101
23551709-0	2013	Granulocyte-colony stimulating factor-producing cervical cancers treated with carbon-ion irradiation.	Carbon	78-84	colony stimulating factor 3	Homo sapiens	0-37
23551709-3	2013	We report two cases of G-CSF-producing uterine cervical cancer who were successfully treated with carbon-ion radiotherapy (C-ion RT).	Carbon	98-104	colony stimulating factor 3	Homo sapiens	23-28
23547862-0	2013	Prophylactic use of granulocyte colony-stimulating factor after consolidation therapy with high-dose cytarabine for acute myeloid leukemia.	Cytarabine	101-111	colony stimulating factor 3	Homo sapiens	20-57
23547862-4	2013	reported that granulocyte colony-stimulating factor administration following consolidation therapy with high-dose cytarabine is associated with decreased hospitalization rate and improved survival.	Cytarabine	114-124	colony stimulating factor 3	Homo sapiens	14-51
22897584-2	2013	Plerixafor may also be used with G-CSF in patients who mobilize poorly or it may be added to chemomobilization to boost mobilization.	plerixafor	0-10	colony stimulating factor 3	Homo sapiens	33-38
22897584-6	2013	As controls we had the first collections from 12 MM patients mobilized with low-dose CY with G-CSF.	Cyclophosphamide	85-87	colony stimulating factor 3	Homo sapiens	93-98
23333777-3	2013	The superiority of plerixafor + granulocyte colony-stimulating factor (G-CSF) over placebo + G-CSF for hematopoietic stem cell mobilization and collection was shown for patients with non-Hodgkin lymphoma in a phase III, prospective, randomized, controlled study.	plerixafor	19-29	colony stimulating factor 3	Homo sapiens	71-76
25060582-1	2013	BACKGROUND: This study re-evaluated the efficacy and tolerability of cisplatin, etoposide, and ifosfamide (VIP) combination chemotherapy as an alternative first-line regimen for patients with disseminated germ cell cancer (GCC) in this granulocyte colony-stimulating factor (G-CSF) era.	Ifosfamide	95-105	colony stimulating factor 3	Homo sapiens	236-273
23453111-2	2013	Granulocyte colony-stimulating factor treatment might attenuate endothelial dysfunction after sirolimus-eluting stent (SES) implantation that may be associated with adverse cardiac events during follow-up.	Sirolimus	94-103	colony stimulating factor 3	Homo sapiens	0-37
23453111-2	2013	Granulocyte colony-stimulating factor treatment might attenuate endothelial dysfunction after sirolimus-eluting stent (SES) implantation that may be associated with adverse cardiac events during follow-up.	ses	119-122	colony stimulating factor 3	Homo sapiens	0-37
23453111-3	2013	This prospective, double-blind, randomized, placebo-controlled study investigated whether G-CSF improved endothelial dysfunction after SES implantation.	ses	135-138	colony stimulating factor 3	Homo sapiens	90-95
23453111-11	2013	CONCLUSION: Granulocyte colony-stimulating factor attenuates endothelial dysfunction after SES implantation.	ses	91-94	colony stimulating factor 3	Homo sapiens	12-49
23132252-3	2013	This study aims to model and optimize the carbon source of auto-induction medium to enhance G-CSF production using artificial neural networks coupled with genetic algorithm.	Carbon	42-48	colony stimulating factor 3	Homo sapiens	92-97
23392933-5	2013	Recently, we have found that several agents including granulocyte colony-stimulating factor (G-CSF), a stem cell enhancer and facilitator;S-methyl-N-diethylthiolcarbamate sulfoxide (DETC-MeSO), an NMDA receptor partial antagonist; sulindac, a potent antioxidant; and taurine, a neuroprotectant and calcium regulator, are effective in protecting against stroke-induced neuronal injury when used alone or in combination in both animal and tissue/cell culture models.	s-methyl-n-diethylthiolcarbamate sulfoxide	138-180	colony stimulating factor 3	Homo sapiens	93-98
23392933-5	2013	Recently, we have found that several agents including granulocyte colony-stimulating factor (G-CSF), a stem cell enhancer and facilitator;S-methyl-N-diethylthiolcarbamate sulfoxide (DETC-MeSO), an NMDA receptor partial antagonist; sulindac, a potent antioxidant; and taurine, a neuroprotectant and calcium regulator, are effective in protecting against stroke-induced neuronal injury when used alone or in combination in both animal and tissue/cell culture models.	S-methyl N,N-diethylthiolcarbamate sulfoxide	182-191	colony stimulating factor 3	Homo sapiens	93-98
23392933-5	2013	Recently, we have found that several agents including granulocyte colony-stimulating factor (G-CSF), a stem cell enhancer and facilitator;S-methyl-N-diethylthiolcarbamate sulfoxide (DETC-MeSO), an NMDA receptor partial antagonist; sulindac, a potent antioxidant; and taurine, a neuroprotectant and calcium regulator, are effective in protecting against stroke-induced neuronal injury when used alone or in combination in both animal and tissue/cell culture models.	Sulindac	231-239	colony stimulating factor 3	Homo sapiens	93-98
23392933-5	2013	Recently, we have found that several agents including granulocyte colony-stimulating factor (G-CSF), a stem cell enhancer and facilitator;S-methyl-N-diethylthiolcarbamate sulfoxide (DETC-MeSO), an NMDA receptor partial antagonist; sulindac, a potent antioxidant; and taurine, a neuroprotectant and calcium regulator, are effective in protecting against stroke-induced neuronal injury when used alone or in combination in both animal and tissue/cell culture models.	Taurine	267-274	colony stimulating factor 3	Homo sapiens	93-98
23811564-1	2013	In this study, the pharmacokinetic and pharmacodynamic properties of Lys(35), Met(N-terminal), and Lys(17)-mono-PEGylated recombinant human granulocyte colony stimulating factor (rhG-CSF) positional isomers were evaluated in rats.	Lysine	69-72	colony stimulating factor 3	Homo sapiens	140-177
23811564-1	2013	In this study, the pharmacokinetic and pharmacodynamic properties of Lys(35), Met(N-terminal), and Lys(17)-mono-PEGylated recombinant human granulocyte colony stimulating factor (rhG-CSF) positional isomers were evaluated in rats.	Lysine	99-102	colony stimulating factor 3	Homo sapiens	140-177
23274395-19	2013	The recommended phase II dose of LE-DT is 85 mg/m(2) without G-CSF or 110 mg/m(2) with G-CSF.	le-dt	33-38	colony stimulating factor 3	Homo sapiens	61-66
23274395-19	2013	The recommended phase II dose of LE-DT is 85 mg/m(2) without G-CSF or 110 mg/m(2) with G-CSF.	le-dt	33-38	colony stimulating factor 3	Homo sapiens	87-92
23283728-6	2013	We present here the detection of in-source and in-solution formation of succinimide and pyroglutamate in the protein granulocyte colony stimulating factor.	succinimide	72-83	colony stimulating factor 3	Homo sapiens	117-154
23283728-6	2013	We present here the detection of in-source and in-solution formation of succinimide and pyroglutamate in the protein granulocyte colony stimulating factor.	Pyrrolidonecarboxylic Acid	88-101	colony stimulating factor 3	Homo sapiens	117-154
23852505-5	2013	Reduced levels of reactive oxygen species indicated that G-CSF-treated IR cells produced fewer free radicals, as compared to the no-IR cells.	Reactive Oxygen Species	18-41	colony stimulating factor 3	Homo sapiens	57-62
25060582-1	2013	BACKGROUND: This study re-evaluated the efficacy and tolerability of cisplatin, etoposide, and ifosfamide (VIP) combination chemotherapy as an alternative first-line regimen for patients with disseminated germ cell cancer (GCC) in this granulocyte colony-stimulating factor (G-CSF) era.	Ifosfamide	95-105	colony stimulating factor 3	Homo sapiens	275-280
24039428-10	2013	We managed to stabilize him with olanzapine and aripiprazole which enabled the heme-oncology group to resume R-CHOP therapy with filgrastim (granulocyte colony-stimulating factor).	Aripiprazole	48-60	colony stimulating factor 3	Homo sapiens	141-178
22790915-11	2013	In addition, DMF reduced TNF-alpha-induced granulocyte colony-stimulating factor (G-CSF) secretion but had no effect on INF-gamma-induced G-CSF secretion.	Dimethyl Fumarate	13-16	colony stimulating factor 3	Homo sapiens	43-80
22790915-11	2013	In addition, DMF reduced TNF-alpha-induced granulocyte colony-stimulating factor (G-CSF) secretion but had no effect on INF-gamma-induced G-CSF secretion.	Dimethyl Fumarate	13-16	colony stimulating factor 3	Homo sapiens	82-87
23411705-3	2013	The NAP activity levels transiently normalized following the administration of granulocyte colony-stimulating factor (G-CSF) in two cases.	nap	4-7	colony stimulating factor 3	Homo sapiens	79-116
23411705-3	2013	The NAP activity levels transiently normalized following the administration of granulocyte colony-stimulating factor (G-CSF) in two cases.	nap	4-7	colony stimulating factor 3	Homo sapiens	118-123
23525060-0	2013	Clozapine re-challenge under the cover of Filgrastim.	Clozapine	0-9	colony stimulating factor 3	Homo sapiens	42-52
23525060-6	2013	The patient was re-challenged with clozapine under the cover of Filgrastim, a Granulocyte-Colony Stimulating Factor.	Clozapine	35-44	colony stimulating factor 3	Homo sapiens	64-74
23525060-6	2013	The patient was re-challenged with clozapine under the cover of Filgrastim, a Granulocyte-Colony Stimulating Factor.	Clozapine	35-44	colony stimulating factor 3	Homo sapiens	78-115
24596527-4	2013	He was on G-CSF after cessation of high-dose and low-dose cytarabine chemotherapy.	Cytarabine	58-68	colony stimulating factor 3	Homo sapiens	10-15
22999386-9	2013	CONCLUSIONS: Our recommended dose for phase II is lapatinib 1000mg/day and docetaxel 100mg/m(2) with G-CSF in HER2 positive non-metastatic breast cancer.	Docetaxel	75-84	colony stimulating factor 3	Homo sapiens	101-106
23391654-5	2013	Furthermore, 5% of the control group and 38% of the bortezomib group received G-CSF alone for CD34+ cell mobilization.	Bortezomib	52-62	colony stimulating factor 3	Homo sapiens	78-83
23177153-5	2012	The interactions between a series of sulfate polysaccharides and granulocyte colony-stimulating factor (G-CSF) are selected as model.	sulfate polysaccharides	37-60	colony stimulating factor 3	Homo sapiens	65-102
23597461-9	2013	Our study also confirmed the superiority of ATG/ALG + CsA regimen \[64.8% (95%CI 57.9% - 71.7%)\] over ATG/ALG alone \[32.6% (95%CI 15.7% - 49.5%)\] with regard to 5-year OS (P &lt; 0.01); but the addition of recombinant human granulocyte colony-stimulating factor (rhG-CSF) to ATG/ALG had no benefit in terms of OS.	Cyclosporine	54-57	colony stimulating factor 3	Homo sapiens	227-264
23177153-5	2012	The interactions between a series of sulfate polysaccharides and granulocyte colony-stimulating factor (G-CSF) are selected as model.	sulfate polysaccharides	37-60	colony stimulating factor 3	Homo sapiens	104-109
23177153-6	2012	Through a 200 mum long heparin affinity column microfabricated inside a channel of 50 mum width and 20 mum height, the binding constant of each G-CSF-polysaccharide binding pair can be obtained within 1h, around one sixth of time needed by traditional capillary electrophoresis based method.	Heparin	23-30	colony stimulating factor 3	Homo sapiens	144-149
23177153-6	2012	Through a 200 mum long heparin affinity column microfabricated inside a channel of 50 mum width and 20 mum height, the binding constant of each G-CSF-polysaccharide binding pair can be obtained within 1h, around one sixth of time needed by traditional capillary electrophoresis based method.	Polysaccharides	150-164	colony stimulating factor 3	Homo sapiens	144-149
23221058-0	2012	[A case of successful treatment of granulocyte colony-stimulating factor producing hepatocellular carcinoma accompanying type B hepatitis with tegafur-uracil].	Tegafur	143-157	colony stimulating factor 3	Homo sapiens	35-72
22837010-7	2012	Induction of both G-CSF and IL-6 by CBLB502 1) is strictly TLR5-dependent, 2) occurs in a CBLB502 dose-dependent manner within its efficacious dose range in both nonirradiated and irradiated mammals, including nonhuman primates, and 3) is critically important for the ability of CBLB502 to rescue irradiated animals from death.	CBLB502	90-97	colony stimulating factor 3	Homo sapiens	18-23
22837010-0	2012	Identification of granulocyte colony-stimulating factor and interleukin-6 as candidate biomarkers of CBLB502 efficacy as a medical radiation countermeasure.	CBLB502	101-108	colony stimulating factor 3	Homo sapiens	18-55
22414093-4	2012	Plerixafor was limited to patients with previous or current stem cell mobilization failure and given after 4 days of G-CSF (n=21) or after chemotherapy and G-CSF (n=12) in patients who mobilized poorly.	plerixafor	0-10	colony stimulating factor 3	Homo sapiens	156-161
22837010-7	2012	Induction of both G-CSF and IL-6 by CBLB502 1) is strictly TLR5-dependent, 2) occurs in a CBLB502 dose-dependent manner within its efficacious dose range in both nonirradiated and irradiated mammals, including nonhuman primates, and 3) is critically important for the ability of CBLB502 to rescue irradiated animals from death.	CBLB502	36-43	colony stimulating factor 3	Homo sapiens	18-23
22837010-8	2012	After evaluation of CBLB502 effects on G-CSF and IL-6 levels in humans, these biomarkers will be useful for accurate prediction of human efficacious CBLB502 doses, a key step in the development of this prospective radiation countermeasure.	CBLB502	20-27	colony stimulating factor 3	Homo sapiens	39-44
22940758-0	2012	Granulocyte colony-stimulating factor potentiates differentiation induction             by all-trans retinoic acid and arsenic trioxide and enhances arsenic uptake in             the acute promyelocytic leukemia cell line HT93A.	Tretinoin	101-114	colony stimulating factor 3	Homo sapiens	0-37
22940758-0	2012	Granulocyte colony-stimulating factor potentiates differentiation induction             by all-trans retinoic acid and arsenic trioxide and enhances arsenic uptake in             the acute promyelocytic leukemia cell line HT93A.	Arsenic Trioxide	119-135	colony stimulating factor 3	Homo sapiens	0-37
22940758-0	2012	Granulocyte colony-stimulating factor potentiates differentiation induction             by all-trans retinoic acid and arsenic trioxide and enhances arsenic uptake in             the acute promyelocytic leukemia cell line HT93A.	Arsenic	119-126	colony stimulating factor 3	Homo sapiens	0-37
22940758-5	2012	G-CSF promoted differentiation-inducing activities of both ATO and ATRA.	Arsenic Trioxide	59-62	colony stimulating factor 3	Homo sapiens	0-5
22940758-5	2012	G-CSF promoted differentiation-inducing activities of both ATO and ATRA.	Tretinoin	67-71	colony stimulating factor 3	Homo sapiens	0-5
22940758-7	2012	Addition of 1 microM ATRA and/or 50 ng/ml G-CSF to ATO did not affect apoptosis compared to ATO treatment alone.	Arsenic Trioxide	51-54	colony stimulating factor 3	Homo sapiens	42-47
22940758-12	2012	G-CSF not only promotes differentiation-inducing activities of both ATRA and ATO, but also makes APL cells vulnerable to increased arsenic uptake.	Tretinoin	68-72	colony stimulating factor 3	Homo sapiens	0-5
22940758-12	2012	G-CSF not only promotes differentiation-inducing activities of both ATRA and ATO, but also makes APL cells vulnerable to increased arsenic uptake.	Arsenic Trioxide	77-80	colony stimulating factor 3	Homo sapiens	0-5
22940758-12	2012	G-CSF not only promotes differentiation-inducing activities of both ATRA and ATO, but also makes APL cells vulnerable to increased arsenic uptake.	Arsenic	131-138	colony stimulating factor 3	Homo sapiens	0-5
22414093-4	2012	Plerixafor was limited to patients with previous or current stem cell mobilization failure and given after 4 days of G-CSF (n=21) or after chemotherapy and G-CSF (n=12) in patients who mobilized poorly.	plerixafor	0-10	colony stimulating factor 3	Homo sapiens	117-122
23098625-12	2012	CONCLUSIONS: Combination of PR-104 with docetaxel or gemcitabine caused dose-limiting and severe myelotoxicity, but prophylactic G-CSF allowed PR-104 dose escalation with docetaxel.	Docetaxel	171-180	colony stimulating factor 3	Homo sapiens	129-134
22993377-18	2012	In conclusion, this modified regimen of docetaxel-cisplatin-capecitabine appears to have comparable efficacy with that reported for the reference regimen, with acceptable toxicity when G-CSF support is provided.	Docetaxel	40-49	colony stimulating factor 3	Homo sapiens	185-190
22850292-6	2012	Second we tested the effect of 6 naturally occurring extremolytes (trehalose, sucrose, ectoine, hydroxyectoine, sorbitol, mannitol) on the thermal stability of G-CSF, using a central composite circumscribed design.	Trehalose	67-76	colony stimulating factor 3	Homo sapiens	160-165
22850292-6	2012	Second we tested the effect of 6 naturally occurring extremolytes (trehalose, sucrose, ectoine, hydroxyectoine, sorbitol, mannitol) on the thermal stability of G-CSF, using a central composite circumscribed design.	Sucrose	78-85	colony stimulating factor 3	Homo sapiens	160-165
22850292-6	2012	Second we tested the effect of 6 naturally occurring extremolytes (trehalose, sucrose, ectoine, hydroxyectoine, sorbitol, mannitol) on the thermal stability of G-CSF, using a central composite circumscribed design.	ectoine	87-94	colony stimulating factor 3	Homo sapiens	160-165
22850292-6	2012	Second we tested the effect of 6 naturally occurring extremolytes (trehalose, sucrose, ectoine, hydroxyectoine, sorbitol, mannitol) on the thermal stability of G-CSF, using a central composite circumscribed design.	hydroxyectoine	96-110	colony stimulating factor 3	Homo sapiens	160-165
22850292-6	2012	Second we tested the effect of 6 naturally occurring extremolytes (trehalose, sucrose, ectoine, hydroxyectoine, sorbitol, mannitol) on the thermal stability of G-CSF, using a central composite circumscribed design.	Sorbitol	112-120	colony stimulating factor 3	Homo sapiens	160-165
22850292-6	2012	Second we tested the effect of 6 naturally occurring extremolytes (trehalose, sucrose, ectoine, hydroxyectoine, sorbitol, mannitol) on the thermal stability of G-CSF, using a central composite circumscribed design.	Mannitol	122-130	colony stimulating factor 3	Homo sapiens	160-165
22850292-7	2012	At low pH (3.8) and low buffer concentration (5 mM) all extremolytes led to a significant increase in thermal stability except the addition of ectoine which resulted in a strong destabilization of G-CSF.	ectoine	143-150	colony stimulating factor 3	Homo sapiens	197-202
22683613-8	2012	In addition, plerixafor plus G-CSF significantly improves the likelihood of optimal HSC collection in patients with higher preapheresis PB CD34(+) cell counts (&gt;=20 cells/muL) compared with placebo plus G-CSF.	plerixafor	13-23	colony stimulating factor 3	Homo sapiens	206-211
22714276-3	2012	We hypothesize that in vitro, the Caco2 model is associated with a constitutive neo-expression of the hematopoietic G-CSF thereby causing an autocrine stimulation of Caco2 growth and proliferation in vitro.	caco2	34-39	colony stimulating factor 3	Homo sapiens	116-121
22714276-3	2012	We hypothesize that in vitro, the Caco2 model is associated with a constitutive neo-expression of the hematopoietic G-CSF thereby causing an autocrine stimulation of Caco2 growth and proliferation in vitro.	caco2	166-171	colony stimulating factor 3	Homo sapiens	116-121
22714276-4	2012	To test our hypothesis, we analyzed mRNA and protein expression of G-CSF in Caco2 cells using reverse transcriptase-PCR and SDS-PAGE.	Sodium Dodecyl Sulfate	124-127	colony stimulating factor 3	Homo sapiens	67-72
22783986-2	2012	The present study was undertaken to evaluate the feasibility and safety of BMC mobilization induced by granulocyte-colony-stimulating factor (G-CSF) in patients undergoing surgery for sacrococcygeal pilonidal cysts (SPC).	bmc	75-78	colony stimulating factor 3	Homo sapiens	103-140
22783986-2	2012	The present study was undertaken to evaluate the feasibility and safety of BMC mobilization induced by granulocyte-colony-stimulating factor (G-CSF) in patients undergoing surgery for sacrococcygeal pilonidal cysts (SPC).	bmc	75-78	colony stimulating factor 3	Homo sapiens	142-147
22993377-18	2012	In conclusion, this modified regimen of docetaxel-cisplatin-capecitabine appears to have comparable efficacy with that reported for the reference regimen, with acceptable toxicity when G-CSF support is provided.	Cisplatin	50-59	colony stimulating factor 3	Homo sapiens	185-190
22719015-0	2012	Granulocyte colony stimulating factor (G-CSF) can allow treatment with clozapine in a patient with severe benign ethnic neutropaenia (BEN): a case report.	Clozapine	71-80	colony stimulating factor 3	Homo sapiens	0-37
23342488-0	2012	[Recombinant granulocyte-colony stimulating factor (filgrastim): optimization of conjugation with polyethylene glycol].	Polyethylene Glycols	98-117	colony stimulating factor 3	Homo sapiens	13-50
23342488-3	2012	Modification of proteins with PEG was performed by selective covalent attachment of the molecule alpha-methyl-PEG-propionaldehyde to the alpha-amino group of the N-terminal methionine amino acid residue of the recombinant GCSF.	Polyethylene Glycols	30-33	colony stimulating factor 3	Homo sapiens	222-226
23342488-3	2012	Modification of proteins with PEG was performed by selective covalent attachment of the molecule alpha-methyl-PEG-propionaldehyde to the alpha-amino group of the N-terminal methionine amino acid residue of the recombinant GCSF.	alpha-methyl-peg-propionaldehyde	97-129	colony stimulating factor 3	Homo sapiens	222-226
23342488-3	2012	Modification of proteins with PEG was performed by selective covalent attachment of the molecule alpha-methyl-PEG-propionaldehyde to the alpha-amino group of the N-terminal methionine amino acid residue of the recombinant GCSF.	methionine amino acid	173-194	colony stimulating factor 3	Homo sapiens	222-226
22719015-0	2012	Granulocyte colony stimulating factor (G-CSF) can allow treatment with clozapine in a patient with severe benign ethnic neutropaenia (BEN): a case report.	Clozapine	71-80	colony stimulating factor 3	Homo sapiens	39-44
22719015-5	2012	In this report, we show that response to granulocyte colony stimulating factor (G-CSF) may be quite variable and difficult to predict, but with careful monitoring it can be used to increase the ANC count and allow continued treatment with clozapine.	Clozapine	239-248	colony stimulating factor 3	Homo sapiens	41-78
22719015-5	2012	In this report, we show that response to granulocyte colony stimulating factor (G-CSF) may be quite variable and difficult to predict, but with careful monitoring it can be used to increase the ANC count and allow continued treatment with clozapine.	Clozapine	239-248	colony stimulating factor 3	Homo sapiens	80-85
22891005-0	2012	Teicoplanin-induced leucopenia with immediate resolution after administration of G-CSF.	Teicoplanin	0-11	colony stimulating factor 3	Homo sapiens	81-86
23071472-9	2012	Additional stimulation with granulocyte-colony stimulating factor (G-CSF) increased the cell death caused by AurA inhibition plus cytarabine treatment.	Cytarabine	130-140	colony stimulating factor 3	Homo sapiens	28-65
23071472-9	2012	Additional stimulation with granulocyte-colony stimulating factor (G-CSF) increased the cell death caused by AurA inhibition plus cytarabine treatment.	Cytarabine	130-140	colony stimulating factor 3	Homo sapiens	67-72
22727711-4	2012	Gel permeation studies showed that the polymer bioconjugates associate with recombinant human granulocyte colony stimulating factor (rh-G-CSF) to form supramolecular nanocomposites according to multi-modal association profiles.	Polymers	39-46	colony stimulating factor 3	Homo sapiens	94-131
22422582-8	2012	The native intramolecular disulfide bonds in the insoluble G-CSF aggregates were largely disrupted as shown by mass spectrometry.	Disulfides	26-35	colony stimulating factor 3	Homo sapiens	59-64
22080963-0	2012	Preemptive dosing of plerixafor given to poor stem cell mobilizers on day 5 of G-CSF administration.	plerixafor	21-31	colony stimulating factor 3	Homo sapiens	79-84
23077791-0	2012	Refolding of recombinant human granulocyte colony stimulating factor: effect of cysteine/cystine redox system.	Cysteine	80-88	colony stimulating factor 3	Homo sapiens	31-68
22080963-1	2012	Plerixafor, given on day 4 of G-CSF treatment is more effective than G-CSF alone in mobilizing hematopoietic progenitor cells.	plerixafor	0-10	colony stimulating factor 3	Homo sapiens	30-35
22080963-4	2012	Plerixafor (0.24 mg/kg s.c.) was given on day 5 of G-CSF followed by apheresis on day 6.	plerixafor	0-10	colony stimulating factor 3	Homo sapiens	51-56
22080963-10	2012	In conclusion, the decision to administer plerixafor can be delayed until after the peak mobilization response to G-CSF has been fully assessed.	plerixafor	42-52	colony stimulating factor 3	Homo sapiens	114-119
23077791-0	2012	Refolding of recombinant human granulocyte colony stimulating factor: effect of cysteine/cystine redox system.	Cystine	89-96	colony stimulating factor 3	Homo sapiens	31-68
23077791-3	2012	In the present study, refolding of recombinant human G-CSF expressed as inclusion bodies (IBs) in E. coli was optimized using cysteine and cystine redox agents.	Cysteine	126-134	colony stimulating factor 3	Homo sapiens	53-58
23077791-3	2012	In the present study, refolding of recombinant human G-CSF expressed as inclusion bodies (IBs) in E. coli was optimized using cysteine and cystine redox agents.	Cystine	139-146	colony stimulating factor 3	Homo sapiens	53-58
23077791-5	2012	The optimized concentrations of cysteine and cystine for correct refolding of G-CSF were found to be 2 mM and 1 mM, respectively.	Cysteine	32-40	colony stimulating factor 3	Homo sapiens	78-83
23077791-5	2012	The optimized concentrations of cysteine and cystine for correct refolding of G-CSF were found to be 2 mM and 1 mM, respectively.	Cystine	45-52	colony stimulating factor 3	Homo sapiens	78-83
23077791-6	2012	The correctly refolded G-CSF was detected as early as 4 h of incubation in renaturation buffer containing optimized concentrations of cysteine (2 mM) and cystine (1 mM) redox agents.	Cysteine	134-142	colony stimulating factor 3	Homo sapiens	23-28
23077791-6	2012	The correctly refolded G-CSF was detected as early as 4 h of incubation in renaturation buffer containing optimized concentrations of cysteine (2 mM) and cystine (1 mM) redox agents.	Cystine	154-161	colony stimulating factor 3	Homo sapiens	23-28
23077791-8	2012	Overall, the results suggested the use of cysteine/cystine redox pair could be an alternative to the costlier redox pairs for successful refolding of G-CSF and possibly other human biotherapeutic proteins of importance.	Cysteine	42-50	colony stimulating factor 3	Homo sapiens	150-155
23077791-8	2012	Overall, the results suggested the use of cysteine/cystine redox pair could be an alternative to the costlier redox pairs for successful refolding of G-CSF and possibly other human biotherapeutic proteins of importance.	Cystine	51-58	colony stimulating factor 3	Homo sapiens	150-155
22465758-0	2012	Pre-emptive plerixafor injection increases blood neutrophil, lymphocyte and monocyte counts in addition to CD34+ counts in patients with non-Hodgkin lymphoma mobilizing poorly with chemotherapy plus G-CSF: potential implications for apheresis and graft composition.	plerixafor	12-22	colony stimulating factor 3	Homo sapiens	199-204
22609192-2	2012	Here we report our results with G-P among patients with at least one mobilization failure with G-CSF alone (G) or G-CSF plus chemotherapy (G-C).	(2S)-1-(2-aminoacetyl)pyrrolidine-2-carbaldehyde	32-35	colony stimulating factor 3	Homo sapiens	95-100
22609192-2	2012	Here we report our results with G-P among patients with at least one mobilization failure with G-CSF alone (G) or G-CSF plus chemotherapy (G-C).	(2S)-1-(2-aminoacetyl)pyrrolidine-2-carbaldehyde	32-35	colony stimulating factor 3	Homo sapiens	114-119
23134856-14	2012	CONCLUSION: Single high-dose etoposide with G-CSF for mobilization of APBSC has a higher achievement ratio, a controllable adverse effect, a promising hematopoiesis recovery, which is an effective and safe mobilizing regimen for patients with hematologic malignancies.	Etoposide	29-38	colony stimulating factor 3	Homo sapiens	44-49
22012661-4	2012	We report on the use of plerixafor in eight pediatric cases either as add-on to chemotherapy plus G-CSF or in remobilization.	plerixafor	24-34	colony stimulating factor 3	Homo sapiens	98-103
23226863-0	2012	Novel use of granulocyte colony stimulating factor as an adjunct for treatment of schizoaffective disorder complicated by sodium valproate induced agranulocytosis.	Valproic Acid	122-138	colony stimulating factor 3	Homo sapiens	13-50
22382679-6	2012	Differences in the hydroxyl radical footprint were measured between Neupogen  and the expired or mishandled GCSF samples, and confirmed by circular dichroism spectroscopy.	Hydroxyl Radical	19-35	colony stimulating factor 3	Homo sapiens	108-112
22415148-1	2012	PURPOSE: We conducted a phase I trial of irinotecan (CPT-11), a topoisomerase I inhibitor, combined with amrubicin, a topoisomerase II inhibitor, with recombinant human granulocyte colony-stimulating factor (rhG-CSF) support to overcome the neutropenia associated with this particular combination.	Irinotecan	41-51	colony stimulating factor 3	Homo sapiens	169-206
22415148-1	2012	PURPOSE: We conducted a phase I trial of irinotecan (CPT-11), a topoisomerase I inhibitor, combined with amrubicin, a topoisomerase II inhibitor, with recombinant human granulocyte colony-stimulating factor (rhG-CSF) support to overcome the neutropenia associated with this particular combination.	Irinotecan	53-59	colony stimulating factor 3	Homo sapiens	169-206
22415148-1	2012	PURPOSE: We conducted a phase I trial of irinotecan (CPT-11), a topoisomerase I inhibitor, combined with amrubicin, a topoisomerase II inhibitor, with recombinant human granulocyte colony-stimulating factor (rhG-CSF) support to overcome the neutropenia associated with this particular combination.	amrubicin	105-114	colony stimulating factor 3	Homo sapiens	169-206
22248715-1	2012	Peripheral blood progenitor cell mobilization with intermediate-dose cyclophosphamide (ID-CY) and granulocyte colony-stimulating factor (G-CSF) has been shown to be more efficacious, albeit more toxic, than low-dose cyclophosphamide (LD-CY) mobilization regimens in patients with multiple myeloma treated with conventional therapies.	Cyclophosphamide	216-232	colony stimulating factor 3	Homo sapiens	137-142
22248715-1	2012	Peripheral blood progenitor cell mobilization with intermediate-dose cyclophosphamide (ID-CY) and granulocyte colony-stimulating factor (G-CSF) has been shown to be more efficacious, albeit more toxic, than low-dose cyclophosphamide (LD-CY) mobilization regimens in patients with multiple myeloma treated with conventional therapies.	ld-cy	234-239	colony stimulating factor 3	Homo sapiens	98-135
22248715-1	2012	Peripheral blood progenitor cell mobilization with intermediate-dose cyclophosphamide (ID-CY) and granulocyte colony-stimulating factor (G-CSF) has been shown to be more efficacious, albeit more toxic, than low-dose cyclophosphamide (LD-CY) mobilization regimens in patients with multiple myeloma treated with conventional therapies.	ld-cy	234-239	colony stimulating factor 3	Homo sapiens	137-142
23573483-0	2012	Effects of human Umbilical Cord Stem Cells and Granulocyte Colony- Stimulating Factor (G-CSF) on Carbon Tetrachloride-Induced Nephrotoxicity.	Carbon Tetrachloride	97-117	colony stimulating factor 3	Homo sapiens	47-85
23573483-0	2012	Effects of human Umbilical Cord Stem Cells and Granulocyte Colony- Stimulating Factor (G-CSF) on Carbon Tetrachloride-Induced Nephrotoxicity.	Carbon Tetrachloride	97-117	colony stimulating factor 3	Homo sapiens	87-92
22422824-7	2012	However, patients treated with the escalated-dose cytarabine regimen benefited from G-CSF priming, with improved event-free survival (P = .01) and overall survival (P = .003), compared with patients without G-CSF undergoing escalated-dose cytarabine treatment.	Cytarabine	50-60	colony stimulating factor 3	Homo sapiens	84-89
22422824-7	2012	However, patients treated with the escalated-dose cytarabine regimen benefited from G-CSF priming, with improved event-free survival (P = .01) and overall survival (P = .003), compared with patients without G-CSF undergoing escalated-dose cytarabine treatment.	Cytarabine	239-249	colony stimulating factor 3	Homo sapiens	84-89
22422824-8	2012	A significant survival advantage of sensitizing AML for chemotherapy with G-CSF was not apparent in the entire study group, but it was seen in patients treated with escalated-dose cytarabine during remission induction.	Cytarabine	180-190	colony stimulating factor 3	Homo sapiens	74-79
22422106-4	2012	Conformational stability of HSA-GCSF was modulated by addition of octanoic acid, which was previously shown to increase the conformational stability of HSA, the least stable domain.	octanoic acid	66-79	colony stimulating factor 3	Homo sapiens	32-36
22018773-0	2012	Life-threatening thrombocytosis following GCSF treatment in a case of clozapine-induced agranulocytosis.	Clozapine	70-79	colony stimulating factor 3	Homo sapiens	42-46
22296221-1	2012	INTRODUCTION: Granulocyte Colony-Stimulating Factor (G-CSF) is commonly used to maintain dose intensity in patients receiving ABVD chemotherapy (doxorubicin, bleomycin, vinblastine and dacarbazine) for Hodgkin lymphoma.	Doxorubicin	145-156	colony stimulating factor 3	Homo sapiens	14-51
22296221-1	2012	INTRODUCTION: Granulocyte Colony-Stimulating Factor (G-CSF) is commonly used to maintain dose intensity in patients receiving ABVD chemotherapy (doxorubicin, bleomycin, vinblastine and dacarbazine) for Hodgkin lymphoma.	Doxorubicin	145-156	colony stimulating factor 3	Homo sapiens	53-58
22296221-1	2012	INTRODUCTION: Granulocyte Colony-Stimulating Factor (G-CSF) is commonly used to maintain dose intensity in patients receiving ABVD chemotherapy (doxorubicin, bleomycin, vinblastine and dacarbazine) for Hodgkin lymphoma.	Bleomycin	158-167	colony stimulating factor 3	Homo sapiens	14-51
22296221-1	2012	INTRODUCTION: Granulocyte Colony-Stimulating Factor (G-CSF) is commonly used to maintain dose intensity in patients receiving ABVD chemotherapy (doxorubicin, bleomycin, vinblastine and dacarbazine) for Hodgkin lymphoma.	Bleomycin	158-167	colony stimulating factor 3	Homo sapiens	53-58
22296221-1	2012	INTRODUCTION: Granulocyte Colony-Stimulating Factor (G-CSF) is commonly used to maintain dose intensity in patients receiving ABVD chemotherapy (doxorubicin, bleomycin, vinblastine and dacarbazine) for Hodgkin lymphoma.	Vinblastine	169-180	colony stimulating factor 3	Homo sapiens	14-51
22296221-1	2012	INTRODUCTION: Granulocyte Colony-Stimulating Factor (G-CSF) is commonly used to maintain dose intensity in patients receiving ABVD chemotherapy (doxorubicin, bleomycin, vinblastine and dacarbazine) for Hodgkin lymphoma.	Vinblastine	169-180	colony stimulating factor 3	Homo sapiens	53-58
22296221-1	2012	INTRODUCTION: Granulocyte Colony-Stimulating Factor (G-CSF) is commonly used to maintain dose intensity in patients receiving ABVD chemotherapy (doxorubicin, bleomycin, vinblastine and dacarbazine) for Hodgkin lymphoma.	Dacarbazine	185-196	colony stimulating factor 3	Homo sapiens	14-51
22296221-1	2012	INTRODUCTION: Granulocyte Colony-Stimulating Factor (G-CSF) is commonly used to maintain dose intensity in patients receiving ABVD chemotherapy (doxorubicin, bleomycin, vinblastine and dacarbazine) for Hodgkin lymphoma.	Dacarbazine	185-196	colony stimulating factor 3	Homo sapiens	53-58
22296221-3	2012	Moreover, G-CSF is expensive (pegfilgrastim: EUR 1540/cycle; 300 mug filgrastim for 7 days: EUR 700/cycle) and is associated with side effects including bone pain and increased risk of bleomycin lung toxicity.	Bleomycin	185-194	colony stimulating factor 3	Homo sapiens	10-15
22296221-6	2012	METHODS: Retrospective analysis of the incidence of febrile neutropenia and treatment delay in a variety of different G-CSF schedules used as secondary prophylaxis in patients receiving ABVD.	ABVD protocol	186-190	colony stimulating factor 3	Homo sapiens	118-123
22018773-4	2012	Here we are presenting a case of clozapine induced agranulocytosis managed with GCSF but had transient but life-threatening thrombocytosis, a very uncommon complication of GCSF therapy.	Clozapine	33-42	colony stimulating factor 3	Homo sapiens	80-84
22018773-4	2012	Here we are presenting a case of clozapine induced agranulocytosis managed with GCSF but had transient but life-threatening thrombocytosis, a very uncommon complication of GCSF therapy.	Clozapine	33-42	colony stimulating factor 3	Homo sapiens	172-176
22458355-7	2012	Furthermore our study suggests that mobilization with plerixafor may be effective in Korean pediatric patients, who have previously been heavily treated and have failed PBSC mobilization with classical chemomobilization, using G-CSF.	plerixafor	54-64	colony stimulating factor 3	Homo sapiens	227-232
22628236-7	2012	Receiver operating characteristic (ROC) curves for the discrimination of the G-CSF group from normal controls showed excellent sensitivity in SD-LALS-NE (at 30.85, sensitivity 95.2%, specificity 76.0%), MN-AL2-NE (at 134.5, sensitivity 90.5%, specificity 83.0%), and SD-AL2-NE (at 16.4, sensitivity 95.2%, specificity 95.2).	sd-lals-ne	142-152	colony stimulating factor 3	Homo sapiens	77-82
22628236-7	2012	Receiver operating characteristic (ROC) curves for the discrimination of the G-CSF group from normal controls showed excellent sensitivity in SD-LALS-NE (at 30.85, sensitivity 95.2%, specificity 76.0%), MN-AL2-NE (at 134.5, sensitivity 90.5%, specificity 83.0%), and SD-AL2-NE (at 16.4, sensitivity 95.2%, specificity 95.2).	mn-al2-ne	203-212	colony stimulating factor 3	Homo sapiens	77-82
22628236-7	2012	Receiver operating characteristic (ROC) curves for the discrimination of the G-CSF group from normal controls showed excellent sensitivity in SD-LALS-NE (at 30.85, sensitivity 95.2%, specificity 76.0%), MN-AL2-NE (at 134.5, sensitivity 90.5%, specificity 83.0%), and SD-AL2-NE (at 16.4, sensitivity 95.2%, specificity 95.2).	sd-al2-ne	267-276	colony stimulating factor 3	Homo sapiens	77-82
22111969-0	2012	Importance of granulocyte colony-stimulating factor prophylaxis in therapy with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone given every 14 days for diffuse large B-cell lymphoma in routine clinical practice.	Cyclophosphamide	91-107	colony stimulating factor 3	Homo sapiens	14-51
22111969-0	2012	Importance of granulocyte colony-stimulating factor prophylaxis in therapy with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone given every 14 days for diffuse large B-cell lymphoma in routine clinical practice.	Doxorubicin	109-120	colony stimulating factor 3	Homo sapiens	14-51
22111969-0	2012	Importance of granulocyte colony-stimulating factor prophylaxis in therapy with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone given every 14 days for diffuse large B-cell lymphoma in routine clinical practice.	Vincristine	122-133	colony stimulating factor 3	Homo sapiens	14-51
22111969-0	2012	Importance of granulocyte colony-stimulating factor prophylaxis in therapy with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone given every 14 days for diffuse large B-cell lymphoma in routine clinical practice.	Prednisolone	138-150	colony stimulating factor 3	Homo sapiens	14-51
22244804-0	2012	Structural identification and biological activity of positional isomers of long-acting and mono-PEGylated recombinant human granulocyte colony-stimulating factor with trimeric-structured methoxy polyethylene glycol N-hydroxysuccinimidyl functional group.	methoxy polyethylene glycol n-hydroxysuccinimidyl	187-236	colony stimulating factor 3	Homo sapiens	124-161
21981351-4	2012	Plerixafor has been recently introduced for clinical use to enhance PBSC mobilization and has been shown to be more effective than granulocyte-colony-stimulating factor (G-CSF) alone in patients with multiple myeloma or non-Hodgkin"s lymphoma.	plerixafor	0-10	colony stimulating factor 3	Homo sapiens	131-168
22227798-0	2012	Using hydrogen/deuterium exchange mass spectrometry to study conformational changes in granulocyte colony stimulating factor upon PEGylation.	Hydrogen	6-14	colony stimulating factor 3	Homo sapiens	87-124
22119930-7	2012	Treatment with G-CSF also reduced CTP scores in group A by a median of 33.3% compared with an increase of 7.1% in group B (P = .001), along with MELD (median reduction of 15.3% compared with an increase of 11.7% in group B; P = .008) and SOFA scores (median reduction of 50% compared with an increase of 50% in group B; P = .001).	Cytidine Triphosphate	34-37	colony stimulating factor 3	Homo sapiens	15-20
22119930-10	2012	CONCLUSIONS: G-CSF therapy more than doubles the percentage of patients with ACLF who survive for 2 months; it also significantly reduces CTP, MELD, and SOFA scores and prevents the development of sepsis, hepatorenal syndrome, and hepatic encephalopathy.	Cytidine Triphosphate	138-141	colony stimulating factor 3	Homo sapiens	13-18
22227798-0	2012	Using hydrogen/deuterium exchange mass spectrometry to study conformational changes in granulocyte colony stimulating factor upon PEGylation.	Deuterium	15-24	colony stimulating factor 3	Homo sapiens	87-124
22227798-3	2012	The combined use of HDX automation technology and data analysis software allowed reproducible and robust measurements of the deuterium incorporation levels for peptic peptides of both PEGylated and non-PEGylated G-CSF.	Deuterium	125-134	colony stimulating factor 3	Homo sapiens	212-217
22227798-4	2012	The results indicated that significant differences in deuterium incorporation were induced by PEGylation of G-CSF, although the overall changes observed were quite small.	Deuterium	54-63	colony stimulating factor 3	Homo sapiens	108-113
21964491-12	2012	As expected, oxygen breathing induced a pronounced vasoconstriction and a decrease red and white cell flux in both, the placebo and the G-CSF group (p&lt;0.01 for both groups).	Oxygen	13-19	colony stimulating factor 3	Homo sapiens	136-141
22015065-0	2012	miR-590-5p, miR-219-5p, miR-15b and miR-628-5p are commonly regulated by IL-3, GM-CSF and G-CSF in acute myeloid leukemia.	590-5p	4-10	colony stimulating factor 3	Homo sapiens	90-95
21416584-2	2012	Priming with the CXCR4 inhibitor plerixafor plus G-CSF was associated with successful stem cell harvest in 5/7 heavily prior-treated patients with stage 4 NB who had previously failed G-CSF priming.	plerixafor	33-43	colony stimulating factor 3	Homo sapiens	184-189
22001752-9	2012	In conclusion, salvage mobilization with plerixafor plus G-CSF is successful in the majority of patients with MM previously treated with lenalidomide.	Lenalidomide	137-149	colony stimulating factor 3	Homo sapiens	57-62
21460870-3	2012	In the VP+G group, median total CD34+ cells collected were 9.34 x 10(6) per kg (range 0.97-180.89), with 42% of all patients having adequate (2 x 10(6) cells per kg) CD 34+ collection after 2 days of apheresis compared with a median in the G-CSF group of 3.83 x 10(6) per kg (range, 0.72-50.38), with only 16% patients having adequate collection after 2 days (P&lt;0.001).	VP protocol	7-9	colony stimulating factor 3	Homo sapiens	240-245
22781604-11	2012	G-CSF alone could obtain satisfactory mobilization results and most of patients well tolerated to the conditioning regimen of melphalan doses from 140 mg/m(2) to 200 mg/m(2).	Melphalan	126-135	colony stimulating factor 3	Homo sapiens	0-5
21882174-5	2012	It was found that of human ferritin light chain, bacterial arginine deiminase, human granulocyte colony stimulating factor were synthesized evidently with the self-assembly function, L-arginine-degrading activity, and the correct secondary structure, respectively, through the fusion expression using N-ePGK.	Arginine	183-193	colony stimulating factor 3	Homo sapiens	85-122
22001752-10	2012	In fludarabine-exposed patients, only 58% of patients will achieve successful salvage mobilization with plerixafor plus G-CSF, suggesting the need for novel mobilization regimens algorithms in this subgroup of patients.	fludarabine	3-14	colony stimulating factor 3	Homo sapiens	120-125
22435747-3	2012	Granulocyte colony-stimulating factor (G-CSF) with plerixafor (G P) is superior to G-CSF alone for SCM in heavily pretreated NHL patients.	plerixafor	51-61	colony stimulating factor 3	Homo sapiens	0-37
22435747-3	2012	Granulocyte colony-stimulating factor (G-CSF) with plerixafor (G P) is superior to G-CSF alone for SCM in heavily pretreated NHL patients.	plerixafor	51-61	colony stimulating factor 3	Homo sapiens	39-44
22065290-7	2012	Half of oncologists use prophylactic G-CSF with TCH.	thiocarbohydrazide	48-51	colony stimulating factor 3	Homo sapiens	37-42
21358682-7	2012	PI3K and p-ERK expression were also decreased in G-CSF-treated NK-92MI cells, and their inhibitors, wortmannin and PD98059, respectively, both enhanced the downregulation of cytotoxicity.	Wortmannin	100-110	colony stimulating factor 3	Homo sapiens	49-54
21358682-7	2012	PI3K and p-ERK expression were also decreased in G-CSF-treated NK-92MI cells, and their inhibitors, wortmannin and PD98059, respectively, both enhanced the downregulation of cytotoxicity.	2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one	115-122	colony stimulating factor 3	Homo sapiens	49-54
21358682-9	2012	Wortmannin, but not PD98059, enhanced the downregulation of TPI in G-CSF-treated NK-92MI cells, indicating a correlation between PI3K and TPI.	Wortmannin	0-10	colony stimulating factor 3	Homo sapiens	67-72
22065290-10	2012	Fifteen patients received prophylactic G-CSF during TCH; none developed neutropenic fever.	thiocarbohydrazide	52-55	colony stimulating factor 3	Homo sapiens	39-44
21740297-9	2012	Omission of G-CSF for uncomplicated neutropenic patients receiving ABVD for Hodgkin lymphoma is cost-saving and safe.	ABVD protocol	67-71	colony stimulating factor 3	Homo sapiens	12-17
22123660-3	2012	RECENT FINDINGS: We review the evidence that lithium increases granulocyte colony-stimulating factor (G-CSF) and augments G-CSF effects, showing its potential use in stem cell mobilization and engraftment of stem cell transplantation.	Lithium	45-52	colony stimulating factor 3	Homo sapiens	102-107
22123660-3	2012	RECENT FINDINGS: We review the evidence that lithium increases granulocyte colony-stimulating factor (G-CSF) and augments G-CSF effects, showing its potential use in stem cell mobilization and engraftment of stem cell transplantation.	Lithium	45-52	colony stimulating factor 3	Homo sapiens	122-127
22143075-7	2012	Significant controversy surrounds the role of granulocyte colony stimulating factor (GCSF) in levamisole-associated agranulocytosis.	Levamisole	94-104	colony stimulating factor 3	Homo sapiens	46-83
22143075-7	2012	Significant controversy surrounds the role of granulocyte colony stimulating factor (GCSF) in levamisole-associated agranulocytosis.	Levamisole	94-104	colony stimulating factor 3	Homo sapiens	85-89
22202080-5	2012	Plerixafor, a CXCR4 antagonist has been found to be a potent stem cell mobilizer and it"s superiority used in combination with G-CSF over G-CSF alone has been seen in non-Hodgkin"s lymphoma and multiple myeloma in double blind randomized phase III clinical trials, leading to FDA (Food and Drug Administration) approval.	plerixafor	0-10	colony stimulating factor 3	Homo sapiens	127-132
22202080-5	2012	Plerixafor, a CXCR4 antagonist has been found to be a potent stem cell mobilizer and it"s superiority used in combination with G-CSF over G-CSF alone has been seen in non-Hodgkin"s lymphoma and multiple myeloma in double blind randomized phase III clinical trials, leading to FDA (Food and Drug Administration) approval.	plerixafor	0-10	colony stimulating factor 3	Homo sapiens	138-143
22123660-3	2012	RECENT FINDINGS: We review the evidence that lithium increases granulocyte colony-stimulating factor (G-CSF) and augments G-CSF effects, showing its potential use in stem cell mobilization and engraftment of stem cell transplantation.	Lithium	45-52	colony stimulating factor 3	Homo sapiens	63-100
22442961-0	2012	[Effects of granulocyte colony-stimulating factor on experimental bleomycin-induced pulmonary fibrosis].	Bleomycin	66-75	colony stimulating factor 3	Homo sapiens	12-49
22442961-2	2012	It is established that G-CSF significantly increases infiltration of alveolar and alveolar duct interstitium by inflammation cells (lymphocytes, neutrophils, plasmocytes) and increases collagen deposition in lung under conditions of bleomycin introduction.	Bleomycin	233-242	colony stimulating factor 3	Homo sapiens	23-28
23326260-16	2012	TGF-beta1 and G-CSF detected in endoscopically collected pancreatic cyst fluid are potential diagnostic biomarkers capable of distinguishing mixed IPMN from BD-IPMN.	bd-ipmn	157-164	colony stimulating factor 3	Homo sapiens	14-19
22860122-0	2012	Aciculatin inhibits granulocyte colony-stimulating factor production by human interleukin 1beta-stimulated fibroblast-like synoviocytes.	aciculatin	0-10	colony stimulating factor 3	Homo sapiens	20-57
23170195-5	2012	Plerixafor has been recently approved to enhance PBSC mobilization in adult patients with multiple myeloma or non-Hodgkin lymphoma and has been shown to be more effective than G-CSF alone.	plerixafor	0-10	colony stimulating factor 3	Homo sapiens	176-181
22479263-9	2012	These effects of thrombin were significantly reduced by the addition of argatroban (M-CSF, p &lt; 0.01; GM-CSF, p &lt; 0.01; G-CSF, p &lt; 0.05).	argatroban	72-82	colony stimulating factor 3	Homo sapiens	125-130
22952917-5	2012	When stimulated with whole sperm cells, the PBMCs from patients with ASA produce less IL-3, IL-11, IL-13, ICAM-1, GCSF and more IL-2, IL-4 and IL-12p70 as compared to healthy women.	Aspirin	69-72	colony stimulating factor 3	Homo sapiens	114-118
22860122-5	2012	Whether aciculatin inhibited IL-1beta-stimulated G-CSF expression, and if so, how, were evaluated using western blot assay, an electrophoretic mobility shift assay, and a reporter gene assay.	aciculatin	8-18	colony stimulating factor 3	Homo sapiens	49-54
22860122-7	2012	Aciculatin markedly inhibited G-CSF expression induced by IL-1beta (10 ng/mL) in a concentration-dependent manner (1-10 microM).	aciculatin	0-10	colony stimulating factor 3	Homo sapiens	30-35
22860122-9	2012	Furthermore, aciculatin significantly inhibited the G-CSF-mediated phosphorylation of Janus kinase-signal transducer and activator of transcription (JAK-STAT) and Akt and neutrophil differentiation from precursor cells.	aciculatin	13-23	colony stimulating factor 3	Homo sapiens	52-57
22860122-10	2012	Our results show that aciculatin inhibits IL-1beta-stimulated G-CSF expression and the subsequent neutrophil differentiation, suggesting that it might have therapeutic potential for inflammatory arthritis.	aciculatin	22-32	colony stimulating factor 3	Homo sapiens	62-67
22289749-6	2012	In patients treated with the ATG plus CsA combination therapy, the response rate was relatively high for children whose disease course was less than six months, bone marrow hematopoietic area was more than 40%, had no severe infections, and experienced granulocyte colony stimulating factor (G-CSF) reaction during the early treatment; however, it was not related to AA subtypes and age.	Cyclosporine	38-41	colony stimulating factor 3	Homo sapiens	253-290
22289749-6	2012	In patients treated with the ATG plus CsA combination therapy, the response rate was relatively high for children whose disease course was less than six months, bone marrow hematopoietic area was more than 40%, had no severe infections, and experienced granulocyte colony stimulating factor (G-CSF) reaction during the early treatment; however, it was not related to AA subtypes and age.	Cyclosporine	38-41	colony stimulating factor 3	Homo sapiens	292-297
22045733-5	2011	Prdx4 inhibits G-CSF-induced signalling and proliferation in myeloid progenitors, depending on its redox-active cysteine core.	Cysteine	112-120	colony stimulating factor 3	Homo sapiens	15-20
21723892-6	2011	The AUC (area under the curve) of the octyl-based polymer formulation showed a 5-fold increase, compared with native G-CSF.	octyl-based polymer	38-57	colony stimulating factor 3	Homo sapiens	117-122
22166826-7	2011	The chemotherapy (gemcitabine and cisplatin) and the molecular target therapy (sunitinib) were administerd but the primary lesion and metastases was progressive and serum G-CSF concentration was elevated to 229 pg/ml.	Sunitinib	79-88	colony stimulating factor 3	Homo sapiens	171-176
21848522-0	2011	Clofarabine with high dose cytarabine and granulocyte colony-stimulating factor (G-CSF) priming for relapsed and refractory acute myeloid leukaemia.	Clofarabine	0-11	colony stimulating factor 3	Homo sapiens	81-86
21832280-7	2011	However, plerixafor through its rapid direct blockage of the CXCR4/CXCL12 chemotaxis pathway and synergy with G-CSF and chemotherapy has become a new and important agent for mobilization.	plerixafor	9-19	colony stimulating factor 3	Homo sapiens	110-115
21617923-0	2011	Prolonged progression-free survival in patients with chronic lymphocytic leukemia receiving granulocyte colony-stimulating factor during treatment with fludarabine, cyclophosphamide, and rituximab.	fludarabine	152-163	colony stimulating factor 3	Homo sapiens	92-129
21617923-0	2011	Prolonged progression-free survival in patients with chronic lymphocytic leukemia receiving granulocyte colony-stimulating factor during treatment with fludarabine, cyclophosphamide, and rituximab.	Cyclophosphamide	165-181	colony stimulating factor 3	Homo sapiens	92-129
21516122-0	2011	Sumoylation of MEL1S at lysine 568 and its interaction with CtBP facilitates its repressor activity and the blockade of G-CSF-induced myeloid differentiation.	ctbp	60-64	colony stimulating factor 3	Homo sapiens	120-125
21516122-5	2011	The expression of MEL1S containing mutated CtBP-interacting motif (CIM) in L-G3 cells still blocked the myeloid differentiation induced by G-CSF.	ctbp	43-47	colony stimulating factor 3	Homo sapiens	139-144
21824038-4	2011	Because of an apparent high incidence of side effects, especially febrile neutropenia (FN) and non-hematologic side effects, the DBCG (The Danish Breast Cancer Cooperative Group) initiated a retrospective study of adverse reactions to the newly introduced regime and all patients were offered primary prophylaxis with growth factors (G-CSF) pr 1/1-2008.	dbcg	129-133	colony stimulating factor 3	Homo sapiens	334-339
22027004-3	2011	We created an N-linked glycosylated form of this cytokine, hG-CSF (Phe140Asn), to assess its biological activity in the promyelocyte cell line HL60.	Nitrogen	14-15	colony stimulating factor 3	Homo sapiens	59-65
22027004-6	2011	These results suggest that the addition of N-linked glycosylation was successful in improving the biological activity of hG-CSF.	Nitrogen	43-44	colony stimulating factor 3	Homo sapiens	121-127
21861545-1	2011	Plerixafor (Mozobil ) is a CXCR4 chemokine receptor antagonist that is indicated for use in combination with granulocyte colony-stimulating factor (G-CSF) to mobilize stem cells to the peripheral blood for collection and subsequent autologous stem-cell transplantation in patients who have non-Hodgkin"s lymphoma (NHL) or multiple myeloma (MM) [US] and in patients who have lymphoma or MM and are poor mobilizers (EU).	plerixafor	0-10	colony stimulating factor 3	Homo sapiens	109-146
21340502-2	2011	Laboratory data demonstrated marked pancytopenia, which we first regarded as a side effect of methotrexate, and leucovorin was administered with granulocyte-colony stimulating factor and transfusions.	Leucovorin	112-122	colony stimulating factor 3	Homo sapiens	145-182
21492180-3	2011	RESULTS: Plerixafor was administered to 64 of 188 patients considered to be at risk for mobilization failure due to either their medical history ("high risk," n = 23) or the occurrence of peripheral blood CD34+ count of fewer than 15 x 10(6) cells/L with a white blood cell count of greater than 10 x 10(9) cells/L after at least 5 days of G-CSF administration (just-in-time, n = 41).	plerixafor	9-19	colony stimulating factor 3	Homo sapiens	340-345
22111065-2	2011	Therefore, the current trial attempted to evaluate the efficacy of granulocyte colony-stimulating factor (G-CSF) priming in remission induction chemotherapy with an intensified dose of Ara-C for newly diagnosed AML.	Cytarabine	185-190	colony stimulating factor 3	Homo sapiens	67-104
20972470-1	2011	The CXCR4-inhibitor plerixafor mobilizes hematopoietic stem cells amplifying the effects of granulocyte-CSF (G-CSF).	plerixafor	20-30	colony stimulating factor 3	Homo sapiens	92-107
20972470-1	2011	The CXCR4-inhibitor plerixafor mobilizes hematopoietic stem cells amplifying the effects of granulocyte-CSF (G-CSF).	plerixafor	20-30	colony stimulating factor 3	Homo sapiens	109-114
22111065-2	2011	Therefore, the current trial attempted to evaluate the efficacy of granulocyte colony-stimulating factor (G-CSF) priming in remission induction chemotherapy with an intensified dose of Ara-C for newly diagnosed AML.	Cytarabine	185-190	colony stimulating factor 3	Homo sapiens	106-111
21668998-5	2011	G-CSFa contains alanine 17 (instead of cysteine 17 as in wild-type G-CSF) as well as four additional amino acids including methionine, arginine, glycine, and serine at the amino-terminus.	Alanine	16-23	colony stimulating factor 3	Homo sapiens	0-5
20708854-15	2011	CONCLUSIONS: One-cycle full-dose docetaxel/cisplatin induction chemotherapy with recombinant human granulocyte colony-stimulating factor followed by pulsed low-dose docetaxel CRT is promising with regard to its antitumor activity, low rates of distant failure, and low toxicity, suggesting that this regimen deserves further investigation.	Docetaxel	33-42	colony stimulating factor 3	Homo sapiens	99-136
20708854-15	2011	CONCLUSIONS: One-cycle full-dose docetaxel/cisplatin induction chemotherapy with recombinant human granulocyte colony-stimulating factor followed by pulsed low-dose docetaxel CRT is promising with regard to its antitumor activity, low rates of distant failure, and low toxicity, suggesting that this regimen deserves further investigation.	Cisplatin	43-52	colony stimulating factor 3	Homo sapiens	99-136
21499162-0	2011	Fluorodeoxyglucose uptake in the bone marrow after granulocyte colony-stimulating factor administration in patients with non-Hodgkin"s lymphoma.	Fluorodeoxyglucose F18	0-18	colony stimulating factor 3	Homo sapiens	51-88
21499162-1	2011	PURPOSE: To clarify the change in the fluorodeoxyglucose (FDG) uptake by the bone marrow over time after administration of granulocyte colony-stimulating factor (G-CSF), we evaluated the correlation between the interval from the last day of administration of G-CSF to positron emission tomography/computed tomography (PET/CT) study and spinal bone marrow accumulation in patients with non-Hodgkin"s lymphoma.	Fluorodeoxyglucose F18	38-56	colony stimulating factor 3	Homo sapiens	123-160
21499162-1	2011	PURPOSE: To clarify the change in the fluorodeoxyglucose (FDG) uptake by the bone marrow over time after administration of granulocyte colony-stimulating factor (G-CSF), we evaluated the correlation between the interval from the last day of administration of G-CSF to positron emission tomography/computed tomography (PET/CT) study and spinal bone marrow accumulation in patients with non-Hodgkin"s lymphoma.	Fluorodeoxyglucose F18	38-56	colony stimulating factor 3	Homo sapiens	162-167
21499162-1	2011	PURPOSE: To clarify the change in the fluorodeoxyglucose (FDG) uptake by the bone marrow over time after administration of granulocyte colony-stimulating factor (G-CSF), we evaluated the correlation between the interval from the last day of administration of G-CSF to positron emission tomography/computed tomography (PET/CT) study and spinal bone marrow accumulation in patients with non-Hodgkin"s lymphoma.	Fluorodeoxyglucose F18	58-61	colony stimulating factor 3	Homo sapiens	123-160
21499162-1	2011	PURPOSE: To clarify the change in the fluorodeoxyglucose (FDG) uptake by the bone marrow over time after administration of granulocyte colony-stimulating factor (G-CSF), we evaluated the correlation between the interval from the last day of administration of G-CSF to positron emission tomography/computed tomography (PET/CT) study and spinal bone marrow accumulation in patients with non-Hodgkin"s lymphoma.	Fluorodeoxyglucose F18	58-61	colony stimulating factor 3	Homo sapiens	162-167
21499162-1	2011	PURPOSE: To clarify the change in the fluorodeoxyglucose (FDG) uptake by the bone marrow over time after administration of granulocyte colony-stimulating factor (G-CSF), we evaluated the correlation between the interval from the last day of administration of G-CSF to positron emission tomography/computed tomography (PET/CT) study and spinal bone marrow accumulation in patients with non-Hodgkin"s lymphoma.	Fluorodeoxyglucose F18	58-61	colony stimulating factor 3	Homo sapiens	259-264
21774806-7	2011	The partial correlation analysis demonstrating the correlation between cytokine levels when controlled for gender, systolic blood pressure, total cholesterol, HDL cholesterol, triglyceride, and serum creatinine levels further demonstrated that G-CSF, GM-CSF, and MCP-1 had significant negative correlations with age, whereas sCD40L and TGF-alpha had significant positive correlations.	Cholesterol	146-157	colony stimulating factor 3	Homo sapiens	244-249
21774806-7	2011	The partial correlation analysis demonstrating the correlation between cytokine levels when controlled for gender, systolic blood pressure, total cholesterol, HDL cholesterol, triglyceride, and serum creatinine levels further demonstrated that G-CSF, GM-CSF, and MCP-1 had significant negative correlations with age, whereas sCD40L and TGF-alpha had significant positive correlations.	Cholesterol	163-174	colony stimulating factor 3	Homo sapiens	244-249
21774806-7	2011	The partial correlation analysis demonstrating the correlation between cytokine levels when controlled for gender, systolic blood pressure, total cholesterol, HDL cholesterol, triglyceride, and serum creatinine levels further demonstrated that G-CSF, GM-CSF, and MCP-1 had significant negative correlations with age, whereas sCD40L and TGF-alpha had significant positive correlations.	Triglycerides	176-188	colony stimulating factor 3	Homo sapiens	244-249
21774806-7	2011	The partial correlation analysis demonstrating the correlation between cytokine levels when controlled for gender, systolic blood pressure, total cholesterol, HDL cholesterol, triglyceride, and serum creatinine levels further demonstrated that G-CSF, GM-CSF, and MCP-1 had significant negative correlations with age, whereas sCD40L and TGF-alpha had significant positive correlations.	Creatinine	200-210	colony stimulating factor 3	Homo sapiens	244-249
21421070-1	2011	This retrospective study was performed to compare results with tacrolimus versus cyclosporine in combination with methotrexate for immunosuppression after allogeneic hematopoietic cell transplantation (HCT) with granulocyte colony-stimulating factor-mobilized blood cells.	Cyclosporine	81-93	colony stimulating factor 3	Homo sapiens	212-249
21421070-1	2011	This retrospective study was performed to compare results with tacrolimus versus cyclosporine in combination with methotrexate for immunosuppression after allogeneic hematopoietic cell transplantation (HCT) with granulocyte colony-stimulating factor-mobilized blood cells.	Methotrexate	114-126	colony stimulating factor 3	Homo sapiens	212-249
21668998-5	2011	G-CSFa contains alanine 17 (instead of cysteine 17 as in wild-type G-CSF) as well as four additional amino acids including methionine, arginine, glycine, and serine at the amino-terminus.	Cysteine	39-47	colony stimulating factor 3	Homo sapiens	0-5
20845054-0	2011	Combination therapy with sorafenib and S-1 for renal cell carcinoma producing granulocyte colony-stimulating factor.	Sorafenib	25-34	colony stimulating factor 3	Homo sapiens	78-115
21658654-3	2011	PATIENTS AND METHODS: Based on an earlier study showing prolonged mobilization of stem cells in patients given plerixafor plus granulocyte colony-stimulating factor (G-CSF), we administered plerixafor at 5 PM and performed apheresis approximately 15 hours later.	plerixafor	190-200	colony stimulating factor 3	Homo sapiens	166-171
21658654-8	2011	A proposed cost-effective use of plerixafor is to administer it to patients who are inadequately mobilized with G-CSF alone or for salvage in patients who fail previous mobilization with chemotherapy plus G-CSF.	plerixafor	33-43	colony stimulating factor 3	Homo sapiens	112-117
21658654-8	2011	A proposed cost-effective use of plerixafor is to administer it to patients who are inadequately mobilized with G-CSF alone or for salvage in patients who fail previous mobilization with chemotherapy plus G-CSF.	plerixafor	33-43	colony stimulating factor 3	Homo sapiens	205-210
20845054-1	2011	We present the first case report of the use of sorafenib and S-1 for the treatment of renal cell carcinoma (RCC) producing granulocyte colony-stimulating factor (G-CSF).	Sorafenib	47-56	colony stimulating factor 3	Homo sapiens	123-160
20845054-1	2011	We present the first case report of the use of sorafenib and S-1 for the treatment of renal cell carcinoma (RCC) producing granulocyte colony-stimulating factor (G-CSF).	Sorafenib	47-56	colony stimulating factor 3	Homo sapiens	162-167
20845054-6	2011	New combination therapy with sorafenib and S-1 exerted a therapeutic effect and apparently decreased serum and urinary G-CSF levels, although the patient died of gastrointestinal perforation.	Sorafenib	29-38	colony stimulating factor 3	Homo sapiens	119-124
20845054-7	2011	The use of combined sorafenib and S-1 may be worthy of consideration in the treatment of RCC producing G-CSF.	Sorafenib	20-29	colony stimulating factor 3	Homo sapiens	103-108
21276613-0	2011	Plerixafor and G-CSF for PBSC mobilization in patients with lymphoma who failed previous attempts with G-CSF and chemotherapy: a REL (Rete Ematologica Lombarda) experience.	plerixafor	0-10	colony stimulating factor 3	Homo sapiens	103-108
21276613-2	2011	Aim of the study was to assess the efficacy of plerixafor and G-CSF in pts with lymphoma who failed previous attempts of PBSC mobilization with conventional schemes of chemotherapy+G-CSF.	plerixafor	47-57	colony stimulating factor 3	Homo sapiens	181-186
21447830-8	2011	Our novel small-molecule Stat3 inhibitor, C188-9, inhibited G-CSF-induced Stat3 phosphorylation, induced apoptosis in AML cell lines and primary samples, and inhibited AML blast colony formation with potencies in the low micromolar range.	C188-9	42-48	colony stimulating factor 3	Homo sapiens	60-65
21456630-1	2011	Pegfilgrastim is a sustained-duration form of filgrastim, a recombinant methionyl form of human granulocyte colony-stimulating factor (G-CSF), to which a 20  kDa polyethylene glycol molecule is covalently bound to the N-terminal methionine residue.	Polyethylene Glycols	162-181	colony stimulating factor 3	Homo sapiens	135-140
21550007-6	2011	However, docetaxel used in fourth-line treatment had higher incidence of neutropenia and more frequent need of granulocyte colony-stimulating factor support compared with pemetrexed in fourth-line treatment.	Docetaxel	9-18	colony stimulating factor 3	Homo sapiens	111-148
20828862-0	2011	Amrubicin at a lower-dose with routine prophylactic use of granulocyte-colony stimulating factor for relapsed small-cell lung cancer.	amrubicin	0-9	colony stimulating factor 3	Homo sapiens	59-96
21663857-9	2011	Febrile neutropenia occurred in 1.5% and 1.6% of patients in the docetaxel arm and the vinorelbine arm, respectively (2P = .950) and the use of granulocyte colony-stimulating factor (G-CSF) was more frequent in patients treated with vinorelbine (37.1% vs. 22.5%; 2P &lt; .001).	Vinorelbine	233-244	colony stimulating factor 3	Homo sapiens	144-181
21315154-4	2011	Three of the four tested macrolides, azithromycin, clarithromycin and roxithromycin, exhibited pronounced, concentration-related reduction of IL-1beta, IL-6, IL-10, TNF-alpha, CCL3, CCL5, CCL20, CCL22, CXCL1, CXCL5, and G-CSF release.	Azithromycin	37-49	colony stimulating factor 3	Homo sapiens	220-225
21292035-3	2011	In this study, we discovered that G-CSF completely prevented mitochondrial swelling and depolarization, and markedly reduced ROS production caused by H(2)O(2)-induced oxidative stress in isolated cardiac mitochondria.	Reactive Oxygen Species	125-128	colony stimulating factor 3	Homo sapiens	34-39
21292035-3	2011	In this study, we discovered that G-CSF completely prevented mitochondrial swelling and depolarization, and markedly reduced ROS production caused by H(2)O(2)-induced oxidative stress in isolated cardiac mitochondria.	Hydrogen Peroxide	150-158	colony stimulating factor 3	Homo sapiens	34-39
21535933-5	2011	METHODS: Recombinant human G-CSF was administered subcutaneously in SAM-P10 mice once daily for consecutive 7 days.	sam-p10	68-75	colony stimulating factor 3	Homo sapiens	27-32
21315154-7	2011	Qualitatively and quantitatively, macrolides exerted distinctive and, compared to other tested classes of compounds, more pronounced immunomodulatory effects, particularly in terms of chemokine (CCL3, CCL5, CCL20, CCL22, and CXCL5), IL-1beta, G-CSF and PAI-1 release.	Macrolides	34-44	colony stimulating factor 3	Homo sapiens	243-248
21315154-4	2011	Three of the four tested macrolides, azithromycin, clarithromycin and roxithromycin, exhibited pronounced, concentration-related reduction of IL-1beta, IL-6, IL-10, TNF-alpha, CCL3, CCL5, CCL20, CCL22, CXCL1, CXCL5, and G-CSF release.	Clarithromycin	51-65	colony stimulating factor 3	Homo sapiens	220-225
21315154-4	2011	Three of the four tested macrolides, azithromycin, clarithromycin and roxithromycin, exhibited pronounced, concentration-related reduction of IL-1beta, IL-6, IL-10, TNF-alpha, CCL3, CCL5, CCL20, CCL22, CXCL1, CXCL5, and G-CSF release.	Roxithromycin	70-83	colony stimulating factor 3	Homo sapiens	220-225
21233311-1	2011	We evaluated the role of granulocyte colony-stimulating factor (G-CSF) in patients with severe aplastic anemia (SAA) treated with antithymocyte globulin (ATG) and cyclosporine (CSA).	saa	112-115	colony stimulating factor 3	Homo sapiens	25-62
21233311-1	2011	We evaluated the role of granulocyte colony-stimulating factor (G-CSF) in patients with severe aplastic anemia (SAA) treated with antithymocyte globulin (ATG) and cyclosporine (CSA).	saa	112-115	colony stimulating factor 3	Homo sapiens	64-69
21233311-1	2011	We evaluated the role of granulocyte colony-stimulating factor (G-CSF) in patients with severe aplastic anemia (SAA) treated with antithymocyte globulin (ATG) and cyclosporine (CSA).	Cyclosporine	163-175	colony stimulating factor 3	Homo sapiens	64-69
21233311-7	2011	G-CSF added to standard ATG and CSA reduces the rate of early infectious episodes and days of hospitalization in very SAA patients and might allow early identification of nonresponders but has no effect on OS, EFS, remission, relapse rates, and mortality.	saa	118-121	colony stimulating factor 3	Homo sapiens	0-5
21256188-8	2011	The presence of alpha-tocopherol also modulated the expression of some cytokines, including CCL2, CCL3, IL-6, CSF3 and CXCL1; increased the antigen loading in monocytes; and increased the recruitment of granulocytes in the dLNs.	alpha-Tocopherol	16-32	colony stimulating factor 3	Homo sapiens	110-114
20880037-4	2011	Plerixafor was limited to patients with previous stem cell mobilization failure and was given in the evening of Day 4 of G-CSF application.	plerixafor	0-10	colony stimulating factor 3	Homo sapiens	121-126
21516268-0	2011	Imatinib plus Granulocyte Colony-Stimulating Factor in Chronic Myeloid Leukemia Patients Who Have Achieved Partial or Complete Cytogenetic Response while on Imatinib.	Imatinib Mesylate	157-165	colony stimulating factor 3	Homo sapiens	14-51
21516268-8	2011	CONCLUSIONS: We conclude that the addition of G-CSF should be considered for patients on imatinib who fail to obtain optimal response to imatinib alone and that this approach deserves further evaluation as frontline therapy for newly diagnosed CML.	Imatinib Mesylate	89-97	colony stimulating factor 3	Homo sapiens	46-51
21516268-8	2011	CONCLUSIONS: We conclude that the addition of G-CSF should be considered for patients on imatinib who fail to obtain optimal response to imatinib alone and that this approach deserves further evaluation as frontline therapy for newly diagnosed CML.	Imatinib Mesylate	137-145	colony stimulating factor 3	Homo sapiens	46-51
21301783-10	2011	In addition, G-CSF enhanced ristocetin-induced platelet aggregation (+18%) whereas TRAP-induced platelet aggregation decreased slightly (-14%) in response to filgrastim.	Ristocetin	28-38	colony stimulating factor 3	Homo sapiens	13-18
21210260-13	2011	We suggest the prophylactic use of granulocyte colony stimulating factor for patients treated with HIO exposure higher than 65 mg L/h.	N-HYDROXY-N-ISOPROPYLOXAMIC ACID	99-102	colony stimulating factor 3	Homo sapiens	35-72
20577218-0	2011	The addition of plerixafor is safe and allows adequate PBSC collection in multiple myeloma and lymphoma patients poor mobilizers after chemotherapy and G-CSF.	plerixafor	16-26	colony stimulating factor 3	Homo sapiens	152-157
21144582-6	2011	Furthermore, a single intramuscular administration of granulocyte colony stimulating factor (GCSF)-encapsulated PEGDA-PEI hydrogel extended the mobilization of mononuclear cells to four days.	pegda-pei hydrogel	112-130	colony stimulating factor 3	Homo sapiens	54-91
21144582-6	2011	Furthermore, a single intramuscular administration of granulocyte colony stimulating factor (GCSF)-encapsulated PEGDA-PEI hydrogel extended the mobilization of mononuclear cells to four days.	pegda-pei hydrogel	112-130	colony stimulating factor 3	Homo sapiens	93-97
20577218-1	2011	We report 13 multiple myeloma (MM) or lymphoma patients who were failing PBSC mobilization after disease-specific chemotherapy and granulocyte-CSF (G-CSF), and received plerixafor to successfully collect PBSCs.	plerixafor	169-179	colony stimulating factor 3	Homo sapiens	148-153
20864248-3	2011	We found that sodium phenyl butyrate alone and 6h-pretreatment with phenyl butyrate or FK228 before the induction of differentiation with all-trans-retinoic acid in the presence of vitamin B3 effectively accelerated and enhanced differentiation to granulocytes in HL-60 but not in NB4 cells as detected by NBT test and the expression of CD11b and CD114 (G-CSFR) using flow cytometric analysis.	Niacinamide	181-191	colony stimulating factor 3	Homo sapiens	354-360
21421450-11	2011	However, the low G-CSF levels in alcoholic sepsis patients might suggest a predisposition to infections in alcohol abusers.	Alcohols	33-40	colony stimulating factor 3	Homo sapiens	17-22
21178645-0	2011	Use of granulocyte colony-stimulating factor for fluorine-18-fluorodeoxyglucose labeling in human leukocytes.	Fluorodeoxyglucose F18	49-79	colony stimulating factor 3	Homo sapiens	7-44
21178645-12	2011	CONCLUSION: Use of G-CSF significantly improved 18F-FDG labeling efficiency without a significant effect on cell viability and retention of radioactivity.	Fluorodeoxyglucose F18	48-55	colony stimulating factor 3	Homo sapiens	19-24
21285407-5	2011	DISCUSSION: Several studies in adults have shown plerixafor to be effective for the mobilization of hematopoietic stem cells when used in combination with G-CSF in adults with non-Hodgkin"s lymphoma and multiple myeloma who failed to mobilize sufficient CD34+ cells with G-CSF alone.	plerixafor	49-59	colony stimulating factor 3	Homo sapiens	271-276
21059898-0	2011	Granulocyte colony-stimulating factor attenuates oxidative stress-induced apoptosis in vascular endothelial cells and exhibits functional and morphologic protective effect in oxygen-induced retinopathy.	Oxygen	175-181	colony stimulating factor 3	Homo sapiens	0-37
21059898-5	2011	Treatment with 100 ng/mL G-CSF significantly reduced H(2)O(2)-induced apoptosis in HRECs from 61.7% to 41.4% (P &lt; .05).	Hydrogen Peroxide	53-61	colony stimulating factor 3	Homo sapiens	25-30
21059898-6	2011	Akt was phosphorylated in HRECs by G-CSF addition, and LY294002, a PI3K inhibitor, significantly attenuated the antiapoptotic effect of G-CSF (by 44.1%, P &lt; .05).	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one	55-63	colony stimulating factor 3	Homo sapiens	136-141
20585044-0	2011	Enhanced c-Met activity promotes G-CSF-induced mobilization of hematopoietic progenitor cells via ROS signaling.	Reactive Oxygen Species	98-101	colony stimulating factor 3	Homo sapiens	33-38
20383210-1	2011	Plerixafor is an inhibitor of CXCR-4 (CXC chemokine receptor-4)/SDF (stromal cell-derived factor)-1 binding used in combination with granulocyte colony-stimulating factor (G-CSF) for mobilization of autologous peripheral blood hematopoietic stem cells (HSCs).	plerixafor	0-10	colony stimulating factor 3	Homo sapiens	133-170
20383210-1	2011	Plerixafor is an inhibitor of CXCR-4 (CXC chemokine receptor-4)/SDF (stromal cell-derived factor)-1 binding used in combination with granulocyte colony-stimulating factor (G-CSF) for mobilization of autologous peripheral blood hematopoietic stem cells (HSCs).	plerixafor	0-10	colony stimulating factor 3	Homo sapiens	172-177
20421869-2	2011	Recent reports have suggested decreases in the number of CD34+ cells collected and increases in the failure rate among patients whose initial therapy contained lenalidomide when mobilized with G-CSF alone.	Lenalidomide	160-172	colony stimulating factor 3	Homo sapiens	193-198
21468240-4	2011	Disruption of the CXCR4/SDF-1 axis by the CXCR4 antagonist, plerixafor, has been demonstrated in Phase II and Phase III trials to improve mobilization when used in conjunction with granulocyte colony-stimulating factor (G-CSF).	plerixafor	60-70	colony stimulating factor 3	Homo sapiens	220-225
20864248-3	2011	We found that sodium phenyl butyrate alone and 6h-pretreatment with phenyl butyrate or FK228 before the induction of differentiation with all-trans-retinoic acid in the presence of vitamin B3 effectively accelerated and enhanced differentiation to granulocytes in HL-60 but not in NB4 cells as detected by NBT test and the expression of CD11b and CD114 (G-CSFR) using flow cytometric analysis.	4-phenylbutyric acid	14-36	colony stimulating factor 3	Homo sapiens	354-360
20864248-3	2011	We found that sodium phenyl butyrate alone and 6h-pretreatment with phenyl butyrate or FK228 before the induction of differentiation with all-trans-retinoic acid in the presence of vitamin B3 effectively accelerated and enhanced differentiation to granulocytes in HL-60 but not in NB4 cells as detected by NBT test and the expression of CD11b and CD114 (G-CSFR) using flow cytometric analysis.	6H	47-49	colony stimulating factor 3	Homo sapiens	354-360
20864248-3	2011	We found that sodium phenyl butyrate alone and 6h-pretreatment with phenyl butyrate or FK228 before the induction of differentiation with all-trans-retinoic acid in the presence of vitamin B3 effectively accelerated and enhanced differentiation to granulocytes in HL-60 but not in NB4 cells as detected by NBT test and the expression of CD11b and CD114 (G-CSFR) using flow cytometric analysis.	Phenylbutyrates	21-36	colony stimulating factor 3	Homo sapiens	354-360
20864248-3	2011	We found that sodium phenyl butyrate alone and 6h-pretreatment with phenyl butyrate or FK228 before the induction of differentiation with all-trans-retinoic acid in the presence of vitamin B3 effectively accelerated and enhanced differentiation to granulocytes in HL-60 but not in NB4 cells as detected by NBT test and the expression of CD11b and CD114 (G-CSFR) using flow cytometric analysis.	romidepsin	87-92	colony stimulating factor 3	Homo sapiens	354-360
21114628-6	2011	Chromatin immunoprecipitation assays showed that LPS enhanced the binding of Oct-2 to the iNOS and G-CSF promoters and that this effect was inhibited by pretreatment with rapamycin.	Sirolimus	171-180	colony stimulating factor 3	Homo sapiens	99-104
21114628-0	2011	Rapamycin inhibits lipopolysaccharide induction of granulocyte-colony stimulating factor and inducible nitric oxide synthase expression in macrophages by reducing the levels of octamer-binding factor-2.	Sirolimus	0-9	colony stimulating factor 3	Homo sapiens	51-88
21098756-4	2010	The patient was treated with a postdialysis subcutaneous dose of plerixafor 160 mug/kg after 4 days of G-CSF therapy.	plerixafor	65-75	colony stimulating factor 3	Homo sapiens	103-108
21894752-19	2011	CONCLUSION: Administration of high cyclophosphamide doses in combination with G-CSF is an effective and safe method of BHSC mobilization providing collection of adequate number of CD34+ cells for double autotransplantation in 96.8% patients.	bhsc	119-123	colony stimulating factor 3	Homo sapiens	78-83
21194460-10	2010	CONCLUSION: HSCT with both G-CSF mobilized PB and BMSCs is a promising approach for heavily transfused and/or allo-immunized patients with SAA.	Lead	43-45	colony stimulating factor 3	Homo sapiens	27-32
21194460-10	2010	CONCLUSION: HSCT with both G-CSF mobilized PB and BMSCs is a promising approach for heavily transfused and/or allo-immunized patients with SAA.	saa	139-142	colony stimulating factor 3	Homo sapiens	27-32
22042783-6	2011	Patients in the FAC + G-CSF arm had a higher delivered dose intensity of doxorubicin in the neoadjuvant and adjuvant settings than those in the standard FAC arm.	Doxorubicin	73-84	colony stimulating factor 3	Homo sapiens	22-27
21194460-3	2010	METHODS: To reduce graft failure and GVHD, we treated fifteen patients with SAA using high- dose of HSCT with both G-CSF mobilized PB and BMSCs from HLA-identical siblings to treat patients with SAA.	Lead	131-133	colony stimulating factor 3	Homo sapiens	115-120
21081700-0	2010	Granulocyte-colony stimulating factor promotes lung metastasis through mobilization of Ly6G+Ly6C+ granulocytes.	ly6g	87-91	colony stimulating factor 3	Homo sapiens	0-37
21081700-0	2010	Granulocyte-colony stimulating factor promotes lung metastasis through mobilization of Ly6G+Ly6C+ granulocytes.	ly6c	92-96	colony stimulating factor 3	Homo sapiens	0-37
21081700-2	2010	In this study, we show that the metastatic tumors we examined overexpress granulocyte-colony stimulating factor (G-CSF), which expands and mobilizes Ly6G+Ly6C+ granulocytes and facilitates their subsequent homing at distant organs even before the arrival of tumor cells.	ly6g	149-153	colony stimulating factor 3	Homo sapiens	74-111
21081700-2	2010	In this study, we show that the metastatic tumors we examined overexpress granulocyte-colony stimulating factor (G-CSF), which expands and mobilizes Ly6G+Ly6C+ granulocytes and facilitates their subsequent homing at distant organs even before the arrival of tumor cells.	ly6g	149-153	colony stimulating factor 3	Homo sapiens	113-118
21081700-2	2010	In this study, we show that the metastatic tumors we examined overexpress granulocyte-colony stimulating factor (G-CSF), which expands and mobilizes Ly6G+Ly6C+ granulocytes and facilitates their subsequent homing at distant organs even before the arrival of tumor cells.	ly6c	154-158	colony stimulating factor 3	Homo sapiens	74-111
21081700-2	2010	In this study, we show that the metastatic tumors we examined overexpress granulocyte-colony stimulating factor (G-CSF), which expands and mobilizes Ly6G+Ly6C+ granulocytes and facilitates their subsequent homing at distant organs even before the arrival of tumor cells.	ly6c	154-158	colony stimulating factor 3	Homo sapiens	113-118
21130416-2	2010	Granulocyte colony-stimulating factor (G-CSF) and chemotherapy have been commonly used to mobilize stem cells, but several new agents, such as the CXCR4 inhibitor plerixafor, inhibit stromal-stem cell interactions to improve stem cell yield.	plerixafor	163-173	colony stimulating factor 3	Homo sapiens	0-37
21130416-2	2010	Granulocyte colony-stimulating factor (G-CSF) and chemotherapy have been commonly used to mobilize stem cells, but several new agents, such as the CXCR4 inhibitor plerixafor, inhibit stromal-stem cell interactions to improve stem cell yield.	plerixafor	163-173	colony stimulating factor 3	Homo sapiens	39-44
20945411-1	2010	The purpose of this study was to evaluate the microchip CGE (MCGE) for the analysis of PEG-modified granulocyte-colony stimulating factor (PEG-G-CSF) prepared with PEG-aldehydes.	Polyethylene Glycols	87-90	colony stimulating factor 3	Homo sapiens	143-148
20738393-6	2010	Addition of plerixafor to G-CSF or more recently to a mobilization regimen consisting of CT + G-CSF is promising as blood CD34(+) counts can be increased three to fivefold to facilitate effective collection with less aphaeresis sessions.	plerixafor	12-22	colony stimulating factor 3	Homo sapiens	94-99
21092320-8	2010	After G-CSF secondary prophylaxis (SP), 4% experienced further FN events.	sp	35-37	colony stimulating factor 3	Homo sapiens	6-11
20499235-1	2010	We investigated the efficacy of the induction therapy involving granulocyte colony-stimulating factor (G-CSF) and low-dose homoharringtonine as well as standard-dose imatinib, which we called the G-CSF + homoharringtonine + imatinib (GHI) regimen, in patients with chronic myelogenous leukemia (CML) in blast crisis who have failed prior single-agent therapy with imatinib.	Imatinib Mesylate	166-174	colony stimulating factor 3	Homo sapiens	196-201
21092001-0	2010	Interferon-alpha suppressed granulocyte colony stimulating factor production is reversed by CL097, a TLR7/8 agonist.	CL097	92-97	colony stimulating factor 3	Homo sapiens	28-65
21092001-5	2010	G-CSF levels in the supernatants of PBMCs isolated from the patients and healthy controls were assessed by enzyme-linked immunosorbent assay following 18 h of culture in the absence or presence of IFN- alpha or the TLR7/8 agonist, CL097.	CL097	231-236	colony stimulating factor 3	Homo sapiens	0-5
20826182-8	2010	Plerixafor acts synergistically with granulocyte colony-stimulating factor (G-CSF), and its usefulness has been proven particularly for the mobilization of HSCs and HPCs for autologous stem cell transplantation in patients with non-Hodgkin"s lymphoma (NHL) or multiple myeloma (MM).	plerixafor	0-10	colony stimulating factor 3	Homo sapiens	76-81
20499235-0	2010	Standard-dose imatinib plus low-dose homoharringtonine and granulocyte colony-stimulating factor is an effective induction therapy for patients with chronic myeloid leukemia in myeloid blast crisis who have failed prior single-agent therapy with imatinib.	Imatinib Mesylate	246-254	colony stimulating factor 3	Homo sapiens	59-96
20945411-1	2010	The purpose of this study was to evaluate the microchip CGE (MCGE) for the analysis of PEG-modified granulocyte-colony stimulating factor (PEG-G-CSF) prepared with PEG-aldehydes.	peg-aldehydes	164-177	colony stimulating factor 3	Homo sapiens	143-148
20945411-3	2010	The MCGE allowed size-based separation and quantitation of PEG-G-CSF.	Polyethylene Glycols	59-62	colony stimulating factor 3	Homo sapiens	63-68
20945411-5	2010	The MCGE was also used to monitor a search for optimal PEG-modification (PEGylation) conditions to produce mono-PEG-G-CSF.	Polyethylene Glycols	55-58	colony stimulating factor 3	Homo sapiens	116-121
20945411-5	2010	The MCGE was also used to monitor a search for optimal PEG-modification (PEGylation) conditions to produce mono-PEG-G-CSF.	mono-peg	107-115	colony stimulating factor 3	Homo sapiens	116-121
20947484-11	2010	ICER was mostly sensitive to hazard ratio (HR) (when varied from 1.46 to 1.09; $3,517/ QALY), discount over the ex-lab price of Taxol  (75%; $6,396/QALY) and granulocyte colony-stimulating factor (G-CSF) prophylactic treatment (when administered in 60% of cycles instead of 100%; cost saving).	Paclitaxel	128-133	colony stimulating factor 3	Homo sapiens	158-195
20732995-10	2010	In addition, MIMLh5 increased the GM-CSF/G-CSF ratio.	mimlh5	13-19	colony stimulating factor 3	Homo sapiens	41-46
20947484-11	2010	ICER was mostly sensitive to hazard ratio (HR) (when varied from 1.46 to 1.09; $3,517/ QALY), discount over the ex-lab price of Taxol  (75%; $6,396/QALY) and granulocyte colony-stimulating factor (G-CSF) prophylactic treatment (when administered in 60% of cycles instead of 100%; cost saving).	Paclitaxel	128-133	colony stimulating factor 3	Homo sapiens	197-202
20804592-0	2010	Protection of taurine and granulocyte colony-stimulating factor against excitotoxicity induced by glutamate in primary cortical neurons.	Glutamic Acid	98-107	colony stimulating factor 3	Homo sapiens	26-63
20677923-1	2010	Fludarabine, cytarabine, granulocyte colony-stimulating factor (G-CSF), and idarubicin (FLAG-IDA) regimen has been proven to be a potentially useful chemotherapy regimen for relapsed or poor-prognosis childhood leukemia.	fludarabine	0-11	colony stimulating factor 3	Homo sapiens	64-69
19303649-0	2010	The effects of G-CSF-induced mobilization of progenitor cells are limited by ADMA.	N,N-dimethylarginine	77-81	colony stimulating factor 3	Homo sapiens	15-20
19303649-12	2010	CONCLUSIONS: Leukocytosis associated with increased MPO activity during G-CSF therapy appears to be responsible for the systemic release of ADMA, which impairs eNOS activity.	N,N-dimethylarginine	140-144	colony stimulating factor 3	Homo sapiens	72-77
20940525-5	2010	Hematoxylin-eosin staining revealed squamous cell carcinoma of the renal pelvis and tumor cells stained strongly positive for G-CSF.	Hematoxylin	0-11	colony stimulating factor 3	Homo sapiens	126-131
20804592-6	2010	CONCLUSION: The results showed that all of these treatments, taurine, G-CSF and the combination of taurine and G-CSF, protected primary cortical neurons against excitotoxicity induced by glutamate.	Glutamic Acid	187-196	colony stimulating factor 3	Homo sapiens	70-75
20804592-6	2010	CONCLUSION: The results showed that all of these treatments, taurine, G-CSF and the combination of taurine and G-CSF, protected primary cortical neurons against excitotoxicity induced by glutamate.	Glutamic Acid	187-196	colony stimulating factor 3	Homo sapiens	111-116
20939442-3	2010	Plerixafor, a CXCR4 receptor antagonist, is now authorised in the European Union for use in combination with G-CSF when stem cell mobilisation with G-CSF alone is unsuccessful.	plerixafor	0-10	colony stimulating factor 3	Homo sapiens	148-153
20696083-6	2010	Pro-inflammatory mediators FGF-2, Fractalkine, GRO, G-CSF, IL-8, IL-1alpha, IP-10, IL-10, and IFN-alpha2 were reduced in the Iota-Carrageenan group.	Carrageenan	125-141	colony stimulating factor 3	Homo sapiens	47-63
20712773-4	2010	In this paper, we review the possible risks of G-CSF mobilization in hemoglobinopathies and we outline the approaches used in an on-going clinical trial in which pretreatment with hydroxyurea is used to reduce potential risks of G-CSF administration to patients with severe beta thalassemia.	Hydroxyurea	180-191	colony stimulating factor 3	Homo sapiens	47-52
20712773-4	2010	In this paper, we review the possible risks of G-CSF mobilization in hemoglobinopathies and we outline the approaches used in an on-going clinical trial in which pretreatment with hydroxyurea is used to reduce potential risks of G-CSF administration to patients with severe beta thalassemia.	Hydroxyurea	180-191	colony stimulating factor 3	Homo sapiens	229-234
19434371-1	2010	PURPOSE: This was a phase I study evaluating the dose limiting toxicity (DLT) and the maximum tolerated dose (MTD) of weekly docetaxel, doxorubicin and daily oral cyclophosphamide with G-CSF support (ConTAC regimen).	Cyclophosphamide	163-179	colony stimulating factor 3	Homo sapiens	185-190
20939442-5	2010	In a trial in 302 myeloma patients, the G-CSF-plerixafor combination was associated with a statistically significantly higher rate of successful mobilisation, defined as collection of at least 6 x 10(6) CD34+ cells after one or two apheresis sessions, than a combination of G-CSF and placebo (71.6% versus 34.4%).	plerixafor	46-56	colony stimulating factor 3	Homo sapiens	40-45
20939442-5	2010	In a trial in 302 myeloma patients, the G-CSF-plerixafor combination was associated with a statistically significantly higher rate of successful mobilisation, defined as collection of at least 6 x 10(6) CD34+ cells after one or two apheresis sessions, than a combination of G-CSF and placebo (71.6% versus 34.4%).	plerixafor	46-56	colony stimulating factor 3	Homo sapiens	274-279
20615204-2	2010	This novel in vivo cleavable disulfide linker, based on a dithiocyclopeptide containing a thrombin-sensitive sequence and an intramolecular disulfide bond, was inserted between transferrin and granulocyte colony-stimulating factor (G-CSF) recombinant fusion protein domains.	Disulfides	29-38	colony stimulating factor 3	Homo sapiens	193-230
20615204-2	2010	This novel in vivo cleavable disulfide linker, based on a dithiocyclopeptide containing a thrombin-sensitive sequence and an intramolecular disulfide bond, was inserted between transferrin and granulocyte colony-stimulating factor (G-CSF) recombinant fusion protein domains.	Disulfides	29-38	colony stimulating factor 3	Homo sapiens	232-237
20615204-2	2010	This novel in vivo cleavable disulfide linker, based on a dithiocyclopeptide containing a thrombin-sensitive sequence and an intramolecular disulfide bond, was inserted between transferrin and granulocyte colony-stimulating factor (G-CSF) recombinant fusion protein domains.	Disulfides	140-149	colony stimulating factor 3	Homo sapiens	193-230
20501800-6	2010	Depletion of DNMT1 using shRNA or decitabine prevents HOXB4 repression by Pu.1 or granulocyte-colony stimulating factor and maintains hematopoietic precursor self-renewal.	Decitabine	34-44	colony stimulating factor 3	Homo sapiens	82-119
20381567-4	2010	ATP activity measured in G-CSF-treated patients was significantly higher than that measured in healthy individuals or "nonmobilized" patients.	Adenosine Triphosphate	0-3	colony stimulating factor 3	Homo sapiens	25-30
20354173-2	2010	G-CSF/dexa treatment not only increases the number of circulating neutrophils but also affects their gene expression.	Dexamethasone	6-10	colony stimulating factor 3	Homo sapiens	0-5
19820726-0	2010	Plerixafor given before the third leukapheresis to rescue an unsuccessful stem cell mobilization with CY and G-CSF.	plerixafor	0-10	colony stimulating factor 3	Homo sapiens	109-114
20565377-10	2010	Because the neutropenia did not recover after we discontinued valganciclovir, the patient was administered granulocyte colony-stimulating factor.	Valganciclovir	62-76	colony stimulating factor 3	Homo sapiens	107-144
20135695-4	2010	The use of high-dose granulocyte colony stimulating factor in patients with NAIN may cause a reversible thrombocytopenia in some patients.	N-(4-azido-3-iodophenethylamidoisobutyl)norepinephrine	76-80	colony stimulating factor 3	Homo sapiens	21-58
19859744-4	2010	Furthermore, the effect of glucose concentration on productivity of rh-GCSF was investigated; 20 g/l of glucose will result in maximum attainable biomass and rh-GCSF in this process.	Glucose	27-34	colony stimulating factor 3	Homo sapiens	71-75
19859744-4	2010	Furthermore, the effect of glucose concentration on productivity of rh-GCSF was investigated; 20 g/l of glucose will result in maximum attainable biomass and rh-GCSF in this process.	Glucose	27-34	colony stimulating factor 3	Homo sapiens	161-165
19859744-4	2010	Furthermore, the effect of glucose concentration on productivity of rh-GCSF was investigated; 20 g/l of glucose will result in maximum attainable biomass and rh-GCSF in this process.	Glucose	104-111	colony stimulating factor 3	Homo sapiens	71-75
19859744-4	2010	Furthermore, the effect of glucose concentration on productivity of rh-GCSF was investigated; 20 g/l of glucose will result in maximum attainable biomass and rh-GCSF in this process.	Glucose	104-111	colony stimulating factor 3	Homo sapiens	161-165
20140432-3	2010	We previously found that a beta-glucan extract from maitake mushroom Grifola frondosa (MBG) enhanced colony forming unit-granulocyte monocyte (CFU-GM) activity of mouse bone marrow and human hematopoietic progenitor cells (HPC), stimulated G-CSF production and spared HPC from doxorubicin toxicity in vitro.	beta-Glucans	27-38	colony stimulating factor 3	Homo sapiens	240-245
20113453-14	2010	CONCLUSIONS: RBCs were significantly reduced and granulocytes and PLTs effectively retained in G-CSF/steroid-mobilized granulocyte components collected with HES and processed by gravity sedimentation.	Steroids	101-108	colony stimulating factor 3	Homo sapiens	95-100
20005931-0	2010	Recombinant human granulocyte colony stimulating factor pre-screening and screening of stabilizing carbohydrates and polyols.	Carbohydrates	99-112	colony stimulating factor 3	Homo sapiens	18-55
20026017-11	2010	The addition of granulocyte-colony stimulating factor (G-CSF) and radiotherapy plays a significant role in t-MN following treatment of childhood acute lymphoblastic leukemia.	t-mn	107-111	colony stimulating factor 3	Homo sapiens	16-53
20026017-11	2010	The addition of granulocyte-colony stimulating factor (G-CSF) and radiotherapy plays a significant role in t-MN following treatment of childhood acute lymphoblastic leukemia.	t-mn	107-111	colony stimulating factor 3	Homo sapiens	55-60
20064484-7	2010	G-CSF-mediated STAT3 phosphorylation and inhibition of TLR agonist-induced cytokine production were prevented by pretreatment of cells with AG-490 (JAK2 inhibitor).	alpha-cyano-(3,4-dihydroxy)-N-benzylcinnamide	140-146	colony stimulating factor 3	Homo sapiens	0-5
20067838-3	2010	Plerixafor (previously known as AMD3100), a selective antagonist of CXCR4, has recently been approved for autologous HSC mobilization in combination with G-CSF.	plerixafor	0-10	colony stimulating factor 3	Homo sapiens	154-159
20685493-14	2010	Plerixafor 0.24 mg/kg SC is administered on the evening of the fourth day of G-CSF dosing, approximately 11 hours before the first apheresis session.	plerixafor	0-10	colony stimulating factor 3	Homo sapiens	77-82
20005931-0	2010	Recombinant human granulocyte colony stimulating factor pre-screening and screening of stabilizing carbohydrates and polyols.	polyol	117-124	colony stimulating factor 3	Homo sapiens	18-55
20361316-6	2010	In conclusion, CZE was better than SDS-CGE for separating PEG-G-CSF conjugates and will be useful for PEGylation studies, such as reaction monitoring for optimization of the PEGylation reaction, and purity and stability tests of PEG-G-CSF.	Polyethylene Glycols	58-61	colony stimulating factor 3	Homo sapiens	62-67
20361316-0	2010	Capillary electrophoretic separation of poly(ethylene glycol)-modified granulocyte-colony stimulating factor.	Polyethylene Glycols	40-61	colony stimulating factor 3	Homo sapiens	71-108
20090448-1	2010	Administration of granulocyte colony stimulating factor can cause homogeneous hypermetabolic activity of bone marrow in positron emission tomography using F-18-fluorodeoxyglucose.	Fluorodeoxyglucose F18	155-178	colony stimulating factor 3	Homo sapiens	18-55
20361316-1	2010	We evaluated the utility of capillary electrophoretic methods for analyzing poly(ethylene glycol) (PEG)-modified granulocyte-colony stimulating factor (G-CSF), a long-acting form of GCSF for the treatment of cancer therapy-induced neutropenia.	Polyethylene Glycols	76-97	colony stimulating factor 3	Homo sapiens	113-150
20361316-1	2010	We evaluated the utility of capillary electrophoretic methods for analyzing poly(ethylene glycol) (PEG)-modified granulocyte-colony stimulating factor (G-CSF), a long-acting form of GCSF for the treatment of cancer therapy-induced neutropenia.	Polyethylene Glycols	76-97	colony stimulating factor 3	Homo sapiens	152-157
20361316-1	2010	We evaluated the utility of capillary electrophoretic methods for analyzing poly(ethylene glycol) (PEG)-modified granulocyte-colony stimulating factor (G-CSF), a long-acting form of GCSF for the treatment of cancer therapy-induced neutropenia.	Polyethylene Glycols	76-97	colony stimulating factor 3	Homo sapiens	182-186
20361316-1	2010	We evaluated the utility of capillary electrophoretic methods for analyzing poly(ethylene glycol) (PEG)-modified granulocyte-colony stimulating factor (G-CSF), a long-acting form of GCSF for the treatment of cancer therapy-induced neutropenia.	Polyethylene Glycols	99-102	colony stimulating factor 3	Homo sapiens	113-150
20361316-1	2010	We evaluated the utility of capillary electrophoretic methods for analyzing poly(ethylene glycol) (PEG)-modified granulocyte-colony stimulating factor (G-CSF), a long-acting form of GCSF for the treatment of cancer therapy-induced neutropenia.	Polyethylene Glycols	99-102	colony stimulating factor 3	Homo sapiens	152-157
20361316-1	2010	We evaluated the utility of capillary electrophoretic methods for analyzing poly(ethylene glycol) (PEG)-modified granulocyte-colony stimulating factor (G-CSF), a long-acting form of GCSF for the treatment of cancer therapy-induced neutropenia.	Polyethylene Glycols	99-102	colony stimulating factor 3	Homo sapiens	182-186
20361316-2	2010	Low- and high-molecularweight PEG-G-CSF conjugates prepared with aldehyde-activated PEG-5K and PEG-20K were separated by high-performance size-exclusion chromatography (HP-SEC), capillary zone electrophoresis (CZE), and sodium dodecyl sulfate-capillary gel electrophoresis (SDS-CGE).	Polyethylene Glycols	30-33	colony stimulating factor 3	Homo sapiens	34-39
20361316-2	2010	Low- and high-molecularweight PEG-G-CSF conjugates prepared with aldehyde-activated PEG-5K and PEG-20K were separated by high-performance size-exclusion chromatography (HP-SEC), capillary zone electrophoresis (CZE), and sodium dodecyl sulfate-capillary gel electrophoresis (SDS-CGE).	Aldehydes	65-73	colony stimulating factor 3	Homo sapiens	34-39
20361316-2	2010	Low- and high-molecularweight PEG-G-CSF conjugates prepared with aldehyde-activated PEG-5K and PEG-20K were separated by high-performance size-exclusion chromatography (HP-SEC), capillary zone electrophoresis (CZE), and sodium dodecyl sulfate-capillary gel electrophoresis (SDS-CGE).	Polyethylene Glycols	84-87	colony stimulating factor 3	Homo sapiens	34-39
20361316-2	2010	Low- and high-molecularweight PEG-G-CSF conjugates prepared with aldehyde-activated PEG-5K and PEG-20K were separated by high-performance size-exclusion chromatography (HP-SEC), capillary zone electrophoresis (CZE), and sodium dodecyl sulfate-capillary gel electrophoresis (SDS-CGE).	Polyethylene Glycols	84-87	colony stimulating factor 3	Homo sapiens	34-39
19597422-6	2010	Mobilization with plerixafor and G-CSF resulted in a median 2.6-fold increase in peripheral blood (PB) CD34+ cell count compared with before plerixafor treatment.	plerixafor	141-151	colony stimulating factor 3	Homo sapiens	33-38
19483760-1	2010	Plerixafor, a novel CXCR4 inhibitor, is effective in mobilizing PBSCs particularly when used in conjunction with G-CSF.	plerixafor	0-10	colony stimulating factor 3	Homo sapiens	113-118
19996324-11	2010	Plerixafor, a novel chemokine receptor antagonist, in combination with G-CSF has demonstrated superiority for achieving collection goals compared to G-CSF alone in 2 Phase 3 trials.	plerixafor	0-10	colony stimulating factor 3	Homo sapiens	149-154
20009003-6	2010	When used with granulocyte colony-stimulating factor (G-CSF), plerixafor helps increase the number of HSCs in the peripheral blood, where they can be collected for use in autologous transplantation.	plerixafor	62-72	colony stimulating factor 3	Homo sapiens	15-52
20009003-6	2010	When used with granulocyte colony-stimulating factor (G-CSF), plerixafor helps increase the number of HSCs in the peripheral blood, where they can be collected for use in autologous transplantation.	plerixafor	62-72	colony stimulating factor 3	Homo sapiens	54-59
20009003-10	2010	An approximate 2- to 3-fold increase in the CD34+ cell count is seen by the first dose of plerixafor after 4 consecutive days of G-CSF treatment.	plerixafor	90-100	colony stimulating factor 3	Homo sapiens	129-134
20159692-4	2010	RESULTS: Compared with the control group, high-concentration FK506 (20 ng/ml) significantly inhibited the secretions of IL-2, IL-6, IL-12, IL-17, IFN-gamma, TNF-alpha, GM-CSF and G-CSF.	Tacrolimus	61-66	colony stimulating factor 3	Homo sapiens	179-184
20159692-6	2010	CONCLUSION: FK506 effectively inhibits the secretion of proinflammatory cytokines including IL-6, IFN-gamma and TNF-alpha and also the secretion of IL-2, IL-12, IL-17, GM-CSF and G-CSF.	Tacrolimus	12-17	colony stimulating factor 3	Homo sapiens	179-184
20137150-4	2010	By using U937 cell line as in vitro model, effect of G-CSF on cell cycle was determined by propidium iodide staining method.	Propidium	91-107	colony stimulating factor 3	Homo sapiens	53-58
20137150-14	2010	G-CSF can enhance cytotoxicity of drugs such as Ara-C and HHT by promoting G(0) phase cells into the reproductive cycle.	Cytarabine	48-53	colony stimulating factor 3	Homo sapiens	0-5
21338187-8	2010	Among those who received naodjuvant chemotherapy (8 patients in each group), among the GCSF prevention group only in one (12%) we had to interrupt radiotherapy, as compared to 6 in the control group due to WBC loss.	naodjuvant	25-35	colony stimulating factor 3	Homo sapiens	87-91
20410588-4	2010	In this study, we administered recombinant human G-CSF into Sprague-Dawley rats with lithium-pilocarpine-induced SE subcutaneously for three times.	lithium-pilocarpine	85-104	colony stimulating factor 3	Homo sapiens	49-54
20300587-3	2010	Here, we report a case of large cisplatin overdose, successfully managed by plasma exchange, intravenous hydration, granulocyte colony-stimulating factor (G-CSF) administration, and other supportive care.	Cisplatin	32-41	colony stimulating factor 3	Homo sapiens	116-153
20300587-3	2010	Here, we report a case of large cisplatin overdose, successfully managed by plasma exchange, intravenous hydration, granulocyte colony-stimulating factor (G-CSF) administration, and other supportive care.	Cisplatin	32-41	colony stimulating factor 3	Homo sapiens	155-160
20133977-3	2010	injected recombinant human granulocyte colony-stimulating factor (G-CSF/filgrastim) was tested in cyclophosphamide (CY)-conditioned mice.	Cyclophosphamide	98-114	colony stimulating factor 3	Homo sapiens	27-64
20397073-3	2010	For patients with multiple myeloma and non-Hodgkin"s Lymphoma, treatment with plerixafor, an inhibitor of CXCL12 binding to CXCR4, plus G-CSF mobilizes stem cells for autologous transplantation to a greater degree than the treatment with G-CSF alone, and in some cases when patients could not be mobilized with cytokines, chemotherapy, or the combination.	plerixafor	78-88	colony stimulating factor 3	Homo sapiens	238-243
20133977-3	2010	injected recombinant human granulocyte colony-stimulating factor (G-CSF/filgrastim) was tested in cyclophosphamide (CY)-conditioned mice.	Cyclophosphamide	116-118	colony stimulating factor 3	Homo sapiens	27-64
20818715-1	2010	BACKGROUND: Plerixafor (Mozobil, AMD3100) with granulocyte-colony stimulating factor (G-CSF) mobilizes more CD34+ cells/kg compared to G-CSF alone.	plerixafor	12-22	colony stimulating factor 3	Homo sapiens	47-84
20818715-1	2010	BACKGROUND: Plerixafor (Mozobil, AMD3100) with granulocyte-colony stimulating factor (G-CSF) mobilizes more CD34+ cells/kg compared to G-CSF alone.	plerixafor	12-22	colony stimulating factor 3	Homo sapiens	86-91
19732808-6	2009	We further indicate that the neutralization of G-CSF with corresponding anti-G-CSF antibodies abolished the neuroprotective effect of LPS pretreatment in N-methyl-D-aspartic acid-induced neuronal injury by MTT/CCK-8 assays and LDH release.	monooxyethylene trimethylolpropane tristearate	206-209	colony stimulating factor 3	Homo sapiens	47-52
21123967-0	2010	Cell cycle-dependent priming action of granulocyte colony-stimulating factor (G-CSF) enhances in vitro apoptosis induction by cytarabine and etoposide in leukemia cell lines.	Cytarabine	126-136	colony stimulating factor 3	Homo sapiens	39-76
21123967-0	2010	Cell cycle-dependent priming action of granulocyte colony-stimulating factor (G-CSF) enhances in vitro apoptosis induction by cytarabine and etoposide in leukemia cell lines.	Cytarabine	126-136	colony stimulating factor 3	Homo sapiens	78-83
21123967-0	2010	Cell cycle-dependent priming action of granulocyte colony-stimulating factor (G-CSF) enhances in vitro apoptosis induction by cytarabine and etoposide in leukemia cell lines.	Etoposide	141-150	colony stimulating factor 3	Homo sapiens	39-76
21123967-0	2010	Cell cycle-dependent priming action of granulocyte colony-stimulating factor (G-CSF) enhances in vitro apoptosis induction by cytarabine and etoposide in leukemia cell lines.	Etoposide	141-150	colony stimulating factor 3	Homo sapiens	78-83
21123967-1	2010	We investigated the priming effect and mechanism of granulocyte colony-stimulating factor (G-CSF) in chemotherapy with low-dose Ara-C and VP-16 for acute myeloid leukemia.	Cytarabine	128-133	colony stimulating factor 3	Homo sapiens	52-89
21123967-1	2010	We investigated the priming effect and mechanism of granulocyte colony-stimulating factor (G-CSF) in chemotherapy with low-dose Ara-C and VP-16 for acute myeloid leukemia.	Cytarabine	128-133	colony stimulating factor 3	Homo sapiens	91-96
21123967-1	2010	We investigated the priming effect and mechanism of granulocyte colony-stimulating factor (G-CSF) in chemotherapy with low-dose Ara-C and VP-16 for acute myeloid leukemia.	Etoposide	138-143	colony stimulating factor 3	Homo sapiens	52-89
21123967-1	2010	We investigated the priming effect and mechanism of granulocyte colony-stimulating factor (G-CSF) in chemotherapy with low-dose Ara-C and VP-16 for acute myeloid leukemia.	Etoposide	138-143	colony stimulating factor 3	Homo sapiens	91-96
21123967-13	2010	G-CSF potentiates Ara-C- and VP-16-induced cytotoxicities through apoptosis induction by mobilizing resting G0-G1-phase cells into S phase.	Cytarabine	18-23	colony stimulating factor 3	Homo sapiens	0-5
21123967-13	2010	G-CSF potentiates Ara-C- and VP-16-induced cytotoxicities through apoptosis induction by mobilizing resting G0-G1-phase cells into S phase.	Etoposide	29-34	colony stimulating factor 3	Homo sapiens	0-5
20530974-1	2010	PURPOSE: On December 15, 2008, the US Food and Drug Administration approved plerixafor (Mozobil; Genzyme Corp.), a new small-molecule inhibitor of the CXCR4 chemokine receptor, for use in combination with granulocyte colony-stimulating factor (G-CSF) to mobilize hematopoietic stem cells (HSC) to the peripheral blood for collection and subsequent autologous transplantation in patients with non-Hodgkin"s lymphoma (NHL) and multiple myeloma (MM).	plerixafor	76-86	colony stimulating factor 3	Homo sapiens	244-249
19666150-3	2009	A systematic study on the effect of varying concentrations of YE indicated several folds higher expression of genes viz., human granulocyte colony stimulating factor (rhGCSF), human interferon alpha 2b (rhIFN-alpha2b) and Staphylokinase (rSAK) in BL21(DE3) cells in the absence of any specific inducer like IPTG or additional lactose.	Isopropyl Thiogalactoside	307-311	colony stimulating factor 3	Homo sapiens	128-165
18544592-9	2009	A significant decrease in mean total nitric oxide (NOx), nitrite, and nitrate levels was also found after G-CSF plus dexamethasone administration.	Nitric Oxide	37-49	colony stimulating factor 3	Homo sapiens	106-111
18544592-9	2009	A significant decrease in mean total nitric oxide (NOx), nitrite, and nitrate levels was also found after G-CSF plus dexamethasone administration.	Nitric Oxide	51-54	colony stimulating factor 3	Homo sapiens	106-111
18544592-9	2009	A significant decrease in mean total nitric oxide (NOx), nitrite, and nitrate levels was also found after G-CSF plus dexamethasone administration.	Nitrites	57-64	colony stimulating factor 3	Homo sapiens	106-111
20155583-6	2010	Bio-Plex analysis demonstrated that asbestos caused an increase in interleukin-13 (IL-13), basic fibroblast growth factor (bFGF), granulocyte colony-stimulating factor (G-CSF), and vascular endothelial growth factor (VEGF).	Asbestos	36-44	colony stimulating factor 3	Homo sapiens	130-167
20155583-6	2010	Bio-Plex analysis demonstrated that asbestos caused an increase in interleukin-13 (IL-13), basic fibroblast growth factor (bFGF), granulocyte colony-stimulating factor (G-CSF), and vascular endothelial growth factor (VEGF).	Asbestos	36-44	colony stimulating factor 3	Homo sapiens	169-174
20437856-1	2010	BACKGROUND: In 1995, we designed and carried out a pilot study on the combination of cisplatin + high dose epirubicin + vinorelbine with granulocyte-colony-stimulating factor support for the induction treatment of unresectable stage IIIAN2 and wet IIIB non-small-cell lung cancer.	Cisplatin	85-94	colony stimulating factor 3	Homo sapiens	137-174
20437856-1	2010	BACKGROUND: In 1995, we designed and carried out a pilot study on the combination of cisplatin + high dose epirubicin + vinorelbine with granulocyte-colony-stimulating factor support for the induction treatment of unresectable stage IIIAN2 and wet IIIB non-small-cell lung cancer.	Epirubicin	107-117	colony stimulating factor 3	Homo sapiens	137-174
19666150-3	2009	A systematic study on the effect of varying concentrations of YE indicated several folds higher expression of genes viz., human granulocyte colony stimulating factor (rhGCSF), human interferon alpha 2b (rhIFN-alpha2b) and Staphylokinase (rSAK) in BL21(DE3) cells in the absence of any specific inducer like IPTG or additional lactose.	Lactose	326-333	colony stimulating factor 3	Homo sapiens	128-165
19169864-0	2009	Glycerol-assisted hydrophobic interaction chromatography improving refolding of recombinant human granulocyte colony-stimulating factor.	Glycerol	0-8	colony stimulating factor 3	Homo sapiens	98-135
18544592-9	2009	A significant decrease in mean total nitric oxide (NOx), nitrite, and nitrate levels was also found after G-CSF plus dexamethasone administration.	Nitrates	70-77	colony stimulating factor 3	Homo sapiens	106-111
20004794-6	2009	Preliminary data for azacitidine combination therapy with erythropoietin, granulocyte colony-stimulating factor, and valproic acid are intriguing but should be treated with caution.	Azacitidine	21-32	colony stimulating factor 3	Homo sapiens	74-111
19732808-6	2009	We further indicate that the neutralization of G-CSF with corresponding anti-G-CSF antibodies abolished the neuroprotective effect of LPS pretreatment in N-methyl-D-aspartic acid-induced neuronal injury by MTT/CCK-8 assays and LDH release.	monooxyethylene trimethylolpropane tristearate	206-209	colony stimulating factor 3	Homo sapiens	77-82
19580698-6	2009	Before treatment with donepezil we found in AD patients significantly decreased SCF plasma concentrations (661.1+/-40.0 pg/ml) compared to healthy controls (997.7+/-33.7 pg/ml, p<0.001) but no significant differences between both groups concerning blood levels of SDF-1, G-CSF and VEGF.	Donepezil	22-31	colony stimulating factor 3	Homo sapiens	271-276
19447168-0	2009	Rho kinase inhibitor Fasudil induces neuroprotection and neurogenesis partially through astrocyte-derived G-CSF.	fasudil	21-28	colony stimulating factor 3	Homo sapiens	106-111
19447168-6	2009	Neutralization of G-CSF in ACM-F and blocking of G-CSF receptor in neuronal cell cultures revealed that Fasudil-induced neuroprotection and/or neurogenesis are mediated partially through astrocyte-derived G-CSF.	fasudil	104-111	colony stimulating factor 3	Homo sapiens	18-23
19447168-6	2009	Neutralization of G-CSF in ACM-F and blocking of G-CSF receptor in neuronal cell cultures revealed that Fasudil-induced neuroprotection and/or neurogenesis are mediated partially through astrocyte-derived G-CSF.	fasudil	104-111	colony stimulating factor 3	Homo sapiens	49-54
19447168-6	2009	Neutralization of G-CSF in ACM-F and blocking of G-CSF receptor in neuronal cell cultures revealed that Fasudil-induced neuroprotection and/or neurogenesis are mediated partially through astrocyte-derived G-CSF.	fasudil	104-111	colony stimulating factor 3	Homo sapiens	49-54
19738066-9	2009	Evidence for rapid elevations in circulating plasma G-CSF, vascular endothelial growth factor, and SDF-1 were also observed in patients with VDA (combretastatin-A4 phosphate)-treated cancer.	24-Ethyl-1alpha,24-dihydroxy-2alpha-(2-hydroxyethoxy)-22-thia-19,27-dinorcholecalciferol	141-144	colony stimulating factor 3	Homo sapiens	52-57
19738066-9	2009	Evidence for rapid elevations in circulating plasma G-CSF, vascular endothelial growth factor, and SDF-1 were also observed in patients with VDA (combretastatin-A4 phosphate)-treated cancer.	fosbretabulin	146-173	colony stimulating factor 3	Homo sapiens	52-57
19762739-9	2009	Sevoflurane inhalation in healthy volunteers did not alter the number of CD133+/CD34+ or KDR+/CD34+ endothelial progenitors in the circulation, but increased the number of colony-forming units (P = 0.034), whereas VEGF and G-CSF plasma levels remained unchanged.	Sevoflurane	0-11	colony stimulating factor 3	Homo sapiens	223-228
19497340-1	2009	Recombinant human granulocyte colony stimulating factor (rhG-CSF) and its PEGylated product "mono-PEG20-GCSF" have already been widely used for treatment of all kinds of neutropenia.	mono-peg20	93-103	colony stimulating factor 3	Homo sapiens	18-55
19796237-10	2009	Since CN patients respond to G-CSF treatment even in the absence of LEF-1 and C/EBPalpha, we conclude that treatment of CN patients with pharmacological doses of G-CSF activates NAMPT/NAD(+)/SIRT1-dependent "emergency" granulopoiesis via C/EBPbeta.	NAD	184-190	colony stimulating factor 3	Homo sapiens	162-167
19749982-3	2009	Quiescence of leukemic stem cells has been suggested as a mechanism conferring insensitivity to imatinib, and exposure to the Granulocyte-Colony Stimulating Factor (G-CSF), together with imatinib, has led to a significant reduction in leukemic stem cells in vitro.	Imatinib Mesylate	96-104	colony stimulating factor 3	Homo sapiens	126-163
19749982-3	2009	Quiescence of leukemic stem cells has been suggested as a mechanism conferring insensitivity to imatinib, and exposure to the Granulocyte-Colony Stimulating Factor (G-CSF), together with imatinib, has led to a significant reduction in leukemic stem cells in vitro.	Imatinib Mesylate	187-195	colony stimulating factor 3	Homo sapiens	126-163
19749982-5	2009	We find that the addition of G-CSF to an imatinib treatment protocol leads to observable effects only if the majority of leukemic stem cells are quiescent; otherwise it does not modulate the leukemic cell burden.	Imatinib Mesylate	41-49	colony stimulating factor 3	Homo sapiens	29-34
19187960-0	2009	Twice daily fludarabine/Ara-C associated to idarubicin, G-CSF and ATRA is an effective salvage regimen in non-promyelocytic acute myeloid leukemia.	fludarabine	12-23	colony stimulating factor 3	Homo sapiens	56-61
19187960-0	2009	Twice daily fludarabine/Ara-C associated to idarubicin, G-CSF and ATRA is an effective salvage regimen in non-promyelocytic acute myeloid leukemia.	Cytarabine	24-29	colony stimulating factor 3	Homo sapiens	56-61
19720922-13	2009	CONCLUSION: Plerixafor and G-CSF were well tolerated and resulted in a significantly higher proportion of patients with non-Hodgkin"s lymphoma achieving the optimal CD34+ cell target for transplantation in fewer apheresis days, compared with G-CSF alone.	plerixafor	12-22	colony stimulating factor 3	Homo sapiens	242-247
19497340-1	2009	Recombinant human granulocyte colony stimulating factor (rhG-CSF) and its PEGylated product "mono-PEG20-GCSF" have already been widely used for treatment of all kinds of neutropenia.	mono-peg20	93-103	colony stimulating factor 3	Homo sapiens	104-108
19497340-2	2009	However, the high required dosage of mono-PEG20-GCSF made it relatively expensive in clinical use.	mono-peg20	37-47	colony stimulating factor 3	Homo sapiens	48-52
18751888-1	2009	PURPOSE: Granulocyte-colony stimulating factor (G-CSF) was used in CALGB 9741 to support dose-dense sequential chemotherapy with doxorubicin and cyclophosphamide (AC) followed by paclitaxel (P) (Citron et al.	Doxorubicin	129-140	colony stimulating factor 3	Homo sapiens	48-53
19218307-0	2009	Preoperative weekly cisplatin-epirubicin-paclitaxel with G-CSF support in triple-negative large operable breast cancer.	Cisplatin	20-29	colony stimulating factor 3	Homo sapiens	57-62
19218307-0	2009	Preoperative weekly cisplatin-epirubicin-paclitaxel with G-CSF support in triple-negative large operable breast cancer.	Epirubicin	30-40	colony stimulating factor 3	Homo sapiens	57-62
19218307-0	2009	Preoperative weekly cisplatin-epirubicin-paclitaxel with G-CSF support in triple-negative large operable breast cancer.	Paclitaxel	41-51	colony stimulating factor 3	Homo sapiens	57-62
19233287-3	2009	In this work, a comparative study was carried out on refolding of recombinant human granulocyte colony-stimulating factor (rhG-CSF) in the presence of different concentrations of urea, guanidinium chloride or arginine.	Urea	179-183	colony stimulating factor 3	Homo sapiens	84-121
19233287-3	2009	In this work, a comparative study was carried out on refolding of recombinant human granulocyte colony-stimulating factor (rhG-CSF) in the presence of different concentrations of urea, guanidinium chloride or arginine.	Guanidine	185-205	colony stimulating factor 3	Homo sapiens	84-121
19233287-3	2009	In this work, a comparative study was carried out on refolding of recombinant human granulocyte colony-stimulating factor (rhG-CSF) in the presence of different concentrations of urea, guanidinium chloride or arginine.	Arginine	209-217	colony stimulating factor 3	Homo sapiens	84-121
19438472-8	2009	Both CR rate (P = 0.006) and overall survival (P = 0.006) were worse with G-CSF in patients aged &lt;40 years, but this may be a chance effect.	Chromium	5-7	colony stimulating factor 3	Homo sapiens	74-79
19345231-6	2009	The generation of cytokines of significance for adhesive and proliferative events in host defense, IL-8 and G-CSF, was also potently impaired by EtP.	ethyl pyruvate	145-148	colony stimulating factor 3	Homo sapiens	108-113
19345231-7	2009	SIGNIFICANCE: Exposure of lung epithelial cells to 2.5-10 mM EtP inhibited the generation of inflammatory-regulating cytokines IL-8 and G-CSF, reduced ICAM-1 and VCAM-1 expression and impeded the adhesiveness of neutrophils to lung epithelial cells.	ethyl pyruvate	61-64	colony stimulating factor 3	Homo sapiens	136-141
19349622-9	2009	Transcriptional activity of the CAST gene was induced by G-CSF/dexamethasone treatment both in vivo and in vitro, whereas the protein expression of CAST was stabilized during culture.	Dexamethasone	63-76	colony stimulating factor 3	Homo sapiens	57-62
19469471-4	2009	Both PEG-C(18)-Mal and the commercial maleimido activated 20 kDa linear PEG (PEG-Mal) were used for conjugation to (17)Cys of recombinant human granulocyte colony stimulating factor (rh-G-CSF).	peg-c	5-10	colony stimulating factor 3	Homo sapiens	144-181
19469471-4	2009	Both PEG-C(18)-Mal and the commercial maleimido activated 20 kDa linear PEG (PEG-Mal) were used for conjugation to (17)Cys of recombinant human granulocyte colony stimulating factor (rh-G-CSF).	Polyethylene Glycols	5-8	colony stimulating factor 3	Homo sapiens	144-181
19469471-4	2009	Both PEG-C(18)-Mal and the commercial maleimido activated 20 kDa linear PEG (PEG-Mal) were used for conjugation to (17)Cys of recombinant human granulocyte colony stimulating factor (rh-G-CSF).	peg-mal	77-84	colony stimulating factor 3	Homo sapiens	144-181
19469471-4	2009	Both PEG-C(18)-Mal and the commercial maleimido activated 20 kDa linear PEG (PEG-Mal) were used for conjugation to (17)Cys of recombinant human granulocyte colony stimulating factor (rh-G-CSF).	Cysteine	119-122	colony stimulating factor 3	Homo sapiens	144-181
18751888-1	2009	PURPOSE: Granulocyte-colony stimulating factor (G-CSF) was used in CALGB 9741 to support dose-dense sequential chemotherapy with doxorubicin and cyclophosphamide (AC) followed by paclitaxel (P) (Citron et al.	Cyclophosphamide	145-161	colony stimulating factor 3	Homo sapiens	48-53
18751888-1	2009	PURPOSE: Granulocyte-colony stimulating factor (G-CSF) was used in CALGB 9741 to support dose-dense sequential chemotherapy with doxorubicin and cyclophosphamide (AC) followed by paclitaxel (P) (Citron et al.	Paclitaxel	179-189	colony stimulating factor 3	Homo sapiens	48-53
19019580-9	2009	CSF lactate was correlated with CSF concentrations of IL-1beta, IL-6, GM-CSF, G-CSF, IFN-gamma and MIP-1beta.	Lactic Acid	4-11	colony stimulating factor 3	Homo sapiens	78-83
19404210-0	2009	XM02, the first biosimilar G-CSF, is safe and effective in reducing the duration of severe neutropenia and incidence of febrile neutropenia in patients with small cell or non-small cell lung cancer receiving platinum-based chemotherapy.	Platinum	208-216	colony stimulating factor 3	Homo sapiens	27-32
19308043-3	2009	Attachment of the polyethylene glycol (PEG) moiety reduces renal excretion and masks proteolytic cleavage sites resulting in elevated G-CSF serum levels for up to 14 days after a single injection.	Polyethylene Glycols	18-37	colony stimulating factor 3	Homo sapiens	134-139
19308043-3	2009	Attachment of the polyethylene glycol (PEG) moiety reduces renal excretion and masks proteolytic cleavage sites resulting in elevated G-CSF serum levels for up to 14 days after a single injection.	Polyethylene Glycols	39-42	colony stimulating factor 3	Homo sapiens	134-139
19377829-6	2009	G-CSF promoted the viability of MSCs, and the promotion was completely inhibited by PKC inhibitor straurosporine and partially inhibited by wortmannin, rapamycin, PD98059, SB203580 or G0697.	straurosporine	98-112	colony stimulating factor 3	Homo sapiens	0-5
19377829-6	2009	G-CSF promoted the viability of MSCs, and the promotion was completely inhibited by PKC inhibitor straurosporine and partially inhibited by wortmannin, rapamycin, PD98059, SB203580 or G0697.	Wortmannin	140-150	colony stimulating factor 3	Homo sapiens	0-5
19377829-6	2009	G-CSF promoted the viability of MSCs, and the promotion was completely inhibited by PKC inhibitor straurosporine and partially inhibited by wortmannin, rapamycin, PD98059, SB203580 or G0697.	Sirolimus	152-161	colony stimulating factor 3	Homo sapiens	0-5
19377829-6	2009	G-CSF promoted the viability of MSCs, and the promotion was completely inhibited by PKC inhibitor straurosporine and partially inhibited by wortmannin, rapamycin, PD98059, SB203580 or G0697.	2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one	163-170	colony stimulating factor 3	Homo sapiens	0-5
19377829-6	2009	G-CSF promoted the viability of MSCs, and the promotion was completely inhibited by PKC inhibitor straurosporine and partially inhibited by wortmannin, rapamycin, PD98059, SB203580 or G0697.	SB 203580	172-180	colony stimulating factor 3	Homo sapiens	0-5
19242319-6	2009	Stratification of G-CSF levels into quartiles revealed a strong association between the highest levels of G-CSF and an increased risk of death and decreased ventilator-free days and organ failure-free days in multivariate analyses controlling for ventilation strategy, Acute Physiology and Chronic Health Evaluation III score, Pao2/Fio2 ratio, creatinine, and platelet count (p &lt; 0.05).	pao2	327-331	colony stimulating factor 3	Homo sapiens	18-23
19242319-6	2009	Stratification of G-CSF levels into quartiles revealed a strong association between the highest levels of G-CSF and an increased risk of death and decreased ventilator-free days and organ failure-free days in multivariate analyses controlling for ventilation strategy, Acute Physiology and Chronic Health Evaluation III score, Pao2/Fio2 ratio, creatinine, and platelet count (p &lt; 0.05).	pao2	327-331	colony stimulating factor 3	Homo sapiens	106-111
19242319-6	2009	Stratification of G-CSF levels into quartiles revealed a strong association between the highest levels of G-CSF and an increased risk of death and decreased ventilator-free days and organ failure-free days in multivariate analyses controlling for ventilation strategy, Acute Physiology and Chronic Health Evaluation III score, Pao2/Fio2 ratio, creatinine, and platelet count (p &lt; 0.05).	fio2	332-336	colony stimulating factor 3	Homo sapiens	18-23
19242319-6	2009	Stratification of G-CSF levels into quartiles revealed a strong association between the highest levels of G-CSF and an increased risk of death and decreased ventilator-free days and organ failure-free days in multivariate analyses controlling for ventilation strategy, Acute Physiology and Chronic Health Evaluation III score, Pao2/Fio2 ratio, creatinine, and platelet count (p &lt; 0.05).	fio2	332-336	colony stimulating factor 3	Homo sapiens	106-111
19242319-6	2009	Stratification of G-CSF levels into quartiles revealed a strong association between the highest levels of G-CSF and an increased risk of death and decreased ventilator-free days and organ failure-free days in multivariate analyses controlling for ventilation strategy, Acute Physiology and Chronic Health Evaluation III score, Pao2/Fio2 ratio, creatinine, and platelet count (p &lt; 0.05).	Creatinine	344-354	colony stimulating factor 3	Homo sapiens	18-23
19242319-6	2009	Stratification of G-CSF levels into quartiles revealed a strong association between the highest levels of G-CSF and an increased risk of death and decreased ventilator-free days and organ failure-free days in multivariate analyses controlling for ventilation strategy, Acute Physiology and Chronic Health Evaluation III score, Pao2/Fio2 ratio, creatinine, and platelet count (p &lt; 0.05).	Creatinine	344-354	colony stimulating factor 3	Homo sapiens	106-111
19233728-2	2009	We therefore designed a regimen for PBPC mobilization in patients with multiple myeloma or pre-treated Non-Hodgkin"s lymphoma based on a combination of low-dose cyclophosphamide (Cy) plus granulocyte colony-stimulating factor (G-CSF) without daily monitoring of peripheral blood CD34+ cells.	PbPc	36-40	colony stimulating factor 3	Homo sapiens	188-225
19233728-2	2009	We therefore designed a regimen for PBPC mobilization in patients with multiple myeloma or pre-treated Non-Hodgkin"s lymphoma based on a combination of low-dose cyclophosphamide (Cy) plus granulocyte colony-stimulating factor (G-CSF) without daily monitoring of peripheral blood CD34+ cells.	PbPc	36-40	colony stimulating factor 3	Homo sapiens	227-232
19136605-8	2009	In addition, G-CSF dramatically improved ATP generation, which rescued Dox-impaired mitochondrial electron transport and oxygen consumption mainly through complex IV.	Adenosine Triphosphate	41-44	colony stimulating factor 3	Homo sapiens	13-18
19379589-1	2009	The objective of this study was to evaluate the efficacy and toxicity of the fludarabine combination with high-dose cytarabine (Ara C), idarubicin and granulocyte colony-stimulating factor (G-CSF) (IDA-FLAG regimen) in treatment of refractory/relapsed acute leukemia (AL) patients.	fludarabine	77-88	colony stimulating factor 3	Homo sapiens	190-195
19619443-13	2009	In concurrent chemoradiotherapy, the application rate of granulocyte colony stimulating factor (G-CSF) was significantly higher in TP group than in DDP group (100% vs. 72.0%, p&lt;0.05).	neotetrazolium	131-133	colony stimulating factor 3	Homo sapiens	57-94
19619443-13	2009	In concurrent chemoradiotherapy, the application rate of granulocyte colony stimulating factor (G-CSF) was significantly higher in TP group than in DDP group (100% vs. 72.0%, p&lt;0.05).	neotetrazolium	131-133	colony stimulating factor 3	Homo sapiens	96-101
19619443-13	2009	In concurrent chemoradiotherapy, the application rate of granulocyte colony stimulating factor (G-CSF) was significantly higher in TP group than in DDP group (100% vs. 72.0%, p&lt;0.05).	Cisplatin	148-151	colony stimulating factor 3	Homo sapiens	57-94
19619443-13	2009	In concurrent chemoradiotherapy, the application rate of granulocyte colony stimulating factor (G-CSF) was significantly higher in TP group than in DDP group (100% vs. 72.0%, p&lt;0.05).	Cisplatin	148-151	colony stimulating factor 3	Homo sapiens	96-101
19136605-8	2009	In addition, G-CSF dramatically improved ATP generation, which rescued Dox-impaired mitochondrial electron transport and oxygen consumption mainly through complex IV.	Doxorubicin	71-74	colony stimulating factor 3	Homo sapiens	13-18
19136605-8	2009	In addition, G-CSF dramatically improved ATP generation, which rescued Dox-impaired mitochondrial electron transport and oxygen consumption mainly through complex IV.	Oxygen	121-127	colony stimulating factor 3	Homo sapiens	13-18
19167685-0	2009	Treatment with plerixafor in non-Hodgkin"s lymphoma and multiple myeloma patients to increase the number of peripheral blood stem cells when given a mobilizing regimen of G-CSF: implications for the heavily pretreated patient.	plerixafor	15-25	colony stimulating factor 3	Homo sapiens	171-176
19212662-9	2009	Moreover, remarkable increases in G-CSF and IL-8 secretions by 8-Br-cAMP-stimulated ESCs during decidualization were completely inhibited by cotreatment with danazol.	8-Bromo Cyclic Adenosine Monophosphate	63-72	colony stimulating factor 3	Homo sapiens	34-39
19212662-9	2009	Moreover, remarkable increases in G-CSF and IL-8 secretions by 8-Br-cAMP-stimulated ESCs during decidualization were completely inhibited by cotreatment with danazol.	Danazol	158-165	colony stimulating factor 3	Homo sapiens	34-39
19040597-1	2009	BACKGROUND: The combination of granulocyte-colony-stimulating factor (G-CSF [filgrastim]) and dexamethasone (G-CSF/dex) is an effective granulocyte mobilization regimen, but the variables that affect donor neutrophil response and granulocyte collection yield are not well characterized.	Dexamethasone	94-107	colony stimulating factor 3	Homo sapiens	109-114
19138532-3	2009	The results revealed that DEX nonspecifically and dose-dependently inhibited the production of 12 cytokines (IL-2, IFN-gamma, TNF-alpha, IL-8, IL-1beta, IL-17, IL-4, IL-5, IL-6, IL-10, IL-13, and G-CSF).	Dexamethasone	26-29	colony stimulating factor 3	Homo sapiens	196-201
19036079-5	2009	This was more notable in children who received idarubicin, fludarabine, ara-C, and granulocyte colony-stimulating factor (IDA-FLAG; ara-C = 7590 mg/m2) (5-year TRM 24 +/- 21% CC vs. 6 +/- 6% AA, 6 +/- 7% AC, P = 0.07) as consolidation therapy compared to idarubicin, dexamethasone, cytarabine, thioguanine, etoposide and daunomycin (IDA-DCTER; ara-C = 800 mg/m2) (5-year TRM 15 +/- 20% CC vs. 8 +/- 6% AA, 4 +/- 6% AC; P = 0.29).	ida-flag	122-130	colony stimulating factor 3	Homo sapiens	83-120
19036079-5	2009	This was more notable in children who received idarubicin, fludarabine, ara-C, and granulocyte colony-stimulating factor (IDA-FLAG; ara-C = 7590 mg/m2) (5-year TRM 24 +/- 21% CC vs. 6 +/- 6% AA, 6 +/- 7% AC, P = 0.07) as consolidation therapy compared to idarubicin, dexamethasone, cytarabine, thioguanine, etoposide and daunomycin (IDA-DCTER; ara-C = 800 mg/m2) (5-year TRM 15 +/- 20% CC vs. 8 +/- 6% AA, 4 +/- 6% AC; P = 0.29).	Cytarabine	132-137	colony stimulating factor 3	Homo sapiens	83-120
19036079-5	2009	This was more notable in children who received idarubicin, fludarabine, ara-C, and granulocyte colony-stimulating factor (IDA-FLAG; ara-C = 7590 mg/m2) (5-year TRM 24 +/- 21% CC vs. 6 +/- 6% AA, 6 +/- 7% AC, P = 0.07) as consolidation therapy compared to idarubicin, dexamethasone, cytarabine, thioguanine, etoposide and daunomycin (IDA-DCTER; ara-C = 800 mg/m2) (5-year TRM 15 +/- 20% CC vs. 8 +/- 6% AA, 4 +/- 6% AC; P = 0.29).	trm	160-163	colony stimulating factor 3	Homo sapiens	83-120
19036079-5	2009	This was more notable in children who received idarubicin, fludarabine, ara-C, and granulocyte colony-stimulating factor (IDA-FLAG; ara-C = 7590 mg/m2) (5-year TRM 24 +/- 21% CC vs. 6 +/- 6% AA, 6 +/- 7% AC, P = 0.07) as consolidation therapy compared to idarubicin, dexamethasone, cytarabine, thioguanine, etoposide and daunomycin (IDA-DCTER; ara-C = 800 mg/m2) (5-year TRM 15 +/- 20% CC vs. 8 +/- 6% AA, 4 +/- 6% AC; P = 0.29).	Actinium	204-206	colony stimulating factor 3	Homo sapiens	83-120
19036079-5	2009	This was more notable in children who received idarubicin, fludarabine, ara-C, and granulocyte colony-stimulating factor (IDA-FLAG; ara-C = 7590 mg/m2) (5-year TRM 24 +/- 21% CC vs. 6 +/- 6% AA, 6 +/- 7% AC, P = 0.07) as consolidation therapy compared to idarubicin, dexamethasone, cytarabine, thioguanine, etoposide and daunomycin (IDA-DCTER; ara-C = 800 mg/m2) (5-year TRM 15 +/- 20% CC vs. 8 +/- 6% AA, 4 +/- 6% AC; P = 0.29).	Idarubicin	255-265	colony stimulating factor 3	Homo sapiens	83-120
19036079-5	2009	This was more notable in children who received idarubicin, fludarabine, ara-C, and granulocyte colony-stimulating factor (IDA-FLAG; ara-C = 7590 mg/m2) (5-year TRM 24 +/- 21% CC vs. 6 +/- 6% AA, 6 +/- 7% AC, P = 0.07) as consolidation therapy compared to idarubicin, dexamethasone, cytarabine, thioguanine, etoposide and daunomycin (IDA-DCTER; ara-C = 800 mg/m2) (5-year TRM 15 +/- 20% CC vs. 8 +/- 6% AA, 4 +/- 6% AC; P = 0.29).	Dexamethasone	267-280	colony stimulating factor 3	Homo sapiens	83-120
19036079-5	2009	This was more notable in children who received idarubicin, fludarabine, ara-C, and granulocyte colony-stimulating factor (IDA-FLAG; ara-C = 7590 mg/m2) (5-year TRM 24 +/- 21% CC vs. 6 +/- 6% AA, 6 +/- 7% AC, P = 0.07) as consolidation therapy compared to idarubicin, dexamethasone, cytarabine, thioguanine, etoposide and daunomycin (IDA-DCTER; ara-C = 800 mg/m2) (5-year TRM 15 +/- 20% CC vs. 8 +/- 6% AA, 4 +/- 6% AC; P = 0.29).	Cytarabine	282-292	colony stimulating factor 3	Homo sapiens	83-120
19036079-5	2009	This was more notable in children who received idarubicin, fludarabine, ara-C, and granulocyte colony-stimulating factor (IDA-FLAG; ara-C = 7590 mg/m2) (5-year TRM 24 +/- 21% CC vs. 6 +/- 6% AA, 6 +/- 7% AC, P = 0.07) as consolidation therapy compared to idarubicin, dexamethasone, cytarabine, thioguanine, etoposide and daunomycin (IDA-DCTER; ara-C = 800 mg/m2) (5-year TRM 15 +/- 20% CC vs. 8 +/- 6% AA, 4 +/- 6% AC; P = 0.29).	Thioguanine	294-305	colony stimulating factor 3	Homo sapiens	83-120
19036079-5	2009	This was more notable in children who received idarubicin, fludarabine, ara-C, and granulocyte colony-stimulating factor (IDA-FLAG; ara-C = 7590 mg/m2) (5-year TRM 24 +/- 21% CC vs. 6 +/- 6% AA, 6 +/- 7% AC, P = 0.07) as consolidation therapy compared to idarubicin, dexamethasone, cytarabine, thioguanine, etoposide and daunomycin (IDA-DCTER; ara-C = 800 mg/m2) (5-year TRM 15 +/- 20% CC vs. 8 +/- 6% AA, 4 +/- 6% AC; P = 0.29).	Etoposide	307-316	colony stimulating factor 3	Homo sapiens	83-120
19036079-5	2009	This was more notable in children who received idarubicin, fludarabine, ara-C, and granulocyte colony-stimulating factor (IDA-FLAG; ara-C = 7590 mg/m2) (5-year TRM 24 +/- 21% CC vs. 6 +/- 6% AA, 6 +/- 7% AC, P = 0.07) as consolidation therapy compared to idarubicin, dexamethasone, cytarabine, thioguanine, etoposide and daunomycin (IDA-DCTER; ara-C = 800 mg/m2) (5-year TRM 15 +/- 20% CC vs. 8 +/- 6% AA, 4 +/- 6% AC; P = 0.29).	Daunorubicin	321-331	colony stimulating factor 3	Homo sapiens	83-120
19036079-5	2009	This was more notable in children who received idarubicin, fludarabine, ara-C, and granulocyte colony-stimulating factor (IDA-FLAG; ara-C = 7590 mg/m2) (5-year TRM 24 +/- 21% CC vs. 6 +/- 6% AA, 6 +/- 7% AC, P = 0.07) as consolidation therapy compared to idarubicin, dexamethasone, cytarabine, thioguanine, etoposide and daunomycin (IDA-DCTER; ara-C = 800 mg/m2) (5-year TRM 15 +/- 20% CC vs. 8 +/- 6% AA, 4 +/- 6% AC; P = 0.29).	Cytarabine	132-137	colony stimulating factor 3	Homo sapiens	83-120
19036079-5	2009	This was more notable in children who received idarubicin, fludarabine, ara-C, and granulocyte colony-stimulating factor (IDA-FLAG; ara-C = 7590 mg/m2) (5-year TRM 24 +/- 21% CC vs. 6 +/- 6% AA, 6 +/- 7% AC, P = 0.07) as consolidation therapy compared to idarubicin, dexamethasone, cytarabine, thioguanine, etoposide and daunomycin (IDA-DCTER; ara-C = 800 mg/m2) (5-year TRM 15 +/- 20% CC vs. 8 +/- 6% AA, 4 +/- 6% AC; P = 0.29).	Actinium	415-417	colony stimulating factor 3	Homo sapiens	83-120
18806833-0	2009	EPO in combination with G-CSF improves mobilization effectiveness after chemotherapy with ifosfamide, epirubicin and etoposide and reduces costs during mobilization and transplantation of autologous hematopoietic progenitor cells.	Ifosfamide	90-100	colony stimulating factor 3	Homo sapiens	24-29
18806833-0	2009	EPO in combination with G-CSF improves mobilization effectiveness after chemotherapy with ifosfamide, epirubicin and etoposide and reduces costs during mobilization and transplantation of autologous hematopoietic progenitor cells.	Epirubicin	102-112	colony stimulating factor 3	Homo sapiens	24-29
18806833-0	2009	EPO in combination with G-CSF improves mobilization effectiveness after chemotherapy with ifosfamide, epirubicin and etoposide and reduces costs during mobilization and transplantation of autologous hematopoietic progenitor cells.	Etoposide	117-126	colony stimulating factor 3	Homo sapiens	24-29
19537526-7	2009	Coadministration of 100 microg/kg x 5 injection of G-CSF with all-trans-retinoic acid (ATRA; 3 mg/ kg/d) for 3 weeks from 2 weeks after PPE instillation significantly inhibited the increase in Lm by 36% (p &lt; 0.01), whereas administration of G-CSF or ATRA alone did not produce significant improvement.	Tretinoin	62-85	colony stimulating factor 3	Homo sapiens	51-56
18987661-2	2009	We previously reported that only 34% of fludarabine-exposed patients mobilized successfully using granulocyte-colony stimulating factor (G-CSF; median 10 microg/kg/day) with or without chemotherapy, with unpredictable kinetics and moderate infectious morbidity.	fludarabine	40-51	colony stimulating factor 3	Homo sapiens	98-135
18987661-2	2009	We previously reported that only 34% of fludarabine-exposed patients mobilized successfully using granulocyte-colony stimulating factor (G-CSF; median 10 microg/kg/day) with or without chemotherapy, with unpredictable kinetics and moderate infectious morbidity.	fludarabine	40-51	colony stimulating factor 3	Homo sapiens	137-142
18987661-14	2009	G-CSF improves PBSC mobilization efficacy after fludarabine exposure, over mobilization using G-CSF as the mobilizing cytokine.	fludarabine	48-59	colony stimulating factor 3	Homo sapiens	0-5
19182797-0	2009	NAMPT is essential for the G-CSF-induced myeloid differentiation via a NAD(+)-sirtuin-1-dependent pathway.	NAD	71-77	colony stimulating factor 3	Homo sapiens	27-32
19182797-2	2009	Intracellular NAMPT and NAD(+) amounts in myeloid cells, as well as plasma NAMPT and NAD(+) levels, were increased by G-CSF treatment of both healthy volunteers and individuals with congenital neutropenia.	NAD	24-30	colony stimulating factor 3	Homo sapiens	118-123
19182797-2	2009	Intracellular NAMPT and NAD(+) amounts in myeloid cells, as well as plasma NAMPT and NAD(+) levels, were increased by G-CSF treatment of both healthy volunteers and individuals with congenital neutropenia.	NAD	85-91	colony stimulating factor 3	Homo sapiens	118-123
19182797-7	2009	These results reveal a decisive role of the NAD(+) metabolic pathway in G-CSF-triggered myelopoiesis.	NAD	44-50	colony stimulating factor 3	Homo sapiens	72-77
19537526-7	2009	Coadministration of 100 microg/kg x 5 injection of G-CSF with all-trans-retinoic acid (ATRA; 3 mg/ kg/d) for 3 weeks from 2 weeks after PPE instillation significantly inhibited the increase in Lm by 36% (p &lt; 0.01), whereas administration of G-CSF or ATRA alone did not produce significant improvement.	Tretinoin	62-85	colony stimulating factor 3	Homo sapiens	244-249
19537526-7	2009	Coadministration of 100 microg/kg x 5 injection of G-CSF with all-trans-retinoic acid (ATRA; 3 mg/ kg/d) for 3 weeks from 2 weeks after PPE instillation significantly inhibited the increase in Lm by 36% (p &lt; 0.01), whereas administration of G-CSF or ATRA alone did not produce significant improvement.	Tretinoin	87-91	colony stimulating factor 3	Homo sapiens	51-56
19537526-7	2009	Coadministration of 100 microg/kg x 5 injection of G-CSF with all-trans-retinoic acid (ATRA; 3 mg/ kg/d) for 3 weeks from 2 weeks after PPE instillation significantly inhibited the increase in Lm by 36% (p &lt; 0.01), whereas administration of G-CSF or ATRA alone did not produce significant improvement.	Tretinoin	87-91	colony stimulating factor 3	Homo sapiens	244-249
19537526-7	2009	Coadministration of 100 microg/kg x 5 injection of G-CSF with all-trans-retinoic acid (ATRA; 3 mg/ kg/d) for 3 weeks from 2 weeks after PPE instillation significantly inhibited the increase in Lm by 36% (p &lt; 0.01), whereas administration of G-CSF or ATRA alone did not produce significant improvement.	Tretinoin	253-257	colony stimulating factor 3	Homo sapiens	51-56
20213395-9	2009	The third study 80961 investigated interval compression i.e. if the CDDP/DOX when given every 2 weeks with GCSF superior to the same two drugs given every 3 weeks.	cddp	68-72	colony stimulating factor 3	Homo sapiens	107-111
19135941-1	2009	Phase I pharmacokinetic (PK) and pharmacodynamic (PD) studies in healthy volunteers demonstrated that plerixafor (AMD3100), a CXCR4 antagonist, administered either alone or with granulocyte colony-stimulating factor (G-CSF), resulted in dose-dependent mobilization of CD34(+) cells in the peripheral blood.	plerixafor	102-112	colony stimulating factor 3	Homo sapiens	217-222
19135941-9	2009	The objectives were to determine the safety and efficacy of plerixafor in patients with NHL and MM, and the PK and PD of a single 240-microg/kg dose of plerixafor administered after 4 days of G-CSF mobilization in these patients.	plerixafor	152-162	colony stimulating factor 3	Homo sapiens	192-197
20213395-9	2009	The third study 80961 investigated interval compression i.e. if the CDDP/DOX when given every 2 weeks with GCSF superior to the same two drugs given every 3 weeks.	Doxorubicin	73-76	colony stimulating factor 3	Homo sapiens	107-111
18727660-0	2009	Prospective trial of mycophenolate mofetil-cyclosporine A prophylaxis for acute GVHD after G-CSF stimulated allogeneic bone marrow transplantation with HLA-identical sibling donors in patients with severe aplastic anemia and hematological malignancies.	mycophenolate mofetil-cyclosporine a	21-57	colony stimulating factor 3	Homo sapiens	91-96
18727660-2	2009	Mycophenolate mofetil and CSA (MMF-CSA) combination has been successfully used for GVHD prophylaxis after non-reduced intensity conditioning (non-RIC) allo-SCT with peripheral blood or non-G-CSF stimulated bone marrow as stem cell source.	Mycophenolic Acid	0-21	colony stimulating factor 3	Homo sapiens	189-194
18727660-2	2009	Mycophenolate mofetil and CSA (MMF-CSA) combination has been successfully used for GVHD prophylaxis after non-reduced intensity conditioning (non-RIC) allo-SCT with peripheral blood or non-G-CSF stimulated bone marrow as stem cell source.	Cyclosporine	26-29	colony stimulating factor 3	Homo sapiens	189-194
18727660-2	2009	Mycophenolate mofetil and CSA (MMF-CSA) combination has been successfully used for GVHD prophylaxis after non-reduced intensity conditioning (non-RIC) allo-SCT with peripheral blood or non-G-CSF stimulated bone marrow as stem cell source.	Cyclosporine	35-38	colony stimulating factor 3	Homo sapiens	189-194
18932257-2	2008	In vitro and ex vivo observations suggest that increases in intracellular ara-C levels influenced by administration of fludarabine and granulocyte colony-stimulating factor (GCSF) increase the effect of ara-C, prompting us to clinically evaluate the efficacy of such combinations.	Cytarabine	74-79	colony stimulating factor 3	Homo sapiens	135-172
19773618-0	2009	[Safety and efficacy study of the recombinant granulocyte colony-stimulating factor for prevention of neutropenia and neutropenia-related complications in women with metastatic breast cancer receiving docetaxel/doxorubicin].	Docetaxel	201-210	colony stimulating factor 3	Homo sapiens	46-83
19773618-0	2009	[Safety and efficacy study of the recombinant granulocyte colony-stimulating factor for prevention of neutropenia and neutropenia-related complications in women with metastatic breast cancer receiving docetaxel/doxorubicin].	Doxorubicin	211-222	colony stimulating factor 3	Homo sapiens	46-83
19773618-1	2009	BACKGROUND: We evaluated efficacy and safety of recombinant granulocyte-colony stimulating factor (rGCSF) used as primary prophylaxis to prevent neutropenia and neutropenia-related complications induced by docetaxel and doxorubicin chemotherapy in patients with metastatic breast cancer.	Docetaxel	206-215	colony stimulating factor 3	Homo sapiens	60-97
19773618-1	2009	BACKGROUND: We evaluated efficacy and safety of recombinant granulocyte-colony stimulating factor (rGCSF) used as primary prophylaxis to prevent neutropenia and neutropenia-related complications induced by docetaxel and doxorubicin chemotherapy in patients with metastatic breast cancer.	Doxorubicin	220-231	colony stimulating factor 3	Homo sapiens	60-97
19929463-1	2009	BACKGROUND AIMS: Previous studies in xenograft models have shown that human peripheral blood progenitor cells (PBPC) mobilized with the CXCR4 antagonist plerixafor (AMD3100) have a higher bone marrow (BM) reconstitution potential than granulocyte-colony-stimulating factor (G-CSF)-mobilized PBPC.	plerixafor	153-163	colony stimulating factor 3	Homo sapiens	235-272
19929463-1	2009	BACKGROUND AIMS: Previous studies in xenograft models have shown that human peripheral blood progenitor cells (PBPC) mobilized with the CXCR4 antagonist plerixafor (AMD3100) have a higher bone marrow (BM) reconstitution potential than granulocyte-colony-stimulating factor (G-CSF)-mobilized PBPC.	plerixafor	153-163	colony stimulating factor 3	Homo sapiens	274-279
18809733-4	2009	We review evidence that lithium increases G-CSF and augments G-CSF effects.	Lithium	24-31	colony stimulating factor 3	Homo sapiens	42-47
18226951-1	2009	BACKGROUND: Abnormally high CSF 3-OMD occurs frequently for RLS patients indicating either increased l-dopa synthesis, limitations in l-dopa decarboxylation or increased MAT/COMT activity, or some combination of these.	Levodopa	101-107	colony stimulating factor 3	Homo sapiens	28-33
18226951-1	2009	BACKGROUND: Abnormally high CSF 3-OMD occurs frequently for RLS patients indicating either increased l-dopa synthesis, limitations in l-dopa decarboxylation or increased MAT/COMT activity, or some combination of these.	Levodopa	134-140	colony stimulating factor 3	Homo sapiens	28-33
21076551-5	2009	Recently a new chemokine receptor CXCR4 antagonist, AMD3100 (plerixafor), was introduced which can be combined with G-CSF mobilization and has been reported to increase the number of harvested stem cells significantly.	plerixafor	61-71	colony stimulating factor 3	Homo sapiens	116-121
21076551-8	2009	CONCLUSION: Plerixafor has the potency to become an important tool in mobilizing HSC, especially in those patients in whom HSC cannot be mobilized by the combination of G-CSF and chemotherapy alone.	plerixafor	12-22	colony stimulating factor 3	Homo sapiens	169-174
19053302-1	2008	A new PEGylating agent, PEG-betaAla-NHCO-OSu, has been studied for protein amino conjugation using human growth hormone (hGH) and granulocyte colony stimulating factor (G-CSF) as model therapeutic proteins.	peg-betaala-nhco-osu	24-44	colony stimulating factor 3	Homo sapiens	130-167
19053302-1	2008	A new PEGylating agent, PEG-betaAla-NHCO-OSu, has been studied for protein amino conjugation using human growth hormone (hGH) and granulocyte colony stimulating factor (G-CSF) as model therapeutic proteins.	peg-betaala-nhco-osu	24-44	colony stimulating factor 3	Homo sapiens	169-174
18932257-2	2008	In vitro and ex vivo observations suggest that increases in intracellular ara-C levels influenced by administration of fludarabine and granulocyte colony-stimulating factor (GCSF) increase the effect of ara-C, prompting us to clinically evaluate the efficacy of such combinations.	Cytarabine	74-79	colony stimulating factor 3	Homo sapiens	174-178
18932257-2	2008	In vitro and ex vivo observations suggest that increases in intracellular ara-C levels influenced by administration of fludarabine and granulocyte colony-stimulating factor (GCSF) increase the effect of ara-C, prompting us to clinically evaluate the efficacy of such combinations.	Cytarabine	203-208	colony stimulating factor 3	Homo sapiens	135-172
18932257-2	2008	In vitro and ex vivo observations suggest that increases in intracellular ara-C levels influenced by administration of fludarabine and granulocyte colony-stimulating factor (GCSF) increase the effect of ara-C, prompting us to clinically evaluate the efficacy of such combinations.	Cytarabine	203-208	colony stimulating factor 3	Homo sapiens	174-178
18932257-5	2008	CONCLUSIONS: Thus, our data lends clinical credence to the observed modulation of ara-C by fludarabine and GCSF.	Cytarabine	82-87	colony stimulating factor 3	Homo sapiens	107-111
19046444-5	2008	In the case of the three studied proteins, G-CSF, His7DeltaN6TNF-alpha, and GFP, a significant amount of protein could be extracted from IBs with 0.2% N-lauroyl sarcosine (NLS) and the proteins retained biological activity although no renaturation procedure was applied.	sarkosyl	151-170	colony stimulating factor 3	Homo sapiens	43-48
19060545-4	2008	RECENT FINDINGS: In kidney and liver transplant recipients, granulocyte colony-stimulating factor (G-CSF) has been used successfully to reverse ganciclovir-induced neutropenia or cytomegalovirus-induced neutropenia.	Ganciclovir	144-155	colony stimulating factor 3	Homo sapiens	60-97
19060545-4	2008	RECENT FINDINGS: In kidney and liver transplant recipients, granulocyte colony-stimulating factor (G-CSF) has been used successfully to reverse ganciclovir-induced neutropenia or cytomegalovirus-induced neutropenia.	Ganciclovir	144-155	colony stimulating factor 3	Homo sapiens	99-104
18682998-1	2008	The fed-batch process using glucose as the sole source of carbon and energy with exponential feeding rate was carried out for high cell density cultivation of recombinant Escherichia coli BL21 (DE3) expressing human granulocyte-colony stimulating factor (hG-CSF).	Glucose	28-35	colony stimulating factor 3	Homo sapiens	216-253
18682998-1	2008	The fed-batch process using glucose as the sole source of carbon and energy with exponential feeding rate was carried out for high cell density cultivation of recombinant Escherichia coli BL21 (DE3) expressing human granulocyte-colony stimulating factor (hG-CSF).	Glucose	28-35	colony stimulating factor 3	Homo sapiens	255-261
18682998-1	2008	The fed-batch process using glucose as the sole source of carbon and energy with exponential feeding rate was carried out for high cell density cultivation of recombinant Escherichia coli BL21 (DE3) expressing human granulocyte-colony stimulating factor (hG-CSF).	Carbon	58-64	colony stimulating factor 3	Homo sapiens	216-253
18682998-2	2008	IPTG was used to induce the expression of hG-CSF at 48 g dry cell wt l(-1) during high cell density culture of recombinant E. coli BL21 (DE3) [pET23a-g-csf].	Isopropyl Thiogalactoside	0-4	colony stimulating factor 3	Homo sapiens	42-48
18682998-2	2008	IPTG was used to induce the expression of hG-CSF at 48 g dry cell wt l(-1) during high cell density culture of recombinant E. coli BL21 (DE3) [pET23a-g-csf].	Isopropyl Thiogalactoside	0-4	colony stimulating factor 3	Homo sapiens	150-155
19099627-3	2008	Cell cycle changes of A3 cells treated with different concentrations of G-CSF for 48 hours were examined by propidium iodide staining method.	Propidium	108-124	colony stimulating factor 3	Homo sapiens	72-77
18801020-2	2008	High-dose methotrexate (HD-MTX) is a standard drug for induction of PCNSL; however, data about the capacity of HD-MTX plus granulocyte-colony-stimulating factor (G-CSF) to mobilize hemopoietic progenitors are lacking.	Methotrexate	10-22	colony stimulating factor 3	Homo sapiens	162-167
18801020-2	2008	High-dose methotrexate (HD-MTX) is a standard drug for induction of PCNSL; however, data about the capacity of HD-MTX plus granulocyte-colony-stimulating factor (G-CSF) to mobilize hemopoietic progenitors are lacking.	hd-mtx	24-30	colony stimulating factor 3	Homo sapiens	162-167
18801020-12	2008	CONCLUSION: HD-MTX plus G-CSF is a powerful combination for stem cell mobilization in patients with PCNSL and permits safe conduction of time-condensed and dose-intense protocols with high-dose therapy followed by stem cell reinfusion after HD-MTX induction.	pcnsl	100-105	colony stimulating factor 3	Homo sapiens	24-29
19099627-7	2008	After incubation with Ara-C and G-CSF for 48 hours, A3 cells were inhibited more obviously compared with incubation with Ara-C alone (p&lt;0.05, Ara-C 10(-5) mol/L and 10(-6) mol/L).	Cytarabine	121-126	colony stimulating factor 3	Homo sapiens	32-37
19099627-7	2008	After incubation with Ara-C and G-CSF for 48 hours, A3 cells were inhibited more obviously compared with incubation with Ara-C alone (p&lt;0.05, Ara-C 10(-5) mol/L and 10(-6) mol/L).	Cytarabine	121-126	colony stimulating factor 3	Homo sapiens	32-37
19099627-8	2008	After incubation with Ara-C, ACR and G-CSF for 48 hours, the apoptotic rate of A3 cells was much more than that after incubation with Ara-C and ACR.	Cytarabine	134-139	colony stimulating factor 3	Homo sapiens	37-42
18764868-4	2008	G-CSF increased reactive oxygen species (ROS) production in human CD34(+) cells, which was abrogated by inhibition of phosphatidylinositol 3-kinase (PI3K) or NADPH oxidase.	Reactive Oxygen Species	16-39	colony stimulating factor 3	Homo sapiens	0-5
18764868-4	2008	G-CSF increased reactive oxygen species (ROS) production in human CD34(+) cells, which was abrogated by inhibition of phosphatidylinositol 3-kinase (PI3K) or NADPH oxidase.	Reactive Oxygen Species	41-44	colony stimulating factor 3	Homo sapiens	0-5
18764868-5	2008	Phosphorylation of ERK1/2 mitogen-activated protein kinase (MAPK) induced by G-CSF inhibited by the antioxidant N-acetyl-L-cysteine (NAC), ERK1/2 inhibitor PD98059, or U0126.	2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one	156-163	colony stimulating factor 3	Homo sapiens	77-82
18764868-5	2008	Phosphorylation of ERK1/2 mitogen-activated protein kinase (MAPK) induced by G-CSF inhibited by the antioxidant N-acetyl-L-cysteine (NAC), ERK1/2 inhibitor PD98059, or U0126.	U 0126	168-173	colony stimulating factor 3	Homo sapiens	77-82
18764868-8	2008	Inhibition of ROS or the ERK pathway remarkably decreased G-CSF-induced OLFM4 expression.	Reactive Oxygen Species	14-17	colony stimulating factor 3	Homo sapiens	58-63
18764868-9	2008	Our results suggest that G-CSF-induced expression of OLFM4 is regulated by the transcription factor NF-kappaB, and that this induction is mediated by the ERK1/2 MAPK signaling pathway through PI3K-driven ROS production.	Reactive Oxygen Species	204-207	colony stimulating factor 3	Homo sapiens	25-30
19015070-0	2008	Phase II study of dose-dense doxorubicin and docetaxel as neoadjunvant chemotherapy with G-CSF support in patients with large or locally advanced breast cancer.	Doxorubicin	29-40	colony stimulating factor 3	Homo sapiens	89-94
19015070-0	2008	Phase II study of dose-dense doxorubicin and docetaxel as neoadjunvant chemotherapy with G-CSF support in patients with large or locally advanced breast cancer.	Docetaxel	45-54	colony stimulating factor 3	Homo sapiens	89-94
19015070-12	2008	CONCLUSIONS: The concomitant dose-dense administration of doxorubicin and docetaxel as neoadjuvant chemotherapy with granulocyte colony stimulating factor support is a feasible and effective schedule with a safe toxicity profile for women with large or locally advanced breast cancer.	Doxorubicin	58-69	colony stimulating factor 3	Homo sapiens	117-154
19015070-12	2008	CONCLUSIONS: The concomitant dose-dense administration of doxorubicin and docetaxel as neoadjuvant chemotherapy with granulocyte colony stimulating factor support is a feasible and effective schedule with a safe toxicity profile for women with large or locally advanced breast cancer.	Docetaxel	74-83	colony stimulating factor 3	Homo sapiens	117-154
18653652-7	2008	Tricultures with EAHY926 released more G-CSF, MIP-1alpha, IL-8 and MIP-1beta than the EAHY926 single culture.	eahy926	17-24	colony stimulating factor 3	Homo sapiens	39-44
19106905-8	2008	The erlotinib cohort received significantly less antiemetic treatment (p&lt;0.0001), erythropoietin stimulating agents (p&lt;0.005) and G-CSF (p&lt;0.001).	Erlotinib Hydrochloride	4-13	colony stimulating factor 3	Homo sapiens	136-141
18847313-4	2008	Plerixafor results in the rapid and reversible mobilization of hematopoietic stem cells into the peripheral circulation and is synergistic when combined with G-CSF.	plerixafor	0-10	colony stimulating factor 3	Homo sapiens	158-163
18847313-5	2008	In clinical studies of autologous stem cell transplantation, the combination of plerixafor and G-CSF allows the collection of large numbers of stem cells in fewer apheresis sessions and can salvage those who fail G-CSF mobilization alone.	plerixafor	80-90	colony stimulating factor 3	Homo sapiens	213-218
18697197-4	2008	Treatment of tumor cells with doxorubicin and cisplatin resulted in a substantial increase in the production of IL-6, CXCL8, CCL2, CCL5, BFGF, G-CSF and VEGF.	Doxorubicin	30-41	colony stimulating factor 3	Homo sapiens	143-148
18697197-4	2008	Treatment of tumor cells with doxorubicin and cisplatin resulted in a substantial increase in the production of IL-6, CXCL8, CCL2, CCL5, BFGF, G-CSF and VEGF.	Cisplatin	46-55	colony stimulating factor 3	Homo sapiens	143-148
18697197-6	2008	Treatment of tumor cells with doxorubicin and antibodies neutralizing G-CSF, CCL2 or CCL5 had higher inhibitory effects than each modality used alone.	Doxorubicin	30-41	colony stimulating factor 3	Homo sapiens	70-75
18843642-4	2008	OBJECTIVES: To determine the effectiveness of G-CSF and GM-CSF in patients with malignant lymphoma with respect to preventing neutropenia, febrile neutropenia and infection; improving quality of life, adherence to treatment protocol, tumour response, freedom from treatment failure (FFTF) and overall survival (OS); and adverse effects.	fftf	283-287	colony stimulating factor 3	Homo sapiens	46-51
18719223-8	2008	This first direct comparison of PBSC mobilization in individual primates demonstrates that peg-G-CSF is equivalent to daily G-CSF and that the addition of pegMGDF to G-CSF improves mobilization.	Polyethylene Glycols	91-94	colony stimulating factor 3	Homo sapiens	95-100
18927273-11	2008	Our results clarify and complement the current American Society of Clinical Oncology recommendations for G-CSF administration in neutropenia: High sustained G-CSF levels are needed to treat severe neutropenia and may be achieved by either CG or pegG.	cysteinylglycine	239-241	colony stimulating factor 3	Homo sapiens	105-110
18927273-11	2008	Our results clarify and complement the current American Society of Clinical Oncology recommendations for G-CSF administration in neutropenia: High sustained G-CSF levels are needed to treat severe neutropenia and may be achieved by either CG or pegG.	cysteinylglycine	239-241	colony stimulating factor 3	Homo sapiens	157-162
18927273-11	2008	Our results clarify and complement the current American Society of Clinical Oncology recommendations for G-CSF administration in neutropenia: High sustained G-CSF levels are needed to treat severe neutropenia and may be achieved by either CG or pegG.	pegg	245-249	colony stimulating factor 3	Homo sapiens	105-110
18927273-11	2008	Our results clarify and complement the current American Society of Clinical Oncology recommendations for G-CSF administration in neutropenia: High sustained G-CSF levels are needed to treat severe neutropenia and may be achieved by either CG or pegG.	pegg	245-249	colony stimulating factor 3	Homo sapiens	157-162
18566325-8	2008	Significantly, however, high-fucose antibody induced superior ADCC in blood from granulocyte colony-stimulating factor-primed donors containing higher numbers of activated polymorphonuclear cells.	Fucose	29-35	colony stimulating factor 3	Homo sapiens	81-118
18644434-10	2008	Loss of Y643 also inhibited Gab2-mediated G-CSF-stimulated cell proliferation.	y643	8-12	colony stimulating factor 3	Homo sapiens	42-47
18816097-3	2008	These phosphorylcholine polymers were conjugated to lysozyme as a model protein, as well as two therapeutic proteins, granulocyte colony stimulating factor (G-CSF) and erythropoietin (EPO).	phosphorylcholine polymers	6-32	colony stimulating factor 3	Homo sapiens	118-155
18816097-3	2008	These phosphorylcholine polymers were conjugated to lysozyme as a model protein, as well as two therapeutic proteins, granulocyte colony stimulating factor (G-CSF) and erythropoietin (EPO).	phosphorylcholine polymers	6-32	colony stimulating factor 3	Homo sapiens	157-162
18644619-9	2008	CONCLUSIONS: The combination of paclitaxel, topotecan and carboplatin with G-CSF support appears active with acceptable toxicity in patients with metastatic or recurrent carcinoma of the endometrium.	Paclitaxel	32-42	colony stimulating factor 3	Homo sapiens	75-80
18644619-9	2008	CONCLUSIONS: The combination of paclitaxel, topotecan and carboplatin with G-CSF support appears active with acceptable toxicity in patients with metastatic or recurrent carcinoma of the endometrium.	Carboplatin	58-69	colony stimulating factor 3	Homo sapiens	75-80
18756367-2	2008	We present the (18)F-fluorodeoxyglucose positron emission tomography/computed tomography ((18)F-FDG-PET/CT) imaging findings of two cases of G-CSF-producing tumor.	f-fluorodeoxyglucose	19-39	colony stimulating factor 3	Homo sapiens	141-146
18493867-0	2008	Granulocyte colony stimulating factor increases drug resistance of leukaemic blast cells to daunorubicin.	Daunorubicin	92-104	colony stimulating factor 3	Homo sapiens	0-37
18493867-6	2008	In this study we investigated how G-CSF might influence the sensitivity of leukemic cells to daunorubicin induced cell death using MTT assay, flow cytometry and Western blot analysis.	Daunorubicin	93-105	colony stimulating factor 3	Homo sapiens	34-39
18493867-6	2008	In this study we investigated how G-CSF might influence the sensitivity of leukemic cells to daunorubicin induced cell death using MTT assay, flow cytometry and Western blot analysis.	monooxyethylene trimethylolpropane tristearate	131-134	colony stimulating factor 3	Homo sapiens	34-39
18493867-7	2008	After pretreatment of KG-1 leukaemic cells with G-CSF a moderate increase in the resistance of these cells to daunorubicin could be observed.	Daunorubicin	110-122	colony stimulating factor 3	Homo sapiens	48-53
18493867-9	2008	In addition, adjuvant treatment of AML patients with G-CSF in order to prevent neutropenia, or its use in priming regimens might result resistance to daunorubicin.	Daunorubicin	150-162	colony stimulating factor 3	Homo sapiens	53-58
18727076-10	2008	CONCLUSIONS: Compared with BMS, SES impair in-stent intima hyperplasia after stenting for acute myocardial infarction and transcoronary transplantation of G-CSF mobilized ASC.	ses	32-35	colony stimulating factor 3	Homo sapiens	155-160
18660424-9	2008	Poly(I:C)-induced expression of IL-6, IL-8, G-CSF, MIP-1beta, exotaxin, RANTES, and ICAM-1 was inhibited differentially by the MAPK inhibitors PD98059 and SB203580 and by JNK inhibitor II.	Poly I-C	0-8	colony stimulating factor 3	Homo sapiens	44-49
18660424-9	2008	Poly(I:C)-induced expression of IL-6, IL-8, G-CSF, MIP-1beta, exotaxin, RANTES, and ICAM-1 was inhibited differentially by the MAPK inhibitors PD98059 and SB203580 and by JNK inhibitor II.	2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one	143-150	colony stimulating factor 3	Homo sapiens	44-49
18660424-7	2008	RESULTS: Poly(I:C) induced the up-regulation of TLR3, the release of IL-6, IL-8, G-CSF, MIP-1beta, eotaxin, and RANTES, and the expression of ICAM-1 and VCAM-1 in corneal fibroblasts.	Poly I-C	9-17	colony stimulating factor 3	Homo sapiens	81-86
18305564-0	2008	Successful peripheral blood stem cell mobilization with granulocyte colony-stimulating factor in a patient with chronic myeloid leukemia achieving a complete cytogenetic remission with dasatinib after failing imatinib.	Dasatinib	185-194	colony stimulating factor 3	Homo sapiens	56-93
18305564-0	2008	Successful peripheral blood stem cell mobilization with granulocyte colony-stimulating factor in a patient with chronic myeloid leukemia achieving a complete cytogenetic remission with dasatinib after failing imatinib.	Imatinib Mesylate	209-217	colony stimulating factor 3	Homo sapiens	56-93
18541199-5	2008	In conclusion, Cy can be added to G-CSF for stem cell mobilization to successfully overcome the suppressive effect of prior treatment with lenalidomide.	Cyclophosphamide	15-17	colony stimulating factor 3	Homo sapiens	34-39
18718074-1	2008	This study was aimed to explore the factors impacting on effect of the recombinant human granulocyte colony-stimulating factor (rhG-CSF) in mobilizing and collecting peripheral blood stem/progenitor cells (PBSPC) from healthy donors, and to determine the optimal time for PBSPC harvest.	pbspc	206-211	colony stimulating factor 3	Homo sapiens	89-126
18751412-1	2008	The case of a young man with stage IV chemoresistant pure seminoma overexpressing KIT, who achieved complete remission (CR) after the administration of imatinib mesylate (400 mg once daily), along with a third-line chemotherapy regimen, consisting of paclitaxel (150 mg/m2), oxaliplatin (100 mg/m2) and gemcitabine (800 mg/m2) every 2 weeks with granulocyte colony-stimulating factor (G-CSF) support is reported.	Imatinib Mesylate	152-169	colony stimulating factor 3	Homo sapiens	346-383
18751412-1	2008	The case of a young man with stage IV chemoresistant pure seminoma overexpressing KIT, who achieved complete remission (CR) after the administration of imatinib mesylate (400 mg once daily), along with a third-line chemotherapy regimen, consisting of paclitaxel (150 mg/m2), oxaliplatin (100 mg/m2) and gemcitabine (800 mg/m2) every 2 weeks with granulocyte colony-stimulating factor (G-CSF) support is reported.	Imatinib Mesylate	152-169	colony stimulating factor 3	Homo sapiens	385-390
18246301-0	2008	Two-stage glycerol feeding for enhancement of recombinant hG-CSF production in a fed-batch culture of Pichia pastoris.	Glycerol	10-18	colony stimulating factor 3	Homo sapiens	58-64
18455782-12	2008	CONCLUSIONS: The combination of paclitaxel, epirubicin and carboplatin with G-CSF support appears active in patients with metastatic or recurrent carcinoma of the endometrium.	Paclitaxel	32-42	colony stimulating factor 3	Homo sapiens	76-81
18455782-12	2008	CONCLUSIONS: The combination of paclitaxel, epirubicin and carboplatin with G-CSF support appears active in patients with metastatic or recurrent carcinoma of the endometrium.	Carboplatin	59-70	colony stimulating factor 3	Homo sapiens	76-81
18500358-9	2008	KEY RESULTS: EtP was several-fold more potent than EtOH in reducing adhesion of neutrophils to activated HUVECs, generation of IL-8 or G-CSF and surface expression of the adhesion molecules.	ethyl pyruvate	13-16	colony stimulating factor 3	Homo sapiens	135-140
18525298-6	2008	Capecitabine was administered at 750 mg/m2 twice daily days 2 to 14 in cohort 1 but only on days 2 to 7 from cohort 2 due to early neutropenia and to allow for prophylactic granulocyte colony-stimulating factor (GCSF) support.	Capecitabine	0-12	colony stimulating factor 3	Homo sapiens	173-210
18489990-0	2008	Long-term follow-up of allogeneic hematopoietic stem cell transplantation for de novo acute myelogenous leukemia with a conditioning regimen of total body irradiation and granulocyte colony-stimulating factor-combined high-dose cytarabine.	Cytarabine	228-238	colony stimulating factor 3	Homo sapiens	171-208
18489990-1	2008	We retrospectively evaluated the efficacy and safety of total body irradiation (TBI) and granulocyte colony-stimulating factor (G-CSF)-combined high-dose cytarabine as a conditioning regimen for allogeneic hematopoietic stem cell transplantation (HSCT) in patients with de novo acute myelogenous leukemia (AML).	Cytarabine	154-164	colony stimulating factor 3	Homo sapiens	89-126
18489990-1	2008	We retrospectively evaluated the efficacy and safety of total body irradiation (TBI) and granulocyte colony-stimulating factor (G-CSF)-combined high-dose cytarabine as a conditioning regimen for allogeneic hematopoietic stem cell transplantation (HSCT) in patients with de novo acute myelogenous leukemia (AML).	Cytarabine	154-164	colony stimulating factor 3	Homo sapiens	128-133
18489990-10	2008	These results suggest that G-CSF-combined high-dose cytarabine could be a promising component of the conditioning regimen for allogeneic HSCT for AML, providing a high DFS and low TRM.	Cytarabine	52-62	colony stimulating factor 3	Homo sapiens	27-32
18006110-8	2008	G-CSF support allowed paclitaxel dose-escalation to 250 mg/m(2).	Paclitaxel	22-32	colony stimulating factor 3	Homo sapiens	0-5
18567557-1	2008	BACKGROUND: ESHAP (etoposide/methylprednisolone/cytarabine/cisplatin) plus granulocyte-colony stimulating factor (G-CSF) is an effective regimen of therapy for advanced non-Hodgkin"s lymphoma (NHL) and peripheral blood progenitor cell (PBPC) mobilization.	eshap	12-17	colony stimulating factor 3	Homo sapiens	114-119
18567557-1	2008	BACKGROUND: ESHAP (etoposide/methylprednisolone/cytarabine/cisplatin) plus granulocyte-colony stimulating factor (G-CSF) is an effective regimen of therapy for advanced non-Hodgkin"s lymphoma (NHL) and peripheral blood progenitor cell (PBPC) mobilization.	Etoposide	19-28	colony stimulating factor 3	Homo sapiens	114-119
18528228-0	2008	Methimazole-induced severe febrile neutropenia responding to recombinant human granulocyte colony stimulating factor.	Methimazole	0-11	colony stimulating factor 3	Homo sapiens	79-116
18485949-8	2008	Granulocyte colony stimulating factor treatment resulted in significantly increased proliferation of SK-N-SH, SK-N-AS, and SHSY-5Y cells.	sk-n-sh	101-108	colony stimulating factor 3	Homo sapiens	0-37
18485949-8	2008	Granulocyte colony stimulating factor treatment resulted in significantly increased proliferation of SK-N-SH, SK-N-AS, and SHSY-5Y cells.	sk-n-as	110-117	colony stimulating factor 3	Homo sapiens	0-37
18292211-7	2008	We suggest that cleavage of the C-terminal lysine residue of SDF-1alpha by CPM leads to attenuated chemotactic responses and could facilitate G-CSF-induced mobilization of HSPC from BM to peripheral blood.	Lysine	43-49	colony stimulating factor 3	Homo sapiens	142-147
18248573-1	2008	BACKGROUND: Pegylated filgrastim (PEG-f), a long-lasting granulocyte-colony-stimulating factor, has been used in different hematologic conditions to shorten chemotherapy-induced neutropenia and to mobilize peripheral blood stem cells.	peg-f	34-39	colony stimulating factor 3	Homo sapiens	57-94
18288776-5	2008	The results showed that 2,3-O-sulfate groups are more important than N-sulfate groups in heparin-G-CSF interaction.	Heparin	89-96	colony stimulating factor 3	Homo sapiens	97-102
18394164-7	2008	RESULTS: Here we describe cloning of the human granulocyte colony-stimulating factor coding DNA sequence, protein expression in E. coli BL21(DE3) host cells in the absence of isopropyl-beta-D-thiogalactopyranoside (IPTG) induction, efficient isolation and solubilization of inclusion bodies by a multi-step washing procedure, and a purification protocol using a single cationic exchange column.	Isopropyl Thiogalactoside	175-213	colony stimulating factor 3	Homo sapiens	47-84
18394164-7	2008	RESULTS: Here we describe cloning of the human granulocyte colony-stimulating factor coding DNA sequence, protein expression in E. coli BL21(DE3) host cells in the absence of isopropyl-beta-D-thiogalactopyranoside (IPTG) induction, efficient isolation and solubilization of inclusion bodies by a multi-step washing procedure, and a purification protocol using a single cationic exchange column.	Isopropyl Thiogalactoside	215-219	colony stimulating factor 3	Homo sapiens	47-84
18342786-12	2008	Treatment with G-CSF, amphotericin B, and a high nucleated cell count of the graft predisposed for the development of ES in this study.	Einsteinium	118-120	colony stimulating factor 3	Homo sapiens	15-20
18412800-0	2008	Granulocyte-colony stimulating factor for the treatment of ritodrine-induced neutropenia.	Ritodrine	59-68	colony stimulating factor 3	Homo sapiens	0-37
18412800-1	2008	We report on three pregnant women with ritodrine-induced neutropenia who were successfully treated with granulocyte-colony stimulating factor (G-CSF).	Ritodrine	39-48	colony stimulating factor 3	Homo sapiens	104-141
18412800-1	2008	We report on three pregnant women with ritodrine-induced neutropenia who were successfully treated with granulocyte-colony stimulating factor (G-CSF).	Ritodrine	39-48	colony stimulating factor 3	Homo sapiens	143-148
18412800-6	2008	G-CSF is one possible treatment in women with ritodrine-induced neutropenia.	Ritodrine	46-55	colony stimulating factor 3	Homo sapiens	0-5
18288776-0	2008	Further characterization of the binding of heparin to granulocyte colony-stimulating factor: importance of sulfate groups.	Heparin	43-50	colony stimulating factor 3	Homo sapiens	54-91
18288776-2	2008	Previously, we have shown that standard heparin binds to granulocyte colony-stimulating factor (G-CSF) with an affinity of 4.8 x 10(5) M(-1).	Heparin	40-47	colony stimulating factor 3	Homo sapiens	57-94
18288776-2	2008	Previously, we have shown that standard heparin binds to granulocyte colony-stimulating factor (G-CSF) with an affinity of 4.8 x 10(5) M(-1).	Heparin	40-47	colony stimulating factor 3	Homo sapiens	96-101
18288776-3	2008	To further study the structural features in heparin that are responsible for this interaction, we studied the bindings of G-CSF and N-desulfated and 2,3-O-desulfated heparin by CZE.	Heparin	44-51	colony stimulating factor 3	Homo sapiens	122-127
18288776-4	2008	Results showed that the N-desulfated heparin had a similar affinity for G-CSF ((5.4 +/- 0.9) x 10(5) M(-1)), but the 2,3-O-desulfated heparin had a 1000-fold lower affinity ((3.4 +/- 1.2) x 10(2) M(-1)) in comparison to standard heparin.	Nitrogen	24-25	colony stimulating factor 3	Homo sapiens	72-77
18614436-7	2008	RESULTS: It has been found that G-CSF affects the activity of granulocyte enzymes by the normalization of decreased values of myeloperoxidase, acid phosphate and increasing the normal values of alkaline phosphate activity.	acid phosphate	143-157	colony stimulating factor 3	Homo sapiens	32-37
18288776-4	2008	Results showed that the N-desulfated heparin had a similar affinity for G-CSF ((5.4 +/- 0.9) x 10(5) M(-1)), but the 2,3-O-desulfated heparin had a 1000-fold lower affinity ((3.4 +/- 1.2) x 10(2) M(-1)) in comparison to standard heparin.	Heparin	37-44	colony stimulating factor 3	Homo sapiens	72-77
18288776-5	2008	The results showed that 2,3-O-sulfate groups are more important than N-sulfate groups in heparin-G-CSF interaction.	2,3-o-sulfate	24-37	colony stimulating factor 3	Homo sapiens	97-102
18288776-5	2008	The results showed that 2,3-O-sulfate groups are more important than N-sulfate groups in heparin-G-CSF interaction.	n-sulfate	69-78	colony stimulating factor 3	Homo sapiens	97-102
17918772-0	2008	Continuous drip infusion of low dose cytarabine and etoposide with granulocyte colony-stimulating factor for elderly patients with acute myeloid leukaemia ineligible for intensive chemotherapy.	Etoposide	52-61	colony stimulating factor 3	Homo sapiens	67-104
18067473-0	2008	Should prophylactic granulocyte-colony stimulating factor be used in multiple myeloma patients developing neutropenia under lenalidomide-based therapy?	Lenalidomide	124-136	colony stimulating factor 3	Homo sapiens	20-57
18202020-5	2008	The z-guggulsterone-mediated inhibition of angiogenesis in vitro correlated with the suppression of secretion of proangiogenic growth factors [e.g., vascular endothelial growth factor (VEGF) and granulocyte colony-stimulating factor], down-regulation of VEGF receptor 2 (VEGF-R2) protein level, and inactivation of Akt.	pregna-4,17-diene-3,16-dione	4-19	colony stimulating factor 3	Homo sapiens	195-233
17906298-0	2008	Gemtuzumab ozogamicin, cytosine arabinoside, G-CSF combination (G-AraMy) in the treatment of elderly patients with poor-prognosis acute myeloid leukemia.	g-aramy	64-71	colony stimulating factor 3	Homo sapiens	45-50
18328147-4	2008	When challenged with granulocyte colony-stimulating factor (G-CSF), granulocyte-macrophage CSF (GM-CSF) or tumor necrosis factor alpha (TNF-alpha), RA neutrophils exhibited reduced responses to these cytokines, which included O2- release, adherence, priming for enhanced O2- release, and phosphorylation of ERK and p38.	Superoxides	271-273	colony stimulating factor 3	Homo sapiens	21-58
18608354-9	2008	Significantly higher LY-C was obtained with G-CSF alone compared with the LD-CY and ID-CY groups.	ly-c	21-25	colony stimulating factor 3	Homo sapiens	44-49
18328147-4	2008	When challenged with granulocyte colony-stimulating factor (G-CSF), granulocyte-macrophage CSF (GM-CSF) or tumor necrosis factor alpha (TNF-alpha), RA neutrophils exhibited reduced responses to these cytokines, which included O2- release, adherence, priming for enhanced O2- release, and phosphorylation of ERK and p38.	Superoxides	226-228	colony stimulating factor 3	Homo sapiens	21-58
17965029-6	2008	A significant inhibitory effect of besifloxacin was observed at 0.1 mg/L for IL-1alpha, at 1 mg/L for G-CSF, IL-1ra and IL-6 and at 30 mg/L for GM-CSF, IL-12p40, IL-1beta, IL-8, IP-10, MCP-1 and MIP-1alpha.	besifloxacin	35-47	colony stimulating factor 3	Homo sapiens	102-107
18284718-4	2007	Therefore, prophylactic use of granulocyte colony-stimulating factor (G-CSF) is widely used to support these regimens and is mandatory to support BEACOPP-escalated and BEACOPP-14 to reduce toxicity and treatment delays.	beacopp-14	168-178	colony stimulating factor 3	Homo sapiens	31-68
18923646-9	2008	Mutations that disrupt G-CSFR ubiquitination at lysine 762 induce aberrant receptor signaling and hyperproliferative responses to G-CSF, which may contribute to leukemic transformation.	Lysine	48-54	colony stimulating factor 3	Homo sapiens	23-28
18569986-0	2008	Recombinant human granulocyte colony-stimulating factor reduces colonic epithelial cell apoptosis and ameliorates murine dextran sulfate sodium-induced colitis.	Dextran Sulfate	121-143	colony stimulating factor 3	Homo sapiens	18-55
17634960-3	2007	In this work, recombinant human granulocyte colony-stimulating factor (rhG-CSF) expressed in Escherichia coli was renatured with simultaneous purification by ion exchange chromatography (IEC) with a Q Sepharose FF column.	Sepharose	201-210	colony stimulating factor 3	Homo sapiens	32-69
18284718-4	2007	Therefore, prophylactic use of granulocyte colony-stimulating factor (G-CSF) is widely used to support these regimens and is mandatory to support BEACOPP-escalated and BEACOPP-14 to reduce toxicity and treatment delays.	beacopp-14	168-178	colony stimulating factor 3	Homo sapiens	70-75
18055984-2	2007	As(2)O(3), Phenylbutyrate (PB) and G-CSF are known to potentiate ATRA effects.	Tretinoin	65-69	colony stimulating factor 3	Homo sapiens	35-40
18004146-0	2007	Clozapine and granulocyte colony-stimulating factor: potential for long-term combination treatment for clozapine-induced neutropenia.	Clozapine	103-112	colony stimulating factor 3	Homo sapiens	14-51
17275936-4	2007	We report on three cases of late stent thrombosis in a cohort of 24 patients who had undergone intracoronary infusion of G-CSF-mobilized ASC after primary stenting for acute myocardial infarction.	asc	137-140	colony stimulating factor 3	Homo sapiens	121-126
17941684-2	2007	In particular, thiol-reactive PEGs have been coupled to the cysteine 17 of granulocyte colony stimulating factor (G-CSF), which is known to be partially buried in a hydrophobic protein pocket.	Sulfhydryl Compounds	15-20	colony stimulating factor 3	Homo sapiens	75-112
17941684-2	2007	In particular, thiol-reactive PEGs have been coupled to the cysteine 17 of granulocyte colony stimulating factor (G-CSF), which is known to be partially buried in a hydrophobic protein pocket.	Cysteine	60-68	colony stimulating factor 3	Homo sapiens	114-119
17923867-0	2007	Intensified dose of cyclophosphamide with G-CSF support versus standard dose combined with platinum in first-line treatment of advanced ovarian cancer a randomised study from the GINECO group.	Cyclophosphamide	20-36	colony stimulating factor 3	Homo sapiens	42-47
17941684-2	2007	In particular, thiol-reactive PEGs have been coupled to the cysteine 17 of granulocyte colony stimulating factor (G-CSF), which is known to be partially buried in a hydrophobic protein pocket.	Sulfhydryl Compounds	15-20	colony stimulating factor 3	Homo sapiens	114-119
17941684-7	2007	The secondary structure of the protein in the G-CSF-PEG conjugates, evaluated using circular dichroism and biological activity assay in cell culture, was maintained with respect to the native protein.	Polyethylene Glycols	52-55	colony stimulating factor 3	Homo sapiens	46-51
17941684-2	2007	In particular, thiol-reactive PEGs have been coupled to the cysteine 17 of granulocyte colony stimulating factor (G-CSF), which is known to be partially buried in a hydrophobic protein pocket.	Polyethylene Glycols	30-34	colony stimulating factor 3	Homo sapiens	75-112
17941684-2	2007	In particular, thiol-reactive PEGs have been coupled to the cysteine 17 of granulocyte colony stimulating factor (G-CSF), which is known to be partially buried in a hydrophobic protein pocket.	Polyethylene Glycols	30-34	colony stimulating factor 3	Homo sapiens	114-119
17941684-2	2007	In particular, thiol-reactive PEGs have been coupled to the cysteine 17 of granulocyte colony stimulating factor (G-CSF), which is known to be partially buried in a hydrophobic protein pocket.	Cysteine	60-68	colony stimulating factor 3	Homo sapiens	75-112
17970641-2	2007	Present agents used for the treatment of neutropenia include G-CSF, GM-CSF and G-CSF conjugated to polyethylene glycol (PEG) as pegylated G-CSF.	Polyethylene Glycols	99-118	colony stimulating factor 3	Homo sapiens	79-84
17970641-2	2007	Present agents used for the treatment of neutropenia include G-CSF, GM-CSF and G-CSF conjugated to polyethylene glycol (PEG) as pegylated G-CSF.	Polyethylene Glycols	99-118	colony stimulating factor 3	Homo sapiens	79-84
17970641-2	2007	Present agents used for the treatment of neutropenia include G-CSF, GM-CSF and G-CSF conjugated to polyethylene glycol (PEG) as pegylated G-CSF.	Polyethylene Glycols	120-123	colony stimulating factor 3	Homo sapiens	79-84
17970641-2	2007	Present agents used for the treatment of neutropenia include G-CSF, GM-CSF and G-CSF conjugated to polyethylene glycol (PEG) as pegylated G-CSF.	Polyethylene Glycols	120-123	colony stimulating factor 3	Homo sapiens	79-84
17581613-4	2007	Among those mobilized with granulocyte-colony stimulating factor (G-CSF) alone, there was a significant decrease in total CD34(+) cells collected (P&lt;0.001), average daily collection (P&lt;0.001), day 1 collection (P&lt;0.001) and increased number of aphereses (P=0.004) in patients treated with lenalidomide compared to those receiving dexamethasone, thalidomide-dexamethasone or VAD.	Lenalidomide	298-310	colony stimulating factor 3	Homo sapiens	27-64
17716984-0	2007	A dose escalation trial of adjuvant cyclophosphamide and epirubicin in combination with 5-fluorouracil using G-CSF support for premenopausal women with breast cancer involving four or more positive nodes.	Fluorouracil	88-102	colony stimulating factor 3	Homo sapiens	109-114
17716984-8	2007	CONCLUSION: A dose-intense and dose-dense regimen of cyclophosphamide, epirubicin and 5-fluorouracil was delivered with G-CSF without apparent increase in acute toxicity.	Cyclophosphamide	53-69	colony stimulating factor 3	Homo sapiens	120-125
17716984-8	2007	CONCLUSION: A dose-intense and dose-dense regimen of cyclophosphamide, epirubicin and 5-fluorouracil was delivered with G-CSF without apparent increase in acute toxicity.	Epirubicin	71-81	colony stimulating factor 3	Homo sapiens	120-125
17716984-8	2007	CONCLUSION: A dose-intense and dose-dense regimen of cyclophosphamide, epirubicin and 5-fluorouracil was delivered with G-CSF without apparent increase in acute toxicity.	Fluorouracil	86-100	colony stimulating factor 3	Homo sapiens	120-125
17692581-4	2007	Recombinant human granulocyte colony stimulating-factor or vehicle was given daily after intoxication (4 days) or before (7 days) and after carbon tetrachloride administration.	Carbon Tetrachloride	140-160	colony stimulating factor 3	Homo sapiens	18-55
17390342-1	2007	We have recently provided evidence that transplantation of G-CSF mobilized peripheral blood mononuclear cells (M-PBMNCs) improves limb ischemia in diabetic patients.	m-pbmncs	111-119	colony stimulating factor 3	Homo sapiens	59-64
17927614-1	2007	Many patients with chronic hepatitis C (HCV) infection undergoing treatment with pegylated interferon-alpha (PEG-IFN-alpha) and ribavirin develop neutropenia requiring dose reduction or granulocyte colony-stimulating factor (G-CSF) supplement.	Ribavirin	128-137	colony stimulating factor 3	Homo sapiens	186-223
17927614-1	2007	Many patients with chronic hepatitis C (HCV) infection undergoing treatment with pegylated interferon-alpha (PEG-IFN-alpha) and ribavirin develop neutropenia requiring dose reduction or granulocyte colony-stimulating factor (G-CSF) supplement.	Ribavirin	128-137	colony stimulating factor 3	Homo sapiens	225-230
17616642-0	2007	G-CSF mobilizes slanDCs (6-sulfo LacNAc+ dendritic cells) with a high proinflammatory capacity.	6-sulfo-LacNac	25-39	colony stimulating factor 3	Homo sapiens	0-5
17616642-4	2007	Here, we demonstrate that slanDCs (14.9 x 10(6)/L to 64.0 x 10(6)/L) are efficiently mobilized by G-CSF and retain their capacity to produce IL-12 and TNF-alpha at high levels.	slandcs	26-33	colony stimulating factor 3	Homo sapiens	98-103
17526862-7	2007	Further follow-up is required to elucidate the role of G-CSF in immunosuppressive therapy for adult SAA.	saa	100-103	colony stimulating factor 3	Homo sapiens	55-60
17581613-4	2007	Among those mobilized with granulocyte-colony stimulating factor (G-CSF) alone, there was a significant decrease in total CD34(+) cells collected (P&lt;0.001), average daily collection (P&lt;0.001), day 1 collection (P&lt;0.001) and increased number of aphereses (P=0.004) in patients treated with lenalidomide compared to those receiving dexamethasone, thalidomide-dexamethasone or VAD.	VAD I protocol	383-386	colony stimulating factor 3	Homo sapiens	27-64
17581613-4	2007	Among those mobilized with granulocyte-colony stimulating factor (G-CSF) alone, there was a significant decrease in total CD34(+) cells collected (P&lt;0.001), average daily collection (P&lt;0.001), day 1 collection (P&lt;0.001) and increased number of aphereses (P=0.004) in patients treated with lenalidomide compared to those receiving dexamethasone, thalidomide-dexamethasone or VAD.	VAD I protocol	383-386	colony stimulating factor 3	Homo sapiens	66-71
17581613-4	2007	Among those mobilized with granulocyte-colony stimulating factor (G-CSF) alone, there was a significant decrease in total CD34(+) cells collected (P&lt;0.001), average daily collection (P&lt;0.001), day 1 collection (P&lt;0.001) and increased number of aphereses (P=0.004) in patients treated with lenalidomide compared to those receiving dexamethasone, thalidomide-dexamethasone or VAD.	Lenalidomide	298-310	colony stimulating factor 3	Homo sapiens	66-71
17581613-4	2007	Among those mobilized with granulocyte-colony stimulating factor (G-CSF) alone, there was a significant decrease in total CD34(+) cells collected (P&lt;0.001), average daily collection (P&lt;0.001), day 1 collection (P&lt;0.001) and increased number of aphereses (P=0.004) in patients treated with lenalidomide compared to those receiving dexamethasone, thalidomide-dexamethasone or VAD.	Dexamethasone	339-352	colony stimulating factor 3	Homo sapiens	27-64
17581613-4	2007	Among those mobilized with granulocyte-colony stimulating factor (G-CSF) alone, there was a significant decrease in total CD34(+) cells collected (P&lt;0.001), average daily collection (P&lt;0.001), day 1 collection (P&lt;0.001) and increased number of aphereses (P=0.004) in patients treated with lenalidomide compared to those receiving dexamethasone, thalidomide-dexamethasone or VAD.	Dexamethasone	339-352	colony stimulating factor 3	Homo sapiens	66-71
17581613-4	2007	Among those mobilized with granulocyte-colony stimulating factor (G-CSF) alone, there was a significant decrease in total CD34(+) cells collected (P&lt;0.001), average daily collection (P&lt;0.001), day 1 collection (P&lt;0.001) and increased number of aphereses (P=0.004) in patients treated with lenalidomide compared to those receiving dexamethasone, thalidomide-dexamethasone or VAD.	Thalidomide	354-365	colony stimulating factor 3	Homo sapiens	27-64
17581613-4	2007	Among those mobilized with granulocyte-colony stimulating factor (G-CSF) alone, there was a significant decrease in total CD34(+) cells collected (P&lt;0.001), average daily collection (P&lt;0.001), day 1 collection (P&lt;0.001) and increased number of aphereses (P=0.004) in patients treated with lenalidomide compared to those receiving dexamethasone, thalidomide-dexamethasone or VAD.	Thalidomide	354-365	colony stimulating factor 3	Homo sapiens	66-71
17581613-4	2007	Among those mobilized with granulocyte-colony stimulating factor (G-CSF) alone, there was a significant decrease in total CD34(+) cells collected (P&lt;0.001), average daily collection (P&lt;0.001), day 1 collection (P&lt;0.001) and increased number of aphereses (P=0.004) in patients treated with lenalidomide compared to those receiving dexamethasone, thalidomide-dexamethasone or VAD.	Dexamethasone	366-379	colony stimulating factor 3	Homo sapiens	27-64
17581613-4	2007	Among those mobilized with granulocyte-colony stimulating factor (G-CSF) alone, there was a significant decrease in total CD34(+) cells collected (P&lt;0.001), average daily collection (P&lt;0.001), day 1 collection (P&lt;0.001) and increased number of aphereses (P=0.004) in patients treated with lenalidomide compared to those receiving dexamethasone, thalidomide-dexamethasone or VAD.	Dexamethasone	366-379	colony stimulating factor 3	Homo sapiens	66-71
17473057-0	2007	5-Androstenediol promotes survival of gamma-irradiated human hematopoietic progenitors through induction of nuclear factor-kappaB activation and granulocyte colony-stimulating factor expression.	Androstenediol	0-16	colony stimulating factor 3	Homo sapiens	145-182
17599307-3	2007	METHODS: In this randomized, placebo-controlled trial, we assessed the efficacy of lenograstim (granulocyte colony-stimulating factor [G-CSF], 263 mu g per day administered intravenously) in ceftazidime-treated patients with severe sepsis caused by suspected melioidosis in Thailand.	Ceftazidime	191-202	colony stimulating factor 3	Homo sapiens	96-133
17855189-8	2007	Peripheral neuropathy, mostly grades 1 and 2, was reported in 29 patients (76.3%), which was seen more frequently in patients &gt;70 years of age (P=0.048).We conclude that the biweekly administration of a docetaxel/gemcitabine combination with G-CSF support constitutes a tolerable and convenient regimen for the treatment of elderly patients with advanced NSCLC, with efficacy similar to that reported in other regimens.	Docetaxel	206-215	colony stimulating factor 3	Homo sapiens	245-250
17473057-7	2007	The survival-enhancing effects of 5-AED on clonogenic cells were abrogated by small interfering RNA inhibition of NFkappaB gene expression and by neutralization of G-CSF with antibody.	Androstenediol	34-39	colony stimulating factor 3	Homo sapiens	164-169
17473057-8	2007	The effects of 5-AED on survival and G-CSF secretion were blocked by the NFkappaB inhibitor N-benzoyloxycarbonyl (Z)-Leu-Leu-leucinal (MG132).	Androstenediol	15-20	colony stimulating factor 3	Homo sapiens	37-42
17473057-8	2007	The effects of 5-AED on survival and G-CSF secretion were blocked by the NFkappaB inhibitor N-benzoyloxycarbonyl (Z)-Leu-Leu-leucinal (MG132).	benzyloxycarbonylleucyl-leucyl-leucine aldehyde	135-140	colony stimulating factor 3	Homo sapiens	37-42
17110459-1	2007	Previous studies suggested a link between the use of G-CSF and increased incidence of myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) after immunosuppressive therapy (IST) for severe aplastic anemia (SAA).	saa	216-219	colony stimulating factor 3	Homo sapiens	53-58
17762397-0	2007	Weekly epirubicin and paclitaxel with granulocyte colony-stimulating factor support in previously untreated metastatic breast cancer patients: a phase II study.	Paclitaxel	22-32	colony stimulating factor 3	Homo sapiens	38-75
17762397-15	2007	In untreated metastatic breast cancer patients, the weekly administration of epirubicin and paclitaxel with granulocyte colony-stimulating factor support seems to be extremely tolerable and active, and deserves further investigation into a phase III trial.	Epirubicin	77-87	colony stimulating factor 3	Homo sapiens	108-145
17762397-15	2007	In untreated metastatic breast cancer patients, the weekly administration of epirubicin and paclitaxel with granulocyte colony-stimulating factor support seems to be extremely tolerable and active, and deserves further investigation into a phase III trial.	Paclitaxel	92-102	colony stimulating factor 3	Homo sapiens	108-145
17631178-4	2007	The main indication for using HGFs, most often granulocyte colony-stimulating factor (G-CSF), in SAA has been to determine whether they increase the response rate to immunosuppressive therapy (IST) and improve survival.	saa	97-100	colony stimulating factor 3	Homo sapiens	47-84
17631178-4	2007	The main indication for using HGFs, most often granulocyte colony-stimulating factor (G-CSF), in SAA has been to determine whether they increase the response rate to immunosuppressive therapy (IST) and improve survival.	saa	97-100	colony stimulating factor 3	Homo sapiens	86-91
17339136-0	2007	Effect of surface histidine mutations and their number on the partitioning and refolding of recombinant human granulocyte-colony stimulating factor (Cys17Ser) in aqueous two-phase systems containing chelated metal ions.	Histidine	18-27	colony stimulating factor 3	Homo sapiens	110-147
17339136-0	2007	Effect of surface histidine mutations and their number on the partitioning and refolding of recombinant human granulocyte-colony stimulating factor (Cys17Ser) in aqueous two-phase systems containing chelated metal ions.	Metals	208-213	colony stimulating factor 3	Homo sapiens	110-147
17339136-4	2007	In this work, the effect of surface histidine mutations and their number on the partitioning and refolding of recombinant human granulocyte-colony stimulating factor Cys17Ser variant (rhG-CSF (C17S)) from solubilized inclusion bodies in aqueous two-phase systems polyethylene glycol (PEG)-dextran, containing metal ions, chelated by dye Light Resistant Yellow 2KT (LR Yellow 2KT)-PEG derivative, was investigated.	Histidine	36-45	colony stimulating factor 3	Homo sapiens	128-165
17339136-4	2007	In this work, the effect of surface histidine mutations and their number on the partitioning and refolding of recombinant human granulocyte-colony stimulating factor Cys17Ser variant (rhG-CSF (C17S)) from solubilized inclusion bodies in aqueous two-phase systems polyethylene glycol (PEG)-dextran, containing metal ions, chelated by dye Light Resistant Yellow 2KT (LR Yellow 2KT)-PEG derivative, was investigated.	Polyethylene Glycols	263-282	colony stimulating factor 3	Homo sapiens	128-165
17339136-4	2007	In this work, the effect of surface histidine mutations and their number on the partitioning and refolding of recombinant human granulocyte-colony stimulating factor Cys17Ser variant (rhG-CSF (C17S)) from solubilized inclusion bodies in aqueous two-phase systems polyethylene glycol (PEG)-dextran, containing metal ions, chelated by dye Light Resistant Yellow 2KT (LR Yellow 2KT)-PEG derivative, was investigated.	Polyethylene Glycols	284-287	colony stimulating factor 3	Homo sapiens	128-165
17339136-4	2007	In this work, the effect of surface histidine mutations and their number on the partitioning and refolding of recombinant human granulocyte-colony stimulating factor Cys17Ser variant (rhG-CSF (C17S)) from solubilized inclusion bodies in aqueous two-phase systems polyethylene glycol (PEG)-dextran, containing metal ions, chelated by dye Light Resistant Yellow 2KT (LR Yellow 2KT)-PEG derivative, was investigated.	Dextrans	289-296	colony stimulating factor 3	Homo sapiens	128-165
17339136-4	2007	In this work, the effect of surface histidine mutations and their number on the partitioning and refolding of recombinant human granulocyte-colony stimulating factor Cys17Ser variant (rhG-CSF (C17S)) from solubilized inclusion bodies in aqueous two-phase systems polyethylene glycol (PEG)-dextran, containing metal ions, chelated by dye Light Resistant Yellow 2KT (LR Yellow 2KT)-PEG derivative, was investigated.	Metals	309-314	colony stimulating factor 3	Homo sapiens	128-165
17339136-4	2007	In this work, the effect of surface histidine mutations and their number on the partitioning and refolding of recombinant human granulocyte-colony stimulating factor Cys17Ser variant (rhG-CSF (C17S)) from solubilized inclusion bodies in aqueous two-phase systems polyethylene glycol (PEG)-dextran, containing metal ions, chelated by dye Light Resistant Yellow 2KT (LR Yellow 2KT)-PEG derivative, was investigated.	Polyethylene Glycols	380-383	colony stimulating factor 3	Homo sapiens	128-165
17442993-10	2007	CONCLUSION: The recommended phase II dose of G3139 is 7 mg/kg/d as a 7-day continuous infusion, with cyclophosphamide 500 mg/m2/d and doxorubicin 30 mg/m2/d on days 5 and 6, followed by GCSF.	oblimersen	45-50	colony stimulating factor 3	Homo sapiens	186-190
17363902-4	2007	Here, we show that a juxtamembrane lysine residue (K632) of the granulocyte colony-stimulating factor receptor (G-CSFR) plays a key role in receptor routing and demonstrate that the effects of SOCS3 on G-CSF signaling to a major extent depend on this lysine.	Lysine	35-41	colony stimulating factor 3	Homo sapiens	112-117
17363902-4	2007	Here, we show that a juxtamembrane lysine residue (K632) of the granulocyte colony-stimulating factor receptor (G-CSFR) plays a key role in receptor routing and demonstrate that the effects of SOCS3 on G-CSF signaling to a major extent depend on this lysine.	k632	51-55	colony stimulating factor 3	Homo sapiens	112-117
17363902-4	2007	Here, we show that a juxtamembrane lysine residue (K632) of the granulocyte colony-stimulating factor receptor (G-CSFR) plays a key role in receptor routing and demonstrate that the effects of SOCS3 on G-CSF signaling to a major extent depend on this lysine.	Lysine	251-257	colony stimulating factor 3	Homo sapiens	112-117
17703736-7	2007	Combination of ATRA, G-CSF and each agent alone, particularly harmaline in optimal dose, resulted in partially additive decrease in cell proliferation.	Harmaline	62-71	colony stimulating factor 3	Homo sapiens	21-26
17593093-7	2007	However, when the 46 patients who underwent systemic M-VAC chemotherapy were investigated, significantly more severe toxicity in leukocytopenia (P = 0.044, odds ratio +infinity, 95% confidence interval 0.9203- +infinity) and a prolonged duration of G-CSF administration (P = 0.013, odds ratio 8.625, 95% confidence interval 1.390-89.98) were observed in patients with the Val allele in comparison to those with the Ile allele.	M-VAC protocol	53-58	colony stimulating factor 3	Homo sapiens	249-254
17334414-3	2007	Here, we show that a single injection of doxorubicin (DOX, 15 mg/kg) induced left ventricular dilatation and dysfunction in mice within 2 weeks, and that these effects were significantly attenuated by human recombinant G-CSF (100 microg/kg/day for 5 days).	Doxorubicin	41-52	colony stimulating factor 3	Homo sapiens	219-224
17334414-3	2007	Here, we show that a single injection of doxorubicin (DOX, 15 mg/kg) induced left ventricular dilatation and dysfunction in mice within 2 weeks, and that these effects were significantly attenuated by human recombinant G-CSF (100 microg/kg/day for 5 days).	Doxorubicin	54-57	colony stimulating factor 3	Homo sapiens	219-224
18214317-2	2007	Treatment with dimethylsulfoxide reduced the content of stromal clonogenic elements in the bone marrow and inhibited mobilization of mesenchymal precursors induced by granulocyte colony-stimulating factor.	Dimethyl Sulfoxide	15-32	colony stimulating factor 3	Homo sapiens	167-204
17284714-8	2007	Use of G-CSF and GM-CSF was associated with more recent diagnosis, younger age, urban residence, fewer comorbidities, receipt of radiation therapy, positive lymph nodes, and cyclophosphamide treatment.	Cyclophosphamide	174-190	colony stimulating factor 3	Homo sapiens	7-12
17454786-4	2007	G-CSF and GM-CSF increased the proliferation and colony-forming ability of K562 cells and protected the cells from busulfan effects.	Busulfan	115-123	colony stimulating factor 3	Homo sapiens	0-5
17454786-6	2007	In the cell line K562, the growth factors G-CSF and GM-CSF protected the cells from the non-cell-cycle-specific alkylating agent busulfan, whereas IFN-alpha demonstrated an additive cytotoxic effect.	Busulfan	129-137	colony stimulating factor 3	Homo sapiens	42-47
17228364-4	2007	In vitro exposure of HPMCs to IL-17A resulted in a time- and dose-dependent release of G-CSF.	hpmcs	21-26	colony stimulating factor 3	Homo sapiens	87-92
17311330-6	2007	IL-6, MIP-1alpha, and G-CSF were negatively correlated with O2 saturation during RSV infection.	Oxygen	60-62	colony stimulating factor 3	Homo sapiens	22-27
17341901-2	2007	CASE REPORT: A 62-year old patient was diagnosed with a diffuse large B-cell lymphoma and treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone under prophylactic G-CSF substitution.	Prednisone	162-172	colony stimulating factor 3	Homo sapiens	192-197
17557562-0	2007	Utility of the clinical practice of administering thrombophilic screening and antithrombotic prophylaxis with low-molecular-weight heparin to healthy donors treated with G-CSF for mobilization of peripheral blood stem cells.	Heparin	131-138	colony stimulating factor 3	Homo sapiens	170-175
17453364-2	2007	A toxicity-based dosing schedule for individually tailored treatment with granulocyte colony-stimulating factor (G-CSF) supported 5-fluorouracil (F), epirubicin (E) and cyclophosphamide (C) (dFEC) was developed and studied in patients with metastatic breast cancer with the purpose to determine its efficiency and toxicity.	Fluorouracil	130-144	colony stimulating factor 3	Homo sapiens	74-111
17220902-0	2007	Total body irradiation and granulocyte colony-stimulating factor-combined high-dose cytarabine as a conditioning regimen in allogeneic hematopoietic stem cell transplantation for advanced myelodysplastic syndrome: a single-institute experience.	Cytarabine	84-94	colony stimulating factor 3	Homo sapiens	27-64
17220902-1	2007	In this study, we retrospectively evaluated the efficacy and safety of total body irradiation (TBI) and granulocyte colony-stimulating factor (G-CSF)-combined high-dose cytarabine as a conditioning regimen for allogeneic hematopoietic stem cell transplantation (HSCT) in patients with advanced myelodysplastic syndrome (MDS).	Cytarabine	169-179	colony stimulating factor 3	Homo sapiens	104-141
17220902-1	2007	In this study, we retrospectively evaluated the efficacy and safety of total body irradiation (TBI) and granulocyte colony-stimulating factor (G-CSF)-combined high-dose cytarabine as a conditioning regimen for allogeneic hematopoietic stem cell transplantation (HSCT) in patients with advanced myelodysplastic syndrome (MDS).	Cytarabine	169-179	colony stimulating factor 3	Homo sapiens	143-148
17220902-8	2007	These results suggest that G-CSF-combined high-dose cytarabine could be a promising component of the conditioning regimen of allogeneic HSCT for advanced MDS, providing a low incidence of both relapse and treatment-related mortality.	Cytarabine	52-62	colony stimulating factor 3	Homo sapiens	27-32
17453364-2	2007	A toxicity-based dosing schedule for individually tailored treatment with granulocyte colony-stimulating factor (G-CSF) supported 5-fluorouracil (F), epirubicin (E) and cyclophosphamide (C) (dFEC) was developed and studied in patients with metastatic breast cancer with the purpose to determine its efficiency and toxicity.	Fluorouracil	130-144	colony stimulating factor 3	Homo sapiens	113-118
17453364-2	2007	A toxicity-based dosing schedule for individually tailored treatment with granulocyte colony-stimulating factor (G-CSF) supported 5-fluorouracil (F), epirubicin (E) and cyclophosphamide (C) (dFEC) was developed and studied in patients with metastatic breast cancer with the purpose to determine its efficiency and toxicity.	Epirubicin	150-160	colony stimulating factor 3	Homo sapiens	113-118
18217407-9	2007	RESULTS: It was found that granulocyte-colony stimulating factor activates phagocytic functions of neutrophils by normalizing low values of phagocytic index and number of granulocytes, reducing dye nitroblue tetrazolium reduction and increasing the number of phagocytic cells.	Nitroblue Tetrazolium	198-219	colony stimulating factor 3	Homo sapiens	27-64
17453364-2	2007	A toxicity-based dosing schedule for individually tailored treatment with granulocyte colony-stimulating factor (G-CSF) supported 5-fluorouracil (F), epirubicin (E) and cyclophosphamide (C) (dFEC) was developed and studied in patients with metastatic breast cancer with the purpose to determine its efficiency and toxicity.	Cyclophosphamide	169-185	colony stimulating factor 3	Homo sapiens	113-118
17453364-2	2007	A toxicity-based dosing schedule for individually tailored treatment with granulocyte colony-stimulating factor (G-CSF) supported 5-fluorouracil (F), epirubicin (E) and cyclophosphamide (C) (dFEC) was developed and studied in patients with metastatic breast cancer with the purpose to determine its efficiency and toxicity.	dfec	191-195	colony stimulating factor 3	Homo sapiens	113-118
17127394-4	2007	Jak2 primarily enlists members of the signal transducer and activator of transcription (STAT) family and Lyn phosphorylates a number of adaptor molecules, which link the G-CSF receptor to phosphatidylinositol (PI) 3"-kinase and extracellular signal-regulated kinases (Erk) pathways.	Phosphatidylinositols	188-208	colony stimulating factor 3	Homo sapiens	170-175
17093103-0	2007	Enhancement of umbilical cord blood cell hematopoiesis by maitake beta-glucan is mediated by granulocyte colony-stimulating factor production.	beta-Glucans	66-77	colony stimulating factor 3	Homo sapiens	93-130
17127320-2	2007	G-CSF binds to its cell-surface receptor (G-CSFR) causing activation via homodimerisation and subsequent phosphorylation on four tyrosine residues of the receptor intracellular domain.	Tyrosine	129-137	colony stimulating factor 3	Homo sapiens	0-5
17181606-0	2007	Prevention of clozapine-induced granulocytopenia/agranulocytosis with granulocyte-colony stimulating factor (G-CSF) in an intellectually disabled patient with schizophrenia.	Clozapine	14-23	colony stimulating factor 3	Homo sapiens	70-107
17703461-1	2007	We report a 45-year-old woman with iron deficient anemia (IDA) who underwent a collection of allogeneic peripheral blood stem cells (PBSCs) induced by granulocyte-colony stimulating factor (G-CSF) after a rapid improvement of IDA by iron replacement.	Iron	35-39	colony stimulating factor 3	Homo sapiens	151-188
17703461-1	2007	We report a 45-year-old woman with iron deficient anemia (IDA) who underwent a collection of allogeneic peripheral blood stem cells (PBSCs) induced by granulocyte-colony stimulating factor (G-CSF) after a rapid improvement of IDA by iron replacement.	Iron	35-39	colony stimulating factor 3	Homo sapiens	190-195
17181606-0	2007	Prevention of clozapine-induced granulocytopenia/agranulocytosis with granulocyte-colony stimulating factor (G-CSF) in an intellectually disabled patient with schizophrenia.	Clozapine	14-23	colony stimulating factor 3	Homo sapiens	109-114
17181606-3	2007	METHOD: In this case report, we describe what we believe are two "firsts" in the clozapine literature: the use of granulocyte-colony stimulating factor on a prophylactic basis in an intellectually disabled patient receiving clozapine for refractory schizophrenia.	Clozapine	81-90	colony stimulating factor 3	Homo sapiens	114-151
17181606-3	2007	METHOD: In this case report, we describe what we believe are two "firsts" in the clozapine literature: the use of granulocyte-colony stimulating factor on a prophylactic basis in an intellectually disabled patient receiving clozapine for refractory schizophrenia.	Clozapine	224-233	colony stimulating factor 3	Homo sapiens	114-151
17181606-4	2007	RESULT: Treatment with granulocyte-colony stimulating factor prevented discontinuation of clozapine, enabling our intellectually disabled patient"s recovery from a schizophrenic illness.	Clozapine	90-99	colony stimulating factor 3	Homo sapiens	23-60
17873305-0	2007	Intensive weekly chemotherapy with docetaxel, epirubicin and carboplatin with G-CSF support in patients with advanced gastric cancer: a Hellenic Cooperative Oncology Group (HeCOG) phase II study.	Docetaxel	35-44	colony stimulating factor 3	Homo sapiens	78-83
17873305-0	2007	Intensive weekly chemotherapy with docetaxel, epirubicin and carboplatin with G-CSF support in patients with advanced gastric cancer: a Hellenic Cooperative Oncology Group (HeCOG) phase II study.	Carboplatin	61-72	colony stimulating factor 3	Homo sapiens	78-83
17409984-0	2006	Phase II trial of paclitaxel, carboplatin, and topotecan with G-CSF support in previously untreated patients with extensive stage small cell lung cancer: Southwest Oncology Group 9914.	Paclitaxel	18-28	colony stimulating factor 3	Homo sapiens	62-67
17176065-2	2006	To address the role of structure on chemical degradation kinetics, comparative oxidation studies of methionine residues in recombinant human granulocyte colony-stimulating factor (rhG-CSF) were performed.	Methionine	100-110	colony stimulating factor 3	Homo sapiens	141-178
17177909-1	2006	The routine use of granulocyte-colony stimulating factor (G-CSF) for 10 days during full-dose cyclophosphamide-doxorubicin-vincristine-prednisone (CHOP) chemotherapy in HIV-associated diffuse non-Hodgkin"s lymphoma (NHL) patients is very expensive in developing countries.	Cyclophosphamide	94-110	colony stimulating factor 3	Homo sapiens	19-56
17177909-1	2006	The routine use of granulocyte-colony stimulating factor (G-CSF) for 10 days during full-dose cyclophosphamide-doxorubicin-vincristine-prednisone (CHOP) chemotherapy in HIV-associated diffuse non-Hodgkin"s lymphoma (NHL) patients is very expensive in developing countries.	Cyclophosphamide	94-110	colony stimulating factor 3	Homo sapiens	58-63
17177909-1	2006	The routine use of granulocyte-colony stimulating factor (G-CSF) for 10 days during full-dose cyclophosphamide-doxorubicin-vincristine-prednisone (CHOP) chemotherapy in HIV-associated diffuse non-Hodgkin"s lymphoma (NHL) patients is very expensive in developing countries.	Doxorubicin	111-122	colony stimulating factor 3	Homo sapiens	19-56
17177909-1	2006	The routine use of granulocyte-colony stimulating factor (G-CSF) for 10 days during full-dose cyclophosphamide-doxorubicin-vincristine-prednisone (CHOP) chemotherapy in HIV-associated diffuse non-Hodgkin"s lymphoma (NHL) patients is very expensive in developing countries.	Doxorubicin	111-122	colony stimulating factor 3	Homo sapiens	58-63
17177909-1	2006	The routine use of granulocyte-colony stimulating factor (G-CSF) for 10 days during full-dose cyclophosphamide-doxorubicin-vincristine-prednisone (CHOP) chemotherapy in HIV-associated diffuse non-Hodgkin"s lymphoma (NHL) patients is very expensive in developing countries.	vincristine-prednisone	123-145	colony stimulating factor 3	Homo sapiens	19-56
17177909-1	2006	The routine use of granulocyte-colony stimulating factor (G-CSF) for 10 days during full-dose cyclophosphamide-doxorubicin-vincristine-prednisone (CHOP) chemotherapy in HIV-associated diffuse non-Hodgkin"s lymphoma (NHL) patients is very expensive in developing countries.	vincristine-prednisone	123-145	colony stimulating factor 3	Homo sapiens	58-63
17155894-2	2006	Pegfilgrastim is a novel recombinant human G-CSF pharmaceutically developed by covalent binding of a polyethylene glycol molecule to the N-terminal sequence of filgrastim.	Polyethylene Glycols	101-120	colony stimulating factor 3	Homo sapiens	43-48
17076657-0	2006	Recombinant human granulocyte colony-stimulating factor protects against MPTP-induced dopaminergic cell death in mice by altering Bcl-2/Bax expression levels.	1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine	73-77	colony stimulating factor 3	Homo sapiens	18-55
27265480-9	2006	There is no direct evidence yet that imatinib mesylate could inhibit the effect of IL-3, G-CSF, GM-CSF, Epo and IGF-I on erythropoiesis.	Imatinib Mesylate	37-54	colony stimulating factor 3	Homo sapiens	89-94
16935429-4	2006	Combinations such as cisplatin-gemcitabine (GC) and intensified, G-CSF supported MVAC have shown more favourable toxicity profile and equal or even improved efficacy.	M-VAC protocol	81-85	colony stimulating factor 3	Homo sapiens	65-70
16982335-12	2006	CONCLUSION: Altogether, our results strongly suggest that cAMP appears to be not only a key pathway controlling CD34(+) survival, but also a mediator of the TPO-, G-CSF- and SCF-mediated cytoprotection.	Cyclic AMP	58-62	colony stimulating factor 3	Homo sapiens	163-168
16988532-1	2006	We evaluated efficacy and toxicity profiles of fludarabine, Ara-C, idarubicin, and G-CSF (Ida-FLAG) combination chemotherapy in 56 refractory and/or relapsed acute leukemia patients.	ida-flag	90-98	colony stimulating factor 3	Homo sapiens	83-88
16936090-6	2006	Triptolide and dexamethasone each inhibited in a concentration-dependent manner the LPS-induced release of IL-6, G-CSF, MCP-1, and IL-8 by corneal fibroblasts.	Dexamethasone	15-28	colony stimulating factor 3	Homo sapiens	113-118
17094396-15	2006	In conclusion, the combination of docetaxel plus cisplatin appears to be a moderately effective regimen with acceptable toxicity when G-CSF support is provided.	Docetaxel	34-43	colony stimulating factor 3	Homo sapiens	134-139
17094396-15	2006	In conclusion, the combination of docetaxel plus cisplatin appears to be a moderately effective regimen with acceptable toxicity when G-CSF support is provided.	Cisplatin	49-58	colony stimulating factor 3	Homo sapiens	134-139
16936090-6	2006	Triptolide and dexamethasone each inhibited in a concentration-dependent manner the LPS-induced release of IL-6, G-CSF, MCP-1, and IL-8 by corneal fibroblasts.	triptolide	0-10	colony stimulating factor 3	Homo sapiens	113-118
16936090-7	2006	Whereas the inhibitory effect of dexamethasone on LPS-induced IL-6 release was greater than that of triptolide, the inhibitory effect of triptolide on LPS-induced G-CSF release was more pronounced than was that of dexamethasone.	triptolide	137-147	colony stimulating factor 3	Homo sapiens	163-168
16936090-10	2006	CONCLUSIONS: Triptolide inhibits the LPS-induced expression of IL-6, chemokines (G-CSF, MCP-1, IL-8), and ICAM-1 in cultured human corneal fibroblasts.	triptolide	13-23	colony stimulating factor 3	Homo sapiens	81-86
16781005-3	2006	Therefore, we conducted a prospective feasibility study designed specifically to evaluate the efficacy of carboplatin (day 1) and irinotecan (days 1, 8, 15) with granulocyte colony-stimulating factor (G-CSF) support in elderly SCLC patients.	Carboplatin	106-117	colony stimulating factor 3	Homo sapiens	201-206
16915572-0	2006	Interactions of dextran sulfates with granulocyte colony-stimulating factor and their effects on leukemia cells.	Dextran Sulfate	16-32	colony stimulating factor 3	Homo sapiens	38-75
16915572-1	2006	The interactions between granulocyte colony-stimulating factor (G-CSF) and dextran sulfate (DS) with different chain lengths and sulfate contents were studied by capillary zone electrophoresis.	Sulfates	83-90	colony stimulating factor 3	Homo sapiens	25-62
16915572-5	2006	The results indicate that the interactions between G-CSF and DS are dependent on the chain lengths and sulfate contents of the saccharides.	Dextran Sulfate	61-63	colony stimulating factor 3	Homo sapiens	51-56
16915572-5	2006	The results indicate that the interactions between G-CSF and DS are dependent on the chain lengths and sulfate contents of the saccharides.	Sulfates	103-110	colony stimulating factor 3	Homo sapiens	51-56
16781005-3	2006	Therefore, we conducted a prospective feasibility study designed specifically to evaluate the efficacy of carboplatin (day 1) and irinotecan (days 1, 8, 15) with granulocyte colony-stimulating factor (G-CSF) support in elderly SCLC patients.	Irinotecan	130-140	colony stimulating factor 3	Homo sapiens	162-199
16781005-3	2006	Therefore, we conducted a prospective feasibility study designed specifically to evaluate the efficacy of carboplatin (day 1) and irinotecan (days 1, 8, 15) with granulocyte colony-stimulating factor (G-CSF) support in elderly SCLC patients.	Irinotecan	130-140	colony stimulating factor 3	Homo sapiens	201-206
16951514-1	2006	OBJECTIVE: To evaluate the protective effect of recombinant human granulocyte colony stimulating factor (rhG-CSF) on acute hepatic failure induced by galactosamine (D-GalN) and lipopolysaccharide (LPS) in mice, and to explore its mechanism.	Galactosamine	150-163	colony stimulating factor 3	Homo sapiens	66-103
16573743-1	2006	The cytotoxic effect of cytarabine (Ara-C) on myeloid leukemic cells is enhanced by concomitant use of granulocyte colony-stimulating factor (G-CSF) in vitro.	Cytarabine	24-34	colony stimulating factor 3	Homo sapiens	103-140
16823956-7	2006	Serum levels of granulocyte-colony stimulating factor (G-CSF) increased early after CP/CPB as compared with pre-CP/CPB (265.0+/-41.7 versus 11.1+/-1.1 pg/mL; P&lt;0.001) and returned to baseline at POD4 (P=0.84 versus pre-CP/CPB).	cpb	87-90	colony stimulating factor 3	Homo sapiens	16-53
16823956-7	2006	Serum levels of granulocyte-colony stimulating factor (G-CSF) increased early after CP/CPB as compared with pre-CP/CPB (265.0+/-41.7 versus 11.1+/-1.1 pg/mL; P&lt;0.001) and returned to baseline at POD4 (P=0.84 versus pre-CP/CPB).	cpb	87-90	colony stimulating factor 3	Homo sapiens	55-60
16573743-1	2006	The cytotoxic effect of cytarabine (Ara-C) on myeloid leukemic cells is enhanced by concomitant use of granulocyte colony-stimulating factor (G-CSF) in vitro.	Cytarabine	24-34	colony stimulating factor 3	Homo sapiens	142-147
16573743-1	2006	The cytotoxic effect of cytarabine (Ara-C) on myeloid leukemic cells is enhanced by concomitant use of granulocyte colony-stimulating factor (G-CSF) in vitro.	Cytarabine	36-41	colony stimulating factor 3	Homo sapiens	103-140
16573743-1	2006	The cytotoxic effect of cytarabine (Ara-C) on myeloid leukemic cells is enhanced by concomitant use of granulocyte colony-stimulating factor (G-CSF) in vitro.	Cytarabine	36-41	colony stimulating factor 3	Homo sapiens	142-147
16573743-2	2006	The feasibility of a conditioning regimen consisting of G-CSF-combined 24 g/m2 Ara-C, 90 mg/m2 fludarabine, and 12 Gy total body irradiation was studied for five patients with acute myelogenous leukemia in cord blood transplantation (CBT).	Cytarabine	79-84	colony stimulating factor 3	Homo sapiens	56-61
16877768-0	2006	Methanol-induced tertiary and secondary structure changes of granulocyte-colony stimulating factor.	Methanol	0-8	colony stimulating factor 3	Homo sapiens	61-98
16729274-0	2006	Effects of pH, temperature, and sucrose on benzyl alcohol-induced aggregation of recombinant human granulocyte colony stimulating factor.	Sucrose	32-39	colony stimulating factor 3	Homo sapiens	99-136
16769985-4	2006	RESULTS: When combined with AC every 2 weeks plus G-CSF, the RPTD of tipifarnib was 200 mg bid administered on days 2 to 7.	tipifarnib	69-79	colony stimulating factor 3	Homo sapiens	50-55
16769988-0	2006	Does granulocyte colony-stimulating factor worsen anemia in early breast cancer patients treated with epirubicin and cyclophosphamide?	Epirubicin	102-112	colony stimulating factor 3	Homo sapiens	5-42
16769988-0	2006	Does granulocyte colony-stimulating factor worsen anemia in early breast cancer patients treated with epirubicin and cyclophosphamide?	Cyclophosphamide	117-133	colony stimulating factor 3	Homo sapiens	5-42
16769988-1	2006	PURPOSE: We report on the effects of granulocyte colony-stimulating factor (G-CSF) on hemoglobin (Hb) value in early breast cancer patients receiving high-dose epirubicin and cyclophosphamide (EC) adjuvant treatment.	Epirubicin	160-170	colony stimulating factor 3	Homo sapiens	37-74
16769988-1	2006	PURPOSE: We report on the effects of granulocyte colony-stimulating factor (G-CSF) on hemoglobin (Hb) value in early breast cancer patients receiving high-dose epirubicin and cyclophosphamide (EC) adjuvant treatment.	Epirubicin	160-170	colony stimulating factor 3	Homo sapiens	76-81
16769988-1	2006	PURPOSE: We report on the effects of granulocyte colony-stimulating factor (G-CSF) on hemoglobin (Hb) value in early breast cancer patients receiving high-dose epirubicin and cyclophosphamide (EC) adjuvant treatment.	Cyclophosphamide	175-191	colony stimulating factor 3	Homo sapiens	37-74
16769988-1	2006	PURPOSE: We report on the effects of granulocyte colony-stimulating factor (G-CSF) on hemoglobin (Hb) value in early breast cancer patients receiving high-dose epirubicin and cyclophosphamide (EC) adjuvant treatment.	Cyclophosphamide	175-191	colony stimulating factor 3	Homo sapiens	76-81
16769988-1	2006	PURPOSE: We report on the effects of granulocyte colony-stimulating factor (G-CSF) on hemoglobin (Hb) value in early breast cancer patients receiving high-dose epirubicin and cyclophosphamide (EC) adjuvant treatment.	ec	193-195	colony stimulating factor 3	Homo sapiens	37-74
16769988-1	2006	PURPOSE: We report on the effects of granulocyte colony-stimulating factor (G-CSF) on hemoglobin (Hb) value in early breast cancer patients receiving high-dose epirubicin and cyclophosphamide (EC) adjuvant treatment.	ec	193-195	colony stimulating factor 3	Homo sapiens	76-81
16769988-10	2006	CONCLUSION: Our data suggest that a G-CSF dose-related effect may play a role in worsening anemia in patients receiving adjuvant EC.	ec	129-131	colony stimulating factor 3	Homo sapiens	36-41
15880369-12	2006	The use of G-CSF and G-CSF with dexamethasone has substantially increased granulocyte yields with yields of 4.1 x 10(10) to 10.8 x 10(10) reported.	Dexamethasone	32-45	colony stimulating factor 3	Homo sapiens	11-16
15880369-12	2006	The use of G-CSF and G-CSF with dexamethasone has substantially increased granulocyte yields with yields of 4.1 x 10(10) to 10.8 x 10(10) reported.	Dexamethasone	32-45	colony stimulating factor 3	Homo sapiens	21-26
16635534-3	2006	They were treated with G-CSF (5 microg/kg b.i.d for three consecutive days) to mobilize BMC, evaluated as circulating CD34+ve cells (flow cytometry) and myeloid CFU-GM progenitors (in vitro colony growth assay).	bmc	88-91	colony stimulating factor 3	Homo sapiens	23-28
16635534-10	2006	CONCLUSIONS: (i) G-CSF mobilization of BMC co-expressing epithelial and stem markers occurred in all cirrhotic patients; (ii) splenomegaly up to 170 mm does not prevent safe BMC mobilization following G-CSF in patients with end stage liver disease; (iii) mobilized BMC may represent an easy immature cell source potentially useful for novel approaches for liver regeneration.	bmc	39-42	colony stimulating factor 3	Homo sapiens	17-22
16729274-0	2006	Effects of pH, temperature, and sucrose on benzyl alcohol-induced aggregation of recombinant human granulocyte colony stimulating factor.	Benzyl Alcohol	43-57	colony stimulating factor 3	Homo sapiens	99-136
16729274-2	2006	In this study, the mechanism of benzyl alcohol-induced aggregation of recombinant human granulocyte colony-stimulating factor (rhGCSF) was investigated by determining the effects of temperature, pH, and sucrose on this process.	Benzyl Alcohol	32-46	colony stimulating factor 3	Homo sapiens	88-125
16729274-2	2006	In this study, the mechanism of benzyl alcohol-induced aggregation of recombinant human granulocyte colony-stimulating factor (rhGCSF) was investigated by determining the effects of temperature, pH, and sucrose on this process.	Sucrose	203-210	colony stimulating factor 3	Homo sapiens	88-125
16298143-5	2006	The amount of recombinant hG-CSF accumulated in culture medium from transgenic rice cell suspension culture on the sugar starvation was determined by time series ELISA.	Sugars	115-120	colony stimulating factor 3	Homo sapiens	26-32
16737933-2	2006	We report a phase I/II study that analyzed the feasibility of mobilizing stem cells from normal donors with peg-G-CSF and the ability of these cells to restore hematopoiesis in allogeneic transplant recipients after myeloablative conditioning.	Polyethylene Glycols	108-111	colony stimulating factor 3	Homo sapiens	112-117
16613688-1	2006	BACKGROUND &amp; OBJECTIVE: Recombinant human granulocyte colony-stimulating factor (rhG-CSF) is effective in the prophylaxis and management of chemotherapy-induced neutropenia, but requires daily administration because of its short half-life.	Adenosine Monophosphate	12-15	colony stimulating factor 3	Homo sapiens	46-83
16597829-0	2006	Modulation of protein aggregation by polyethylene glycol conjugation: GCSF as a case study.	Polyethylene Glycols	37-56	colony stimulating factor 3	Homo sapiens	70-74
16597829-3	2006	In this study, conducted under physiological pH and temperature, N-terminal attachment of a 20 kDa PEG moiety to GCSF had the ability to (1) prevent protein precipitation by rendering the aggregates soluble, and (2) slow the rate of aggregation relative to GCSF.	Polyethylene Glycols	99-102	colony stimulating factor 3	Homo sapiens	113-117
16597829-3	2006	In this study, conducted under physiological pH and temperature, N-terminal attachment of a 20 kDa PEG moiety to GCSF had the ability to (1) prevent protein precipitation by rendering the aggregates soluble, and (2) slow the rate of aggregation relative to GCSF.	Polyethylene Glycols	99-102	colony stimulating factor 3	Homo sapiens	257-261
16597829-4	2006	Our data suggest that PEG-GCSF solubility was mediated by favorable solvation of water molecules around the PEG group.	Polyethylene Glycols	22-25	colony stimulating factor 3	Homo sapiens	26-30
16597829-4	2006	Our data suggest that PEG-GCSF solubility was mediated by favorable solvation of water molecules around the PEG group.	Water	81-86	colony stimulating factor 3	Homo sapiens	26-30
16597829-4	2006	Our data suggest that PEG-GCSF solubility was mediated by favorable solvation of water molecules around the PEG group.	Polyethylene Glycols	108-111	colony stimulating factor 3	Homo sapiens	26-30
16597829-5	2006	PEG-GCSF appeared to aggregate on the same pathway as that of GCSF, as evidenced by (a) almost identical secondary structural transitions accompanying aggregation, (b) almost identical covalent character in the aggregates, and (c) the ability of PEG-GCSF to rescue GCSF precipitation.	Polyethylene Glycols	0-3	colony stimulating factor 3	Homo sapiens	4-8
16597829-9	2006	The data is most compatible with a model where PEG conjugation preserves the mechanism underlying protein aggregation in GCSF, steric hindrance by PEG influences aggregation rate, while aqueous solubility is mediated by polar PEG groups on the aggregate surface.	Polyethylene Glycols	47-50	colony stimulating factor 3	Homo sapiens	121-125
16545729-1	2006	We previously reported results in 71 patients with advanced hematologic malignancies given HLA-matched unrelated granulocyte colony-stimulating factor-mobilized peripheral blood mononuclear cell (G-PBMC) grafts after fludarabine 90 mg/m(2), 2 Gy of total body irradiation, and postgrafting mycophenolate mofetil (MMF) 15 mg/kg twice daily and cyclosporine 6.25 mg/kg twice daily orally.	Mycophenolic Acid	290-311	colony stimulating factor 3	Homo sapiens	113-150
16545729-1	2006	We previously reported results in 71 patients with advanced hematologic malignancies given HLA-matched unrelated granulocyte colony-stimulating factor-mobilized peripheral blood mononuclear cell (G-PBMC) grafts after fludarabine 90 mg/m(2), 2 Gy of total body irradiation, and postgrafting mycophenolate mofetil (MMF) 15 mg/kg twice daily and cyclosporine 6.25 mg/kg twice daily orally.	Mycophenolic Acid	313-316	colony stimulating factor 3	Homo sapiens	113-150
16545729-1	2006	We previously reported results in 71 patients with advanced hematologic malignancies given HLA-matched unrelated granulocyte colony-stimulating factor-mobilized peripheral blood mononuclear cell (G-PBMC) grafts after fludarabine 90 mg/m(2), 2 Gy of total body irradiation, and postgrafting mycophenolate mofetil (MMF) 15 mg/kg twice daily and cyclosporine 6.25 mg/kg twice daily orally.	fludarabine	217-228	colony stimulating factor 3	Homo sapiens	113-150
16545729-1	2006	We previously reported results in 71 patients with advanced hematologic malignancies given HLA-matched unrelated granulocyte colony-stimulating factor-mobilized peripheral blood mononuclear cell (G-PBMC) grafts after fludarabine 90 mg/m(2), 2 Gy of total body irradiation, and postgrafting mycophenolate mofetil (MMF) 15 mg/kg twice daily and cyclosporine 6.25 mg/kg twice daily orally.	Cyclosporine	343-355	colony stimulating factor 3	Homo sapiens	113-150
16565560-7	2006	One month later, a Thallium-201 single photon emission computed tomography revealed the increased percentage uptake and the reduced extent and severity scores in the G-CSF angina group.	Thallium	19-27	colony stimulating factor 3	Homo sapiens	166-171
16638224-7	2006	It is concluded that high-dose etoposide with G-CSF is an effective and safe mobilizing regimen for autologous peripheral blood stem progenitor cells in patients with hematologic malignancies.	Etoposide	31-40	colony stimulating factor 3	Homo sapiens	46-51
16517764-10	2006	There was greater improvement in neurologic functioning between baseline and 12-month follow-up in the G-CSF group than in the control group (NIHSS: 59% change in the mean G-CSF group score v. 36% in the mean control group score, ESS: 33% v. 20%, EMS: 106% v. 58%, BI: 120% v. 60%).	nihss	142-147	colony stimulating factor 3	Homo sapiens	103-108
16423477-0	2006	G-CSF loaded biodegradable PLGA nanoparticles prepared by a single oil-in-water emulsion method.	Oils	67-70	colony stimulating factor 3	Homo sapiens	0-5
16423477-0	2006	G-CSF loaded biodegradable PLGA nanoparticles prepared by a single oil-in-water emulsion method.	Water	74-79	colony stimulating factor 3	Homo sapiens	0-5
16517764-10	2006	There was greater improvement in neurologic functioning between baseline and 12-month follow-up in the G-CSF group than in the control group (NIHSS: 59% change in the mean G-CSF group score v. 36% in the mean control group score, ESS: 33% v. 20%, EMS: 106% v. 58%, BI: 120% v. 60%).	nihss	142-147	colony stimulating factor 3	Homo sapiens	172-177
16423477-1	2006	A new formulation method was developed for preparing poly(D,L-lactic-co-glycolic acid) (PLGA) nanoparticles loaded with recombinant human granulocyte colony-stimulating factor (rhG-CSF).	Polylactic Acid-Polyglycolic Acid Copolymer	53-86	colony stimulating factor 3	Homo sapiens	138-175
16517764-10	2006	There was greater improvement in neurologic functioning between baseline and 12-month follow-up in the G-CSF group than in the control group (NIHSS: 59% change in the mean G-CSF group score v. 36% in the mean control group score, ESS: 33% v. 20%, EMS: 106% v. 58%, BI: 120% v. 60%).	ESS	230-233	colony stimulating factor 3	Homo sapiens	103-108
16517764-10	2006	There was greater improvement in neurologic functioning between baseline and 12-month follow-up in the G-CSF group than in the control group (NIHSS: 59% change in the mean G-CSF group score v. 36% in the mean control group score, ESS: 33% v. 20%, EMS: 106% v. 58%, BI: 120% v. 60%).	Bismuth	265-267	colony stimulating factor 3	Homo sapiens	103-108
16517764-11	2006	Although at 12 months there was no difference between the 2 groups in cerebral uptake of fluorodeoxyglucose in the ischemic core, uptake in the area surrounding the core was significantly improved in the G-CSF group compared with the control group.	Fluorodeoxyglucose F18	89-107	colony stimulating factor 3	Homo sapiens	204-209
16551865-7	2006	RESULTS: G-CSF treatment induced homing of large number of labeled BMCs to the submandibular glands after irradiation.	S-benzyl-N-malonylcysteine	67-71	colony stimulating factor 3	Homo sapiens	9-14
16520664-0	2006	Weekly paclitaxel, 5-fluorouracil and folinic acid with granulocyte colony-stimulating factor support in metastatic breast cancer patients: a phase II study.	Paclitaxel	7-17	colony stimulating factor 3	Homo sapiens	56-93
16427611-4	2006	Structural simulations based on the crystallographic structure of KW-2228, a stable and potent analog of human G-CSF, led us to choose 4-aminobenzoic acid (Abz) as a part of the linker.	4-Aminobenzoic Acid	135-154	colony stimulating factor 3	Homo sapiens	111-116
16427611-4	2006	Structural simulations based on the crystallographic structure of KW-2228, a stable and potent analog of human G-CSF, led us to choose 4-aminobenzoic acid (Abz) as a part of the linker.	4-Aminobenzoic Acid	156-159	colony stimulating factor 3	Homo sapiens	111-116
16520664-14	2006	Thus, in metastatic breast cancer patients pre-treated with anthracyclines, the weekly administration of paclitaxel, 5-FU and folinic acid with G-CSF support seems to be extremely tolerable and active.	Anthracyclines	60-74	colony stimulating factor 3	Homo sapiens	144-149
16520664-0	2006	Weekly paclitaxel, 5-fluorouracil and folinic acid with granulocyte colony-stimulating factor support in metastatic breast cancer patients: a phase II study.	Leucovorin	38-50	colony stimulating factor 3	Homo sapiens	56-93
16520664-14	2006	Thus, in metastatic breast cancer patients pre-treated with anthracyclines, the weekly administration of paclitaxel, 5-FU and folinic acid with G-CSF support seems to be extremely tolerable and active.	Paclitaxel	105-115	colony stimulating factor 3	Homo sapiens	144-149
16520664-14	2006	Thus, in metastatic breast cancer patients pre-treated with anthracyclines, the weekly administration of paclitaxel, 5-FU and folinic acid with G-CSF support seems to be extremely tolerable and active.	Fluorouracil	117-121	colony stimulating factor 3	Homo sapiens	144-149
16520664-1	2006	We conducted a phase II study to determine the activity and tolerability of weekly paclitaxel, 5-fluorouracil (5-FU) and folinic acid plus granulocyte colony-stimulating factor (G-CSF) support in anthracycline-pre-treated or -resistant metastatic breast cancer patients.	Anthracyclines	196-209	colony stimulating factor 3	Homo sapiens	139-176
16520664-14	2006	Thus, in metastatic breast cancer patients pre-treated with anthracyclines, the weekly administration of paclitaxel, 5-FU and folinic acid with G-CSF support seems to be extremely tolerable and active.	Leucovorin	126-138	colony stimulating factor 3	Homo sapiens	144-149
16714776-14	2006	14-day-long incubation of HL-60 cells with VA in conditioned medium (source of IL-3, SCF, G-CSF) caused increase in EC(50) to 4 mmol/l, while in MOLT-4 cells (cultivation without conditioned medium), the EC(50) decreased to 0.63 mmol/l.	Valproic Acid	43-45	colony stimulating factor 3	Homo sapiens	90-95
16282349-0	2006	G-CSF induced reactive oxygen species involves Lyn-PI3-kinase-Akt and contributes to myeloid cell growth.	Reactive Oxygen Species	14-37	colony stimulating factor 3	Homo sapiens	0-5
16282349-3	2006	G-CSF stimulation showed a time- and dose-dependent increase in ROS production, correlating with activation of Lyn and Akt.	ros	64-67	colony stimulating factor 3	Homo sapiens	0-5
16282349-4	2006	Inhibition of Lyn, PI3-kinase, and Akt abrogated G-CSF-induced ROS production.	ros	63-66	colony stimulating factor 3	Homo sapiens	49-54
16282349-7	2006	G-CSF induced both serine phosphorylation and membrane translocation of p47phox, a subunit of NADPH oxidase.	Serine	19-25	colony stimulating factor 3	Homo sapiens	0-5
16282349-10	2006	G-CSF-induced ROS production was enhanced in bone marrow-derived neutrophils expressing G-CSFRdelta715, a truncated receptor.	ros	14-17	colony stimulating factor 3	Homo sapiens	0-5
16282349-11	2006	The antioxidant N-acetyl-L-cysteine diminished G-CSF-induced ROS production and cell proliferation by inhibiting Akt activation.	Acetylcysteine	16-35	colony stimulating factor 3	Homo sapiens	47-52
16282349-11	2006	The antioxidant N-acetyl-L-cysteine diminished G-CSF-induced ROS production and cell proliferation by inhibiting Akt activation.	ros	61-64	colony stimulating factor 3	Homo sapiens	47-52
16282349-12	2006	These data suggest that the G-CSF-induced Lyn-PI3K-Akt pathway drives ROS production.	ros	70-73	colony stimulating factor 3	Homo sapiens	28-33
17176123-0	2006	Effects of site-specific polyethylene glycol modification of recombinant human granulocyte colony-stimulating factor on its biologic activities.	Polyethylene Glycols	25-44	colony stimulating factor 3	Homo sapiens	79-116
16503719-7	2006	Atorvastatin significantly reduced the production of epithelial neutrophil-activating peptide-78, interleukin-6, interleukin-8, and monocyte chemotactic protein-1 (p&lt;0.001 to p&lt;0.05) in a concentration-dependent manner without affecting basal production of interleukin-10, fibroblast growth factor, and granulocyte colony stimulating factor.	Atorvastatin	0-12	colony stimulating factor 3	Homo sapiens	309-346
16195327-2	2006	Short-term G-CSF stimulation resulted in a rapid tyrosine dephosphorylation of p27Kip1 accompanied by a change in its binding preferences to cdks.	Tyrosine	49-57	colony stimulating factor 3	Homo sapiens	11-16
16531264-3	2006	In stem cell donors cobalamin and homocysteine levels increased after G-CSF administration.	Vitamin B 12	20-29	colony stimulating factor 3	Homo sapiens	70-75
16531264-5	2006	We hypothesize that the increased homocysteine levels in patients with CML and donors treated with G-CSF may be the result of a functional methylcobalamin deficiency due to decreased transcobalamin levels.	Homocysteine	34-46	colony stimulating factor 3	Homo sapiens	99-104
16441592-2	2006	Recently a polyethylene glycol-conjugated G-CSF (pegfilgrastim) was introduced that has a substantially longer t(1/2) than the original formula.	Polyethylene Glycols	11-30	colony stimulating factor 3	Homo sapiens	42-47
16441593-7	2006	SaO(2) was significantly decreased after G-CSF administration (p = 0.0002).	sao(2)	0-6	colony stimulating factor 3	Homo sapiens	41-46
16168442-6	2006	500 pg/ml), and it was able to enhance the proliferation of DMSO treated HL-60 cells, suggesting that the transgenic urine-derived hG-CSF was bioactive.	Dimethyl Sulfoxide	60-64	colony stimulating factor 3	Homo sapiens	131-137
16428509-0	2006	Intermittent exposure of primitive quiescent chronic myeloid leukemia cells to granulocyte-colony stimulating factor in vitro promotes their elimination by imatinib mesylate.	Imatinib Mesylate	156-173	colony stimulating factor 3	Homo sapiens	79-116
16428509-2	2006	The present study was designed to investigate whether either continuous or intermittent exposure of these cells to granulocyte-colony stimulating factor (G-CSF) in vitro can overcome this limitation to the effectiveness of imatinib mesylate therapy.	Imatinib Mesylate	223-240	colony stimulating factor 3	Homo sapiens	115-152
16428509-2	2006	The present study was designed to investigate whether either continuous or intermittent exposure of these cells to granulocyte-colony stimulating factor (G-CSF) in vitro can overcome this limitation to the effectiveness of imatinib mesylate therapy.	Imatinib Mesylate	223-240	colony stimulating factor 3	Homo sapiens	154-159
16428509-7	2006	Cultures containing imatinib mesylate and intermittently added G-CSF also showed the greatest reduction in the total number of cells present after 12 days (5-fold more than imatinib mesylate alone).	Imatinib Mesylate	173-190	colony stimulating factor 3	Homo sapiens	63-68
16428509-8	2006	CONCLUSION: Intermittent exposure to G-CSF can enhance the effect of imatinib mesylate on CML cells by specifically targeting the primitive quiescent leukemic elements.	Imatinib Mesylate	69-86	colony stimulating factor 3	Homo sapiens	37-42
16428509-9	2006	A protocol for treating chronic-phase CML patients with imatinib mesylate that incorporates intermittent G-CSF exposure may offer a novel strategy for obtaining improved responses in vivo.	Imatinib Mesylate	56-73	colony stimulating factor 3	Homo sapiens	105-110
16211258-3	2005	The PKC activator phorbol 12-myristate 13-acetate (PMA) stimulated the production of GM-CSF in a dose-dependent manner and reduced G-CSF in the cell lines.	Tetradecanoylphorbol Acetate	18-49	colony stimulating factor 3	Homo sapiens	131-136
16003389-4	2006	Granulocyte colony-stimulating factor (G-CSF) increases mitochondrial respiration and calcium accumulation capacity and subsequently blocks ATRA-induced apoptosis.	Calcium	86-93	colony stimulating factor 3	Homo sapiens	0-37
16003389-4	2006	Granulocyte colony-stimulating factor (G-CSF) increases mitochondrial respiration and calcium accumulation capacity and subsequently blocks ATRA-induced apoptosis.	Calcium	86-93	colony stimulating factor 3	Homo sapiens	39-44
16003389-4	2006	Granulocyte colony-stimulating factor (G-CSF) increases mitochondrial respiration and calcium accumulation capacity and subsequently blocks ATRA-induced apoptosis.	Tretinoin	140-144	colony stimulating factor 3	Homo sapiens	0-37
16003389-4	2006	Granulocyte colony-stimulating factor (G-CSF) increases mitochondrial respiration and calcium accumulation capacity and subsequently blocks ATRA-induced apoptosis.	Tretinoin	140-144	colony stimulating factor 3	Homo sapiens	39-44
16003389-6	2006	Thus, the properties of ATRA and G-CSF to modulate mitochondrial respiration and intracellular calcium control are novel findings, which give insight into their precise molecular mode of action.	Calcium	95-102	colony stimulating factor 3	Homo sapiens	33-38
16275869-7	2005	Morphological and functional improvement with G-CSF was corroborated by enhanced metabolic activity and 18F-deoxyglucose uptake in the infarct zone (P&lt;0.001 versus control).	18f-deoxyglucose	104-120	colony stimulating factor 3	Homo sapiens	46-51
16413391-0	2006	Granulocyte colony-stimulating factor enhances the in vitro cytotoxicity of gemtuzumab ozogamicin against acute myeloid leukemia cell lines and primary blast cells.	OZOGAMICIN	87-97	colony stimulating factor 3	Homo sapiens	0-37
16553037-0	2006	Successful treatment of methimazole-induced severe aplastic anemia with recombinant human granulocyte colony-stimulating factor and high-dosage steroids.	Methimazole	24-35	colony stimulating factor 3	Homo sapiens	90-127
16533747-1	2005	To facilitate more economical medical care, we carried out a prospective study of whether a THP-COP regimen (cyclophosphamide, pirarubicin, vincristine, and prednisolone) with low-dose granulocyte colony-stimulating factor (G-CSF) would effectively treat non-Hodgkin"s lymphoma (NHL).	Prednisolone	157-169	colony stimulating factor 3	Homo sapiens	185-222
16211258-3	2005	The PKC activator phorbol 12-myristate 13-acetate (PMA) stimulated the production of GM-CSF in a dose-dependent manner and reduced G-CSF in the cell lines.	Tetradecanoylphorbol Acetate	51-54	colony stimulating factor 3	Homo sapiens	131-136
15932900-5	2005	Dose-dense (14-day) CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) with G-CSF support produces better results than 21-day CHOP in patients with previously untreated aggressive lymphoma, without additional toxicity.	Prednisone	74-84	colony stimulating factor 3	Homo sapiens	91-96
16224535-2	2005	We report that the G-CSF and FMS-like tyrosine kinase 3 ligand (Flt-3L) chimeric cytokine, progenipoietin-1, markedly expands the splenic and hepatic NKT cell population and enhances functional responses to alpha-galactosylceramide.	alpha-galactosylceramide	207-231	colony stimulating factor 3	Homo sapiens	19-24
16199204-3	2005	Albumin pretreatment significantly reduced CD11b expression and L-selectin shedding induced by fMLP and ROS production induced by PMA, G-CSF combined with PMA or LPS-fMLP, or anti-HNA-1a combined with PMA.	Reactive Oxygen Species	104-107	colony stimulating factor 3	Homo sapiens	135-140
16186594-7	2005	Increasing age, doxorubicin, bleomycin, vinblastine, and dacarbazine as initial therapy, and granulocyte colony-stimulating factor use were associated with the development of BPT.	bpt	175-178	colony stimulating factor 3	Homo sapiens	93-130
16230423-7	2005	Further, VCAM1 (-1591T&gt;C) and CSF3 (Ex4-165C&gt;T) were associated, respectively, with decreased (P = 0.041) and increased (P = 0.076) CFU-GEMM progenitor cell colony formation in 29 benzene-exposed workers.	Benzene	186-193	colony stimulating factor 3	Homo sapiens	33-37
16142818-7	2005	We demonstrate the incorporation of the glycosylamino acids--although with low suppression efficiency--into the human interleukin granulocyte-colony stimulating factor (hG-CSF), as verified by the ELISA technique.	glycosylamino acids	40-59	colony stimulating factor 3	Homo sapiens	169-175
16033816-5	2005	It is interesting that activation of these signaling molecules by G-CSF was prolonged by pretreating cells with actinomycin D or cyclohexamide, suggesting that de novo protein synthesis is required for appropriate termination of G-CSF-R signaling.	Dactinomycin	112-125	colony stimulating factor 3	Homo sapiens	66-71
16033816-5	2005	It is interesting that activation of these signaling molecules by G-CSF was prolonged by pretreating cells with actinomycin D or cyclohexamide, suggesting that de novo protein synthesis is required for appropriate termination of G-CSF-R signaling.	4-[2-(3,5-dimethyl-2-oxocyclohexyl)-2-hydroxyethyl]piperidine-2,6-dione	129-142	colony stimulating factor 3	Homo sapiens	66-71
16033816-9	2005	These data indicate that Tyr 729 of the G-CSF-R is required for SOCS1- and SOCS3-mediated negative regulation of G-CSF-R signaling and that the duration and intensity of G-CSF-induced Stat5 activation are regulated by two distinct mechanisms.	Tyrosine	25-28	colony stimulating factor 3	Homo sapiens	40-45
16152782-0	2005	[Neutropenia induced by taxoids and its control with granulocyte colony-stimulating factor].	Taxoids	24-31	colony stimulating factor 3	Homo sapiens	53-91
15980881-2	2005	To study the value of granulocyte colony-stimulating factor (G-CSF) in PGF, we retrospectively analyzed 81 episodes of PGF in 66 patients transplanted from 01/94 to 01/99 from an HLA-identical sibling (n = 45) or an unrelated (n = 21) donor.	Prostaglandins F	71-74	colony stimulating factor 3	Homo sapiens	61-66
15980881-12	2005	In conclusion, hematological response after 3 days with G-CSF predicted a better survival for patients with PGF after allo-SCT.	Prostaglandins F	108-111	colony stimulating factor 3	Homo sapiens	56-61
16144933-2	2005	In the present study, we compared the in vitro and in vivo effects of proerythroid treatment with erythropoietin + granulocyte colony-stimulating factor (G-CSF) on myelodysplastic erythropoiesis regarding apoptosis and preferential growth of clones with cytogenetic abnormalities.	proerythroid	70-82	colony stimulating factor 3	Homo sapiens	115-152
16144933-2	2005	In the present study, we compared the in vitro and in vivo effects of proerythroid treatment with erythropoietin + granulocyte colony-stimulating factor (G-CSF) on myelodysplastic erythropoiesis regarding apoptosis and preferential growth of clones with cytogenetic abnormalities.	proerythroid	70-82	colony stimulating factor 3	Homo sapiens	154-159
16100743-0	2005	Separation, identification, and interaction of heparin oligosaccharides with granulocyte-colony stimulating factor using capillary electrophoresis and mass spectrometry.	heparin oligosaccharides	47-71	colony stimulating factor 3	Homo sapiens	77-114
16100743-1	2005	A capillary electrophoresis (CE) method was developed for the separation of heparin oligosaccharides compatible to study the interactions between the oligosaccharides and granulocyte-colony stimulating factor (G-CSF).	heparin oligosaccharides	76-100	colony stimulating factor 3	Homo sapiens	210-215
16100743-1	2005	A capillary electrophoresis (CE) method was developed for the separation of heparin oligosaccharides compatible to study the interactions between the oligosaccharides and granulocyte-colony stimulating factor (G-CSF).	Oligosaccharides	84-100	colony stimulating factor 3	Homo sapiens	210-215
16100743-7	2005	Furthermore, interactions between G-CSF and the oligosaccharides were studied by using capillary zone electrophoresis (CZE) under the above separation conditions.	Oligosaccharides	48-64	colony stimulating factor 3	Homo sapiens	34-39
16100743-8	2005	It was found that larger oligosaccharides could interact with G-CSF while smaller oligosaccharides were not observed to bind to G-CSF under the experimental conditions.	Oligosaccharides	25-41	colony stimulating factor 3	Homo sapiens	62-67
16100743-9	2005	In conclusion, the purified heparinase could selectively degrade heparin into oligosaccharides and the interaction between G-CSF and heparin was correlated with the chain length of heparin.	Heparin	28-35	colony stimulating factor 3	Homo sapiens	123-128
16100743-9	2005	In conclusion, the purified heparinase could selectively degrade heparin into oligosaccharides and the interaction between G-CSF and heparin was correlated with the chain length of heparin.	Oligosaccharides	78-94	colony stimulating factor 3	Homo sapiens	123-128
16100743-9	2005	In conclusion, the purified heparinase could selectively degrade heparin into oligosaccharides and the interaction between G-CSF and heparin was correlated with the chain length of heparin.	Heparin	65-72	colony stimulating factor 3	Homo sapiens	123-128
16100743-9	2005	In conclusion, the purified heparinase could selectively degrade heparin into oligosaccharides and the interaction between G-CSF and heparin was correlated with the chain length of heparin.	Heparin	65-72	colony stimulating factor 3	Homo sapiens	123-128
16158825-3	2005	Granulocyte colony-stimulating factor was infused continuously, starting 12 hours before Ara-C therapy and continuing until the end of Ara-C therapy.	Cytarabine	89-94	colony stimulating factor 3	Homo sapiens	0-37
16120623-2	2005	METHODS: Accidentally, we observed a complete response (CR) in a patient undergoing chemotherapy with bleomycin, vincristine or Oncovin, CCNU or lomustine, dacarbazine (BOLD) regimen for metastatic melanoma including brain metastases, who was also treated with G-CSF to manage a concomitant leukopenia.	Bleomycin	102-111	colony stimulating factor 3	Homo sapiens	261-266
16120623-2	2005	METHODS: Accidentally, we observed a complete response (CR) in a patient undergoing chemotherapy with bleomycin, vincristine or Oncovin, CCNU or lomustine, dacarbazine (BOLD) regimen for metastatic melanoma including brain metastases, who was also treated with G-CSF to manage a concomitant leukopenia.	Dacarbazine	156-167	colony stimulating factor 3	Homo sapiens	261-266
16350786-13	2005	In an effort to develop a novel microfluidic based drug screening platform, systematic studies on the interaction between granulocyte colony-stimulating factor (G-CSF) and sulfated oligosaccharides were carried out at both molecular and cellular levels.	Oligosaccharides	181-197	colony stimulating factor 3	Homo sapiens	122-159
15993849-3	2005	Exposure of A549 to ethanol (0.1-1%) dose-dependently inhibited (by 15-49%) the release of G-CSF and IL-8, but not of M-CSF, triggered by IL1beta or TNFalpha.	Ethanol	20-27	colony stimulating factor 3	Homo sapiens	91-96
16158825-3	2005	Granulocyte colony-stimulating factor was infused continuously, starting 12 hours before Ara-C therapy and continuing until the end of Ara-C therapy.	Cytarabine	135-140	colony stimulating factor 3	Homo sapiens	0-37
15814645-0	2005	A phase I clinical, pharmacologic, and biologic study of thrombopoietin and granulocyte colony-stimulating factor in children receiving ifosfamide, carboplatin, and etoposide chemotherapy for recurrent or refractory solid tumors: a Children"s Oncology Group experience.	Etoposide	165-174	colony stimulating factor 3	Homo sapiens	76-113
15837093-7	2005	At the follow-up, G-CSF treated had improved in CCS classification, NTG consumption and angina attacks, but the controls only in CCS classification.	Nitroglycerin	68-71	colony stimulating factor 3	Homo sapiens	18-23
29899681-0	2005	Site-Specific Protein PEGylation: Application to Cysteine Analogs of Recombinant Human Granulocyte Colony-Stimulating Factor.	Cysteine	49-57	colony stimulating factor 3	Homo sapiens	87-124
15753051-9	2005	Pulmonary complications caused by G-CSF include cough, dyspnea, and interstitial or alveolar pulmonary edema with mild-to-severe deterioration of blood oxygen level.	Oxygen	152-158	colony stimulating factor 3	Homo sapiens	34-39
15865083-3	2005	G-CSF was administered during epirubicin-vinorelbine treatment.	Epirubicin	30-40	colony stimulating factor 3	Homo sapiens	0-5
15865083-3	2005	G-CSF was administered during epirubicin-vinorelbine treatment.	Vinorelbine	41-52	colony stimulating factor 3	Homo sapiens	0-5
15494432-3	2005	G-CSF treatment also induced an increase in serum levels of soluble uPAR (suPAR).	supar	74-79	colony stimulating factor 3	Homo sapiens	0-5
15494432-4	2005	Cleaved forms of suPAR (c-suPAR) were released in vitro by PBMNCs and were also detected in the serum of G-CSF-treated donors.	supar	17-22	colony stimulating factor 3	Homo sapiens	105-110
15494432-4	2005	Cleaved forms of suPAR (c-suPAR) were released in vitro by PBMNCs and were also detected in the serum of G-CSF-treated donors.	c-supar	24-31	colony stimulating factor 3	Homo sapiens	105-110
15791811-8	2005	Among patients in this study attaining CR, the probability of relapse was reduced when they had been assigned to treatment with G-CSF along with induction chemotherapy.	Chromium	39-41	colony stimulating factor 3	Homo sapiens	128-133
15640521-4	2005	IL-1beta promoted the elaboration of G-CSF, which was augmented by PGE(2).	Prostaglandins E	67-70	colony stimulating factor 3	Homo sapiens	37-42
15842138-2	2005	METHODS: Seventy-nine patients with anterior AMI were randomly divided into three groups, they were treated with conventional Western medical treatment, but to the puerarin group (PG) and the G-CSF group (GCG) puerarin and G-CSF was given additionally, respectively.	gallocatechin gallate	205-208	colony stimulating factor 3	Homo sapiens	192-197
15842138-2	2005	METHODS: Seventy-nine patients with anterior AMI were randomly divided into three groups, they were treated with conventional Western medical treatment, but to the puerarin group (PG) and the G-CSF group (GCG) puerarin and G-CSF was given additionally, respectively.	puerarin	210-218	colony stimulating factor 3	Homo sapiens	192-197
15699110-6	2005	Thus, a population of cytokine-expanded GM precursors function as regulatory APCs, suggesting that G-CSF derivatives may have application in disorders characterized by a loss of self-tolerance.	gm	40-42	colony stimulating factor 3	Homo sapiens	99-104
15365768-0	2005	Granulocyte colony-stimulating factor-induced capillary leak syndrome confirmed by extravascular lung water measurements.	Water	102-107	colony stimulating factor 3	Homo sapiens	0-37
15365768-1	2005	The study purpose was to report the first case of granulocyte colony-stimulating factor (G-CSF)-induced capillary leak syndrome (CLS) in which serial extravascular lung water (EVLW) measurements were performed and to compare this case with previously reported cases.	Water	169-174	colony stimulating factor 3	Homo sapiens	50-87
15365768-1	2005	The study purpose was to report the first case of granulocyte colony-stimulating factor (G-CSF)-induced capillary leak syndrome (CLS) in which serial extravascular lung water (EVLW) measurements were performed and to compare this case with previously reported cases.	Water	169-174	colony stimulating factor 3	Homo sapiens	89-94
15640521-9	2005	In contrast, AH 6809 and L-161,982 in combination competitively antagonized PGE(2)-induced G-CSF release.	Dinoprostone	76-82	colony stimulating factor 3	Homo sapiens	91-96
15640521-10	2005	Augmentation of G-CSF release by PGE(2) was mimicked by 8-BrcAMP and abolished in cells infected with an adenovirus vector encoding an inhibitor protein of cAMP-dependent protein kinase (PKA).	Prostaglandins E	33-36	colony stimulating factor 3	Homo sapiens	16-21
15528403-8	2005	The opposing (1)effect of E-ring (2)8-isoprostanes on GM-CSF and G-CSF release was mimicked by 8-bromo-cAMP and abolished in cells infected with an adenovirus vector encoding an inhibitor protein of cAMP-dependent protein kinase (PKA).	8-epi-prostaglandin F2alpha	36-50	colony stimulating factor 3	Homo sapiens	65-70
15717132-2	2005	The mPEG derivative was successfully conjugated with two proteins: recombinant human granulocyte-colony stimulating factor (rhG-CSF) and consensus interferon (C-IFN).	monomethoxypolyethylene glycol	4-8	colony stimulating factor 3	Homo sapiens	85-122
15735921-12	2005	CONCLUSION: Paclitaxel and topotecan with G-CSF support exhibits modest activity in adults with recurrent or refractory glioblastoma and anaplastic astrocytoma.	Topotecan	27-36	colony stimulating factor 3	Homo sapiens	42-47
15528403-3	2005	Here, we report the effect of a variety of E- and Falpha-ring 8-isoprostanes on the release of granulocyte/macrophage colony-stimulating factor (GM-CSF) and granulocyte colony-stimulating factor (G-CSF) from human airway smooth muscle (HASM) cells stimulated with interleukin-1beta (IL-1beta).	e- and falpha-ring 8-isoprostanes	43-76	colony stimulating factor 3	Homo sapiens	157-194
15528403-8	2005	The opposing (1)effect of E-ring (2)8-isoprostanes on GM-CSF and G-CSF release was mimicked by 8-bromo-cAMP and abolished in cells infected with an adenovirus vector encoding an inhibitor protein of cAMP-dependent protein kinase (PKA).	8-Bromo Cyclic Adenosine Monophosphate	95-107	colony stimulating factor 3	Homo sapiens	65-70
15528403-3	2005	Here, we report the effect of a variety of E- and Falpha-ring 8-isoprostanes on the release of granulocyte/macrophage colony-stimulating factor (GM-CSF) and granulocyte colony-stimulating factor (G-CSF) from human airway smooth muscle (HASM) cells stimulated with interleukin-1beta (IL-1beta).	e- and falpha-ring 8-isoprostanes	43-76	colony stimulating factor 3	Homo sapiens	196-201
15528403-9	2005	Together, these data demonstrate that E-ring 8-isoprostanes regulate the secretion of GM-CSF and G-CSF from HASM cells by a cAMP- and PKA-dependent mechanism.	e-ring 8-isoprostanes	38-59	colony stimulating factor 3	Homo sapiens	97-102
15528403-4	2005	The elaboration of GM-CSF and G-CSF by IL-1beta was inhibited and augmented, respectively, in a concentration-dependent manner by 8-iso-prostaglandin (PG) E(1) and 8-iso-PGE(2), but not by 8-iso-PGF(1alpha), 8-iso-PGF(2alpha), and 8-iso-PGF(3)alpha.	8-iso-prostaglandin	130-149	colony stimulating factor 3	Homo sapiens	30-35
15528403-4	2005	The elaboration of GM-CSF and G-CSF by IL-1beta was inhibited and augmented, respectively, in a concentration-dependent manner by 8-iso-prostaglandin (PG) E(1) and 8-iso-PGE(2), but not by 8-iso-PGF(1alpha), 8-iso-PGF(2alpha), and 8-iso-PGF(3)alpha.	8-iso-pge	164-173	colony stimulating factor 3	Homo sapiens	30-35
15528403-9	2005	Together, these data demonstrate that E-ring 8-isoprostanes regulate the secretion of GM-CSF and G-CSF from HASM cells by a cAMP- and PKA-dependent mechanism.	Cyclic AMP	124-128	colony stimulating factor 3	Homo sapiens	97-102
15528403-4	2005	The elaboration of GM-CSF and G-CSF by IL-1beta was inhibited and augmented, respectively, in a concentration-dependent manner by 8-iso-prostaglandin (PG) E(1) and 8-iso-PGE(2), but not by 8-iso-PGF(1alpha), 8-iso-PGF(2alpha), and 8-iso-PGF(3)alpha.	8-iso-pgf	189-198	colony stimulating factor 3	Homo sapiens	30-35
15528403-10	2005	Moreover, antagonist studies revealed that 8-iso-PGE(1) and 8-iso-PGE(2) act solely via EP(2) -receptors to inhibit GM-CSF release, whereas both EP(2)- and EP(4)-receptor subtypes positively regulate G-CSF output.	8-iso-pge	43-52	colony stimulating factor 3	Homo sapiens	200-205
15528403-4	2005	The elaboration of GM-CSF and G-CSF by IL-1beta was inhibited and augmented, respectively, in a concentration-dependent manner by 8-iso-prostaglandin (PG) E(1) and 8-iso-PGE(2), but not by 8-iso-PGF(1alpha), 8-iso-PGF(2alpha), and 8-iso-PGF(3)alpha.	8-iso-pgf	208-217	colony stimulating factor 3	Homo sapiens	30-35
15528403-4	2005	The elaboration of GM-CSF and G-CSF by IL-1beta was inhibited and augmented, respectively, in a concentration-dependent manner by 8-iso-prostaglandin (PG) E(1) and 8-iso-PGE(2), but not by 8-iso-PGF(1alpha), 8-iso-PGF(2alpha), and 8-iso-PGF(3)alpha.	8-iso-pgf	208-217	colony stimulating factor 3	Homo sapiens	30-35
15528403-10	2005	Moreover, antagonist studies revealed that 8-iso-PGE(1) and 8-iso-PGE(2) act solely via EP(2) -receptors to inhibit GM-CSF release, whereas both EP(2)- and EP(4)-receptor subtypes positively regulate G-CSF output.	8-iso-pge	60-69	colony stimulating factor 3	Homo sapiens	200-205
15540243-0	2005	Granulocyte--colony-stimulating factor (Filgrastim) may overcome imatinib-induced neutropenia in patients with chronic-phase myelogenous leukemia.	Imatinib Mesylate	65-73	colony stimulating factor 3	Homo sapiens	0-38
15531906-1	2005	Following induction therapy and 4 g/m(2) cyclophosphamide, a single dose of 12 mg polyethyleneglycol-conjugated G-CSF (pegfilgrastim; n=12) or daily doses of unconjugated G-CSF (8.5 mug/kg/day) (n=12) were administered to myeloma patients.	Polyethylene Glycols	82-100	colony stimulating factor 3	Homo sapiens	112-117
15613908-0	2005	Biweekly docetaxel and vinorelbine with granulocyte colony-stimulating factor support for patients with anthracycline-resistant metastatic breast cancer.	Vinorelbine	23-34	colony stimulating factor 3	Homo sapiens	40-85
15613908-0	2005	Biweekly docetaxel and vinorelbine with granulocyte colony-stimulating factor support for patients with anthracycline-resistant metastatic breast cancer.	Anthracyclines	104-117	colony stimulating factor 3	Homo sapiens	40-85
16392893-1	2005	Pegfilgrastim (Neulasta), the sustained-duration form of filgrastim (recombinant human granulocyte colony-stimulating factor [G-CSF]), is created by the addition of a polyethylene glycol (PEG) moiety to filgrastim.	Polyethylene Glycols	167-186	colony stimulating factor 3	Homo sapiens	87-124
16392893-1	2005	Pegfilgrastim (Neulasta), the sustained-duration form of filgrastim (recombinant human granulocyte colony-stimulating factor [G-CSF]), is created by the addition of a polyethylene glycol (PEG) moiety to filgrastim.	Polyethylene Glycols	167-186	colony stimulating factor 3	Homo sapiens	126-131
16020968-13	2005	CONCLUSIONS: Biweekly DTX/CPT-11 with G-CSF support is a well-tolerated and highly effective approach in anthracycline-/paclitaxel-pretreated patients.	Docetaxel	22-25	colony stimulating factor 3	Homo sapiens	38-43
17523775-11	2005	The use of prophylactic G-CSF allowed the administration of high doses of docetaxel with minimal myelosuppression.	Docetaxel	74-83	colony stimulating factor 3	Homo sapiens	24-29
16188671-6	2005	Subsequently, JCOG developed a new alternating multi-agent chemotherapy including MCNU and carboplatin with prophyractic use of G-CSF, resulting 35% of CR rate and 31% of 2-year OS.	Chromium	152-154	colony stimulating factor 3	Homo sapiens	128-133
15541478-6	2005	Inhibition of tyrosine phosphatase activity by pervanadate restored the ability of G-CSF to activate MAPK in mature neutrophils.	pervanadate	47-58	colony stimulating factor 3	Homo sapiens	83-88
16172536-1	2005	Bone marrow cells (BMC) obtained from normal and cyclophosphamide (CY)-treated mice were cultured in the presence of recombinant human granulocyte-colony stimulating factor (rhG-CSF) and their effector cell activities inhibiting growth of C. albicans were examined.	Cyclophosphamide	49-65	colony stimulating factor 3	Homo sapiens	135-172
16020968-13	2005	CONCLUSIONS: Biweekly DTX/CPT-11 with G-CSF support is a well-tolerated and highly effective approach in anthracycline-/paclitaxel-pretreated patients.	Irinotecan	26-32	colony stimulating factor 3	Homo sapiens	38-43
16020968-13	2005	CONCLUSIONS: Biweekly DTX/CPT-11 with G-CSF support is a well-tolerated and highly effective approach in anthracycline-/paclitaxel-pretreated patients.	Anthracyclines	105-118	colony stimulating factor 3	Homo sapiens	38-43
16020968-13	2005	CONCLUSIONS: Biweekly DTX/CPT-11 with G-CSF support is a well-tolerated and highly effective approach in anthracycline-/paclitaxel-pretreated patients.	Paclitaxel	120-130	colony stimulating factor 3	Homo sapiens	38-43
15771240-0	2005	Effects of excipients on the hydrogen peroxide-induced oxidation of methionine residues in granulocyte colony-stimulating factor.	Hydrogen Peroxide	29-46	colony stimulating factor 3	Homo sapiens	91-128
15899616-5	2004	Conversely, two randomized trials have demonstrated that dose-dense scheduled chemotherapy with G-CSF support, containing an anthracycline, cyclophosphamide and paclitaxel, improves clinical outcomes compared with the same regimen administered every 3 weeks.	Anthracyclines	125-138	colony stimulating factor 3	Homo sapiens	96-101
15771240-0	2005	Effects of excipients on the hydrogen peroxide-induced oxidation of methionine residues in granulocyte colony-stimulating factor.	Methionine	68-78	colony stimulating factor 3	Homo sapiens	91-128
15771240-1	2005	PURPOSE: The objective of this study was to elucidate the different mechanisms of action of different excipients on the oxidation of Met1, Met122, Met127, and Met138 in granulocyte colony-stimulating factor (G-CSF) by using hydrogen peroxide as the oxidant.	Hydrogen Peroxide	224-241	colony stimulating factor 3	Homo sapiens	169-206
15771240-5	2005	RESULTS: The current work reveals that the preferential excluding excipients sorbitol, sucrose, and trehalose, in the concentration range 0-30% (w/v), and the preferential binding excipients urea and guanidine hydrochloride, in the concentration range 0-0.8 M, do not affect the oxidation of methionine residues in G-CSF at pH 4.5.	Urea	191-195	colony stimulating factor 3	Homo sapiens	315-320
15771240-6	2005	The chelating agents citrate and EDTA have different effects on the rates of oxidation of methionine residues in G-CSF.	Citric Acid	21-28	colony stimulating factor 3	Homo sapiens	113-118
15771240-6	2005	The chelating agents citrate and EDTA have different effects on the rates of oxidation of methionine residues in G-CSF.	Edetic Acid	33-37	colony stimulating factor 3	Homo sapiens	113-118
15771240-6	2005	The chelating agents citrate and EDTA have different effects on the rates of oxidation of methionine residues in G-CSF.	Methionine	90-100	colony stimulating factor 3	Homo sapiens	113-118
15771240-8	2005	EDTA decreases the rates of oxidation of methionine residues in G-CSF, such that its effect becomes more and more as its concentration is increased from 0 to 200 mM.	Edetic Acid	0-4	colony stimulating factor 3	Homo sapiens	64-69
15771240-8	2005	EDTA decreases the rates of oxidation of methionine residues in G-CSF, such that its effect becomes more and more as its concentration is increased from 0 to 200 mM.	Methionine	41-51	colony stimulating factor 3	Homo sapiens	64-69
15771240-9	2005	The efficacy of EDTA on the rates of oxidation of the four methionine residues in G-CSF follows the order Met122 &gt; Met127 &gt; Met138 &gt; Met1.	Edetic Acid	16-20	colony stimulating factor 3	Homo sapiens	82-87
15771240-9	2005	The efficacy of EDTA on the rates of oxidation of the four methionine residues in G-CSF follows the order Met122 &gt; Met127 &gt; Met138 &gt; Met1.	Methionine	59-69	colony stimulating factor 3	Homo sapiens	82-87
15771240-10	2005	CONCLUSIONS: Our results indicate that EDTA can protect the methionine residues in G-CSF against oxidation induced by hydrogen peroxide.	Edetic Acid	39-43	colony stimulating factor 3	Homo sapiens	83-88
15771240-10	2005	CONCLUSIONS: Our results indicate that EDTA can protect the methionine residues in G-CSF against oxidation induced by hydrogen peroxide.	Methionine	60-70	colony stimulating factor 3	Homo sapiens	83-88
15771240-10	2005	CONCLUSIONS: Our results indicate that EDTA can protect the methionine residues in G-CSF against oxidation induced by hydrogen peroxide.	Hydrogen Peroxide	118-135	colony stimulating factor 3	Homo sapiens	83-88
15600366-0	2004	Oxidation of methionine residues in aqueous solutions: free methionine and methionine in granulocyte colony-stimulating factor.	Methionine	13-23	colony stimulating factor 3	Homo sapiens	89-126
15600366-1	2004	The free energy barriers and a mechanism of the oxidation of the amino acid methionine in water and in granulocyte colony-stimulating factor (G-CSF) are analyzed via combined quantum mechanical and molecular mechanical (QM/MM) methods, constrained molecular dynamics, and committor probability calculations.	Methionine	76-86	colony stimulating factor 3	Homo sapiens	103-140
15600366-1	2004	The free energy barriers and a mechanism of the oxidation of the amino acid methionine in water and in granulocyte colony-stimulating factor (G-CSF) are analyzed via combined quantum mechanical and molecular mechanical (QM/MM) methods, constrained molecular dynamics, and committor probability calculations.	Methionine	76-86	colony stimulating factor 3	Homo sapiens	142-147
15600366-5	2004	The computed free energies of the oxidation of methionine residues in G-CSF indicate that the protein environment has insignificant effects on the reaction barriers of oxidation.	Methionine	47-57	colony stimulating factor 3	Homo sapiens	70-75
15899616-5	2004	Conversely, two randomized trials have demonstrated that dose-dense scheduled chemotherapy with G-CSF support, containing an anthracycline, cyclophosphamide and paclitaxel, improves clinical outcomes compared with the same regimen administered every 3 weeks.	Cyclophosphamide	140-156	colony stimulating factor 3	Homo sapiens	96-101
15899616-5	2004	Conversely, two randomized trials have demonstrated that dose-dense scheduled chemotherapy with G-CSF support, containing an anthracycline, cyclophosphamide and paclitaxel, improves clinical outcomes compared with the same regimen administered every 3 weeks.	Paclitaxel	161-171	colony stimulating factor 3	Homo sapiens	96-101
15646653-1	2004	Stimulation of human neutrophils with granulocyte colony-stimulating factor (G-CSF), granulocyte-macrophage CSF (GM-CSF), or tumor necrosis factor alpha (TNF) resulted in phosphorylation of Akt, the potency being GM-CSF &gt; G-CSF = TNF, which was inhibited by wortmannin.	Wortmannin	261-271	colony stimulating factor 3	Homo sapiens	38-75
15547723-0	2004	The effect of G-CSF on the in vitro cytotoxicity of cytarabine and fludarabine in the FLAG combination in pediatric acute myeloid leukemia.	Cytarabine	52-62	colony stimulating factor 3	Homo sapiens	14-19
15646653-5	2004	Actin reorganization and morphological changes induced by G-CSF or GM-CSF were also inhibited by wortmannin, whereas these responses induced by TNF were unaffected by wortmannin.	Wortmannin	97-107	colony stimulating factor 3	Homo sapiens	58-63
15547723-0	2004	The effect of G-CSF on the in vitro cytotoxicity of cytarabine and fludarabine in the FLAG combination in pediatric acute myeloid leukemia.	fludarabine	67-78	colony stimulating factor 3	Homo sapiens	14-19
15547723-2	2004	In this study we characterized the interactions between fludarabine, ara-C and G-CSF in vitro using AML blasts.	fludarabine	56-67	colony stimulating factor 3	Homo sapiens	79-84
15685835-3	2004	With the addition of granulocyte colony-stimulating factor (G-CSF [Neupogen]) to the regimen, patients received epirubicin at clinically relevant doses after dose-escalation.	Epirubicin	112-122	colony stimulating factor 3	Homo sapiens	21-58
15547723-4	2004	The LCS decreased significantly from 69.7 to 54.0% when blasts were exposed to G-CSF 21 h prior to incubation with ara-C (p=0.01).	Cytarabine	115-120	colony stimulating factor 3	Homo sapiens	79-84
15685835-3	2004	With the addition of granulocyte colony-stimulating factor (G-CSF [Neupogen]) to the regimen, patients received epirubicin at clinically relevant doses after dose-escalation.	Epirubicin	112-122	colony stimulating factor 3	Homo sapiens	60-65
15273712-4	2004	With the introduction of the recombinant myeloid growth factor, granulocyte-colony stimulating factor (G-CSF), the quantity of granulocytes that could be harvested was substantially increased leading to renewed interest in the clinical application of GTX.	hexylglutathione	251-254	colony stimulating factor 3	Homo sapiens	64-101
15648272-5	2004	Therefore, the different effects of free methionine, acetylcysteine, and glutathione on the rates of oxidation of methionine residues in G-CSF are consistent with their different reactivity toward oxidation by H2O2.	Acetylcysteine	53-67	colony stimulating factor 3	Homo sapiens	137-142
15648272-5	2004	Therefore, the different effects of free methionine, acetylcysteine, and glutathione on the rates of oxidation of methionine residues in G-CSF are consistent with their different reactivity toward oxidation by H2O2.	Glutathione	73-84	colony stimulating factor 3	Homo sapiens	137-142
15648272-5	2004	Therefore, the different effects of free methionine, acetylcysteine, and glutathione on the rates of oxidation of methionine residues in G-CSF are consistent with their different reactivity toward oxidation by H2O2.	Methionine	114-124	colony stimulating factor 3	Homo sapiens	137-142
15648272-5	2004	Therefore, the different effects of free methionine, acetylcysteine, and glutathione on the rates of oxidation of methionine residues in G-CSF are consistent with their different reactivity toward oxidation by H2O2.	Hydrogen Peroxide	210-214	colony stimulating factor 3	Homo sapiens	137-142
15648272-12	2004	CONCLUSIONS: Our results demonstrate that free methionine is an effective antioxidant to protect G-CSF against methionine oxidation at pH 4.5.	Methionine	47-57	colony stimulating factor 3	Homo sapiens	97-102
15648272-12	2004	CONCLUSIONS: Our results demonstrate that free methionine is an effective antioxidant to protect G-CSF against methionine oxidation at pH 4.5.	Methionine	111-121	colony stimulating factor 3	Homo sapiens	97-102
15648272-0	2004	Effects of antioxidants on the hydrogen peroxide-mediated oxidation of methionine residues in granulocyte colony-stimulating factor and human parathyroid hormone fragment 13-34.	Hydrogen Peroxide	31-48	colony stimulating factor 3	Homo sapiens	94-131
15648272-0	2004	Effects of antioxidants on the hydrogen peroxide-mediated oxidation of methionine residues in granulocyte colony-stimulating factor and human parathyroid hormone fragment 13-34.	Methionine	71-81	colony stimulating factor 3	Homo sapiens	94-131
15648272-1	2004	PURPOSE: The effects and mechanisms of different antioxidants, methionine, glutathione, acetylcysteine, and ascorbic acid (AscH2), on the oxidation of methionine residues in granulocyte colony-stimulating factor (G-CSF) and human parathyroid hormone fragment 13-34 (hPTH 13-34) by hydrogen peroxide (H2O2) were quantified and analyzed.	Methionine	63-73	colony stimulating factor 3	Homo sapiens	174-211
15648272-1	2004	PURPOSE: The effects and mechanisms of different antioxidants, methionine, glutathione, acetylcysteine, and ascorbic acid (AscH2), on the oxidation of methionine residues in granulocyte colony-stimulating factor (G-CSF) and human parathyroid hormone fragment 13-34 (hPTH 13-34) by hydrogen peroxide (H2O2) were quantified and analyzed.	Glutathione	75-86	colony stimulating factor 3	Homo sapiens	174-211
15648272-1	2004	PURPOSE: The effects and mechanisms of different antioxidants, methionine, glutathione, acetylcysteine, and ascorbic acid (AscH2), on the oxidation of methionine residues in granulocyte colony-stimulating factor (G-CSF) and human parathyroid hormone fragment 13-34 (hPTH 13-34) by hydrogen peroxide (H2O2) were quantified and analyzed.	Acetylcysteine	88-102	colony stimulating factor 3	Homo sapiens	174-211
15648272-1	2004	PURPOSE: The effects and mechanisms of different antioxidants, methionine, glutathione, acetylcysteine, and ascorbic acid (AscH2), on the oxidation of methionine residues in granulocyte colony-stimulating factor (G-CSF) and human parathyroid hormone fragment 13-34 (hPTH 13-34) by hydrogen peroxide (H2O2) were quantified and analyzed.	Ascorbic Acid	108-121	colony stimulating factor 3	Homo sapiens	174-211
15648272-1	2004	PURPOSE: The effects and mechanisms of different antioxidants, methionine, glutathione, acetylcysteine, and ascorbic acid (AscH2), on the oxidation of methionine residues in granulocyte colony-stimulating factor (G-CSF) and human parathyroid hormone fragment 13-34 (hPTH 13-34) by hydrogen peroxide (H2O2) were quantified and analyzed.	asch2	123-128	colony stimulating factor 3	Homo sapiens	174-211
15648272-1	2004	PURPOSE: The effects and mechanisms of different antioxidants, methionine, glutathione, acetylcysteine, and ascorbic acid (AscH2), on the oxidation of methionine residues in granulocyte colony-stimulating factor (G-CSF) and human parathyroid hormone fragment 13-34 (hPTH 13-34) by hydrogen peroxide (H2O2) were quantified and analyzed.	Methionine	151-161	colony stimulating factor 3	Homo sapiens	174-211
15648272-1	2004	PURPOSE: The effects and mechanisms of different antioxidants, methionine, glutathione, acetylcysteine, and ascorbic acid (AscH2), on the oxidation of methionine residues in granulocyte colony-stimulating factor (G-CSF) and human parathyroid hormone fragment 13-34 (hPTH 13-34) by hydrogen peroxide (H2O2) were quantified and analyzed.	Methionine	151-161	colony stimulating factor 3	Homo sapiens	213-218
15648272-1	2004	PURPOSE: The effects and mechanisms of different antioxidants, methionine, glutathione, acetylcysteine, and ascorbic acid (AscH2), on the oxidation of methionine residues in granulocyte colony-stimulating factor (G-CSF) and human parathyroid hormone fragment 13-34 (hPTH 13-34) by hydrogen peroxide (H2O2) were quantified and analyzed.	Hydrogen Peroxide	281-298	colony stimulating factor 3	Homo sapiens	174-211
15648272-1	2004	PURPOSE: The effects and mechanisms of different antioxidants, methionine, glutathione, acetylcysteine, and ascorbic acid (AscH2), on the oxidation of methionine residues in granulocyte colony-stimulating factor (G-CSF) and human parathyroid hormone fragment 13-34 (hPTH 13-34) by hydrogen peroxide (H2O2) were quantified and analyzed.	Hydrogen Peroxide	300-304	colony stimulating factor 3	Homo sapiens	174-211
15648272-3	2004	RESULTS: At pH 4.5, free methionine reduces, glutathione and acetylcysteine have no obvious effect on, and AscH2 promotes the rates of oxidation of methionine residues in G-CSF.	Methionine	148-158	colony stimulating factor 3	Homo sapiens	171-176
15648272-4	2004	The H2O2-induced oxidation rate constants for free methionine, acetylcysteine, and glutathione at pH 4.5 were measured to be 32.07, 1.00, and 1.63 M(-1)h(-1), respectively, while the oxidation rate constant for Met1, the most readily oxidizable methionine residue in G-CSF, is 13.95 M(-1)h(-1).	Hydrogen Peroxide	4-8	colony stimulating factor 3	Homo sapiens	267-272
15648272-4	2004	The H2O2-induced oxidation rate constants for free methionine, acetylcysteine, and glutathione at pH 4.5 were measured to be 32.07, 1.00, and 1.63 M(-1)h(-1), respectively, while the oxidation rate constant for Met1, the most readily oxidizable methionine residue in G-CSF, is 13.95 M(-1)h(-1).	Methionine	51-61	colony stimulating factor 3	Homo sapiens	267-272
15648272-4	2004	The H2O2-induced oxidation rate constants for free methionine, acetylcysteine, and glutathione at pH 4.5 were measured to be 32.07, 1.00, and 1.63 M(-1)h(-1), respectively, while the oxidation rate constant for Met1, the most readily oxidizable methionine residue in G-CSF, is 13.95 M(-1)h(-1).	Glutathione	83-94	colony stimulating factor 3	Homo sapiens	267-272
15648272-5	2004	Therefore, the different effects of free methionine, acetylcysteine, and glutathione on the rates of oxidation of methionine residues in G-CSF are consistent with their different reactivity toward oxidation by H2O2.	Methionine	41-51	colony stimulating factor 3	Homo sapiens	137-142
15238428-5	2004	The day-10 (Mann-Whitney U test; P = .012) and day-14 (P = .025) neutrophil counts were significantly lower in patients receiving PIs, though there were no differences in the number of days of granulocyte colony-stimulating factor (G-CSF) administered between groups (P = .16).	Monothiopyrophosphoric acid	130-133	colony stimulating factor 3	Homo sapiens	232-237
15273712-4	2004	With the introduction of the recombinant myeloid growth factor, granulocyte-colony stimulating factor (G-CSF), the quantity of granulocytes that could be harvested was substantially increased leading to renewed interest in the clinical application of GTX.	hexylglutathione	251-254	colony stimulating factor 3	Homo sapiens	103-108
15273712-6	2004	Infusion of G-CSF stimulated GTX results in measurable increases in the recipients" neutrophil count and may reduce the duration and severity of neutropenia.	hexylglutathione	29-32	colony stimulating factor 3	Homo sapiens	12-17
15627641-4	2004	The inhibitory effect of G-CSF pretreatment on TNF production is partially reversed by addition of an anti-IL-10 antibody, and completely reversed by combined addition of anti-IL-10 antibody and the cyclooxygenase (COX) inhibitor, ketoprofen.	Ketoprofen	231-241	colony stimulating factor 3	Homo sapiens	25-30
15727166-1	2004	OBJECTIVE: To evaluate the therapeutic effects of recombinant human erythropoietin (rhEPO) and recombinant human granulocyte colony stimulating factor (rhG-CSF) on sulfur mustard (SM) induced toxicity in dogs.	Mustard Gas	164-178	colony stimulating factor 3	Homo sapiens	113-150
15358478-0	2004	A patient with granulocyte-colony stimulating factor-producing endometrial cancer who responded to high-dose cisplatin, cyclophosphamide and adriamycin.	Cisplatin	109-118	colony stimulating factor 3	Homo sapiens	15-52
15358478-0	2004	A patient with granulocyte-colony stimulating factor-producing endometrial cancer who responded to high-dose cisplatin, cyclophosphamide and adriamycin.	Cyclophosphamide	120-136	colony stimulating factor 3	Homo sapiens	15-52
15358478-0	2004	A patient with granulocyte-colony stimulating factor-producing endometrial cancer who responded to high-dose cisplatin, cyclophosphamide and adriamycin.	Doxorubicin	141-151	colony stimulating factor 3	Homo sapiens	15-52
15470038-0	2004	Granulocyte colony-stimulating factor modulates alpha-galactosylceramide-responsive human Valpha24+Vbeta11+NKT cells.	alpha-galactosylceramide	48-72	colony stimulating factor 3	Homo sapiens	0-37
15627641-0	2004	Granulocyte colony-stimulating factor decreases tumor necrosis factor production in whole blood: role of interleukin-10 and prostaglandin E(2).	Prostaglandins E	124-139	colony stimulating factor 3	Homo sapiens	0-37
15627641-5	2004	These results suggest that G-CSF decreases TNF production in this experimental model by increasing production of IL-10 and PGE(2), which are both known inhibitors of TNF production.	Prostaglandins E	123-126	colony stimulating factor 3	Homo sapiens	27-32
15377466-1	2004	BACKGROUND AND OBJECTIVES: In a previous study we showed that patients with severe aplastic anemia (SAA) treated with anti-lymphocyte globulin (ALG), cyclosporin (CyA) and granulocyte colony-stimulating factor (G-CSF) 5 micro g/kg/day had an encouraging outcome.	saa	100-103	colony stimulating factor 3	Homo sapiens	172-209
15553045-6	2004	G-CSF enables continuous treatment with high-dose imatinib.	Imatinib Mesylate	50-58	colony stimulating factor 3	Homo sapiens	0-5
15292935-0	2004	Phase I-II study of irinotecan (CPT-11) plus nedaplatin (254-S) with recombinant human granulocyte colony-stimulating factor support in patients with advanced or recurrent cervical cancer.	Irinotecan	20-30	colony stimulating factor 3	Homo sapiens	87-124
15380050-7	2004	The effect of G-CSF, GM-CSF, IL3 and M-CSF on daunorubicin mediated cytotoxicity in K562 cells was measured using the MTT assay.	Daunorubicin	46-58	colony stimulating factor 3	Homo sapiens	14-19
15377466-1	2004	BACKGROUND AND OBJECTIVES: In a previous study we showed that patients with severe aplastic anemia (SAA) treated with anti-lymphocyte globulin (ALG), cyclosporin (CyA) and granulocyte colony-stimulating factor (G-CSF) 5 micro g/kg/day had an encouraging outcome.	saa	100-103	colony stimulating factor 3	Homo sapiens	211-216
15377466-1	2004	BACKGROUND AND OBJECTIVES: In a previous study we showed that patients with severe aplastic anemia (SAA) treated with anti-lymphocyte globulin (ALG), cyclosporin (CyA) and granulocyte colony-stimulating factor (G-CSF) 5 micro g/kg/day had an encouraging outcome.	Cyclosporine	150-161	colony stimulating factor 3	Homo sapiens	172-209
15377466-1	2004	BACKGROUND AND OBJECTIVES: In a previous study we showed that patients with severe aplastic anemia (SAA) treated with anti-lymphocyte globulin (ALG), cyclosporin (CyA) and granulocyte colony-stimulating factor (G-CSF) 5 micro g/kg/day had an encouraging outcome.	Cyclosporine	150-161	colony stimulating factor 3	Homo sapiens	211-216
15377466-14	2004	INTERPRETATION AND CONCLUSIONS: Increasing the dose of G-CSF does not appear to reduce early deaths, does not improve peripheral blood counts nor survival, and may reduce the response rate in patients with SAA receiving ALG and CyA.	saa	206-209	colony stimulating factor 3	Homo sapiens	55-60
15217942-4	2004	EXPERIMENTAL DESIGN: We administered rituximab with CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) treatment with G-CSF to 15 patients with follicular lymphoma, and we investigated the safety and efficacy of this regimen.	Doxorubicin	76-87	colony stimulating factor 3	Homo sapiens	129-134
15208496-12	2004	An additional patient given 6 GBq of 188Re-lipiodol demonstrated myelosuppression, which recovered with granulocyte colony-stimulating factor (GCSF) and platelet support.	(188)Re-lipiodol	37-51	colony stimulating factor 3	Homo sapiens	104-141
15208496-12	2004	An additional patient given 6 GBq of 188Re-lipiodol demonstrated myelosuppression, which recovered with granulocyte colony-stimulating factor (GCSF) and platelet support.	(188)Re-lipiodol	37-51	colony stimulating factor 3	Homo sapiens	143-147
15197801-0	2004	Granulocyte-colony-stimulating factor (filgrastim) may overcome imatinib-induced neutropenia in patients with chronic-phase chronic myelogenous leukemia.	Imatinib Mesylate	64-72	colony stimulating factor 3	Homo sapiens	0-37
15197801-4	2004	The authors investigated the ability of granulocyte-colony-stimulating factor (filgrastim) to reverse imatinib-associated neutropenia, thereby allowing for more continuous imatinib administration.	Imatinib Mesylate	102-110	colony stimulating factor 3	Homo sapiens	40-77
15197801-4	2004	The authors investigated the ability of granulocyte-colony-stimulating factor (filgrastim) to reverse imatinib-associated neutropenia, thereby allowing for more continuous imatinib administration.	Imatinib Mesylate	172-180	colony stimulating factor 3	Homo sapiens	40-77
15197811-8	2004	In minimally pretreated patients, G-CSF allowed paclitaxel dose escalation to 110 mg/m(2).	Paclitaxel	48-58	colony stimulating factor 3	Homo sapiens	34-39
15338063-1	2004	OBJECTIVE: In a recently completed randomised clinical trial in patients with colorectal cancer resections the combination of the granulocyte-colony stimulating factor (G-CSF) + cefuroxime/ metronidazole (cef/met) was superior to ofloxacin/metronidazole (ofl/met).	Ofloxacin	230-239	colony stimulating factor 3	Homo sapiens	130-167
15338063-1	2004	OBJECTIVE: In a recently completed randomised clinical trial in patients with colorectal cancer resections the combination of the granulocyte-colony stimulating factor (G-CSF) + cefuroxime/ metronidazole (cef/met) was superior to ofloxacin/metronidazole (ofl/met).	Metronidazole	240-253	colony stimulating factor 3	Homo sapiens	130-167
15555260-1	2004	OBJECTIVE: To evaluate the efficacy of mitoxantrone combined high dose of cytarabine and recombinant human granulocyte colony-stimulating factor (MAG) regimen for mobilizing autologous peripheral blood stem cells (APBSC) in patients with hematopoietic malignancies.	Mitoxantrone	39-51	colony stimulating factor 3	Homo sapiens	107-144
15222004-3	2004	The current study was conducted to assess the feasibility of reducing time intervals between cycles while delivering standard doses of docetaxel with granulocyte-colony-stimulating factor (G-CSF; lenograstim).	Docetaxel	135-144	colony stimulating factor 3	Homo sapiens	150-187
15222004-3	2004	The current study was conducted to assess the feasibility of reducing time intervals between cycles while delivering standard doses of docetaxel with granulocyte-colony-stimulating factor (G-CSF; lenograstim).	Docetaxel	135-144	colony stimulating factor 3	Homo sapiens	189-194
15222004-9	2004	CONCLUSIONS: Introduction of G-CSF (lenograstim) as primary prophylaxis allowed the administration of docetaxel every 14 days with manageable toxicities.	Docetaxel	102-111	colony stimulating factor 3	Homo sapiens	29-34
15217942-4	2004	EXPERIMENTAL DESIGN: We administered rituximab with CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) treatment with G-CSF to 15 patients with follicular lymphoma, and we investigated the safety and efficacy of this regimen.	Vincristine	89-100	colony stimulating factor 3	Homo sapiens	129-134
15217942-4	2004	EXPERIMENTAL DESIGN: We administered rituximab with CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) treatment with G-CSF to 15 patients with follicular lymphoma, and we investigated the safety and efficacy of this regimen.	Prednisone	102-112	colony stimulating factor 3	Homo sapiens	129-134
15223604-7	2004	Moreover, in vitro and in vivo studies demonstrated that G-CSF may act as a co-stimulus augmenting the response of PML-RARalpha acute promyelocytic leukemia cells to all-trans-retinoic acid treatment.	Tretinoin	176-189	colony stimulating factor 3	Homo sapiens	57-62
15181605-8	2004	In patients with breast cancer, the key Cancer and Leukemia Group B 9741 trial showed that dose-dense doxorubicin, cyclophosphamide, and paclitaxel chemotherapy with granulocyte colony-stimulating factor (G-CSF), repeated every 2 weeks, is superior to the same regimen administered at standard 3-weekly intervals.	Doxorubicin	102-113	colony stimulating factor 3	Homo sapiens	166-203
15181605-8	2004	In patients with breast cancer, the key Cancer and Leukemia Group B 9741 trial showed that dose-dense doxorubicin, cyclophosphamide, and paclitaxel chemotherapy with granulocyte colony-stimulating factor (G-CSF), repeated every 2 weeks, is superior to the same regimen administered at standard 3-weekly intervals.	Paclitaxel	137-147	colony stimulating factor 3	Homo sapiens	166-203
15181605-8	2004	In patients with breast cancer, the key Cancer and Leukemia Group B 9741 trial showed that dose-dense doxorubicin, cyclophosphamide, and paclitaxel chemotherapy with granulocyte colony-stimulating factor (G-CSF), repeated every 2 weeks, is superior to the same regimen administered at standard 3-weekly intervals.	Paclitaxel	137-147	colony stimulating factor 3	Homo sapiens	205-210
15123426-0	2004	Regulation of LIP level and ROS formation through interaction of H-ferritin with G-CSF receptor.	Reactive Oxygen Species	28-31	colony stimulating factor 3	Homo sapiens	81-86
15123426-13	2004	G-CSF-induced changes in the level of LIP and ROS formation could be blocked by pretreatment with iron chelators that repressed the expression of H-ferritin.	Reactive Oxygen Species	46-49	colony stimulating factor 3	Homo sapiens	0-5
15123426-13	2004	G-CSF-induced changes in the level of LIP and ROS formation could be blocked by pretreatment with iron chelators that repressed the expression of H-ferritin.	Iron	98-102	colony stimulating factor 3	Homo sapiens	0-5
15123426-14	2004	In addition, the phosphorylation of STAT3 induced by G-CSF was decreased in iron chelator-treated hematopoietic cells.	Iron	76-80	colony stimulating factor 3	Homo sapiens	53-58
15123426-16	2004	ROS, acting as a second messenger, might take part in G-CSF receptor signal transduction.	Reactive Oxygen Species	0-3	colony stimulating factor 3	Homo sapiens	54-59
15136221-6	2004	These effects were blocked by the presence of SB203580, a p38 MAPK inhibitor, by U0126, a MAPK p42/44 inhibitor, and by inhibiting the G-CSF receptor with a specific antibody.	SB 203580	46-54	colony stimulating factor 3	Homo sapiens	135-140
15060747-7	2004	The addition of DXM to G-CSF diminished some symptoms, particularly bone pain, headache and the frequency of requests for analgesics.	Dexamethasone	16-19	colony stimulating factor 3	Homo sapiens	23-28
15145212-6	2004	RESULTS: The G-CSF/IgG-Fc and G-CSF/IgG-C(H) fusion proteins were secreted from transfected COS cells primarily as disulfide-linked homodimers.	Disulfides	115-124	colony stimulating factor 3	Homo sapiens	13-18
15145212-6	2004	RESULTS: The G-CSF/IgG-Fc and G-CSF/IgG-C(H) fusion proteins were secreted from transfected COS cells primarily as disulfide-linked homodimers.	Disulfides	115-124	colony stimulating factor 3	Homo sapiens	30-35
15068906-0	2004	Induction of differentiation of retinoic acid-resistant acute promyelocytic leukemia cells by the combination of all-trans retinoic acid and granulocyte colony-stimulating factor.	Tretinoin	32-45	colony stimulating factor 3	Homo sapiens	141-178
15068906-1	2004	An acute promyelocytic leukemia (APL) cell line with natural resistance to all-trans retinoic acid (ATRA), UF-1, was induced to differentiate into mature granulocyte when treated with the combination of ATRA and granulocyte colony-stimulating factor (G-CSF), while neither of them alone was capable of inducing the differentiation effectively.	Tretinoin	85-98	colony stimulating factor 3	Homo sapiens	212-249
15068906-1	2004	An acute promyelocytic leukemia (APL) cell line with natural resistance to all-trans retinoic acid (ATRA), UF-1, was induced to differentiate into mature granulocyte when treated with the combination of ATRA and granulocyte colony-stimulating factor (G-CSF), while neither of them alone was capable of inducing the differentiation effectively.	Tretinoin	100-104	colony stimulating factor 3	Homo sapiens	212-249
15068906-1	2004	An acute promyelocytic leukemia (APL) cell line with natural resistance to all-trans retinoic acid (ATRA), UF-1, was induced to differentiate into mature granulocyte when treated with the combination of ATRA and granulocyte colony-stimulating factor (G-CSF), while neither of them alone was capable of inducing the differentiation effectively.	Tretinoin	100-104	colony stimulating factor 3	Homo sapiens	251-256
15026024-5	2004	We used an enzymatic approach to remove the carbohydrate residues from glycosylated G-CSF and tested this material for its stability in serum.	Carbohydrates	44-56	colony stimulating factor 3	Homo sapiens	84-89
15033663-22	2004	CONCLUSIONS: Docetaxel 160 mg/m(2) was delivered with G-CSF support with a very low rate of febrile neutropenia.	Docetaxel	13-22	colony stimulating factor 3	Homo sapiens	54-59
15117429-5	2004	A phase III study in 571 patients comparing pemetrexed with docetaxel demonstrated clinically equivalent therapeutic outcomes in second-line treatment of patients with recurrent NSCLC; however, patients on the pemetrexed arm had a more favorable hematologic toxicity profile, with fewer episodes of neutropenia, neutropenic fever, and infections and less use of granulocyte colony-stimulating factor support.	Pemetrexed	210-220	colony stimulating factor 3	Homo sapiens	362-399
14604978-1	2004	Several lines of investigation suggest that granulocyte colony-stimulating factor (G-CSF) augments all-trans retinoic acid (ATRA)-induced neutrophil differentiation in acute promyelocytic leukemia (APL).	Tretinoin	99-122	colony stimulating factor 3	Homo sapiens	44-81
14604978-1	2004	Several lines of investigation suggest that granulocyte colony-stimulating factor (G-CSF) augments all-trans retinoic acid (ATRA)-induced neutrophil differentiation in acute promyelocytic leukemia (APL).	Tretinoin	99-122	colony stimulating factor 3	Homo sapiens	83-88
14604978-1	2004	Several lines of investigation suggest that granulocyte colony-stimulating factor (G-CSF) augments all-trans retinoic acid (ATRA)-induced neutrophil differentiation in acute promyelocytic leukemia (APL).	Tretinoin	124-128	colony stimulating factor 3	Homo sapiens	44-81
14604978-1	2004	Several lines of investigation suggest that granulocyte colony-stimulating factor (G-CSF) augments all-trans retinoic acid (ATRA)-induced neutrophil differentiation in acute promyelocytic leukemia (APL).	Tretinoin	124-128	colony stimulating factor 3	Homo sapiens	83-88
14604978-10	2004	The addition of G-CSF with ATRA during NB4 induction resulted in STAT3 phosphorylation but did not enhance differentiation.	Tretinoin	27-31	colony stimulating factor 3	Homo sapiens	16-21
15004848-0	2004	Capillary zone electrophoresis investigation of the interaction between heparin and granulocyte-colony stimulating factor.	Heparin	72-79	colony stimulating factor 3	Homo sapiens	84-121
14871251-3	2004	Strikingly, high-dose cytarabine and etoposide plus granulocyte colony stimulating factor (G-CSF) mobilized PBSC harvests from acute myeloid leukaemia (AML) patients containing the highest number of myeloid lin(neg)CD11c(pos) DC (mean: 7.04 x 106/kg, range: 1.46-19.67) which was 18.1-fold higher than in non-AML patients mobilized using chemotherapy (CT) regimens plus G-CSF.	Cytarabine	22-32	colony stimulating factor 3	Homo sapiens	370-375
14871251-3	2004	Strikingly, high-dose cytarabine and etoposide plus granulocyte colony stimulating factor (G-CSF) mobilized PBSC harvests from acute myeloid leukaemia (AML) patients containing the highest number of myeloid lin(neg)CD11c(pos) DC (mean: 7.04 x 106/kg, range: 1.46-19.67) which was 18.1-fold higher than in non-AML patients mobilized using chemotherapy (CT) regimens plus G-CSF.	Etoposide	37-46	colony stimulating factor 3	Homo sapiens	370-375
15004848-3	2004	The binding constants of the two different groups of heparins with G-CSF, calculated from the Scatchard plot by regression, were 4.805 x 10(5) M(-1) and 4.579 x 10(5) M(-1), respectively.	Heparin	53-61	colony stimulating factor 3	Homo sapiens	67-72
15004848-4	2004	The two binding constants measured are of the same order of magnitude at 10(5) M(-1), indicating that LMWH contains most of the functional groups bound to G-CSF by standard heparin.	Heparin, Low-Molecular-Weight	102-106	colony stimulating factor 3	Homo sapiens	155-160
15004848-4	2004	The two binding constants measured are of the same order of magnitude at 10(5) M(-1), indicating that LMWH contains most of the functional groups bound to G-CSF by standard heparin.	Heparin	173-180	colony stimulating factor 3	Homo sapiens	155-160
15075667-1	2004	The purpose of this study was (i) to determine the maximum tolerated dose (MTD) of docetaxel that can be administered in combination with Doxil, given without and with granulocyte colony stimulating factor (G-CSF), (ii) to define the pharmacokinetics (PK) of docetaxel when used in combination with Doxil, and (iii) to make preliminary observations on the anti-tumor activity of this combination in patients with metastatic solid tumors.	Docetaxel	83-92	colony stimulating factor 3	Homo sapiens	168-205
14657210-0	2004	The significance of carbohydrates on G-CSF: differential sensitivity of G-CSFs to human neutrophil elastase degradation.	Carbohydrates	20-33	colony stimulating factor 3	Homo sapiens	37-42
14657210-7	2004	The significance of sugar residues on glycosylated G-CSF in providing protection against the effects of elastase was investigated using enzymatically deglycosylated G-CSF and a mutated form of the G-CSF molecule that was expressed in yeast but was NG.	Sugars	20-25	colony stimulating factor 3	Homo sapiens	51-56
15139398-6	2004	Amifostine acts as a protector of salivary glands GM-CSF and G-CSF stimulate proliferation of mucosal basal cells.	Amifostine	0-10	colony stimulating factor 3	Homo sapiens	61-66
14744147-0	2004	Molecular dynamics simulations and oxidation rates of methionine residues of granulocyte colony-stimulating factor at different pH values.	Methionine	54-64	colony stimulating factor 3	Homo sapiens	77-114
14744147-1	2004	To understand the connection between the conformation of a protein molecule and the oxidation of its methionine residues, we measured the rates of oxidation of methionine residues by H(2)O(2) in granulocyte colony-stimulating factor (G-CSF) as a function of pH and also studied the structural properties of this protein as a function of pH via molecular dynamics simulations.	Methionine	160-170	colony stimulating factor 3	Homo sapiens	234-239
14744147-2	2004	We found that each of the four methionine groups in G-CSF have significant and different rates of oxidation as a function of pH.	Methionine	31-41	colony stimulating factor 3	Homo sapiens	52-57
14744147-4	2004	The structural properties of G-CSF as a function of pH are evaluated in terms of properties such as hydrogen bonding, deviations from X-ray structure, helical/helical packing, and the atomic covariance fluctuation matrix of alpha-carbons.	Hydrogen	100-108	colony stimulating factor 3	Homo sapiens	29-34
14744147-4	2004	The structural properties of G-CSF as a function of pH are evaluated in terms of properties such as hydrogen bonding, deviations from X-ray structure, helical/helical packing, and the atomic covariance fluctuation matrix of alpha-carbons.	Carbon	230-237	colony stimulating factor 3	Homo sapiens	29-34
15000944-0	2004	[Splenic and bone marrow increased 18F-FDG uptake in a PET scan performed following treatment with G-CSF].	Fluorodeoxyglucose F18	35-42	colony stimulating factor 3	Homo sapiens	99-104
15075667-1	2004	The purpose of this study was (i) to determine the maximum tolerated dose (MTD) of docetaxel that can be administered in combination with Doxil, given without and with granulocyte colony stimulating factor (G-CSF), (ii) to define the pharmacokinetics (PK) of docetaxel when used in combination with Doxil, and (iii) to make preliminary observations on the anti-tumor activity of this combination in patients with metastatic solid tumors.	Docetaxel	83-92	colony stimulating factor 3	Homo sapiens	207-212
15075667-12	2004	The recommended phase II dose of Doxil/docetaxel is 30/60 mg/m(2), q3 weeks, without G-CSF.	liposomal doxorubicin	33-38	colony stimulating factor 3	Homo sapiens	85-90
15075667-12	2004	The recommended phase II dose of Doxil/docetaxel is 30/60 mg/m(2), q3 weeks, without G-CSF.	Docetaxel	39-48	colony stimulating factor 3	Homo sapiens	85-90
14610236-0	2004	Granulocyte colony-stimulating factor (filgrastim) treatment primes for increased ex vivo inducible prostanoid release.	Prostaglandins	100-110	colony stimulating factor 3	Homo sapiens	0-37
14610236-1	2004	We investigated whether anti-inflammatory effects of treatment with granulocyte colony-stimulating factor (G-CSF, filgrastim) are mediated via prostaglandin E(2) (PGE(2)) induction.	Dinoprostone	143-161	colony stimulating factor 3	Homo sapiens	107-112
14610236-4	2004	The increase in neutrophilic granulocytes initiated by G-CSF was augmented significantly by flurbiprofen.	Flurbiprofen	92-104	colony stimulating factor 3	Homo sapiens	55-60
14610236-5	2004	Lipopolysaccharide-induced PGE(2) and thromboxane (TxB(2)) release were increased 8 h after G-CSF treatment.	Prostaglandins E	27-30	colony stimulating factor 3	Homo sapiens	92-97
14610236-9	2004	When flurbiprofen was given before injection, one volunteer each reported side effects in the G-CSF and in the saline group.	Flurbiprofen	5-17	colony stimulating factor 3	Homo sapiens	94-99
14610236-10	2004	These data show that G-CSF primes for increased PGE(2) and TxB(2) release.	Prostaglandins E	48-51	colony stimulating factor 3	Homo sapiens	21-26
14665607-0	2004	Docetaxel and cisplatin with granulocyte colony-stimulating factor (G-CSF) versus MVAC with G-CSF in advanced urothelial carcinoma: a multicenter, randomized, phase III study from the Hellenic Cooperative Oncology Group.	Cisplatin	14-23	colony stimulating factor 3	Homo sapiens	29-66
14665607-0	2004	Docetaxel and cisplatin with granulocyte colony-stimulating factor (G-CSF) versus MVAC with G-CSF in advanced urothelial carcinoma: a multicenter, randomized, phase III study from the Hellenic Cooperative Oncology Group.	Cisplatin	14-23	colony stimulating factor 3	Homo sapiens	68-73
14665607-13	2004	G-CSF-supported MVAC is well tolerated and could be used instead of classic MVAC as first-line treatment in advanced urothelial carcinoma.	mvac	16-20	colony stimulating factor 3	Homo sapiens	0-5
12954601-7	2004	G-CSF-induced responses were almost completely abolished by PD-98059 and were unaffected by SB-203580.	2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one	60-68	colony stimulating factor 3	Homo sapiens	0-5
14725899-8	2004	The PI3 kinase inhibitors LY294002 and wortmannin substituted for G-CSF in combination with IL-3 since proliferation in the presence of LY294002/wortmannin+IL-3 was enhanced to the same extent as in the presence of G-CSF+IL-3.	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one	26-34	colony stimulating factor 3	Homo sapiens	215-220
15124675-8	2004	The synergism between Ara-C and STI-571 was even more pronounced in Raji and HL-60 cells when 300 ng/ml G-CSF were added at the beginning of the culture period.	Cytarabine	22-27	colony stimulating factor 3	Homo sapiens	104-109
15124675-8	2004	The synergism between Ara-C and STI-571 was even more pronounced in Raji and HL-60 cells when 300 ng/ml G-CSF were added at the beginning of the culture period.	Imatinib Mesylate	32-39	colony stimulating factor 3	Homo sapiens	104-109
15266474-4	2004	OBJECTIVES: To determine the effectiveness of G-CSF and GM-CSF in patients with malignant lymphoma with respect to preventing neutropenia, febrile neutropenia and infection; improving quality of life, adherence to treatment protocol, tumour response, freedom from treatment failure (FFTF) and overall survival (OS); and adverse effects.	fftf	283-287	colony stimulating factor 3	Homo sapiens	46-51
14725909-9	2004	5-Azacytidine, a DNA methylation blocking agent, inhibited G-CSF in vitro induction of allele-specific replication.	Azacitidine	0-13	colony stimulating factor 3	Homo sapiens	59-64
14726661-0	2004	A phase II study of topotecan and cyclophosphamide with G-CSF in patients with advanced small cell lung cancer.	Topotecan	20-29	colony stimulating factor 3	Homo sapiens	56-61
14726661-0	2004	A phase II study of topotecan and cyclophosphamide with G-CSF in patients with advanced small cell lung cancer.	Cyclophosphamide	34-50	colony stimulating factor 3	Homo sapiens	56-61
14718443-13	2004	G-CSF in serum and IL-8 in BALF correlated negatively with PaO(2)/fraction of inspired oxygen (FIO(2)) ratio.	Oxygen	87-93	colony stimulating factor 3	Homo sapiens	0-5
14725899-8	2004	The PI3 kinase inhibitors LY294002 and wortmannin substituted for G-CSF in combination with IL-3 since proliferation in the presence of LY294002/wortmannin+IL-3 was enhanced to the same extent as in the presence of G-CSF+IL-3.	Wortmannin	39-49	colony stimulating factor 3	Homo sapiens	215-220
14725899-8	2004	The PI3 kinase inhibitors LY294002 and wortmannin substituted for G-CSF in combination with IL-3 since proliferation in the presence of LY294002/wortmannin+IL-3 was enhanced to the same extent as in the presence of G-CSF+IL-3.	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one	136-144	colony stimulating factor 3	Homo sapiens	66-71
14725899-8	2004	The PI3 kinase inhibitors LY294002 and wortmannin substituted for G-CSF in combination with IL-3 since proliferation in the presence of LY294002/wortmannin+IL-3 was enhanced to the same extent as in the presence of G-CSF+IL-3.	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one	136-144	colony stimulating factor 3	Homo sapiens	215-220
14725899-8	2004	The PI3 kinase inhibitors LY294002 and wortmannin substituted for G-CSF in combination with IL-3 since proliferation in the presence of LY294002/wortmannin+IL-3 was enhanced to the same extent as in the presence of G-CSF+IL-3.	Wortmannin	145-155	colony stimulating factor 3	Homo sapiens	66-71
15079154-4	2004	Promising results have been published in recent years using fludarabine-containing combination therapy for AML, most commonly fludarabine +cytarabine + granulocyte colony-stimulating factor (G-CSF) [FLAG], FLAG + mitoxantrone (FLANG), or FLAG + idarubicin (FLAG-Ida).	fludarabine	60-71	colony stimulating factor 3	Homo sapiens	152-189
14979480-1	2004	The present study was performed to examine whether the expression of CD64 Fc gamma receptor type I (FcgammaRI) on both neutrophils and monocytes can be modulated by multiple daily administrations of granulocyte colony-stimulating factor (G-CSF) to patients with non-Hodgkin"s lymphoma in neutropenia caused by CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) chemotherapy.	Cyclophosphamide	316-332	colony stimulating factor 3	Homo sapiens	199-236
14979480-1	2004	The present study was performed to examine whether the expression of CD64 Fc gamma receptor type I (FcgammaRI) on both neutrophils and monocytes can be modulated by multiple daily administrations of granulocyte colony-stimulating factor (G-CSF) to patients with non-Hodgkin"s lymphoma in neutropenia caused by CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) chemotherapy.	Cyclophosphamide	316-332	colony stimulating factor 3	Homo sapiens	238-243
14979480-1	2004	The present study was performed to examine whether the expression of CD64 Fc gamma receptor type I (FcgammaRI) on both neutrophils and monocytes can be modulated by multiple daily administrations of granulocyte colony-stimulating factor (G-CSF) to patients with non-Hodgkin"s lymphoma in neutropenia caused by CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) chemotherapy.	Doxorubicin	334-345	colony stimulating factor 3	Homo sapiens	199-236
14979480-1	2004	The present study was performed to examine whether the expression of CD64 Fc gamma receptor type I (FcgammaRI) on both neutrophils and monocytes can be modulated by multiple daily administrations of granulocyte colony-stimulating factor (G-CSF) to patients with non-Hodgkin"s lymphoma in neutropenia caused by CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) chemotherapy.	Doxorubicin	334-345	colony stimulating factor 3	Homo sapiens	238-243
14979480-1	2004	The present study was performed to examine whether the expression of CD64 Fc gamma receptor type I (FcgammaRI) on both neutrophils and monocytes can be modulated by multiple daily administrations of granulocyte colony-stimulating factor (G-CSF) to patients with non-Hodgkin"s lymphoma in neutropenia caused by CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) chemotherapy.	Vincristine	347-358	colony stimulating factor 3	Homo sapiens	199-236
14979480-1	2004	The present study was performed to examine whether the expression of CD64 Fc gamma receptor type I (FcgammaRI) on both neutrophils and monocytes can be modulated by multiple daily administrations of granulocyte colony-stimulating factor (G-CSF) to patients with non-Hodgkin"s lymphoma in neutropenia caused by CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) chemotherapy.	Vincristine	347-358	colony stimulating factor 3	Homo sapiens	238-243
14979480-1	2004	The present study was performed to examine whether the expression of CD64 Fc gamma receptor type I (FcgammaRI) on both neutrophils and monocytes can be modulated by multiple daily administrations of granulocyte colony-stimulating factor (G-CSF) to patients with non-Hodgkin"s lymphoma in neutropenia caused by CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) chemotherapy.	Prednisone	364-374	colony stimulating factor 3	Homo sapiens	199-236
14979480-1	2004	The present study was performed to examine whether the expression of CD64 Fc gamma receptor type I (FcgammaRI) on both neutrophils and monocytes can be modulated by multiple daily administrations of granulocyte colony-stimulating factor (G-CSF) to patients with non-Hodgkin"s lymphoma in neutropenia caused by CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) chemotherapy.	Prednisone	364-374	colony stimulating factor 3	Homo sapiens	238-243
15033698-0	2003	G-CSF modulates LPS-induced apoptosis and IL-8 in human microvascular endothelial cells: involvement of calcium signaling.	Calcium	104-111	colony stimulating factor 3	Homo sapiens	0-5
14693061-1	2003	BACKGROUND &amp; OBJECTIVE: Mobilization of hematopoietic stem cells from healthy donors by stimulators such as granulocyte colony stimulating factor (G-CSF) in allogeneic peripheral blood stem cell transplantation (allo- PBSCT) is increasingly used clinically; however, the mechanism, the dose, and the schedule are not fully understood.	Adenosine Monophosphate	12-15	colony stimulating factor 3	Homo sapiens	112-149
14693061-1	2003	BACKGROUND &amp; OBJECTIVE: Mobilization of hematopoietic stem cells from healthy donors by stimulators such as granulocyte colony stimulating factor (G-CSF) in allogeneic peripheral blood stem cell transplantation (allo- PBSCT) is increasingly used clinically; however, the mechanism, the dose, and the schedule are not fully understood.	Adenosine Monophosphate	12-15	colony stimulating factor 3	Homo sapiens	151-156
15493056-5	2004	The combination of G-CSF and dexamethasone resulted in higher WBC count than G-CSF alone (39.4 +/- 7.8 vs. 34.8 +/- 8.3/nl).	Dexamethasone	29-42	colony stimulating factor 3	Homo sapiens	77-82
15493056-6	2004	Glucose (136 +/- 45 mg/dl) and lactate dehydrogenase (195 +/- 38) increased significantly after stimulation with G-CSF plus dexamethasone but returned to baseline levels at the follow-up visit.	Glucose	0-7	colony stimulating factor 3	Homo sapiens	113-118
15033698-11	2003	Caspase 3 activity induced by LPS (24 h) or by staurosporin (6 h) was found to be dramatically downregulated by the G-CSF preincubation protocol.	Staurosporine	47-59	colony stimulating factor 3	Homo sapiens	116-121
14642127-6	2003	RESULTS: After 96 hours exposure to arsenic trioxide, 10 - 6 mol/L in vitro or 10 mg/d in vivo, APL cells showed a significant increase of IL-1(beta) (P &lt; 0.05) and G-CSF (P &lt; 0.05) production, and a significant decrease of IL-6 (P &lt; 0.05) and IL-8 (P &lt; 0.05).	Arsenic Trioxide	36-52	colony stimulating factor 3	Homo sapiens	168-173
14703065-0	2003	Dose-dense vinorelbine and paclitaxel with granulocyte colony-stimulating factor in metastatic breast cancer patients: anti-tumor activity and peripheral blood progenitor cell mobilization capability.	Paclitaxel	27-37	colony stimulating factor 3	Homo sapiens	43-80
12842982-7	2003	For all patients and for the subgroups given and not given granulocyte colony-stimulating factor (G-CSF), the 95% credible interval for the relative risk of failure in the PBB group was nearly centered at 1.0.	pbb	172-175	colony stimulating factor 3	Homo sapiens	98-103
14642127-10	2003	CONCLUSION: IL-1(beta) and G-CSF secretion may play an important role in the proliferation of APL cells after exposure to arsenic trioxide.	Arsenic Trioxide	122-138	colony stimulating factor 3	Homo sapiens	27-32
14556916-11	2003	Furthermore, since systematic dose reduction can impact on outcome, primary prophylactic use of G-CSF for all elderly patients receiving curative myelotoxic chemotherapy (cyclophosphamide, doxorubicin, vincristine and prednisolone (CHOP) or CHOP-like) is indicated and we suggest a risk-adapted strategy with primary prophylactic G-CSF administration in high-risk patients.	Cyclophosphamide	171-187	colony stimulating factor 3	Homo sapiens	96-101
14556916-11	2003	Furthermore, since systematic dose reduction can impact on outcome, primary prophylactic use of G-CSF for all elderly patients receiving curative myelotoxic chemotherapy (cyclophosphamide, doxorubicin, vincristine and prednisolone (CHOP) or CHOP-like) is indicated and we suggest a risk-adapted strategy with primary prophylactic G-CSF administration in high-risk patients.	Doxorubicin	189-200	colony stimulating factor 3	Homo sapiens	96-101
14745140-2	2003	Granulocyte colony-stimulating factor (G-CSF), although not having detectable effect by itself, exerted the additive effects on lipid droplet formation in NB4 cells when combined with ATRA.	Tretinoin	184-188	colony stimulating factor 3	Homo sapiens	0-37
14745140-2	2003	Granulocyte colony-stimulating factor (G-CSF), although not having detectable effect by itself, exerted the additive effects on lipid droplet formation in NB4 cells when combined with ATRA.	Tretinoin	184-188	colony stimulating factor 3	Homo sapiens	39-44
14561489-4	2003	In this study we generated a mutant granulocyte colony-stimulating factor (G-CSF) termed G-CSF.E20K in which this residue is substituted to Lys.	Lysine	140-143	colony stimulating factor 3	Homo sapiens	36-73
14651772-10	2003	Patients treated with AC with intensified doses of cyclophosphamide requiring G-CSF support had increased rates of treatment-related AML/MDS, even though the incidence was slight relative to breast cancer relapse.	Cyclophosphamide	51-67	colony stimulating factor 3	Homo sapiens	78-83
14561489-4	2003	In this study we generated a mutant granulocyte colony-stimulating factor (G-CSF) termed G-CSF.E20K in which this residue is substituted to Lys.	Lysine	140-143	colony stimulating factor 3	Homo sapiens	75-80
14561489-4	2003	In this study we generated a mutant granulocyte colony-stimulating factor (G-CSF) termed G-CSF.E20K in which this residue is substituted to Lys.	Lysine	140-143	colony stimulating factor 3	Homo sapiens	89-94
14994920-6	2003	Using Carboplatin with G-CSF and Cyclophosphamide with G-CSF we collected respectively a median value of 6.75 and 7.3 x 10(6) CD34+ cells/kg.	Cyclophosphamide	33-49	colony stimulating factor 3	Homo sapiens	55-60
14584290-4	2003	She underwent 6 cycles of EPOCH-G (etoposide, vincristine, adriamycin, cyclophosphamide, prednisolone, G-CSF) therapy, and obtained complete remission.	epoch-g	26-33	colony stimulating factor 3	Homo sapiens	103-108
12930322-0	2003	Elevation of extracellular adenosine mobilizes haematopoietic progenitor cells and granulocytes into peripheral blood and enhances the mobilizing effects of granulocyte colony-stimulating factor.	Adenosine	27-36	colony stimulating factor 3	Homo sapiens	157-194
12930322-6	2003	When the combination of DP + AMP + G-CSF was given under the 4-d regimen, the mobilizing effects of its administration were additive when compared with those of DP + AMP alone or G-CSF alone.	dp + amp	24-32	colony stimulating factor 3	Homo sapiens	179-184
12930322-6	2003	When the combination of DP + AMP + G-CSF was given under the 4-d regimen, the mobilizing effects of its administration were additive when compared with those of DP + AMP alone or G-CSF alone.	dp + amp	161-169	colony stimulating factor 3	Homo sapiens	35-40
12930322-7	2003	The observed ability of the drugs elevating extracellular adenosine to enhance the mobilizing action of G-CSF points out possible practical utilization of the findings presented here.	Adenosine	58-67	colony stimulating factor 3	Homo sapiens	104-109
12921217-2	2003	Pegfilgrastim is created with pegylation technology, whereby a 20-kD polyethylene glycol moiety is conjugated to filgrastim (recombinant human G-CSF), resulting in a larger molecule.	Polyethylene Glycols	69-88	colony stimulating factor 3	Homo sapiens	143-148
12915593-1	2003	PURPOSE: To investigate whether the relative dose-intensity of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy could be improved by prophylactic administration of granulocyte colony-stimulating factor (G-CSF) in elderly patients with aggressive non-Hodgkin"s lymphoma (NHL).	Cyclophosphamide	63-79	colony stimulating factor 3	Homo sapiens	194-231
12915593-1	2003	PURPOSE: To investigate whether the relative dose-intensity of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy could be improved by prophylactic administration of granulocyte colony-stimulating factor (G-CSF) in elderly patients with aggressive non-Hodgkin"s lymphoma (NHL).	Doxorubicin	81-92	colony stimulating factor 3	Homo sapiens	194-231
12915593-1	2003	PURPOSE: To investigate whether the relative dose-intensity of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy could be improved by prophylactic administration of granulocyte colony-stimulating factor (G-CSF) in elderly patients with aggressive non-Hodgkin"s lymphoma (NHL).	Vincristine	94-105	colony stimulating factor 3	Homo sapiens	194-231
12915593-1	2003	PURPOSE: To investigate whether the relative dose-intensity of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy could be improved by prophylactic administration of granulocyte colony-stimulating factor (G-CSF) in elderly patients with aggressive non-Hodgkin"s lymphoma (NHL).	Prednisone	111-121	colony stimulating factor 3	Homo sapiens	194-231
12930926-4	2003	Idarubicin and amsacrin were given at the end of a cycle to allow the cell-cycle-dependent cytotoxicity of cytarabine in the context of G-CSF to have a greater effect.	Idarubicin	0-10	colony stimulating factor 3	Homo sapiens	136-141
12930926-4	2003	Idarubicin and amsacrin were given at the end of a cycle to allow the cell-cycle-dependent cytotoxicity of cytarabine in the context of G-CSF to have a greater effect.	Amsacrine	15-23	colony stimulating factor 3	Homo sapiens	136-141
12884304-0	2003	Cyclic AMP increases endogenous granulocyte colony-stimulating factor formation in monocytes and THP-1 macrophages despite attenuated TNF-alpha formation.	Cyclic AMP	0-10	colony stimulating factor 3	Homo sapiens	32-69
12884304-4	2003	Surprisingly, G-CSF formation was enhanced in lipopolysaccharide (LPS)-stimulated blood from a pentoxifylline-treated patient.	Pentoxifylline	95-109	colony stimulating factor 3	Homo sapiens	14-19
12884304-5	2003	In the presence of dibutyryl-cAMP, forskolin, tolafentrine or 3-isobutyl-1-methylxanthine, LPS-induced G-CSF formation was enhanced in THP-1 cells, primary monocytes and whole blood.	Bucladesine	19-33	colony stimulating factor 3	Homo sapiens	103-108
12884304-5	2003	In the presence of dibutyryl-cAMP, forskolin, tolafentrine or 3-isobutyl-1-methylxanthine, LPS-induced G-CSF formation was enhanced in THP-1 cells, primary monocytes and whole blood.	Colforsin	35-44	colony stimulating factor 3	Homo sapiens	103-108
12884304-5	2003	In the presence of dibutyryl-cAMP, forskolin, tolafentrine or 3-isobutyl-1-methylxanthine, LPS-induced G-CSF formation was enhanced in THP-1 cells, primary monocytes and whole blood.	tolafentrine	46-58	colony stimulating factor 3	Homo sapiens	103-108
12884304-5	2003	In the presence of dibutyryl-cAMP, forskolin, tolafentrine or 3-isobutyl-1-methylxanthine, LPS-induced G-CSF formation was enhanced in THP-1 cells, primary monocytes and whole blood.	1-Methyl-3-isobutylxanthine	62-89	colony stimulating factor 3	Homo sapiens	103-108
12884304-6	2003	Correspondingly,rp-8-bromo-cAMP suppressed LPS-induced G-CSF release.	rp-8-bromo-camp	16-31	colony stimulating factor 3	Homo sapiens	55-60
12884304-7	2003	Addition of prostaglandin E(2) enhanced and indomethacin suppressed G-CSF formation.	Indomethacin	44-56	colony stimulating factor 3	Homo sapiens	68-73
12884304-8	2003	Reporter gene studies showed that dibutyryl-cAMP enhanced LPS-induced G-CSF promoter activity, indicating a transcriptional up-regulation.	dibutyryl	34-43	colony stimulating factor 3	Homo sapiens	70-75
12884304-8	2003	Reporter gene studies showed that dibutyryl-cAMP enhanced LPS-induced G-CSF promoter activity, indicating a transcriptional up-regulation.	Cyclic AMP	44-48	colony stimulating factor 3	Homo sapiens	70-75
12884304-9	2003	Furthermore, disruption of a newly identified putative cAMP-responsive element (CRE) in the G-CSF promoter demonstrated the regulatory role for G-CSF gene transcription.	Cyclic AMP	55-59	colony stimulating factor 3	Homo sapiens	92-97
12884304-9	2003	Furthermore, disruption of a newly identified putative cAMP-responsive element (CRE) in the G-CSF promoter demonstrated the regulatory role for G-CSF gene transcription.	Cyclic AMP	55-59	colony stimulating factor 3	Homo sapiens	144-149
12884304-10	2003	In conclusion, endogenous G-CSF formation critically depends on both TNF-alpha and cyclooxygenase products, exerting effects via cAMP and the CRE in the G-CSF promoter.	Cyclic AMP	129-133	colony stimulating factor 3	Homo sapiens	26-31
12818373-4	2003	Wortmannin, a specific inhibitor of PI3K, partially inhibited G-CSF-induced p70 S6K activity, c-Myc expression, and G-CSF-dependent proliferation, whereas rapamycin, an inhibitor of p70 S6K, completely inhibited p70 S6K activity, c-Myc expression, and G-CSF-dependent proliferation, indicating that the extent of c-Myc inhibition by these inhibitors correlates with a reduction in proliferation, and that c-Myc is downstream from PI3K/p70 S6K.	Wortmannin	0-10	colony stimulating factor 3	Homo sapiens	62-67
12872353-0	2003	High-dose ifosfamide with mesna and granulocyte-colony-stimulating factor (recombinant human G-CSF) in patients with unresectable malignant mesothelioma.	Ifosfamide	10-20	colony stimulating factor 3	Homo sapiens	93-98
12818373-4	2003	Wortmannin, a specific inhibitor of PI3K, partially inhibited G-CSF-induced p70 S6K activity, c-Myc expression, and G-CSF-dependent proliferation, whereas rapamycin, an inhibitor of p70 S6K, completely inhibited p70 S6K activity, c-Myc expression, and G-CSF-dependent proliferation, indicating that the extent of c-Myc inhibition by these inhibitors correlates with a reduction in proliferation, and that c-Myc is downstream from PI3K/p70 S6K.	Wortmannin	0-10	colony stimulating factor 3	Homo sapiens	116-121
12818373-4	2003	Wortmannin, a specific inhibitor of PI3K, partially inhibited G-CSF-induced p70 S6K activity, c-Myc expression, and G-CSF-dependent proliferation, whereas rapamycin, an inhibitor of p70 S6K, completely inhibited p70 S6K activity, c-Myc expression, and G-CSF-dependent proliferation, indicating that the extent of c-Myc inhibition by these inhibitors correlates with a reduction in proliferation, and that c-Myc is downstream from PI3K/p70 S6K.	Wortmannin	0-10	colony stimulating factor 3	Homo sapiens	116-121
12818373-7	2003	An antisense oligonucleotide for c-myc inhibited both G-CSF-dependent enhancement of c-Myc expression and proliferation in Trf-R(+) cells, but did not enhance the differentiation in terms of O(2)(-)-generating ability or fMLP-R expression.	Oligonucleotides	13-28	colony stimulating factor 3	Homo sapiens	54-59
12531794-1	2003	This study was designed to test the hypothesis that administration of granulocyte colony-stimulating factor (G-CSF; filgrastim) during induction chemotherapy with CHOP (cyclophosphamide, vincristine, doxorubicin, prednisone) or CNOP (doxorubicin replaced with mitoxantrone) in elderly patients with aggressive non-Hodgkin lymphoma (NHL) improves time to treatment failure (TTF), complete remission (CR) rate, and overall survival (OS).	Cyclophosphamide	169-185	colony stimulating factor 3	Homo sapiens	70-107
12743738-8	2003	The MTD of paclitaxel proved to be 160 mg/m(2), and the DLT was neutropenia, which improved well following treatment with G-CSF.	Paclitaxel	11-21	colony stimulating factor 3	Homo sapiens	122-127
14727458-7	2003	In the case of bone marrow suppression, colchicine should be continued with injections of G-CSF, whereas if the bone marrow is hypercellular it is suggested to use steroids and colchicine concomitantly.	Colchicine	40-50	colony stimulating factor 3	Homo sapiens	90-95
12531794-1	2003	This study was designed to test the hypothesis that administration of granulocyte colony-stimulating factor (G-CSF; filgrastim) during induction chemotherapy with CHOP (cyclophosphamide, vincristine, doxorubicin, prednisone) or CNOP (doxorubicin replaced with mitoxantrone) in elderly patients with aggressive non-Hodgkin lymphoma (NHL) improves time to treatment failure (TTF), complete remission (CR) rate, and overall survival (OS).	Cyclophosphamide	169-185	colony stimulating factor 3	Homo sapiens	109-114
12531794-1	2003	This study was designed to test the hypothesis that administration of granulocyte colony-stimulating factor (G-CSF; filgrastim) during induction chemotherapy with CHOP (cyclophosphamide, vincristine, doxorubicin, prednisone) or CNOP (doxorubicin replaced with mitoxantrone) in elderly patients with aggressive non-Hodgkin lymphoma (NHL) improves time to treatment failure (TTF), complete remission (CR) rate, and overall survival (OS).	Vincristine	187-198	colony stimulating factor 3	Homo sapiens	70-107
12531794-1	2003	This study was designed to test the hypothesis that administration of granulocyte colony-stimulating factor (G-CSF; filgrastim) during induction chemotherapy with CHOP (cyclophosphamide, vincristine, doxorubicin, prednisone) or CNOP (doxorubicin replaced with mitoxantrone) in elderly patients with aggressive non-Hodgkin lymphoma (NHL) improves time to treatment failure (TTF), complete remission (CR) rate, and overall survival (OS).	Doxorubicin	200-211	colony stimulating factor 3	Homo sapiens	109-114
12531794-1	2003	This study was designed to test the hypothesis that administration of granulocyte colony-stimulating factor (G-CSF; filgrastim) during induction chemotherapy with CHOP (cyclophosphamide, vincristine, doxorubicin, prednisone) or CNOP (doxorubicin replaced with mitoxantrone) in elderly patients with aggressive non-Hodgkin lymphoma (NHL) improves time to treatment failure (TTF), complete remission (CR) rate, and overall survival (OS).	Prednisone	213-223	colony stimulating factor 3	Homo sapiens	70-107
12531794-1	2003	This study was designed to test the hypothesis that administration of granulocyte colony-stimulating factor (G-CSF; filgrastim) during induction chemotherapy with CHOP (cyclophosphamide, vincristine, doxorubicin, prednisone) or CNOP (doxorubicin replaced with mitoxantrone) in elderly patients with aggressive non-Hodgkin lymphoma (NHL) improves time to treatment failure (TTF), complete remission (CR) rate, and overall survival (OS).	Prednisone	213-223	colony stimulating factor 3	Homo sapiens	109-114
12531794-1	2003	This study was designed to test the hypothesis that administration of granulocyte colony-stimulating factor (G-CSF; filgrastim) during induction chemotherapy with CHOP (cyclophosphamide, vincristine, doxorubicin, prednisone) or CNOP (doxorubicin replaced with mitoxantrone) in elderly patients with aggressive non-Hodgkin lymphoma (NHL) improves time to treatment failure (TTF), complete remission (CR) rate, and overall survival (OS).	cnop	228-232	colony stimulating factor 3	Homo sapiens	70-107
12531794-1	2003	This study was designed to test the hypothesis that administration of granulocyte colony-stimulating factor (G-CSF; filgrastim) during induction chemotherapy with CHOP (cyclophosphamide, vincristine, doxorubicin, prednisone) or CNOP (doxorubicin replaced with mitoxantrone) in elderly patients with aggressive non-Hodgkin lymphoma (NHL) improves time to treatment failure (TTF), complete remission (CR) rate, and overall survival (OS).	cnop	228-232	colony stimulating factor 3	Homo sapiens	109-114
12531794-1	2003	This study was designed to test the hypothesis that administration of granulocyte colony-stimulating factor (G-CSF; filgrastim) during induction chemotherapy with CHOP (cyclophosphamide, vincristine, doxorubicin, prednisone) or CNOP (doxorubicin replaced with mitoxantrone) in elderly patients with aggressive non-Hodgkin lymphoma (NHL) improves time to treatment failure (TTF), complete remission (CR) rate, and overall survival (OS).	Doxorubicin	234-245	colony stimulating factor 3	Homo sapiens	70-107
12531794-1	2003	This study was designed to test the hypothesis that administration of granulocyte colony-stimulating factor (G-CSF; filgrastim) during induction chemotherapy with CHOP (cyclophosphamide, vincristine, doxorubicin, prednisone) or CNOP (doxorubicin replaced with mitoxantrone) in elderly patients with aggressive non-Hodgkin lymphoma (NHL) improves time to treatment failure (TTF), complete remission (CR) rate, and overall survival (OS).	Doxorubicin	234-245	colony stimulating factor 3	Homo sapiens	109-114
12531794-1	2003	This study was designed to test the hypothesis that administration of granulocyte colony-stimulating factor (G-CSF; filgrastim) during induction chemotherapy with CHOP (cyclophosphamide, vincristine, doxorubicin, prednisone) or CNOP (doxorubicin replaced with mitoxantrone) in elderly patients with aggressive non-Hodgkin lymphoma (NHL) improves time to treatment failure (TTF), complete remission (CR) rate, and overall survival (OS).	Mitoxantrone	260-272	colony stimulating factor 3	Homo sapiens	70-107
12531794-1	2003	This study was designed to test the hypothesis that administration of granulocyte colony-stimulating factor (G-CSF; filgrastim) during induction chemotherapy with CHOP (cyclophosphamide, vincristine, doxorubicin, prednisone) or CNOP (doxorubicin replaced with mitoxantrone) in elderly patients with aggressive non-Hodgkin lymphoma (NHL) improves time to treatment failure (TTF), complete remission (CR) rate, and overall survival (OS).	Mitoxantrone	260-272	colony stimulating factor 3	Homo sapiens	109-114
12875692-11	2003	Infusion of donor PBPC mobilized by G-CSF seems to have more potentiated graft-versus-leukemia (GVL) effect than DDL infusion.	PbPc	18-22	colony stimulating factor 3	Homo sapiens	36-41
12702535-3	2003	Use of prophylactic granulocyte colony-stimulating factor (G-CSF) may allow higher doses of docetaxel to be administered with potentially greater anticancer efficacy.	Docetaxel	92-101	colony stimulating factor 3	Homo sapiens	20-57
12702535-3	2003	Use of prophylactic granulocyte colony-stimulating factor (G-CSF) may allow higher doses of docetaxel to be administered with potentially greater anticancer efficacy.	Docetaxel	92-101	colony stimulating factor 3	Homo sapiens	59-64
12702535-4	2003	The objectives of this study were to determine the maximum tolerated dose (MTD) and toxicity profile of docetaxel given with G-CSF support.	Docetaxel	104-113	colony stimulating factor 3	Homo sapiens	125-130
12702535-17	2003	CONCLUSIONS: Docetaxel may be escalated considerably above standard doses when administered with G-CSF support.	Docetaxel	13-22	colony stimulating factor 3	Homo sapiens	97-102
12926135-0	2003	Docetaxel and epirubicin supported by granulocyte colony-stimulating factor first-line in advanced breast cancer.	Epirubicin	14-24	colony stimulating factor 3	Homo sapiens	38-75
12790662-6	2003	For the GCSF analogues studied here, two point mutations as well as a poly(ethylene glycol) chemical conjugate were found to have increased potencies despite comparable or slightly lower affinities, and trafficking was predicted to be the responsible mechanism.	Polyethylene Glycols	70-91	colony stimulating factor 3	Homo sapiens	8-12
12702898-1	2003	Short-term treatment with granulocyte colony-stimulating factor has been successful in reducing the duration of clozapine-induced agranulocytosis.	Clozapine	112-121	colony stimulating factor 3	Homo sapiens	26-63
12873158-9	2003	Our results indicated that ATRA supplemented with vitamin D(3) and granulocyte colony-stimulating factor affords robust, rapid, and reproducible differentiation of both cell types.	Tretinoin	27-31	colony stimulating factor 3	Homo sapiens	67-104
12771616-2	2003	Increased use of granulocyte colony-stimulating factor in patients receiving chemotherapy has been paralleled by an increased incidence of bleomycin-induced pulmonary toxicity.	Bleomycin	139-148	colony stimulating factor 3	Homo sapiens	17-54
12711450-0	2003	PEGylation of G-CSF using cleavable oligo-lactic acid linkage.	Lactic Acid	42-53	colony stimulating factor 3	Homo sapiens	14-19
12684699-1	2003	Normal human endometrial stromal cells (ESCs) stimulated with 8-Br-cAMP secrete significantly large amounts of PRL and granulocyte colony-stimulating factor (G-CSF), whereas unstimulated stromal cells secreted little.	8-Bromo Cyclic Adenosine Monophosphate	62-71	colony stimulating factor 3	Homo sapiens	119-156
12684699-1	2003	Normal human endometrial stromal cells (ESCs) stimulated with 8-Br-cAMP secrete significantly large amounts of PRL and granulocyte colony-stimulating factor (G-CSF), whereas unstimulated stromal cells secreted little.	8-Bromo Cyclic Adenosine Monophosphate	62-71	colony stimulating factor 3	Homo sapiens	158-163
12684699-8	2003	These results indicate that M-CSF enhances G-CSF secretion from 8-Br-cAMP-unstimulated human endometrial stromal cells but not from 8-Br-cAMP-stimulated stromal cells, thus suggesting that there exists a functional subpopulation of G-CSF-secreting stromal cells that are different from the predecidualized ESCs that differentiate into PRL-secreting ESCs under stimuli with 8-Br-cAMP.	8-Bromo Cyclic Adenosine Monophosphate	64-73	colony stimulating factor 3	Homo sapiens	43-48
12684699-8	2003	These results indicate that M-CSF enhances G-CSF secretion from 8-Br-cAMP-unstimulated human endometrial stromal cells but not from 8-Br-cAMP-stimulated stromal cells, thus suggesting that there exists a functional subpopulation of G-CSF-secreting stromal cells that are different from the predecidualized ESCs that differentiate into PRL-secreting ESCs under stimuli with 8-Br-cAMP.	8-br	64-68	colony stimulating factor 3	Homo sapiens	43-48
12684699-8	2003	These results indicate that M-CSF enhances G-CSF secretion from 8-Br-cAMP-unstimulated human endometrial stromal cells but not from 8-Br-cAMP-stimulated stromal cells, thus suggesting that there exists a functional subpopulation of G-CSF-secreting stromal cells that are different from the predecidualized ESCs that differentiate into PRL-secreting ESCs under stimuli with 8-Br-cAMP.	Cyclic AMP	69-73	colony stimulating factor 3	Homo sapiens	43-48
12702182-1	2003	BACKGROUND: PBPC donors given G-CSF experience splenic enlargement and, rarely, spontaneous rupture of the spleen.	PbPc	12-16	colony stimulating factor 3	Homo sapiens	30-35
12711450-4	2003	mPEG-OLA-PC derivatives were conjugated to primary amine groups of recombinant human granulocyte-colony stimulating factor.	mpeg-ola-pc	0-11	colony stimulating factor 3	Homo sapiens	85-122
12711450-4	2003	mPEG-OLA-PC derivatives were conjugated to primary amine groups of recombinant human granulocyte-colony stimulating factor.	Amines	51-56	colony stimulating factor 3	Homo sapiens	85-122
12711450-5	2003	PEGylated G-CSF conjugated with mPEG-OLA-PC derivatives consisted of native, mono-, di-, and tri-PEGylated species, and they did not show any apparent conformational changes even after PEGylation.	mpeg-ola	32-40	colony stimulating factor 3	Homo sapiens	10-15
12711450-6	2003	When incubating in pH 7.4 buffer at 37 degrees C for 2 days, mPEG-OLA-G-CSF conjugates liberated mPEG by cleaving the OLA spacer, resulting in the gradual regeneration of G-CSF.	monomethoxypolyethylene glycol	61-65	colony stimulating factor 3	Homo sapiens	70-75
12711450-6	2003	When incubating in pH 7.4 buffer at 37 degrees C for 2 days, mPEG-OLA-G-CSF conjugates liberated mPEG by cleaving the OLA spacer, resulting in the gradual regeneration of G-CSF.	monomethoxypolyethylene glycol	61-65	colony stimulating factor 3	Homo sapiens	171-176
12711450-6	2003	When incubating in pH 7.4 buffer at 37 degrees C for 2 days, mPEG-OLA-G-CSF conjugates liberated mPEG by cleaving the OLA spacer, resulting in the gradual regeneration of G-CSF.	monomethoxypolyethylene glycol	97-101	colony stimulating factor 3	Homo sapiens	70-75
12711450-6	2003	When incubating in pH 7.4 buffer at 37 degrees C for 2 days, mPEG-OLA-G-CSF conjugates liberated mPEG by cleaving the OLA spacer, resulting in the gradual regeneration of G-CSF.	monomethoxypolyethylene glycol	97-101	colony stimulating factor 3	Homo sapiens	171-176
12634979-8	2003	DeltaAUC4-10 of the G-CSF-stimulated ECP response decreased by a mean of 76.8% after PRED compared with DEXA and to controls ( p&lt;0.02), and this difference had disappeared at 25 h. DEXA did not elicit any effect towards the G-CSF-stimulated ECP response.	deltaauc4-10	0-12	colony stimulating factor 3	Homo sapiens	20-25
12804178-2	2003	Recent studies show that in the presence of recombinant human granulocyte colony-stimulating factor (rhG-CSF), docetaxel (DXT) is an effective mobilization agent.	Docetaxel	111-120	colony stimulating factor 3	Homo sapiens	62-99
12804178-2	2003	Recent studies show that in the presence of recombinant human granulocyte colony-stimulating factor (rhG-CSF), docetaxel (DXT) is an effective mobilization agent.	dxt	122-125	colony stimulating factor 3	Homo sapiens	62-99
12663705-9	2003	In patients receiving two or four cycles of C at 2,400 mg/m(2) with granulocyte colony-stimulating factor (G-CSF) support, cumulative incidence of AML/MDS at 5 years was 1.01% (95% confidence interval [CI], 0.63% to 1.62%), compared with 0.21% (95% CI, 0.11% to 0.41%) for patients treated with standard AC.	Cyclophosphamide	44-45	colony stimulating factor 3	Homo sapiens	68-105
12663705-9	2003	In patients receiving two or four cycles of C at 2,400 mg/m(2) with granulocyte colony-stimulating factor (G-CSF) support, cumulative incidence of AML/MDS at 5 years was 1.01% (95% confidence interval [CI], 0.63% to 1.62%), compared with 0.21% (95% CI, 0.11% to 0.41%) for patients treated with standard AC.	Cyclophosphamide	44-45	colony stimulating factor 3	Homo sapiens	107-112
12663705-11	2003	CONCLUSION: AC regimens employing intensified doses of cyclophosphamide requiring G-CSF support were characterized by increased rates of subsequent AML/MDS, although the incidence of AML/MDS was small relative to that of breast cancer relapse.	Cyclophosphamide	55-71	colony stimulating factor 3	Homo sapiens	82-87
12682643-0	2003	G-CSF for imatinib-induced neutropenia.	Imatinib Mesylate	10-18	colony stimulating factor 3	Homo sapiens	0-5
12844025-2	2003	CASE REPORT: This case report describes acute respiratory distress syndrome, due to diffuse pneumonitis, in a patient with malignant non-Hodgkin"s lymphoma being treated with combination chemotherapy which included doxorubicin, cyclophosphamide, bleomycin, vindesin and intrathecal methotrexate with G-CSF (filgrastine- Neupogen).	Cyclophosphamide	228-244	colony stimulating factor 3	Homo sapiens	300-305
12844025-2	2003	CASE REPORT: This case report describes acute respiratory distress syndrome, due to diffuse pneumonitis, in a patient with malignant non-Hodgkin"s lymphoma being treated with combination chemotherapy which included doxorubicin, cyclophosphamide, bleomycin, vindesin and intrathecal methotrexate with G-CSF (filgrastine- Neupogen).	Bleomycin	246-255	colony stimulating factor 3	Homo sapiens	300-305
12844025-2	2003	CASE REPORT: This case report describes acute respiratory distress syndrome, due to diffuse pneumonitis, in a patient with malignant non-Hodgkin"s lymphoma being treated with combination chemotherapy which included doxorubicin, cyclophosphamide, bleomycin, vindesin and intrathecal methotrexate with G-CSF (filgrastine- Neupogen).	Vindesine	257-265	colony stimulating factor 3	Homo sapiens	300-305
12844025-2	2003	CASE REPORT: This case report describes acute respiratory distress syndrome, due to diffuse pneumonitis, in a patient with malignant non-Hodgkin"s lymphoma being treated with combination chemotherapy which included doxorubicin, cyclophosphamide, bleomycin, vindesin and intrathecal methotrexate with G-CSF (filgrastine- Neupogen).	Methotrexate	282-294	colony stimulating factor 3	Homo sapiens	300-305
12844025-2	2003	CASE REPORT: This case report describes acute respiratory distress syndrome, due to diffuse pneumonitis, in a patient with malignant non-Hodgkin"s lymphoma being treated with combination chemotherapy which included doxorubicin, cyclophosphamide, bleomycin, vindesin and intrathecal methotrexate with G-CSF (filgrastine- Neupogen).	filgrastine	307-318	colony stimulating factor 3	Homo sapiens	300-305
12650998-0	2003	Mutation of surface-exposed histidine residues of recombinant human granulocyte-colony stimulating factor (Cys17Ser) impacts on interaction with chelated metal ions and refolding in aqueous two-phase systems.	Histidine	28-37	colony stimulating factor 3	Homo sapiens	68-105
12650998-0	2003	Mutation of surface-exposed histidine residues of recombinant human granulocyte-colony stimulating factor (Cys17Ser) impacts on interaction with chelated metal ions and refolding in aqueous two-phase systems.	Metals	154-159	colony stimulating factor 3	Homo sapiens	68-105
12650998-1	2003	Site directed mutagenesis of Cys17--&gt;Ser17 form of recombinant human granulocyte colony stimulating factor (rhG-CSF C17S) for sequential replacing of surface His(43) and His(52) with alanine was used to identify residues critical for the protein interaction with metal ions, in particular Ni(2+) chelated by dye Light Resistant Yellow 2 KT (LR Yellow 2KT)-polyethyleneglycol (PEG), and refolding after partitioning of inclusion bodies in aqueous two-phase systems.	Metals	266-271	colony stimulating factor 3	Homo sapiens	72-109
12650998-1	2003	Site directed mutagenesis of Cys17--&gt;Ser17 form of recombinant human granulocyte colony stimulating factor (rhG-CSF C17S) for sequential replacing of surface His(43) and His(52) with alanine was used to identify residues critical for the protein interaction with metal ions, in particular Ni(2+) chelated by dye Light Resistant Yellow 2 KT (LR Yellow 2KT)-polyethyleneglycol (PEG), and refolding after partitioning of inclusion bodies in aqueous two-phase systems.	Polyethylene Glycols	359-377	colony stimulating factor 3	Homo sapiens	72-109
12650998-1	2003	Site directed mutagenesis of Cys17--&gt;Ser17 form of recombinant human granulocyte colony stimulating factor (rhG-CSF C17S) for sequential replacing of surface His(43) and His(52) with alanine was used to identify residues critical for the protein interaction with metal ions, in particular Ni(2+) chelated by dye Light Resistant Yellow 2 KT (LR Yellow 2KT)-polyethyleneglycol (PEG), and refolding after partitioning of inclusion bodies in aqueous two-phase systems.	Polyethylene Glycols	379-382	colony stimulating factor 3	Homo sapiens	72-109
12634979-8	2003	DeltaAUC4-10 of the G-CSF-stimulated ECP response decreased by a mean of 76.8% after PRED compared with DEXA and to controls ( p&lt;0.02), and this difference had disappeared at 25 h. DEXA did not elicit any effect towards the G-CSF-stimulated ECP response.	deltaauc4-10	0-12	colony stimulating factor 3	Homo sapiens	227-232
12634979-8	2003	DeltaAUC4-10 of the G-CSF-stimulated ECP response decreased by a mean of 76.8% after PRED compared with DEXA and to controls ( p&lt;0.02), and this difference had disappeared at 25 h. DEXA did not elicit any effect towards the G-CSF-stimulated ECP response.	Dexamethasone	104-108	colony stimulating factor 3	Homo sapiens	20-25
12634979-8	2003	DeltaAUC4-10 of the G-CSF-stimulated ECP response decreased by a mean of 76.8% after PRED compared with DEXA and to controls ( p&lt;0.02), and this difference had disappeared at 25 h. DEXA did not elicit any effect towards the G-CSF-stimulated ECP response.	Dexamethasone	184-188	colony stimulating factor 3	Homo sapiens	20-25
12634979-8	2003	DeltaAUC4-10 of the G-CSF-stimulated ECP response decreased by a mean of 76.8% after PRED compared with DEXA and to controls ( p&lt;0.02), and this difference had disappeared at 25 h. DEXA did not elicit any effect towards the G-CSF-stimulated ECP response.	Dexamethasone	184-188	colony stimulating factor 3	Homo sapiens	227-232
12661801-0	2003	Treatment of carbimazole-induced agranulocytosis and sepsis with granulocyte colony stimulating factor.	Carbimazole	13-24	colony stimulating factor 3	Homo sapiens	65-102
12661801-1	2003	We present the management of agranulocytosis and neutropenic sepsis secondary to carbimazole with recombinant human granulocyte colony stimulating factor (G-CSF).	Carbimazole	81-92	colony stimulating factor 3	Homo sapiens	116-153
12661801-1	2003	We present the management of agranulocytosis and neutropenic sepsis secondary to carbimazole with recombinant human granulocyte colony stimulating factor (G-CSF).	Carbimazole	81-92	colony stimulating factor 3	Homo sapiens	155-160
12661801-4	2003	G-CSF was used as an adjunctive therapy with discontinuation of carbimazole, barrier nursing and a broad-spectrum antibiotic regimen to treat her neutropenic sepsis.	Carbimazole	64-75	colony stimulating factor 3	Homo sapiens	0-5
12393423-5	2003	G-CSF-induced up-regulation of cIAP2 mRNA and protein, phosphorylation of signal transducer and activator of transcription 3 (STAT3), and the antiapoptotic effects were inhibited by pretreatment of cells with AG490, a specific inhibitor of Janus kinase 2 (JAK2).	alpha-cyano-(3,4-dihydroxy)-N-benzylcinnamide	209-214	colony stimulating factor 3	Homo sapiens	0-5
12688309-5	2003	It is likely that the addition of granulocyte colony stimulating factor (G-CSF) may further improve the effects of FA (FLAG) or 2-CdA (CLAG).	clag	135-139	colony stimulating factor 3	Homo sapiens	34-71
12688309-5	2003	It is likely that the addition of granulocyte colony stimulating factor (G-CSF) may further improve the effects of FA (FLAG) or 2-CdA (CLAG).	clag	135-139	colony stimulating factor 3	Homo sapiens	73-78
12605126-0	2003	Facilitation of tacrolimus-induced heart-allograft acceptability by pretransplant host treatment with granulocyte colony-stimulating factor: interleukin-12-restricted suppression of intragraft monokine mRNA expression.	Tacrolimus	16-26	colony stimulating factor 3	Homo sapiens	102-139
12529294-4	2003	However, GM-CSF and G-CSF priming of ROS production were significantly decreased in MDS patients.	Reactive Oxygen Species	37-40	colony stimulating factor 3	Homo sapiens	20-25
12393561-4	2003	Moreover, we have previously reported that G-CSF inhibits Fas-induced caspase activation in sideroblastic anemia (RARS).	ammonium ferrous sulfate	58-61	colony stimulating factor 3	Homo sapiens	43-48
12627849-2	2003	Granulocyte colony-stimulating factor (G-CSF) by itself had no effect on NB4 cells but exerted additional enhancing effects on the respiratory burst activity in the presence of ATRA.	Tretinoin	177-181	colony stimulating factor 3	Homo sapiens	0-37
26680916-0	2003	The Efficacy and Safety of DA-3030 (Recombinant Human Granulocyte Colony-Stimulating Factor) in Neutropenia after the Remission Induction Chemotherapy in Patients with Acute Myelogenous Leukemia.	da-3030	27-34	colony stimulating factor 3	Homo sapiens	54-91
26680916-1	2003	PURPOSE: This study was conducted to determine the efficacy and safety of DA-3030 (a recombinant methionyl human granulocyte colony-stimulating factor, rhG-CSF), after remission induction chemotherapy, in patients with acute myelogenous leukemia (AML).	da-3030	74-81	colony stimulating factor 3	Homo sapiens	113-150
12604417-0	2003	Granulocyte colony-stimulating factor reverses cytopenia and may permit cytogenetic responses in patients with chronic myeloid leukemia treated with imatinib mesylate.	Imatinib Mesylate	149-166	colony stimulating factor 3	Homo sapiens	0-37
12708493-0	2003	Cyclooxygenase-2 inhibitor NS-398 suppresses cell growth and constitutive production of granulocyte-colony stimulating factor and granulocyte macrophage-colony stimulating factor in lung cancer cells.	N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide	27-33	colony stimulating factor 3	Homo sapiens	88-125
12708493-5	2003	We confirmed that the selective COX-2 inhibitor, NS-398 suppressed the constitutive production of G-CSF and GM-CSF, and the cell growth in both OKa-C-1 and MI-4 cell lines.	N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide	49-55	colony stimulating factor 3	Homo sapiens	98-103
12708493-6	2003	Prostaglandin E2 (PGE2) reversed the inhibitions of G-CSF and GM-CSF expression, as well as cell growth, by NS-398.	Dinoprostone	0-16	colony stimulating factor 3	Homo sapiens	52-57
12708493-6	2003	Prostaglandin E2 (PGE2) reversed the inhibitions of G-CSF and GM-CSF expression, as well as cell growth, by NS-398.	Dinoprostone	18-22	colony stimulating factor 3	Homo sapiens	52-57
12708493-10	2003	We found that NS-398 inhibits G-CSF and GM-CSF production and cell growth through an extracellular signal-regulated kinase kinase (MEK) signaling pathway in these cell lines.	N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide	14-20	colony stimulating factor 3	Homo sapiens	30-35
12627849-2	2003	Granulocyte colony-stimulating factor (G-CSF) by itself had no effect on NB4 cells but exerted additional enhancing effects on the respiratory burst activity in the presence of ATRA.	Tretinoin	177-181	colony stimulating factor 3	Homo sapiens	39-44
12627849-4	2003	Unlike ATRA, G-CSF enhanced superoxide release stimulated by the chemotactic peptide but not by phorbol ester.	Superoxides	28-38	colony stimulating factor 3	Homo sapiens	13-18
12627849-7	2003	Fundamentally identical but slightly different phenomena for the cell surface expression of CD33 and CD10 were observed in the normal human bone marrow mononuclear cells; G-CSF induced CD10 even in the absence of ATRA and down-regulated CD33 in normal cells.	Tretinoin	213-217	colony stimulating factor 3	Homo sapiens	171-176
12621489-8	2003	Patients receiving G-CSF alone mobilized significantly more total DC2s than did those receiving etoposide plus G-CSF (median 6.2 x 10(6)/kg vs 2.9 x 10(6)/kg, P=0.001).	dc2s	66-70	colony stimulating factor 3	Homo sapiens	19-24
12668156-1	2003	Pretransplant treatment of recipients with recombinant human granulocyte colony-stimulating factor (rhG-CSF, 250 microg/kg/day s.c. for 5 days) facilitates heart allograft acceptance in tacrolimus-treated rat recipients.	Tacrolimus	186-196	colony stimulating factor 3	Homo sapiens	61-98
12542495-10	2003	In addition, G-CSF administration to five lymphoma patients after consecutive courses of CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) chemotherapy, resulted in telomere length preservation or elongation, as opposed to marked attrition in patients who did not receive growth factors.	Cyclophosphamide	95-111	colony stimulating factor 3	Homo sapiens	13-18
12542495-10	2003	In addition, G-CSF administration to five lymphoma patients after consecutive courses of CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) chemotherapy, resulted in telomere length preservation or elongation, as opposed to marked attrition in patients who did not receive growth factors.	Doxorubicin	113-124	colony stimulating factor 3	Homo sapiens	13-18
12542495-10	2003	In addition, G-CSF administration to five lymphoma patients after consecutive courses of CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) chemotherapy, resulted in telomere length preservation or elongation, as opposed to marked attrition in patients who did not receive growth factors.	Vincristine	126-137	colony stimulating factor 3	Homo sapiens	13-18
12542495-10	2003	In addition, G-CSF administration to five lymphoma patients after consecutive courses of CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) chemotherapy, resulted in telomere length preservation or elongation, as opposed to marked attrition in patients who did not receive growth factors.	Prednisone	139-149	colony stimulating factor 3	Homo sapiens	13-18
12621490-1	2003	Cyclophosphamide with granulocyte colony stimulating factor (G-CSF) is commonly used to mobilize stem cells in multiple myeloma.	Cyclophosphamide	0-16	colony stimulating factor 3	Homo sapiens	22-59
12621490-1	2003	Cyclophosphamide with granulocyte colony stimulating factor (G-CSF) is commonly used to mobilize stem cells in multiple myeloma.	Cyclophosphamide	0-16	colony stimulating factor 3	Homo sapiens	61-66
12621492-7	2003	ES was seen more frequently in patients who received GM-CSF (GM-CSF 24% vs G-CSF 4%, p=0.0001).	Einsteinium	0-2	colony stimulating factor 3	Homo sapiens	75-80
12538457-10	2003	CONCLUSIONS: Using G-CSF support allows substantial dose escalation of docetaxel.	Docetaxel	71-80	colony stimulating factor 3	Homo sapiens	19-24
12469168-10	2003	G-CSF support was given in 1/8, 4/8, and 5/8 patients treated at the 10, 13 and 16 mg/m(2) docetaxel dose levels respectively.	Docetaxel	91-100	colony stimulating factor 3	Homo sapiens	0-5
12665678-13	2003	The docetaxel dose can be safely escalated to 145 mg/m(2) every 21 d with GCSF support, a 45% increase above the standard recommended phase II dose.	Docetaxel	4-13	colony stimulating factor 3	Homo sapiens	74-78
12488547-7	2003	This is consistent with clinical studies on a polyethylene glycol chemical conjugate of GCSF termed SD/01.	Polyethylene Glycols	46-65	colony stimulating factor 3	Homo sapiens	88-92
12538457-0	2003	Phase I and pharmacokinetic study of escalating dose of docetaxel administered with granulocyte colony-stimulating factor support in adult advanced solid tumors.	Docetaxel	56-65	colony stimulating factor 3	Homo sapiens	84-121
12538457-1	2003	PURPOSE: The purpose of our study was to assess the feasibility, toxicity, and pharmacokinetics of an escalating dose of docetaxel when administered with granulocyte colony-stimulating factor (G-CSF) support every 3 weeks.	Docetaxel	121-130	colony stimulating factor 3	Homo sapiens	154-191
12538457-1	2003	PURPOSE: The purpose of our study was to assess the feasibility, toxicity, and pharmacokinetics of an escalating dose of docetaxel when administered with granulocyte colony-stimulating factor (G-CSF) support every 3 weeks.	Docetaxel	121-130	colony stimulating factor 3	Homo sapiens	193-198
12568303-1	2003	Granulocyte colony-stimulating factor (G-CSF) has been shown to affect the biochemical markers of bone metabolism, including serum bone alkaline phosphatase (BALP), serum osteocalcin, and urine deoxypyridinoline.	deoxypyridinoline	194-211	colony stimulating factor 3	Homo sapiens	0-37
12568303-1	2003	Granulocyte colony-stimulating factor (G-CSF) has been shown to affect the biochemical markers of bone metabolism, including serum bone alkaline phosphatase (BALP), serum osteocalcin, and urine deoxypyridinoline.	deoxypyridinoline	194-211	colony stimulating factor 3	Homo sapiens	39-44
12568303-10	2003	Consistent with the notion that G-CSF affects bone metabolism, a significant correlation was observed between CD34+ cell yield and the increase in urine deoxypyridinoline but not for the changes in serum BALP and osteocalcin levels.	deoxypyridinoline	153-170	colony stimulating factor 3	Homo sapiens	32-37
12636093-5	2002	G-CSF (300 mcg/day) was administered s.c. 12 hours before starting fludarabine and was continued for five days.	fludarabine	67-78	colony stimulating factor 3	Homo sapiens	0-5
12649775-7	2003	Our findings argue against the hypothesis that clozapine-mediated inhibition of G-CSF or granulocyte-macrophage colony-stimulating factor (GM-CSF) release is involved in CA development.	Clozapine	47-56	colony stimulating factor 3	Homo sapiens	80-85
12402145-1	2002	This pilot phase I/II study intended to determine the maximum tolerated dose of cyclophosphamide and thiotepa administered on four consecutive courses with peripheral blood progenitor cell and granulocyte-colony stimulating factor support, as first-line therapy for hormone-refractory metastatic breast cancer patients.	Cyclophosphamide	80-96	colony stimulating factor 3	Homo sapiens	193-230
12402145-1	2002	This pilot phase I/II study intended to determine the maximum tolerated dose of cyclophosphamide and thiotepa administered on four consecutive courses with peripheral blood progenitor cell and granulocyte-colony stimulating factor support, as first-line therapy for hormone-refractory metastatic breast cancer patients.	Thiotepa	101-109	colony stimulating factor 3	Homo sapiens	193-230
12377653-21	2002	CONCLUSIONS: A brief tumor-reducing program with two cycles of DHAP given in short intervals supported by G-CSF is effective and well-tolerated in patients with relapsed and refractory HD.	Dihydroxyacetone Phosphate	63-67	colony stimulating factor 3	Homo sapiens	106-111
12419756-8	2002	The highest administered dose level with G-CSF was docetaxel 85 mg/m(2) and epirubicin 105 mg/m(2) with DLTs in five of six patients.	Docetaxel	51-60	colony stimulating factor 3	Homo sapiens	41-46
12419756-8	2002	The highest administered dose level with G-CSF was docetaxel 85 mg/m(2) and epirubicin 105 mg/m(2) with DLTs in five of six patients.	Epirubicin	76-86	colony stimulating factor 3	Homo sapiens	41-46
12419756-12	2002	CONCLUSIONS: The recommended dose level of docetaxel 85 mg/m(2), epirubicin 90 mg/m(2) and cyclophosphamide 600 mg/m(2) with G-CSF support has a favorable toxicity profile and is suitable for further investigation in phase II and III trials.	Docetaxel	43-52	colony stimulating factor 3	Homo sapiens	125-130
12419756-12	2002	CONCLUSIONS: The recommended dose level of docetaxel 85 mg/m(2), epirubicin 90 mg/m(2) and cyclophosphamide 600 mg/m(2) with G-CSF support has a favorable toxicity profile and is suitable for further investigation in phase II and III trials.	Cyclophosphamide	91-107	colony stimulating factor 3	Homo sapiens	125-130
12373597-5	2002	With the addition of G-CSF the maximum tolerated dose was docetaxel 75 mg/m(2) on day 1 and ifosfamide 2750 mg/m(2)/day on days 1-3.	Ifosfamide	92-102	colony stimulating factor 3	Homo sapiens	21-26
12419756-0	2002	Phase I and pharmacokinetic study of docetaxel in combination with epirubicin and cyclophosphamide in advanced cancer: dose escalation possible with granulocyte colony-stimulating factor, but not with prophylactic antibiotics.	Docetaxel	37-46	colony stimulating factor 3	Homo sapiens	149-186
12425755-9	2002	The up-front prophylactic use of G-CSF is a reasonable supportive therapy for patients treated with docetaxel/anthracycline-based combination chemotherapy.	Docetaxel	100-109	colony stimulating factor 3	Homo sapiens	33-38
12425755-9	2002	The up-front prophylactic use of G-CSF is a reasonable supportive therapy for patients treated with docetaxel/anthracycline-based combination chemotherapy.	Anthracyclines	110-123	colony stimulating factor 3	Homo sapiens	33-38
12382084-3	2002	The aim of this study was to assess the effect and safety of G-CSF mobilized granulocyte transfusions (GTX) in four neutropenic pediatric patients with sepsis.	hexylglutathione	103-106	colony stimulating factor 3	Homo sapiens	61-66
12161759-2	2002	We demonstrate this approach for granulocyte colony-stimulating factor by using computationally predicted histidine substitutions that switch protonation states between cell-surface and endosomal pH.	Histidine	106-115	colony stimulating factor 3	Homo sapiens	33-70
12237471-1	2002	The folding kinetics of G-CSF were determined by trp-fluorescence and far-UV circular dichroism.	Tryptophan	49-52	colony stimulating factor 3	Homo sapiens	24-29
12237471-5	2002	G-CSF contains two trp residues, and their contribution to the fluorescent-detected kinetics were deciphered through the use of single-site trp mutants.	Tryptophan	19-22	colony stimulating factor 3	Homo sapiens	0-5
12237471-5	2002	G-CSF contains two trp residues, and their contribution to the fluorescent-detected kinetics were deciphered through the use of single-site trp mutants.	Tryptophan	140-143	colony stimulating factor 3	Homo sapiens	0-5
12235519-5	2002	Multivariate analysis showed that the only positive predictive factor for developing ES was mobilization with high-dose G-CSF (12 microg/kg twice daily) (RR 3.88, CI 95% 1.73-8.67; P &lt; 0.0005).	Einsteinium	85-87	colony stimulating factor 3	Homo sapiens	120-125
12367797-17	2002	CONCLUSIONS: In our experience the biweekly combination of DCT and GEM is active and well tolerated and can be administered without G-CSF primary prophylaxis reducing treatment costs.	Docetaxel	59-62	colony stimulating factor 3	Homo sapiens	132-137
12367797-17	2002	CONCLUSIONS: In our experience the biweekly combination of DCT and GEM is active and well tolerated and can be administered without G-CSF primary prophylaxis reducing treatment costs.	gemcitabine	67-70	colony stimulating factor 3	Homo sapiens	132-137
12176053-4	2002	Wortmannin, a specific inhibitor of PI3K, partially inhibited G-CSF-induced p70 S6K activity and G-CSF-dependent proliferation, whereas rapamycin, an inhibitor of p70 S6K, completely inhibited these activities.	Wortmannin	0-10	colony stimulating factor 3	Homo sapiens	62-67
12176053-4	2002	Wortmannin, a specific inhibitor of PI3K, partially inhibited G-CSF-induced p70 S6K activity and G-CSF-dependent proliferation, whereas rapamycin, an inhibitor of p70 S6K, completely inhibited these activities.	Wortmannin	0-10	colony stimulating factor 3	Homo sapiens	97-102
12151959-0	2002	Phase I trial of topotecan plus vinorelbine with/without filgrastim (G-CSF) in patients with refractory malignancies.	Topotecan	17-26	colony stimulating factor 3	Homo sapiens	69-74
12430673-5	2002	Patients mobilized with SCF plus G-CSF plus CCP showed the highest numbers of neutrophils and monocytes, whereas the highest numbers of lymphocytes and NK cells were observed in LPs from G-CSF-mobilized patients.	lps	178-181	colony stimulating factor 3	Homo sapiens	187-192
12151959-0	2002	Phase I trial of topotecan plus vinorelbine with/without filgrastim (G-CSF) in patients with refractory malignancies.	Vinorelbine	32-43	colony stimulating factor 3	Homo sapiens	69-74
12161101-9	2002	The AMC showed a significant increase in the GM-CSF group (during the whole follow up period) and in the G-CSF group (for the first 3 days of follow up).	7-amino-4-methylcoumarin	4-7	colony stimulating factor 3	Homo sapiens	105-110
12375667-9	2002	The combination of glycosylated G-CSF with DXM allows a significant dose reduction in G-CSF for PMN mobilization and collection as compared with higher G-CSF doses alone.	Dexamethasone	43-46	colony stimulating factor 3	Homo sapiens	86-91
12375667-9	2002	The combination of glycosylated G-CSF with DXM allows a significant dose reduction in G-CSF for PMN mobilization and collection as compared with higher G-CSF doses alone.	Dexamethasone	43-46	colony stimulating factor 3	Homo sapiens	86-91
12191567-0	2002	FLAG-IDA regimen (fludarabine, cytarabine, idarubicin and G-CSF) in the treatment of patients with high-risk myeloid malignancies.	flag-ida	0-8	colony stimulating factor 3	Homo sapiens	58-63
12080323-4	2002	GCSF at a dosage of 30 to 100 ng/mL, a concentration range that primes superoxide release, stimulated a 60% to 100% increase in gelatinase release from tertiary granules but did not stimulate lactoferrin release from secondary granules.	Superoxides	71-81	colony stimulating factor 3	Homo sapiens	0-4
12080351-0	2002	Modulations of dose intensity of doxorubicin and cyclophosphamide in association with G-CSF and peripheral blood stem cells in adjuvant chemotherapy for breast cancer: comparative evaluation of completion and safety of three intensive regimens.	Doxorubicin	33-44	colony stimulating factor 3	Homo sapiens	86-91
12045462-0	2002	Phase I study of carboplatin, irinotecan and docetaxel on a divided schedule with recombinant human granulocyte colony stimulating factor support in patients with stage IIIB or IV non-small cell lung cancer.	Carboplatin	17-28	colony stimulating factor 3	Homo sapiens	100-137
12123334-2	2002	Theoretically, this approach could be hazardous with infusional 5-fluorouracil (5-FU) chemotherapy, since G-CSF-stimulated neutrophil proliferation would be occurring in the face of continuous S-phase active 5-FU.	Fluorouracil	64-78	colony stimulating factor 3	Homo sapiens	106-111
12123334-2	2002	Theoretically, this approach could be hazardous with infusional 5-fluorouracil (5-FU) chemotherapy, since G-CSF-stimulated neutrophil proliferation would be occurring in the face of continuous S-phase active 5-FU.	Fluorouracil	80-84	colony stimulating factor 3	Homo sapiens	106-111
12080351-0	2002	Modulations of dose intensity of doxorubicin and cyclophosphamide in association with G-CSF and peripheral blood stem cells in adjuvant chemotherapy for breast cancer: comparative evaluation of completion and safety of three intensive regimens.	Cyclophosphamide	49-65	colony stimulating factor 3	Homo sapiens	86-91
12079515-2	2002	The culture supernatant of MI-4 contained high levels of granulocyte colony stimulating factor (G-CSF).	mi-4	27-31	colony stimulating factor 3	Homo sapiens	57-94
12039931-12	2002	CONCLUSION: The epirubicin-vinorelbine combination with G-CSF support has been shown in this study to be highly active as first-line treatment of metastatic breast cancer patients, with significant although transient toxicity.	Epirubicin	16-26	colony stimulating factor 3	Homo sapiens	56-61
12079515-2	2002	The culture supernatant of MI-4 contained high levels of granulocyte colony stimulating factor (G-CSF).	mi-4	27-31	colony stimulating factor 3	Homo sapiens	96-101
11792410-1	2002	Mitoxantrone, etoposide and prednisone (MEP)-based regimens using granulocyte colony-stimulating factor (G-CSF) were designed for relapsed and CHOP-resistant diffuse large B-cell lymphomas in a single institution, and the therapeutic effects and adverse reactions were studied.	Mitoxantrone	0-12	colony stimulating factor 3	Homo sapiens	66-103
11972091-3	2002	PATIENTS AND METHODS: The authors evaluated the activity of the combination of cyclophosphamide (500 mg/m2 per day for 5 days) and etoposide (100 mg/m2 per day for 5 days) given with granulocyte colony-stimulating factor (G-CSF) to children with osteosarcoma unresponsive to conventional treatment.	Cyclophosphamide	79-95	colony stimulating factor 3	Homo sapiens	183-220
11953891-5	2002	Cytokine-induced release of granulocyte-macrophage-colony stimulating factor, granulocyte-colony stimulating factor and macrophage-colony stimulating factor was significantly increased by cisplatin and 6-mercaptopurine.	Cisplatin	188-197	colony stimulating factor 3	Homo sapiens	78-115
11953891-5	2002	Cytokine-induced release of granulocyte-macrophage-colony stimulating factor, granulocyte-colony stimulating factor and macrophage-colony stimulating factor was significantly increased by cisplatin and 6-mercaptopurine.	Mercaptopurine	202-218	colony stimulating factor 3	Homo sapiens	78-115
11953891-6	2002	Taxol only increased macrophage-colony stimulating factor release while reduced that of granulocyte-colony stimulating factor.	Paclitaxel	0-5	colony stimulating factor 3	Homo sapiens	88-125
12040471-6	2002	Starting G-CSF on day +1 does not result in faster neutrophil engraftment but in later onset and consequently, slightly shorter duration of neutropenia in patients who receive melphalan 200 mg/m(2) and CD34(+) cell doses &gt;3.0 x 10(6)/kg.	Melphalan	176-185	colony stimulating factor 3	Homo sapiens	9-14
12064461-6	2002	Dianisidine- and nonspecific esterase-positive TER-3 cells increase with granulocyte-colony stimulating factor (G-CSF) rather than with IL-3.	Dianisidine	0-11	colony stimulating factor 3	Homo sapiens	73-110
12064461-6	2002	Dianisidine- and nonspecific esterase-positive TER-3 cells increase with granulocyte-colony stimulating factor (G-CSF) rather than with IL-3.	Dianisidine	0-11	colony stimulating factor 3	Homo sapiens	112-117
12084169-9	2002	Leukotriene B4 production was reduced after the fourth G-CSF stimulation in the donor blood and enhanced in the granulocyte concentrate after apheresis.	Leukotriene B4	0-14	colony stimulating factor 3	Homo sapiens	55-60
11792410-1	2002	Mitoxantrone, etoposide and prednisone (MEP)-based regimens using granulocyte colony-stimulating factor (G-CSF) were designed for relapsed and CHOP-resistant diffuse large B-cell lymphomas in a single institution, and the therapeutic effects and adverse reactions were studied.	Mitoxantrone	0-12	colony stimulating factor 3	Homo sapiens	105-110
11865046-2	2002	In addition to several copies of the AU-rich element the G-CSF mRNA also contains a destabilizing region that includes several predicted stem-loop structures.	Gold	37-39	colony stimulating factor 3	Homo sapiens	57-62
11792410-1	2002	Mitoxantrone, etoposide and prednisone (MEP)-based regimens using granulocyte colony-stimulating factor (G-CSF) were designed for relapsed and CHOP-resistant diffuse large B-cell lymphomas in a single institution, and the therapeutic effects and adverse reactions were studied.	Prednisone	28-38	colony stimulating factor 3	Homo sapiens	66-103
11792410-1	2002	Mitoxantrone, etoposide and prednisone (MEP)-based regimens using granulocyte colony-stimulating factor (G-CSF) were designed for relapsed and CHOP-resistant diffuse large B-cell lymphomas in a single institution, and the therapeutic effects and adverse reactions were studied.	Prednisone	28-38	colony stimulating factor 3	Homo sapiens	105-110
11792410-1	2002	Mitoxantrone, etoposide and prednisone (MEP)-based regimens using granulocyte colony-stimulating factor (G-CSF) were designed for relapsed and CHOP-resistant diffuse large B-cell lymphomas in a single institution, and the therapeutic effects and adverse reactions were studied.	mep	40-43	colony stimulating factor 3	Homo sapiens	66-103
11865633-5	2002	The influence on the actual CDDP dose was observed with or without use of G-CSF or by recommended dose of CDDP, while no influence by 5-HT3 antagonist was observed.	Cisplatin	28-32	colony stimulating factor 3	Homo sapiens	74-79
11756198-0	2002	Liposomal amphotericin B (AmBisome) compared with amphotericin B +/- FMLP induces significantly less in vitro neutrophil aggregation with granulocyte-colony-stimulating factor/dexamethasone-mobilized allogeneic donor neutrophils.	Amphotericin B	10-24	colony stimulating factor 3	Homo sapiens	138-175
11781253-5	2002	These G-CSF effects were inhibited by cycloheximide.	Cycloheximide	38-51	colony stimulating factor 3	Homo sapiens	6-11
11840291-4	2002	Both G-CSF and FL induced phosphorylation of extracellular signal-regulated kinases (ERKs) while p38 mitogen activated protein (MAP) kinase was phosphorylated only in response to G-CSF but not FL.	fl	15-17	colony stimulating factor 3	Homo sapiens	179-184
12513828-10	2002	Comparing the frequencies of CFU-GM in patients and donors, patients" PBPCs were more sensitive to G-CSF+SCF and GMix (G-CSF+SCF+IL-3+GM-CSF), especially to G-CSF alone than donors.	gmix	113-117	colony stimulating factor 3	Homo sapiens	119-124
12513828-10	2002	Comparing the frequencies of CFU-GM in patients and donors, patients" PBPCs were more sensitive to G-CSF+SCF and GMix (G-CSF+SCF+IL-3+GM-CSF), especially to G-CSF alone than donors.	gmix	113-117	colony stimulating factor 3	Homo sapiens	119-124
11978940-5	2002	According to the literature, in almost all patients with acute myeloid leukaemia or MDS who were reported to achieve CR by G-CSF, the course was associated with infection, although our case did not have this complication during the course of G-CSF therapy.	Chromium	117-119	colony stimulating factor 3	Homo sapiens	123-128
12416471-9	2002	Several regimens have been proposed for stem cells mobilization including: High-dose cyclophosphamide and G or GM-CSF, G-CSF alone, and cyclophosphamide and etoposide with G-CSF... ect.. Further attempts to improve the results of autotransplantation have included intensification with tandem transplantations (double transplants) and reduction of tumor cells in stem cell infusion.	Etoposide	157-166	colony stimulating factor 3	Homo sapiens	172-177
11756198-0	2002	Liposomal amphotericin B (AmBisome) compared with amphotericin B +/- FMLP induces significantly less in vitro neutrophil aggregation with granulocyte-colony-stimulating factor/dexamethasone-mobilized allogeneic donor neutrophils.	liposomal amphotericin B	26-34	colony stimulating factor 3	Homo sapiens	138-175
11852999-5	2002	The aim of this study was to determine the MTD of vinorelbine and docetaxel given in combination with G-CSF.	Vinorelbine	50-61	colony stimulating factor 3	Homo sapiens	102-107
11852999-19	2002	CONCLUSION: The combination of vinorelbine, docetaxel, and G-CSF in our hands has proven to be a toxic regimen, even when relatively low doses of vinorelbine and docetaxel are given.	Vinorelbine	146-157	colony stimulating factor 3	Homo sapiens	59-64
11852999-19	2002	CONCLUSION: The combination of vinorelbine, docetaxel, and G-CSF in our hands has proven to be a toxic regimen, even when relatively low doses of vinorelbine and docetaxel are given.	Docetaxel	162-171	colony stimulating factor 3	Homo sapiens	59-64
12479594-9	2002	Beneficial responses to granulocyte colony-stimulating factor (G-CSF; filgrastim) in elderly patients have been found in aggressive non-Hodgkin"s lymphoma with standard cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) therapy and acute myeloid leukaemia (AML) during induction and consolidation chemotherapy.	Cyclophosphamide	169-185	colony stimulating factor 3	Homo sapiens	24-61
12479594-9	2002	Beneficial responses to granulocyte colony-stimulating factor (G-CSF; filgrastim) in elderly patients have been found in aggressive non-Hodgkin"s lymphoma with standard cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) therapy and acute myeloid leukaemia (AML) during induction and consolidation chemotherapy.	Cyclophosphamide	169-185	colony stimulating factor 3	Homo sapiens	63-68
12479594-9	2002	Beneficial responses to granulocyte colony-stimulating factor (G-CSF; filgrastim) in elderly patients have been found in aggressive non-Hodgkin"s lymphoma with standard cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) therapy and acute myeloid leukaemia (AML) during induction and consolidation chemotherapy.	Doxorubicin	187-198	colony stimulating factor 3	Homo sapiens	24-61
12479594-9	2002	Beneficial responses to granulocyte colony-stimulating factor (G-CSF; filgrastim) in elderly patients have been found in aggressive non-Hodgkin"s lymphoma with standard cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) therapy and acute myeloid leukaemia (AML) during induction and consolidation chemotherapy.	Doxorubicin	187-198	colony stimulating factor 3	Homo sapiens	63-68
12479594-9	2002	Beneficial responses to granulocyte colony-stimulating factor (G-CSF; filgrastim) in elderly patients have been found in aggressive non-Hodgkin"s lymphoma with standard cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) therapy and acute myeloid leukaemia (AML) during induction and consolidation chemotherapy.	Vincristine	200-211	colony stimulating factor 3	Homo sapiens	24-61
12479594-9	2002	Beneficial responses to granulocyte colony-stimulating factor (G-CSF; filgrastim) in elderly patients have been found in aggressive non-Hodgkin"s lymphoma with standard cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) therapy and acute myeloid leukaemia (AML) during induction and consolidation chemotherapy.	Vincristine	200-211	colony stimulating factor 3	Homo sapiens	63-68
12479594-9	2002	Beneficial responses to granulocyte colony-stimulating factor (G-CSF; filgrastim) in elderly patients have been found in aggressive non-Hodgkin"s lymphoma with standard cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) therapy and acute myeloid leukaemia (AML) during induction and consolidation chemotherapy.	Prednisone	216-226	colony stimulating factor 3	Homo sapiens	24-61
12479594-9	2002	Beneficial responses to granulocyte colony-stimulating factor (G-CSF; filgrastim) in elderly patients have been found in aggressive non-Hodgkin"s lymphoma with standard cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) therapy and acute myeloid leukaemia (AML) during induction and consolidation chemotherapy.	Prednisone	216-226	colony stimulating factor 3	Homo sapiens	63-68
11958365-3	2001	In spite of the fact that lithium and granulocyte colony stimulating factor (G-CSF) have been shown to reverse CIG, many such patients are consigned to treatment with antipsychotic agents that have failed in the past.	2-AMINO-6-CHLOROPYRAZINE	111-114	colony stimulating factor 3	Homo sapiens	38-75
11784333-1	2002	Stimulation with granulocyte colony-stimulating factor (G-CSF) induces myeloid precursor cells to differentiate into neutrophils, and tyrosine phosphorylation of certain cellular proteins is crucial to this process.	Tyrosine	134-142	colony stimulating factor 3	Homo sapiens	17-54
11784333-1	2002	Stimulation with granulocyte colony-stimulating factor (G-CSF) induces myeloid precursor cells to differentiate into neutrophils, and tyrosine phosphorylation of certain cellular proteins is crucial to this process.	Tyrosine	134-142	colony stimulating factor 3	Homo sapiens	56-61
11823031-6	2002	We treated him with G-CSF-mobilized stem cells from his heterozygote, human leukocyte antigen-matched brother after RIC with fludarabine and cyclophosphamide.	fludarabine	125-136	colony stimulating factor 3	Homo sapiens	20-25
11823031-6	2002	We treated him with G-CSF-mobilized stem cells from his heterozygote, human leukocyte antigen-matched brother after RIC with fludarabine and cyclophosphamide.	Cyclophosphamide	141-157	colony stimulating factor 3	Homo sapiens	20-25
12189565-2	2002	MATERIALS AND METHODS: ATRA was administered orally at 45 mg/m(2)/day on days 1-14 and 25 mg/m(2)/day on days 15-28 of two standard cycles (idarubicin, etoposide, cytarabine, G-CSF) and of up to three high-dose courses (cytarabine, G-CSF).	Tretinoin	23-27	colony stimulating factor 3	Homo sapiens	175-180
12189565-2	2002	MATERIALS AND METHODS: ATRA was administered orally at 45 mg/m(2)/day on days 1-14 and 25 mg/m(2)/day on days 15-28 of two standard cycles (idarubicin, etoposide, cytarabine, G-CSF) and of up to three high-dose courses (cytarabine, G-CSF).	Tretinoin	23-27	colony stimulating factor 3	Homo sapiens	232-237
11831843-0	2002	Granulocyte colony stimulating factor treatment for delayed recovery of ticlopidine-related neutropenia.	Ticlopidine	72-83	colony stimulating factor 3	Homo sapiens	0-37
11958365-3	2001	In spite of the fact that lithium and granulocyte colony stimulating factor (G-CSF) have been shown to reverse CIG, many such patients are consigned to treatment with antipsychotic agents that have failed in the past.	2-AMINO-6-CHLOROPYRAZINE	111-114	colony stimulating factor 3	Homo sapiens	77-82
11843253-1	2001	BACKGROUND: The combination of doxorubicin, paclitaxel, and cisplatin has activity in gynecologic malignancies but requires colony stimulating factor (G-CSF) support.	Doxorubicin	31-42	colony stimulating factor 3	Homo sapiens	151-156
11843253-1	2001	BACKGROUND: The combination of doxorubicin, paclitaxel, and cisplatin has activity in gynecologic malignancies but requires colony stimulating factor (G-CSF) support.	Paclitaxel	44-54	colony stimulating factor 3	Homo sapiens	151-156
11958365-7	2001	This case dramatizes the importance of lithium (or G-CSF) augmentation in those patients to maintain clozapine treatment so that their neutropenia can be reversed, and they can continue to benefit from the unique antipsychotic qualities of clozapine.	Clozapine	101-110	colony stimulating factor 3	Homo sapiens	51-56
11843253-1	2001	BACKGROUND: The combination of doxorubicin, paclitaxel, and cisplatin has activity in gynecologic malignancies but requires colony stimulating factor (G-CSF) support.	Cisplatin	60-69	colony stimulating factor 3	Homo sapiens	151-156
11753545-11	2001	These results confirm that ifosfamide and vinorelbine-based chemotherapy regimen with G-CSF support can be successfully and safely used to mobilize PBSCs.	Ifosfamide	27-37	colony stimulating factor 3	Homo sapiens	86-91
11747033-6	2001	Upon granulocyte colony stimulating factor treatment, the water proton signal in the lumbar spine is not further augmented.	Water	58-63	colony stimulating factor 3	Homo sapiens	5-42
11851944-1	2001	A 28-year-old man with lymphoblastic lymphoma received G-CSF mobilized stem cells from his HLA identical sister, who had been taking methotrexate for psoriasis until 1 month prior to harvest.	Methotrexate	133-145	colony stimulating factor 3	Homo sapiens	55-60
11720428-0	2001	Accelerated cisplatin and high-dose epirubicin with G-CSF support in patients with relapsed non-small-cell lung cancer: feasibility and efficacy.	Epirubicin	36-46	colony stimulating factor 3	Homo sapiens	52-57
11720428-11	2001	None of the patients encountered dose-limiting toxicity in the first course, which confirmed that epirubicin 135 mg m(-2) could be combined with cisplatin 60 mg m(-2) and accelerated by G-CSF support to a 14-day-schedule.	Epirubicin	98-108	colony stimulating factor 3	Homo sapiens	186-191
11720428-20	2001	Accelerated cisplatin and high-dose epirubicin with G-CSF support is a feasible and promising regimen in relapsed NSCLC.	Epirubicin	36-46	colony stimulating factor 3	Homo sapiens	52-57
11745183-15	2001	CONCLUSIONS: Treatment with two cycles of mitoxantrone 25 mg/m2 and cyclophosphamide 4000 mg/m2 with G-CSF but without stem cell support was well tolerated.	Cyclophosphamide	68-84	colony stimulating factor 3	Homo sapiens	101-106
11822765-6	2001	When G-CSF was added, dose escalation beyond 350 mg/m2 could not be achieved due to grade 2-3 toxicities that prevented on-time retreatment with CPT-11.	Irinotecan	145-151	colony stimulating factor 3	Homo sapiens	5-10
11822765-11	2001	CONCLUSIONS: When administered every two weeks, the recommended phase II starting dose of CPT-11 is 250 mg/m2 when given alone and 300 mg/m2 when supported by G-CSF.	Irinotecan	90-96	colony stimulating factor 3	Homo sapiens	159-164
11753545-11	2001	These results confirm that ifosfamide and vinorelbine-based chemotherapy regimen with G-CSF support can be successfully and safely used to mobilize PBSCs.	Vinorelbine	42-53	colony stimulating factor 3	Homo sapiens	86-91
11683584-6	2001	To identify the cytokine region defined by mAbs, hG-CSF was digested with different proteolytic enzymes: Arg-C, Glu-C, trypsin and alpha chymotrypsin.	Arginine	105-108	colony stimulating factor 3	Homo sapiens	49-55
11676607-7	2001	Insertion of a small oligopeptide (13 amino acids) containing the histidine hexamer and factor Xa cleavage site between the signal peptide and the mature hG-CSF protein allowed successful secretion of hG-CSF into the periplasm without cell lysis.	Histidine	66-75	colony stimulating factor 3	Homo sapiens	201-207
11989602-3	2001	The aim of this paper is to underline the importance of planned splenectomy in these patients even if they have metastatic disease, and to propose an intensive chemotherapy regimen consisting of anthracyclines, ifosfamide and mesna with G-CSF support.	Mesna	226-231	colony stimulating factor 3	Homo sapiens	237-242
11683584-6	2001	To identify the cytokine region defined by mAbs, hG-CSF was digested with different proteolytic enzymes: Arg-C, Glu-C, trypsin and alpha chymotrypsin.	Glutamic Acid	112-115	colony stimulating factor 3	Homo sapiens	49-55
11550287-3	2001	YSK-21 grows well in a medium containing recombinant human granulocyte colony-stimulating factor (rhG-CSF), granulocyte-macrophage colony-stimulating factor (rhGM-CSF), or interleukin-3 (rhIL-3).	ysk-21	0-6	colony stimulating factor 3	Homo sapiens	59-96
11559949-4	2001	Using the human G-CSF responsive MPD cell line, we specifically inhibited MEK using PD 98059 and also transfected MPD cells with a constitutively active MEK construct.	2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one	84-92	colony stimulating factor 3	Homo sapiens	16-21
11516093-1	2001	The Australian Leukaemia Study Group (ALSG) investigated whether G-CSF would accelerate haemopoietic recovery after induction treatment for acute myeloid leukaemia (AML) intensified with high-dose cytarabine, and therefore improve response rates and survival.	Cytarabine	197-207	colony stimulating factor 3	Homo sapiens	65-70
11468284-3	2001	Alanine scanning mutagenesis was used to show that residues in the Ig-like domain of the G-CSF-R (Phe(75), Gln(87), and Gln(91)) interact with G-CSF.	Alanine	0-7	colony stimulating factor 3	Homo sapiens	89-94
11468284-3	2001	Alanine scanning mutagenesis was used to show that residues in the Ig-like domain of the G-CSF-R (Phe(75), Gln(87), and Gln(91)) interact with G-CSF.	Phenylalanine	98-101	colony stimulating factor 3	Homo sapiens	89-94
11468284-3	2001	Alanine scanning mutagenesis was used to show that residues in the Ig-like domain of the G-CSF-R (Phe(75), Gln(87), and Gln(91)) interact with G-CSF.	Glutamine	107-110	colony stimulating factor 3	Homo sapiens	89-94
11468284-3	2001	Alanine scanning mutagenesis was used to show that residues in the Ig-like domain of the G-CSF-R (Phe(75), Gln(87), and Gln(91)) interact with G-CSF.	Glutamine	120-123	colony stimulating factor 3	Homo sapiens	89-94
11564071-2	2001	Granulocyte colony-stimulating factor (G-CSF) was infused continuously from 12 h before until the end of Ara-C therapy to enhance the antileukaemia effect of Ara-C.	Cytarabine	105-110	colony stimulating factor 3	Homo sapiens	0-37
11564071-2	2001	Granulocyte colony-stimulating factor (G-CSF) was infused continuously from 12 h before until the end of Ara-C therapy to enhance the antileukaemia effect of Ara-C.	Cytarabine	105-110	colony stimulating factor 3	Homo sapiens	39-44
11564071-2	2001	Granulocyte colony-stimulating factor (G-CSF) was infused continuously from 12 h before until the end of Ara-C therapy to enhance the antileukaemia effect of Ara-C.	Cytarabine	158-163	colony stimulating factor 3	Homo sapiens	0-37
11564071-2	2001	Granulocyte colony-stimulating factor (G-CSF) was infused continuously from 12 h before until the end of Ara-C therapy to enhance the antileukaemia effect of Ara-C.	Cytarabine	158-163	colony stimulating factor 3	Homo sapiens	39-44
11516093-9	2001	We conclude that the granulopoietic stimulating effect of G-CSF is observed after induction therapy for AML intensified by high-dose cytarabine, resulting in an improvement in a number of clinically important parameters with no major adverse effects.	Cytarabine	133-143	colony stimulating factor 3	Homo sapiens	58-63
11466671-1	2001	BACKGROUND: To address the feasibility and outcome of moderate dose intensification with granulocyte-colony stimulating factor (G-CSF) for patients with aggressive non-Hodgkin lymphoma (NHL), the Cancer and Leukemia Group B (CALGB) conducted two studies evaluating dose-escalated cyclophosphamide and etoposide in the cyclophosphamide, doxorubicin, vincristine, prednisone, etoposide (CHOPE) regimen.	Vincristine	349-360	colony stimulating factor 3	Homo sapiens	128-133
11583191-9	2001	At the third step (epirubicin 90 mg/m2) G-CSF allowed a safe escalation of docetaxel up to 90 mg/m2.	Epirubicin	19-29	colony stimulating factor 3	Homo sapiens	40-45
11583191-9	2001	At the third step (epirubicin 90 mg/m2) G-CSF allowed a safe escalation of docetaxel up to 90 mg/m2.	Docetaxel	75-84	colony stimulating factor 3	Homo sapiens	40-45
12578590-0	2001	[Low Concentrations of STI571 Enhances beta1 Integrin Mediated Inhibitory Effect on Proliferation of Myeloid Progenitors in Ph(+)Chronic Myeloid Leukemia] To investigate whether ABL specific tyrosine kinase specific inhibitor STI571 can restore beta1 integrin mediated negative effect on Ph(+) chronic myeloid leukemia(CML), the inhibitory effect of beta 1 integrin activator (beta1 integrin activating antibody 8A2, cytokines such as GM-CSF, G-CSF and SCF) and/or FN on the granulocyte-macrophage colony forming unit (CFU-GM) from 16 patients with Ph(+)CML and 13 normal individuals were examined; the bone marrow mononuclear cells (BMMNC) before and after ABL kinase specific inhibitor STI571 pretreatment (0.1 micro mol/L for 30-60 minutes) were target cells in this study.	Imatinib Mesylate	23-29	colony stimulating factor 3	Homo sapiens	443-448
11509813-4	2001	(3) Are alveolar macrophages a source of airway G-CSF and GM-CSF? (4) Is in vitro expression of G-CSF and GM-CSF by airway macrophages modified by dexamethasone, endotoxin, or hyperoxia?	Dexamethasone	147-160	colony stimulating factor 3	Homo sapiens	96-101
11509813-12	2001	G-CSF and GM-CSF expression by these macrophages was increased by endotoxin, decreased by dexamethasone, and unchanged by hyperoxia.	Dexamethasone	90-103	colony stimulating factor 3	Homo sapiens	0-5
11489808-0	2001	Cisplatin, etoposide, and paclitaxel with granulocyte colony-stimulating factor in untreated patients with extensive-stage small cell lung cancer: a phase II trial of the Southwest Oncology Group.	Paclitaxel	26-36	colony stimulating factor 3	Homo sapiens	42-79
11466671-1	2001	BACKGROUND: To address the feasibility and outcome of moderate dose intensification with granulocyte-colony stimulating factor (G-CSF) for patients with aggressive non-Hodgkin lymphoma (NHL), the Cancer and Leukemia Group B (CALGB) conducted two studies evaluating dose-escalated cyclophosphamide and etoposide in the cyclophosphamide, doxorubicin, vincristine, prednisone, etoposide (CHOPE) regimen.	Cyclophosphamide	280-296	colony stimulating factor 3	Homo sapiens	128-133
11466671-1	2001	BACKGROUND: To address the feasibility and outcome of moderate dose intensification with granulocyte-colony stimulating factor (G-CSF) for patients with aggressive non-Hodgkin lymphoma (NHL), the Cancer and Leukemia Group B (CALGB) conducted two studies evaluating dose-escalated cyclophosphamide and etoposide in the cyclophosphamide, doxorubicin, vincristine, prednisone, etoposide (CHOPE) regimen.	Etoposide	301-310	colony stimulating factor 3	Homo sapiens	128-133
11466671-1	2001	BACKGROUND: To address the feasibility and outcome of moderate dose intensification with granulocyte-colony stimulating factor (G-CSF) for patients with aggressive non-Hodgkin lymphoma (NHL), the Cancer and Leukemia Group B (CALGB) conducted two studies evaluating dose-escalated cyclophosphamide and etoposide in the cyclophosphamide, doxorubicin, vincristine, prednisone, etoposide (CHOPE) regimen.	Cyclophosphamide	318-334	colony stimulating factor 3	Homo sapiens	128-133
11466671-1	2001	BACKGROUND: To address the feasibility and outcome of moderate dose intensification with granulocyte-colony stimulating factor (G-CSF) for patients with aggressive non-Hodgkin lymphoma (NHL), the Cancer and Leukemia Group B (CALGB) conducted two studies evaluating dose-escalated cyclophosphamide and etoposide in the cyclophosphamide, doxorubicin, vincristine, prednisone, etoposide (CHOPE) regimen.	Doxorubicin	336-347	colony stimulating factor 3	Homo sapiens	128-133
11466671-1	2001	BACKGROUND: To address the feasibility and outcome of moderate dose intensification with granulocyte-colony stimulating factor (G-CSF) for patients with aggressive non-Hodgkin lymphoma (NHL), the Cancer and Leukemia Group B (CALGB) conducted two studies evaluating dose-escalated cyclophosphamide and etoposide in the cyclophosphamide, doxorubicin, vincristine, prednisone, etoposide (CHOPE) regimen.	Prednisone	362-372	colony stimulating factor 3	Homo sapiens	128-133
11466671-1	2001	BACKGROUND: To address the feasibility and outcome of moderate dose intensification with granulocyte-colony stimulating factor (G-CSF) for patients with aggressive non-Hodgkin lymphoma (NHL), the Cancer and Leukemia Group B (CALGB) conducted two studies evaluating dose-escalated cyclophosphamide and etoposide in the cyclophosphamide, doxorubicin, vincristine, prednisone, etoposide (CHOPE) regimen.	Etoposide	374-383	colony stimulating factor 3	Homo sapiens	128-133
11466671-1	2001	BACKGROUND: To address the feasibility and outcome of moderate dose intensification with granulocyte-colony stimulating factor (G-CSF) for patients with aggressive non-Hodgkin lymphoma (NHL), the Cancer and Leukemia Group B (CALGB) conducted two studies evaluating dose-escalated cyclophosphamide and etoposide in the cyclophosphamide, doxorubicin, vincristine, prednisone, etoposide (CHOPE) regimen.	chope	385-390	colony stimulating factor 3	Homo sapiens	128-133
11408509-10	2001	When used with G-CSF, it is Doxil 30 mg/m(2) and docetaxel 75 mg/m(2) every 4 weeks.	liposomal doxorubicin	28-33	colony stimulating factor 3	Homo sapiens	15-20
11408206-8	2001	rhG-CSF clearance (CL(G-CSF)) correlated significantly with the ANC (r = 0.613; P &lt; 0.001) and CL(CR) (r = 0.632; P &lt; 0.001).	Chromium	101-103	colony stimulating factor 3	Homo sapiens	19-27
11408206-9	2001	Multiple linear regression analysis showed that the combination of the ANC and CL(CR) accounted for 57.4% of the variation of CL(G-CSF).	Chromium	82-84	colony stimulating factor 3	Homo sapiens	126-134
11408206-10	2001	In patients with an ANC of &lt;1,000/microl, CL(CR) accounted for 72.9% of the variation of CL(G-CSF) (P &lt; 0.001).	Chromium	48-50	colony stimulating factor 3	Homo sapiens	92-100
11410799-0	2001	Randomized study of dose or schedule modification of granulocyte colony-stimulating factor in platinum-based chemotherapy for elderly patients with lung cancer.	Platinum	94-102	colony stimulating factor 3	Homo sapiens	53-90
11497396-1	2001	The object of this study was to determine the efficacy and safety of glycosylated recombinant human granulocyte colony-stimulating factor (rHuG-CSF; lenograstim) after combination chemotherapy consisting of ranimustine, vindesine, melphalan and prednisolone (MCNU-VMP).	Vindesine	220-229	colony stimulating factor 3	Homo sapiens	100-137
11497396-1	2001	The object of this study was to determine the efficacy and safety of glycosylated recombinant human granulocyte colony-stimulating factor (rHuG-CSF; lenograstim) after combination chemotherapy consisting of ranimustine, vindesine, melphalan and prednisolone (MCNU-VMP).	Melphalan	231-240	colony stimulating factor 3	Homo sapiens	100-137
11497396-1	2001	The object of this study was to determine the efficacy and safety of glycosylated recombinant human granulocyte colony-stimulating factor (rHuG-CSF; lenograstim) after combination chemotherapy consisting of ranimustine, vindesine, melphalan and prednisolone (MCNU-VMP).	Prednisolone	245-257	colony stimulating factor 3	Homo sapiens	100-137
11408509-4	2001	RESULTS: In conjunction with docetaxel 75 mg/m(2) every 4 weeks, the MTD of Doxil was 30 mg/m(2) and required granulocyte colony-stimulating factor (G-CSF) to prevent febrile neutropenia.	liposomal doxorubicin	76-81	colony stimulating factor 3	Homo sapiens	110-147
11408509-4	2001	RESULTS: In conjunction with docetaxel 75 mg/m(2) every 4 weeks, the MTD of Doxil was 30 mg/m(2) and required granulocyte colony-stimulating factor (G-CSF) to prevent febrile neutropenia.	liposomal doxorubicin	76-81	colony stimulating factor 3	Homo sapiens	149-154
11408509-10	2001	When used with G-CSF, it is Doxil 30 mg/m(2) and docetaxel 75 mg/m(2) every 4 weeks.	Docetaxel	49-58	colony stimulating factor 3	Homo sapiens	15-20
11432350-0	2001	[Effect of G-CSF (nartograstim) on neutropenia (leukopenia) induced by taxane in metastatic breast cancer--time-course changes in neutrophil and leukocyte counts].	taxane	71-77	colony stimulating factor 3	Homo sapiens	11-16
11442492-5	2001	Samples with a high PA (&gt; median of the whole group) were more likely to produce interleukin 3, granulocyte macrophage colony-stimulating factor (GM-CSF), granulocyte CSF (G-CSF) (56%, 43% and 50%) than cells with a low PA (33%, 36% and 36%; n.s.).	Protactinium	20-22	colony stimulating factor 3	Homo sapiens	175-180
11442492-6	2001	The effect of priming by exogenous GM-CSF or G-CSF was significantly more pronounced in samples with a low PA than in rapidly proliferating samples (P &lt; 0.01).	Protactinium	107-109	colony stimulating factor 3	Homo sapiens	45-50
11404490-1	2001	The purpose of this phase II trial was to evaluate the toxicity of a sequential chemoradiotherapy approach using docetaxel, cisplatin, and 5-fluorouracil (5-FU) (DCF) with granulocyte colony-stimulating factor support in previously untreated patients with locally advanced head and neck cancer (HNC).	Fluorouracil	139-153	colony stimulating factor 3	Homo sapiens	172-209
11404490-1	2001	The purpose of this phase II trial was to evaluate the toxicity of a sequential chemoradiotherapy approach using docetaxel, cisplatin, and 5-fluorouracil (5-FU) (DCF) with granulocyte colony-stimulating factor support in previously untreated patients with locally advanced head and neck cancer (HNC).	Fluorouracil	155-159	colony stimulating factor 3	Homo sapiens	172-209
11404490-1	2001	The purpose of this phase II trial was to evaluate the toxicity of a sequential chemoradiotherapy approach using docetaxel, cisplatin, and 5-fluorouracil (5-FU) (DCF) with granulocyte colony-stimulating factor support in previously untreated patients with locally advanced head and neck cancer (HNC).	Pentostatin	162-165	colony stimulating factor 3	Homo sapiens	172-209
11410492-15	2001	These results suggest that dexrazoxane as a 96-h infusion can be safely administered with granulocyte-colony stimulating factor at doses that achieve plasma levels that have been demonstrated previously to inhibit topoisomerase II activity and to induce apoptosis in vitro.	Dexrazoxane	27-38	colony stimulating factor 3	Homo sapiens	90-127
11438975-8	2001	Combined ifosfamide/epirubicin and standard G-CSF is able to mobilize sufficient PBPC without serious side-effects for patients with MM and for purging procedures resulting in a high proportion of complete remissions after tandem high-dose melphalan chemotherapy.	Melphalan	240-249	colony stimulating factor 3	Homo sapiens	44-49
11432350-2	2001	However, these taxane compounds induced neutropenia and leukopenia, which may be reversed by G-CSF (Nartograstim).	taxane	15-21	colony stimulating factor 3	Homo sapiens	93-98
11336465-0	2001	A weekly regimen of cisplatin, paclitaxel and topotecan with granulocyte-colony stimulating factor support for patients with extensive disease small cell lung cancer: a phase II study.	Cisplatin	20-29	colony stimulating factor 3	Homo sapiens	61-98
11336465-0	2001	A weekly regimen of cisplatin, paclitaxel and topotecan with granulocyte-colony stimulating factor support for patients with extensive disease small cell lung cancer: a phase II study.	Topotecan	46-55	colony stimulating factor 3	Homo sapiens	61-98
11336465-1	2001	The present study was aimed at defining the antitumour activity of the cisplatin-paclitaxel-topotecan (CPT) weekly administration with G-CSF support in chemo-naive SCLC patients with extensive disease (ED-SCLC).	Cisplatin	71-80	colony stimulating factor 3	Homo sapiens	135-140
11336465-1	2001	The present study was aimed at defining the antitumour activity of the cisplatin-paclitaxel-topotecan (CPT) weekly administration with G-CSF support in chemo-naive SCLC patients with extensive disease (ED-SCLC).	Paclitaxel	81-91	colony stimulating factor 3	Homo sapiens	135-140
11368434-3	2001	We showed that G-CSF significantly reduced Fas-mediated caspase-8 and caspase-3-like activity and the degree of nuclear apoptotic changes in bone marrow from nine RARS patients.	ammonium ferrous sulfate	43-46	colony stimulating factor 3	Homo sapiens	15-20
11436102-0	2001	High-dose melphalan with G-CSF-stimulated whole blood rescue followed by stem cell harvesting and busulphan/cyclophosphamide with autologous stem cell transplantation in multiple myeloma.	Melphalan	10-19	colony stimulating factor 3	Homo sapiens	25-30
11436102-0	2001	High-dose melphalan with G-CSF-stimulated whole blood rescue followed by stem cell harvesting and busulphan/cyclophosphamide with autologous stem cell transplantation in multiple myeloma.	Busulfan	98-107	colony stimulating factor 3	Homo sapiens	25-30
11436102-0	2001	High-dose melphalan with G-CSF-stimulated whole blood rescue followed by stem cell harvesting and busulphan/cyclophosphamide with autologous stem cell transplantation in multiple myeloma.	Cyclophosphamide	108-124	colony stimulating factor 3	Homo sapiens	25-30
11304774-1	2001	PURPOSE: To evaluate whether an accelerated-intensified cyclophosphamide, epirubicin, and fluorouracil (CEF) chemotherapy regimen with the support of granulocyte colony-stimulating factor (G-CSF) induces a higher activity and efficacy compared with standard CEF in metastatic breast cancer patients.	Fluorouracil	90-102	colony stimulating factor 3	Homo sapiens	150-187
11346705-7	2001	Identical doses of PBPCs mobilized by GM-/G-CSF + EPO and G-CSF + EPO drove comparable hematopoietic recovery after reinfusion in patients treated with identical high-dose chemotherapy.	pbpcs	19-24	colony stimulating factor 3	Homo sapiens	42-47
11346705-8	2001	CONCLUSION: The sequential administration of GM-CSF and G-CSF in combination with EPO is feasible and improves the PBPC collection efficiency after platinum-based intensive polychemotherapy, associating high PBPC mobilization to high collection efficiency during apheresis.	Platinum	148-156	colony stimulating factor 3	Homo sapiens	56-61
11304774-1	2001	PURPOSE: To evaluate whether an accelerated-intensified cyclophosphamide, epirubicin, and fluorouracil (CEF) chemotherapy regimen with the support of granulocyte colony-stimulating factor (G-CSF) induces a higher activity and efficacy compared with standard CEF in metastatic breast cancer patients.	Cyclophosphamide	56-72	colony stimulating factor 3	Homo sapiens	150-187
11304774-1	2001	PURPOSE: To evaluate whether an accelerated-intensified cyclophosphamide, epirubicin, and fluorouracil (CEF) chemotherapy regimen with the support of granulocyte colony-stimulating factor (G-CSF) induces a higher activity and efficacy compared with standard CEF in metastatic breast cancer patients.	cef	104-107	colony stimulating factor 3	Homo sapiens	150-187
11304774-1	2001	PURPOSE: To evaluate whether an accelerated-intensified cyclophosphamide, epirubicin, and fluorouracil (CEF) chemotherapy regimen with the support of granulocyte colony-stimulating factor (G-CSF) induces a higher activity and efficacy compared with standard CEF in metastatic breast cancer patients.	Epirubicin	74-84	colony stimulating factor 3	Homo sapiens	150-187
11304774-1	2001	PURPOSE: To evaluate whether an accelerated-intensified cyclophosphamide, epirubicin, and fluorouracil (CEF) chemotherapy regimen with the support of granulocyte colony-stimulating factor (G-CSF) induces a higher activity and efficacy compared with standard CEF in metastatic breast cancer patients.	cef	258-261	colony stimulating factor 3	Homo sapiens	150-187
11378548-0	2001	Secondary prophylactic G-CSF (filgrastim) administration in chemotherapy of stage I and II Hodgkin"s lymphoma with ABVD.	ABVD protocol	115-119	colony stimulating factor 3	Homo sapiens	23-28
11398891-11	2001	G-CSF 5 microg/kg subcutaneously starting day 6 permitted further topotecan dose escalation.	Topotecan	66-75	colony stimulating factor 3	Homo sapiens	0-5
11301181-4	2001	Both Leridistim and G-CSF induced receptor tyrosine phosphorylation to a similar maximal level.	Tyrosine	43-51	colony stimulating factor 3	Homo sapiens	20-25
11283920-10	2001	In vitro exposure of MPC cultures to dexamethasone resulted in the down-regulation of IL-6, G-CSF, and GM-CSF in both normal and myeloma MPC cultures.	Dexamethasone	37-50	colony stimulating factor 3	Homo sapiens	92-97
11378548-1	2001	UNLABELLED: The purpose of this study was to determine the effect of granulocyte colony-stimulating factor (filgrastim, G-CSF) for maintenance of chemotherapy dose-intensity in patients with stage I or II Hodgkin"s lymphoma treated with six cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD).	Doxorubicin	251-262	colony stimulating factor 3	Homo sapiens	69-106
11378548-1	2001	UNLABELLED: The purpose of this study was to determine the effect of granulocyte colony-stimulating factor (filgrastim, G-CSF) for maintenance of chemotherapy dose-intensity in patients with stage I or II Hodgkin"s lymphoma treated with six cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD).	Bleomycin	264-273	colony stimulating factor 3	Homo sapiens	69-106
11378548-1	2001	UNLABELLED: The purpose of this study was to determine the effect of granulocyte colony-stimulating factor (filgrastim, G-CSF) for maintenance of chemotherapy dose-intensity in patients with stage I or II Hodgkin"s lymphoma treated with six cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD).	Vinblastine	275-286	colony stimulating factor 3	Homo sapiens	69-106
11378548-1	2001	UNLABELLED: The purpose of this study was to determine the effect of granulocyte colony-stimulating factor (filgrastim, G-CSF) for maintenance of chemotherapy dose-intensity in patients with stage I or II Hodgkin"s lymphoma treated with six cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD).	Dacarbazine	292-303	colony stimulating factor 3	Homo sapiens	69-106
11378548-1	2001	UNLABELLED: The purpose of this study was to determine the effect of granulocyte colony-stimulating factor (filgrastim, G-CSF) for maintenance of chemotherapy dose-intensity in patients with stage I or II Hodgkin"s lymphoma treated with six cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD).	ABVD protocol	305-309	colony stimulating factor 3	Homo sapiens	69-106
11378548-8	2001	IN CONCLUSION: Secondary prophylactic G-CSF administration was necessary in more than half of patients with stage I or II Hodgkin"s lymphoma during chemotherapy with ABVD.	ABVD protocol	166-170	colony stimulating factor 3	Homo sapiens	38-43
11237694-3	2001	The eluted His-Ig/G-CSF complex could be separated from excess G-CSF by Ni-NTA column chromatography.	Histidine	11-14	colony stimulating factor 3	Homo sapiens	18-23
11237694-3	2001	The eluted His-Ig/G-CSF complex could be separated from excess G-CSF by Ni-NTA column chromatography.	Histidine	11-14	colony stimulating factor 3	Homo sapiens	63-68
11237694-3	2001	The eluted His-Ig/G-CSF complex could be separated from excess G-CSF by Ni-NTA column chromatography.	ni-nta	72-78	colony stimulating factor 3	Homo sapiens	18-23
11237694-3	2001	The eluted His-Ig/G-CSF complex could be separated from excess G-CSF by Ni-NTA column chromatography.	ni-nta	72-78	colony stimulating factor 3	Homo sapiens	63-68
11241232-1	2001	BACKGROUND: The purpose of the study was to determine the maximum tolerated dose (MTD) of vinorelbine and paclitaxel given concomitantly in patients with advanced breast carcinoma, the toxicity of this combination, and whether the addition of granulocyte colony-stimulating factor (G-CSF) would allow administration of higher doses of the combination.	Vinorelbine	90-101	colony stimulating factor 3	Homo sapiens	243-280
11181665-12	2001	CONCLUSION: The combination of paclitaxel, doxorubicin, and cisplatin at relevant single-agent doses is active and feasible with the addition of G-CSF.	Paclitaxel	31-41	colony stimulating factor 3	Homo sapiens	145-150
11241232-1	2001	BACKGROUND: The purpose of the study was to determine the maximum tolerated dose (MTD) of vinorelbine and paclitaxel given concomitantly in patients with advanced breast carcinoma, the toxicity of this combination, and whether the addition of granulocyte colony-stimulating factor (G-CSF) would allow administration of higher doses of the combination.	Vinorelbine	90-101	colony stimulating factor 3	Homo sapiens	282-287
11181665-12	2001	CONCLUSION: The combination of paclitaxel, doxorubicin, and cisplatin at relevant single-agent doses is active and feasible with the addition of G-CSF.	Doxorubicin	43-54	colony stimulating factor 3	Homo sapiens	145-150
17039083-0	2001	Early onset methotrexate-induced pancytopenia and response to G-CSF: a report of two cases.	Methotrexate	12-24	colony stimulating factor 3	Homo sapiens	62-67
11181665-12	2001	CONCLUSION: The combination of paclitaxel, doxorubicin, and cisplatin at relevant single-agent doses is active and feasible with the addition of G-CSF.	Cisplatin	60-69	colony stimulating factor 3	Homo sapiens	145-150
11372732-0	2001	Effect of granulocyte colony-stimulating factor on chemotherapeutic activity of cytosine arabinoside in acute leukemic cell lines.	Cytarabine	80-100	colony stimulating factor 3	Homo sapiens	10-47
11261332-7	2001	These results indicate that high-dose etoposide phosphate with G-CSF is safe, well tolerated, and may be effective in peripheral blood stem cell (PBSC) mobilization in patients who had previously failed to mobilize.	etoposide phosphate	38-57	colony stimulating factor 3	Homo sapiens	63-68
17039083-3	2001	We report two cases of early-onset methotrexate-induced pancytopenia that were successfully treated with granulocyte colony-stimulating factor (G-CSF).	Methotrexate	35-47	colony stimulating factor 3	Homo sapiens	105-142
17039083-3	2001	We report two cases of early-onset methotrexate-induced pancytopenia that were successfully treated with granulocyte colony-stimulating factor (G-CSF).	Methotrexate	35-47	colony stimulating factor 3	Homo sapiens	144-149
11289399-6	2001	G-CSF increased neutrophil superoxide production to 12.1 in diabetic patients with foot infections and to 19.8 in controls (p&lt;0.05 for each).	Superoxides	27-37	colony stimulating factor 3	Homo sapiens	0-5
11255792-4	2001	To assess the mechanism of abortion and fetal death in rabbits given G-CSF, 125I-labeled NTG was given intravenously on Day 18 of pregnancy after repeated administration of cold NTG on Days 6 through 17 of pregnancy, and the feto-maternal distribution of radioactivity was examined.	Nitroglycerin	89-92	colony stimulating factor 3	Homo sapiens	69-74
11205919-0	2001	A phase I clinical, pharmacological, and biological trial of interleukin 6 plus granulocyte-colony stimulating factor after ifosfamide, carboplatin, and etoposide in children with recurrent/refractory solid tumors: enhanced hematological responses but a high incidence of grade III/IV constitutional toxicities.	Etoposide	153-162	colony stimulating factor 3	Homo sapiens	80-117
11239221-3	2001	Gly-G-CSF was given subcutaneously at a dose of 10 microg per kg per day in two divided doses over 3 days and was followed by a leukapheresis (on the 4th day) 12 hours after the last dose.	Glycine	0-3	colony stimulating factor 3	Homo sapiens	4-9
11239221-9	2001	CONCLUSION: A schedule consisting of 3-day administration of gly-G-CSF followed by a single leukapheresis can be proposed and widely accepted by healthy donors, as 84 percent of them reach the target in the estimated time with a reduced drug exposure.	Glycine	61-64	colony stimulating factor 3	Homo sapiens	65-70
11239222-0	2001	PBPC mobilization with paclitaxel, ifosfamide, and G-CSF with or without amifostine: results of a prospective randomized trial.	PbPc	0-4	colony stimulating factor 3	Homo sapiens	51-56
11239224-2	2001	In this study, the relationship between PBPC mobilization and blood levels of G-CSF, endogenous cytokines (IL-8, SCF, thrombopoietin [TPO]), and the vascular cell adhesion molecule-1 (VCAM-1) was analyzed in patients with malignancy who were undergoing a PBPC mobilization regimen.	PbPc	40-44	colony stimulating factor 3	Homo sapiens	78-83
27405694-0	2001	Successful Cytoreduction with CAG (cytarabine, Aclarubicin and G-CSF) Therapy in Refractory Acute Myelogenous Leukemia before Allogeneic Stem Cell Transplantation.	GUANOSINE 5'-TRIPHOSPHATE P3-[1-(2-NITROPHENYL)ETHYL ESTER]	30-33	colony stimulating factor 3	Homo sapiens	63-68
11281378-10	2001	In conclusion, the administration of two cycles of high-dose mitoxantrone and cyclophosphamide with G-CSF support is safe and feasible.	Cyclophosphamide	78-94	colony stimulating factor 3	Homo sapiens	100-105
11201384-6	2001	Even though the patient exhibited bone marrow suppression and G-CSF was administered twice for neutropenia, there were no adverse effects except mild alopecia, again suggesting the possibility that paclitaxel is effective chemotherapy for recurrent breast cancer.	Paclitaxel	198-208	colony stimulating factor 3	Homo sapiens	62-67
27419352-0	2001	Methimazole-Induced Agranulocytosis and Quick Recovery with G-CSF.	Methimazole	0-11	colony stimulating factor 3	Homo sapiens	60-65
11561692-3	2001	9-AC was infused over 72 h at a dose of 1,100 microg/m2 per day (approximately 46 microg/m2/h) every 2 weeks, with granulocyte-colony stimulating factor (G-CSF) support.	9-aminocamptothecin	0-4	colony stimulating factor 3	Homo sapiens	154-159
27419352-4	2001	We think that in patients with methimazole-induced agranulocytosis, G-CSF may reduce the risk and severity of infection and in some cases should be accepted as a part of the standard therapy.	Methimazole	31-42	colony stimulating factor 3	Homo sapiens	68-73
15373581-0	2001	Development of anti-Bw6 reactivity in patients receiving r-GCSF: a preliminary report.	(3~{R})-4-cyclopropyl-1,3-dimethyl-6-(1~{H}-pyrrol-2-yl)-3~{H}-quinoxalin-2-one	20-23	colony stimulating factor 3	Homo sapiens	59-63
11735678-14	2001	In two large head-to-head comparative clinical trials, paclitaxel plus cisplatin was associated with significantly greater response rates than cisplatin in combination with either teniposide or etoposide, and a survival advantage was shown for paclitaxel plus cisplatin (with or without G-CSF) over etoposide plus cisplatin.	Paclitaxel	55-65	colony stimulating factor 3	Homo sapiens	287-292
11115564-0	2001	Prognostic results of cisplatin IP and carboplatin IV with G-CSF in patients with ovarian cancer.	Cisplatin	22-31	colony stimulating factor 3	Homo sapiens	59-64
11115564-0	2001	Prognostic results of cisplatin IP and carboplatin IV with G-CSF in patients with ovarian cancer.	Carboplatin	39-50	colony stimulating factor 3	Homo sapiens	59-64
11735678-14	2001	In two large head-to-head comparative clinical trials, paclitaxel plus cisplatin was associated with significantly greater response rates than cisplatin in combination with either teniposide or etoposide, and a survival advantage was shown for paclitaxel plus cisplatin (with or without G-CSF) over etoposide plus cisplatin.	Cisplatin	71-80	colony stimulating factor 3	Homo sapiens	287-292
11172538-7	2001	In addition, when a combination of retinoic acid and the hematopoietic growth factor granulocyte colony-stimulating factor (G-CSF) is applied, the cells may be forced to undergo terminal differentiation, both in vitro and in vivo.	Tretinoin	35-48	colony stimulating factor 3	Homo sapiens	124-129
11070335-5	2001	DEX induced an increase in granulocyte counts, which was positively correlated with increases in the circulating amounts of G-CSF and paralleled by decreased lymphocyte and monocyte counts.	Dexamethasone	0-3	colony stimulating factor 3	Homo sapiens	124-129
11094146-0	2000	G-CSF plasma levels in clozapine-induced neutropenia.	Clozapine	23-32	colony stimulating factor 3	Homo sapiens	0-5
11204230-3	2000	It was demonstrated that chelated mercury contained free sites for interaction with proteins such as bromelain and recombinant human granulocyte colony stimulating factor from E. coli.	Mercury	34-41	colony stimulating factor 3	Homo sapiens	133-170
11204231-0	2000	Comparative studies of recombinant human granulocyte-colony stimulating factor, its Ser-17 and (His)6-tagged forms interaction with metal ions by means of immobilized metal ion affinity partitioning.	Metals	132-137	colony stimulating factor 3	Homo sapiens	41-78
11204231-0	2000	Comparative studies of recombinant human granulocyte-colony stimulating factor, its Ser-17 and (His)6-tagged forms interaction with metal ions by means of immobilized metal ion affinity partitioning.	Metals	167-172	colony stimulating factor 3	Homo sapiens	41-78
11204231-2	2000	The chelation capability of the reactive dye Light Resistant Yellow 2KT towards metal ions, particularly mercury(II) was evaluated in the pH range 5.0-7.0, and it was shown that the dye-Hg(II) complex has a free site for the interaction with human recombinant granulocyte-colony stimulating factor (rhG-CSF) from Escherichia coli.	Metals	80-85	colony stimulating factor 3	Homo sapiens	260-297
11094146-1	2000	BACKGROUND: Clinical reports emphasize the therapeutic usefulness of granulocyte colony-stimulating factor (G-CSF) in clozapine-induced granulocytopenia.	Clozapine	118-127	colony stimulating factor 3	Homo sapiens	69-106
11094146-1	2000	BACKGROUND: Clinical reports emphasize the therapeutic usefulness of granulocyte colony-stimulating factor (G-CSF) in clozapine-induced granulocytopenia.	Clozapine	118-127	colony stimulating factor 3	Homo sapiens	108-113
11094146-3	2000	METHODS: We monitored G-CSF and white blood cell (WBC) counts in a 73-year-old patient who developed granulocytopenia while being treated with clozapine for schizoaffective disorder.	Clozapine	143-152	colony stimulating factor 3	Homo sapiens	22-27
11094146-11	2000	We conclude that monitoring of G-CSF levels may serve as a useful tool in the follow-up of patients in whom clozapine-induced bone marrow damage is suspected.	Clozapine	108-117	colony stimulating factor 3	Homo sapiens	31-36
11192322-9	2000	RESULTS: Neutrophils from patients receiving 50, 100 or 150 microg/m2 G-CSF, but not from control patients or those receiving 25 microg/m2, showed significantly increased phagocytosis and killing at 96 h. Doses of 50 or 150 microg/m2 G-CSF resulted in increased superoxide production at 96 h. No patients discontinued treatment as a consequence of side effects related to G-CSF administration.	Superoxides	262-272	colony stimulating factor 3	Homo sapiens	70-75
11228059-5	2000	Co-stimulation of the stromal cells with 8-Br-cAMP and G-CSF enhanced prolactin secretion from the stimulated cells in a G-CSF concentration-dependent manner without any change in viable cell numbers.	8-Bromo Cyclic Adenosine Monophosphate	41-50	colony stimulating factor 3	Homo sapiens	121-126
11146160-11	2000	When small daily doses of oral prednisone were then administered to the patient with conventional doses of subcutaneous G-CSF, the patient responded with increased neutrophil numbers and with a complete reversal of the infectious problems.	Prednisone	31-41	colony stimulating factor 3	Homo sapiens	120-125
11228059-7	2000	These results indicate that G-CSF enhances cAMP-mediated decidualization of human endometrial stromal cells in an autocrine or paracrine fashion.	Cyclic AMP	43-47	colony stimulating factor 3	Homo sapiens	28-33
11152575-6	2000	Neutrophil chemotaxis and stimulated lysozyme release were decreased throughout G-CSF treatment, whereas respiratory burst activity, phagocytic activity, and intracellular calcium concentration were enhanced by G-CSF.	Calcium	172-179	colony stimulating factor 3	Homo sapiens	211-216
11177597-11	2000	When our results were compared to a matched cohort receiving G-CSF alone, the docetaxel group demonstrated a superior CD34 cells/kg yield (p = &lt;0.001).	Docetaxel	78-87	colony stimulating factor 3	Homo sapiens	61-66
11137204-7	2000	RESULTS: At the dose of CPT-11 120 mg/m2, three out of four enrolled patients presented DLTs (grade 4 neutropenia, febrile neutropenia and delayed diarrhea); the addition of G-CSF at this level did not permit further dose-escalation.	Irinotecan	24-30	colony stimulating factor 3	Homo sapiens	174-179
11071637-7	2000	G-CSF, but not SCF, induces the tyrosine phosphorylation of STAT1 and STAT3, transcription factors that can mediate the induction of c-fos.	Tyrosine	32-40	colony stimulating factor 3	Homo sapiens	0-5
11066054-10	2000	Bacterial/fungal infections were slightly less frequent in the G-CSF group with CAV (P = 0.11) but not with P/VP.	Phosphorus	85-86	colony stimulating factor 3	Homo sapiens	63-68
11071637-9	2000	The pathways by which SCF and G-CSF lead to serine phosphorylation of STAT3 are distinct and are partially dependent on phosphatidylinositol-3 kinase and ERKs, pathways that are also necessary for the synergistic effects of SCF and G-CSF on proliferation and c-fos induction.	Serine	44-50	colony stimulating factor 3	Homo sapiens	30-35
11071637-9	2000	The pathways by which SCF and G-CSF lead to serine phosphorylation of STAT3 are distinct and are partially dependent on phosphatidylinositol-3 kinase and ERKs, pathways that are also necessary for the synergistic effects of SCF and G-CSF on proliferation and c-fos induction.	Serine	44-50	colony stimulating factor 3	Homo sapiens	232-237
11110057-1	2000	PURPOSE: A phase II study was performed to investigate the efficacy and tolerance of alternating docetaxel and epirubicin/cyclophosphamide plus recombinant human granulocyte colony-stimulating factor (G-CSF) in patients with advanced breast cancer who failed previous non-anthracycline/taxane-containing palliative chemotherapy.	Anthracyclines	272-285	colony stimulating factor 3	Homo sapiens	162-199
11095375-0	2000	Correction of mesalazine-induced neutropenia with high-dose G-CSF.	Mesalamine	14-24	colony stimulating factor 3	Homo sapiens	60-65
11142689-0	2000	Phase I study of carboplatin, docetaxel and irinotecan with recombinant human granulocyte colony stimulating factor support in patients with advanced non-small cell lung cancer.	Carboplatin	17-28	colony stimulating factor 3	Homo sapiens	78-115
11142689-0	2000	Phase I study of carboplatin, docetaxel and irinotecan with recombinant human granulocyte colony stimulating factor support in patients with advanced non-small cell lung cancer.	Irinotecan	44-54	colony stimulating factor 3	Homo sapiens	78-115
11142689-1	2000	A phase I study was conducted in patients with stage IIIB or IV non-small cell lung cancer to determine the maximum tolerated dose (MTD) of irinotecan combined with a fixed schedule of docetaxel and carboplatin with recombinant human granulocyte colony stimulating factor (rhG-CSF) (nartograstim) support.	Irinotecan	140-150	colony stimulating factor 3	Homo sapiens	234-271
11110057-1	2000	PURPOSE: A phase II study was performed to investigate the efficacy and tolerance of alternating docetaxel and epirubicin/cyclophosphamide plus recombinant human granulocyte colony-stimulating factor (G-CSF) in patients with advanced breast cancer who failed previous non-anthracycline/taxane-containing palliative chemotherapy.	Anthracyclines	272-285	colony stimulating factor 3	Homo sapiens	201-206
11110057-1	2000	PURPOSE: A phase II study was performed to investigate the efficacy and tolerance of alternating docetaxel and epirubicin/cyclophosphamide plus recombinant human granulocyte colony-stimulating factor (G-CSF) in patients with advanced breast cancer who failed previous non-anthracycline/taxane-containing palliative chemotherapy.	taxane	286-292	colony stimulating factor 3	Homo sapiens	162-199
11110057-1	2000	PURPOSE: A phase II study was performed to investigate the efficacy and tolerance of alternating docetaxel and epirubicin/cyclophosphamide plus recombinant human granulocyte colony-stimulating factor (G-CSF) in patients with advanced breast cancer who failed previous non-anthracycline/taxane-containing palliative chemotherapy.	taxane	286-292	colony stimulating factor 3	Homo sapiens	201-206
11006039-0	2000	Cisplatin-paclitaxel-cyclophosphamide with G-CSF in primary advanced epithelial ovarian cancer.	Cisplatin	0-9	colony stimulating factor 3	Homo sapiens	43-48
11012671-1	2000	The Gadd45gamma (growth arrest and DNA damage-inducible) gene is activated transcriptionally by at least two kinds of agents: DNA damaging agent such as methyl methanesulfonate (MMS) and UV radiation, or cytokines such as interleukin (IL)-6, IL-2 and granulocyte colony-stimulating factor (G-CSF).	Methyl Methanesulfonate	153-176	colony stimulating factor 3	Homo sapiens	251-288
11012671-1	2000	The Gadd45gamma (growth arrest and DNA damage-inducible) gene is activated transcriptionally by at least two kinds of agents: DNA damaging agent such as methyl methanesulfonate (MMS) and UV radiation, or cytokines such as interleukin (IL)-6, IL-2 and granulocyte colony-stimulating factor (G-CSF).	Methyl Methanesulfonate	153-176	colony stimulating factor 3	Homo sapiens	290-296
11012671-1	2000	The Gadd45gamma (growth arrest and DNA damage-inducible) gene is activated transcriptionally by at least two kinds of agents: DNA damaging agent such as methyl methanesulfonate (MMS) and UV radiation, or cytokines such as interleukin (IL)-6, IL-2 and granulocyte colony-stimulating factor (G-CSF).	Methyl Methanesulfonate	178-181	colony stimulating factor 3	Homo sapiens	251-288
11012671-1	2000	The Gadd45gamma (growth arrest and DNA damage-inducible) gene is activated transcriptionally by at least two kinds of agents: DNA damaging agent such as methyl methanesulfonate (MMS) and UV radiation, or cytokines such as interleukin (IL)-6, IL-2 and granulocyte colony-stimulating factor (G-CSF).	Methyl Methanesulfonate	178-181	colony stimulating factor 3	Homo sapiens	290-296
11057460-6	2000	An increase in killing correlated with increases in production of superoxide (r = 0.96) and hydrogen peroxide (r= 0.97) by ALF neutrophils after incubation with 1,000 and 5,000 IU/ml of G-CSF when formylmethionylleucylphenylalanine (fMLP) was the stimulant.	Superoxides	66-76	colony stimulating factor 3	Homo sapiens	186-191
11057460-6	2000	An increase in killing correlated with increases in production of superoxide (r = 0.96) and hydrogen peroxide (r= 0.97) by ALF neutrophils after incubation with 1,000 and 5,000 IU/ml of G-CSF when formylmethionylleucylphenylalanine (fMLP) was the stimulant.	Hydrogen Peroxide	92-109	colony stimulating factor 3	Homo sapiens	186-191
11057460-6	2000	An increase in killing correlated with increases in production of superoxide (r = 0.96) and hydrogen peroxide (r= 0.97) by ALF neutrophils after incubation with 1,000 and 5,000 IU/ml of G-CSF when formylmethionylleucylphenylalanine (fMLP) was the stimulant.	N-Formylmethionine Leucyl-Phenylalanine	197-231	colony stimulating factor 3	Homo sapiens	186-191
11057460-7	2000	G-CSF at 5,000 IU/ml increased the production of hydrogen peroxide (P&lt; 0.01) when zymosan was the stimulant.	Hydrogen Peroxide	49-66	colony stimulating factor 3	Homo sapiens	0-5
11057460-7	2000	G-CSF at 5,000 IU/ml increased the production of hydrogen peroxide (P&lt; 0.01) when zymosan was the stimulant.	Leu-Thr	70-72	colony stimulating factor 3	Homo sapiens	0-5
11057460-7	2000	G-CSF at 5,000 IU/ml increased the production of hydrogen peroxide (P&lt; 0.01) when zymosan was the stimulant.	Zymosan	85-92	colony stimulating factor 3	Homo sapiens	0-5
11006039-0	2000	Cisplatin-paclitaxel-cyclophosphamide with G-CSF in primary advanced epithelial ovarian cancer.	Paclitaxel	10-20	colony stimulating factor 3	Homo sapiens	43-48
11006039-0	2000	Cisplatin-paclitaxel-cyclophosphamide with G-CSF in primary advanced epithelial ovarian cancer.	Cyclophosphamide	21-37	colony stimulating factor 3	Homo sapiens	43-48
11091499-8	2000	Addition of anti-G-CSF antibody (Ab) to ACS decreased CAFC recruitment significantly, whereas anti-IL-3 Ab had no significant effect.	cafc	54-58	colony stimulating factor 3	Homo sapiens	17-22
11019836-12	2000	We conclude that docetaxel with G-CSF effectively mobilises PBPCs with apheresis needing to be commenced approximately 8 days after docetaxel administration.	Docetaxel	17-26	colony stimulating factor 3	Homo sapiens	32-37
10856307-9	2000	Delivery of the human granulocyte colony-stimulating factor gene in EBV-based plasmids increased circulating white blood counts for at least 2 months following a single CLDC-based intravenous co-injection.	cldc	169-173	colony stimulating factor 3	Homo sapiens	22-59
10993214-1	2000	We examined the effect of cytochalasin B (CB) or granulocyte colony stimulating factor (GCSF) on superoxide radical (O2-) production of neutrophils by phorbor myristate acetate (PMA)-stimulation.	Superoxides	97-115	colony stimulating factor 3	Homo sapiens	88-92
10993214-1	2000	We examined the effect of cytochalasin B (CB) or granulocyte colony stimulating factor (GCSF) on superoxide radical (O2-) production of neutrophils by phorbor myristate acetate (PMA)-stimulation.	Superoxides	117-119	colony stimulating factor 3	Homo sapiens	88-92
11019836-12	2000	We conclude that docetaxel with G-CSF effectively mobilises PBPCs with apheresis needing to be commenced approximately 8 days after docetaxel administration.	Docetaxel	132-141	colony stimulating factor 3	Homo sapiens	32-37
11035615-0	2000	Chemotherapy consisting of doxorubicin, bleomycin, vinblastine, and dacarbazine with granulocyte-colony-stimulating factor in HIV-infected patients with newly diagnosed Hodgkin"s disease: a prospective, multi-institutional AIDS clinical trials group study (ACTG 149).	Doxorubicin	27-38	colony stimulating factor 3	Homo sapiens	85-122
10993214-1	2000	We examined the effect of cytochalasin B (CB) or granulocyte colony stimulating factor (GCSF) on superoxide radical (O2-) production of neutrophils by phorbor myristate acetate (PMA)-stimulation.	phorbor myristate acetate	151-176	colony stimulating factor 3	Homo sapiens	88-92
10993214-2	2000	It was observed that O2- generation of intact and GCSF-treated neutrophils by PMA-stimulation showed a lag during the early stage, and was largely inhibited by 1-(5-isoquinoline-sulfonyl)-3-methyl-piperazine (200 microm) or GF109203X (GFX) (0.2 microM), but not by ethanol (1%) and wortmannin (100 nM).	Superoxides	21-23	colony stimulating factor 3	Homo sapiens	50-54
10993214-2	2000	It was observed that O2- generation of intact and GCSF-treated neutrophils by PMA-stimulation showed a lag during the early stage, and was largely inhibited by 1-(5-isoquinoline-sulfonyl)-3-methyl-piperazine (200 microm) or GF109203X (GFX) (0.2 microM), but not by ethanol (1%) and wortmannin (100 nM).	Tetradecanoylphorbol Acetate	78-81	colony stimulating factor 3	Homo sapiens	50-54
10993214-2	2000	It was observed that O2- generation of intact and GCSF-treated neutrophils by PMA-stimulation showed a lag during the early stage, and was largely inhibited by 1-(5-isoquinoline-sulfonyl)-3-methyl-piperazine (200 microm) or GF109203X (GFX) (0.2 microM), but not by ethanol (1%) and wortmannin (100 nM).	1-(5-isoquinolinylsulfonyl)-3-methylpiperazine	160-207	colony stimulating factor 3	Homo sapiens	50-54
10993214-2	2000	It was observed that O2- generation of intact and GCSF-treated neutrophils by PMA-stimulation showed a lag during the early stage, and was largely inhibited by 1-(5-isoquinoline-sulfonyl)-3-methyl-piperazine (200 microm) or GF109203X (GFX) (0.2 microM), but not by ethanol (1%) and wortmannin (100 nM).	bisindolylmaleimide I	224-233	colony stimulating factor 3	Homo sapiens	50-54
10993214-2	2000	It was observed that O2- generation of intact and GCSF-treated neutrophils by PMA-stimulation showed a lag during the early stage, and was largely inhibited by 1-(5-isoquinoline-sulfonyl)-3-methyl-piperazine (200 microm) or GF109203X (GFX) (0.2 microM), but not by ethanol (1%) and wortmannin (100 nM).	bisindolylmaleimide I	235-238	colony stimulating factor 3	Homo sapiens	50-54
10993214-2	2000	It was observed that O2- generation of intact and GCSF-treated neutrophils by PMA-stimulation showed a lag during the early stage, and was largely inhibited by 1-(5-isoquinoline-sulfonyl)-3-methyl-piperazine (200 microm) or GF109203X (GFX) (0.2 microM), but not by ethanol (1%) and wortmannin (100 nM).	Ethanol	265-272	colony stimulating factor 3	Homo sapiens	50-54
10993214-2	2000	It was observed that O2- generation of intact and GCSF-treated neutrophils by PMA-stimulation showed a lag during the early stage, and was largely inhibited by 1-(5-isoquinoline-sulfonyl)-3-methyl-piperazine (200 microm) or GF109203X (GFX) (0.2 microM), but not by ethanol (1%) and wortmannin (100 nM).	Wortmannin	282-292	colony stimulating factor 3	Homo sapiens	50-54
10993214-4	2000	Although translocation of p47phox and p67phox to the membrane fraction by PMA-stimulation of intact and GCSF-treated neutrophils occurred in parallel with O2- production, that of CB-treated neutrophils by PMA-stimulation was not always proportional to O2- production.	Tetradecanoylphorbol Acetate	74-77	colony stimulating factor 3	Homo sapiens	104-108
10993214-4	2000	Although translocation of p47phox and p67phox to the membrane fraction by PMA-stimulation of intact and GCSF-treated neutrophils occurred in parallel with O2- production, that of CB-treated neutrophils by PMA-stimulation was not always proportional to O2- production.	Superoxides	155-157	colony stimulating factor 3	Homo sapiens	104-108
10993214-4	2000	Although translocation of p47phox and p67phox to the membrane fraction by PMA-stimulation of intact and GCSF-treated neutrophils occurred in parallel with O2- production, that of CB-treated neutrophils by PMA-stimulation was not always proportional to O2- production.	Superoxides	252-254	colony stimulating factor 3	Homo sapiens	104-108
11079171-6	2000	Paclitaxel, 200 to 250 mg/m2, was given by 24-hour infusion on day 1, followed by cisplatin, 75 mg/m2, on day 2, with granulocyte colony stimulating factor support.	Paclitaxel	0-10	colony stimulating factor 3	Homo sapiens	118-155
10995003-6	2000	High-dose cyclophosphamide was given with G-CSF support (5 microg/kg/day days 3-12).	Cyclophosphamide	10-26	colony stimulating factor 3	Homo sapiens	42-47
10997975-13	2000	Thus, 50% of DLCLs in CR seem to mobilize significantly malignant cells at regeneration under G-CSF.	Chromium	22-24	colony stimulating factor 3	Homo sapiens	94-99
11035615-0	2000	Chemotherapy consisting of doxorubicin, bleomycin, vinblastine, and dacarbazine with granulocyte-colony-stimulating factor in HIV-infected patients with newly diagnosed Hodgkin"s disease: a prospective, multi-institutional AIDS clinical trials group study (ACTG 149).	Dacarbazine	68-79	colony stimulating factor 3	Homo sapiens	85-122
10955859-15	2000	Docetaxel with G-CSF support is an active drug and well tolerated by patients with advanced gastric cancer.	Docetaxel	0-9	colony stimulating factor 3	Homo sapiens	15-20
10937789-0	2000	Granulocyte colony-stimulating factor plasma levels during clozapine- and olanzapine-induced granulocytopenia.	Clozapine	59-68	colony stimulating factor 3	Homo sapiens	0-37
10937789-0	2000	Granulocyte colony-stimulating factor plasma levels during clozapine- and olanzapine-induced granulocytopenia.	Olanzapine	74-84	colony stimulating factor 3	Homo sapiens	0-37
10942233-10	2000	Further, the % inhibition of 3H-thymidine uptake of cell lines positively correlated with the amount of their intracellular G-CSF measured by enzyme immunoassay, suggesting an autocrine growth mechanism via the G-CSF/G-CSFR interaction.	Tritium	29-31	colony stimulating factor 3	Homo sapiens	124-129
10982237-0	2000	Mobilization with etoposide and granulocyte colony-stimulating factor can replace bone marrow harvesting in patients with malignant lymphoma who previously failed to mobilize sufficient stem cells with cyclophosphamide and G-CSF.	Etoposide	18-27	colony stimulating factor 3	Homo sapiens	223-228
10982237-0	2000	Mobilization with etoposide and granulocyte colony-stimulating factor can replace bone marrow harvesting in patients with malignant lymphoma who previously failed to mobilize sufficient stem cells with cyclophosphamide and G-CSF.	Cyclophosphamide	202-218	colony stimulating factor 3	Homo sapiens	32-69
10942233-10	2000	Further, the % inhibition of 3H-thymidine uptake of cell lines positively correlated with the amount of their intracellular G-CSF measured by enzyme immunoassay, suggesting an autocrine growth mechanism via the G-CSF/G-CSFR interaction.	Tritium	29-31	colony stimulating factor 3	Homo sapiens	211-216
10942233-10	2000	Further, the % inhibition of 3H-thymidine uptake of cell lines positively correlated with the amount of their intracellular G-CSF measured by enzyme immunoassay, suggesting an autocrine growth mechanism via the G-CSF/G-CSFR interaction.	Thymidine	32-41	colony stimulating factor 3	Homo sapiens	124-129
10942233-10	2000	Further, the % inhibition of 3H-thymidine uptake of cell lines positively correlated with the amount of their intracellular G-CSF measured by enzyme immunoassay, suggesting an autocrine growth mechanism via the G-CSF/G-CSFR interaction.	Thymidine	32-41	colony stimulating factor 3	Homo sapiens	211-216
11016746-0	2000	Cisplatin-epirubicin-paclitaxel weekly administration with G-CSF support in advanced breast cancer.	Cisplatin	0-9	colony stimulating factor 3	Homo sapiens	59-64
10984896-0	2000	Diffuse bone increase uptake of gallium-67 related to cyclophosphamide and recombinant human granulocyte-colony stimulating factor (rHuG-CSF) administration.	Gallium	32-39	colony stimulating factor 3	Homo sapiens	93-130
10930995-4	2000	Similarly, priming with GM-CSF or G-CSF increased both the proliferative activity of AML blasts by a median of 1.84- and 1.64-fold, respectively, and the incorporation of AraC into the DNA (1.29- and 1.40-fold respectively).	Cytarabine	171-175	colony stimulating factor 3	Homo sapiens	34-39
11006941-1	2000	AIM: To study the effect of G-CSF therapy directly by MRI and 1H MRS in the lumbar and femoral bone marrow and differentiate between malignant bone marrow infiltration (MBMI) and reconversion of red marrow.	Hydrogen	62-64	colony stimulating factor 3	Homo sapiens	28-33
10953296-2	2000	Both G-CSF preparations similarly enhanced the N-Formyl-Met-Leu-Phe-induced-migration of human peripheral blood polymorphonuclear cells, but did not significantly affect the proliferation of human oral tumor cell lines (HSC-2, HSG).	N-Formylmethionine Leucyl-Phenylalanine	47-67	colony stimulating factor 3	Homo sapiens	5-10
10953296-6	2000	These data suggest that the carbohydrate moiety in G-CSF might confer unique biological activities.	Carbohydrates	28-40	colony stimulating factor 3	Homo sapiens	51-56
11016746-0	2000	Cisplatin-epirubicin-paclitaxel weekly administration with G-CSF support in advanced breast cancer.	Epirubicin	10-20	colony stimulating factor 3	Homo sapiens	59-64
11016746-0	2000	Cisplatin-epirubicin-paclitaxel weekly administration with G-CSF support in advanced breast cancer.	Paclitaxel	21-31	colony stimulating factor 3	Homo sapiens	59-64
11032370-4	2000	Human G-CSF from transgenic goat milk increased the total number of white blood cells in C57BL/6N mice with leucopenia induced by cyclophosphamide (CPA).	Cyclophosphamide	130-146	colony stimulating factor 3	Homo sapiens	6-11
10873410-9	2000	CONCLUSION: The combination of paclitaxel with cisplatin with G-CSF support appears active in patients with metastatic or recurrent carcinoma of the endometrium.	Paclitaxel	31-41	colony stimulating factor 3	Homo sapiens	62-67
10873410-9	2000	CONCLUSION: The combination of paclitaxel with cisplatin with G-CSF support appears active in patients with metastatic or recurrent carcinoma of the endometrium.	Cisplatin	47-56	colony stimulating factor 3	Homo sapiens	62-67
10942062-0	2000	A phase I-II study of concomitant chemoradiotherapy with paclitaxel (one-hour infusion), 5-fluorouracil and hydroxyurea with granulocyte colony stimulating factor support for patients with poor prognosis head and neck cancer.	Hydroxyurea	108-119	colony stimulating factor 3	Homo sapiens	125-162
10864197-0	2000	Dose-dense epirubicin and paclitaxel with G-CSF: a study of decreasing intervals in metastatic breast cancer.	Paclitaxel	26-36	colony stimulating factor 3	Homo sapiens	42-47
10885427-6	2000	G-CSF pretreatment elevated the circulating PMNL (3.6+/-0.4 (mean+/-SEM) to 8.3+/-1X10(9) x L(-1), p&lt;0.05) and PMNL(BrdU) (5.4+/-2.1 to 12.5+/-3.1%, p&lt;0.05) counts at 8 h with little further increase caused by the subsequent 2 h pneumonia.	Bromodeoxyuridine	119-123	colony stimulating factor 3	Homo sapiens	0-5
10885427-8	2000	Morphometric studies of the lung showed that the total number of PMNL sequestered in lung capillaries were increased in the G-CSF group and the percentage of the these PMNL that were BrdU-labelled, was higher than in circulating blood (p&lt;0.05).	Bromodeoxyuridine	183-187	colony stimulating factor 3	Homo sapiens	124-129
10885427-9	2000	In the G-CSF group, only 11.2+/-2.6% of the PMNL that migrated into the airspaces were PMNL(BrdU) compared to 50.8+/-8% PMNL(BrdU) in the pulmonary capillaries.	Bromodeoxyuridine	92-96	colony stimulating factor 3	Homo sapiens	7-12
10931170-7	2000	G-CSF and M-CSF gradually decreased after DFPPs was started.	dfpps	42-47	colony stimulating factor 3	Homo sapiens	0-5
11108571-5	2000	G-CSF caused the transformants expressing G-CSFR to display a morphological characteristic of mature granulocytes, upregulated CD11b on the cell surface, and improved NBT reduction activity.	Nitroblue Tetrazolium	167-170	colony stimulating factor 3	Homo sapiens	0-5
11031727-1	2000	Recombinant human granulocyte colony-stimulating factor (rhG-CSF) was evaluated for its effects on granulopoiesis recovery in mice pretreated with cyclophosphamide.	Cyclophosphamide	147-163	colony stimulating factor 3	Homo sapiens	18-55
11032370-4	2000	Human G-CSF from transgenic goat milk increased the total number of white blood cells in C57BL/6N mice with leucopenia induced by cyclophosphamide (CPA).	Cyclophosphamide	148-151	colony stimulating factor 3	Homo sapiens	6-11
10779444-4	2000	G-CSF-induced neutrophils of patients with SCN are functionally defective (eg, chemotaxis, superoxide anion generation, Ca(++ )mobilization).	Superoxides	91-107	colony stimulating factor 3	Homo sapiens	0-5
11876998-6	2000	The G-CSF induced NB4 cell apoptosis was efficiently inhibited by AC-DEVD-CHO.	acetyl-aspartyl-glutamyl-valyl-aspartal	66-77	colony stimulating factor 3	Homo sapiens	4-9
10779444-7	2000	This study determined that the guanosine diphosphate (GDP)-dissociation inhibitor RhoGDI is overexpressed at the protein level in patients" neutrophils and that overexpression is a result of G-CSF treatment.	Guanosine Diphosphate	31-52	colony stimulating factor 3	Homo sapiens	191-196
10779444-7	2000	This study determined that the guanosine diphosphate (GDP)-dissociation inhibitor RhoGDI is overexpressed at the protein level in patients" neutrophils and that overexpression is a result of G-CSF treatment.	Guanosine Diphosphate	54-57	colony stimulating factor 3	Homo sapiens	191-196
10808203-0	2000	Purging of G-CSF-mobilized peripheral autografts in acute leukemia with mafosfamide and amifostine to protect normal progenitor cells.	mafosfamide	72-83	colony stimulating factor 3	Homo sapiens	11-16
10828862-4	2000	Although T cell proliferative and cytokine (IFN-gamma and IL-4) responses to alloantigen stimulation and Con A were significantly reduced in post-G-CSF NAC, they were restored by the removal of non-T cells from post-G-CSF NAC.	nac	152-155	colony stimulating factor 3	Homo sapiens	146-151
10784622-14	2000	CONCLUSION: We report the first clinical trial that used a cross-over design showing that high-dose cyclophosphamide plus G-CSF results in mobilization of more progenitors then GM-CSF plus G-CSF when tested in the same patient regardless of sequence of administration, although the regimen is associated with greater morbidity.	Cyclophosphamide	100-116	colony stimulating factor 3	Homo sapiens	189-194
10803520-3	2000	The number of IL-3- or GM-CSF-induced CFU-GM with 3 x 10(-7) M ATRA was 3.25+/-1.13, and 2.17+/-0.8-fold greater respectively, compared to controls without ATRA, while G-CSF had no effect and the ratio of colony-induced with or without ATRA was 1.06+/-0.17 (P = 0.00012).	Tretinoin	63-67	colony stimulating factor 3	Homo sapiens	168-173
10848817-6	2000	Cells in group B were appropriately primed by G-CSF, GM-CSF, tumour necrosis factor alpha and IL-1beta for enhanced release of O2 -.	Superoxides	127-129	colony stimulating factor 3	Homo sapiens	46-51
10848830-6	2000	In contrast, pre-exposure to HGFs led to significant increases in AraCTP formation (G-CSF 556.0 ng/107 cells, 2.31-fold increase, P &lt; 0.001; GM-CSF 447.9 ng/107 cells, 1.87-fold increase, P &lt; 0.0001).	aractp	66-72	colony stimulating factor 3	Homo sapiens	84-89
10802421-0	2000	Colchicine-induced bone marrow suppression: treatment with granulocyte colony-stimulating factor.	Colchicine	0-10	colony stimulating factor 3	Homo sapiens	59-96
10802421-4	2000	In this article, we present three cases of colchicine toxicity in which granulocyte colony-stimulating factor (G-CSF) was used to treat bone marrow depression.	Colchicine	43-53	colony stimulating factor 3	Homo sapiens	72-109
10802421-4	2000	In this article, we present three cases of colchicine toxicity in which granulocyte colony-stimulating factor (G-CSF) was used to treat bone marrow depression.	Colchicine	43-53	colony stimulating factor 3	Homo sapiens	111-116
10802421-6	2000	In view of the critical nature of the bone marrow depression and multi-organ toxicity induced by colchicine, we believe that consideration of the use of G-CSF to shorten the duration of neutropenia is warranted.	Colchicine	97-107	colony stimulating factor 3	Homo sapiens	153-158
10808203-0	2000	Purging of G-CSF-mobilized peripheral autografts in acute leukemia with mafosfamide and amifostine to protect normal progenitor cells.	Amifostine	88-98	colony stimulating factor 3	Homo sapiens	11-16
10706857-10	2000	This update confirms a high probability for SAA patients of becoming transfusion independent and of surviving after treatment with ALG, CyA, 6Mpred, and G-CSF, with a significant effect of neutrophil counts on outcome.	saa	44-47	colony stimulating factor 3	Homo sapiens	153-158
10735900-6	2000	RESULTS: CDI was significantly increased in the G-CSF group compared with the non-G-CSF group (mean +/- 95% confidence interval, 105 +/- 5% v 91 +/- 4%; P &lt;.001).	1,1'-Carbonyldiimidazole	9-12	colony stimulating factor 3	Homo sapiens	48-53
10735900-11	2000	CONCLUSION: G-CSF can increase CDI in high-risk childhood ALL.	1,1'-Carbonyldiimidazole	31-34	colony stimulating factor 3	Homo sapiens	12-17
10865191-3	2000	Arabinosylated lipoarabinomannan (ARA-LAM) stimulated hyporesponsiveness by reducing TNF-alpha, GM-CSF, G-CSF, IL-10, and IL-6 release similarly to LPS, but caused no changes in IL-8 secretion.	lipoarabinomannan	15-32	colony stimulating factor 3	Homo sapiens	104-109
10865191-3	2000	Arabinosylated lipoarabinomannan (ARA-LAM) stimulated hyporesponsiveness by reducing TNF-alpha, GM-CSF, G-CSF, IL-10, and IL-6 release similarly to LPS, but caused no changes in IL-8 secretion.	ara-lam	34-41	colony stimulating factor 3	Homo sapiens	104-109
10696133-0	2000	Successful treatment of vancomycin-resistant Enterococcus sepsis in a neutropenic patient with G-CSF-mobilized granulocyte transfusions.	Vancomycin	24-34	colony stimulating factor 3	Homo sapiens	95-100
10810400-6	2000	Furthermore, granulocyte-colony stimulating (G-CSF) factor was administered in order to reduce neutropenia related to docetaxel.	Docetaxel	118-127	colony stimulating factor 3	Homo sapiens	45-50
10696078-4	2000	Moreover, the differential regulation of GM-CSF and G-CSF release by COX-2 was mimicked by the prostacyclin (PGI(2)) mimetic, cicaprost.	Epoprostenol	95-107	colony stimulating factor 3	Homo sapiens	52-57
10696078-4	2000	Moreover, the differential regulation of GM-CSF and G-CSF release by COX-2 was mimicked by the prostacyclin (PGI(2)) mimetic, cicaprost.	Epoprostenol	109-115	colony stimulating factor 3	Homo sapiens	52-57
10696078-4	2000	Moreover, the differential regulation of GM-CSF and G-CSF release by COX-2 was mimicked by the prostacyclin (PGI(2)) mimetic, cicaprost.	cicaprost	126-135	colony stimulating factor 3	Homo sapiens	52-57
10696078-5	2000	These observations suggest that PGI(2), released following the induction of COX-2, differentially regulates the release of GM-CSF (suppresses) and G-CSF (potentiates) from human vascular cells.	Epoprostenol	32-38	colony stimulating factor 3	Homo sapiens	147-152
10739006-0	2000	Aclarubicin induces differentiation of leukemic progenitors in myelodysplastic syndrome cooperating with granulocyte colony-stimulating factor.	Aclarubicin	0-11	colony stimulating factor 3	Homo sapiens	105-142
10774251-5	2000	The patient was treated with continuous-drip infusion of low-dose cytarabine and etoposide with G-CSF (AVG therapy).	Etoposide	81-90	colony stimulating factor 3	Homo sapiens	96-101
10644984-8	2000	G-CSF induced the tyrosine phosphorylation of Cbl and increased activity of PI 3-kinase in wild-type and syk-deficient, but non in lyn-deficient, cells.	Tyrosine	18-26	colony stimulating factor 3	Homo sapiens	0-5
10629575-0	2000	Ticlopidine-induced aplastic anemia and quick recovery with G-CSF: case report and literature review.	Ticlopidine	0-11	colony stimulating factor 3	Homo sapiens	60-65
10629575-1	2000	We report here a case of ticlopidine-induced aplastic anemia that responded to G-CSF and review the literature.	Ticlopidine	25-36	colony stimulating factor 3	Homo sapiens	79-84
10629575-10	2000	G-CSF may be helpful in the treatment of ticlopidine-induced aplastic anemia.	Ticlopidine	41-52	colony stimulating factor 3	Homo sapiens	0-5
10675076-2	2000	We report unexpected ischaemic colitis in six patients associated with docetaxel-based therapy, three of whom were treated in a phase I study designed to establish the maximum tolerated dose of this combination with the prophylactic use of granulocyte-colony-stimulating factor.	Docetaxel	71-80	colony stimulating factor 3	Homo sapiens	240-277
10644984-9	2000	Inhibition of Shc by over-expression of its SH2 or PTB domains or PI 3-kinase by either treatment with wortmannin or expression of the CblY731F mutant decreased G-CSF-induced DNA synthesis.	Wortmannin	103-113	colony stimulating factor 3	Homo sapiens	161-166
11920185-6	2000	Morphometric studies of the lung show a reduced sequestration of BrdU-labeled PMN in lung microvessels in G-CSF-treated animals (P&lt;0.05) and a approximately 14-fold (G-CSF-group) vs a approximately 65-fold (control-group) enrichment of BrdU-labeled PMN in lung tissue if compared to circulating blood.	Bromodeoxyuridine	239-243	colony stimulating factor 3	Homo sapiens	106-111
10962806-8	2000	PBPC mobilization was done with G-CSF at a dose of 10 micrograms/kg/day subcutaneously for four days, pheresis started on day 5.	PbPc	0-4	colony stimulating factor 3	Homo sapiens	32-37
11138457-3	2000	METHODS: DOC was administered first at 60 mg/m2 without G-CSF and at 60, 70, and 80 mg/m2 with G-CSF by 1-h infusion on day 1 of the odd-numbered cycles (1, 3, 5, etc.)	Docetaxel	9-12	colony stimulating factor 3	Homo sapiens	95-100
11138457-13	2000	DOC was then de-escalated to 70 mg/m2 and delivered with TOPO 0.75 mg/m2 and G-CSF (cohort IV).	Docetaxel	0-3	colony stimulating factor 3	Homo sapiens	77-82
10637255-4	2000	Preliminary, nonrandomized feasibility studies showed that doxorubicin, cyclophosphamide, and etoposide (ACE) could be given every 2 (instead of the usual 3) weeks with granulocyte colony-stimulating factor (G-CSF) (lenograstim; Chugai-Rh?one-Poulenc, Tokyo, Japan) support.	Doxorubicin	59-70	colony stimulating factor 3	Homo sapiens	169-206
10637255-4	2000	Preliminary, nonrandomized feasibility studies showed that doxorubicin, cyclophosphamide, and etoposide (ACE) could be given every 2 (instead of the usual 3) weeks with granulocyte colony-stimulating factor (G-CSF) (lenograstim; Chugai-Rh?one-Poulenc, Tokyo, Japan) support.	Doxorubicin	59-70	colony stimulating factor 3	Homo sapiens	208-213
10637255-4	2000	Preliminary, nonrandomized feasibility studies showed that doxorubicin, cyclophosphamide, and etoposide (ACE) could be given every 2 (instead of the usual 3) weeks with granulocyte colony-stimulating factor (G-CSF) (lenograstim; Chugai-Rh?one-Poulenc, Tokyo, Japan) support.	Cyclophosphamide	72-88	colony stimulating factor 3	Homo sapiens	169-206
10637255-4	2000	Preliminary, nonrandomized feasibility studies showed that doxorubicin, cyclophosphamide, and etoposide (ACE) could be given every 2 (instead of the usual 3) weeks with granulocyte colony-stimulating factor (G-CSF) (lenograstim; Chugai-Rh?one-Poulenc, Tokyo, Japan) support.	Cyclophosphamide	72-88	colony stimulating factor 3	Homo sapiens	208-213
10637255-4	2000	Preliminary, nonrandomized feasibility studies showed that doxorubicin, cyclophosphamide, and etoposide (ACE) could be given every 2 (instead of the usual 3) weeks with granulocyte colony-stimulating factor (G-CSF) (lenograstim; Chugai-Rh?one-Poulenc, Tokyo, Japan) support.	Etoposide	94-103	colony stimulating factor 3	Homo sapiens	169-206
10637255-4	2000	Preliminary, nonrandomized feasibility studies showed that doxorubicin, cyclophosphamide, and etoposide (ACE) could be given every 2 (instead of the usual 3) weeks with granulocyte colony-stimulating factor (G-CSF) (lenograstim; Chugai-Rh?one-Poulenc, Tokyo, Japan) support.	Etoposide	94-103	colony stimulating factor 3	Homo sapiens	208-213
11920185-6	2000	Morphometric studies of the lung show a reduced sequestration of BrdU-labeled PMN in lung microvessels in G-CSF-treated animals (P&lt;0.05) and a approximately 14-fold (G-CSF-group) vs a approximately 65-fold (control-group) enrichment of BrdU-labeled PMN in lung tissue if compared to circulating blood.	Bromodeoxyuridine	65-69	colony stimulating factor 3	Homo sapiens	106-111
10938528-0	2000	Absorption enhancement of a protein drug by nitric oxide donor: effect on nasal absorption of human granulocyte colony-stimulating factor.	Nitric Oxide	44-56	colony stimulating factor 3	Homo sapiens	100-137
10938528-1	2000	The objective of this study was to evaluate the effect of a nitric oxide (NO) donor, S-nitroso-N-acetyl-DL-penicillamine (SNAP), on the nasal absorption of recombinant human granulocyte colony-stimulating factor (rhG-CSF) in rabbits and to evaluate the irritation (cytotoxicity) potential of the NO donor on the mucosal membrane using a cultured cell system (strain KB, human epidermoid carcinoma of the floor of the mouth).	Nitric Oxide	60-72	colony stimulating factor 3	Homo sapiens	174-211
10938528-1	2000	The objective of this study was to evaluate the effect of a nitric oxide (NO) donor, S-nitroso-N-acetyl-DL-penicillamine (SNAP), on the nasal absorption of recombinant human granulocyte colony-stimulating factor (rhG-CSF) in rabbits and to evaluate the irritation (cytotoxicity) potential of the NO donor on the mucosal membrane using a cultured cell system (strain KB, human epidermoid carcinoma of the floor of the mouth).	Penicillamine	107-120	colony stimulating factor 3	Homo sapiens	174-211
10938528-3	2000	The serum G-CSF concentration and the increased total leukocyte count were markedly decreased by the presence of the NO scavenger, 2-(4-carboxyphenyl)-4,4,5,5-tetramethyl-imidazole-1-oxyl 3-oxide sodium salt (carboxy-PTIO), in combination with rhG-CSF and SNAP.	2-(4-carboxyphenyl)-4,4,5,5-tetramethyl-imidazole-1-oxyl 3-oxide sodium salt	131-207	colony stimulating factor 3	Homo sapiens	10-15
10938528-3	2000	The serum G-CSF concentration and the increased total leukocyte count were markedly decreased by the presence of the NO scavenger, 2-(4-carboxyphenyl)-4,4,5,5-tetramethyl-imidazole-1-oxyl 3-oxide sodium salt (carboxy-PTIO), in combination with rhG-CSF and SNAP.	1,3-dihydroxy-4,4,5,5-tetramethyl-2-(4-carboxyphenyl)tetrahydroimidazole	209-221	colony stimulating factor 3	Homo sapiens	10-15
11124653-2	2000	Herein, we describe the case of a 73-year-old woman with breast cancer metastatic to the liver, who developed noncardiogenic pulmonary edema (NPE) while on treatment with gemcitabine plus docetaxel combination with granulocyte colony-stimulating factor (G-CSF) support.	gemcitabine	171-182	colony stimulating factor 3	Homo sapiens	254-259
11124653-2	2000	Herein, we describe the case of a 73-year-old woman with breast cancer metastatic to the liver, who developed noncardiogenic pulmonary edema (NPE) while on treatment with gemcitabine plus docetaxel combination with granulocyte colony-stimulating factor (G-CSF) support.	Docetaxel	188-197	colony stimulating factor 3	Homo sapiens	254-259
10661570-1	2000	The activity of a granulocyte colony-stimulating factor (G-CSF) mutein (nartograstim; [NTG]) conjugated with an average of two polyethylene glycol (PEG) chains per protein molecule was examined in cynomolgus monkeys following a single s.c. injection.	Polyethylene Glycols	127-146	colony stimulating factor 3	Homo sapiens	57-62
10661570-1	2000	The activity of a granulocyte colony-stimulating factor (G-CSF) mutein (nartograstim; [NTG]) conjugated with an average of two polyethylene glycol (PEG) chains per protein molecule was examined in cynomolgus monkeys following a single s.c. injection.	Polyethylene Glycols	148-151	colony stimulating factor 3	Homo sapiens	57-62
10661570-12	2000	These results demonstrate that conjugation of a G-CSF mutein with high molecular weight PEG results in a preparation that can induce prolonged elevation of neutrophils in normal nonhuman primates following a single injection.	Polyethylene Glycols	88-91	colony stimulating factor 3	Homo sapiens	48-53
11721444-0	1999	The relationship between the levels of granulocyte colony-stimulating factor and leukocytosis induced by all-trans retinoic acid in acute promyelocytic leukemia.	Tretinoin	105-128	colony stimulating factor 3	Homo sapiens	39-76
10590370-1	1999	BACKGROUND: The primary purpose of this study was to establish the maximum tolerated dose (MTD) of intravenous melphalan in combination with paclitaxel and cisplatin plus granulocyte-colony stimulating factor (G-CSF) in patients with suboptimal advanced epithelial ovarian carcinoma or primary peritoneal carcinoma.	Melphalan	111-120	colony stimulating factor 3	Homo sapiens	210-215
11721444-2	1999	METHODS: Enzyme linked immunosorbent assay (ELISA) method was used for detecting levels of serum granulocyte colony-stimulating factor (G-CSF) in 47 cases of acute promyelocytic leukemia (APL) during the treatment with all-trans retinoic acid (ATRA).	Tretinoin	229-242	colony stimulating factor 3	Homo sapiens	97-134
11721444-2	1999	METHODS: Enzyme linked immunosorbent assay (ELISA) method was used for detecting levels of serum granulocyte colony-stimulating factor (G-CSF) in 47 cases of acute promyelocytic leukemia (APL) during the treatment with all-trans retinoic acid (ATRA).	Tretinoin	229-242	colony stimulating factor 3	Homo sapiens	136-141
11721444-2	1999	METHODS: Enzyme linked immunosorbent assay (ELISA) method was used for detecting levels of serum granulocyte colony-stimulating factor (G-CSF) in 47 cases of acute promyelocytic leukemia (APL) during the treatment with all-trans retinoic acid (ATRA).	Tretinoin	244-248	colony stimulating factor 3	Homo sapiens	97-134
11721444-2	1999	METHODS: Enzyme linked immunosorbent assay (ELISA) method was used for detecting levels of serum granulocyte colony-stimulating factor (G-CSF) in 47 cases of acute promyelocytic leukemia (APL) during the treatment with all-trans retinoic acid (ATRA).	Tretinoin	244-248	colony stimulating factor 3	Homo sapiens	136-141
11721444-4	1999	After ATRA treatment, both serum G-CSF level and WBC number increased in 68.1% of the cases.	Tretinoin	6-10	colony stimulating factor 3	Homo sapiens	33-38
10515892-3	1999	Whereas IFNgamma and granulocyte colony-stimulating factor (G-CSF) are efficient inducers of STAT1 and STAT3 tyrosine phosphorylation in polymorphonuclear neutrophils (PMN), IL-10 fails to trigger STAT1 and STAT3 tyrosine and serine phosphorylation, therefore explaining its inability to induce the FcgammaRI expression in these cells.	Tyrosine	109-117	colony stimulating factor 3	Homo sapiens	21-58
10556954-2	1999	The purpose of this study was to evaluate the activity of paclitaxel 170 mg/m2 and cyclophosphamide 2 g/m2 (CP) with filgrastim (human G-CSF) for mobilization of PBPCs as the first or second maneuver after failure with filgrastim alone.	pbpcs	162-167	colony stimulating factor 3	Homo sapiens	135-140
10602303-1	1999	This study examined the applicability of luminol-dependent chemiluminescence (CL) response of neutrophils to assess the degree of stress of spinal surgery by measuring the capacity of circulating neutrophils to produce reactive oxygen species and the levels of serum cytokines: interleukin(IL)-1beta, IL-6, IL-8, tumour necrosis factor (TNF)-alpha and granulocyte colony stimulating factor (G-CSF).	Luminol	41-48	colony stimulating factor 3	Homo sapiens	352-389
10602303-1	1999	This study examined the applicability of luminol-dependent chemiluminescence (CL) response of neutrophils to assess the degree of stress of spinal surgery by measuring the capacity of circulating neutrophils to produce reactive oxygen species and the levels of serum cytokines: interleukin(IL)-1beta, IL-6, IL-8, tumour necrosis factor (TNF)-alpha and granulocyte colony stimulating factor (G-CSF).	Luminol	41-48	colony stimulating factor 3	Homo sapiens	391-396
10662479-13	1999	Sensitivity analyses demonstrated that the addition of G-CSF to conventional amphotericin B in the treatment of a presumed deep-seated fungal infection offers not only clinical benefits, but cost benefits which are robust to changes in clinical and economic parameters.	Amphotericin B	77-91	colony stimulating factor 3	Homo sapiens	55-60
10515892-3	1999	Whereas IFNgamma and granulocyte colony-stimulating factor (G-CSF) are efficient inducers of STAT1 and STAT3 tyrosine phosphorylation in polymorphonuclear neutrophils (PMN), IL-10 fails to trigger STAT1 and STAT3 tyrosine and serine phosphorylation, therefore explaining its inability to induce the FcgammaRI expression in these cells.	Tyrosine	109-117	colony stimulating factor 3	Homo sapiens	60-65
10515892-3	1999	Whereas IFNgamma and granulocyte colony-stimulating factor (G-CSF) are efficient inducers of STAT1 and STAT3 tyrosine phosphorylation in polymorphonuclear neutrophils (PMN), IL-10 fails to trigger STAT1 and STAT3 tyrosine and serine phosphorylation, therefore explaining its inability to induce the FcgammaRI expression in these cells.	Tyrosine	213-221	colony stimulating factor 3	Homo sapiens	60-65
10515892-3	1999	Whereas IFNgamma and granulocyte colony-stimulating factor (G-CSF) are efficient inducers of STAT1 and STAT3 tyrosine phosphorylation in polymorphonuclear neutrophils (PMN), IL-10 fails to trigger STAT1 and STAT3 tyrosine and serine phosphorylation, therefore explaining its inability to induce the FcgammaRI expression in these cells.	Serine	226-232	colony stimulating factor 3	Homo sapiens	60-65
10706456-0	1999	Intensive dose ifosfamide and etoposide with G-CSF for stem cell mobilization in patients with non-Hodgkin"s lymphoma.	Etoposide	30-39	colony stimulating factor 3	Homo sapiens	45-50
10521070-20	1999	Key Words: Paclitaxel-G-CSF-Small-cell lung cancer-North Central Cancer Treatment Group.	Paclitaxel	11-21	colony stimulating factor 3	Homo sapiens	22-27
10537336-6	1999	PBPCs mobilized with GM-CSF/G-CSF were markedly enriched for CD14+ DC progenitor cells as compared with those mobilized with G-CSF alone.	pbpcs	0-5	colony stimulating factor 3	Homo sapiens	28-33
10493966-12	1999	Topotecan followed by G-CSF + rhEPO mobilizes CPCs effectively.	cytidylyl-(3'-5')-cytidine	46-50	colony stimulating factor 3	Homo sapiens	22-27
10516673-2	1999	We have previously reported that G-IVE (G-CSF, ifosphamide, VP-16, epirubicin) improves the yield of CD34+ cells mobilised in patients with lymphoproliferative disorders compared with cyclophosphamide 3 g/m2 and G-CSF (G/CYCLO).	Epirubicin	67-77	colony stimulating factor 3	Homo sapiens	212-217
10464278-6	1999	G-CSF-induced tyrosine phosphorylation of STAT 3 in Trf-R(-) cells much more than in Trf-R(+) cells.	Tyrosine	14-22	colony stimulating factor 3	Homo sapiens	0-5
10464278-9	1999	Rapamycin, an inhibitor of p70 S6 kinase activity, inhibited G-CSF-dependent proliferation of Trf-R(+) cells and increased fMLP-R expression on these cells.	Sirolimus	0-9	colony stimulating factor 3	Homo sapiens	61-66
10446877-0	1999	Granulocyte colony-stimulating factor treatment for cyclophosphamide-induced severe neutropenia in Wegener"s granulomatosis.	Cyclophosphamide	52-68	colony stimulating factor 3	Homo sapiens	0-37
10572602-4	1999	PATIENTS AND METHODS: Moderately elevated doses of ifosfamide-epirubicin (cycles 1 and 3) and of carboplatin-etoposide (cycles 2 and 4) were given with G-CSF and peripheral blood stem-cell (PBSC) support.	Ifosfamide	51-61	colony stimulating factor 3	Homo sapiens	152-157
10492365-1	1999	UNLABELLED: Using PET, we investigated the change in 18F-fluorordeoxyglucose (FDG) uptake in the spleen after granulocyte colony-stimulating factor (G-CSF) treatment.	18f-fluorordeoxyglucose	53-76	colony stimulating factor 3	Homo sapiens	110-147
10492365-1	1999	UNLABELLED: Using PET, we investigated the change in 18F-fluorordeoxyglucose (FDG) uptake in the spleen after granulocyte colony-stimulating factor (G-CSF) treatment.	18f-fluorordeoxyglucose	53-76	colony stimulating factor 3	Homo sapiens	149-154
10492365-1	1999	UNLABELLED: Using PET, we investigated the change in 18F-fluorordeoxyglucose (FDG) uptake in the spleen after granulocyte colony-stimulating factor (G-CSF) treatment.	fluorescein-digalactoside	78-81	colony stimulating factor 3	Homo sapiens	110-147
10492365-1	1999	UNLABELLED: Using PET, we investigated the change in 18F-fluorordeoxyglucose (FDG) uptake in the spleen after granulocyte colony-stimulating factor (G-CSF) treatment.	fluorescein-digalactoside	78-81	colony stimulating factor 3	Homo sapiens	149-154
10492365-5	1999	RESULTS: During G-CSF treatment (n = 10), 9 scans (90%) showed increased splenic FDG uptake (3 slightly, 6 substantially).	fluorescein-digalactoside	81-84	colony stimulating factor 3	Homo sapiens	16-21
10492365-9	1999	Similar to the change in the bone marrow, the SULs in the spleen significantly increased during G-CSF treatment (baseline, 1.50+/-0.31, versus during G-CSF, 2.69+/-0.84; P = 0.0004), then decreased after discontinuation of G-CSF (1.65+/-0.23).	Sulfisoxazole	46-50	colony stimulating factor 3	Homo sapiens	96-101
10492365-9	1999	Similar to the change in the bone marrow, the SULs in the spleen significantly increased during G-CSF treatment (baseline, 1.50+/-0.31, versus during G-CSF, 2.69+/-0.84; P = 0.0004), then decreased after discontinuation of G-CSF (1.65+/-0.23).	Sulfisoxazole	46-50	colony stimulating factor 3	Homo sapiens	150-155
10492365-9	1999	Similar to the change in the bone marrow, the SULs in the spleen significantly increased during G-CSF treatment (baseline, 1.50+/-0.31, versus during G-CSF, 2.69+/-0.84; P = 0.0004), then decreased after discontinuation of G-CSF (1.65+/-0.23).	Sulfisoxazole	46-50	colony stimulating factor 3	Homo sapiens	150-155
10492365-11	1999	CONCLUSION: Substantially increased FDG uptake was observed in the spleen during and after G-CSF treatment, although this change was less frequent and not as marked as the change observed in the bone marrow.	fluorescein-digalactoside	36-39	colony stimulating factor 3	Homo sapiens	91-96
10498172-0	1999	Captopril-induced toxic epidermal necrolysis and agranulocytosis successfully treated with granulocyte colony-stimulating factor.	Captopril	0-9	colony stimulating factor 3	Homo sapiens	91-128
10509155-2	1999	PATIENTS AND METHODS: Fifty-two patients with previously untreated advanced breast cancer were treated with epirubicin (25 mg/m2/week) and vinorelbine (25 mg/m2/week) with G-CSF support, for 24 consecutive weeks.	Vinorelbine	139-150	colony stimulating factor 3	Homo sapiens	172-177
10417333-3	1999	Here we demonstrate, with a site-specific antibody, that STAT3 is phosphorylated on Ser-727 in human neutrophils stimulated with chemotactic factors (N-formyl-methionyl-leucyl-phenylalanine and complement C5a), cytokines [granulocyte/macrophage colony-stimulating factor (GM-CSF) and granulocyte colony-stimulating factor (G-CSF)], or a protein kinase C activator (PMA).	Serine	84-87	colony stimulating factor 3	Homo sapiens	284-321
10417333-3	1999	Here we demonstrate, with a site-specific antibody, that STAT3 is phosphorylated on Ser-727 in human neutrophils stimulated with chemotactic factors (N-formyl-methionyl-leucyl-phenylalanine and complement C5a), cytokines [granulocyte/macrophage colony-stimulating factor (GM-CSF) and granulocyte colony-stimulating factor (G-CSF)], or a protein kinase C activator (PMA).	Serine	84-87	colony stimulating factor 3	Homo sapiens	323-330
10514258-6	1999	In our recent report, various immunoblotting analyses have shown that the presence of a core N-glycosylation resident in the hIL-1beta fragment is likely to be of crucial importance in the high-level secretion of hG-CSF from the recombinant S. cerevisiae.	Nitrogen	93-94	colony stimulating factor 3	Homo sapiens	213-219
10514258-7	1999	When the N-glycosylation was completely blocked with the addition of tunicamycin to the culture, the secretion of hG-CSF and hGH was decreased to a negligible level although the other host-derived proteins were well secreted to the culture broth regardless of the presence of tunicamycin.	Nitrogen	9-10	colony stimulating factor 3	Homo sapiens	114-120
10514258-7	1999	When the N-glycosylation was completely blocked with the addition of tunicamycin to the culture, the secretion of hG-CSF and hGH was decreased to a negligible level although the other host-derived proteins were well secreted to the culture broth regardless of the presence of tunicamycin.	Tunicamycin	69-80	colony stimulating factor 3	Homo sapiens	114-120
10514258-7	1999	When the N-glycosylation was completely blocked with the addition of tunicamycin to the culture, the secretion of hG-CSF and hGH was decreased to a negligible level although the other host-derived proteins were well secreted to the culture broth regardless of the presence of tunicamycin.	Tunicamycin	276-287	colony stimulating factor 3	Homo sapiens	114-120
10446877-1	1999	OBJECTIVE: To examine the efficacy and safety of recombinant human granulocyte colony-stimulating factor (rHuG-CSF) in the treatment of cyclophosphamide (CYC)-induced severe neutropenia (&lt;1,000 neutrophils/microl) in patients with generalized Wegener"s granulomatosis (WG).	Cyclophosphamide	136-152	colony stimulating factor 3	Homo sapiens	67-104
10446877-1	1999	OBJECTIVE: To examine the efficacy and safety of recombinant human granulocyte colony-stimulating factor (rHuG-CSF) in the treatment of cyclophosphamide (CYC)-induced severe neutropenia (&lt;1,000 neutrophils/microl) in patients with generalized Wegener"s granulomatosis (WG).	Cyclophosphamide	154-157	colony stimulating factor 3	Homo sapiens	67-104
10466441-0	1999	Granulocyte colony-stimulating factor-supported combined immunosuppressive therapy (antilymphocyte globulin, cyclosporine, and methylprednisolone) in patients with aplastic anemia: tolerability, efficacy, and changes in the progenitor cell compartment.	Cyclosporine	109-121	colony stimulating factor 3	Homo sapiens	0-37
10460592-2	1999	Based on the marked circadian rhythm of cortisol levels, we hypothesized that plasma levels of G-CSF may also show a diurnal rhythm.	Hydrocortisone	40-48	colony stimulating factor 3	Homo sapiens	95-100
10428509-8	1999	Simultaneous treatment with G-CSF and zVAD-fmk additively blocked ATRA-induced apoptosis.	Tretinoin	66-70	colony stimulating factor 3	Homo sapiens	28-33
10465132-9	1999	The results demonstrated that the best time to collect PBSC by means of leukapheresis is post G-CSF used as rescue after ifosfamide treatment.	Ifosfamide	121-131	colony stimulating factor 3	Homo sapiens	94-99
10465132-11	1999	Moreover, during this preoperative treatment, we identified the best time to collect a sufficient number of PBSCs, that is after 9-10 days of G-CSF treatment following the first cycle of ifosfamide.	Ifosfamide	187-197	colony stimulating factor 3	Homo sapiens	142-147
10678097-0	1999	Anti-inflammatory and nitric oxide-inhibiting properties of granulocyte colony-stimulating factor.	Nitric Oxide	22-34	colony stimulating factor 3	Homo sapiens	60-97
10678097-3	1999	Since the suppressive effects of G-CSF on the production of pro-inflammatory mediators like TNF-alpha and nitric oxide are most likely neither cell type nor tissue specific, it is conceivable that NO release induced by pro-inflammatory mediators can be reduced by G-CSF in various organ systems and in different forms of shock.	Nitric Oxide	106-118	colony stimulating factor 3	Homo sapiens	33-38
10466441-0	1999	Granulocyte colony-stimulating factor-supported combined immunosuppressive therapy (antilymphocyte globulin, cyclosporine, and methylprednisolone) in patients with aplastic anemia: tolerability, efficacy, and changes in the progenitor cell compartment.	Methylprednisolone	127-145	colony stimulating factor 3	Homo sapiens	0-37
10430075-11	1999	Granulocyte colony-stimulating factor (G-CSF; 5 microg/kg/day) was administered s.c. from day 6, routinely after 250 mg/m2 dose of paclitaxel or after a lower dose of paclitaxel if ANC &lt;500/microl or febrile neutropenia was observed.	Paclitaxel	131-141	colony stimulating factor 3	Homo sapiens	0-37
10652614-5	1999	Hexadecyl-N,N,N-trimethyl-hexanolamine(HePC6), which has no, or only marginal antitumoral activity but comparable physicochemical properties to HePC, also stimulates the G-CSF-dependent colony formation in a dose-dependent manner.	hexadecyl-n,n,n-trimethyl-hexanolamine	0-38	colony stimulating factor 3	Homo sapiens	170-175
10652614-5	1999	Hexadecyl-N,N,N-trimethyl-hexanolamine(HePC6), which has no, or only marginal antitumoral activity but comparable physicochemical properties to HePC, also stimulates the G-CSF-dependent colony formation in a dose-dependent manner.	hexadecylphospho(N,N,N-trimethylamino)hexanol	39-44	colony stimulating factor 3	Homo sapiens	170-175
10430075-14	1999	In previously untreated patients, the maximally tolerated dose of paclitaxel in the drug regimen was determined to be 170 mg/m2 without and 250 mg/m2 with G-CSF support.	Paclitaxel	66-76	colony stimulating factor 3	Homo sapiens	155-160
10390196-7	1999	The outcome of cyclophosphamide/G-CSF mobilization was correlated with the response to the test dose of G-CSF.	Cyclophosphamide	15-31	colony stimulating factor 3	Homo sapiens	104-109
10414449-5	1999	Our results have shown that ATRA induces an increased expression of IL-8, IL-1beta, TNF-alpha and ICAM-1 in APL cells, which can be amplified by the addition of G-CSF.	Tretinoin	28-32	colony stimulating factor 3	Homo sapiens	161-166
10414449-7	1999	Furthermore, G-CSF, through its potent differentiating activity, may increase the risk of such complications during ATRA treatment.	Tretinoin	116-120	colony stimulating factor 3	Homo sapiens	13-18
10339483-2	1999	Exposure of WEHI-3B D+ myelomonocytic leukemia and myeloid LGM-1 cells overexpressing the G-CSFR to G-CSF resulted in induction of differentiation as measured by (1) the ability to reduce nitroblue tetrazolium (NBT), (2) the expression of Mac-I antigen, and (3) the expression of FcgammaII/III receptor.	Nitroblue Tetrazolium	188-209	colony stimulating factor 3	Homo sapiens	90-95
10425535-0	1999	The development of bone changes induced in rats by recombinant human granulocyte colony-stimulating factor is suppressed by bisphosphonate.	Diphosphonates	124-138	colony stimulating factor 3	Homo sapiens	69-106
10695110-0	1999	The use of recombinant human G-CSF in the treatment of propylthiouracil-induced agranulocytosis.	Propylthiouracil	55-71	colony stimulating factor 3	Homo sapiens	29-34
10695110-4	1999	We think that in patients with propylthiouracil-induced agranulocytosis, G-CSF will reduce the risk and severity of infection, and should be accepted as a part of the standard therapy.	Propylthiouracil	31-47	colony stimulating factor 3	Homo sapiens	73-78
10467951-0	1999	Pharmacokinetics and pharmacological effect of recombinant human granulocyte colony-stimulating factor conjugated to poly(styrene-co-maleic acid) in rats.	styrene-maleic acid polymer	117-145	colony stimulating factor 3	Homo sapiens	65-102
10467951-1	1999	A new derivative of recombinant human granulocyte colony-stimulating factor (rhG-CSF) has been synthesized by conjugating rhG-CSF to poly(styrene-co-maleic acid) (poly(styrene-co-maleic acid)-rhG-CSF) to try to avoid glomerular filtration and thus potentiate the neutrophil-proliferating activity of rhG-CSF.	styrene-maleic acid polymer	133-161	colony stimulating factor 3	Homo sapiens	38-75
10467951-1	1999	A new derivative of recombinant human granulocyte colony-stimulating factor (rhG-CSF) has been synthesized by conjugating rhG-CSF to poly(styrene-co-maleic acid) (poly(styrene-co-maleic acid)-rhG-CSF) to try to avoid glomerular filtration and thus potentiate the neutrophil-proliferating activity of rhG-CSF.	styrene-maleic acid polymer	163-191	colony stimulating factor 3	Homo sapiens	38-75
10364174-5	1999	To identify residues in G-CSF that interact with Arg288, selected charged residues in G-CSF were mutated to Ala.	Alanine	108-111	colony stimulating factor 3	Homo sapiens	24-29
10362718-11	1999	Immunoreactive leukotriene B4 receptor, interleukin-8, granulocyte colony-stimulating factor, and monocyte chemoattractant protein-1 significantly increased in supernatant fluids in response to bleomycin.	Bleomycin	194-203	colony stimulating factor 3	Homo sapiens	55-132
10339483-2	1999	Exposure of WEHI-3B D+ myelomonocytic leukemia and myeloid LGM-1 cells overexpressing the G-CSFR to G-CSF resulted in induction of differentiation as measured by (1) the ability to reduce nitroblue tetrazolium (NBT), (2) the expression of Mac-I antigen, and (3) the expression of FcgammaII/III receptor.	Nitroblue Tetrazolium	211-214	colony stimulating factor 3	Homo sapiens	90-95
10414907-4	1999	Here we report the results of using etoposide as a mobilizing agent in 16 patients with primary resistant or relapsed malignant lymphoma who had failed prior mobilization of peripheral blood stem cells (PBSC) with cyclophosphamide (4 g/m2) followed by G-CSF.	Etoposide	36-45	colony stimulating factor 3	Homo sapiens	252-257
10414919-2	1999	Aliquots of PBPC were obtained after 4 days of G-CSF and/or GM-CSF and again during G-CSF-stimulated recovery from myelosuppressive doses of cyclophosphamide.	Cyclophosphamide	141-157	colony stimulating factor 3	Homo sapiens	84-89
10414919-6	1999	There was a greater frequency of tumor cell contamination in aphereses performed during G-CSF-stimulated recovery from cyclophosphamide than in collections primed by cytokine alone (13% vs 23%; P = 0.08), although this did not reach statistical significance.	Cyclophosphamide	119-135	colony stimulating factor 3	Homo sapiens	88-93
10414907-9	1999	These results indicate that etoposide + G-CSF is a highly effective mobilization regimen in patients who have failed cyclophosphamide mobilization.	Cyclophosphamide	117-133	colony stimulating factor 3	Homo sapiens	40-45
10366791-2	1999	Recombinant human G-CSF (rh-G-CSF) is available in two forms: a non-glycosylated (E. Coli-derived), and a glycosylated CHO-derived rhG-CSF.	CAV protocol	119-122	colony stimulating factor 3	Homo sapiens	18-23
10372615-0	1999	Granulocyte colony-stimulating factor ameliorates life-threatening infections after combined therapy with barbiturates and mild hypothermia in patients with severe head injuries.	Barbiturates	106-118	colony stimulating factor 3	Homo sapiens	0-37
10437653-0	1999	Inhibition of inducible nitric oxide synthase gene expression and nitric oxide synthesis in vascular smooth muscle cells by granulocyte-colony stimulating factor in vitro.	Nitric Oxide	24-36	colony stimulating factor 3	Homo sapiens	124-161
10437653-5	1999	In addition, the co-application of G-CSF resulted in a decreased IFN-gamma/LPS mediated iNOS protein generation as detected by immunoblotting methods after 24 and 48 h. Measurement of the stable NO metabolites showed a significant reduction of nitrite/nitrate concentrations following co-incubation of VSMC with G-CSF + IFN-gamma/LPS (242.57 +/- 10.73 nmol NO2-/NO3-/mg cell protein, n = 8) as compared to IFN-gamma/LPS treatment (306.20 +/- 19.26 nmol NO2-/NO3-/mg cell protein, n = 8, P &lt; 0.05) following a 24-h incubation protocol.	Nitrites	244-251	colony stimulating factor 3	Homo sapiens	35-40
10437653-5	1999	In addition, the co-application of G-CSF resulted in a decreased IFN-gamma/LPS mediated iNOS protein generation as detected by immunoblotting methods after 24 and 48 h. Measurement of the stable NO metabolites showed a significant reduction of nitrite/nitrate concentrations following co-incubation of VSMC with G-CSF + IFN-gamma/LPS (242.57 +/- 10.73 nmol NO2-/NO3-/mg cell protein, n = 8) as compared to IFN-gamma/LPS treatment (306.20 +/- 19.26 nmol NO2-/NO3-/mg cell protein, n = 8, P &lt; 0.05) following a 24-h incubation protocol.	Nitrates	252-259	colony stimulating factor 3	Homo sapiens	35-40
10437653-5	1999	In addition, the co-application of G-CSF resulted in a decreased IFN-gamma/LPS mediated iNOS protein generation as detected by immunoblotting methods after 24 and 48 h. Measurement of the stable NO metabolites showed a significant reduction of nitrite/nitrate concentrations following co-incubation of VSMC with G-CSF + IFN-gamma/LPS (242.57 +/- 10.73 nmol NO2-/NO3-/mg cell protein, n = 8) as compared to IFN-gamma/LPS treatment (306.20 +/- 19.26 nmol NO2-/NO3-/mg cell protein, n = 8, P &lt; 0.05) following a 24-h incubation protocol.	vsmc	302-306	colony stimulating factor 3	Homo sapiens	35-40
10437653-5	1999	In addition, the co-application of G-CSF resulted in a decreased IFN-gamma/LPS mediated iNOS protein generation as detected by immunoblotting methods after 24 and 48 h. Measurement of the stable NO metabolites showed a significant reduction of nitrite/nitrate concentrations following co-incubation of VSMC with G-CSF + IFN-gamma/LPS (242.57 +/- 10.73 nmol NO2-/NO3-/mg cell protein, n = 8) as compared to IFN-gamma/LPS treatment (306.20 +/- 19.26 nmol NO2-/NO3-/mg cell protein, n = 8, P &lt; 0.05) following a 24-h incubation protocol.	Nitrogen Dioxide	357-360	colony stimulating factor 3	Homo sapiens	35-40
10437653-5	1999	In addition, the co-application of G-CSF resulted in a decreased IFN-gamma/LPS mediated iNOS protein generation as detected by immunoblotting methods after 24 and 48 h. Measurement of the stable NO metabolites showed a significant reduction of nitrite/nitrate concentrations following co-incubation of VSMC with G-CSF + IFN-gamma/LPS (242.57 +/- 10.73 nmol NO2-/NO3-/mg cell protein, n = 8) as compared to IFN-gamma/LPS treatment (306.20 +/- 19.26 nmol NO2-/NO3-/mg cell protein, n = 8, P &lt; 0.05) following a 24-h incubation protocol.	Nitrogen Dioxide	453-456	colony stimulating factor 3	Homo sapiens	35-40
10437653-5	1999	In addition, the co-application of G-CSF resulted in a decreased IFN-gamma/LPS mediated iNOS protein generation as detected by immunoblotting methods after 24 and 48 h. Measurement of the stable NO metabolites showed a significant reduction of nitrite/nitrate concentrations following co-incubation of VSMC with G-CSF + IFN-gamma/LPS (242.57 +/- 10.73 nmol NO2-/NO3-/mg cell protein, n = 8) as compared to IFN-gamma/LPS treatment (306.20 +/- 19.26 nmol NO2-/NO3-/mg cell protein, n = 8, P &lt; 0.05) following a 24-h incubation protocol.	punky blue	362-365	colony stimulating factor 3	Homo sapiens	35-40
10437653-6	1999	This inhibitory effect of G-CSF was still present after a 48 h incubation period (G-CSF + IFN-gamma/LPS: 319.56 +/- 6.26 nmol NO2-/NO3-/mg cell protein; IFN-gamma/LPS: 489.20 +/- 27.15 nmol NO2-/NO3-/mg cell protein (P &lt; 0.05), n = 8, respectively).	Nitrogen Dioxide	126-130	colony stimulating factor 3	Homo sapiens	26-31
10437653-6	1999	This inhibitory effect of G-CSF was still present after a 48 h incubation period (G-CSF + IFN-gamma/LPS: 319.56 +/- 6.26 nmol NO2-/NO3-/mg cell protein; IFN-gamma/LPS: 489.20 +/- 27.15 nmol NO2-/NO3-/mg cell protein (P &lt; 0.05), n = 8, respectively).	Nitrogen Dioxide	126-130	colony stimulating factor 3	Homo sapiens	82-87
10437653-6	1999	This inhibitory effect of G-CSF was still present after a 48 h incubation period (G-CSF + IFN-gamma/LPS: 319.56 +/- 6.26 nmol NO2-/NO3-/mg cell protein; IFN-gamma/LPS: 489.20 +/- 27.15 nmol NO2-/NO3-/mg cell protein (P &lt; 0.05), n = 8, respectively).	punky blue	131-134	colony stimulating factor 3	Homo sapiens	26-31
10437653-6	1999	This inhibitory effect of G-CSF was still present after a 48 h incubation period (G-CSF + IFN-gamma/LPS: 319.56 +/- 6.26 nmol NO2-/NO3-/mg cell protein; IFN-gamma/LPS: 489.20 +/- 27.15 nmol NO2-/NO3-/mg cell protein (P &lt; 0.05), n = 8, respectively).	punky blue	131-134	colony stimulating factor 3	Homo sapiens	82-87
10437653-6	1999	This inhibitory effect of G-CSF was still present after a 48 h incubation period (G-CSF + IFN-gamma/LPS: 319.56 +/- 6.26 nmol NO2-/NO3-/mg cell protein; IFN-gamma/LPS: 489.20 +/- 27.15 nmol NO2-/NO3-/mg cell protein (P &lt; 0.05), n = 8, respectively).	Nitrogen Dioxide	126-129	colony stimulating factor 3	Homo sapiens	26-31
10437653-6	1999	This inhibitory effect of G-CSF was still present after a 48 h incubation period (G-CSF + IFN-gamma/LPS: 319.56 +/- 6.26 nmol NO2-/NO3-/mg cell protein; IFN-gamma/LPS: 489.20 +/- 27.15 nmol NO2-/NO3-/mg cell protein (P &lt; 0.05), n = 8, respectively).	Nitrogen Dioxide	126-129	colony stimulating factor 3	Homo sapiens	82-87
10228066-6	1999	G-CSF pretreatment up-regulated CD11b/c expression on circulating polymorphonuclear leukocytes, augmented the recruitment of neutrophils into the lung, and enhanced the phagocytic activity of circulating and recruited neutrophils in both the absence and presence of acute ethanol intoxication.	Ethanol	272-279	colony stimulating factor 3	Homo sapiens	0-5
10228066-8	1999	These data suggest that G-CSF may be useful in the prevention or treatment of infections in persons immunocompromised by alcohol.	Alcohols	121-128	colony stimulating factor 3	Homo sapiens	24-29
10418556-3	1999	METHODS: A multicenter dose-finding study of glycosylated G-CSF (lenograstim) for the mobilization of PBSCs following adjuvant CAF chemotherapy (cyclophosphamide, doxorubicin and 5-fluorouracil) was performed in 38 patients with postoperative breast cancer.	Cyclophosphamide	145-161	colony stimulating factor 3	Homo sapiens	58-63
10229865-13	1999	The concentrations of IL-8, G-CSF, monocyte chemoattractant protein-1, GM-CSF, and TGF-beta in the supernatant fluids significantly increased in response to bleomycin.	Bleomycin	157-166	colony stimulating factor 3	Homo sapiens	28-33
10336453-0	1999	The role of STAT3 in granulocyte colony-stimulating factor-induced enhancement of neutrophilic differentiation of Me2SO-treated HL-60 cells.	me2so	114-119	colony stimulating factor 3	Homo sapiens	21-58
10336453-2	1999	The role of granulocyte colony-stimulating factor (G-CSF) on neutrophilic differentiation of Me2SO-treated HL-60 cells was studied.	me2so	93-98	colony stimulating factor 3	Homo sapiens	12-49
10336453-2	1999	The role of granulocyte colony-stimulating factor (G-CSF) on neutrophilic differentiation of Me2SO-treated HL-60 cells was studied.	me2so	93-98	colony stimulating factor 3	Homo sapiens	51-56
10336453-3	1999	G-CSF augmented the functional maturation of Me2SO-treated HL-60 cells in terms of both O-2-generating ability and expression of the formyl-methionyl-leucyl-phenylalanine receptor.	me2so	45-50	colony stimulating factor 3	Homo sapiens	0-5
10336453-4	1999	G-CSF induced enhancement of cell growth in Me2SO-treated HL-60 cells.	me2so	44-49	colony stimulating factor 3	Homo sapiens	0-5
10336453-5	1999	These results indicate that G-CSF is a potent enhancer for the differentiation and proliferation of Me2SO-treated HL-60 cells.	me2so	100-105	colony stimulating factor 3	Homo sapiens	28-33
10336453-7	1999	On the other hand, G-CSF rapidly induced tyrosine phosphorylation of signal transducers and activators of transcription-3 (STAT3), but did not induce serine727 phosphorylation.	Tyrosine	41-49	colony stimulating factor 3	Homo sapiens	19-24
10358698-3	1999	The FLAG (fludarabine, high-dose cytarabine, and G-CSF) regimen is as intensive but less cardiotoxic because of the avoidance of anthracyclines.	Anthracyclines	129-143	colony stimulating factor 3	Homo sapiens	49-54
10336453-8	1999	From the analysis of confocal laser scanning fluorescence microscopy and differential centrifugation, it was clearly demonstrated that G-CSF induced nuclear translocation of tyrosine-phosphorylated STAT3.	Tyrosine	174-182	colony stimulating factor 3	Homo sapiens	135-140
10336453-10	1999	Notably, in the presence of GM-CSF, G-CSF induced the tyrosine phosphorylation of STAT3 but failed to induce the nuclear translocation of tyrosine-phosphorylated STAT3.	Tyrosine	54-62	colony stimulating factor 3	Homo sapiens	36-41
10336453-13	1999	PD98059, an MEK1 inhibitor, inhibited the G-CSF-dependent serine727 phosphorylation of STAT3 and blocked the inhibitory effect of GM-CSF on G-CSF-dependent nuclear translocation of STAT3.	2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one	0-7	colony stimulating factor 3	Homo sapiens	42-47
10336453-13	1999	PD98059, an MEK1 inhibitor, inhibited the G-CSF-dependent serine727 phosphorylation of STAT3 and blocked the inhibitory effect of GM-CSF on G-CSF-dependent nuclear translocation of STAT3.	2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one	0-7	colony stimulating factor 3	Homo sapiens	140-145
10336453-13	1999	PD98059, an MEK1 inhibitor, inhibited the G-CSF-dependent serine727 phosphorylation of STAT3 and blocked the inhibitory effect of GM-CSF on G-CSF-dependent nuclear translocation of STAT3.	serine727	58-67	colony stimulating factor 3	Homo sapiens	42-47
10336453-14	1999	These results suggest that G-CSF-dependent nuclear translocation of STAT3 coordinates with the promotion of neutrophilic differentiation in Me2SO-treated HL-60 cells.	me2so	140-145	colony stimulating factor 3	Homo sapiens	27-32
10232468-0	1999	Fluorine-18 fluorodeoxyglucose splenic uptake from extramedullary hematopoiesis after granulocyte colony-stimulating factor stimulation.	Fluorine	0-8	colony stimulating factor 3	Homo sapiens	86-123
10371409-5	1999	Treatment of PMNs with granulocyte colony-stimulating factor (G-CSF) attenuated the inhibitory effect seen with prior ethanol exposure.	Ethanol	118-125	colony stimulating factor 3	Homo sapiens	23-60
10371409-5	1999	Treatment of PMNs with granulocyte colony-stimulating factor (G-CSF) attenuated the inhibitory effect seen with prior ethanol exposure.	Ethanol	118-125	colony stimulating factor 3	Homo sapiens	62-67
10371409-6	1999	CONCLUSIONS: These data demonstrate that the functional state of PMNs from uninfected as well as SIV-infected rhesus macaques is impaired by direct exposure to intoxicating concentrations of ethanol and that this effect can be attenuated by G-CSF.	Ethanol	191-198	colony stimulating factor 3	Homo sapiens	241-246
10371409-8	1999	Furthermore, G-CSF may be useful in overcoming the suppressive effects of ethanol on PMN function in such patients.	Ethanol	74-81	colony stimulating factor 3	Homo sapiens	13-18
10226739-3	1999	Granulocyte colony-stimulating factor may play a pivotal role in the induction of lipopolysaccharide desensitization by nontoxic lipid A analogues proposed for the prevention of sepsis; granulocyte macrophage colony-stimulating factor may be useful in reversing the immune paralysis described in later stages of sepsis.	Lipid A	129-136	colony stimulating factor 3	Homo sapiens	0-37
10232468-0	1999	Fluorine-18 fluorodeoxyglucose splenic uptake from extramedullary hematopoiesis after granulocyte colony-stimulating factor stimulation.	18 fluorodeoxyglucose	9-30	colony stimulating factor 3	Homo sapiens	86-123
10410150-1	1999	Two phase I studies (CIC-therapy) were conducted in advanced non-small cell lung cancer (NSCLC) to determine the maximum tolerable dose (MTD) of CPT-11 combined with cisplatin and ifosfamide, and MTD of cisplatin combined with CPT-11 and ifosfamide with G-CSF support, respectively.	Irinotecan	145-151	colony stimulating factor 3	Homo sapiens	254-259
10194425-2	1999	Granulocyte colony-stimulating factor (G-CSF) has been considered to be potentially synergistic with ATRA in this regard.	Tretinoin	101-105	colony stimulating factor 3	Homo sapiens	0-37
10334525-15	1999	CONCLUSION: Administration of 96-hour paclitaxel infusion and subsequent weekly vinorelbine with G-CSF support is well tolerated.	Vinorelbine	80-91	colony stimulating factor 3	Homo sapiens	97-102
10698549-0	1999	Reduction of Cys36-Cys42 and Cys64-Cys74 disulfide bonds in recombinant human granulocyte colony stimulating factor.	Disulfides	41-50	colony stimulating factor 3	Homo sapiens	78-115
10698549-1	1999	The Cys36-Cys42 and Cys64-Cys74 disulfide bonds in recombinant methionyl human granulocyte colony-stimulating factor were reduced to sulfhydryls with dithiothreitol or mercury.	Disulfides	32-41	colony stimulating factor 3	Homo sapiens	79-116
10698549-1	1999	The Cys36-Cys42 and Cys64-Cys74 disulfide bonds in recombinant methionyl human granulocyte colony-stimulating factor were reduced to sulfhydryls with dithiothreitol or mercury.	Dithiothreitol	150-164	colony stimulating factor 3	Homo sapiens	79-116
10698549-1	1999	The Cys36-Cys42 and Cys64-Cys74 disulfide bonds in recombinant methionyl human granulocyte colony-stimulating factor were reduced to sulfhydryls with dithiothreitol or mercury.	Mercury	168-175	colony stimulating factor 3	Homo sapiens	79-116
10698549-4	1999	These observations are explained by repulsive forces between dithiothreitol and regions in granulocyte colony-stimulating factor which intensify in these pH-regions.	Dithiothreitol	61-75	colony stimulating factor 3	Homo sapiens	91-128
10213206-2	1999	This Phase I trial was designed to determine the maximum tolerated dose, the dose-limiting toxicities, and the incidence and severity of other toxicities of docetaxel with filgrastim (G-CSF) support in children with refractory solid tumors.	Docetaxel	157-166	colony stimulating factor 3	Homo sapiens	184-189
10194377-1	1999	The sequence of granulocyte colony-stimulating factor (G-CSF) has been circularly permuted by introducing new chain termini into interhelical loops and by constraining the N- and C-terminal helices, either by direct linkage of the termini (L0) or by substitution of the amino-terminal 10-residue segment with a seven-residue linker composed of glycines and serines (L1).	Glycine	344-352	colony stimulating factor 3	Homo sapiens	16-53
10194377-1	1999	The sequence of granulocyte colony-stimulating factor (G-CSF) has been circularly permuted by introducing new chain termini into interhelical loops and by constraining the N- and C-terminal helices, either by direct linkage of the termini (L0) or by substitution of the amino-terminal 10-residue segment with a seven-residue linker composed of glycines and serines (L1).	Glycine	344-352	colony stimulating factor 3	Homo sapiens	55-60
10194377-1	1999	The sequence of granulocyte colony-stimulating factor (G-CSF) has been circularly permuted by introducing new chain termini into interhelical loops and by constraining the N- and C-terminal helices, either by direct linkage of the termini (L0) or by substitution of the amino-terminal 10-residue segment with a seven-residue linker composed of glycines and serines (L1).	Serine	357-364	colony stimulating factor 3	Homo sapiens	16-53
10194377-1	1999	The sequence of granulocyte colony-stimulating factor (G-CSF) has been circularly permuted by introducing new chain termini into interhelical loops and by constraining the N- and C-terminal helices, either by direct linkage of the termini (L0) or by substitution of the amino-terminal 10-residue segment with a seven-residue linker composed of glycines and serines (L1).	Serine	357-364	colony stimulating factor 3	Homo sapiens	55-60
10194377-5	1999	The thermodynamic stability of the cpG-CSFs toward urea was found to correlate with their relative ability to stimulate proliferation of G-CSF responsive cells.	Urea	51-55	colony stimulating factor 3	Homo sapiens	37-42
10213206-5	1999	G-CSF (5 microg/kg/day) was administered s.c., starting 48 h after docetaxel and continuing until the post-nadir neutrophil count reached 10,000/microl.	Docetaxel	67-76	colony stimulating factor 3	Homo sapiens	0-5
10213206-13	1999	The maximum tolerated dose of docetaxel with G-CSF support in children is 185 mg/m2, which is 50% higher than the maximum tolerated dose of docetaxel alone in children and 85 % higher than the recommended adult dose.	Docetaxel	30-39	colony stimulating factor 3	Homo sapiens	45-50
10221506-6	1999	Among them, granulocyte colony-stimulating factor (G-CSF) is unique in that it preferentially stimulates clonal growth, but not self-renewal, in many APL cases, and synergistically enhances the differentiation-inducing effect of ATRA when used in combination.	Tretinoin	229-233	colony stimulating factor 3	Homo sapiens	12-49
10234303-6	1999	Hence, we administered cisplatin + vincristine + doxorubicin + etoposide (CODE) with G-CSF for its high-dose intensity.	Vincristine	35-46	colony stimulating factor 3	Homo sapiens	85-90
10210322-8	1999	However, we found that RA opposed anti-apoptotic effects of G-CSF and GM-CSF on CD34+ cells (G-CSF: 8% dead cells at day 6; G-CSF + RA: 20%; GM-CSF: 12%; GM-CSF + RA: 27%).	Tretinoin	23-25	colony stimulating factor 3	Homo sapiens	60-65
10210322-8	1999	However, we found that RA opposed anti-apoptotic effects of G-CSF and GM-CSF on CD34+ cells (G-CSF: 8% dead cells at day 6; G-CSF + RA: 20%; GM-CSF: 12%; GM-CSF + RA: 27%).	Tretinoin	23-25	colony stimulating factor 3	Homo sapiens	93-98
10210322-8	1999	However, we found that RA opposed anti-apoptotic effects of G-CSF and GM-CSF on CD34+ cells (G-CSF: 8% dead cells at day 6; G-CSF + RA: 20%; GM-CSF: 12%; GM-CSF + RA: 27%).	Tretinoin	23-25	colony stimulating factor 3	Homo sapiens	93-98
10561191-0	1999	Erythropoietin addition to granulocyte colony-stimulating factor abrogates life-threatening neutropenia and increases peripheral-blood progenitor-cell mobilization after epirubicin, paclitaxel, and cisplatin combination chemotherapy: results of a randomized comparison.	Epirubicin	170-180	colony stimulating factor 3	Homo sapiens	27-64
10561191-0	1999	Erythropoietin addition to granulocyte colony-stimulating factor abrogates life-threatening neutropenia and increases peripheral-blood progenitor-cell mobilization after epirubicin, paclitaxel, and cisplatin combination chemotherapy: results of a randomized comparison.	Paclitaxel	182-192	colony stimulating factor 3	Homo sapiens	27-64
10561191-0	1999	Erythropoietin addition to granulocyte colony-stimulating factor abrogates life-threatening neutropenia and increases peripheral-blood progenitor-cell mobilization after epirubicin, paclitaxel, and cisplatin combination chemotherapy: results of a randomized comparison.	Cisplatin	198-207	colony stimulating factor 3	Homo sapiens	27-64
10221506-6	1999	Among them, granulocyte colony-stimulating factor (G-CSF) is unique in that it preferentially stimulates clonal growth, but not self-renewal, in many APL cases, and synergistically enhances the differentiation-inducing effect of ATRA when used in combination.	Tretinoin	229-233	colony stimulating factor 3	Homo sapiens	51-56
10211753-8	1999	Serum levels of uric acid (UA) and lactic dehydrogenase (LDH) increased under G-CSF, and platelets decreased after G-CSF discontinuation.	Uric Acid	16-25	colony stimulating factor 3	Homo sapiens	78-83
10210543-6	1999	When cisplatin was added to this regimen, the observed myelosuppression necessitated the addition of granulocyte colony-stimulating factor.	Cisplatin	5-14	colony stimulating factor 3	Homo sapiens	101-138
10211753-8	1999	Serum levels of uric acid (UA) and lactic dehydrogenase (LDH) increased under G-CSF, and platelets decreased after G-CSF discontinuation.	Uric Acid	27-29	colony stimulating factor 3	Homo sapiens	78-83
10355578-2	1999	In a previously reported phase I trial (Lind et al., J Clin Oncol 1996; 14: 800-5), carboplatin dose intensity was increased by the use of G-CSF to support the bone marrow and using pharmacokinetically-guided carboplatin dosing.	Carboplatin	84-95	colony stimulating factor 3	Homo sapiens	139-144
10355583-0	1999	Cisplatin-topotecan-paclitaxel weekly administration with G-CSF support for ovarian and small-cell lung cancer patients: a dose-finding study.	Cisplatin	0-9	colony stimulating factor 3	Homo sapiens	58-63
10355583-0	1999	Cisplatin-topotecan-paclitaxel weekly administration with G-CSF support for ovarian and small-cell lung cancer patients: a dose-finding study.	Topotecan	10-19	colony stimulating factor 3	Homo sapiens	58-63
10355583-0	1999	Cisplatin-topotecan-paclitaxel weekly administration with G-CSF support for ovarian and small-cell lung cancer patients: a dose-finding study.	Paclitaxel	20-30	colony stimulating factor 3	Homo sapiens	58-63
10424407-14	1999	CONCLUSION: This trial shows the activity of paclitaxel and mitoxantrone in ABC and finds that a dose of 14 mg/m2 of mitoxantrone is the MTD in combination with a fixed dose of 175 mg/m2 of paclitaxel without granulocyte colony stimulating factor (G-CSF).	Mitoxantrone	117-129	colony stimulating factor 3	Homo sapiens	209-246
10100555-13	1999	Ifosfamide with G-CSF in combination with doxorubicin or paclitaxel achieves effective mobilization of PBPC and anti-tumor activity with minimal toxicity.	Ifosfamide	0-10	colony stimulating factor 3	Homo sapiens	16-21
10424407-14	1999	CONCLUSION: This trial shows the activity of paclitaxel and mitoxantrone in ABC and finds that a dose of 14 mg/m2 of mitoxantrone is the MTD in combination with a fixed dose of 175 mg/m2 of paclitaxel without granulocyte colony stimulating factor (G-CSF).	Mitoxantrone	117-129	colony stimulating factor 3	Homo sapiens	248-253
10053098-0	1999	A phase II double-blind randomized study of the simultaneous administration of recombinant human interleukin-6 and recombinant human granulocyte colony-stimulating factor following paclitaxel and carboplatin chemotherapy in patients with advanced epithelial ovarian cancer.	Paclitaxel	181-191	colony stimulating factor 3	Homo sapiens	133-170
9917323-1	1999	Chemical modification and mutagenesis of methionines in recombinant human granulocyte colony-stimulating factor (G-CSF) were investigated.	Methionine	41-52	colony stimulating factor 3	Homo sapiens	113-118
10071262-8	1999	G-CSF support permitted further dose escalation of cisplatin and topotecan.	Cisplatin	51-60	colony stimulating factor 3	Homo sapiens	0-5
10071262-8	1999	G-CSF support permitted further dose escalation of cisplatin and topotecan.	Topotecan	65-74	colony stimulating factor 3	Homo sapiens	0-5
10071277-16	1999	CONCLUSION: The reported combination of docetaxel and mitoxantrone with G-CSF support is a safe, intensified, well-tolerated, and effective regimen as first-line treatment in patients with MBC.	Mitoxantrone	54-66	colony stimulating factor 3	Homo sapiens	72-77
10071279-8	1999	CONCLUSION: When combined with doxorubicin (60 mg/m2) and dexrazoxane (600 mg/m2), paclitaxel given as a 3-hour infusion had an MTD of 150 mg/m2, and G-CSF was required to prevent febrile neutropenia.	Paclitaxel	83-93	colony stimulating factor 3	Homo sapiens	150-155
10071282-0	1999	Combined irinotecan and oxaliplatin plus granulocyte colony-stimulating factor in patients with advanced fluoropyrimidine/leucovorin-pretreated colorectal cancer.	2-fluoropyrimidine	105-121	colony stimulating factor 3	Homo sapiens	41-78
10071282-0	1999	Combined irinotecan and oxaliplatin plus granulocyte colony-stimulating factor in patients with advanced fluoropyrimidine/leucovorin-pretreated colorectal cancer.	Leucovorin	122-132	colony stimulating factor 3	Homo sapiens	41-78
10071282-11	1999	CONCLUSION: Our data suggest that the combination of irinotecan and oxaliplatin with or without G-CSF has substantial antitumor activity in patients with progressive fluoropyrimidine/leucovorin-pretreated colorectal cancer.	2-fluoropyrimidine	166-182	colony stimulating factor 3	Homo sapiens	96-101
10071282-11	1999	CONCLUSION: Our data suggest that the combination of irinotecan and oxaliplatin with or without G-CSF has substantial antitumor activity in patients with progressive fluoropyrimidine/leucovorin-pretreated colorectal cancer.	Leucovorin	183-193	colony stimulating factor 3	Homo sapiens	96-101
10221375-4	1999	Comparing the IP and PIP, the mean number of G-CSF doses (0.29 vs 0.51) and pharmacy costs per day ($112 vs $200) decreased, with no change in the number of patients requiring G-CSF.	pip	21-24	colony stimulating factor 3	Homo sapiens	45-50
9917323-0	1999	Chemical modification and site-directed mutagenesis of methionine residues in recombinant human granulocyte colony-stimulating factor: effect on stability and biological activity.	Methionine	55-65	colony stimulating factor 3	Homo sapiens	96-133
9917323-1	1999	Chemical modification and mutagenesis of methionines in recombinant human granulocyte colony-stimulating factor (G-CSF) were investigated.	Methionine	41-52	colony stimulating factor 3	Homo sapiens	74-111
10025378-0	1999	Concurrent administration of vinorelbine with recombinant human granulocyte colony-stimulating factor: an effective method of increasing dose intensity.	Vinorelbine	29-40	colony stimulating factor 3	Homo sapiens	64-101
9917323-2	1999	Selective oxidation of G-CSF by H2O2 and t-butyl hydroperoxide leads to generation of different oxidized forms.	Hydrogen Peroxide	32-36	colony stimulating factor 3	Homo sapiens	23-28
9917323-2	1999	Selective oxidation of G-CSF by H2O2 and t-butyl hydroperoxide leads to generation of different oxidized forms.	tert-Butylhydroperoxide	41-62	colony stimulating factor 3	Homo sapiens	23-28
9917323-4	1999	All methionines in G-CSF are reactive, with reaction kinetics following the order of Met1&gt;Met138&gt;Met127&gt;&gt;&gt;Met122.	Methionine	4-15	colony stimulating factor 3	Homo sapiens	19-24
9917323-11	1999	G-CSF variants with Leu replacement at Met127 or at Met138 are not completely resistant to oxidation-induced inactivation, while the variant with Leu replacement at both sites is more stable and can retain in vitro biological activity following oxidation.	Leucine	20-23	colony stimulating factor 3	Homo sapiens	0-5
10071455-0	1999	Effect of granulocyte-colony stimulating factor on empiric therapy with flomoxef sodium and tobramycin in febrile neutropenic patients with hematological malignancies.	flomoxef	72-87	colony stimulating factor 3	Homo sapiens	10-47
10029158-0	1999	IL-1beta mediates diethyldithiocarbamate-induced granulocyte colony-stimulating factor production and hematopoiesis.	Ditiocarb	18-40	colony stimulating factor 3	Homo sapiens	49-86
10029158-2	1999	The mechanism of DDTC-mediated chemoprotection is believed to involve the induction and release of several cytokines, including interleukin-1 beta (IL-1beta), tumor necrosis factor-alpha (TNF-alpha), and granulocyte colony-stimulating factor (G-CSF).	Ditiocarb	17-21	colony stimulating factor 3	Homo sapiens	204-241
10029158-2	1999	The mechanism of DDTC-mediated chemoprotection is believed to involve the induction and release of several cytokines, including interleukin-1 beta (IL-1beta), tumor necrosis factor-alpha (TNF-alpha), and granulocyte colony-stimulating factor (G-CSF).	Ditiocarb	17-21	colony stimulating factor 3	Homo sapiens	243-248
10029158-3	1999	In the present study the roles of IL-1beta and TNF-alpha in DDTC-mediated G-CSF induction were examined using human long-term bone marrow cultures (hLTBMCs).	Ditiocarb	60-64	colony stimulating factor 3	Homo sapiens	74-79
10029158-4	1999	Administration of IL-1 receptor antagonist (IL-1ra) to DDTC-treated hLTBMCs obviated the G-CSF induction profile and blocked the resultant colony proliferation, indicating that IL-1beta mediates DDTC-induced G-CSF release and hematopoiesis.	Ditiocarb	55-59	colony stimulating factor 3	Homo sapiens	89-94
10029158-4	1999	Administration of IL-1 receptor antagonist (IL-1ra) to DDTC-treated hLTBMCs obviated the G-CSF induction profile and blocked the resultant colony proliferation, indicating that IL-1beta mediates DDTC-induced G-CSF release and hematopoiesis.	Ditiocarb	55-59	colony stimulating factor 3	Homo sapiens	208-213
10029158-4	1999	Administration of IL-1 receptor antagonist (IL-1ra) to DDTC-treated hLTBMCs obviated the G-CSF induction profile and blocked the resultant colony proliferation, indicating that IL-1beta mediates DDTC-induced G-CSF release and hematopoiesis.	Ditiocarb	195-199	colony stimulating factor 3	Homo sapiens	208-213
10029165-0	1999	Priming with G-CSF effectively enhances low-dose Ara-C-induced in vivo apoptosis in myeloid leukemia cells.	Cytarabine	49-54	colony stimulating factor 3	Homo sapiens	13-18
10029165-4	1999	In all but one patient, half killing concentration (LC50) of Ara-C was significantly reduced in the presence of G-CSF (by 400- and 1.45-fold, median: 21-fold).	Cytarabine	61-66	colony stimulating factor 3	Homo sapiens	112-117
10029165-6	1999	In vitro killing tests using a G-CSF-dependent leukemic cell line suggested that addition of G-CSF potentiates Ara-C-induced cytotoxicity through the mechanism of apoptosis.	Cytarabine	111-116	colony stimulating factor 3	Homo sapiens	31-36
10029165-6	1999	In vitro killing tests using a G-CSF-dependent leukemic cell line suggested that addition of G-CSF potentiates Ara-C-induced cytotoxicity through the mechanism of apoptosis.	Cytarabine	111-116	colony stimulating factor 3	Homo sapiens	93-98
10037178-9	1999	DLTs, mainly myelosuppression, occurring during the first course of therapy were noted in four of six and five of eight patients treated with 40 mg/m2 losoxantrone and 135 mg/m2 paclitaxel over 24 and 3 h, respectively, without G-CSF.	losoxantrone	151-163	colony stimulating factor 3	Homo sapiens	228-233
10071455-0	1999	Effect of granulocyte-colony stimulating factor on empiric therapy with flomoxef sodium and tobramycin in febrile neutropenic patients with hematological malignancies.	Tobramycin	92-102	colony stimulating factor 3	Homo sapiens	10-47
10022594-1	1999	The purpose of this study was to examine the effect of dexamethasone (DEX) on the production of granulocyte and granulocyte-macrophage colony stimulating factors (G-CSF and GM-CSF) by neonatal mononuclear cells.	Dexamethasone	55-68	colony stimulating factor 3	Homo sapiens	112-168
10022594-1	1999	The purpose of this study was to examine the effect of dexamethasone (DEX) on the production of granulocyte and granulocyte-macrophage colony stimulating factors (G-CSF and GM-CSF) by neonatal mononuclear cells.	Dexamethasone	70-73	colony stimulating factor 3	Homo sapiens	112-168
10022594-4	1999	The PMA/PHA-induced increase in G-CSF production was markedly augmented by the addition of DEX to cell cultures.	Dexamethasone	91-94	colony stimulating factor 3	Homo sapiens	32-37
10022594-5	1999	DEX augmented production of G-CSF was significantly less in mononuclear cells from preterm infants.	Dexamethasone	0-3	colony stimulating factor 3	Homo sapiens	28-33
10022594-10	1999	The data show DEX induced differential regulation of infant peripheral blood mononuclear cell production of G-CSF and GM-CSF.	Dexamethasone	14-17	colony stimulating factor 3	Homo sapiens	108-113
10022594-12	1999	Further, the neutrophilia observed in DEX-treated infants may be due to enhanced G-CSF production.	Dexamethasone	38-41	colony stimulating factor 3	Homo sapiens	81-86
10529507-4	1999	Further, NAP restoration in ATRA- and G-CSF-treated cultures was accompanied by increased morphologic differentiation of the CML clone.	nap	9-12	colony stimulating factor 3	Homo sapiens	38-43
10199205-11	1999	Although ATRA was administered at a dose of 80 mg/day for more than 2 months, the number of myelocytes and promyelocytes increased Finally CAG (cytarabine, aclarubicin, G-CSF) therapy was initiated, but the patient died due to intracranial invasion and hemorrhage accompanied by disseminated intravascular coagulation.	Tretinoin	9-13	colony stimulating factor 3	Homo sapiens	169-174
9935235-9	1999	Furthermore, stimulation of IMC-2 cells with rG-CSF induced rapid activation of tyrosine-phosphorylated JAK1, suggesting that the G-CSF signal may be transduced into the cells through G-CSFR.	Tyrosine	80-88	colony stimulating factor 3	Homo sapiens	46-51
10595815-14	1999	The cost of chemotherapy administration, more doses of G-CSF, transfusions, and hospitalizations caused cyclophosphamide, etoposide, and G-CSF to be more expensive than G-CSF alone.	Cyclophosphamide	104-120	colony stimulating factor 3	Homo sapiens	55-60
10197796-10	1999	These results demonstrate that priming with 10 microg/kg G-CSF alone is well tolerated and effective in mobilizing sufficient numbers of CD34+ cells in breast cancer patients and provide prompt engraftment after CTM high-dose chemotherapy.	cyclohexane-1,2,4-tris(methylenesulfonate)	212-215	colony stimulating factor 3	Homo sapiens	57-62
9864179-2	1999	G-CSF exclusively tyrosine-phosphorylated extracellular signal-regulated kinase (ERK).	Tyrosine	18-26	colony stimulating factor 3	Homo sapiens	0-5
9864179-8	1999	MEK inhibitor (PD98059) reduced tyrosine phosphorylation of ERK, but not p38 MAPK, induced by G-CSF, GM-CSF, or TNF.	2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one	15-22	colony stimulating factor 3	Homo sapiens	94-99
9864179-8	1999	MEK inhibitor (PD98059) reduced tyrosine phosphorylation of ERK, but not p38 MAPK, induced by G-CSF, GM-CSF, or TNF.	Tyrosine	32-40	colony stimulating factor 3	Homo sapiens	94-99
9864153-0	1999	Tyrosine-dependent and -independent mechanisms of STAT3 activation by the human granulocyte colony-stimulating factor (G-CSF) receptor are differentially utilized depending on G-CSF concentration.	Tyrosine	0-8	colony stimulating factor 3	Homo sapiens	119-124
10197801-0	1999	The cytotoxicity of mafosfamide on G-CSF mobilized hematopoietic progenitors is reduced by SH groups of albumin--implications for further purging strategies.	mafosfamide	20-31	colony stimulating factor 3	Homo sapiens	35-40
10197801-2	1999	To determine the influence of protein-bound SH groups in the incubation medium, the cytotoxicity of mafosfamide on G-CSF mobilized CD34+/- cells was evaluated by short-term culture assays and drug concentration measurements.	mafosfamide	100-111	colony stimulating factor 3	Homo sapiens	115-120
10321506-0	1999	A phase II study of irinotecan and infusional cisplatin with recombinant human granulocyte colony-stimulating factor support for advanced non-small-cell lung cancer.	Irinotecan	20-30	colony stimulating factor 3	Homo sapiens	79-116
9923546-0	1999	Phase II study of mitoxantrone by 14-day continuous infusion with granulocyte colony-stimulating factor (GCSF) support in patients with metastatic breast cancer and limited prior therapy.	Mitoxantrone	18-30	colony stimulating factor 3	Homo sapiens	66-103
9923546-0	1999	Phase II study of mitoxantrone by 14-day continuous infusion with granulocyte colony-stimulating factor (GCSF) support in patients with metastatic breast cancer and limited prior therapy.	Mitoxantrone	18-30	colony stimulating factor 3	Homo sapiens	105-109
9923546-5	1999	Mitoxantrone, 1.5 mg/m2 per day, was given by continuous intravenous infusion for 14 consecutive days repeated every 21 days with concomitant granulocyte colony-stimulating factor support.	Mitoxantrone	0-12	colony stimulating factor 3	Homo sapiens	142-179
9923557-0	1999	Docetaxel and granulocyte colony-stimulating factor in patients with advanced non-small-cell lung cancer previously treated with platinum-based chemotherapy: a multicenter phase II trial.	Platinum	129-137	colony stimulating factor 3	Homo sapiens	14-51
9923557-1	1999	PURPOSE: To investigate the activity of docetaxel and granulocyte colony-stimulating factor support (G-CSF) in patients with advanced non-small-cell lung cancer (NSCLC) previously treated with cisplatin.	Cisplatin	193-202	colony stimulating factor 3	Homo sapiens	54-99
9923557-1	1999	PURPOSE: To investigate the activity of docetaxel and granulocyte colony-stimulating factor support (G-CSF) in patients with advanced non-small-cell lung cancer (NSCLC) previously treated with cisplatin.	Cisplatin	193-202	colony stimulating factor 3	Homo sapiens	101-106
9923557-3	1999	Docetaxel at 100 mg/m2 was given as a 1-h infusion with G-CSF (rhG-CSF given s.c. at 150 microg/m2) support from day 2 to day 8 every 3 weeks; all patients received premedication with corticosteroids.	Docetaxel	0-9	colony stimulating factor 3	Homo sapiens	56-61
10321506-0	1999	A phase II study of irinotecan and infusional cisplatin with recombinant human granulocyte colony-stimulating factor support for advanced non-small-cell lung cancer.	Cisplatin	46-55	colony stimulating factor 3	Homo sapiens	79-116
10935167-4	1999	In the culture containing FL + SCF + G-CSF + GM-CSF, the total cell expansion ratio reached the maximum (385.30 +/- 163.51-fold) at 28 days, whereas in the culture with FL + SCF + IL-3 + IL-6, CFU-GMs expansion ratio reached a plateau (409.52 +/- 189.50-fold) at 28 days.	gms	197-200	colony stimulating factor 3	Homo sapiens	37-42
10447584-1	1999	PURPOSE: To evaluate the pharmacokinetics of paclitaxel and cisplatin administered in combination with bleomycin and etoposide and Granulocyte Colony-Stimulating Factor (G-CSF) in patients with advanced solid tumours.	Paclitaxel	45-55	colony stimulating factor 3	Homo sapiens	170-175
10447584-2	1999	METHODS: Patients were recruited to a phase I trial where escalating doses of paclitaxel (125 to 200 mg/m(2)) were administered in combination with etoposide 100 or 120 mg/m(2), and fixed dose of cisplatin 20 mg/m(2) and bleomycin 30 mg, with the concomitant use of G-CSF.	Paclitaxel	78-88	colony stimulating factor 3	Homo sapiens	266-271
10048953-0	1999	Changing biodistribution of gallium during G-CSF treatment in non- Hodgkin"s disease.	Gallium	28-35	colony stimulating factor 3	Homo sapiens	43-48
10378632-0	1999	A pilot study of increasing dose intensity of epirubicin and ifosfamide in patients with small cell lung cancer by using recombinant granulocyte colony-stimulating factor.	Epirubicin	46-56	colony stimulating factor 3	Homo sapiens	133-170
10378632-0	1999	A pilot study of increasing dose intensity of epirubicin and ifosfamide in patients with small cell lung cancer by using recombinant granulocyte colony-stimulating factor.	Ifosfamide	61-71	colony stimulating factor 3	Homo sapiens	133-170
9923454-12	1999	Our results indicate that FL is a potent and safe agent for the mobilization of PB-PCs and is synergistic with G-CSF.	fl	26-28	colony stimulating factor 3	Homo sapiens	111-116
11399571-7	1999	Addition of granulocyte colony stimulating factor to empiric amphotericin B significantly reduced the number of patients requiring salvage therapy with lipid-associated or liposomal formulations of amphotericin B addition of granulocyte colony stimulating factor to empiric intravenous amphotericin B improves the response rate and thereby reduces the number of patients requiring salvage therapy with liposomal or lipid-associated preparations of amphotericin B.	Amphotericin B	198-212	colony stimulating factor 3	Homo sapiens	12-49
11399566-2	1999	The progenitor cells were mobilized by treatment with cyclophosphamide + granulocyte - colony stimulating factor (G-CSF) in patients with multiple myeloma.	Cyclophosphamide	54-70	colony stimulating factor 3	Homo sapiens	114-119
11399571-7	1999	Addition of granulocyte colony stimulating factor to empiric amphotericin B significantly reduced the number of patients requiring salvage therapy with lipid-associated or liposomal formulations of amphotericin B addition of granulocyte colony stimulating factor to empiric intravenous amphotericin B improves the response rate and thereby reduces the number of patients requiring salvage therapy with liposomal or lipid-associated preparations of amphotericin B.	Amphotericin B	198-212	colony stimulating factor 3	Homo sapiens	12-49
11399571-0	1999	Malignancy: Granulocyte Colony Stimulating Factor Increases the Efficacy of Conventional Amphotericin in the Treatment of Presumed Deep-Seated Fungal Infection in Neutropenic Patients following Intensive Chemotherapy or Bone Marrow Transplantation for Haematological Malignancies.	Amphotericin B	89-101	colony stimulating factor 3	Homo sapiens	12-49
27420550-2	1999	The progenitor cells were mobilized by treatment with cyclophosphamide + granulocyte-colony stimulating factor (G-CSF) in patients with multiple myeloma.	Cyclophosphamide	54-70	colony stimulating factor 3	Homo sapiens	112-117
11399571-7	1999	Addition of granulocyte colony stimulating factor to empiric amphotericin B significantly reduced the number of patients requiring salvage therapy with lipid-associated or liposomal formulations of amphotericin B addition of granulocyte colony stimulating factor to empiric intravenous amphotericin B improves the response rate and thereby reduces the number of patients requiring salvage therapy with liposomal or lipid-associated preparations of amphotericin B.	Amphotericin B	198-212	colony stimulating factor 3	Homo sapiens	12-49
18521274-2	1999	To define the maximally tolerated dose (MTD) of ifosfamide when given with G-CSF on an every other week schedule, and to define the MTD of edatrexate that can be given every two weeks with an intense schedule of ifosfamide.Patients and Methods.	Ifosfamide	48-58	colony stimulating factor 3	Homo sapiens	75-80
9949294-11	1999	We conclude that intravenous CMF with a cyclophosphamide dose of 1,500 mg/m2 given at 3-week intervals with the selective use of prophylactic G-CSF is feasible as adjuvant treatment for patients with breast cancer.	CMF regimen	29-32	colony stimulating factor 3	Homo sapiens	142-147
9950270-3	1999	Pretreatment of HUVEC with PTX significantly antagonized TNF-, IL-1-, and G-CSF-activated transmigration of neutrophils.	Pentoxifylline	27-30	colony stimulating factor 3	Homo sapiens	74-79
9885374-0	1999	Optimal timing (Preemptive versus supportive) of granulocyte colony-stimulating factor administration following high-dose cyclophosphamide.	Cyclophosphamide	122-138	colony stimulating factor 3	Homo sapiens	49-86
9989882-3	1998	As mobilising chemotherapy, cyclophosphamide, etoposide, doxorubicin and cytosine arabinoside were the drugs most frequently used in association with G-CSF for a total of 47 courses.	Cyclophosphamide	28-44	colony stimulating factor 3	Homo sapiens	150-155
9845529-5	1998	hG-CSF also had stimulatory effects on the formation of blast cell colonies in cultures using 5-fluorouracil-resistant hematopoietic progenitors and clone-sorted Lin-c-Kit+Sca-1(+) primitive hematopoietic cells.	Fluorouracil	94-108	colony stimulating factor 3	Homo sapiens	0-6
9862674-1	1998	In a manner similar to many other cytokines, treatment of cells with granulocyte CSF (G-CSF) has been shown to induce the tyrosine phosphorylation of the STAT proteins.	Tyrosine	122-130	colony stimulating factor 3	Homo sapiens	81-91
9862674-2	1998	Activation of Stat1 and Stat5 by G-CSF requires the membrane-proximal cytoplasmic domain of the receptor, including box1 and box2, while G-CSF-stimulated tyrosine phosphorylation of Stat3 also requires a region distal to box 2.	Tyrosine	154-162	colony stimulating factor 3	Homo sapiens	137-142
9989882-3	1998	As mobilising chemotherapy, cyclophosphamide, etoposide, doxorubicin and cytosine arabinoside were the drugs most frequently used in association with G-CSF for a total of 47 courses.	Etoposide	46-55	colony stimulating factor 3	Homo sapiens	150-155
9989882-3	1998	As mobilising chemotherapy, cyclophosphamide, etoposide, doxorubicin and cytosine arabinoside were the drugs most frequently used in association with G-CSF for a total of 47 courses.	Doxorubicin	57-68	colony stimulating factor 3	Homo sapiens	150-155
9989882-3	1998	As mobilising chemotherapy, cyclophosphamide, etoposide, doxorubicin and cytosine arabinoside were the drugs most frequently used in association with G-CSF for a total of 47 courses.	Cytarabine	73-93	colony stimulating factor 3	Homo sapiens	150-155
9850026-5	1998	Escalated BEACOPP uses higher doses of cyclophosphamide, doxorubicin, and etoposide with granulocyte colony-stimulating factor (G-CSF) support.	BEACOPP protocol	10-17	colony stimulating factor 3	Homo sapiens	89-126
9885444-4	1998	Hematological complications of mesalazine are rare, but if bone marrow suppression is detected, immediate cessation of the drug and intensive immunosuppressive treatment with G-CSF should be considered.	Mesalamine	31-41	colony stimulating factor 3	Homo sapiens	175-180
9887248-2	1998	The purpose of this phase I study was to determine the maximal dose of doxorubicin that could be added to standard doses of paclitaxel and cisplatin with G-CSF support.	Doxorubicin	71-82	colony stimulating factor 3	Homo sapiens	154-159
9887248-2	1998	The purpose of this phase I study was to determine the maximal dose of doxorubicin that could be added to standard doses of paclitaxel and cisplatin with G-CSF support.	Cisplatin	139-148	colony stimulating factor 3	Homo sapiens	154-159
9885438-7	1998	The results of the immunoprecipitation studies showed tyrosine phosphorylation of signal transducers and activators of transcription (Stat) 5 induced by G-CSF, GM-CSF, IL-3 and/or TPO in six cases, that of extracellular signal-regulated kinase (ERK) by GM-CSF in two cases and that of p38 by TNF in three cases.	Tyrosine	54-62	colony stimulating factor 3	Homo sapiens	153-158
9885444-0	1998	Mesalazine-associated severe aplastic anemia successfully treated with antithymocyte globulin, cyclosporine and granulocyte colony-stimulating factor.	Mesalamine	0-10	colony stimulating factor 3	Homo sapiens	112-149
9850026-5	1998	Escalated BEACOPP uses higher doses of cyclophosphamide, doxorubicin, and etoposide with granulocyte colony-stimulating factor (G-CSF) support.	BEACOPP protocol	10-17	colony stimulating factor 3	Homo sapiens	128-133
9951685-2	1998	The function of the sugar chain, accounting for approximately 4% of the molecular weight of lenograstim (and native G-CSF), is not known.	Sugars	20-25	colony stimulating factor 3	Homo sapiens	116-121
9808267-6	1998	The suppression of inducible nitric oxide synthase gene expression in L2 cells by G-CSF may represent a beneficial counterregulatory effect on excessive NO synthesis induced by proinflammatory cytokines in the lung.	nitric	29-35	colony stimulating factor 3	Homo sapiens	82-87
9787189-3	1998	Because G-CSF has been shown to induce osteoporosis in patients with congenital neutropenia and in G-CSF-overexpressing transgenic mice, we hypothesized that short-term G-CSF administration may be sufficient to induce bone resorption, resulting in the release of soluble calcium in the endosteum leading in turn to the inhibition of attachment to fibronectin and the egress of HPC from the BM.	Calcium	271-278	colony stimulating factor 3	Homo sapiens	8-13
10028846-8	1998	In vitro cultures of peroxidase-negative CML blastic cells revealed that G-CSF stimulated the induction of blastic cells into the cell cycle and that blastic cell apoptosis was more pronounced in cells cultured with G-CSF plus Ara-C than with G-CSF or Ara-C alone.	Cytarabine	252-257	colony stimulating factor 3	Homo sapiens	216-221
10028846-8	1998	In vitro cultures of peroxidase-negative CML blastic cells revealed that G-CSF stimulated the induction of blastic cells into the cell cycle and that blastic cell apoptosis was more pronounced in cells cultured with G-CSF plus Ara-C than with G-CSF or Ara-C alone.	Cytarabine	252-257	colony stimulating factor 3	Homo sapiens	216-221
9849692-4	1998	PBPC were mobilized from 18 patients using cyclophosphamide (4.5 g/m2) and G-CSF (10 microg/kg/day).	PbPc	0-4	colony stimulating factor 3	Homo sapiens	75-80
9849693-15	1998	For patients with an adequately mobilized PBPC graft, the initiation of G-CSF can be delayed until day +7 post-PBPC reinfusion.	PbPc	42-46	colony stimulating factor 3	Homo sapiens	72-77
10080674-5	1998	A hematopoietic growth factor (G-CSF) was used only for patients reaching codified nadir count values.	nadir	83-88	colony stimulating factor 3	Homo sapiens	31-36
9736531-2	1998	The present study was designed to investigate the effect of human recombinant granulocyte colony-stimulating factor (G-CSF), which is reported to be beneficial in experimental models of inflammation, on the pharmacokinetics and biliary excretion of CPZ in rats.	Cefoperazone	249-252	colony stimulating factor 3	Homo sapiens	78-115
9797080-0	1998	Granulocyte colony-stimulating factor shortens duration of critical neutropenia and prolongs disease-free survival after sequential high-dose cytosine arabinoside and mitoxantrone (S-HAM) salvage therapy for refractory and relapsed acute myeloid leukemia.	Cytarabine	142-162	colony stimulating factor 3	Homo sapiens	0-37
9797080-0	1998	Granulocyte colony-stimulating factor shortens duration of critical neutropenia and prolongs disease-free survival after sequential high-dose cytosine arabinoside and mitoxantrone (S-HAM) salvage therapy for refractory and relapsed acute myeloid leukemia.	Mitoxantrone	167-179	colony stimulating factor 3	Homo sapiens	0-37
9764585-1	1998	High-dose etoposide (2.0-2.4 g m(-2)) with granulocyte colony-stimulating factor (G-CSF) is an effective strategy to mobilize peripheral blood progenitor cells (PBPCs), although in some patients this is associated with significant toxicity.	Etoposide	10-19	colony stimulating factor 3	Homo sapiens	43-80
9764585-1	1998	High-dose etoposide (2.0-2.4 g m(-2)) with granulocyte colony-stimulating factor (G-CSF) is an effective strategy to mobilize peripheral blood progenitor cells (PBPCs), although in some patients this is associated with significant toxicity.	Etoposide	10-19	colony stimulating factor 3	Homo sapiens	82-87
9764585-11	1998	These data suggest that high-dose etoposide with G-CSF is an efficient mobilization regimen in the majority of heavily pretreated patients, including those who have previously failed on high-dose cyclophosphamide with G-CSF.	Etoposide	34-43	colony stimulating factor 3	Homo sapiens	49-54
9764585-11	1998	These data suggest that high-dose etoposide with G-CSF is an efficient mobilization regimen in the majority of heavily pretreated patients, including those who have previously failed on high-dose cyclophosphamide with G-CSF.	Etoposide	34-43	colony stimulating factor 3	Homo sapiens	218-223
9846011-1	1998	Tumor necrosis factor (TNF), granulocyte-macrophage colony-stimulating factor (GM-CSF) and granulocyte colony-stimulating factor (G-CSF) rapidly primed human neutrophils for enhanced superoxide (O2-) release, and membrane depolarization stimulated by chemotactic peptide (N-formyl-methionyl-leucyl-phenylalanine), interleukin 8, concanavalin A (Con A) and ionomycin.	Superoxides	183-193	colony stimulating factor 3	Homo sapiens	91-128
9846011-1	1998	Tumor necrosis factor (TNF), granulocyte-macrophage colony-stimulating factor (GM-CSF) and granulocyte colony-stimulating factor (G-CSF) rapidly primed human neutrophils for enhanced superoxide (O2-) release, and membrane depolarization stimulated by chemotactic peptide (N-formyl-methionyl-leucyl-phenylalanine), interleukin 8, concanavalin A (Con A) and ionomycin.	Superoxides	183-193	colony stimulating factor 3	Homo sapiens	130-135
9846011-1	1998	Tumor necrosis factor (TNF), granulocyte-macrophage colony-stimulating factor (GM-CSF) and granulocyte colony-stimulating factor (G-CSF) rapidly primed human neutrophils for enhanced superoxide (O2-) release, and membrane depolarization stimulated by chemotactic peptide (N-formyl-methionyl-leucyl-phenylalanine), interleukin 8, concanavalin A (Con A) and ionomycin.	Superoxides	195-197	colony stimulating factor 3	Homo sapiens	91-128
9846011-1	1998	Tumor necrosis factor (TNF), granulocyte-macrophage colony-stimulating factor (GM-CSF) and granulocyte colony-stimulating factor (G-CSF) rapidly primed human neutrophils for enhanced superoxide (O2-) release, and membrane depolarization stimulated by chemotactic peptide (N-formyl-methionyl-leucyl-phenylalanine), interleukin 8, concanavalin A (Con A) and ionomycin.	Superoxides	195-197	colony stimulating factor 3	Homo sapiens	130-135
9846011-1	1998	Tumor necrosis factor (TNF), granulocyte-macrophage colony-stimulating factor (GM-CSF) and granulocyte colony-stimulating factor (G-CSF) rapidly primed human neutrophils for enhanced superoxide (O2-) release, and membrane depolarization stimulated by chemotactic peptide (N-formyl-methionyl-leucyl-phenylalanine), interleukin 8, concanavalin A (Con A) and ionomycin.	Ionomycin	356-365	colony stimulating factor 3	Homo sapiens	91-128
9846011-1	1998	Tumor necrosis factor (TNF), granulocyte-macrophage colony-stimulating factor (GM-CSF) and granulocyte colony-stimulating factor (G-CSF) rapidly primed human neutrophils for enhanced superoxide (O2-) release, and membrane depolarization stimulated by chemotactic peptide (N-formyl-methionyl-leucyl-phenylalanine), interleukin 8, concanavalin A (Con A) and ionomycin.	Ionomycin	356-365	colony stimulating factor 3	Homo sapiens	130-135
9736531-2	1998	The present study was designed to investigate the effect of human recombinant granulocyte colony-stimulating factor (G-CSF), which is reported to be beneficial in experimental models of inflammation, on the pharmacokinetics and biliary excretion of CPZ in rats.	Cefoperazone	249-252	colony stimulating factor 3	Homo sapiens	117-122
9805386-1	1998	In an attempt to generate a stable non-glycosylated cytokine receptor homology (CRH) domain (Tyr97-Ala309) of human granulocyte-colony stimulating factor (G-CSF) receptor, two free cysteines in the CRH domain were converted to serine by site-directed mutagenesis.	Serine	227-233	colony stimulating factor 3	Homo sapiens	116-153
9716583-8	1998	The patients assigned to receive G-CSF had a higher CR rate and fewer deaths during remission induction than did those receiving placebo (P = .04 by the chi-square test for trend).	Chromium	52-54	colony stimulating factor 3	Homo sapiens	33-38
9728932-9	1998	We conclude that mobilization by cyclophosphamide plus G-CSF leads to a lower number of malignant cells per CD34+ cell in LPs compared with G-CSF alone.	lps	122-125	colony stimulating factor 3	Homo sapiens	55-60
9777888-7	1998	G-CSF produced higher CR rates but had no effect on survival or disease-free survival.	Chromium	22-24	colony stimulating factor 3	Homo sapiens	0-5
9728932-4	1998	We analyzed the percentage of malignant cells and the number of CD34+ PBSCs in LPs mobilized by granulocyte colony-stimulating factor (G-CSF) alone (LP-S) compared with high-dose cyclophosphamide plus G-CSF (LP-CY) in patients with multiple myeloma (MM).	lps	79-82	colony stimulating factor 3	Homo sapiens	96-133
9728932-4	1998	We analyzed the percentage of malignant cells and the number of CD34+ PBSCs in LPs mobilized by granulocyte colony-stimulating factor (G-CSF) alone (LP-S) compared with high-dose cyclophosphamide plus G-CSF (LP-CY) in patients with multiple myeloma (MM).	lps	79-82	colony stimulating factor 3	Homo sapiens	135-140
9728567-0	1998	Inhibition of neutrophil apoptosis and modulation of the inflammatory response by granulocyte colony-stimulating factor in healthy and ethanol-treated human volunteers.	Ethanol	135-142	colony stimulating factor 3	Homo sapiens	82-119
9803142-5	1998	In the second case we report the use of granulocyte colony-stimulating factor (G-CSF) for treatment of a patient with methimazole-induced granulocytopenia.	Methimazole	118-129	colony stimulating factor 3	Homo sapiens	40-77
9803142-5	1998	In the second case we report the use of granulocyte colony-stimulating factor (G-CSF) for treatment of a patient with methimazole-induced granulocytopenia.	Methimazole	118-129	colony stimulating factor 3	Homo sapiens	79-84
9777751-0	1998	Methimazole-induced aplastic anemia in third exposure: successful treatment with recombinant human granulocyte colony-stimulating factor.	Methimazole	0-11	colony stimulating factor 3	Homo sapiens	99-136
9694504-5	1998	The effects of TPO, EPO, and G-CSF on Mks, erythrocytes, and granulocytes, respectively, were dependent on the O2 tension.	Oxygen	111-113	colony stimulating factor 3	Homo sapiens	29-34
9708936-2	1998	BACKGROUND: The purpose of this study was to analyze whether the addition of granulocyte-colony stimulating factor (G-CSF) to platinum-based combination chemotherapy could increase platinum dose intensity and response rates and decrease hematologic toxicity in patients with advanced epithelial ovarian carcinoma.	Platinum	181-189	colony stimulating factor 3	Homo sapiens	77-114
9708936-2	1998	BACKGROUND: The purpose of this study was to analyze whether the addition of granulocyte-colony stimulating factor (G-CSF) to platinum-based combination chemotherapy could increase platinum dose intensity and response rates and decrease hematologic toxicity in patients with advanced epithelial ovarian carcinoma.	Platinum	181-189	colony stimulating factor 3	Homo sapiens	116-121
9708936-11	1998	CONCLUSIONS; The addition of G-CSF to this platinum-based chemotherapy regimen in patients with advanced ovarian carcinoma resulted in a modest increment in platinum dose intensity and appeared to reduce the incidence of Grade 3-4 neutropenia.	Platinum	43-51	colony stimulating factor 3	Homo sapiens	29-34
9708936-11	1998	CONCLUSIONS; The addition of G-CSF to this platinum-based chemotherapy regimen in patients with advanced ovarian carcinoma resulted in a modest increment in platinum dose intensity and appeared to reduce the incidence of Grade 3-4 neutropenia.	Platinum	157-165	colony stimulating factor 3	Homo sapiens	29-34
9731855-5	1998	RESULTS: Culture in the presence of ethanol, lipopolysaccharide, or lipopolysaccharide and ethanol resulted in the increased transcription and secretion of granulocyte colony-stimulating factor, regulated on activation normal T cell expressed and secreted, and interleukin-6 at significantly greater levels (P &lt; .01) than control cultures.	Ethanol	36-43	colony stimulating factor 3	Homo sapiens	156-193
9731855-5	1998	RESULTS: Culture in the presence of ethanol, lipopolysaccharide, or lipopolysaccharide and ethanol resulted in the increased transcription and secretion of granulocyte colony-stimulating factor, regulated on activation normal T cell expressed and secreted, and interleukin-6 at significantly greater levels (P &lt; .01) than control cultures.	Ethanol	91-98	colony stimulating factor 3	Homo sapiens	156-193
9777269-4	1998	These findings suggest the possibility of IL-3/G-CSF/cytosine arabinoside (Ara-C) combination therapy, which may be able to enhance the cytotoxic effect of Ara-C on AML progenitor cells powerfully in a wider range of patients including cases refractory for IL-3/Ara-C combination therapy.	Cytarabine	53-73	colony stimulating factor 3	Homo sapiens	47-52
9777269-4	1998	These findings suggest the possibility of IL-3/G-CSF/cytosine arabinoside (Ara-C) combination therapy, which may be able to enhance the cytotoxic effect of Ara-C on AML progenitor cells powerfully in a wider range of patients including cases refractory for IL-3/Ara-C combination therapy.	Cytarabine	75-80	colony stimulating factor 3	Homo sapiens	47-52
9777269-4	1998	These findings suggest the possibility of IL-3/G-CSF/cytosine arabinoside (Ara-C) combination therapy, which may be able to enhance the cytotoxic effect of Ara-C on AML progenitor cells powerfully in a wider range of patients including cases refractory for IL-3/Ara-C combination therapy.	Cytarabine	156-161	colony stimulating factor 3	Homo sapiens	47-52
9777269-4	1998	These findings suggest the possibility of IL-3/G-CSF/cytosine arabinoside (Ara-C) combination therapy, which may be able to enhance the cytotoxic effect of Ara-C on AML progenitor cells powerfully in a wider range of patients including cases refractory for IL-3/Ara-C combination therapy.	Cytarabine	156-161	colony stimulating factor 3	Homo sapiens	47-52
9710433-0	1998	Granulocyte colony-stimulating factor administration to HIV-infected subjects augments reduced leukotriene synthesis and anticryptococcal activity in neutrophils.	Leukotrienes	95-106	colony stimulating factor 3	Homo sapiens	0-37
9692399-7	1998	We report a patient with my+Ph+ALL in whom the administration of G-CSF after high-dose Cytarabin and Mitoxantrone led to a significant mobilization of leukemic cells and contamination of the stem cell harvest during cytologic marrow remission.	Cytarabine	87-96	colony stimulating factor 3	Homo sapiens	65-70
9692399-7	1998	We report a patient with my+Ph+ALL in whom the administration of G-CSF after high-dose Cytarabin and Mitoxantrone led to a significant mobilization of leukemic cells and contamination of the stem cell harvest during cytologic marrow remission.	Mitoxantrone	101-113	colony stimulating factor 3	Homo sapiens	65-70
9722065-7	1998	Upon hematologic recovery, a second G-CSF mobilized non-T cell-depleted peripheral stem cell transplant from the same donor was given after pretransplant conditioning with busulphan and cyclophosphamide.	Cyclophosphamide	186-202	colony stimulating factor 3	Homo sapiens	36-41
9722289-0	1998	IDA-FLAG (idarubicin, fludarabine, cytarabine, G-CSF), an effective remission-induction therapy for poor-prognosis AML of childhood prior to allogeneic or autologous bone marrow transplantation: experiences of a phase II trial.	ida-flag	0-8	colony stimulating factor 3	Homo sapiens	47-52
9722310-2	1998	From the two-dimensional gel electrophoresis analysis of phosphoproteins, a 45 kD phosphoprotein in the cytosolic fraction of DMSO-pretreated HL-60 cells was rapidly dephosphorylated by the addition of G-CSF.	Dimethyl Sulfoxide	126-130	colony stimulating factor 3	Homo sapiens	202-207
9722310-5	1998	Phosphoamino acid analysis showed that only serine residue of 45 kD phosphoprotein was phosphorylated, suggesting that G-CSF induced an activation of serine phosphatase.	Phosphoamino Acids	0-17	colony stimulating factor 3	Homo sapiens	119-124
9722310-5	1998	Phosphoamino acid analysis showed that only serine residue of 45 kD phosphoprotein was phosphorylated, suggesting that G-CSF induced an activation of serine phosphatase.	Serine	44-50	colony stimulating factor 3	Homo sapiens	119-124
9694504-9	1998	In contrast, approximately twice as many CD15+ cells were produced in G-CSF-containing cultures under 5% vs. 20%) O2.	Oxygen	114-116	colony stimulating factor 3	Homo sapiens	70-75
9694504-10	1998	The numbers of CFU-Mk in TPO-containing and CFU-GM in G-CSF-containing cultures were larger under 5% O2.	gm	48-50	colony stimulating factor 3	Homo sapiens	54-59
9694504-10	1998	The numbers of CFU-Mk in TPO-containing and CFU-GM in G-CSF-containing cultures were larger under 5% O2.	Oxygen	101-103	colony stimulating factor 3	Homo sapiens	54-59
9694504-12	1998	Our data also suggest that TPO, EPO, and G-CSF elicit stimulatory cross-lineage effects in the presence of IL-3 and SCF, and that these effects, too, are often dependent on O2 tension.	Oxygen	173-175	colony stimulating factor 3	Homo sapiens	41-46
9726439-5	1998	G-CSF treatment of granulocytic precursor cell lines (HL-60, NFS-60, KG-1) resulted in PKA activation, measured by phosphorylation of Kemptide, a peptide substrate.	kemptide	134-142	colony stimulating factor 3	Homo sapiens	0-5
9720473-0	1998	A dose finding study for the combination of epidoxorubicin and vinorelbine, delivered every two weeks with G-CSF support, in advanced breast cancer.	Epirubicin	44-58	colony stimulating factor 3	Homo sapiens	107-112
9720473-0	1998	A dose finding study for the combination of epidoxorubicin and vinorelbine, delivered every two weeks with G-CSF support, in advanced breast cancer.	Vinorelbine	63-74	colony stimulating factor 3	Homo sapiens	107-112
9726439-7	1998	H-89, a specific inhibitor of PKA, blocked G-CSF-induced PKA activation in HL-60 cells but did not affect ligand-induced downmodulation of G-CSF-R.	N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide	0-4	colony stimulating factor 3	Homo sapiens	43-48
9681085-6	1998	Paclitaxel doses of 175 mg/m2 and 150 mg/m2 produced dose-limiting myelosuppression, and the RPTD was determined to be paclitaxel 135 mg/m2 with ifosfamide 1.2 g/m2/day on days 1-3 and vinorelbine 20 mg/m2/ day on days 1-3 with G-CSF support.	Paclitaxel	0-10	colony stimulating factor 3	Homo sapiens	228-233
9711905-10	1998	Phosphopeptide affinity and phosphopeptide inhibition studies indicate that Stat3alpha and Stat3beta are recruited to the G-CSF receptor complex through their interaction with the receptor at phosphotyrosines Y704 and Y744.	Phosphotyrosine	192-208	colony stimulating factor 3	Homo sapiens	122-127
9711921-0	1998	A phase I trial of standard and cyclophosphamide dose-escalated CHOP with granulocyte colony stimulating factor in elderly patients with non-Hodgkin"s lymphoma.	Cyclophosphamide	32-48	colony stimulating factor 3	Homo sapiens	74-111
9711921-1	1998	The purpose of this study was to assess the safety and feasibility of using standard and escalated doses of cyclophosphamide with doxorubicin, vincristine and prednisone (CHOP) plus granulocyte colony stimulating factor (G-CSF) to treat elderly patients who have advanced stage intermediate grade lymphoma.	Cyclophosphamide	108-124	colony stimulating factor 3	Homo sapiens	221-226
9626789-1	1998	The authors evaluated the novel chemotherapeutic regimen of paclitaxel (Taxol, Bristol-Myers Squibb, Princeton, NJ, U.S.A.) plus doxorubicin plus filgrastim--a granulocyte colony-stimulating factor (G-CSF)--in advanced or metastatic sarcoma.	Paclitaxel	60-70	colony stimulating factor 3	Homo sapiens	160-197
9662268-6	1998	We evaluated 5-FU-treated human CD34+ PBSC proliferation in cultures with Epo, G-CSF, and IL-3, in the presence or absence of IL-12.	Fluorouracil	13-17	colony stimulating factor 3	Homo sapiens	79-84
9662268-8	1998	However, in cultures of 5-FU-treated human CD34+ cells, the most efficient combination was IL-3 + Epo + G-CSF + Accessory cells (CD34-).	Fluorouracil	24-28	colony stimulating factor 3	Homo sapiens	104-109
9661038-0	1998	Inhibitory effect of erythromycin on superoxide anion production by human neutrophils primed with granulocyte-colony stimulating factor.	Erythromycin	21-33	colony stimulating factor 3	Homo sapiens	98-135
9661038-0	1998	Inhibitory effect of erythromycin on superoxide anion production by human neutrophils primed with granulocyte-colony stimulating factor.	Superoxides	37-53	colony stimulating factor 3	Homo sapiens	98-135
9696194-4	1998	We aim to determine if G-CSF administration is associated with improved survival in patients with DMAC in a retrospective, cohort study.	dimethylacetamide	98-102	colony stimulating factor 3	Homo sapiens	23-28
9696194-9	1998	In the subgroup treated with clarithromycin, G-CSF was also associated with increased survival (377 days vs 252 days, P&lt;0.01).	Clarithromycin	29-43	colony stimulating factor 3	Homo sapiens	45-50
9696194-10	1998	Cox proportional hazards model showed a decreased risk of death in patients treated with G-CSF (RH=0.22, P&lt;0.01), clarithromycin (RH=0.13, P&lt;0.01) and ethambutol (RH=0.51, P=0.02).	Ethambutol	157-167	colony stimulating factor 3	Homo sapiens	89-94
9696194-13	1998	Addition of G-CSF to a regimen of clarithromycin and ethambutol may increase survival in DMAC and should be studied prospectively.	Clarithromycin	34-48	colony stimulating factor 3	Homo sapiens	12-17
9696194-13	1998	Addition of G-CSF to a regimen of clarithromycin and ethambutol may increase survival in DMAC and should be studied prospectively.	Ethambutol	53-63	colony stimulating factor 3	Homo sapiens	12-17
9696194-13	1998	Addition of G-CSF to a regimen of clarithromycin and ethambutol may increase survival in DMAC and should be studied prospectively.	dimethylacetamide	89-93	colony stimulating factor 3	Homo sapiens	12-17
11189514-2	1998	METHODS: The modulation effect of granulocyte-colony stimulating factor(G-CSF) on the mdr1 gene expression in AML cells was studied in vitro by using polymerase chain reaction(PCR), in vitro cell culture, immunocytochemical and MTT assays.	monooxyethylene trimethylolpropane tristearate	228-231	colony stimulating factor 3	Homo sapiens	34-71
11189514-2	1998	METHODS: The modulation effect of granulocyte-colony stimulating factor(G-CSF) on the mdr1 gene expression in AML cells was studied in vitro by using polymerase chain reaction(PCR), in vitro cell culture, immunocytochemical and MTT assays.	monooxyethylene trimethylolpropane tristearate	228-231	colony stimulating factor 3	Homo sapiens	72-77
9645570-8	1998	For an ANC of 20000/microl or greater, the G-CSF serum level fell under the maximal in vitro stimulation threshold of 10 ng/ml within 12 h. This preliminary pharmacokinetic data seems to suggest that an ANC-adjusted G-CSF dosing schedule might improve the design of PBPC mobilization regimens.	PbPc	266-270	colony stimulating factor 3	Homo sapiens	43-48
9645570-8	1998	For an ANC of 20000/microl or greater, the G-CSF serum level fell under the maximal in vitro stimulation threshold of 10 ng/ml within 12 h. This preliminary pharmacokinetic data seems to suggest that an ANC-adjusted G-CSF dosing schedule might improve the design of PBPC mobilization regimens.	PbPc	266-270	colony stimulating factor 3	Homo sapiens	216-221
9636844-4	1998	Effector cells stimulated by such molecules (data with macrophage colony-stimulating factor, granulocyte colony-stimulating factor, and granulocyte-macrophage colony-stimulating factor with azoles are presented as examples) also have enhanced synergistic activity with antifungals.	Azoles	190-196	colony stimulating factor 3	Homo sapiens	93-184
9578604-2	1998	G-CSF enhanced O-2 generating ability of HL-60 cells whose differentiation had been initiated by dimethylsulfoxide (DMSO) or retinoic acid (RA).	Dimethyl Sulfoxide	97-114	colony stimulating factor 3	Homo sapiens	0-5
9681236-0	1998	Severe bactrim-induced neutropenia with reversal of CD4+/CD8+ lymphocyte ratio: response to recombinant human granulocyte-colony stimulating factor (R-metHUG-CSF).	Trimethoprim, Sulfamethoxazole Drug Combination	7-14	colony stimulating factor 3	Homo sapiens	110-147
9590144-1	1998	We sought to determine the role of granulocyte colony-stimulating factor (G-CSF) as an adjunct therapy in high-dose cytarabine-containing chemotherapy (HD C/T) for children with acute leukemia.	Cytarabine	116-126	colony stimulating factor 3	Homo sapiens	35-72
9590144-1	1998	We sought to determine the role of granulocyte colony-stimulating factor (G-CSF) as an adjunct therapy in high-dose cytarabine-containing chemotherapy (HD C/T) for children with acute leukemia.	Cytarabine	116-126	colony stimulating factor 3	Homo sapiens	74-79
9590144-5	1998	Prophylactic G-CSF was given in 57 courses (Group B) as 200 microg/m2/d SC started one day after the completion of HD C/T and continued until the neutrophil recovery was maintained.	Arsenic	20-22	colony stimulating factor 3	Homo sapiens	13-18
9590146-4	1998	Based on these observations, we administered recombinant human G-CSF to a patient with APL in the third relapse that was resistant to both cytotoxic agents and all trans retinoic acid, in an attempt to sensitize the leukemic cells to cell-cycle-dependent agents.	Tretinoin	170-183	colony stimulating factor 3	Homo sapiens	63-68
9578604-2	1998	G-CSF enhanced O-2 generating ability of HL-60 cells whose differentiation had been initiated by dimethylsulfoxide (DMSO) or retinoic acid (RA).	Tretinoin	140-142	colony stimulating factor 3	Homo sapiens	0-5
9638581-1	1998	The oxidation of methionine residues in recombinant methionyl human granulocyte colony stimulating factor with hydrogen peroxide has been investigated.	Methionine	17-27	colony stimulating factor 3	Homo sapiens	68-105
9638581-1	1998	The oxidation of methionine residues in recombinant methionyl human granulocyte colony stimulating factor with hydrogen peroxide has been investigated.	Hydrogen Peroxide	111-128	colony stimulating factor 3	Homo sapiens	68-105
9834621-5	1998	With 50 micrograms of G-CSF, the [3H] thymidine uptake was 11,100 +/- 2,200 DPM and the control uptake was 7,970 +/- 1,820 DPM.	Tritium	34-36	colony stimulating factor 3	Homo sapiens	22-27
9834621-5	1998	With 50 micrograms of G-CSF, the [3H] thymidine uptake was 11,100 +/- 2,200 DPM and the control uptake was 7,970 +/- 1,820 DPM.	Thymidine	38-47	colony stimulating factor 3	Homo sapiens	22-27
9578604-3	1998	The O-2 generations by the differentiated HL-60 cells in response to opsonized zymosan (OZ), formyl-Met-Leu-Phe (fMLP), and IgG-coated zymosan were increased two- to fourfold as a result of incubation of the cells undergoing the differentiation with G-CSF.	Zymosan	135-142	colony stimulating factor 3	Homo sapiens	250-255
9578604-7	1998	Assuming that the signaling pathways linking OZ or fMLP receptor might be enhanced by G-CSF, alteration in the cellular sn-1, 2-diacylglycerols (DAG) level upon stimulation with OZ or fMLP was compared between the G-CSF-treated and nontreated cells.	dag	145-148	colony stimulating factor 3	Homo sapiens	86-91
9578604-8	1998	Whereas DAG level was not increased by the stimulation in the cells treated with DMSO alone, a significant increase in DAG level upon the stimulation was observed in the cells treated with G-CSF and DMSO.	dag	119-122	colony stimulating factor 3	Homo sapiens	189-194
9578604-9	1998	These results suggest that G-CSF would enhance the organization of a receptor-linked DAG generating system in the differentiating cells, leading the cells to generate more O2.	dag	85-88	colony stimulating factor 3	Homo sapiens	27-32
9578604-9	1998	These results suggest that G-CSF would enhance the organization of a receptor-linked DAG generating system in the differentiating cells, leading the cells to generate more O2.	Oxygen	172-174	colony stimulating factor 3	Homo sapiens	27-32
9578604-2	1998	G-CSF enhanced O-2 generating ability of HL-60 cells whose differentiation had been initiated by dimethylsulfoxide (DMSO) or retinoic acid (RA).	Dimethyl Sulfoxide	116-120	colony stimulating factor 3	Homo sapiens	0-5
9578604-2	1998	G-CSF enhanced O-2 generating ability of HL-60 cells whose differentiation had been initiated by dimethylsulfoxide (DMSO) or retinoic acid (RA).	Tretinoin	125-138	colony stimulating factor 3	Homo sapiens	0-5
9674019-3	1998	The patients receiving peripheral blood (PB) + G-CSF had significantly shorter median durations of antibiotic therapy, hospital stay and polymorphonucleate (PMN) recovery.	polymorphonucleate	137-155	colony stimulating factor 3	Homo sapiens	47-52
9613778-0	1998	Combination chemotherapy with mitoguazon, ifosfamide, MTX, etoposide (MIME) and G-CSF can efficiently mobilize PBPC in patients with Hodgkin"s and non-Hodgkin"s lymphoma.	PbPc	111-115	colony stimulating factor 3	Homo sapiens	80-85
9694607-0	1998	Weekly paclitaxel-cisplatin administration with G-CSF support in advanced breast cancer.	Paclitaxel	7-17	colony stimulating factor 3	Homo sapiens	48-53
9694607-0	1998	Weekly paclitaxel-cisplatin administration with G-CSF support in advanced breast cancer.	Cisplatin	18-27	colony stimulating factor 3	Homo sapiens	48-53
9694607-24	1998	CONCLUSIONS: Weekly paclitaxel and cisplatin with G-CSF support is an active and particularly well tolerated treatment for patients with either unpretreated or pretreated metastatic breast cancer.	Cisplatin	35-44	colony stimulating factor 3	Homo sapiens	50-55
9590656-1	1998	The aim of this study was to develop an inexpensive method for reducing the number of differentiated cells from granulocyte colony-stimulating factor-mobilized leukocytapheresis products (LPs) containing peripheral blood stem cells.	lps	188-191	colony stimulating factor 3	Homo sapiens	112-149
9635370-6	1998	Neutrophils isolated from patients treated with G-CSF and stimulated with PMA produced less (superoxide anion) O2- after therapy.	Superoxides	93-109	colony stimulating factor 3	Homo sapiens	48-53
9636831-4	1998	The first 89 consecutive patients who have received nine courses q three weeks of individually dose-escalated and G-CSF (filgrastim)-supported FEC (5-fluorouracil (5-FU), epirubicin, and cyclophosphamide) therapy given with ciprofloxacin prophylaxis were included in this analysis.	Fluorouracil	148-162	colony stimulating factor 3	Homo sapiens	114-119
9592981-5	1998	RESULTS: G-CSF support significantly reduced the frequency of day-1 drug dose reductions (p &lt; 0.001) and of chemotherapy delays (p &lt; 0.001), and improved the actual delivered doses of adriamycin, cyclophosphamide and etoposide (p &lt; 0.02).	Doxorubicin	190-200	colony stimulating factor 3	Homo sapiens	9-14
9592981-5	1998	RESULTS: G-CSF support significantly reduced the frequency of day-1 drug dose reductions (p &lt; 0.001) and of chemotherapy delays (p &lt; 0.001), and improved the actual delivered doses of adriamycin, cyclophosphamide and etoposide (p &lt; 0.02).	Cyclophosphamide	202-218	colony stimulating factor 3	Homo sapiens	9-14
9592981-5	1998	RESULTS: G-CSF support significantly reduced the frequency of day-1 drug dose reductions (p &lt; 0.001) and of chemotherapy delays (p &lt; 0.001), and improved the actual delivered doses of adriamycin, cyclophosphamide and etoposide (p &lt; 0.02).	Etoposide	223-232	colony stimulating factor 3	Homo sapiens	9-14
9635370-6	1998	Neutrophils isolated from patients treated with G-CSF and stimulated with PMA produced less (superoxide anion) O2- after therapy.	Superoxides	111-113	colony stimulating factor 3	Homo sapiens	48-53
9490708-11	1998	In conclusion, this method represents a simple and reproducible two-step procedure to obtain a highly efficient purging of T or B cells from G-CSF expanded and mobilized CPCs.	cytidylyl-(3'-5')-cytidine	170-174	colony stimulating factor 3	Homo sapiens	141-146
9684932-10	1998	Circulating pheripheral blood system cells PBSC in patients exposed to G-CSF for stem cell mobilization exhibited significantly increased levels of phosphotyrosine.	Phosphotyrosine	148-163	colony stimulating factor 3	Homo sapiens	71-76
9684932-11	1998	In vitro exposure of CD34+ progenitors to growth factors (G-CSF, IL-3, SCF) raised the levels of tyrosine phosphorylation in bone marrow and cord blood.	Tyrosine	97-105	colony stimulating factor 3	Homo sapiens	58-63
9528829-0	1998	Timing of recombinant human granulocyte colony-stimulating factor administration on neutropenia induced by cyclophosphamide in normal mice.	Cyclophosphamide	107-123	colony stimulating factor 3	Homo sapiens	28-65
9685943-0	1998	Polyalkylcyanoacrylate nanoparticles as carriers for granulocyte-colony stimulating factor (G-CSF).	polyalkylcyanoacrylate	0-22	colony stimulating factor 3	Homo sapiens	53-90
9685943-0	1998	Polyalkylcyanoacrylate nanoparticles as carriers for granulocyte-colony stimulating factor (G-CSF).	polyalkylcyanoacrylate	0-22	colony stimulating factor 3	Homo sapiens	92-97
9602269-14	1998	CONCLUSIONS: The docetaxel-cisplatin combination is an active regimen in advanced NSCLC, but hematologic toxicity remains high despite the prophylactic use of G-CSF.	Docetaxel	17-26	colony stimulating factor 3	Homo sapiens	159-164
9602269-14	1998	CONCLUSIONS: The docetaxel-cisplatin combination is an active regimen in advanced NSCLC, but hematologic toxicity remains high despite the prophylactic use of G-CSF.	Cisplatin	27-36	colony stimulating factor 3	Homo sapiens	159-164
9506771-2	1998	The mechanisms for these effects however are not fully elucidated, but it has been demonstrated that dexamethasone enhances release of colony stimulating factor (G-CSF) in-vitro.	Dexamethasone	101-114	colony stimulating factor 3	Homo sapiens	162-167
9506771-3	1998	We therefore hypothesized, that dexamethasone may increase plasma levels of G-CSF.	Dexamethasone	32-45	colony stimulating factor 3	Homo sapiens	76-81
9506771-6	1998	The low dose of dexamethasone increased G-CSF levels from a baseline of 15.5 ng/L (CI: 10.6-20.4) by 240% (CI: 115-366%) at 24 hours.	Dexamethasone	16-29	colony stimulating factor 3	Homo sapiens	40-45
9506771-7	1998	The high dexamethasone dose increased G-CSF levels from a baseline of 12.3 ng/L (CI: 9.7-14.9) by 871% (CI: 592-1149%) at 24 hours (p=0.008 for all comparisons).	Dexamethasone	9-22	colony stimulating factor 3	Homo sapiens	38-43
9506771-10	1998	In conclusion, dexamethasone dose dependently increases G-CSF levels in healthy men, an effect which may account for some of its effects on neutrophils.	Dexamethasone	15-28	colony stimulating factor 3	Homo sapiens	56-61
9535207-5	1998	The three-drug regimen of vinorelbine, paclitaxel, and ifosfamide with granulocyte colony-stimulating factor was evaluated in a phase I trial.	Ifosfamide	55-65	colony stimulating factor 3	Homo sapiens	71-108
9619915-6	1998	In contrast to ATRA, GCSF increased Gm colony size but not numbers in semi-solid cultures of normal marrow MNC, which suggests the cytokine augments post-progenitor amplification.	gm	36-38	colony stimulating factor 3	Homo sapiens	21-25
9476927-0	1998	Diffuse bony uptake of thallium-201-chloride in the granulocyte colony-stimulating factor-producing lung carcinoma.	thallium chloride	23-44	colony stimulating factor 3	Homo sapiens	52-89
9613979-7	1998	When compared to G-CSF only, mobilization with high dose cyclophosphamide appeared to result in superior hematopoietic stem cell collections.	Cyclophosphamide	57-73	colony stimulating factor 3	Homo sapiens	17-22
9452436-1	1998	Treatment of cells with granulocyte colony-stimulating factor (G-CSF) leads to tyrosine phosphorylation of cellular proteins.	Tyrosine	79-87	colony stimulating factor 3	Homo sapiens	24-61
9452436-1	1998	Treatment of cells with granulocyte colony-stimulating factor (G-CSF) leads to tyrosine phosphorylation of cellular proteins.	Tyrosine	79-87	colony stimulating factor 3	Homo sapiens	63-68
9452436-4	1998	G-CSF-dependent tyrosyl phosphorylation of Jak1 and Jak2 occurred in all three cell lines.	cyclo(tyrosyl-tyrosyl)	16-23	colony stimulating factor 3	Homo sapiens	0-5
9452436-5	1998	Wild-type and syk-deficient transfectants responded to G-CSF in a dose-responsive fashion with increased thymidine incorporation, but none of the clones of lyn-deficient transfectants did.	Thymidine	105-114	colony stimulating factor 3	Homo sapiens	55-60
9452436-7	1998	Ectopic expression in wild-type cells of the kinase-inactive form of Lyn, but not of the kinase-inactive form of Jak2, inhibited thymidine incorporation in response to G-CSF.	Thymidine	129-138	colony stimulating factor 3	Homo sapiens	168-173
9553662-0	1998	High-dose topotecan with granulocyte-colony stimulating factor in fluoropyrimidine-refractory colorectal cancer: a phase II and pharmacodynamic study.	Topotecan	10-19	colony stimulating factor 3	Homo sapiens	25-62
9553662-0	1998	High-dose topotecan with granulocyte-colony stimulating factor in fluoropyrimidine-refractory colorectal cancer: a phase II and pharmacodynamic study.	2-fluoropyrimidine	66-82	colony stimulating factor 3	Homo sapiens	25-62
9553662-1	1998	PURPOSE: The premise for this study was that topotecan (TPT) resistance in preclinical studies is associated with low level expression of the p-glycoprotein (Pgp) multi-drug transporter conferred by the multi-drug resistant (MDR) phenotype, which might be overcome in clinical practice by administering moderately (2.3-fold) higher doses of TPT that have shown to be feasible with granulocyte colony-stimulating factor (G-CSF) support.	Topotecan	45-54	colony stimulating factor 3	Homo sapiens	381-418
9553662-1	1998	PURPOSE: The premise for this study was that topotecan (TPT) resistance in preclinical studies is associated with low level expression of the p-glycoprotein (Pgp) multi-drug transporter conferred by the multi-drug resistant (MDR) phenotype, which might be overcome in clinical practice by administering moderately (2.3-fold) higher doses of TPT that have shown to be feasible with granulocyte colony-stimulating factor (G-CSF) support.	Topotecan	45-54	colony stimulating factor 3	Homo sapiens	420-425
9553662-1	1998	PURPOSE: The premise for this study was that topotecan (TPT) resistance in preclinical studies is associated with low level expression of the p-glycoprotein (Pgp) multi-drug transporter conferred by the multi-drug resistant (MDR) phenotype, which might be overcome in clinical practice by administering moderately (2.3-fold) higher doses of TPT that have shown to be feasible with granulocyte colony-stimulating factor (G-CSF) support.	Topotecan	56-59	colony stimulating factor 3	Homo sapiens	381-418
9553662-1	1998	PURPOSE: The premise for this study was that topotecan (TPT) resistance in preclinical studies is associated with low level expression of the p-glycoprotein (Pgp) multi-drug transporter conferred by the multi-drug resistant (MDR) phenotype, which might be overcome in clinical practice by administering moderately (2.3-fold) higher doses of TPT that have shown to be feasible with granulocyte colony-stimulating factor (G-CSF) support.	Topotecan	56-59	colony stimulating factor 3	Homo sapiens	420-425
9553662-5	1998	This dose of TPT was previously determined to be the maximal tolerated dose (MTD) with G-CSF support in a phase I study involving solid tumor patients with similar risk factors for myelosuppression.	Topotecan	13-16	colony stimulating factor 3	Homo sapiens	87-92
9553662-16	1998	Total TPT exposure was significantly higher than drug exposure achieved in similar patients at an identical dose in a previous phase I study of TPT and G-CSF, which may explain why more severe myelosuppressive effects occurred in the present study.	Topotecan	6-9	colony stimulating factor 3	Homo sapiens	152-157
9469365-0	1998	Phase I study of concomitant chemoradiotherapy with paclitaxel, fluorouracil, and hydroxyurea with granulocyte colony-stimulating factor support for patients with poor-prognosis cancer of the head and neck.	Hydroxyurea	82-93	colony stimulating factor 3	Homo sapiens	99-136
9450813-0	1998	Megakaryocyte progenitors derived from bone marrow or G-CSF-mobilized peripheral blood CD34 cells show a distinct phenotype and responsiveness to interleukin-3 (IL-3) and PEG-recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF).	Polyethylene Glycols	171-174	colony stimulating factor 3	Homo sapiens	54-59
9763108-2	1998	To pursue this possibility we evaluated the effect of 4-hydroperoxycyclophosphamide (4-HC) treatment on granulocyte colony-stimulating factor-mobilized peripheral blood stem cells (G-PBSC) and their subsequent expansion potential.	perfosfamide	54-83	colony stimulating factor 3	Homo sapiens	104-141
9763108-2	1998	To pursue this possibility we evaluated the effect of 4-hydroperoxycyclophosphamide (4-HC) treatment on granulocyte colony-stimulating factor-mobilized peripheral blood stem cells (G-PBSC) and their subsequent expansion potential.	perfosfamide	85-89	colony stimulating factor 3	Homo sapiens	104-141
9464244-4	1998	Pretreatment with phorbol ester, IL-1 beta, or IFN-gamma increased the level of G-CSF, GM-CSF, and M-CSF in KU-19-19 CM.	Phorbol Esters	18-31	colony stimulating factor 3	Homo sapiens	80-85
9528719-9	1998	Multivariate analysis using Cox Proportional Hazards Model showed decreased risk of death in patients treated with G-CSF, ARs, PCPP.	polybis(carbophenoxypropane)	127-131	colony stimulating factor 3	Homo sapiens	115-120
9763108-0	1998	Ex vivo expansion of immature 4-hydroperoxycyclophosphamide-resistant progenitor cells from G-CSF-mobilized peripheral blood.	perfosfamide	30-59	colony stimulating factor 3	Homo sapiens	92-97
9685063-11	1998	We conclude that G-CSF and IL-3 augment the effect of daunorubicin on normal hematopoietic progenitor cells.	Daunorubicin	54-66	colony stimulating factor 3	Homo sapiens	17-22
9534838-0	1998	Treatment of severe clozapine-induced neutropenia with granulocyte colony-stimulating factor (G-CSF).	Clozapine	20-29	colony stimulating factor 3	Homo sapiens	55-92
9534838-0	1998	Treatment of severe clozapine-induced neutropenia with granulocyte colony-stimulating factor (G-CSF).	Clozapine	20-29	colony stimulating factor 3	Homo sapiens	94-99
9523740-1	1998	PURPOSE: To investigate the effect of granulocyte colony-stimulating factor (G-CSF) on the pharmacokinetics and pharmacodynamics of the new morpholino anthracycline drug MX2.	Anthracyclines	151-164	colony stimulating factor 3	Homo sapiens	38-75
9523740-1	1998	PURPOSE: To investigate the effect of granulocyte colony-stimulating factor (G-CSF) on the pharmacokinetics and pharmacodynamics of the new morpholino anthracycline drug MX2.	Anthracyclines	151-164	colony stimulating factor 3	Homo sapiens	77-82
9689553-0	1998	Methylprednisolone-induced neutrophil leukocytosis--down-modulation of neutrophil L-selectin and Mac-1 expression and induction of granulocyte-colony stimulating factor.	Methylprednisolone	0-18	colony stimulating factor 3	Homo sapiens	131-168
21494447-2	1998	Clozapineinduced agranulocytosis is reversible with the use of cytokines like granulocyte-colony stimulating factor (G-CSF).	clozapineinduced	0-16	colony stimulating factor 3	Homo sapiens	78-115
9442966-0	1998	G-CSF induced bone marrow hyperplasia: characteristic appearance on total body blood pool and delayed Tc-99m MDP bone scan.	tc-99	102-107	colony stimulating factor 3	Homo sapiens	0-5
9442966-0	1998	G-CSF induced bone marrow hyperplasia: characteristic appearance on total body blood pool and delayed Tc-99m MDP bone scan.	Acetylmuramyl-Alanyl-Isoglutamine	109-112	colony stimulating factor 3	Homo sapiens	0-5
10051965-0	1998	Effect of divalent polyethylene glycol units, conjugated on human granulocyte colony-stimulating factor, on biological activities in vitro and in vivo.	divalent polyethylene glycol	10-38	colony stimulating factor 3	Homo sapiens	66-103
10051965-1	1998	New divalent (two-chain type) polyethylene glycol (PEG) conjugates of a derivative of human recombinant granulocyte colony-stimulating factor (rhG-CSF), ND28, were synthesized by a novel conjugation method using triazine ring and amino butyric acid, and separated into mono-, di- and tri-PEG2(two chains)-ND28 with high purity of more than 90%, to examine the effect of the number of PEG units on their biological properties.	Polyethylene Glycols	30-49	colony stimulating factor 3	Homo sapiens	104-141
10051965-1	1998	New divalent (two-chain type) polyethylene glycol (PEG) conjugates of a derivative of human recombinant granulocyte colony-stimulating factor (rhG-CSF), ND28, were synthesized by a novel conjugation method using triazine ring and amino butyric acid, and separated into mono-, di- and tri-PEG2(two chains)-ND28 with high purity of more than 90%, to examine the effect of the number of PEG units on their biological properties.	Polyethylene Glycols	51-54	colony stimulating factor 3	Homo sapiens	104-141
10051965-1	1998	New divalent (two-chain type) polyethylene glycol (PEG) conjugates of a derivative of human recombinant granulocyte colony-stimulating factor (rhG-CSF), ND28, were synthesized by a novel conjugation method using triazine ring and amino butyric acid, and separated into mono-, di- and tri-PEG2(two chains)-ND28 with high purity of more than 90%, to examine the effect of the number of PEG units on their biological properties.	Triazines	212-220	colony stimulating factor 3	Homo sapiens	104-141
10051965-1	1998	New divalent (two-chain type) polyethylene glycol (PEG) conjugates of a derivative of human recombinant granulocyte colony-stimulating factor (rhG-CSF), ND28, were synthesized by a novel conjugation method using triazine ring and amino butyric acid, and separated into mono-, di- and tri-PEG2(two chains)-ND28 with high purity of more than 90%, to examine the effect of the number of PEG units on their biological properties.	Aminobutyrates	230-248	colony stimulating factor 3	Homo sapiens	104-141
10051965-1	1998	New divalent (two-chain type) polyethylene glycol (PEG) conjugates of a derivative of human recombinant granulocyte colony-stimulating factor (rhG-CSF), ND28, were synthesized by a novel conjugation method using triazine ring and amino butyric acid, and separated into mono-, di- and tri-PEG2(two chains)-ND28 with high purity of more than 90%, to examine the effect of the number of PEG units on their biological properties.	Polyethylene Glycols	288-291	colony stimulating factor 3	Homo sapiens	104-141
21494447-2	1998	Clozapineinduced agranulocytosis is reversible with the use of cytokines like granulocyte-colony stimulating factor (G-CSF).	clozapineinduced	0-16	colony stimulating factor 3	Homo sapiens	117-122
9928576-7	1998	For women with 4-9 involved nodes, sequential treatment A(doxorubicin)-T(paclitaxel)-C(cyclophosphamide) with G-CSF is being compared to AC x 4 followed by high-dose chemotherapy with stem cell support.	Cyclophosphamide	87-103	colony stimulating factor 3	Homo sapiens	110-115
9740541-1	1998	A phase I trial of a 24-hour infusion of paclitaxel was conducted to identify the maximum tolerated dose of paclitaxel with granulocyte colony-stimulating factor (G-CSF) in patients with unresectable malignancy previously untreated with chemotherapy.	Paclitaxel	41-51	colony stimulating factor 3	Homo sapiens	124-161
9740541-1	1998	A phase I trial of a 24-hour infusion of paclitaxel was conducted to identify the maximum tolerated dose of paclitaxel with granulocyte colony-stimulating factor (G-CSF) in patients with unresectable malignancy previously untreated with chemotherapy.	Paclitaxel	41-51	colony stimulating factor 3	Homo sapiens	163-168
9740541-1	1998	A phase I trial of a 24-hour infusion of paclitaxel was conducted to identify the maximum tolerated dose of paclitaxel with granulocyte colony-stimulating factor (G-CSF) in patients with unresectable malignancy previously untreated with chemotherapy.	Paclitaxel	108-118	colony stimulating factor 3	Homo sapiens	124-161
9740541-1	1998	A phase I trial of a 24-hour infusion of paclitaxel was conducted to identify the maximum tolerated dose of paclitaxel with granulocyte colony-stimulating factor (G-CSF) in patients with unresectable malignancy previously untreated with chemotherapy.	Paclitaxel	108-118	colony stimulating factor 3	Homo sapiens	163-168
9740541-5	1998	Paclitaxel can be safely administered as a 24-hour infusion at 300 mg/m2 with G-CSF.	Paclitaxel	0-10	colony stimulating factor 3	Homo sapiens	78-83
9704061-5	1997	To this end, we studied the effects of pentoxifylline on TNF- and G-CSF-induced modulation of neutrophil chemotaxis and O2 release.	Pentoxifylline	39-53	colony stimulating factor 3	Homo sapiens	66-71
9708450-10	1998	We conclude that G-CSF-combined repeated BHAC-DMP postremission therapy is feasible.	bhac-dmp	41-49	colony stimulating factor 3	Homo sapiens	17-22
9389719-0	1997	Cyclophosphamide, doxorubicin, vincristine, prednisone dose intensification with granulocyte colony-stimulating factor markedly depletes stem cell reserve for autologous bone marrow transplantation.	Cyclophosphamide	0-16	colony stimulating factor 3	Homo sapiens	81-118
9389719-0	1997	Cyclophosphamide, doxorubicin, vincristine, prednisone dose intensification with granulocyte colony-stimulating factor markedly depletes stem cell reserve for autologous bone marrow transplantation.	Doxorubicin	18-29	colony stimulating factor 3	Homo sapiens	81-118
9389719-0	1997	Cyclophosphamide, doxorubicin, vincristine, prednisone dose intensification with granulocyte colony-stimulating factor markedly depletes stem cell reserve for autologous bone marrow transplantation.	Vincristine	31-42	colony stimulating factor 3	Homo sapiens	81-118
9389719-0	1997	Cyclophosphamide, doxorubicin, vincristine, prednisone dose intensification with granulocyte colony-stimulating factor markedly depletes stem cell reserve for autologous bone marrow transplantation.	Prednisone	44-54	colony stimulating factor 3	Homo sapiens	81-118
9704061-5	1997	To this end, we studied the effects of pentoxifylline on TNF- and G-CSF-induced modulation of neutrophil chemotaxis and O2 release.	Oxygen	120-122	colony stimulating factor 3	Homo sapiens	66-71
9373271-5	1997	However, inhibition of protein synthesis with cycloheximide and actinomycin D led to loss of the 57-kD subunit even in the presence of G-CSF.	Dactinomycin	64-77	colony stimulating factor 3	Homo sapiens	135-140
9815635-4	1997	The objectives of this study were: to determine either the maximum tolerated dose of Ara-AC or to safely achieve target plasma levels of 2-5 microgram/ml when Ara-AC was administered as a 24-h infusion with granulocyte colony-stimulating factor (G-CSF) to patients with advanced refractory malignancies; to characterize the pharmacokinetic behavior of Ara-AC with G-CSF; and to define the relationship of Ara-AC pharmacokinetics to toxicity.	fazarabine	159-165	colony stimulating factor 3	Homo sapiens	207-244
9432046-0	1997	G-CSF after peripheral blood stem cell transplantation in lymphoma patients significantly accelerated neutrophil recovery and shortened time in hospital: results of a randomized BNLI trial.	bnli	178-182	colony stimulating factor 3	Homo sapiens	0-5
9815632-18	1997	We conclude that two courses of high-dose cyclophosphamide and doxorubicin using granulocyte colony-stimulating factor are feasible and safe with tolerable myocardial toxicity as evidenced by serial endomyocardial biopsies.	Cyclophosphamide	42-58	colony stimulating factor 3	Homo sapiens	81-118
9815632-18	1997	We conclude that two courses of high-dose cyclophosphamide and doxorubicin using granulocyte colony-stimulating factor are feasible and safe with tolerable myocardial toxicity as evidenced by serial endomyocardial biopsies.	Doxorubicin	63-74	colony stimulating factor 3	Homo sapiens	81-118
9815635-4	1997	The objectives of this study were: to determine either the maximum tolerated dose of Ara-AC or to safely achieve target plasma levels of 2-5 microgram/ml when Ara-AC was administered as a 24-h infusion with granulocyte colony-stimulating factor (G-CSF) to patients with advanced refractory malignancies; to characterize the pharmacokinetic behavior of Ara-AC with G-CSF; and to define the relationship of Ara-AC pharmacokinetics to toxicity.	fazarabine	159-165	colony stimulating factor 3	Homo sapiens	207-244
9815635-0	1997	Phase I and pharmacological trial of fazarabine (Ara-AC) with granulocyte colony-stimulating factor.	fazarabine	37-47	colony stimulating factor 3	Homo sapiens	62-99
9815635-4	1997	The objectives of this study were: to determine either the maximum tolerated dose of Ara-AC or to safely achieve target plasma levels of 2-5 microgram/ml when Ara-AC was administered as a 24-h infusion with granulocyte colony-stimulating factor (G-CSF) to patients with advanced refractory malignancies; to characterize the pharmacokinetic behavior of Ara-AC with G-CSF; and to define the relationship of Ara-AC pharmacokinetics to toxicity.	fazarabine	159-165	colony stimulating factor 3	Homo sapiens	207-244
9815635-0	1997	Phase I and pharmacological trial of fazarabine (Ara-AC) with granulocyte colony-stimulating factor.	fazarabine	49-55	colony stimulating factor 3	Homo sapiens	62-99
9815635-11	1997	Ara-AC can be safely administered in doses that result in plasma concentrations of 2-5 microgram/ml, if it is given with G-CSF.	fazarabine	0-6	colony stimulating factor 3	Homo sapiens	121-126
9450923-4	1997	Cells from all three sources that had been expanded ex vivo in the presence of stem cell factor (SCF), interleukin-3 (IL-3), IL-6, and granulocyte colony-stimulating factor (G-CSF) showed transduction efficiencies ranging from 5-45%, as measured by acquisition of G418 resistance.	antibiotic G 418	264-268	colony stimulating factor 3	Homo sapiens	174-179
15989586-16	1997	High-dose anticancer chemotherapy with granulocyte-colony stimulating factor (G-CSF) or autologous bone marrow transplantation has allowed the dose intensity of anthracyclines to be increased, and has improved the response rate to about 70% in selected patients with MBC.	Anthracyclines	161-175	colony stimulating factor 3	Homo sapiens	39-76
15989586-16	1997	High-dose anticancer chemotherapy with granulocyte-colony stimulating factor (G-CSF) or autologous bone marrow transplantation has allowed the dose intensity of anthracyclines to be increased, and has improved the response rate to about 70% in selected patients with MBC.	Anthracyclines	161-175	colony stimulating factor 3	Homo sapiens	78-83
9369412-8	1997	Despite the administration of granulocyte colony-stimulating factor (G-CSF), however, the white blood cell count decreased in many patients, suggesting the necessity for further study of this regimen to modify the dose of THP.	pirarubicin	222-225	colony stimulating factor 3	Homo sapiens	69-74
9367827-5	1997	Further experiments demonstrated that in THP-1 cells pretreated with PMA, Dex potently synergized with IL-1 to stimulate G-CSF production.	Tetradecanoylphorbol Acetate	69-72	colony stimulating factor 3	Homo sapiens	121-126
9367827-0	1997	Dexamethasone and interleukin-1 potently synergize to stimulate the production of granulocyte colony-stimulating factor in differentiated THP-1 cells.	Dexamethasone	0-13	colony stimulating factor 3	Homo sapiens	82-119
9367827-5	1997	Further experiments demonstrated that in THP-1 cells pretreated with PMA, Dex potently synergized with IL-1 to stimulate G-CSF production.	Dexamethasone	74-77	colony stimulating factor 3	Homo sapiens	121-126
9367827-1	1997	The human monocytic leukemic cell line, THP-1, which differentiates toward macrophages in response to phorbol 12-myristate 13-acetate (PMA) was investigated for its ability to produce granulocyte colony-stimulating factor (G-CSF).	Tetradecanoylphorbol Acetate	135-138	colony stimulating factor 3	Homo sapiens	184-221
9367827-2	1997	G-CSF protein was neither produced during PMA-induced differentiation nor in response to dexamethasone (Dex) alone.	Tetradecanoylphorbol Acetate	42-45	colony stimulating factor 3	Homo sapiens	0-5
9317171-1	1997	BACKGROUND: This Phase I/II study investigates increasingly high doses of ifosfamide combined with full dose doxorubicin chemotherapy supported with peripheral blood stem cells (PBSC) and granulocyte-colony stimulating factor (G-CSF) in patients with metastatic soft tissue sarcoma (STS).	Ifosfamide	74-84	colony stimulating factor 3	Homo sapiens	227-232
9367827-2	1997	G-CSF protein was neither produced during PMA-induced differentiation nor in response to dexamethasone (Dex) alone.	Dexamethasone	89-102	colony stimulating factor 3	Homo sapiens	0-5
9367827-2	1997	G-CSF protein was neither produced during PMA-induced differentiation nor in response to dexamethasone (Dex) alone.	Dexamethasone	104-107	colony stimulating factor 3	Homo sapiens	0-5
9367827-3	1997	However, when combined, PMA and Dex synergistically stimulated THP-1 cells to produce G-CSF.	Tetradecanoylphorbol Acetate	24-27	colony stimulating factor 3	Homo sapiens	86-91
9367827-3	1997	However, when combined, PMA and Dex synergistically stimulated THP-1 cells to produce G-CSF.	Dexamethasone	32-35	colony stimulating factor 3	Homo sapiens	86-91
9367827-4	1997	The synergistic interaction between PMA and Dex on G-CSF production appeared to be mediated through the production of interleukin-1 (IL-1) since neutralization of IL-1 activity completely inhibited G-CSF production.	Tetradecanoylphorbol Acetate	36-39	colony stimulating factor 3	Homo sapiens	51-56
9367827-4	1997	The synergistic interaction between PMA and Dex on G-CSF production appeared to be mediated through the production of interleukin-1 (IL-1) since neutralization of IL-1 activity completely inhibited G-CSF production.	Tetradecanoylphorbol Acetate	36-39	colony stimulating factor 3	Homo sapiens	198-203
9367827-4	1997	The synergistic interaction between PMA and Dex on G-CSF production appeared to be mediated through the production of interleukin-1 (IL-1) since neutralization of IL-1 activity completely inhibited G-CSF production.	Dexamethasone	44-47	colony stimulating factor 3	Homo sapiens	51-56
9367827-4	1997	The synergistic interaction between PMA and Dex on G-CSF production appeared to be mediated through the production of interleukin-1 (IL-1) since neutralization of IL-1 activity completely inhibited G-CSF production.	Dexamethasone	44-47	colony stimulating factor 3	Homo sapiens	198-203
9383226-10	1997	We suggest that "patient-dependent" criteria for starting G-CSF are reasonable especially in patients conditioned with protocols only slowly inducing neutropenia: eg NHL and HD patients after BEAM, MM after L-PAM or patients after busulphan and cyclophosphamide (BUCY2).	Busulfan	231-240	colony stimulating factor 3	Homo sapiens	58-63
9383226-10	1997	We suggest that "patient-dependent" criteria for starting G-CSF are reasonable especially in patients conditioned with protocols only slowly inducing neutropenia: eg NHL and HD patients after BEAM, MM after L-PAM or patients after busulphan and cyclophosphamide (BUCY2).	Cyclophosphamide	245-261	colony stimulating factor 3	Homo sapiens	58-63
9402167-0	1997	Multiple cycles of high-dose doxorubicin and cyclophosphamide with G-CSF mobilized peripheral blood progenitor cell support in patients with metastatic breast cancer.	Cyclophosphamide	45-61	colony stimulating factor 3	Homo sapiens	67-72
9383226-10	1997	We suggest that "patient-dependent" criteria for starting G-CSF are reasonable especially in patients conditioned with protocols only slowly inducing neutropenia: eg NHL and HD patients after BEAM, MM after L-PAM or patients after busulphan and cyclophosphamide (BUCY2).	bucy2	263-268	colony stimulating factor 3	Homo sapiens	58-63
9394074-0	1997	Carbimazole induced agranulocytosis: rescue with human recombinant granulocyte colony stimulating factor.	Carbimazole	0-11	colony stimulating factor 3	Homo sapiens	67-104
9401275-3	1997	A total of 16 patients were consecutively treated with granulocyte colony-stimulating factor (G-CSF)-combined high-dose chemotherapy (busulfan, etoposide and Ara-C) followed by autotransplantation of peripheral blood progenitor cells, which had been collected after the consolidation chemotherapy.	Cytarabine	158-163	colony stimulating factor 3	Homo sapiens	94-99
9401275-2	1997	We conducted a clinical trial to increase the chemosensitivity of residual leukemic cells by combining G-CSF to marrow-ablative chemotherapy, including cytosine arabinoside (Ara-C), and facilitated by autologous blood cell transplantation (ABCT) for treatment of acute myelogenous leukemia (AML) in first complete remission.	Cytarabine	152-172	colony stimulating factor 3	Homo sapiens	103-108
9401275-3	1997	A total of 16 patients were consecutively treated with granulocyte colony-stimulating factor (G-CSF)-combined high-dose chemotherapy (busulfan, etoposide and Ara-C) followed by autotransplantation of peripheral blood progenitor cells, which had been collected after the consolidation chemotherapy.	Busulfan	134-142	colony stimulating factor 3	Homo sapiens	55-92
9401275-3	1997	A total of 16 patients were consecutively treated with granulocyte colony-stimulating factor (G-CSF)-combined high-dose chemotherapy (busulfan, etoposide and Ara-C) followed by autotransplantation of peripheral blood progenitor cells, which had been collected after the consolidation chemotherapy.	Busulfan	134-142	colony stimulating factor 3	Homo sapiens	94-99
9401275-3	1997	A total of 16 patients were consecutively treated with granulocyte colony-stimulating factor (G-CSF)-combined high-dose chemotherapy (busulfan, etoposide and Ara-C) followed by autotransplantation of peripheral blood progenitor cells, which had been collected after the consolidation chemotherapy.	Etoposide	144-153	colony stimulating factor 3	Homo sapiens	94-99
9324281-1	1997	The study was designed to determine whether administration of granulocyte colony-stimulating factor (G-CSF) following fludarabine would reduce the incidences of myelosuppression and infections.	fludarabine	118-129	colony stimulating factor 3	Homo sapiens	62-99
9390210-0	1997	A phase II study of high-dose epirubicin (EPI) plus cyclophosphamide (CPA) with G-CSF for breast cancer patients with visceral metastases or hormone-independent tumors: a trial of the Japan Clinical Oncology Group.	Epirubicin	30-40	colony stimulating factor 3	Homo sapiens	80-85
9390210-0	1997	A phase II study of high-dose epirubicin (EPI) plus cyclophosphamide (CPA) with G-CSF for breast cancer patients with visceral metastases or hormone-independent tumors: a trial of the Japan Clinical Oncology Group.	Cyclophosphamide	70-73	colony stimulating factor 3	Homo sapiens	80-85
9324281-1	1997	The study was designed to determine whether administration of granulocyte colony-stimulating factor (G-CSF) following fludarabine would reduce the incidences of myelosuppression and infections.	fludarabine	118-129	colony stimulating factor 3	Homo sapiens	101-106
9402332-0	1997	Viability and quantification of progenitor cells in venesected blood from patients receiving escalated-dose epirubicin and cyclophosphamide with G-CSF for lymphoma: potential role in further increasing dose-intensity.	Cyclophosphamide	123-139	colony stimulating factor 3	Homo sapiens	145-150
9324281-10	1997	The use of G-CSF following fludarabine in high-risk patients with CLL resulted in a significant decrease in myelosuppression and pneumonia.	fludarabine	27-38	colony stimulating factor 3	Homo sapiens	11-16
9346226-0	1997	Phase I trial of paclitaxel, carboplatin, and methotrexate with granulocyte colony-stimulating factor and leucovorin in advanced transitional cell carcinoma.	Paclitaxel	17-27	colony stimulating factor 3	Homo sapiens	64-101
9346226-0	1997	Phase I trial of paclitaxel, carboplatin, and methotrexate with granulocyte colony-stimulating factor and leucovorin in advanced transitional cell carcinoma.	Methotrexate	46-58	colony stimulating factor 3	Homo sapiens	64-101
9302457-0	1997	Severe reversible thrombocytopenia caused by recombinant human granulocyte colony-stimulating factor in an AIDS patient receiving chronic ganciclovir therapy.	Ganciclovir	138-149	colony stimulating factor 3	Homo sapiens	63-100
9310604-11	1997	After 7 days" treatment, neutrophil superoxide production was significantly higher in the G-CSF group than in the placebo group (16.1 [4.2-24.2] vs 7.3 [2.1-11.5] nmol per 10(6) neutrophils in 30 min; p &lt; 0.0001).	Superoxides	36-46	colony stimulating factor 3	Homo sapiens	90-95
9374100-15	1997	At these doses, four cycles of doxorubicin, paclitaxel, and cyclophosphamide with PBPC and granulocyte colony-stimulating factor support every 21 days was well tolerated and showed evidence of activity.	Cyclophosphamide	60-76	colony stimulating factor 3	Homo sapiens	91-128
9287329-7	1997	The NF/G-CSF was purified by affinity chromatography using an oligonucleotide of GRE.	Oligonucleotides	62-77	colony stimulating factor 3	Homo sapiens	7-12
9339752-7	1997	Multivariate analysis revealed that cyclophosphamide and G-CSF priming before collection of hematopoietic precursors (P &lt; 0.001) was a positive predictor of rapid engraftment and prior exposure to melphalan given orally (P = 0.02) was a negative predictor of subsequent platelet engraftment.	Melphalan	200-209	colony stimulating factor 3	Homo sapiens	57-62
9331973-9	1997	In conclusion, DMSO- or RA-treated HL-60 cells are useful for the measurement of bioactivity of hG-CSF.	Dimethyl Sulfoxide	15-19	colony stimulating factor 3	Homo sapiens	96-102
9331973-9	1997	In conclusion, DMSO- or RA-treated HL-60 cells are useful for the measurement of bioactivity of hG-CSF.	Tretinoin	24-26	colony stimulating factor 3	Homo sapiens	96-102
9427795-0	1997	A new schedule for etoposide, epidoxorubicin and cisplatin with granulocyte colony stimulating factor for advanced gastric cancer: a feasibility study.	Etoposide	19-28	colony stimulating factor 3	Homo sapiens	64-101
9427795-0	1997	A new schedule for etoposide, epidoxorubicin and cisplatin with granulocyte colony stimulating factor for advanced gastric cancer: a feasibility study.	Cisplatin	49-58	colony stimulating factor 3	Homo sapiens	64-101
9332315-6	1997	When adhesion was measured in the presence of Mn2+, which increases the functional activity of integrins, an even higher increase of neutrophil and eosinophil basal adhesion was noted 4 and 7 d, respectively, after start of G-CSF administration.	Manganese(2+)	46-50	colony stimulating factor 3	Homo sapiens	224-229
9311440-9	1997	IN CONCLUSION: paclitaxel is active in patients with squamous cell cancer of the cervix and is well tolerated in this dose schedule with G-CSF support.	Paclitaxel	15-25	colony stimulating factor 3	Homo sapiens	137-142
9327154-0	1997	A dose-seeking trial of edatrexate in combination with vinblastine, adriamycin, cisplatin, and filgrastim (EVAC/G-CSF) in patients with advanced malignancies: promising antineoplastic activity against non-small cell lung carcinomas.	edatrexate	24-34	colony stimulating factor 3	Homo sapiens	112-117
9327154-15	1997	CONCLUSIONS: The maximum tolerated dose and the recommended phase II dose of edatrexate is 100 mg/m2/day when administered as part of the EVAC/G-CSF program following schedule 3.	edatrexate	77-87	colony stimulating factor 3	Homo sapiens	143-148
9815838-13	1997	Sequential IL-3/G-CSF given prior to and following high-dose etoposide and cyclophosphamide is safe and is a feasible strategy to compare in prospective randomized trials to patients treated with only postchemotherapy IL-3 and G-CSF and to patients treated with peripheral blood stem cell support.	Etoposide	61-70	colony stimulating factor 3	Homo sapiens	16-21
9815838-13	1997	Sequential IL-3/G-CSF given prior to and following high-dose etoposide and cyclophosphamide is safe and is a feasible strategy to compare in prospective randomized trials to patients treated with only postchemotherapy IL-3 and G-CSF and to patients treated with peripheral blood stem cell support.	Cyclophosphamide	75-91	colony stimulating factor 3	Homo sapiens	16-21
9310121-1	1997	We have demonstrated recently that methotrexate (MTX) inhibits superoxide generation and chemotaxis induced by N-formylmethionyl-leucyl-phenylalanine (fMLP) in neutrophils primed by granulocyte colony-stimulating factor (G-CSF).	Methotrexate	35-47	colony stimulating factor 3	Homo sapiens	182-219
9310121-1	1997	We have demonstrated recently that methotrexate (MTX) inhibits superoxide generation and chemotaxis induced by N-formylmethionyl-leucyl-phenylalanine (fMLP) in neutrophils primed by granulocyte colony-stimulating factor (G-CSF).	Methotrexate	35-47	colony stimulating factor 3	Homo sapiens	221-226
9310121-1	1997	We have demonstrated recently that methotrexate (MTX) inhibits superoxide generation and chemotaxis induced by N-formylmethionyl-leucyl-phenylalanine (fMLP) in neutrophils primed by granulocyte colony-stimulating factor (G-CSF).	Methotrexate	49-52	colony stimulating factor 3	Homo sapiens	182-219
9310121-1	1997	We have demonstrated recently that methotrexate (MTX) inhibits superoxide generation and chemotaxis induced by N-formylmethionyl-leucyl-phenylalanine (fMLP) in neutrophils primed by granulocyte colony-stimulating factor (G-CSF).	Methotrexate	49-52	colony stimulating factor 3	Homo sapiens	221-226
9310121-1	1997	We have demonstrated recently that methotrexate (MTX) inhibits superoxide generation and chemotaxis induced by N-formylmethionyl-leucyl-phenylalanine (fMLP) in neutrophils primed by granulocyte colony-stimulating factor (G-CSF).	N-Formylmethionine Leucyl-Phenylalanine	111-149	colony stimulating factor 3	Homo sapiens	182-219
9310121-5	1997	Furthermore, MTX caused a significant inhibition of both superoxide production induced by phorbol 12-myristate-13-acetate and chemotaxis induced by interleukin 8 in G-CSF-primed neutrophils.	Methotrexate	13-16	colony stimulating factor 3	Homo sapiens	165-170
9364865-1	1997	We report a case of severe aplastic anemia (SAA) treated with granulocyte colony-stimulating factor (G-CSF), cyclosporin A and danazole, in which myelodysplastic syndrome (MDS) with monosomy 7 developed eight months later.	saa	44-47	colony stimulating factor 3	Homo sapiens	62-99
9364865-1	1997	We report a case of severe aplastic anemia (SAA) treated with granulocyte colony-stimulating factor (G-CSF), cyclosporin A and danazole, in which myelodysplastic syndrome (MDS) with monosomy 7 developed eight months later.	saa	44-47	colony stimulating factor 3	Homo sapiens	101-106
9364865-2	1997	A 24-year-old woman was diagnosed as having SAA and was initially treated with G-CSF, cyclosporin A and danazole.	saa	44-47	colony stimulating factor 3	Homo sapiens	79-84
9364865-6	1997	Among seven previous reports published in Japan since 1992, in which MDS/acute myelogenous leukemia (AML) developed from SAA treated with G-CSF, six showed monosomy 7.	saa	121-124	colony stimulating factor 3	Homo sapiens	138-143
9364865-7	1997	Careful observation for leukemic transformation is therefore indicated in patients with SAA who are treated with G-CSF.	saa	88-91	colony stimulating factor 3	Homo sapiens	113-118
9364868-0	1997	[Acute myeloblastic leukemia showing pronounced skin infiltration during administration of low-dose cytarabine and etoposide with granulocyte colony-stimulating factor].	Etoposide	115-124	colony stimulating factor 3	Homo sapiens	130-167
9277051-0	1997	Prediction of growth sensitivity of acute promyelocytic leukemia cells to granulocyte colony-stimulating factor using 7AAD/PY during administration of all-trans retinoic acid.	2-octenal	155-160	colony stimulating factor 3	Homo sapiens	74-111
9257887-2	1997	The aim of this study was to evaluate the feasibility of a high-dose intensity doxorubicin-cyclophosphamide regimen with supporting G-CSF and blood stem cells.	Doxorubicin	79-90	colony stimulating factor 3	Homo sapiens	132-137
9257887-2	1997	The aim of this study was to evaluate the feasibility of a high-dose intensity doxorubicin-cyclophosphamide regimen with supporting G-CSF and blood stem cells.	Cyclophosphamide	91-107	colony stimulating factor 3	Homo sapiens	132-137
9257887-11	1997	We have established a safe, outpatient, high-dose intensity doxorubicin-cyclophosphamide regimen with supporting G-CSF and blood stem cells which can be submitted for comparison with the current standards.	Doxorubicin	60-71	colony stimulating factor 3	Homo sapiens	113-118
9257887-11	1997	We have established a safe, outpatient, high-dose intensity doxorubicin-cyclophosphamide regimen with supporting G-CSF and blood stem cells which can be submitted for comparison with the current standards.	Cyclophosphamide	72-88	colony stimulating factor 3	Homo sapiens	113-118
9277051-0	1997	Prediction of growth sensitivity of acute promyelocytic leukemia cells to granulocyte colony-stimulating factor using 7AAD/PY during administration of all-trans retinoic acid.	Tretinoin	161-174	colony stimulating factor 3	Homo sapiens	74-111
9277051-5	1997	In one patient, APL cells harvested from marrow during the first 3 weeks of ATRA administration showed distinct growth sensitivity to G-CSF ex vivo, and the cells harvested after a 4-week exposure to ATRA appeared to have lost this sensitivity.	Tretinoin	76-80	colony stimulating factor 3	Homo sapiens	134-139
9277051-6	1997	In this patient, G-CSF could be safely administered after 4 weeks of ATRA therapy.	Tretinoin	69-73	colony stimulating factor 3	Homo sapiens	17-22
9277051-7	1997	7AAD/PY analysis is useful for predicting growth sensitivity of APL cells to G-CSF during ATRA administration.	Tretinoin	90-94	colony stimulating factor 3	Homo sapiens	77-82
9364542-8	1997	The maximum tolerated dose of docetaxel in combination with carboplatin (target area under the time-concentration curve of 6 mg/mL.min) is 90 mg/m2 without granulocyte-colony stimulating factor (G-CSF) (filgrastim [Neupogen]) support and 100 mg/m2 with G-CSF support.	Docetaxel	30-39	colony stimulating factor 3	Homo sapiens	156-193
9389365-6	1997	The rationale of the St Jude"s R4 was to optimize the schedule of the second course of ara-C at a time when the patient"s endogenous G-CSF concentration was increased and thus maximize the percent of cells captured in S phase.	Cytarabine	87-92	colony stimulating factor 3	Homo sapiens	133-138
9379681-6	1997	Although there is no denying the possibility that cytosine arabinoside is partly responsible, our results strongly suggest that G-CSF plays the main role in differentiation of leukemic cells into a monocyte lineage inducing apoptosis in vivo in this patient.	Cytarabine	50-70	colony stimulating factor 3	Homo sapiens	128-133
9364542-8	1997	The maximum tolerated dose of docetaxel in combination with carboplatin (target area under the time-concentration curve of 6 mg/mL.min) is 90 mg/m2 without granulocyte-colony stimulating factor (G-CSF) (filgrastim [Neupogen]) support and 100 mg/m2 with G-CSF support.	Docetaxel	30-39	colony stimulating factor 3	Homo sapiens	195-200
9364542-8	1997	The maximum tolerated dose of docetaxel in combination with carboplatin (target area under the time-concentration curve of 6 mg/mL.min) is 90 mg/m2 without granulocyte-colony stimulating factor (G-CSF) (filgrastim [Neupogen]) support and 100 mg/m2 with G-CSF support.	Docetaxel	30-39	colony stimulating factor 3	Homo sapiens	253-258
9364542-8	1997	The maximum tolerated dose of docetaxel in combination with carboplatin (target area under the time-concentration curve of 6 mg/mL.min) is 90 mg/m2 without granulocyte-colony stimulating factor (G-CSF) (filgrastim [Neupogen]) support and 100 mg/m2 with G-CSF support.	Carboplatin	60-71	colony stimulating factor 3	Homo sapiens	156-193
9364542-8	1997	The maximum tolerated dose of docetaxel in combination with carboplatin (target area under the time-concentration curve of 6 mg/mL.min) is 90 mg/m2 without granulocyte-colony stimulating factor (G-CSF) (filgrastim [Neupogen]) support and 100 mg/m2 with G-CSF support.	Carboplatin	60-71	colony stimulating factor 3	Homo sapiens	195-200
9364542-8	1997	The maximum tolerated dose of docetaxel in combination with carboplatin (target area under the time-concentration curve of 6 mg/mL.min) is 90 mg/m2 without granulocyte-colony stimulating factor (G-CSF) (filgrastim [Neupogen]) support and 100 mg/m2 with G-CSF support.	Carboplatin	60-71	colony stimulating factor 3	Homo sapiens	253-258
9220971-2	1997	To determine unambiguously the protein conformations of G-CSF and the receptor in the complex, we have prepared uniformly 13C/15N isotope labeled G-CSF to resolve its amide I" band from that of the receptor in the IR spectrum of the complex.	13c/15n	122-129	colony stimulating factor 3	Homo sapiens	146-151
9220971-2	1997	To determine unambiguously the protein conformations of G-CSF and the receptor in the complex, we have prepared uniformly 13C/15N isotope labeled G-CSF to resolve its amide I" band from that of the receptor in the IR spectrum of the complex.	Amides	167-172	colony stimulating factor 3	Homo sapiens	146-151
9226159-4	1997	In addition, G-CSF induces the tyrosine phosphorylation of the receptor and members of the signal transducers and activators of transcription (Stat) family, including Stat3, as well as Stat1 and Stat5, depending on the cells involved.	Tyrosine	31-39	colony stimulating factor 3	Homo sapiens	13-18
9226159-2	1997	G-CSF uses a receptor of the cytokine receptor superfamily and, in common with all members of the family, induces the tyrosine phosphorylation and activation of members of the Janus protein tyrosine kinase (Jak) family.	Tyrosine	118-126	colony stimulating factor 3	Homo sapiens	0-5
9226159-3	1997	In both myeloid cells and a human fibrosarcoma cell line expressing the G-CSF receptor, G-CSF induces the tyrosine phosphorylation and activation of Jak1, Jak2, and Tyk2.	Tyrosine	106-114	colony stimulating factor 3	Homo sapiens	72-77
9217040-0	1997	Hyperfractionated radiation therapy and 5-fluorouracil, cisplatin, and mitomycin-C (+/- granulocyte-colony stimulating factor) in the treatment of patients with locally advanced head and neck carcinoma.	Fluorouracil	40-54	colony stimulating factor 3	Homo sapiens	88-125
9217040-0	1997	Hyperfractionated radiation therapy and 5-fluorouracil, cisplatin, and mitomycin-C (+/- granulocyte-colony stimulating factor) in the treatment of patients with locally advanced head and neck carcinoma.	Mitomycin	71-82	colony stimulating factor 3	Homo sapiens	88-125
9249051-0	1997	NMR investigations of the role of the sugar moiety in glycosylated recombinant human granulocyte-colony-stimulating factor.	Sugars	38-43	colony stimulating factor 3	Homo sapiens	85-122
9249051-4	1997	To clarify the molecular basis for the stabilisation effect of saccharide moieties on human G-CSF the whole glycoprotein expressed in CHO cells has been investigated by means of two 1H-NMR-spectroscopy and two 1H-detected-heteronuclear 1H-13C experiments at natural abundance, and compared with the non-glycosylated form.	Carbohydrates	63-73	colony stimulating factor 3	Homo sapiens	92-97
15251798-0	1997	Recombinant human granulocyte colony-stimulating factor in treatment of methimazole-induced agranulocytosis.	Methimazole	72-83	colony stimulating factor 3	Homo sapiens	18-55
15251798-1	1997	OBJECTIVE: To describe a patient with methimazole-induced agranulocytosis who was treated with recombinant human granulocyte colony-stimulating factor (G-CSF).	Methimazole	38-49	colony stimulating factor 3	Homo sapiens	113-150
15251798-1	1997	OBJECTIVE: To describe a patient with methimazole-induced agranulocytosis who was treated with recombinant human granulocyte colony-stimulating factor (G-CSF).	Methimazole	38-49	colony stimulating factor 3	Homo sapiens	152-157
15251798-7	1997	Because the recovery time for thionamide-induced agranulocytosis typically ranges from 1 to 2 weeks and sometimes is even longer, G-CSF may have been beneficial in accelerating the return of the granulocytes.	thionamide	30-40	colony stimulating factor 3	Homo sapiens	130-135
9250800-6	1997	Patients in early G-CSF group recovered significantly faster from the neutropenic nadir (p &lt; 0.002), contracted less infectious complications (p = 0.007), and required less intravenous antibiotic (p = 0.008) and antifungal (p = 0.002) medications.	nadir	82-87	colony stimulating factor 3	Homo sapiens	18-23
15251798-8	1997	CONCLUSION: Only a small number of patients with thionamide-induced agranulocytosis have had G-CSF treatment, and most outcomes have generally supported a beneficial effect.	thionamide	49-59	colony stimulating factor 3	Homo sapiens	93-98
9271776-0	1997	The influence of clozapine treatment on plasma granulocyte colony-stimulating (G-CSF) levels.	Clozapine	17-26	colony stimulating factor 3	Homo sapiens	79-84
9271776-3	1997	In addition, G-CSF has successfully been used to treat clozapine-induced agranulocytosis.	Clozapine	55-64	colony stimulating factor 3	Homo sapiens	13-18
9271776-4	1997	We performed a longitudinal investigation of the plasma levels of G-CSF in 20 schizophrenic patients during six weeks of clozapine treatment.	Clozapine	121-130	colony stimulating factor 3	Homo sapiens	66-71
9271776-5	1997	Clozapine transiently increased plasma G-CSF levels in 55% of the subjects studied.	Clozapine	0-9	colony stimulating factor 3	Homo sapiens	39-44
9271776-8	1997	The results presented suggest that G-CSF is involved in clozapine-induced increases in granulocyte counts seen early during treatment.	Clozapine	56-65	colony stimulating factor 3	Homo sapiens	35-40
9167751-0	1997	Standard-dose recombinant human granulocyte colony-stimulating factor (rhG-CSF) allows safe and repeated administration of high-dose cyclophosphamide, etoposide, and cisplatin (CEP).	Cyclophosphamide	133-149	colony stimulating factor 3	Homo sapiens	32-69
9167751-0	1997	Standard-dose recombinant human granulocyte colony-stimulating factor (rhG-CSF) allows safe and repeated administration of high-dose cyclophosphamide, etoposide, and cisplatin (CEP).	Etoposide	151-160	colony stimulating factor 3	Homo sapiens	32-69
9167751-0	1997	Standard-dose recombinant human granulocyte colony-stimulating factor (rhG-CSF) allows safe and repeated administration of high-dose cyclophosphamide, etoposide, and cisplatin (CEP).	Cisplatin	166-175	colony stimulating factor 3	Homo sapiens	32-69
9167751-0	1997	Standard-dose recombinant human granulocyte colony-stimulating factor (rhG-CSF) allows safe and repeated administration of high-dose cyclophosphamide, etoposide, and cisplatin (CEP).	ethephon	177-180	colony stimulating factor 3	Homo sapiens	32-69
9215604-7	1997	It is concluded that single-agent carboplatin, with the adjunct of prophylactic G-CSF, can be administered with adequate dose intensity, and is an effective and acceptable palliative treatment for patients with relapse after first-line cisplatin-based chemotherapy.	Carboplatin	34-45	colony stimulating factor 3	Homo sapiens	80-85
9197330-3	1997	In serum-driven agar cultures, G-CSF stimulated the proliferation of HPP-CFC in a dose dependent manner (r = 0.92).	Agar	16-20	colony stimulating factor 3	Homo sapiens	31-36
9194183-1	1997	We performed a series of experiments using alanine-scanning mutagenesis to locate side chains within human granulocyte colony-stimulating factor (G-CSF) that are involved in human G-CSF receptor binding.	Alanine	43-50	colony stimulating factor 3	Homo sapiens	107-144
9194183-1	1997	We performed a series of experiments using alanine-scanning mutagenesis to locate side chains within human granulocyte colony-stimulating factor (G-CSF) that are involved in human G-CSF receptor binding.	Alanine	43-50	colony stimulating factor 3	Homo sapiens	146-151
9194183-1	1997	We performed a series of experiments using alanine-scanning mutagenesis to locate side chains within human granulocyte colony-stimulating factor (G-CSF) that are involved in human G-CSF receptor binding.	Alanine	43-50	colony stimulating factor 3	Homo sapiens	180-185
9194183-5	1997	These studies show that there is a region of five charged residues on helices A and C employed by G-CSF in binding its receptor, with the most important residue in this binding patch being Glu 19.	Glutamic Acid	189-192	colony stimulating factor 3	Homo sapiens	98-103
9164225-1	1997	PURPOSE: To define the maximum-tolerated dose (MTD) of liposome-encapsulated doxorubicin (LED) when used every 2 weeks with granulocyte colony-stimulating factor (G-CSF) in patients with advanced soft tissue sarcoma.	Doxorubicin	77-88	colony stimulating factor 3	Homo sapiens	124-161
9377855-2	1997	A phase I-II study was designed in order to verify toxicity, maximum tolerated dose and activity of CBDCA, CTX and VP-16 given with Granulocyte Colony Stimulating Factor (G-CSF) and thymopentin (TP5), without bone marrow support.	Carboplatin	100-105	colony stimulating factor 3	Homo sapiens	171-176
9146556-4	1997	The use of granulocyte colony stimulating factor for leukopenia associated with MTX toxicity is discussed.	Methotrexate	80-83	colony stimulating factor 3	Homo sapiens	11-48
9209832-2	1997	Like other cytokines, G-CSF induces intracellular protein tyrosine phosphorylation and activates various signaling cascades.	Tyrosine	58-66	colony stimulating factor 3	Homo sapiens	22-27
9164225-1	1997	PURPOSE: To define the maximum-tolerated dose (MTD) of liposome-encapsulated doxorubicin (LED) when used every 2 weeks with granulocyte colony-stimulating factor (G-CSF) in patients with advanced soft tissue sarcoma.	Doxorubicin	77-88	colony stimulating factor 3	Homo sapiens	163-168
9134173-0	1997	Indium-labeled white blood cells apheresed from donors receiving G-CSF localize to sites of inflammation when infused into allogeneic bone marrow transplant recipients.	Indium	0-6	colony stimulating factor 3	Homo sapiens	65-70
9194390-9	1997	ATRA was restarted along with granulocyte-colony stimulating factor (G-CSF).	Tretinoin	0-4	colony stimulating factor 3	Homo sapiens	69-74
9134173-4	1997	Five neutropenic allogeneic bone marrow transplant (BMT) patients each received a fresh infusion of G-CSF-mobilized indium-labeled irradiated white blood cells (WBC) apheresed from HLA-matched normal donors on day +5 post-transplant.	Indium	116-122	colony stimulating factor 3	Homo sapiens	100-105
9134173-5	1997	Localization of activity on delayed scintigraphic images of indium-labeled WBC scans to sites of tissue damage (oral/nasopharynx in two patients with mucositis and terminal ileum/cecum in one with diarrhea) occurred, and supports the hypothesis that G-CSF-mobilized HLA-matched donor neutrophils which have been irradiated are functional after infusion into neutropenic recipients.	Indium	60-66	colony stimulating factor 3	Homo sapiens	250-255
9154449-0	1997	Granulocyte-colony stimulating factor in the treatment of colchicine poisoning.	Colchicine	58-68	colony stimulating factor 3	Homo sapiens	0-37
9150345-1	1997	All-trans-retinoic acid (ATRA) has been used as a potent therapeutic agent to induce differentiation of acute promyelocytic leukemia (APL) cells, and granulocyte colony-stimulating factor (G-CSF) has been reported to enhance this effect of ATRA in vitro.	Tretinoin	0-23	colony stimulating factor 3	Homo sapiens	189-194
9193328-0	1997	Comparative study of dose escalation versus interval reduction to obtain dose-intensification of epirubicin and cyclophosphamide with granulocyte colony-stimulating factor in advanced breast cancer.	Cyclophosphamide	112-128	colony stimulating factor 3	Homo sapiens	134-171
9193331-0	1997	Dose-intensive vinorelbine with concurrent granulocyte colony-stimulating factor support in paclitaxel-refractory metastatic breast cancer.	Paclitaxel	92-102	colony stimulating factor 3	Homo sapiens	43-80
9193331-6	1997	Vinorelbine was given initially at 30 mg/m2/wk, then at 35 mg/m2/wk in a phase I/II design, which involved first intermittent (6 days of 7) and then continuous (daily) administration of G-CSF at 5 micrograms/kg.	Vinorelbine	0-11	colony stimulating factor 3	Homo sapiens	186-191
9193331-17	1997	CONCLUSION: Concurrent administration of weekly vinoralbine and daily G-CSF is feasible and permits an increase in DDI for vinorelbine of 43% to 76% over that reported in series without growth factor support.	Vinorelbine	123-134	colony stimulating factor 3	Homo sapiens	70-75
9178837-6	1997	Thus, G-CSF supplementation may improve the rate of infectious complications by reducing the duration of fludarabine-induced neutrocytopenia.	fludarabine	105-116	colony stimulating factor 3	Homo sapiens	6-11
9150345-1	1997	All-trans-retinoic acid (ATRA) has been used as a potent therapeutic agent to induce differentiation of acute promyelocytic leukemia (APL) cells, and granulocyte colony-stimulating factor (G-CSF) has been reported to enhance this effect of ATRA in vitro.	Tretinoin	240-244	colony stimulating factor 3	Homo sapiens	150-187
9150345-1	1997	All-trans-retinoic acid (ATRA) has been used as a potent therapeutic agent to induce differentiation of acute promyelocytic leukemia (APL) cells, and granulocyte colony-stimulating factor (G-CSF) has been reported to enhance this effect of ATRA in vitro.	Tretinoin	240-244	colony stimulating factor 3	Homo sapiens	189-194
15622763-5	1997	RESULTS: Serum G-CSF levels in 70.4% (38 of 54 cases) of the CAA patients were increased (272.76 +/- 58.39ng/L).	caa	61-64	colony stimulating factor 3	Homo sapiens	15-20
9144683-5	1997	Significant differences in response were observed between the cisplatin/etoposide and paclitaxel/cisplatin/G-CSF groups and the cisplatin/etoposide and paclitaxel/cisplatin groups; there was no significant difference between patients treated with paclitaxel/cisplatin vs paclitaxel/cisplatin/G-CSF.	Paclitaxel	86-96	colony stimulating factor 3	Homo sapiens	292-297
15622763-8	1997	Serum G-CSF levels in almost 30% (12 of 54 cases) of the CAA patients were not increased.	caa	57-60	colony stimulating factor 3	Homo sapiens	6-11
9095330-19	1997	G-CSF use allows the increase DHAD dosage up to 18 mg/m2/cycle, but its use may be linked to the occurrence of sometimes severe cumulative hematological toxicity.	Mitoxantrone	30-34	colony stimulating factor 3	Homo sapiens	0-5
9118704-1	1997	STUDY OBJECTIVES: The purpose of this study is to determine whether co-administration of granulocyte colony stimulating factor (G-CSF) and bleomycin results in enhanced pulmonary toxicity compared with bleomycin alone.	Bleomycin	202-211	colony stimulating factor 3	Homo sapiens	89-126
9074411-7	1997	Leukaemic cells derived from seven (four acute-type, one chronic-type and two lymphoma-type) of the 14 patients proliferated in vitro in response to G-CSF, as measured by [3H]thymidine incorporation; maximum responses were at G-CSF concentrations of 10-100 ng/ml.	Tritium	172-174	colony stimulating factor 3	Homo sapiens	149-154
9074411-7	1997	Leukaemic cells derived from seven (four acute-type, one chronic-type and two lymphoma-type) of the 14 patients proliferated in vitro in response to G-CSF, as measured by [3H]thymidine incorporation; maximum responses were at G-CSF concentrations of 10-100 ng/ml.	Thymidine	175-184	colony stimulating factor 3	Homo sapiens	149-154
9118704-8	1997	RESULTS: Of the 29 patients who received concurrent chemotherapy and G-CSF, ten (34%; 95% confidence interval [CI], 17.9 to 54.3%) were believed to have clinically significant bleomycin toxicity.	Bleomycin	176-185	colony stimulating factor 3	Homo sapiens	69-74
9175313-0	1997	Early hemopoietic progenitors in the peripheral blood of patients with severe aplastic anemia (SAA) after treatment with antilymphocyte globulin (ALG), cyclosporin-A and G-CSF.	saa	95-98	colony stimulating factor 3	Homo sapiens	170-175
9155540-0	1997	A phase I study of irinotecan and infusional cisplatin with recombinant human granulocyte colony-stimulating factor support in the treatment of advanced non-small cell lung cancer.	Irinotecan	19-29	colony stimulating factor 3	Homo sapiens	78-115
9155540-1	1997	We conducted a phase I study to examine whether support with recombinant human granulocyte colony-stimulating factor (rG-CSF) would permit dose intensification of irinotecan (CPT-11) in combination with cisplatin (20 mg/m2 x 5 days) in non-small cell lung cancer (NSCLC) patients.	Irinotecan	163-173	colony stimulating factor 3	Homo sapiens	79-116
9155540-1	1997	We conducted a phase I study to examine whether support with recombinant human granulocyte colony-stimulating factor (rG-CSF) would permit dose intensification of irinotecan (CPT-11) in combination with cisplatin (20 mg/m2 x 5 days) in non-small cell lung cancer (NSCLC) patients.	Irinotecan	175-181	colony stimulating factor 3	Homo sapiens	79-116
9150714-6	1997	G-CSF induced PMNs showed a significantly (p &lt; 0.05) decreased chemokinetic response (d5) as well as a reduced chemotaxis towards zymosan activated serum, FMLP and IL-8, respectively.	Zymosan	133-140	colony stimulating factor 3	Homo sapiens	0-5
9175313-1	1997	BACKGROUND AND OBJECTIVE: We previously reported that patients with acquired severe aplastic anemia (SAA) treated with antilymphocyte globulin (ALG), 6-methylprednisolone, cyclosporin A (CyA) and granulocyte colony-stimulating factor (G-CSF) can mobilize peripheral blood hemopoietic progenitors (PBHP).	saa	101-104	colony stimulating factor 3	Homo sapiens	235-240
9175313-1	1997	BACKGROUND AND OBJECTIVE: We previously reported that patients with acquired severe aplastic anemia (SAA) treated with antilymphocyte globulin (ALG), 6-methylprednisolone, cyclosporin A (CyA) and granulocyte colony-stimulating factor (G-CSF) can mobilize peripheral blood hemopoietic progenitors (PBHP).	Cyclosporine	172-185	colony stimulating factor 3	Homo sapiens	235-240
9053493-1	1997	PURPOSE: As an alternative to single-cycle cyclophosphamide, thiotepa, and carboplatin (CTCb) intensification, we evaluated the feasibility of administering one-quarter dose CTCb for four cycles with peripheral-blood progenitor-cell (PBPC) and filgrastim (granulocyte colony-stimulating factor [G-CSF]) in advanced-stage breast cancer patients.	ctcb	174-178	colony stimulating factor 3	Homo sapiens	295-300
9028941-11	1997	However, longer incubation with Ara-C (16 to 18 hours), in the presence of SCF, IL-3 and G-CSF, or IL-6, showed that more than 60% of LTC-IC are actually cycling, with no difference being found with BM cells.	Cytarabine	32-37	colony stimulating factor 3	Homo sapiens	89-94
9053502-8	1997	CONCLUSION: Etoposide plus G-CSF is an effective and safe method for mobilization of PBPCs.	pbpcs	85-90	colony stimulating factor 3	Homo sapiens	27-32
9028308-0	1997	Granulocyte-colony stimulating factor (filgrastim) accelerates granulocyte recovery after intensive postremission chemotherapy for acute myeloid leukemia with aziridinyl benzoquinone and mitoxantrone: Cancer and Leukemia Group B study 9022.	diaziquone	159-182	colony stimulating factor 3	Homo sapiens	0-37
9028308-0	1997	Granulocyte-colony stimulating factor (filgrastim) accelerates granulocyte recovery after intensive postremission chemotherapy for acute myeloid leukemia with aziridinyl benzoquinone and mitoxantrone: Cancer and Leukemia Group B study 9022.	Mitoxantrone	187-199	colony stimulating factor 3	Homo sapiens	0-37
9028308-1	1997	This study evaluated the effect of filgrastim (granulocyte colony-stimulating factor [G-CSF]) on the duration of granulocytopenia and thrombocytopenia after intensive consolidation therapy with diaziquone (AZO) and mitroxantrone for patients less than 60 years of age with acute myeloid leukemia (AML) in complete remission.	diaziquone	194-204	colony stimulating factor 3	Homo sapiens	86-91
9028308-8	1997	G-CSF markedly shortened the duration of granulocytopenia in patients with AML receiving intensive postremission consolidation with AZQ and mitoxantrone.	diaziquone	132-135	colony stimulating factor 3	Homo sapiens	0-5
9028308-8	1997	G-CSF markedly shortened the duration of granulocytopenia in patients with AML receiving intensive postremission consolidation with AZQ and mitoxantrone.	Mitoxantrone	140-152	colony stimulating factor 3	Homo sapiens	0-5
9053493-12	1997	CONCLUSION: It is feasible to administer repetitive cycles of one-quarter dose CTCb intensification with PBPC and G-CSF.	ctcb	79-83	colony stimulating factor 3	Homo sapiens	114-119
9106021-0	1997	Ifosfamide, cisplatin and etoposide (ICE) combined chemotherapy with recombinant human granulocyte colony-stimulating factor support in small cell lung cancer.	Ifosfamide	0-10	colony stimulating factor 3	Homo sapiens	87-124
9053494-5	1997	RESULTS: The medians of average daily CD34+ cell yields for patients who received paclitaxel plus CY, CE, and CEP with G-CSF were 12.9, 11.03, and 5.37 x 10(6)/kg, respectively, compared with 2.02 x 10(6)/kg in the reference group that received CY with G-CSF (P = &lt; .0001, .002, and .09, respectively).	Paclitaxel	82-92	colony stimulating factor 3	Homo sapiens	119-124
9053494-6	1997	On first-day collections, patients who received paclitaxel plus CY, CE, and CEP with G-CSF yielded medians of 11.07, 8.09, and 3.52 x 10(6) CD34+ cells/kg, respectively, compared with 0.90 x 10(6)/kg in the reference group that received CY with G-CSF (P = .0006, .02, and .09, respectively).	Paclitaxel	48-58	colony stimulating factor 3	Homo sapiens	85-90
9053494-6	1997	On first-day collections, patients who received paclitaxel plus CY, CE, and CEP with G-CSF yielded medians of 11.07, 8.09, and 3.52 x 10(6) CD34+ cells/kg, respectively, compared with 0.90 x 10(6)/kg in the reference group that received CY with G-CSF (P = .0006, .02, and .09, respectively).	Paclitaxel	48-58	colony stimulating factor 3	Homo sapiens	245-250
9053494-6	1997	On first-day collections, patients who received paclitaxel plus CY, CE, and CEP with G-CSF yielded medians of 11.07, 8.09, and 3.52 x 10(6) CD34+ cells/kg, respectively, compared with 0.90 x 10(6)/kg in the reference group that received CY with G-CSF (P = .0006, .02, and .09, respectively).	Cysteine	237-239	colony stimulating factor 3	Homo sapiens	85-90
9053499-5	1997	With G-CSF support, one of three patients experienced both dose-limiting mucositis and fatal neutropenic sepsis at a dose of paclitaxel 180 mg/m2/96 hours and cisplatin 80 mg/m2.	Paclitaxel	125-135	colony stimulating factor 3	Homo sapiens	5-10
9053499-5	1997	With G-CSF support, one of three patients experienced both dose-limiting mucositis and fatal neutropenic sepsis at a dose of paclitaxel 180 mg/m2/96 hours and cisplatin 80 mg/m2.	Cisplatin	159-168	colony stimulating factor 3	Homo sapiens	5-10
9053499-11	1997	CONCLUSION: The MTD without G-CSF is paclitaxel 120 mg/m2/96 hours and cisplatin 80 mg/m2, and the MTD with G-CSF is paclitaxel 160 mg/m2/96 hours and cisplatin 80 mg/m2.	Paclitaxel	117-127	colony stimulating factor 3	Homo sapiens	108-113
27406861-7	1997	G-CSF may be useful in the treatment of severe resistant infections and it may be of benefit when used after treatment with ATG and cyclosporin.	Cyclosporine	132-143	colony stimulating factor 3	Homo sapiens	0-5
9051093-6	1997	Dexamethasone significantly increased the maximal ANC induced by either dose of G-CSF alone (p &lt; 0.05).	Dexamethasone	0-13	colony stimulating factor 3	Homo sapiens	80-85
9051093-9	1997	CONCLUSION: Dexamethasone significantly increases the level of neutrophilia induced in normal subjects by G-CSF.	Dexamethasone	12-25	colony stimulating factor 3	Homo sapiens	106-111
9292744-1	1997	The main objective of this study was to assess to what extent filgrastim (G-CSF, Amgen-Roche) can facilitate administration of the full dose intensity of MOPP/ABVD chemotherapy to patients with Hodgkin"s disease.	MOPP protocol	154-158	colony stimulating factor 3	Homo sapiens	74-79
9292744-1	1997	The main objective of this study was to assess to what extent filgrastim (G-CSF, Amgen-Roche) can facilitate administration of the full dose intensity of MOPP/ABVD chemotherapy to patients with Hodgkin"s disease.	ABVD protocol	159-163	colony stimulating factor 3	Homo sapiens	74-79
9043028-0	1997	Paclitaxel, ifosfamide and cisplatin with granulocyte colony-stimulating factor or recombinant human interleukin 3 and granulocyte colony-stimulating factor in ovarian cancer: a feasibility study.	Paclitaxel	0-10	colony stimulating factor 3	Homo sapiens	42-79
9043028-0	1997	Paclitaxel, ifosfamide and cisplatin with granulocyte colony-stimulating factor or recombinant human interleukin 3 and granulocyte colony-stimulating factor in ovarian cancer: a feasibility study.	Cisplatin	27-36	colony stimulating factor 3	Homo sapiens	42-79
8971093-0	1997	Effect of granulocyte-colony stimulating factor on generation of oxygen-derived free radicals and myeloperoxidase activity in neutrophils from poorly controlled NIDDM patients.	Oxygen	65-71	colony stimulating factor 3	Homo sapiens	10-47
8971093-0	1997	Effect of granulocyte-colony stimulating factor on generation of oxygen-derived free radicals and myeloperoxidase activity in neutrophils from poorly controlled NIDDM patients.	Free Radicals	80-93	colony stimulating factor 3	Homo sapiens	10-47
8971093-3	1997	In both control and diabetic neutrophils, G-CSF significantly enhanced both CLA-DCL (175% in control and 156% in diabetic) and L-DCL (283% in control and 346% in diabetic).	cla-dcl	76-83	colony stimulating factor 3	Homo sapiens	42-47
8971093-3	1997	In both control and diabetic neutrophils, G-CSF significantly enhanced both CLA-DCL (175% in control and 156% in diabetic) and L-DCL (283% in control and 346% in diabetic).	l-dcl	127-132	colony stimulating factor 3	Homo sapiens	42-47
8971093-4	1997	In diabetic neutrophils, the enhancing effect of G-CSF on L-DCL was more sensitive than on CLA-DCL (P &lt; 0.001).	l-dcl	58-63	colony stimulating factor 3	Homo sapiens	49-54
8971093-5	1997	There was a positive correlation between HbA(1c) and the enhancing effect of G-CSF on L-DCL in diabetic patients (P &lt; 0.05), but not on CLA-DCL.	l-dcl	86-91	colony stimulating factor 3	Homo sapiens	77-82
8971093-8	1997	Because bacterial infection still accounts for an important cause of morbidity and mortality in diabetic patients, these data suggest that G-CSF may be useful as a drug to prevent the aggravation of bacterial infection by improving neutrophil function, especially through H2O2-MPO-OCl(-) mechanism, in poorly controlled diabetic patients.	Hydrogen Peroxide	272-276	colony stimulating factor 3	Homo sapiens	139-144
8971093-8	1997	Because bacterial infection still accounts for an important cause of morbidity and mortality in diabetic patients, these data suggest that G-CSF may be useful as a drug to prevent the aggravation of bacterial infection by improving neutrophil function, especially through H2O2-MPO-OCl(-) mechanism, in poorly controlled diabetic patients.	ocl	281-284	colony stimulating factor 3	Homo sapiens	139-144
8989903-6	1997	Tyrosine phosphorylation of 42-kDa protein stimulated by G-CSF, GM-CSF, and TNF was observed in CML neutrophils to be identical to that in normal neutrophils.	Tyrosine	0-8	colony stimulating factor 3	Homo sapiens	57-62
9035144-3	1997	Expression of the luciferase gene increased up to 1,740-fold and of the human granulocyte-colony stimulating factor (hG-CSF) gene up to 569-fold due to prolonged circulation time of injected CLDC, and increased uptake and retention in tissues.	cldc	191-195	colony stimulating factor 3	Homo sapiens	78-115
9035144-3	1997	Expression of the luciferase gene increased up to 1,740-fold and of the human granulocyte-colony stimulating factor (hG-CSF) gene up to 569-fold due to prolonged circulation time of injected CLDC, and increased uptake and retention in tissues.	cldc	191-195	colony stimulating factor 3	Homo sapiens	117-123
9045339-1	1997	This phase I/II study sought to determine the response rate and toxicity profile of escalating doses of paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) when administered with fixed doses of cisplatin with granulocyte colony-stimulating factor support in 28 patients with head or neck cancer.	Paclitaxel	104-114	colony stimulating factor 3	Homo sapiens	221-258
9001413-10	1997	Although the treatment-related toxicity is high, a high CR rate can be obtained in these poor-risk AML patients with the use of intensive chemotherapy in combination with G-CSF, although the role of the latter is still to be proven.	Chromium	56-58	colony stimulating factor 3	Homo sapiens	171-176
9547675-1	1997	PURPOSE: To define the maximum tolerated dose of etoposide phosphate when used with G-CSF in the treatment of patients with refractory malignancies.	etoposide phosphate	49-68	colony stimulating factor 3	Homo sapiens	84-89
9547675-10	1997	CONCLUSIONS: In pretreated patients, the maximum tolerated dose of etoposide phosphate with G-CSF is 1938 mg/m2 (equivalent to etoposide 1700 mg/m2).	etoposide phosphate	67-86	colony stimulating factor 3	Homo sapiens	92-97
9547675-10	1997	CONCLUSIONS: In pretreated patients, the maximum tolerated dose of etoposide phosphate with G-CSF is 1938 mg/m2 (equivalent to etoposide 1700 mg/m2).	Etoposide	67-76	colony stimulating factor 3	Homo sapiens	92-97
8996136-15	1997	CONCLUSION: For previously treated patients, the recommended dose of topotecan in this schedule is 0.75 mg/m2/d without growth factor support and 1.0 mg/ m2/d if it is administered with G-CSF.	Topotecan	69-78	colony stimulating factor 3	Homo sapiens	186-191
8996140-11	1997	CONCLUSION: The recommended doses of TPT on a daily times-five schedule combined with PTX-24 in these patients were 0.75 mg/m2/d and 135 mg/m2, respectively, with G-CSF support.	Topotecan	37-40	colony stimulating factor 3	Homo sapiens	163-168
8996136-5	1997	Once the MTD was defined, granulocyte colony-stimulating factor (G-CSF) was added to the regimen in an attempt to escalate further the dose of topotecan.	Topotecan	143-152	colony stimulating factor 3	Homo sapiens	26-63
8996136-5	1997	Once the MTD was defined, granulocyte colony-stimulating factor (G-CSF) was added to the regimen in an attempt to escalate further the dose of topotecan.	Topotecan	143-152	colony stimulating factor 3	Homo sapiens	65-70
9037362-1	1996	PURPOSE: To identify the highest possible dose of cyclophosphamide (C) and etoposide (E) to be given with high-dose doxorubicin (D) and filgrastim (G-CSF) but without stem cell support in high-risk non-Hodgkin"s lymphoma.	Cyclophosphamide	50-66	colony stimulating factor 3	Homo sapiens	148-153
9170212-4	1997	Addition of SCF (50 ng/ml) to methyl-cellulose cultures stimulated with maximal concentrations of G-CSF, GM-CSF, interleukin 3 and erythropoietin significantly increased the growth (mean +/- SE) of CFU-Mix (7.7 +/- 1.7 versus 2.4 +/- 0.6, p &lt; or = 0.0001), BFU-E (47 +/- 10 versus 32 +/- 6, p &lt; or = 0.002) and CFU-GM (173 +/- 31 versus 112 +/- 20, p &lt; or = 0.0001).	Methylcellulose	30-46	colony stimulating factor 3	Homo sapiens	98-103
9037362-1	1996	PURPOSE: To identify the highest possible dose of cyclophosphamide (C) and etoposide (E) to be given with high-dose doxorubicin (D) and filgrastim (G-CSF) but without stem cell support in high-risk non-Hodgkin"s lymphoma.	Etoposide	75-84	colony stimulating factor 3	Homo sapiens	148-153
8946932-5	1996	Growth factor responsive cells are more Ara-C sensitive in G-CSF than in GM-CSF or IL-3.	Cytarabine	40-45	colony stimulating factor 3	Homo sapiens	59-64
8946866-12	1996	CONCLUSION: In 30 women with primary advanced ovarian cancer, G-CSF allowed a 50% dose escalation of etoposide and ifosfamide from 0.8 to 1.2 dose intensity.	Etoposide	101-110	colony stimulating factor 3	Homo sapiens	62-67
8946866-12	1996	CONCLUSION: In 30 women with primary advanced ovarian cancer, G-CSF allowed a 50% dose escalation of etoposide and ifosfamide from 0.8 to 1.2 dose intensity.	Ifosfamide	115-125	colony stimulating factor 3	Homo sapiens	62-67
8890691-0	1996	Granulocyte colony-stimulating factor treatment of clozapine-induced agranulocytosis.	Clozapine	51-60	colony stimulating factor 3	Homo sapiens	0-37
9011117-0	1996	Effect of recombinant human granulocyte colony-stimulating factor on combination therapy with aztreonam and clindamycin for infections in neutropenic patients with hematologic diseases.	Aztreonam	94-103	colony stimulating factor 3	Homo sapiens	28-65
9011117-0	1996	Effect of recombinant human granulocyte colony-stimulating factor on combination therapy with aztreonam and clindamycin for infections in neutropenic patients with hematologic diseases.	Clindamycin	108-119	colony stimulating factor 3	Homo sapiens	28-65
9011117-1	1996	The present multicenter study was performed to evaluate the effect of recombinant human granulocyte-colony stimulating factor (rhG-CSF) on combination therapy using aztreonam (AZT) and clindamycin (CLDM) to treat severe infection in neutropenic patients with hematologic diseases.	Aztreonam	165-174	colony stimulating factor 3	Homo sapiens	88-125
9011117-1	1996	The present multicenter study was performed to evaluate the effect of recombinant human granulocyte-colony stimulating factor (rhG-CSF) on combination therapy using aztreonam (AZT) and clindamycin (CLDM) to treat severe infection in neutropenic patients with hematologic diseases.	Aztreonam	176-179	colony stimulating factor 3	Homo sapiens	88-125
9011117-1	1996	The present multicenter study was performed to evaluate the effect of recombinant human granulocyte-colony stimulating factor (rhG-CSF) on combination therapy using aztreonam (AZT) and clindamycin (CLDM) to treat severe infection in neutropenic patients with hematologic diseases.	Clindamycin	185-196	colony stimulating factor 3	Homo sapiens	88-125
9011117-1	1996	The present multicenter study was performed to evaluate the effect of recombinant human granulocyte-colony stimulating factor (rhG-CSF) on combination therapy using aztreonam (AZT) and clindamycin (CLDM) to treat severe infection in neutropenic patients with hematologic diseases.	Clindamycin	198-202	colony stimulating factor 3	Homo sapiens	88-125
8973359-2	1996	DNA concatenamers containing additional expression units can also be prepared: we exploited this feature by co-polymerizing expression units coding for granulocyte colony-stimulating factor (G-CSF) with cassettes for dihydrofolate reductase (DHFR) and for neomycin (Nm) resistance, as selectable markers.	Neomycin	256-264	colony stimulating factor 3	Homo sapiens	191-196
8997128-9	1996	These findings suggest that combined therapy of ATRA and G-CSF is effective to the low responder to ATRA and that combined use of ATRA and prednisolone reduces the side effect of ATRA without diminishing the favorable effect on differentiation.	Tretinoin	100-104	colony stimulating factor 3	Homo sapiens	57-62
8997128-9	1996	These findings suggest that combined therapy of ATRA and G-CSF is effective to the low responder to ATRA and that combined use of ATRA and prednisolone reduces the side effect of ATRA without diminishing the favorable effect on differentiation.	Tretinoin	100-104	colony stimulating factor 3	Homo sapiens	57-62
8997128-9	1996	These findings suggest that combined therapy of ATRA and G-CSF is effective to the low responder to ATRA and that combined use of ATRA and prednisolone reduces the side effect of ATRA without diminishing the favorable effect on differentiation.	Tretinoin	100-104	colony stimulating factor 3	Homo sapiens	57-62
9006749-0	1996	Effect of granulocyte colony-stimulating factor administration in elderly patients with aggressive non-Hodgkin"s lymphoma treated with a pirarubicin-combination chemotherapy regimen.	pirarubicin	137-148	colony stimulating factor 3	Homo sapiens	10-47
8955505-2	1996	METHODS: Endometrial expression of messenger ribonucleic acids for G-CSF and its receptor were studied using reverse transcriptase-polymerase chain reaction.	ribonucleic	45-56	colony stimulating factor 3	Homo sapiens	67-72
8888741-17	1996	CONCLUSIONS: In heavily pretreated children, the MTD for topotecan given by intermittent 30-min infusion for 5 days is 1.4 mg/m2 without GCSF and 2.0 mg/m2/day with GCSF.	Topotecan	57-66	colony stimulating factor 3	Homo sapiens	137-141
8959393-15	1996	At present, polyethylene glycol derivatives of G-CSF are being developed to reduce the frequency of G-CSF administration.	Polyethylene Glycols	12-31	colony stimulating factor 3	Homo sapiens	47-52
8959393-15	1996	At present, polyethylene glycol derivatives of G-CSF are being developed to reduce the frequency of G-CSF administration.	Polyethylene Glycols	12-31	colony stimulating factor 3	Homo sapiens	100-105
9014745-0	1996	High-dose melphalan with re-infusion of unprocessed, G-CSF-primed whole blood is effective and non-toxic therapy in multiple myeloma.	Melphalan	10-19	colony stimulating factor 3	Homo sapiens	53-58
8892651-2	1996	The priming effects produced by recombinant human granulocyte CSF (rhGCSF) and TNF-alpha (rhTNF-alpha) on FMLP-stimulated superoxide production in human and rabbit blood neutrophils were compared with their effects in their respective tissue neutrophils, i.e., human salivary and rabbit peritoneal neutrophils.	Superoxides	122-132	colony stimulating factor 3	Homo sapiens	50-74
8888741-17	1996	CONCLUSIONS: In heavily pretreated children, the MTD for topotecan given by intermittent 30-min infusion for 5 days is 1.4 mg/m2 without GCSF and 2.0 mg/m2/day with GCSF.	Topotecan	57-66	colony stimulating factor 3	Homo sapiens	165-169
8986067-2	1996	The superoxide production of blood leukocytes increased by treatment of G-CSF with its dose dependency.	Superoxides	4-14	colony stimulating factor 3	Homo sapiens	72-77
8923783-0	1996	Administration of granulocyte colony-stimulating factor during remission induction therapy with all-trans retinoic acid for acute promyelocytic leukemia.	Tretinoin	106-119	colony stimulating factor 3	Homo sapiens	18-55
8855989-0	1996	Phase I study of simultaneous dose escalation and schedule acceleration of cyclophosphamide-doxorubicin-etoposide using granulocyte colony-stimulating factor with or without antimicrobial prophylaxis in patients with small-cell lung cancer.	Cyclophosphamide	75-91	colony stimulating factor 3	Homo sapiens	120-157
8982296-1	1996	ACES (Ara-C, carboplatin, etoposide, steroids) therapy using granulocyte-colony stimulating factor (G-CSF) was designed for relapsed or refractory non-Hodgkin"s lymphoma (NHL), and the therapeutic effects and adverse reactions were studied.	Steroids	37-45	colony stimulating factor 3	Homo sapiens	61-98
8923783-1	1996	Granulocyte colony-stimulating factor (G-CSF) enhances the differentiation of acute promyelocytic leukemia (APL) cells induced by all-trans retinoic acid (ATRA) in vitro.	2-octenal	134-139	colony stimulating factor 3	Homo sapiens	0-37
8923783-1	1996	Granulocyte colony-stimulating factor (G-CSF) enhances the differentiation of acute promyelocytic leukemia (APL) cells induced by all-trans retinoic acid (ATRA) in vitro.	2-octenal	134-139	colony stimulating factor 3	Homo sapiens	39-44
8923783-1	1996	Granulocyte colony-stimulating factor (G-CSF) enhances the differentiation of acute promyelocytic leukemia (APL) cells induced by all-trans retinoic acid (ATRA) in vitro.	Tretinoin	140-153	colony stimulating factor 3	Homo sapiens	0-37
8923783-1	1996	Granulocyte colony-stimulating factor (G-CSF) enhances the differentiation of acute promyelocytic leukemia (APL) cells induced by all-trans retinoic acid (ATRA) in vitro.	Tretinoin	140-153	colony stimulating factor 3	Homo sapiens	39-44
8923783-1	1996	Granulocyte colony-stimulating factor (G-CSF) enhances the differentiation of acute promyelocytic leukemia (APL) cells induced by all-trans retinoic acid (ATRA) in vitro.	Tretinoin	155-159	colony stimulating factor 3	Homo sapiens	0-37
8923783-1	1996	Granulocyte colony-stimulating factor (G-CSF) enhances the differentiation of acute promyelocytic leukemia (APL) cells induced by all-trans retinoic acid (ATRA) in vitro.	Tretinoin	155-159	colony stimulating factor 3	Homo sapiens	39-44
8923783-2	1996	Accordingly, we initiated a pilot study on G-CSF in APL patients who developed neutropenia and severe infection during remission induction therapy with ATRA.	Tretinoin	152-156	colony stimulating factor 3	Homo sapiens	43-48
8923783-5	1996	Our findings suggest that administration of G-CSF combined with ATRA can improve the hematological state in APL patients not previously receiving ATRA therapy.	Tretinoin	146-150	colony stimulating factor 3	Homo sapiens	44-49
9816325-14	1996	For Phase II studies of minimally treated adults with solid tumors, the recommended topotecan starting dose administered by 24-h continuous infusion is 10 mg/m2 without G-CSF.	Topotecan	84-93	colony stimulating factor 3	Homo sapiens	169-174
8943758-1	1996	In order to study the pathogenesis of plasma cell dyscrasias with associated clinical features of chronic neutrophilic leukaemia, the concentration of granulocyte-colony stimulating factor (G-CSF) was measured in a patient, a 73 year old man, who underwent steroid pulse therapy.	Steroids	257-264	colony stimulating factor 3	Homo sapiens	151-188
8943758-1	1996	In order to study the pathogenesis of plasma cell dyscrasias with associated clinical features of chronic neutrophilic leukaemia, the concentration of granulocyte-colony stimulating factor (G-CSF) was measured in a patient, a 73 year old man, who underwent steroid pulse therapy.	Steroids	257-264	colony stimulating factor 3	Homo sapiens	190-195
8943758-2	1996	High G-CSF concentrations and leucocyte counts prior to treatment declined rapidly on administration of dexamethazone, but rose subsequently.	Dexamethasone	104-117	colony stimulating factor 3	Homo sapiens	5-10
8941411-13	1996	In measurable metastatic gastric carcinoma, only one PR occurred among 20 previously untreated patients given paclitaxel 250 mg/m2 over 24 hours with granulocyte colony-stimulating factor in a phase II Eastern Cooperative Oncology Group study.	Paclitaxel	110-120	colony stimulating factor 3	Homo sapiens	150-187
8794774-0	1996	Stabilization of granulocyte colony-stimulating factor and structurally analogous growth factors by anionic phospholipids.	Phospholipids	108-121	colony stimulating factor 3	Homo sapiens	17-54
8794774-1	1996	Recombinant granulocyte colony-stimulating factor (rhG-CSF) interacts with liposomes composed of the anionic phospholipid dioleoylphosphatidylglycerol (DOPG), and this interaction enhances the stability of the protein [Collins, D., &amp; Cha, Y.	phospholipid dioleoylphosphatidylglycerol	109-150	colony stimulating factor 3	Homo sapiens	12-49
8794774-1	1996	Recombinant granulocyte colony-stimulating factor (rhG-CSF) interacts with liposomes composed of the anionic phospholipid dioleoylphosphatidylglycerol (DOPG), and this interaction enhances the stability of the protein [Collins, D., &amp; Cha, Y.	1,2-dioleoyl-sn-glycero-3-phosphoglycerol	152-156	colony stimulating factor 3	Homo sapiens	12-49
8883586-6	1996	In other studies we determined the effect of increasing concentrations of ZDV on production of granulocyte colony-stimulating factor (G-CSF) protein [enzyme-linked immunosorbent assay (ELISA)] and mRNA by fetal and maternal monocytes, and on production of erythropoietin protein (ELISA) and mRNA by Hep3B cells.	Zidovudine	74-77	colony stimulating factor 3	Homo sapiens	95-132
8883586-6	1996	In other studies we determined the effect of increasing concentrations of ZDV on production of granulocyte colony-stimulating factor (G-CSF) protein [enzyme-linked immunosorbent assay (ELISA)] and mRNA by fetal and maternal monocytes, and on production of erythropoietin protein (ELISA) and mRNA by Hep3B cells.	Zidovudine	74-77	colony stimulating factor 3	Homo sapiens	134-139
8797373-1	1996	An on-line, automated, HPLC method was developed for the separation and detection of recombinant human methionyl granulocyte colony stimulating factor (GCSF) and GCSF modified with poly(ethylene glycol) (PEG-GCSF) in rat serum.	Polyethylene Glycols	181-202	colony stimulating factor 3	Homo sapiens	162-166
8797373-1	1996	An on-line, automated, HPLC method was developed for the separation and detection of recombinant human methionyl granulocyte colony stimulating factor (GCSF) and GCSF modified with poly(ethylene glycol) (PEG-GCSF) in rat serum.	Polyethylene Glycols	181-202	colony stimulating factor 3	Homo sapiens	162-166
8932983-7	1996	As positive controls, a group of patients treated with cyclophosphamide/G-CSF showed significant increases in GM-CFU (P = 0.018), E-BFU (P = 0.018) and P delta progenitors (P = 0.028).	Cyclophosphamide	55-71	colony stimulating factor 3	Homo sapiens	72-77
8753812-2	1996	G-CSF protein was neither produced during PMA-induced differentiation nor in response to retinoic acid (RA) alone.	Tretinoin	89-102	colony stimulating factor 3	Homo sapiens	0-5
8841050-16	1996	In conclusion, adverse reactions caused by the combination therapy with CPT-11 and CDDP (CPT-11: 50-60 mg/m2 on days 1, 8 and 15, CDDP: 50-60 mg/m2 on day 1) can be relieved by short term administration of G-CSF and it is suggested that the combination therapy may be effective in treating ovarian carcinoma.	Irinotecan	72-78	colony stimulating factor 3	Homo sapiens	206-211
8841050-16	1996	In conclusion, adverse reactions caused by the combination therapy with CPT-11 and CDDP (CPT-11: 50-60 mg/m2 on days 1, 8 and 15, CDDP: 50-60 mg/m2 on day 1) can be relieved by short term administration of G-CSF and it is suggested that the combination therapy may be effective in treating ovarian carcinoma.	Cisplatin	83-87	colony stimulating factor 3	Homo sapiens	206-211
8841050-16	1996	In conclusion, adverse reactions caused by the combination therapy with CPT-11 and CDDP (CPT-11: 50-60 mg/m2 on days 1, 8 and 15, CDDP: 50-60 mg/m2 on day 1) can be relieved by short term administration of G-CSF and it is suggested that the combination therapy may be effective in treating ovarian carcinoma.	Irinotecan	89-95	colony stimulating factor 3	Homo sapiens	206-211
8841050-16	1996	In conclusion, adverse reactions caused by the combination therapy with CPT-11 and CDDP (CPT-11: 50-60 mg/m2 on days 1, 8 and 15, CDDP: 50-60 mg/m2 on day 1) can be relieved by short term administration of G-CSF and it is suggested that the combination therapy may be effective in treating ovarian carcinoma.	Cisplatin	130-134	colony stimulating factor 3	Homo sapiens	206-211
8954183-0	1996	Impact of recombinant human granulocyte colony stimulating factor on dose intensity and toxicity of three cycles of methotrexate, vinblastine, doxorubicin and cisplatin in patients with previously untreated urothelial bladder carcinoma.	Methotrexate	116-128	colony stimulating factor 3	Homo sapiens	28-65
8954183-0	1996	Impact of recombinant human granulocyte colony stimulating factor on dose intensity and toxicity of three cycles of methotrexate, vinblastine, doxorubicin and cisplatin in patients with previously untreated urothelial bladder carcinoma.	Doxorubicin	143-154	colony stimulating factor 3	Homo sapiens	28-65
8954183-0	1996	Impact of recombinant human granulocyte colony stimulating factor on dose intensity and toxicity of three cycles of methotrexate, vinblastine, doxorubicin and cisplatin in patients with previously untreated urothelial bladder carcinoma.	Cisplatin	159-168	colony stimulating factor 3	Homo sapiens	28-65
8753812-0	1996	Production of granulocyte colony-stimulating factor by THP-1 cells in response to retinoic acid and phorbol ester is mediated through the autocrine production of interleukin-1.	Tretinoin	82-95	colony stimulating factor 3	Homo sapiens	14-51
8753812-0	1996	Production of granulocyte colony-stimulating factor by THP-1 cells in response to retinoic acid and phorbol ester is mediated through the autocrine production of interleukin-1.	Phorbol Esters	100-113	colony stimulating factor 3	Homo sapiens	14-51
8753812-1	1996	The human monocytic leukemic cell line, THP-1, which differentiates toward macrophages in response to phorbol 12-myristate 13-acetate (PMA) was investigated for its ability to produce granulocyte colony-stimulating factor (G-CSF).	Tetradecanoylphorbol Acetate	135-138	colony stimulating factor 3	Homo sapiens	184-221
8753812-2	1996	G-CSF protein was neither produced during PMA-induced differentiation nor in response to retinoic acid (RA) alone.	Tetradecanoylphorbol Acetate	42-45	colony stimulating factor 3	Homo sapiens	0-5
8753812-2	1996	G-CSF protein was neither produced during PMA-induced differentiation nor in response to retinoic acid (RA) alone.	Tretinoin	104-106	colony stimulating factor 3	Homo sapiens	0-5
8753812-4	1996	The synergistic interaction between PMA and RA on G-CSF production appeared to be mediated primarily through production of interleukin-1 beta (IL-1 beta) since neutralization of IL-1 beta activity inhibited about 80% of G-CSF production.	Tetradecanoylphorbol Acetate	36-39	colony stimulating factor 3	Homo sapiens	50-55
8753812-4	1996	The synergistic interaction between PMA and RA on G-CSF production appeared to be mediated primarily through production of interleukin-1 beta (IL-1 beta) since neutralization of IL-1 beta activity inhibited about 80% of G-CSF production.	Tetradecanoylphorbol Acetate	36-39	colony stimulating factor 3	Homo sapiens	220-225
8753812-4	1996	The synergistic interaction between PMA and RA on G-CSF production appeared to be mediated primarily through production of interleukin-1 beta (IL-1 beta) since neutralization of IL-1 beta activity inhibited about 80% of G-CSF production.	Tretinoin	44-46	colony stimulating factor 3	Homo sapiens	50-55
8753812-4	1996	The synergistic interaction between PMA and RA on G-CSF production appeared to be mediated primarily through production of interleukin-1 beta (IL-1 beta) since neutralization of IL-1 beta activity inhibited about 80% of G-CSF production.	Tretinoin	44-46	colony stimulating factor 3	Homo sapiens	220-225
8753812-5	1996	It has been previously reported that IL-1 potently synergizes with RA to stimulate G-CSF production by THP-1 cells pretreated with PMA Using synthetic ligands to RA receptors (RAR) and retinoid X receptors (RXR) that selectively bind and activate RAR-RXR and RXR-RXR dimers respectively, we showed that the ability of RA to synergize with IL-1 was signaled through RAR-RXR heterodimer pathway.	Tretinoin	67-69	colony stimulating factor 3	Homo sapiens	83-88
8753812-5	1996	It has been previously reported that IL-1 potently synergizes with RA to stimulate G-CSF production by THP-1 cells pretreated with PMA Using synthetic ligands to RA receptors (RAR) and retinoid X receptors (RXR) that selectively bind and activate RAR-RXR and RXR-RXR dimers respectively, we showed that the ability of RA to synergize with IL-1 was signaled through RAR-RXR heterodimer pathway.	Tetradecanoylphorbol Acetate	131-134	colony stimulating factor 3	Homo sapiens	83-88
8753812-5	1996	It has been previously reported that IL-1 potently synergizes with RA to stimulate G-CSF production by THP-1 cells pretreated with PMA Using synthetic ligands to RA receptors (RAR) and retinoid X receptors (RXR) that selectively bind and activate RAR-RXR and RXR-RXR dimers respectively, we showed that the ability of RA to synergize with IL-1 was signaled through RAR-RXR heterodimer pathway.	Tretinoin	162-164	colony stimulating factor 3	Homo sapiens	83-88
8753812-6	1996	Finally, we demonstrated that RA can also enhance IL-1-induced G-CSF production in primary monocytes of human peripheral blood.	Tretinoin	30-32	colony stimulating factor 3	Homo sapiens	63-68
8663432-8	1996	The oxoETEs, LTB4, GM-CSF, and G-CSF all stimulated PMN to activate the MAPKs and cPLA2, as defined by shifts in these proteins" electrophoretic mobility and tyrosine phosphorylation of the MAPKs.	Tyrosine	158-166	colony stimulating factor 3	Homo sapiens	31-36
8759907-4	1996	A challenge test of G-CSF showed an increase in the platelet count and an augmentation of ADP- and collagen-induced platelet aggregation.	Adenosine Diphosphate	90-93	colony stimulating factor 3	Homo sapiens	20-25
9816298-19	1996	Paclitaxel is active in patients with squamous cell cancer of the cervix and is well tolerated at this dose schedule with G-CSF support.	Paclitaxel	0-10	colony stimulating factor 3	Homo sapiens	122-127
8911114-6	1996	We conclude that neutropenia secondary to suramin is unpredictable and responds to G-CSF administration permitting further suramin therapy.	Suramin	42-49	colony stimulating factor 3	Homo sapiens	83-88
8911114-6	1996	We conclude that neutropenia secondary to suramin is unpredictable and responds to G-CSF administration permitting further suramin therapy.	Suramin	123-130	colony stimulating factor 3	Homo sapiens	83-88
8882958-7	1996	After stem-cell reinfusion, 55% of the PBPC group received GCSF versus 24% in the BM group.	PbPc	39-43	colony stimulating factor 3	Homo sapiens	59-63
8840537-10	1996	These results suggest that low dose G-CSF effectively and safely mobilizes a sufficient quantity of PMN from GT-donors without excessive superoxide generation from the transfused cells.	Superoxides	137-147	colony stimulating factor 3	Homo sapiens	36-41
8760796-7	1996	Fas-mediated neutrophil apoptosis was suppressed by incubation with G-CSF, GM-CSF, IFN-gamma, TNF-alpha, or dexamethasone, as well as the selective tyrosine kinase inhibitors, herbimycin A and genistein.	ammonium ferrous sulfate	0-3	colony stimulating factor 3	Homo sapiens	68-73
8703906-1	1996	Alanine scanning mutagenesis of human granulocyte colony-stimulating factor (G-CSF) was used to identify residues critical for the cell-proliferative activity of the protein.	Alanine	0-7	colony stimulating factor 3	Homo sapiens	38-75
8703906-1	1996	Alanine scanning mutagenesis of human granulocyte colony-stimulating factor (G-CSF) was used to identify residues critical for the cell-proliferative activity of the protein.	Alanine	0-7	colony stimulating factor 3	Homo sapiens	77-82
8974788-11	1996	The EORTC LCG is currently studying the relative value of various intercalating agents during induction, and of the G-CSF as well, and, during remission the autologous peripheral stem cells compared to bone marrow transplantation.	eortc lcg	4-13	colony stimulating factor 3	Homo sapiens	116-121
8647914-0	1996	Methotrexate inhibits superoxide production and chemotaxis in neutrophils activated by granulocyte colony-stimulating factor.	Methotrexate	0-12	colony stimulating factor 3	Homo sapiens	87-124
8647914-0	1996	Methotrexate inhibits superoxide production and chemotaxis in neutrophils activated by granulocyte colony-stimulating factor.	Superoxides	22-32	colony stimulating factor 3	Homo sapiens	87-124
8647914-1	1996	Treatment of circulating human neutrophils with recombinant human granulocyte colony-stimulating factor (rhG-CSF) for 30 min augmented superoxide generation and chemotaxis induced by N-formylmethionyl-leucyl-phenylalanine (fMLP) in a dose dependent manner.	N-Formylmethionine Leucyl-Phenylalanine	183-221	colony stimulating factor 3	Homo sapiens	66-103
8647914-1	1996	Treatment of circulating human neutrophils with recombinant human granulocyte colony-stimulating factor (rhG-CSF) for 30 min augmented superoxide generation and chemotaxis induced by N-formylmethionyl-leucyl-phenylalanine (fMLP) in a dose dependent manner.	Superoxides	135-145	colony stimulating factor 3	Homo sapiens	66-103
8683231-2	1996	MATERIALS AND METHODS: The recommended phase II dose of weekly CPT-11 administered as a 90-minute infusion is 145 mg/m2 with granulocyte colony-stimulating factor (G-CSF) and maximal antidiarrheal support.	Irinotecan	63-69	colony stimulating factor 3	Homo sapiens	125-162
8683231-2	1996	MATERIALS AND METHODS: The recommended phase II dose of weekly CPT-11 administered as a 90-minute infusion is 145 mg/m2 with granulocyte colony-stimulating factor (G-CSF) and maximal antidiarrheal support.	Irinotecan	63-69	colony stimulating factor 3	Homo sapiens	164-169
9387319-2	1996	ELISA method was used in detecting levels of serum granulocyle colony-stimulating factor (G-CSF) in 47 cases of APL during treatment with ATRA.	Tretinoin	138-142	colony stimulating factor 3	Homo sapiens	51-88
8819077-0	1996	Heterogeneous effects of G-CSF and GM-CSF on cell growth and ara-C cytotoxicity in childhood leukemias which express myeloid markers.	Cytarabine	61-66	colony stimulating factor 3	Homo sapiens	25-30
8819077-7	1996	These results indicate the heterogeneous effects of G-CSF and GM-CSF on cell growth and ara-C sensitivity in childhood leukemia cells.	Cytarabine	88-93	colony stimulating factor 3	Homo sapiens	52-57
8810839-0	1996	Adsorption of recombinant human granulocyte colony stimulating factor (rhG-CSF) to polyvinyl chloride, polypropylene, and glass: effect of solvent additives.	Polyvinyl Chloride	83-101	colony stimulating factor 3	Homo sapiens	32-69
8926688-0	1996	[IDA-FLAG (idarubicin, fludarabine, high dosage cytarabine and G-CSF)--an effective therapy regimen in treatment of recurrent acute myelocytic leukemia in children and adolescents.	ida-flag	1-9	colony stimulating factor 3	Homo sapiens	63-68
9387319-2	1996	ELISA method was used in detecting levels of serum granulocyle colony-stimulating factor (G-CSF) in 47 cases of APL during treatment with ATRA.	Tretinoin	138-142	colony stimulating factor 3	Homo sapiens	90-95
9387319-4	1996	After ATRA treatment, both serum G-CSF level and WBC number increased in 68.1% of the cases.	Tretinoin	6-10	colony stimulating factor 3	Homo sapiens	33-38
8645591-1	1996	We have evaluated the feasibility of an increase in dose intensity of the cisplatin, epidoxorubicin and cyclophosphamide (PEC) regimen, with granulocyte colony-stimulating factor (G-CSF) support, in 22 patients with advanced ovarian cancer.	Epirubicin	85-99	colony stimulating factor 3	Homo sapiens	180-185
8767319-0	1996	[Ticlopidine-induced pancytopenia: therapy of agranulocytosis with granulocyte colony stimulating factor].	Ticlopidine	1-12	colony stimulating factor 3	Homo sapiens	67-104
8638644-3	1996	The spontaneous production of G-CSF by BMF was below the detectable level.	BMF	39-42	colony stimulating factor 3	Homo sapiens	30-35
8807097-15	1996	Twenty-two of 24 (92%) patients receiving CE with G-CSF achieved a target level of 5 x 10(6) CD34+ cells/kg or more as compared to 11 of 19 (58%) patients receiving G-CSF alone (P = 0.01) and six of 14 (43%) patients receiving CY with G or GM-CSF (P = 0.001).	Cyclophosphamide	227-229	colony stimulating factor 3	Homo sapiens	50-55
8724545-1	1996	The adenine nucleoside analogue, fludarabine phosphate, in combination with cytosine-arabinoside (Ara-C) and granulocyte-colony stimulating factor (G-CSF) (the so called FLAG regimen) has recently been shown to be effective in the treatment of poor-prognosis acute non-lymphoid leukaemia.	Adenosine	4-22	colony stimulating factor 3	Homo sapiens	109-146
8793147-3	1996	RESULTS: Cytokines, granulocyte colony-stimulating factor (G-CSF) and granulocyte-macrophage colony-stimulating factor (GM-CSF), appear to shorten the duration of clozapine-induced neutropenia.	Clozapine	163-172	colony stimulating factor 3	Homo sapiens	20-57
8793147-3	1996	RESULTS: Cytokines, granulocyte colony-stimulating factor (G-CSF) and granulocyte-macrophage colony-stimulating factor (GM-CSF), appear to shorten the duration of clozapine-induced neutropenia.	Clozapine	163-172	colony stimulating factor 3	Homo sapiens	59-64
8762814-1	1996	We previously identified a receptor for granulocyte colony-stimulating factor (G-CSFR) on platelet membranes, and reported that G-CSF enhanced ADP-induced platelet aggregation.	Adenosine Diphosphate	143-146	colony stimulating factor 3	Homo sapiens	40-77
8762814-1	1996	We previously identified a receptor for granulocyte colony-stimulating factor (G-CSFR) on platelet membranes, and reported that G-CSF enhanced ADP-induced platelet aggregation.	Adenosine Diphosphate	143-146	colony stimulating factor 3	Homo sapiens	79-85
8762814-1	1996	We previously identified a receptor for granulocyte colony-stimulating factor (G-CSFR) on platelet membranes, and reported that G-CSF enhanced ADP-induced platelet aggregation.	Adenosine Diphosphate	143-146	colony stimulating factor 3	Homo sapiens	79-84
8677441-9	1996	These findings indicate that ifosfamide-containing combination chemotherapy regimens have activity in advanced non-small cell lung cancer and are well tolerated when administered with granulocyte colony-stimulating factor.	Ifosfamide	29-39	colony stimulating factor 3	Homo sapiens	184-221
8884748-4	1996	In addition, gp130-interactive proteins and granulocyte colony-stimulating factor (G-CSF) utilize another binding site (site III) at the boundary between CD loop and helix D. CNTF triggers the association of receptor components, resulting in activation of a signal transduction cascade mediated by specific intracellular protein tyrosine kinases.	Cadmium	154-156	colony stimulating factor 3	Homo sapiens	44-81
8884748-4	1996	In addition, gp130-interactive proteins and granulocyte colony-stimulating factor (G-CSF) utilize another binding site (site III) at the boundary between CD loop and helix D. CNTF triggers the association of receptor components, resulting in activation of a signal transduction cascade mediated by specific intracellular protein tyrosine kinases.	Cadmium	154-156	colony stimulating factor 3	Homo sapiens	83-88
8804544-3	1996	Amphotericin B lipid complex (ABLC), 5 mg/kg/day, in conjunction with repeated surgical debridement of the sinuses and correction of neutropenia with granulocyte colony stimulating factor (GCSF), led to clinical and mycologic cure.	amphotericin b lipid	0-20	colony stimulating factor 3	Homo sapiens	150-187
8660524-0	1996	Preparation of pyridylaminated O-linked sugar chains from glycoproteins blotted on a polyvinylidene difluoride membrane and application to human granulocyte colony-stimulating factor.	o-linked sugar	31-45	colony stimulating factor 3	Homo sapiens	145-182
8647290-4	1996	In keeping with this result, treatment of neutrophils with G-CSF led to tyrosine phosphorylation of STAT3, as determined by immunoprecipitation followed by immunoblotting with antiphosphotyrosine antibodies.	Tyrosine	72-80	colony stimulating factor 3	Homo sapiens	59-64
8804544-3	1996	Amphotericin B lipid complex (ABLC), 5 mg/kg/day, in conjunction with repeated surgical debridement of the sinuses and correction of neutropenia with granulocyte colony stimulating factor (GCSF), led to clinical and mycologic cure.	amphotericin b lipid	0-20	colony stimulating factor 3	Homo sapiens	189-193
8804544-3	1996	Amphotericin B lipid complex (ABLC), 5 mg/kg/day, in conjunction with repeated surgical debridement of the sinuses and correction of neutropenia with granulocyte colony stimulating factor (GCSF), led to clinical and mycologic cure.	liposomal amphotericin B	30-34	colony stimulating factor 3	Homo sapiens	150-187
8767533-7	1996	A patient with Vaquez"s disease, in remission for 15 years and presenting a progressive increase in bone marrow and peripheral myeloblasts, did not have a positive response to the administration of ATRA; however, the association of G-CSF to ATRA was followed by a complete remission.	Tretinoin	241-245	colony stimulating factor 3	Homo sapiens	232-237
8641405-9	1996	In conclusion, FLAG is an active and tolerable combination in refractory ALL, particularly in cases with myeloid antigen expression where G-CSF appears to improve efficacy, probably increasing ara-C incorporation into the DNA of leukemic cells.	Cytarabine	193-198	colony stimulating factor 3	Homo sapiens	138-143
8641405-6	1996	In vitro 3H ara-C incorporation into cellular DNA resulted significantly increased by Fludarabine (in 7/9 tested cases) and, furthermore, by the association of Fludarabine G-CSF in 5 evaluable ALL/My+ cases; in contrast, no effect of G-CSF addition to Fludarabine was observed in 4 ALL/My.	3h ara-c	9-17	colony stimulating factor 3	Homo sapiens	172-177
8641405-6	1996	In vitro 3H ara-C incorporation into cellular DNA resulted significantly increased by Fludarabine (in 7/9 tested cases) and, furthermore, by the association of Fludarabine G-CSF in 5 evaluable ALL/My+ cases; in contrast, no effect of G-CSF addition to Fludarabine was observed in 4 ALL/My.	3h ara-c	9-17	colony stimulating factor 3	Homo sapiens	234-239
8797041-1	1996	To examine the effect of human granulocyte colony-stimulating factor (G-CSF) on the hemopoietic response to repeated treatment with the anticancer drug cyclophosphamide (CPA) in mice, we determined the optimal time interval between CPA doses which was required to equalize the recovery of neutrophils in the first and second cycle.	Cyclophosphamide	170-173	colony stimulating factor 3	Homo sapiens	70-75
8624378-12	1996	This pilot study demonstrates that treatment with ATRA/G-CSF/EPO/tocopherol is well tolerated, leading to normalization of neutrophil counts in most, and to improvement of platelets and red blood cells in a significant subgroup of patients.	Tretinoin	50-54	colony stimulating factor 3	Homo sapiens	55-60
8622080-1	1996	PURPOSE: The goals of this study were to define the efficacy and toxicity of doxorubicin and dose-escalated cyclophosphamide (Cy) along with granulocyte colony-stimulating factor (G-CSF) in the treatment of hormone-refractory prostate cancer (HRPC), to determine the maximal-tolerated dose (MTD) of Cy in this regimen, and to evaluate the impact of prior pelvic irradiation (XRT) on MTD and toxicity.	Cyclophosphamide	299-301	colony stimulating factor 3	Homo sapiens	180-185
8641981-9	1996	Dexamethasone treatment inhibited the transcription of G-CSF and PTHrP genes.	Dexamethasone	0-13	colony stimulating factor 3	Homo sapiens	55-60
8622073-11	1996	CONCLUSION: A dose of CY at 2,000 mg/m2 can be administered every 2 weeks with DOX and G-CSF for eight cycles in the outpatient setting with manageable toxicity.	Cyclophosphamide	22-24	colony stimulating factor 3	Homo sapiens	87-92
8622074-9	1996	CONCLUSION: A 5-day course of G-CSF in patients with prior chemotherapy delays due to prolonged neutropenia seems to be a safe and cost-effective schedule to maintain CMF or doxorubicin-CMF dose-intensity in the adjuvant treatment of breast cancer.	Doxorubicin	174-185	colony stimulating factor 3	Homo sapiens	30-35
8622080-0	1996	Doxorubicin and dose-escalated cyclophosphamide with granulocyte colony-stimulating factor for the treatment of hormone-resistant prostate cancer.	Cyclophosphamide	31-47	colony stimulating factor 3	Homo sapiens	53-90
8624378-12	1996	This pilot study demonstrates that treatment with ATRA/G-CSF/EPO/tocopherol is well tolerated, leading to normalization of neutrophil counts in most, and to improvement of platelets and red blood cells in a significant subgroup of patients.	Tocopherols	65-75	colony stimulating factor 3	Homo sapiens	55-60
8630373-0	1996	Tryptophan 650 of human granulocyte colony-stimulating factor (G-CSF) receptor, implicated in the activation of JAK2, is also required for G-CSF-mediated activation of signaling complexes of the p21ras route.	Tryptophan	0-10	colony stimulating factor 3	Homo sapiens	63-68
8605966-0	1996	Bryostatin 1 acts synergistically with interleukin-1 alpha to induce secretion of G-CSF and other cytokines from marrow stromal cells.	bryostatin 1	0-12	colony stimulating factor 3	Homo sapiens	82-87
8648378-0	1996	Phase I and pharmacologic study of high doses of the topoisomerase I inhibitor topotecan with granulocyte colony-stimulating factor in patients with solid tumors.	Topotecan	79-88	colony stimulating factor 3	Homo sapiens	94-131
8648378-1	1996	PURPOSE: To evaluate the feasibility of escalating doses of the topoisomerase I (topo I) inhibitor topotecan (TPT) with granulocyte colony-stimulating factor (G-CSF) in minimally pretreated adults with solid tumors and to study whether G-CSF scheduling variably affects the ability to escalate TPT doses.	Topotecan	99-108	colony stimulating factor 3	Homo sapiens	120-157
8648378-1	1996	PURPOSE: To evaluate the feasibility of escalating doses of the topoisomerase I (topo I) inhibitor topotecan (TPT) with granulocyte colony-stimulating factor (G-CSF) in minimally pretreated adults with solid tumors and to study whether G-CSF scheduling variably affects the ability to escalate TPT doses.	Topotecan	99-108	colony stimulating factor 3	Homo sapiens	159-164
8648378-1	1996	PURPOSE: To evaluate the feasibility of escalating doses of the topoisomerase I (topo I) inhibitor topotecan (TPT) with granulocyte colony-stimulating factor (G-CSF) in minimally pretreated adults with solid tumors and to study whether G-CSF scheduling variably affects the ability to escalate TPT doses.	Topotecan	99-108	colony stimulating factor 3	Homo sapiens	236-241
8648378-7	1996	However, dose escalation of TPT with G-CSF on a posttreatment schedule proceeded to 4.2 mg/m2/d.	Topotecan	28-31	colony stimulating factor 3	Homo sapiens	37-42
8648378-13	1996	CONCLUSION: G-CSF administered after 5 daily 30-minute infusions of TPT permits a 2.3-fold dose escalation of TPT above the MTD in solid-tumor patients, whereas concurrent therapy with G-CSF and TPT results in severe myelosuppression.	Topotecan	68-71	colony stimulating factor 3	Homo sapiens	12-17
8648378-13	1996	CONCLUSION: G-CSF administered after 5 daily 30-minute infusions of TPT permits a 2.3-fold dose escalation of TPT above the MTD in solid-tumor patients, whereas concurrent therapy with G-CSF and TPT results in severe myelosuppression.	Topotecan	110-113	colony stimulating factor 3	Homo sapiens	12-17
8648378-13	1996	CONCLUSION: G-CSF administered after 5 daily 30-minute infusions of TPT permits a 2.3-fold dose escalation of TPT above the MTD in solid-tumor patients, whereas concurrent therapy with G-CSF and TPT results in severe myelosuppression.	Topotecan	110-113	colony stimulating factor 3	Homo sapiens	12-17
8648379-7	1996	CONCLUSION: The recommended phase II dose of 9-AC given by 72-hour infusion every 2 weeks is 35 microg/m2/h without G-CSF or 47 microg/m2/h with G-CSF support.	9-aminocamptothecin	45-49	colony stimulating factor 3	Homo sapiens	116-121
8648379-7	1996	CONCLUSION: The recommended phase II dose of 9-AC given by 72-hour infusion every 2 weeks is 35 microg/m2/h without G-CSF or 47 microg/m2/h with G-CSF support.	9-aminocamptothecin	45-49	colony stimulating factor 3	Homo sapiens	145-150
8610230-16	1996	The maximum tolerated dose of vinorelbine given on days 1, 2, and 3 is 30 mg/m2 when given with ifosfamide at 1.6 g/m2 on days 1, 2, and 3 and granulocyte colony-stimulating factor support.	Vinorelbine	30-41	colony stimulating factor 3	Homo sapiens	143-180
8622027-2	1996	PATIENTS AND METHODS: A phase I study of escalating target area under the curves (AUCs) of carboplatin with G-CSF (filgrastim) ws undertaken.	Carboplatin	91-102	colony stimulating factor 3	Homo sapiens	108-113
8616019-1	1996	We evaluated the effects of high-dose recombinant human granulocyte colony-stimulating factor (rhG-CSF) therapy on N-formyl-methionyl-leucyl-phenylalanine (FMLP)-induced chemotaxis and superoxide (O2-) production in neutrophils from four patients with aplastic anaemia.	N-Formylmethionine Leucyl-Phenylalanine	156-160	colony stimulating factor 3	Homo sapiens	56-93
8774656-0	1996	Sequential granulocyte colony-stimulating factor increases cisplatin cytotoxicity in human epithelial ovarian cancer cell lines.	Cisplatin	59-68	colony stimulating factor 3	Homo sapiens	11-48
8774656-5	1996	Simultaneous G-CSF decreased cisplatin cytotoxicity in five cell lines (7-45%).	Cisplatin	29-38	colony stimulating factor 3	Homo sapiens	13-18
8774656-6	1996	Sequential G-CSF increased cisplatin cytotoxicity in all six cell lines (5-108%).	Cisplatin	27-36	colony stimulating factor 3	Homo sapiens	11-16
8774656-8	1996	Simultaneous G-CSF may decrease cisplatin cytotoxicity, while sequential G-CSF appears to increase cisplatin cytotoxicity.	Cisplatin	99-108	colony stimulating factor 3	Homo sapiens	73-78
8634418-1	1996	Previous studies have shown that retinoic acid (RA), similar to tumor necrosis factor-alpha (TNF-alpha), can act as a bifunctional regulator of the growth of bone marrow progenitors, in that it can stimulate granulocyte-macrophage colony-stimulating factor (GM-CSF)- or interleukin-3 (IL-3)-induced GM colony formation, but potently inhibit G-CSF-induced growth.	Tretinoin	33-46	colony stimulating factor 3	Homo sapiens	341-346
8634418-1	1996	Previous studies have shown that retinoic acid (RA), similar to tumor necrosis factor-alpha (TNF-alpha), can act as a bifunctional regulator of the growth of bone marrow progenitors, in that it can stimulate granulocyte-macrophage colony-stimulating factor (GM-CSF)- or interleukin-3 (IL-3)-induced GM colony formation, but potently inhibit G-CSF-induced growth.	Tretinoin	48-50	colony stimulating factor 3	Homo sapiens	341-346
8634426-1	1996	Single-cell suspensions of granulocyte colony-stimulating factor (G-CSF)-mobilized peripheral blood mononuclear cells (G-PBMC) cultured in alpha minimal essential medium (alphaMEM) containing 10% fetal bovine serum formed multicellular aggregates within 24 hours.	alpha minimal essential medium	139-169	colony stimulating factor 3	Homo sapiens	27-64
8622023-0	1996	Phase I/II study of 72-hour infusional paclitaxel and doxorubicin with granulocyte colony-stimulating factor in patients with metastatic breast cancer.	Doxorubicin	54-65	colony stimulating factor 3	Homo sapiens	71-108
8622027-1	1996	PURPOSE: The aim of this study was to increase the dose intensity of carboplatin in women with International Federation of Gynecology and Obstetrics (FIGO) Stage Ic-IV epithelial ovarian cancer with the use of granulocyte colony-stimulating factor (G-CSF; filgrastim; Amgen, Thousand Oaks, CA).	Carboplatin	69-80	colony stimulating factor 3	Homo sapiens	210-247
8622027-1	1996	PURPOSE: The aim of this study was to increase the dose intensity of carboplatin in women with International Federation of Gynecology and Obstetrics (FIGO) Stage Ic-IV epithelial ovarian cancer with the use of granulocyte colony-stimulating factor (G-CSF; filgrastim; Amgen, Thousand Oaks, CA).	Carboplatin	69-80	colony stimulating factor 3	Homo sapiens	249-254
8622027-4	1996	G-CSF was given at a dose of 5 microg/kg/d starting 24 hours after carboplatin administration and lasting until 24 hours before the next cycle and until day 14 after the last cycle.	Carboplatin	67-78	colony stimulating factor 3	Homo sapiens	0-5
8732454-2	1996	Serum G-CSF levels increased with the mean peak values at 4 h after the HDMP therapy (mean +/- SD: 488.1 +/- 125.8 pg/ml vs. saline control 74.4 +/- 21.9 pg/ml, P &lt; 0.01).	Sodium Chloride	125-131	colony stimulating factor 3	Homo sapiens	6-11
8642855-9	1996	Response to Ara-C by growth factor responsive blast cells is influenced by the factor in the cultures; cells are more sensitive in cultures with G-CSF and less sensitive when GM-CSF is present.	Cytarabine	12-17	colony stimulating factor 3	Homo sapiens	145-150
8608222-2	1996	G-CSF induces tyrosine phosphorylation of Jak1, Jak2, STAT1, and STAT3.	Tyrosine	14-22	colony stimulating factor 3	Homo sapiens	0-5
8680517-7	1996	Exciting new management strategies appear to be the use of granulocyte colony-stimulating factor to enhance neutrophilia and zidovudine to reduce vertical transmission of HIV infection.	Zidovudine	125-135	colony stimulating factor 3	Homo sapiens	59-96
8637222-10	1996	These preliminary data suggest that short-course HDMP treatment could decrease serum TNF-alpha and gamma-INF and increase G-CSF and GM-CSF levels.	hdmp	49-53	colony stimulating factor 3	Homo sapiens	122-127
8640159-5	1996	PBPC were collected during granulocyte colony-stimulating factor (G-CSF)-enhanced leukocyte recovery following treatment with high-dose cytarabine and mitoxantrone (HAM).	Mitoxantrone	151-163	colony stimulating factor 3	Homo sapiens	66-71
8732454-0	1996	Increased serum human granulocyte colony-stimulating factor (G-CSF) levels following intravenous infusion of high-dose methylprednisolone.	Methylprednisolone	119-137	colony stimulating factor 3	Homo sapiens	22-59
8732454-0	1996	Increased serum human granulocyte colony-stimulating factor (G-CSF) levels following intravenous infusion of high-dose methylprednisolone.	Methylprednisolone	119-137	colony stimulating factor 3	Homo sapiens	61-66
8629035-6	1996	Hematologic toxicities were dose limiting with the biweekly and low-dose 24-hour paclitaxel/cisplatin combinations; with granulocyte colony-stimulating factor, neurotoxicity became a prominent cumulative toxicity of the high-dose paclitaxel/cisplatin combination.	Paclitaxel	81-91	colony stimulating factor 3	Homo sapiens	121-158
8636780-1	1996	PURPOSE: We compared hematologic and clinical effects of granulocyte-macrophage colony-stimulating factor (GM-CSF) and granulocyte colony-stimulating factor (G-CSF) after treatment with high-dose cyclophosphamide (HD-CTX, 7 g/m2), given as the first phase of a high-dose sequential chemotherapy program that includes a myeloablative therapy with mobilized progenitor cell autografting.	Cyclophosphamide	196-212	colony stimulating factor 3	Homo sapiens	119-156
8629035-6	1996	Hematologic toxicities were dose limiting with the biweekly and low-dose 24-hour paclitaxel/cisplatin combinations; with granulocyte colony-stimulating factor, neurotoxicity became a prominent cumulative toxicity of the high-dose paclitaxel/cisplatin combination.	Cisplatin	92-101	colony stimulating factor 3	Homo sapiens	121-158
8629035-6	1996	Hematologic toxicities were dose limiting with the biweekly and low-dose 24-hour paclitaxel/cisplatin combinations; with granulocyte colony-stimulating factor, neurotoxicity became a prominent cumulative toxicity of the high-dose paclitaxel/cisplatin combination.	Paclitaxel	230-240	colony stimulating factor 3	Homo sapiens	121-158
8629035-6	1996	Hematologic toxicities were dose limiting with the biweekly and low-dose 24-hour paclitaxel/cisplatin combinations; with granulocyte colony-stimulating factor, neurotoxicity became a prominent cumulative toxicity of the high-dose paclitaxel/cisplatin combination.	Cisplatin	241-250	colony stimulating factor 3	Homo sapiens	121-158
8629035-12	1996	However, granulocyte colony-stimulating factor has ameliorated myelosuppression and allowed considerable dose escalation of cyclophosphamide.	Cyclophosphamide	124-140	colony stimulating factor 3	Homo sapiens	9-46
8547662-6	1996	Retinoic acid (RA) was the strongest inducer of defensin mRNA accumulation, even at doses too low to effect morphologic changes; the initial (first 48 hours), gradual increase resulted from transcriptional activation and was enhanced by granulocyte colony-stimulating factor.	Tretinoin	0-13	colony stimulating factor 3	Homo sapiens	237-274
8742097-1	1996	It was our intention to verify if increases of granulocyte colony stimulating factor (G-CSF) dose were able to reduce treatment delays due to leukopenia in our weekly regimen of cisplatin (40 mg/m2), epidoxorubicin (35 mg/m2), 6S-leucovorin (250 mg/m2) and 5-fluorouracil (500 mg/m2), usually supported by G-CSF at a dose of 5 mu g/kg.	Cisplatin	178-187	colony stimulating factor 3	Homo sapiens	47-84
8742097-1	1996	It was our intention to verify if increases of granulocyte colony stimulating factor (G-CSF) dose were able to reduce treatment delays due to leukopenia in our weekly regimen of cisplatin (40 mg/m2), epidoxorubicin (35 mg/m2), 6S-leucovorin (250 mg/m2) and 5-fluorouracil (500 mg/m2), usually supported by G-CSF at a dose of 5 mu g/kg.	Cisplatin	178-187	colony stimulating factor 3	Homo sapiens	86-91
8742097-1	1996	It was our intention to verify if increases of granulocyte colony stimulating factor (G-CSF) dose were able to reduce treatment delays due to leukopenia in our weekly regimen of cisplatin (40 mg/m2), epidoxorubicin (35 mg/m2), 6S-leucovorin (250 mg/m2) and 5-fluorouracil (500 mg/m2), usually supported by G-CSF at a dose of 5 mu g/kg.	Epirubicin	200-214	colony stimulating factor 3	Homo sapiens	47-84
8742097-1	1996	It was our intention to verify if increases of granulocyte colony stimulating factor (G-CSF) dose were able to reduce treatment delays due to leukopenia in our weekly regimen of cisplatin (40 mg/m2), epidoxorubicin (35 mg/m2), 6S-leucovorin (250 mg/m2) and 5-fluorouracil (500 mg/m2), usually supported by G-CSF at a dose of 5 mu g/kg.	Epirubicin	200-214	colony stimulating factor 3	Homo sapiens	86-91
8742097-1	1996	It was our intention to verify if increases of granulocyte colony stimulating factor (G-CSF) dose were able to reduce treatment delays due to leukopenia in our weekly regimen of cisplatin (40 mg/m2), epidoxorubicin (35 mg/m2), 6S-leucovorin (250 mg/m2) and 5-fluorouracil (500 mg/m2), usually supported by G-CSF at a dose of 5 mu g/kg.	Levoleucovorin	227-240	colony stimulating factor 3	Homo sapiens	47-84
8742097-1	1996	It was our intention to verify if increases of granulocyte colony stimulating factor (G-CSF) dose were able to reduce treatment delays due to leukopenia in our weekly regimen of cisplatin (40 mg/m2), epidoxorubicin (35 mg/m2), 6S-leucovorin (250 mg/m2) and 5-fluorouracil (500 mg/m2), usually supported by G-CSF at a dose of 5 mu g/kg.	Levoleucovorin	227-240	colony stimulating factor 3	Homo sapiens	86-91
8742097-1	1996	It was our intention to verify if increases of granulocyte colony stimulating factor (G-CSF) dose were able to reduce treatment delays due to leukopenia in our weekly regimen of cisplatin (40 mg/m2), epidoxorubicin (35 mg/m2), 6S-leucovorin (250 mg/m2) and 5-fluorouracil (500 mg/m2), usually supported by G-CSF at a dose of 5 mu g/kg.	Fluorouracil	257-271	colony stimulating factor 3	Homo sapiens	47-84
8742097-1	1996	It was our intention to verify if increases of granulocyte colony stimulating factor (G-CSF) dose were able to reduce treatment delays due to leukopenia in our weekly regimen of cisplatin (40 mg/m2), epidoxorubicin (35 mg/m2), 6S-leucovorin (250 mg/m2) and 5-fluorouracil (500 mg/m2), usually supported by G-CSF at a dose of 5 mu g/kg.	Fluorouracil	257-271	colony stimulating factor 3	Homo sapiens	86-91
8630941-2	1996	BACKGROUND: We performed a Phase I-II trial to determine the maximum tolerated dose of carboplatin (CBDCA) with a fixed dose of VP-16 and granulocyte-colony stimulating factor (G-CSF) in small cell lung cancer (SCLC) patients.	Carboplatin	87-98	colony stimulating factor 3	Homo sapiens	138-175
8612310-1	1996	The purpose of the present study was to determine the maximally tolerated dose of thioTEPA given with fixed high-dose cyclophosphamide (CPA) and cisplatin (cDDP) followed by autologous bone marrow (ABM) with or without granulocyte colony-stimulating factor (G-CSF)-primed peripheral-blood progenitor cells (PBPCs) in patients with advanced malignancies.	Thiotepa	82-90	colony stimulating factor 3	Homo sapiens	219-256
8612310-1	1996	The purpose of the present study was to determine the maximally tolerated dose of thioTEPA given with fixed high-dose cyclophosphamide (CPA) and cisplatin (cDDP) followed by autologous bone marrow (ABM) with or without granulocyte colony-stimulating factor (G-CSF)-primed peripheral-blood progenitor cells (PBPCs) in patients with advanced malignancies.	Thiotepa	82-90	colony stimulating factor 3	Homo sapiens	258-263
8630941-2	1996	BACKGROUND: We performed a Phase I-II trial to determine the maximum tolerated dose of carboplatin (CBDCA) with a fixed dose of VP-16 and granulocyte-colony stimulating factor (G-CSF) in small cell lung cancer (SCLC) patients.	Carboplatin	87-98	colony stimulating factor 3	Homo sapiens	177-182
8599980-9	1996	G-CSF significantly enhanced the cytotoxic effect of daunorubicin, mitoxantrone, etoposide and Ara-C by 20-40%, which GM-CSF and IL-3 showed a significantly increased toxicity for Ara-C only.	Daunorubicin	53-65	colony stimulating factor 3	Homo sapiens	0-5
8599980-9	1996	G-CSF significantly enhanced the cytotoxic effect of daunorubicin, mitoxantrone, etoposide and Ara-C by 20-40%, which GM-CSF and IL-3 showed a significantly increased toxicity for Ara-C only.	Mitoxantrone	67-79	colony stimulating factor 3	Homo sapiens	0-5
8765429-6	1996	In all, 25 patients were treated with granulocyte colony-stimulating factor (G-CSF) after CPC administration.	cpc	90-93	colony stimulating factor 3	Homo sapiens	77-82
8987246-9	1996	Haemopoietic growth factors such as G-CSF, when given after immunosuppressive therapy such as antilymphocyte globulin and cyclosporin for aplastic anaemia, may act partly by reducing the increased level of apoptosis, resulting in improved stem cell survival.	Cyclosporine	122-133	colony stimulating factor 3	Homo sapiens	36-41
8599980-9	1996	G-CSF significantly enhanced the cytotoxic effect of daunorubicin, mitoxantrone, etoposide and Ara-C by 20-40%, which GM-CSF and IL-3 showed a significantly increased toxicity for Ara-C only.	Etoposide	81-90	colony stimulating factor 3	Homo sapiens	0-5
8599980-9	1996	G-CSF significantly enhanced the cytotoxic effect of daunorubicin, mitoxantrone, etoposide and Ara-C by 20-40%, which GM-CSF and IL-3 showed a significantly increased toxicity for Ara-C only.	Cytarabine	95-100	colony stimulating factor 3	Homo sapiens	0-5
8599980-9	1996	G-CSF significantly enhanced the cytotoxic effect of daunorubicin, mitoxantrone, etoposide and Ara-C by 20-40%, which GM-CSF and IL-3 showed a significantly increased toxicity for Ara-C only.	Cytarabine	180-185	colony stimulating factor 3	Homo sapiens	0-5
7485112-0	1995	Sustained granulocyte recovery after G-CSF in a patient with ticlopidine-induced severe aplastic anemia.	Ticlopidine	61-72	colony stimulating factor 3	Homo sapiens	37-42
8536792-11	1996	In patients treated with mitomycin C and TNF, G-CSF levels increased at 4 hours after TNF initiation (mean 3886 +/- 2009 pg/mL; p = 0.004), remained elevated at 6 hours (mean 2140 +/- 1131 pg/mL; p = 0.004), and subsequently declined.	Mitomycin	25-36	colony stimulating factor 3	Homo sapiens	46-51
8668656-0	1996	Enteral bioavailability of human granulocyte colony stimulating factor conjugated with poly(ethylene glycol).	Polyethylene Glycols	87-108	colony stimulating factor 3	Homo sapiens	33-70
8668656-6	1996	CONCLUSIONS: The possible mechanisms of enteral delivery of PEG-G-CSF are discussed.	Polyethylene Glycols	60-63	colony stimulating factor 3	Homo sapiens	64-69
8927660-0	1996	The treatment of clozapine-associated agranulocytosis with granulocyte colony-stimulating factor (G-CSF).	Clozapine	17-26	colony stimulating factor 3	Homo sapiens	59-96
8927660-0	1996	The treatment of clozapine-associated agranulocytosis with granulocyte colony-stimulating factor (G-CSF).	Clozapine	17-26	colony stimulating factor 3	Homo sapiens	98-103
8927660-1	1996	During a 5-year period, 6 patients with clozapine-associated agranulocytosis who received granulocyte colony-stimulating factor (G-CSF) were compared with 5 subjects who did not receive this treatment.	Clozapine	40-49	colony stimulating factor 3	Homo sapiens	90-127
8927660-1	1996	During a 5-year period, 6 patients with clozapine-associated agranulocytosis who received granulocyte colony-stimulating factor (G-CSF) were compared with 5 subjects who did not receive this treatment.	Clozapine	40-49	colony stimulating factor 3	Homo sapiens	129-134
8927660-7	1996	Until efficacy studies prove otherwise, G-CSF administered soon after the diagnosis of clozapine-associated agranulocytosis may shorten the duration of hospitalization and thus prove cost-effective.	Clozapine	87-96	colony stimulating factor 3	Homo sapiens	40-45
8536785-7	1996	IL-1 alpha-induced GM-CSF, IL-1 beta, IL-6, IL-11, and LIF mRNA levels were reduced by the addition of dexamethasone, whereas dexamethasone had no influence on the amounts of IL-1 alpha-induced G-CSF mRNA.	Dexamethasone	103-116	colony stimulating factor 3	Homo sapiens	194-199
8558227-8	1996	Dose-limiting toxicity of grade 4 neutropenia for longer than 5 days and grade 4 thrombocytopenia occurred in three of five patients treated with paclitaxel 160 mg/m2 CIVI and cyclophosphamide 3,300 mg/m2 followed by G-CSF.	Paclitaxel	146-156	colony stimulating factor 3	Homo sapiens	217-222
8558227-15	1996	CONCLUSION: Paclitaxel by 72-hour CIVI with daily cyclophosphamide followed by G-CSF can be administered safely in the ambulatory setting, has acceptable toxicity, and is an active regimen in the treatment of metastatic breast cancer.	Paclitaxel	12-22	colony stimulating factor 3	Homo sapiens	79-84
10387976-31	1996	G-CSF also enhances neutrophil function in the presence of bacterial products, and it acts on mature neutrophils to enhance cellular motility, the production of bioactive oxygen, and microbicidal activity.	Oxygen	171-177	colony stimulating factor 3	Homo sapiens	0-5
8554326-8	1995	In the cross-linked peptide, Lys-242 of the receptor cross-linked the amino terminal Met of G-CSF through the cross-linker.	Lysine	29-32	colony stimulating factor 3	Homo sapiens	92-97
8554326-10	1995	The results show that the N-terminal Met of G-CSF is located at a distance of approximately 11 A from a reactive Lys-242 of the receptor in the ligand-receptor complex.	Lysine	113-116	colony stimulating factor 3	Homo sapiens	44-49
8547119-1	1995	In order to develop a non-isotopic quantitative assay of granulocyte colony-stimulating factor (G-CSF) receptors on human or murine cells, we devised a flow-cytometric assay using cells stained with biotin-labelled G-CSF (b-G-CSF) and a streptavidin-RED670 conjugate.	Biotin	199-205	colony stimulating factor 3	Homo sapiens	57-94
8547119-1	1995	In order to develop a non-isotopic quantitative assay of granulocyte colony-stimulating factor (G-CSF) receptors on human or murine cells, we devised a flow-cytometric assay using cells stained with biotin-labelled G-CSF (b-G-CSF) and a streptavidin-RED670 conjugate.	Biotin	199-205	colony stimulating factor 3	Homo sapiens	96-101
7492767-3	1995	We demonstrate that FL is a potent stimulator of the in vitro growth of granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin-3 (IL-3), or G-CSF-dependent granulocyte-macrophage committed precursors from Lin- CD34+ bone marrow cells of normal donors.	fl	20-22	colony stimulating factor 3	Homo sapiens	156-161
7499311-6	1995	The stimulatory effect of G-CSF on IL-8R expression is transcriptional as it is inhibited by actinomycin D and is evident in nuclear run-on analyses.	Dactinomycin	93-106	colony stimulating factor 3	Homo sapiens	26-31
7497618-0	1995	Intracellular magnesium content of mononuclear blood cells and granulocytes isolated from leukemic, infected, and granulocyte colony-stimulating factor-treated patients.	Magnesium	14-23	colony stimulating factor 3	Homo sapiens	114-151
8929647-3	1995	Culture of his marrow cells at diagnosis showed that granulocyte colony-stimulating factor (G-CSF) promoted cell proliferation, while all-trans retinoic acid (ATRA) inhibited the proliferative effect of G-CSF and induced differentiation.	Tretinoin	144-157	colony stimulating factor 3	Homo sapiens	203-208
8929647-3	1995	Culture of his marrow cells at diagnosis showed that granulocyte colony-stimulating factor (G-CSF) promoted cell proliferation, while all-trans retinoic acid (ATRA) inhibited the proliferative effect of G-CSF and induced differentiation.	Tretinoin	159-163	colony stimulating factor 3	Homo sapiens	203-208
8786961-0	1995	Prolonged circulation of recombinant human granulocyte-colony stimulating factor by covalent linkage to albumin through a heterobifunctional polyethylene glycol.	Polyethylene Glycols	141-160	colony stimulating factor 3	Homo sapiens	43-80
8786961-1	1995	PURPOSE: Recombinant human granulocyte-colony stimulating factor (rhG-CSF) was covalently conjugated to both rat and human serum albumin (RSA and HSA respectively) to increases the circulating half life (t1/2) of rhG-CSF.	rabbit sperm membrane autoantigen	138-141	colony stimulating factor 3	Homo sapiens	27-64
8786961-1	1995	PURPOSE: Recombinant human granulocyte-colony stimulating factor (rhG-CSF) was covalently conjugated to both rat and human serum albumin (RSA and HSA respectively) to increases the circulating half life (t1/2) of rhG-CSF.	Altretamine	146-149	colony stimulating factor 3	Homo sapiens	27-64
8523055-3	1995	The study was designed to determine the maximum-tolerated dosages (MTD) of cyclophosphamide and doxorubicin that could be used in a high-dose cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) regimen with granulocyte colony-stimulating factor (G-CSF) support and to assess preliminarily the efficacy of the regimen.	Cyclophosphamide	75-91	colony stimulating factor 3	Homo sapiens	221-258
8523055-3	1995	The study was designed to determine the maximum-tolerated dosages (MTD) of cyclophosphamide and doxorubicin that could be used in a high-dose cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) regimen with granulocyte colony-stimulating factor (G-CSF) support and to assess preliminarily the efficacy of the regimen.	Cyclophosphamide	75-91	colony stimulating factor 3	Homo sapiens	260-265
8523055-3	1995	The study was designed to determine the maximum-tolerated dosages (MTD) of cyclophosphamide and doxorubicin that could be used in a high-dose cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) regimen with granulocyte colony-stimulating factor (G-CSF) support and to assess preliminarily the efficacy of the regimen.	Doxorubicin	96-107	colony stimulating factor 3	Homo sapiens	221-258
8523055-3	1995	The study was designed to determine the maximum-tolerated dosages (MTD) of cyclophosphamide and doxorubicin that could be used in a high-dose cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) regimen with granulocyte colony-stimulating factor (G-CSF) support and to assess preliminarily the efficacy of the regimen.	Doxorubicin	96-107	colony stimulating factor 3	Homo sapiens	260-265
8535676-7	1995	The serum G-CSF levels in patients with UBT correlated with the increase of grade and the progression of the stage of UBT.	N-[(R)-({[(Benzyloxy)carbonyl]amino}methyl)(Hydroxy)phosphoryl]-L-Leucylglycine	40-43	colony stimulating factor 3	Homo sapiens	10-15
7497463-3	1995	In this paper, data are summarized revealing the ability of WBH to induce elevated plasma levels of granulocyte-colony stimulating factor (G-CSF), interleukin-1 beta (IL-1 beta), interleukin-6 (IL-6), interleukin-8 (IL-8), interleukin-10 (IL-10), and tumor necrosis factor-alpha (TNF-alpha) within hours of WBH.	wbh	60-63	colony stimulating factor 3	Homo sapiens	100-137
7497463-3	1995	In this paper, data are summarized revealing the ability of WBH to induce elevated plasma levels of granulocyte-colony stimulating factor (G-CSF), interleukin-1 beta (IL-1 beta), interleukin-6 (IL-6), interleukin-8 (IL-8), interleukin-10 (IL-10), and tumor necrosis factor-alpha (TNF-alpha) within hours of WBH.	wbh	60-63	colony stimulating factor 3	Homo sapiens	139-144
7577476-0	1995	Laevofolinic acid, 5-fluorouracil, cyclophosphamide and escalating doses of epirubicin with granulocyte colony-stimulating factor support in locally advanced and/or metastatic breast carcinoma: a phase I-II study of the Southern Italy Oncology Group (GOIM).	Epirubicin	76-86	colony stimulating factor 3	Homo sapiens	92-129
7577476-19	1995	Use of G-CSF allows epirubicin dosage to be increased up to 120 mg m-2 cycle-1, but its use may be linked to the occurrence of sometimes severe cumulative haematological toxicity.	Epirubicin	20-30	colony stimulating factor 3	Homo sapiens	7-12
8535676-1	1995	OBJECTIVES: To measure the serum levels of granulocyte colony-stimulating factor (G-CSF) in patients with urinary bladder tumour (UBT) or various urological malignant tumours, and to assess G-CSF production by tumour cells.	N-[(R)-({[(Benzyloxy)carbonyl]amino}methyl)(Hydroxy)phosphoryl]-L-Leucylglycine	130-133	colony stimulating factor 3	Homo sapiens	43-80
7579336-1	1995	The protein tyrosine kinases JAK1 and JAK2 are phosphorylated tyrosine after the interaction of granulocyte colony-stimulating factor (G-CSF) with its transmembrane receptor.	Tyrosine	12-20	colony stimulating factor 3	Homo sapiens	96-133
7579336-1	1995	The protein tyrosine kinases JAK1 and JAK2 are phosphorylated tyrosine after the interaction of granulocyte colony-stimulating factor (G-CSF) with its transmembrane receptor.	Tyrosine	12-20	colony stimulating factor 3	Homo sapiens	135-140
7579336-4	1995	We have shown that G-CSF-induced tyrosine phosphorylation and kinase activation of JAK2 requires the membrane proximal 57 amino acids of the cytoplasmic domain.	Tyrosine	33-41	colony stimulating factor 3	Homo sapiens	19-24
7579336-5	1995	In contrast, maximal Stat3 tyrosine phosphorylation required amino acids 96 to 183 of the G-CSF-R cytoplasmic domain, Stat3 DNA binding could occur with a receptor truncated 96 amino acids from the transmembrane domain and containing a single tyrosine residue, but was reduced in comparison with the full-length receptor.	Tyrosine	27-35	colony stimulating factor 3	Homo sapiens	90-95
7579336-5	1995	In contrast, maximal Stat3 tyrosine phosphorylation required amino acids 96 to 183 of the G-CSF-R cytoplasmic domain, Stat3 DNA binding could occur with a receptor truncated 96 amino acids from the transmembrane domain and containing a single tyrosine residue, but was reduced in comparison with the full-length receptor.	Tyrosine	243-251	colony stimulating factor 3	Homo sapiens	90-95
8717185-2	1995	According to Leo Sachs proposals on the proliferation-differentiation balance impairment in malignancies we have shown various orientation for the differentiation therapy: inhibition of malignant cells using low dose of Cytosine Arabinoside in acute myeloid leukemia; suppression of the growth factor effect such as the role of interferon in hairy cell leukemia; targetted differentiation process by all trans retinoic acid in acute promyelocytic leukemia with the obtention of complete remission in all cases; differentiation of malignant and normal cells by G-CSF in acute myeloid leukemia in elderly patients.	Cytarabine	220-240	colony stimulating factor 3	Homo sapiens	560-565
8535676-1	1995	OBJECTIVES: To measure the serum levels of granulocyte colony-stimulating factor (G-CSF) in patients with urinary bladder tumour (UBT) or various urological malignant tumours, and to assess G-CSF production by tumour cells.	N-[(R)-({[(Benzyloxy)carbonyl]amino}methyl)(Hydroxy)phosphoryl]-L-Leucylglycine	130-133	colony stimulating factor 3	Homo sapiens	82-87
8535676-7	1995	The serum G-CSF levels in patients with UBT correlated with the increase of grade and the progression of the stage of UBT.	N-[(R)-({[(Benzyloxy)carbonyl]amino}methyl)(Hydroxy)phosphoryl]-L-Leucylglycine	118-121	colony stimulating factor 3	Homo sapiens	10-15
8535676-11	1995	CONCLUSION: These results suggest that elevated serum G-CSF level might be associated with a poor prognosis in patients with UBT and be due to the production of G-CSF by UBT cells.	N-[(R)-({[(Benzyloxy)carbonyl]amino}methyl)(Hydroxy)phosphoryl]-L-Leucylglycine	125-128	colony stimulating factor 3	Homo sapiens	54-59
8535676-11	1995	CONCLUSION: These results suggest that elevated serum G-CSF level might be associated with a poor prognosis in patients with UBT and be due to the production of G-CSF by UBT cells.	N-[(R)-({[(Benzyloxy)carbonyl]amino}methyl)(Hydroxy)phosphoryl]-L-Leucylglycine	170-173	colony stimulating factor 3	Homo sapiens	54-59
8535676-11	1995	CONCLUSION: These results suggest that elevated serum G-CSF level might be associated with a poor prognosis in patients with UBT and be due to the production of G-CSF by UBT cells.	N-[(R)-({[(Benzyloxy)carbonyl]amino}methyl)(Hydroxy)phosphoryl]-L-Leucylglycine	170-173	colony stimulating factor 3	Homo sapiens	161-166
8583722-6	1995	Chemotherapy with vindesine, ifosfamide, and cisplatin resulted in shrinkage of the gingival mass, and a decrease in the G-CSF level to 66 pg/ml.	Cisplatin	45-54	colony stimulating factor 3	Homo sapiens	121-126
8749950-0	1995	Shorter interval between cycles of cyclophosphamide, doxorubicin, cisplatin using recombinant human granulocyte colony-stimulating factor for urothelial cancer--phase I/II study.	Cyclophosphamide	35-51	colony stimulating factor 3	Homo sapiens	100-137
8749950-0	1995	Shorter interval between cycles of cyclophosphamide, doxorubicin, cisplatin using recombinant human granulocyte colony-stimulating factor for urothelial cancer--phase I/II study.	Doxorubicin	53-64	colony stimulating factor 3	Homo sapiens	100-137
8749950-0	1995	Shorter interval between cycles of cyclophosphamide, doxorubicin, cisplatin using recombinant human granulocyte colony-stimulating factor for urothelial cancer--phase I/II study.	Cisplatin	66-75	colony stimulating factor 3	Homo sapiens	100-137
8749950-3	1995	METHODS: A phase I/II study was conducted to assess whether the interval between cycles of CISCA (cyclophosphamide, doxorubicin, cisplatin) chemotherapy could be shortened under support of recombinant human granulocyte colony-stimulating factor (rhG-CSF) for urothelial cancer.	Cyclophosphamide	98-114	colony stimulating factor 3	Homo sapiens	207-244
8583722-6	1995	Chemotherapy with vindesine, ifosfamide, and cisplatin resulted in shrinkage of the gingival mass, and a decrease in the G-CSF level to 66 pg/ml.	Vindesine	18-27	colony stimulating factor 3	Homo sapiens	121-126
7489718-2	1995	The cytoplasmic region of G-CSFR carries four tyrosine residues in its C-terminal half.	Tyrosine	46-54	colony stimulating factor 3	Homo sapiens	26-32
7489718-3	1995	We constructed mutant receptors in which each tyrosine residue of G-CSFR was mutated to phenylalanine.	Tyrosine	46-54	colony stimulating factor 3	Homo sapiens	66-72
7489718-3	1995	We constructed mutant receptors in which each tyrosine residue of G-CSFR was mutated to phenylalanine.	Phenylalanine	88-101	colony stimulating factor 3	Homo sapiens	66-72
7489718-6	1995	Mutation of the most distal tyrosine residue (Tyr763) abolished the ability of G-CSFR to stimulate the tyrosine phosphorylation of a cellular protein with an M(r) of 54 kDa.	Tyrosine	28-36	colony stimulating factor 3	Homo sapiens	79-85
7489718-6	1995	Mutation of the most distal tyrosine residue (Tyr763) abolished the ability of G-CSFR to stimulate the tyrosine phosphorylation of a cellular protein with an M(r) of 54 kDa.	Tyrosine	103-111	colony stimulating factor 3	Homo sapiens	79-85
7489718-7	1995	These results indicated that the regions around the three tyrosine residues of G-CSFR play essential and distinct roles in signal transduction.	Tyrosine	58-66	colony stimulating factor 3	Homo sapiens	79-85
8588511-1	1995	A chemiluminescence sandwich enzyme immunoassay, using a glucose oxidase (GO) label, was developed for detecting attomole amounts of human granulocyte colony stimulating factor (G-CSF).	attomole	113-121	colony stimulating factor 3	Homo sapiens	139-176
8588511-1	1995	A chemiluminescence sandwich enzyme immunoassay, using a glucose oxidase (GO) label, was developed for detecting attomole amounts of human granulocyte colony stimulating factor (G-CSF).	attomole	113-121	colony stimulating factor 3	Homo sapiens	178-183
8583722-6	1995	Chemotherapy with vindesine, ifosfamide, and cisplatin resulted in shrinkage of the gingival mass, and a decrease in the G-CSF level to 66 pg/ml.	Ifosfamide	29-39	colony stimulating factor 3	Homo sapiens	121-126
8576941-4	1995	Vesnarinone [OPC-8212; 3,4-dihydro-6-(4-(3,4-dimethoxybenzoil)-1-piperazinyl)-2(1H)- quinolinone] at 26 mumol/l significantly suppressed the production of IL-6, granulocyte macrophage colony stimulating factor (GM-CSF) and granulocyte colony stimulating factor (G-CSF) induced by IL-1 beta.	vesnarinone	0-11	colony stimulating factor 3	Homo sapiens	223-260
8691577-0	1995	[Assessment of cardiac toxicity by 123I-MIBG myocardial SPECT in elderly non-Hodgkin lymphoma patients treated with COP-BLAM and G-CSF].	3-Iodobenzylguanidine	35-44	colony stimulating factor 3	Homo sapiens	129-134
8711266-0	1995	Effect of rh-GMCSF and rh-GCSF on oxygen free radical production by human neutrophils and blood monocyte-derived human macrophages.	oxygen free radical	34-53	colony stimulating factor 3	Homo sapiens	26-30
8711266-1	1995	The in vitro effect of recombinant human granulocyte-macrophage colony stimulating factor (rh-GMCSF) and recombinant human granulocyte colony stimulating factor (rh-GCSF) on oxygen free radical (OFR) generation by human neutrophils and blood monocytes derived human macrophages stimulated with phorbol myristate acetate was investigated and compared.	oxygen free radical	174-193	colony stimulating factor 3	Homo sapiens	123-160
8605651-0	1995	Methimazole-induced agranulocytosis treated with recombinant human granulocyte colony-stimulating factor (rhG-CSF): a case report.	Methimazole	0-11	colony stimulating factor 3	Homo sapiens	67-104
8564703-6	1995	c-kit antisense oligonucleotides reduced the colony formation supported by IL-3 or G-CSF or, in the absence of growth factor, in only 2 of 10 patients tested.	Oligonucleotides	16-32	colony stimulating factor 3	Homo sapiens	83-88
8804472-9	1995	Both TSH and melatonin decreased after G-CSF, without, however, significant differences with respect to the values seen on saline alone.	Thyrotropin	5-8	colony stimulating factor 3	Homo sapiens	39-44
8804472-9	1995	Both TSH and melatonin decreased after G-CSF, without, however, significant differences with respect to the values seen on saline alone.	Melatonin	13-22	colony stimulating factor 3	Homo sapiens	39-44
7475451-3	1995	METHODS: CTCb (cyclophosphamide 6 g/m2, thiotepa 500 mg/m2 and carboplatin 800 mg/m2) was administered with autologous peripheral hematopoietic progenitor cells transplantation (TACPHP) and granulocytic colony stimulating factor (G-CSF) 5 micrograms/kg/day to 27 patients with breast cancer: 9 in stage IV in complete remission, 12 in stage II with &gt; or = 10 affected lymph nodes and 6 in stage III.	CTCb regimen	9-13	colony stimulating factor 3	Homo sapiens	190-228
7475451-3	1995	METHODS: CTCb (cyclophosphamide 6 g/m2, thiotepa 500 mg/m2 and carboplatin 800 mg/m2) was administered with autologous peripheral hematopoietic progenitor cells transplantation (TACPHP) and granulocytic colony stimulating factor (G-CSF) 5 micrograms/kg/day to 27 patients with breast cancer: 9 in stage IV in complete remission, 12 in stage II with &gt; or = 10 affected lymph nodes and 6 in stage III.	CTCb regimen	9-13	colony stimulating factor 3	Homo sapiens	230-235
8581378-10	1995	During G-CSF application, isolated neutrophils were highly cytotoxic in the presence of MDX-210 in vitro.	MDX-H210 antibody	88-95	colony stimulating factor 3	Homo sapiens	7-12
8576941-4	1995	Vesnarinone [OPC-8212; 3,4-dihydro-6-(4-(3,4-dimethoxybenzoil)-1-piperazinyl)-2(1H)- quinolinone] at 26 mumol/l significantly suppressed the production of IL-6, granulocyte macrophage colony stimulating factor (GM-CSF) and granulocyte colony stimulating factor (G-CSF) induced by IL-1 beta.	vesnarinone	0-11	colony stimulating factor 3	Homo sapiens	262-267
8576941-4	1995	Vesnarinone [OPC-8212; 3,4-dihydro-6-(4-(3,4-dimethoxybenzoil)-1-piperazinyl)-2(1H)- quinolinone] at 26 mumol/l significantly suppressed the production of IL-6, granulocyte macrophage colony stimulating factor (GM-CSF) and granulocyte colony stimulating factor (G-CSF) induced by IL-1 beta.	vesnarinone	13-21	colony stimulating factor 3	Homo sapiens	223-260
8576941-4	1995	Vesnarinone [OPC-8212; 3,4-dihydro-6-(4-(3,4-dimethoxybenzoil)-1-piperazinyl)-2(1H)- quinolinone] at 26 mumol/l significantly suppressed the production of IL-6, granulocyte macrophage colony stimulating factor (GM-CSF) and granulocyte colony stimulating factor (G-CSF) induced by IL-1 beta.	vesnarinone	13-21	colony stimulating factor 3	Homo sapiens	262-267
7474409-1	1995	A study was conducted to evaluate the impact of cisplatin, doxorubicin, cyclophosphamide and etoposide (PACE) with granulocyte colony-stimulating factor (G-CSF) on advanced thymoma or thymic cancer.	Cisplatin	48-57	colony stimulating factor 3	Homo sapiens	115-152
7474409-1	1995	A study was conducted to evaluate the impact of cisplatin, doxorubicin, cyclophosphamide and etoposide (PACE) with granulocyte colony-stimulating factor (G-CSF) on advanced thymoma or thymic cancer.	Cisplatin	48-57	colony stimulating factor 3	Homo sapiens	154-159
8576941-4	1995	Vesnarinone [OPC-8212; 3,4-dihydro-6-(4-(3,4-dimethoxybenzoil)-1-piperazinyl)-2(1H)- quinolinone] at 26 mumol/l significantly suppressed the production of IL-6, granulocyte macrophage colony stimulating factor (GM-CSF) and granulocyte colony stimulating factor (G-CSF) induced by IL-1 beta.	3,4-dihydro-6-(4-(3,4-dimethoxybenzoil)-1-piperazinyl)-2(1h)- quinolinone	23-96	colony stimulating factor 3	Homo sapiens	223-260
7474409-1	1995	A study was conducted to evaluate the impact of cisplatin, doxorubicin, cyclophosphamide and etoposide (PACE) with granulocyte colony-stimulating factor (G-CSF) on advanced thymoma or thymic cancer.	Etoposide	93-102	colony stimulating factor 3	Homo sapiens	115-152
8576941-4	1995	Vesnarinone [OPC-8212; 3,4-dihydro-6-(4-(3,4-dimethoxybenzoil)-1-piperazinyl)-2(1H)- quinolinone] at 26 mumol/l significantly suppressed the production of IL-6, granulocyte macrophage colony stimulating factor (GM-CSF) and granulocyte colony stimulating factor (G-CSF) induced by IL-1 beta.	3,4-dihydro-6-(4-(3,4-dimethoxybenzoil)-1-piperazinyl)-2(1h)- quinolinone	23-96	colony stimulating factor 3	Homo sapiens	262-267
8575155-0	1995	Rheumatoid arthritis exacerbation by G-CSF treatment for bucillamine-induced agranulocytosis.	bucillamine	57-68	colony stimulating factor 3	Homo sapiens	37-42
8664192-4	1995	The pharmacokinetics of paclitaxel and its metabolites were investigated in anthracycline-resistant breast cancer patients treated with high-dose paclitaxel and granulocyte colony-stimulating factor (G-CSF) support.	Paclitaxel	24-34	colony stimulating factor 3	Homo sapiens	161-198
7577641-1	1995	Several studies have demonstrated that G-CSF, GM-CSF and, in particular, IL-3 can effectively recruit acute myeloid leukaemia (AML) blasts into the cell cycle, resulting in a significant increase in cytosine-arabinoside (Ara-C) mediated cytotoxicity in vitro.	Cytarabine	199-219	colony stimulating factor 3	Homo sapiens	39-44
7577641-1	1995	Several studies have demonstrated that G-CSF, GM-CSF and, in particular, IL-3 can effectively recruit acute myeloid leukaemia (AML) blasts into the cell cycle, resulting in a significant increase in cytosine-arabinoside (Ara-C) mediated cytotoxicity in vitro.	Cytarabine	221-226	colony stimulating factor 3	Homo sapiens	39-44
7543309-4	1995	In normal human subjects injected with G-CSF at 5 or 10 micrograms/kg/d, the proportions of PB myeloid (-1 +/- 4%) and erythroid (0% +/- 8%) progenitor cells in S phase were very low compared with the proportion of myeloid progenitor cells in S phase in normal BM (34% +/- 10%).	pb myeloid	92-102	colony stimulating factor 3	Homo sapiens	39-44
7542171-8	1995	Finally, the proliferation of the cultured cancer cells was stimulated by exogenous G-CSF administration, and this stimulation was inhibited by adding anti-G-CSF antibody, as demonstrated by both the flow cytometric bromodeoxyuridine incorporation technique and the [3H]thymidine incorporation assay.	Bromodeoxyuridine	216-233	colony stimulating factor 3	Homo sapiens	156-161
7541186-0	1995	Astemizole in the treatment of granulocyte colony-stimulating factor-induced bone pain.	Astemizole	0-10	colony stimulating factor 3	Homo sapiens	31-68
7542496-0	1995	In vitro killing of neuroblastoma cells by neutrophils derived from granulocyte colony-stimulating factor-treated cancer patients using an anti-disialoganglioside/anti-Fc gamma RI bispecific antibody.	sialogangliosides	144-162	colony stimulating factor 3	Homo sapiens	68-105
8535401-0	1995	Increase in total blood leukocyte count following intranasal administration of recombinant human granulocyte colony-stimulating factor (rhG-CSF) in rabbits with cyclophosphamide-induced leukopenia.	Cyclophosphamide	161-177	colony stimulating factor 3	Homo sapiens	97-134
7542171-8	1995	Finally, the proliferation of the cultured cancer cells was stimulated by exogenous G-CSF administration, and this stimulation was inhibited by adding anti-G-CSF antibody, as demonstrated by both the flow cytometric bromodeoxyuridine incorporation technique and the [3H]thymidine incorporation assay.	Tritium	267-269	colony stimulating factor 3	Homo sapiens	84-89
7542171-8	1995	Finally, the proliferation of the cultured cancer cells was stimulated by exogenous G-CSF administration, and this stimulation was inhibited by adding anti-G-CSF antibody, as demonstrated by both the flow cytometric bromodeoxyuridine incorporation technique and the [3H]thymidine incorporation assay.	Tritium	267-269	colony stimulating factor 3	Homo sapiens	156-161
8565989-3	1995	GCSF had no direct benefit, but GCSF combined with fluconazole extended survival beyond that for fluconazole alone and reduced renal tissue counts below those for fluconazole alone.	Fluconazole	97-108	colony stimulating factor 3	Homo sapiens	32-36
8565989-3	1995	GCSF had no direct benefit, but GCSF combined with fluconazole extended survival beyond that for fluconazole alone and reduced renal tissue counts below those for fluconazole alone.	Fluconazole	97-108	colony stimulating factor 3	Homo sapiens	32-36
7543855-5	1995	G-CSFR-expressing clones (a) acquired the capacity to respond to the differentiation-inducing properties of G-CSF and retinoic acid, (b) formed colonies which exhibited a dispersed phenotype, and (c) exhibited near diploid DNA ploidy.	Tretinoin	118-131	colony stimulating factor 3	Homo sapiens	0-5
7578366-0	1995	Vitamin B12 mediated oral delivery systems for granulocyte-colony stimulating factor and erythropoietin.	Vitamin B 12	0-11	colony stimulating factor 3	Homo sapiens	47-84
7489143-8	1995	A small phase I study was performed to assess the toxicity of infusing 1000-2000 mL of PBPC cultured for 3 days at 3-10 x 10(6)/mL with IL-3/GM-CSF/G-CSF in LifeCell bags.	PbPc	87-91	colony stimulating factor 3	Homo sapiens	148-153
7543699-0	1995	High-dose paclitaxel with granulocyte colony-stimulating factor in patients with advanced breast cancer refractory to anthracycline therapy: a European Cancer Center trial.	Paclitaxel	10-20	colony stimulating factor 3	Homo sapiens	26-63
7543699-0	1995	High-dose paclitaxel with granulocyte colony-stimulating factor in patients with advanced breast cancer refractory to anthracycline therapy: a European Cancer Center trial.	Anthracyclines	118-131	colony stimulating factor 3	Homo sapiens	26-63
7578366-1	1995	As a prelude to the development of orally active erythropoietin (EPO) and granulocyte-colony stimulating factor (G-CSF), conjugates have been formed between these molecules and vitamin B12.	Vitamin B 12	177-188	colony stimulating factor 3	Homo sapiens	74-111
7578366-1	1995	As a prelude to the development of orally active erythropoietin (EPO) and granulocyte-colony stimulating factor (G-CSF), conjugates have been formed between these molecules and vitamin B12.	Vitamin B 12	177-188	colony stimulating factor 3	Homo sapiens	113-118
7578366-3	1995	A potentially biodegradable linkage was formed between vitamin B12 and G-CSF by reaction of the buried thiol in G-CSF with a long chain dithiopyridyl derivative of vitamin B12.	Vitamin B 12	55-66	colony stimulating factor 3	Homo sapiens	112-117
7578366-3	1995	A potentially biodegradable linkage was formed between vitamin B12 and G-CSF by reaction of the buried thiol in G-CSF with a long chain dithiopyridyl derivative of vitamin B12.	Sulfhydryl Compounds	103-108	colony stimulating factor 3	Homo sapiens	71-76
7578366-3	1995	A potentially biodegradable linkage was formed between vitamin B12 and G-CSF by reaction of the buried thiol in G-CSF with a long chain dithiopyridyl derivative of vitamin B12.	Sulfhydryl Compounds	103-108	colony stimulating factor 3	Homo sapiens	112-117
7578366-3	1995	A potentially biodegradable linkage was formed between vitamin B12 and G-CSF by reaction of the buried thiol in G-CSF with a long chain dithiopyridyl derivative of vitamin B12.	Vitamin B 12	164-175	colony stimulating factor 3	Homo sapiens	71-76
7541450-1	1995	PURPOSE: Here we evaluate Taxol (paclitaxel; Bristol-Myers Squibb, Princeton, NJ) and cyclophosphamide (CY) with recombinant human granulocyte colony-stimulating factor (rhG-CSF) for mobilization of peripheral-blood stem cells (PBSCs) for autologous stem-cell transplantation in patients with breast and ovarian cancer.	Paclitaxel	26-31	colony stimulating factor 3	Homo sapiens	131-168
8789288-10	1995	In contrast to IL-10, IL-4 also inhibited the spontaneous (3/5) and cytokine induced (5/5) secretion of G-CSF and GM-CSF (4/5) protein in the cases in which an enhancement of the 3H-TdR uptake was noticed.	Tritium	179-181	colony stimulating factor 3	Homo sapiens	104-109
21552804-0	1995	Retinoic Acid potently stimulates the production of granulocyte-colony-stimulating factor in the human monocytic thp-1 cell-line.	Tretinoin	0-13	colony stimulating factor 3	Homo sapiens	52-89
21552804-2	1995	We report that all-trans retinoic acid (tRA) synergizes with LPS to enhance the production of granulocyte colony-stimulating factor (G-CSF) in PMA-treated cells, whereas the production of granulocyte-macrophage CSF, interleukin 1-beta (IL-1-beta), and tumor necrosis factor-alpha (TNF-alpha) is minimally affected by tRA.	Tretinoin	25-38	colony stimulating factor 3	Homo sapiens	94-131
21552804-2	1995	We report that all-trans retinoic acid (tRA) synergizes with LPS to enhance the production of granulocyte colony-stimulating factor (G-CSF) in PMA-treated cells, whereas the production of granulocyte-macrophage CSF, interleukin 1-beta (IL-1-beta), and tumor necrosis factor-alpha (TNF-alpha) is minimally affected by tRA.	Tretinoin	25-38	colony stimulating factor 3	Homo sapiens	133-138
21552804-2	1995	We report that all-trans retinoic acid (tRA) synergizes with LPS to enhance the production of granulocyte colony-stimulating factor (G-CSF) in PMA-treated cells, whereas the production of granulocyte-macrophage CSF, interleukin 1-beta (IL-1-beta), and tumor necrosis factor-alpha (TNF-alpha) is minimally affected by tRA.	Tretinoin	40-43	colony stimulating factor 3	Homo sapiens	94-131
21552804-2	1995	We report that all-trans retinoic acid (tRA) synergizes with LPS to enhance the production of granulocyte colony-stimulating factor (G-CSF) in PMA-treated cells, whereas the production of granulocyte-macrophage CSF, interleukin 1-beta (IL-1-beta), and tumor necrosis factor-alpha (TNF-alpha) is minimally affected by tRA.	Tretinoin	40-43	colony stimulating factor 3	Homo sapiens	133-138
7541450-1	1995	PURPOSE: Here we evaluate Taxol (paclitaxel; Bristol-Myers Squibb, Princeton, NJ) and cyclophosphamide (CY) with recombinant human granulocyte colony-stimulating factor (rhG-CSF) for mobilization of peripheral-blood stem cells (PBSCs) for autologous stem-cell transplantation in patients with breast and ovarian cancer.	Paclitaxel	33-43	colony stimulating factor 3	Homo sapiens	131-168
7541450-1	1995	PURPOSE: Here we evaluate Taxol (paclitaxel; Bristol-Myers Squibb, Princeton, NJ) and cyclophosphamide (CY) with recombinant human granulocyte colony-stimulating factor (rhG-CSF) for mobilization of peripheral-blood stem cells (PBSCs) for autologous stem-cell transplantation in patients with breast and ovarian cancer.	Cyclophosphamide	104-106	colony stimulating factor 3	Homo sapiens	131-168
7581092-4	1995	Of the 43 patients with normal BM, 19 received BM alone and 24 received BM plus G-CSF mobilized PBPC.	PbPc	96-100	colony stimulating factor 3	Homo sapiens	80-85
7540842-1	1995	Granulocyte colony-stimulating factor(G-CSF), but not granulocyte-macrophage CSF(GM-CSF), induced tyrosine phosphorylation of 95-kDa protein in 13 cases of primary human acute myelogenous leukemic cells.	Tyrosine	98-106	colony stimulating factor 3	Homo sapiens	0-43
7540842-3	1995	In addition, p95vav was tyrosine-phosphorylated only in G-CSF-stimulated cells.	Tyrosine	24-32	colony stimulating factor 3	Homo sapiens	56-61
7539582-0	1995	Etoposide, dexamethasone, and continuous-infusion cyclophosphamide with G-CSF for VAD-resistant multiple myeloma.	Cyclophosphamide	50-66	colony stimulating factor 3	Homo sapiens	72-77
7539582-0	1995	Etoposide, dexamethasone, and continuous-infusion cyclophosphamide with G-CSF for VAD-resistant multiple myeloma.	VAD I protocol	82-85	colony stimulating factor 3	Homo sapiens	72-77
7581092-8	1995	Of the marrow-positive patients, there was a slightly shortened granulocyte recovery, shortened hospital stays and lessened amphotericin usage in the patients who received CY/G-CSF-mobilized PBPC compared with the CY-mobilized patients.	Amphotericin B	124-136	colony stimulating factor 3	Homo sapiens	175-180
7540644-0	1995	Modulation of human G-CSF receptor mRNA and protein in normal and leukemic myeloid cells by G-CSF and retinoic acid.	Tretinoin	102-115	colony stimulating factor 3	Homo sapiens	20-25
7540644-10	1995	Furthermore, the ability of retinoic acid to up-regulate G-CSF receptor may account for the synergistic effect of G-CSF and retinoic acid in differentiation induction of acute promyelocytic leukemia.	Tretinoin	28-41	colony stimulating factor 3	Homo sapiens	57-62
7540644-10	1995	Furthermore, the ability of retinoic acid to up-regulate G-CSF receptor may account for the synergistic effect of G-CSF and retinoic acid in differentiation induction of acute promyelocytic leukemia.	Tretinoin	124-137	colony stimulating factor 3	Homo sapiens	57-62
7542790-0	1995	Methimazole agranulocytosis treated with recombinant human granulocyte colony stimulating factor.	Methimazole	0-11	colony stimulating factor 3	Homo sapiens	59-96
7545489-4	1995	Our results show that G-CSF was able to maintain the proliferative activity of BM cells in the presence of ceftazidime if it was added to the culture medium during the early phase of exposure of BM to ceftazidime.	Ceftazidime	107-118	colony stimulating factor 3	Homo sapiens	22-27
7541156-17	1995	Although dose limiting at a paclitaxel dose of 135 mg/m2, granulocytopenia can be reduced substantially with granulocyte colony-stimulating factor, allowing sequential dose escalation of paclitaxel to 175 mg/m2 and 215 mg/m2 in 70% of patients receiving three or more cycles.	Paclitaxel	187-197	colony stimulating factor 3	Homo sapiens	109-146
7545489-0	1995	Role of granulocyte colony-stimulating factor in preventing ceftazidime-induced myelosuppression in vitro.	Ceftazidime	60-71	colony stimulating factor 3	Homo sapiens	8-45
7545489-4	1995	Our results show that G-CSF was able to maintain the proliferative activity of BM cells in the presence of ceftazidime if it was added to the culture medium during the early phase of exposure of BM to ceftazidime.	Ceftazidime	201-212	colony stimulating factor 3	Homo sapiens	22-27
7545489-3	1995	The present study was carried out to define the role of G-CSF in preventing the ceftazidime-induced suppression of BM progenitor cells in vitro, and to define the mechanisms involved in ceftazidime-induced myelosuppression.	Ceftazidime	80-91	colony stimulating factor 3	Homo sapiens	56-61
7545489-8	1995	These data suggest that G-CSF prevents the ceftazidime-induced myelosuppression by antagonizing the suppressive effect of TNF and by enhancing the proliferative activity of BM.	Ceftazidime	43-54	colony stimulating factor 3	Homo sapiens	24-29
7553050-5	1995	We examined the effect of recombinant human interferon gamma (rh-IFN-gamma) and granulocyte colony stimulating factor (G-CSF) on CL of EB-LCL in vitro.	eb-lcl	135-141	colony stimulating factor 3	Homo sapiens	80-117
7541335-14	1995	Thus, lenograstim, like other CSFs, is a valuable adjunct to cytotoxic chemotherapy for the treatment of nonmyelogenous cancers, including myeloablative regimens followed by stem cell rescue with BMT and/or PBPC infusion.	PbPc	207-211	colony stimulating factor 3	Homo sapiens	6-17
7536471-0	1995	Site-specific conjugation of diethylenetriaminepentaacetic acid to recombinant human granulocyte-colony-stimulating factor: preservation of protein structure and function.	Pentetic Acid	29-63	colony stimulating factor 3	Homo sapiens	85-122
7536471-1	1995	The chelating agent diethylenetriaminepentaacetic acid (DTPA) was conjugated site-specifically to the N-terminus of recombinant human granulocyte-colony-stimulating factor (rhG-CSF) by reaction of the protein with DTPA dianhydride at an initial pH of 6.0.	Pentetic Acid	20-54	colony stimulating factor 3	Homo sapiens	134-171
7536471-1	1995	The chelating agent diethylenetriaminepentaacetic acid (DTPA) was conjugated site-specifically to the N-terminus of recombinant human granulocyte-colony-stimulating factor (rhG-CSF) by reaction of the protein with DTPA dianhydride at an initial pH of 6.0.	Pentetic Acid	56-60	colony stimulating factor 3	Homo sapiens	134-171
7536471-1	1995	The chelating agent diethylenetriaminepentaacetic acid (DTPA) was conjugated site-specifically to the N-terminus of recombinant human granulocyte-colony-stimulating factor (rhG-CSF) by reaction of the protein with DTPA dianhydride at an initial pH of 6.0.	cyclic DTPA anhydride	214-230	colony stimulating factor 3	Homo sapiens	134-171
7539624-3	1995	Binding of G-CSF to BL cell lines was measured by chemical crosslinking of 125I-G-CSF, and proliferation by thymidine incorporation.	Thymidine	108-117	colony stimulating factor 3	Homo sapiens	11-16
7539624-4	1995	Inducibility of the G-CSF receptor was studied by stimulation with interleukin-1 beta, tumour necrosis factor-alpha, Staphylococcus aureus Cowan A, anti-human IgM, phorbol myristate acetate, calcium ionophore A23187, and by infection in vitro by immortalizing and non-immortalizing strains of EBV.	Tetradecanoylphorbol Acetate	164-189	colony stimulating factor 3	Homo sapiens	20-25
7539624-4	1995	Inducibility of the G-CSF receptor was studied by stimulation with interleukin-1 beta, tumour necrosis factor-alpha, Staphylococcus aureus Cowan A, anti-human IgM, phorbol myristate acetate, calcium ionophore A23187, and by infection in vitro by immortalizing and non-immortalizing strains of EBV.	Calcium	191-198	colony stimulating factor 3	Homo sapiens	20-25
7539624-4	1995	Inducibility of the G-CSF receptor was studied by stimulation with interleukin-1 beta, tumour necrosis factor-alpha, Staphylococcus aureus Cowan A, anti-human IgM, phorbol myristate acetate, calcium ionophore A23187, and by infection in vitro by immortalizing and non-immortalizing strains of EBV.	Calcimycin	209-215	colony stimulating factor 3	Homo sapiens	20-25
8826913-0	1995	Phase I/II study of carboplatin and oral etoposide with granulocyte-colony stimulating factor in advanced nonsmall cell lung cancer.	Carboplatin	20-31	colony stimulating factor 3	Homo sapiens	56-93
8826913-0	1995	Phase I/II study of carboplatin and oral etoposide with granulocyte-colony stimulating factor in advanced nonsmall cell lung cancer.	Etoposide	41-50	colony stimulating factor 3	Homo sapiens	56-93
8826913-2	1995	A Phase I/II study was conducted to determine whether the addition of the granulocyte-colony stimulating factor (G-CSF) allows the administration of higher doses of CBCDA.	cbcda	165-170	colony stimulating factor 3	Homo sapiens	74-111
8826913-2	1995	A Phase I/II study was conducted to determine whether the addition of the granulocyte-colony stimulating factor (G-CSF) allows the administration of higher doses of CBCDA.	cbcda	165-170	colony stimulating factor 3	Homo sapiens	113-118
7670404-5	1995	Even the primitive stem cells treated with very high doses of mafosfamide (2 to 4 times the usually recommended dose) responded to a combination of SCF + GM-CSF + G-CSF + IL-3 in liquid marrow culture, suggesting that they were functionally spared by the treatment.	mafosfamide	62-73	colony stimulating factor 3	Homo sapiens	163-168
8589272-4	1995	Dexamethasone (DEX) had no effect on the induction of IL-1 beta mRNA, while it enhanced the G-CSF-, ATRA- and (ATRA+G-CSF) dependent secretion of the cytokine.	Dexamethasone	0-13	colony stimulating factor 3	Homo sapiens	92-97
8589272-4	1995	Dexamethasone (DEX) had no effect on the induction of IL-1 beta mRNA, while it enhanced the G-CSF-, ATRA- and (ATRA+G-CSF) dependent secretion of the cytokine.	Dexamethasone	0-13	colony stimulating factor 3	Homo sapiens	116-121
8589272-4	1995	Dexamethasone (DEX) had no effect on the induction of IL-1 beta mRNA, while it enhanced the G-CSF-, ATRA- and (ATRA+G-CSF) dependent secretion of the cytokine.	Dexamethasone	15-18	colony stimulating factor 3	Homo sapiens	92-97
8589272-4	1995	Dexamethasone (DEX) had no effect on the induction of IL-1 beta mRNA, while it enhanced the G-CSF-, ATRA- and (ATRA+G-CSF) dependent secretion of the cytokine.	Dexamethasone	15-18	colony stimulating factor 3	Homo sapiens	116-121
7613145-3	1995	The immunosuppressive agents CsA and FK506 enhanced the release of leukotriene B4 (LTB4) from human neutrophil granulocytes dependent on the priming with G-CSF and IL-3.	Cyclosporine	29-32	colony stimulating factor 3	Homo sapiens	154-159
7613145-3	1995	The immunosuppressive agents CsA and FK506 enhanced the release of leukotriene B4 (LTB4) from human neutrophil granulocytes dependent on the priming with G-CSF and IL-3.	Tacrolimus	37-42	colony stimulating factor 3	Homo sapiens	154-159
7613145-3	1995	The immunosuppressive agents CsA and FK506 enhanced the release of leukotriene B4 (LTB4) from human neutrophil granulocytes dependent on the priming with G-CSF and IL-3.	Leukotriene B4	67-81	colony stimulating factor 3	Homo sapiens	154-159
7539516-2	1995	G-CSF induced tyrosine phosphorylation of a set of proteins with few different components according to the cell lines.	Tyrosine	14-22	colony stimulating factor 3	Homo sapiens	0-5
7549841-7	1995	A significant correlation was found between G-CSF and neopterin levels (r = 0.578, p &lt; 0.001), thus indicating an origin of the cytokine from monocytes and macrophages.	Neopterin	54-63	colony stimulating factor 3	Homo sapiens	44-49
7542115-0	1995	Benzene and its metabolite, hydroquinone, induce granulocytic differentiation in myeloblasts by interacting with cellular signaling pathways activated by granulocyte colony-stimulating factor.	Benzene	0-7	colony stimulating factor 3	Homo sapiens	154-191
7542115-0	1995	Benzene and its metabolite, hydroquinone, induce granulocytic differentiation in myeloblasts by interacting with cellular signaling pathways activated by granulocyte colony-stimulating factor.	hydroquinone	28-40	colony stimulating factor 3	Homo sapiens	154-191
8826913-14	1995	CONCLUSION: The administration of G-CSF permits safe escalation of CBDCA dose and AUC up to 600 mg/m2 and 8 respectively, in combination with a fixed dose of oral etoposide.	Carboplatin	67-72	colony stimulating factor 3	Homo sapiens	34-39
7534716-0	1995	G-CSF is a major component of colony-stimulating activity (CSA) in the plasma of patients with multiple myeloma after treatment with high-dose melphalan (HDM).	Melphalan	143-152	colony stimulating factor 3	Homo sapiens	0-5
7534716-4	1995	In plasma from patients who received recombinant human granulocyte colony-stimulating factor (rhG-CSF), in addition to an autograft, CSA reached a maximum earlier (7 days).	Cyclosporine	133-136	colony stimulating factor 3	Homo sapiens	55-92
7553050-5	1995	We examined the effect of recombinant human interferon gamma (rh-IFN-gamma) and granulocyte colony stimulating factor (G-CSF) on CL of EB-LCL in vitro.	eb-lcl	135-141	colony stimulating factor 3	Homo sapiens	119-124
7533518-0	1995	The use of granulocyte colony-stimulating factor to deliver four cycles of ifosfamide and epirubicin every 14 days in women with advanced or metastatic breast cancer.	Ifosfamide	75-85	colony stimulating factor 3	Homo sapiens	11-48
7535055-4	1995	Challenge of NB4 cells with G-CSF, dbcAMP and ATRA causes a much higher induction of LAP relative to that observed in the presence of ATRA+G-CSF or ATRA+dbcAMP.	Tretinoin	46-50	colony stimulating factor 3	Homo sapiens	139-144
7535055-4	1995	Challenge of NB4 cells with G-CSF, dbcAMP and ATRA causes a much higher induction of LAP relative to that observed in the presence of ATRA+G-CSF or ATRA+dbcAMP.	Bucladesine	153-159	colony stimulating factor 3	Homo sapiens	28-33
7535055-5	1995	Treatment of NB4 with ATRA and G-CSF results in increases in the tyrosine phosphorylation of several proteins.	Tyrosine	65-73	colony stimulating factor 3	Homo sapiens	31-36
7533518-0	1995	The use of granulocyte colony-stimulating factor to deliver four cycles of ifosfamide and epirubicin every 14 days in women with advanced or metastatic breast cancer.	Epirubicin	90-100	colony stimulating factor 3	Homo sapiens	11-48
9815970-7	1995	Comparison of F-ara-ATP pharmacokinetics in circulating AML cells of patients on the fludarabine/ara- C/G-CSF regimen demonstrated that the area under concentration time curve (AUC) of F-ara-ATP increased significantly (median, 1.4-fold; range, 0.9-1.5; P = 0.045) after G-CSF infusion.	2-fluoro-araATP	14-23	colony stimulating factor 3	Homo sapiens	104-109
7538455-1	1995	The authors report on two non-Hodgkin"s lymphoma cases which showed markedly enhanced Ga-67 uptake of granulopoietic area induced by recombinant human granulocyte colony-stimulating factor (rhG-CSF) administration.	Gallium	86-88	colony stimulating factor 3	Homo sapiens	151-188
7538455-4	1995	In this study, the results of the two cases were: 1) G-CSF enhanced the accumulation of Ga-67 citrate in the granulopoietic area; 2) the marked uptake of red marrow looked like involvement; and 3) in contrast, the involved area became relatively "cold."	gallium citrate	88-101	colony stimulating factor 3	Homo sapiens	53-58
9815972-0	1995	A phase I study of ifosfamide and doxorubicin with recombinant human granulocyte colony-stimulating factor in stage IV breast cancer.	Ifosfamide	19-29	colony stimulating factor 3	Homo sapiens	69-106
9815972-0	1995	A phase I study of ifosfamide and doxorubicin with recombinant human granulocyte colony-stimulating factor in stage IV breast cancer.	Doxorubicin	34-45	colony stimulating factor 3	Homo sapiens	69-106
7584671-7	1995	In vitro preincubation of neutrophils from the same patients with GM-CSF, G-CSF, or TNF showed that O2- production by neutrophils from patients receiving GM-CSF could not be further enhanced, whereas O2- production by neutrophils derived from patients receiving G-CSF could be further augmented by TNF but not by GM-CSF.	Superoxides	100-102	colony stimulating factor 3	Homo sapiens	74-79
7540958-0	1995	Human fibroblasts (KMST-6/RAS cell line) transformed with 60Co gamma-rays and c-Ha-ras oncogene produce a large amount of granulocyte colony-stimulating factor (G-CSF); production is enhanced by cAMP, theophylline, and butyrate.	Cyclic AMP	195-199	colony stimulating factor 3	Homo sapiens	161-166
7540958-0	1995	Human fibroblasts (KMST-6/RAS cell line) transformed with 60Co gamma-rays and c-Ha-ras oncogene produce a large amount of granulocyte colony-stimulating factor (G-CSF); production is enhanced by cAMP, theophylline, and butyrate.	Theophylline	201-213	colony stimulating factor 3	Homo sapiens	161-166
7540958-0	1995	Human fibroblasts (KMST-6/RAS cell line) transformed with 60Co gamma-rays and c-Ha-ras oncogene produce a large amount of granulocyte colony-stimulating factor (G-CSF); production is enhanced by cAMP, theophylline, and butyrate.	Butyrates	219-227	colony stimulating factor 3	Homo sapiens	161-166
7540958-3	1995	cAMP and theophylline, alone or in combination, and butyrate significantly enhanced G-CSF production, but dexamethasone or 5-azacytidine did not.	Cyclic AMP	0-4	colony stimulating factor 3	Homo sapiens	84-89
7540958-3	1995	cAMP and theophylline, alone or in combination, and butyrate significantly enhanced G-CSF production, but dexamethasone or 5-azacytidine did not.	Theophylline	9-21	colony stimulating factor 3	Homo sapiens	84-89
7540958-3	1995	cAMP and theophylline, alone or in combination, and butyrate significantly enhanced G-CSF production, but dexamethasone or 5-azacytidine did not.	Butyrates	52-60	colony stimulating factor 3	Homo sapiens	84-89
9815970-0	1995	Modulation of the cellular metabolism of cytarabine and fludarabine by granulocyte-colony-stimulating factor during therapy of acute myelogenous leukemia.	Cytarabine	41-51	colony stimulating factor 3	Homo sapiens	71-108
9815970-0	1995	Modulation of the cellular metabolism of cytarabine and fludarabine by granulocyte-colony-stimulating factor during therapy of acute myelogenous leukemia.	fludarabine	56-67	colony stimulating factor 3	Homo sapiens	71-108
9815970-1	1995	Previous in vitro investigations demonstrated that human leukemia cells, when incubated with hematopoietic growth factors such as granulocyte-colony-stimulating factor (G-CSF), augment the accumulation of the triphosphate 1-beta-D-arabinofuranosylcytosine (ara-C cytarabine).	triphosphate 1-beta-d-arabinofuranosylcytosine	209-255	colony stimulating factor 3	Homo sapiens	130-167
9815970-1	1995	Previous in vitro investigations demonstrated that human leukemia cells, when incubated with hematopoietic growth factors such as granulocyte-colony-stimulating factor (G-CSF), augment the accumulation of the triphosphate 1-beta-D-arabinofuranosylcytosine (ara-C cytarabine).	triphosphate 1-beta-d-arabinofuranosylcytosine	209-255	colony stimulating factor 3	Homo sapiens	169-174
9815970-1	1995	Previous in vitro investigations demonstrated that human leukemia cells, when incubated with hematopoietic growth factors such as granulocyte-colony-stimulating factor (G-CSF), augment the accumulation of the triphosphate 1-beta-D-arabinofuranosylcytosine (ara-C cytarabine).	Cytarabine	257-262	colony stimulating factor 3	Homo sapiens	130-167
9815970-1	1995	Previous in vitro investigations demonstrated that human leukemia cells, when incubated with hematopoietic growth factors such as granulocyte-colony-stimulating factor (G-CSF), augment the accumulation of the triphosphate 1-beta-D-arabinofuranosylcytosine (ara-C cytarabine).	Cytarabine	257-262	colony stimulating factor 3	Homo sapiens	169-174
9815970-1	1995	Previous in vitro investigations demonstrated that human leukemia cells, when incubated with hematopoietic growth factors such as granulocyte-colony-stimulating factor (G-CSF), augment the accumulation of the triphosphate 1-beta-D-arabinofuranosylcytosine (ara-C cytarabine).	Cytarabine	263-273	colony stimulating factor 3	Homo sapiens	130-167
9815970-7	1995	Comparison of F-ara-ATP pharmacokinetics in circulating AML cells of patients on the fludarabine/ara- C/G-CSF regimen demonstrated that the area under concentration time curve (AUC) of F-ara-ATP increased significantly (median, 1.4-fold; range, 0.9-1.5; P = 0.045) after G-CSF infusion.	2-fluoro-araATP	14-23	colony stimulating factor 3	Homo sapiens	271-276
9815970-1	1995	Previous in vitro investigations demonstrated that human leukemia cells, when incubated with hematopoietic growth factors such as granulocyte-colony-stimulating factor (G-CSF), augment the accumulation of the triphosphate 1-beta-D-arabinofuranosylcytosine (ara-C cytarabine).	Cytarabine	263-273	colony stimulating factor 3	Homo sapiens	169-174
9815970-7	1995	Comparison of F-ara-ATP pharmacokinetics in circulating AML cells of patients on the fludarabine/ara- C/G-CSF regimen demonstrated that the area under concentration time curve (AUC) of F-ara-ATP increased significantly (median, 1.4-fold; range, 0.9-1.5; P = 0.045) after G-CSF infusion.	2-fluoro-araATP	185-194	colony stimulating factor 3	Homo sapiens	104-109
9815970-7	1995	Comparison of F-ara-ATP pharmacokinetics in circulating AML cells of patients on the fludarabine/ara- C/G-CSF regimen demonstrated that the area under concentration time curve (AUC) of F-ara-ATP increased significantly (median, 1.4-fold; range, 0.9-1.5; P = 0.045) after G-CSF infusion.	2-fluoro-araATP	185-194	colony stimulating factor 3	Homo sapiens	271-276
9815970-10	1995	Because fludarabine potentiates the accumulation of ara-CTP, the effect of G-CSF on ara-CTP metabolism may not be evident in the AML blasts of patients on the fludarabine/ara-C/G-CSF regimen.	ara-ctp	84-91	colony stimulating factor 3	Homo sapiens	75-80
9815970-12	1995	The AUC of ara-CTP accumulation in these patients decreased by a median of 48% after G-CSF infusion.	ara-ctp	11-18	colony stimulating factor 3	Homo sapiens	85-90
9815970-13	1995	Consistent with these in vivo investigations, ex vivo ara-CTP accumulation was decreased in the AML blasts after G-CSF infusion.	ara-ctp	54-61	colony stimulating factor 3	Homo sapiens	113-118
9815970-14	1995	Based on these data it could be concluded that (a) infusion of G-CSF before fludarabine augmented the rate of F-ara-ATP synthesis in circulating AML blasts during therapy, suggesting that G-CSF may benefit fludarabine therapy by biological modulation; (b) G-CSF did not increase ara-CTP accumulation, rather it may have caused it to decrease; and (c) these data imply that when G-CSF and ara-C are used in combination, administration of fludarabine prior to ara-C may maintain the ara-CTP AUC.	2-fluoro-araATP	110-119	colony stimulating factor 3	Homo sapiens	63-68
9815970-14	1995	Based on these data it could be concluded that (a) infusion of G-CSF before fludarabine augmented the rate of F-ara-ATP synthesis in circulating AML blasts during therapy, suggesting that G-CSF may benefit fludarabine therapy by biological modulation; (b) G-CSF did not increase ara-CTP accumulation, rather it may have caused it to decrease; and (c) these data imply that when G-CSF and ara-C are used in combination, administration of fludarabine prior to ara-C may maintain the ara-CTP AUC.	2-fluoro-araATP	110-119	colony stimulating factor 3	Homo sapiens	188-193
9815970-14	1995	Based on these data it could be concluded that (a) infusion of G-CSF before fludarabine augmented the rate of F-ara-ATP synthesis in circulating AML blasts during therapy, suggesting that G-CSF may benefit fludarabine therapy by biological modulation; (b) G-CSF did not increase ara-CTP accumulation, rather it may have caused it to decrease; and (c) these data imply that when G-CSF and ara-C are used in combination, administration of fludarabine prior to ara-C may maintain the ara-CTP AUC.	2-fluoro-araATP	110-119	colony stimulating factor 3	Homo sapiens	188-193
9815970-14	1995	Based on these data it could be concluded that (a) infusion of G-CSF before fludarabine augmented the rate of F-ara-ATP synthesis in circulating AML blasts during therapy, suggesting that G-CSF may benefit fludarabine therapy by biological modulation; (b) G-CSF did not increase ara-CTP accumulation, rather it may have caused it to decrease; and (c) these data imply that when G-CSF and ara-C are used in combination, administration of fludarabine prior to ara-C may maintain the ara-CTP AUC.	2-fluoro-araATP	110-119	colony stimulating factor 3	Homo sapiens	188-193
9815970-14	1995	Based on these data it could be concluded that (a) infusion of G-CSF before fludarabine augmented the rate of F-ara-ATP synthesis in circulating AML blasts during therapy, suggesting that G-CSF may benefit fludarabine therapy by biological modulation; (b) G-CSF did not increase ara-CTP accumulation, rather it may have caused it to decrease; and (c) these data imply that when G-CSF and ara-C are used in combination, administration of fludarabine prior to ara-C may maintain the ara-CTP AUC.	fludarabine	206-217	colony stimulating factor 3	Homo sapiens	63-68
9815970-14	1995	Based on these data it could be concluded that (a) infusion of G-CSF before fludarabine augmented the rate of F-ara-ATP synthesis in circulating AML blasts during therapy, suggesting that G-CSF may benefit fludarabine therapy by biological modulation; (b) G-CSF did not increase ara-CTP accumulation, rather it may have caused it to decrease; and (c) these data imply that when G-CSF and ara-C are used in combination, administration of fludarabine prior to ara-C may maintain the ara-CTP AUC.	fludarabine	206-217	colony stimulating factor 3	Homo sapiens	188-193
9815970-14	1995	Based on these data it could be concluded that (a) infusion of G-CSF before fludarabine augmented the rate of F-ara-ATP synthesis in circulating AML blasts during therapy, suggesting that G-CSF may benefit fludarabine therapy by biological modulation; (b) G-CSF did not increase ara-CTP accumulation, rather it may have caused it to decrease; and (c) these data imply that when G-CSF and ara-C are used in combination, administration of fludarabine prior to ara-C may maintain the ara-CTP AUC.	fludarabine	206-217	colony stimulating factor 3	Homo sapiens	188-193
9815970-14	1995	Based on these data it could be concluded that (a) infusion of G-CSF before fludarabine augmented the rate of F-ara-ATP synthesis in circulating AML blasts during therapy, suggesting that G-CSF may benefit fludarabine therapy by biological modulation; (b) G-CSF did not increase ara-CTP accumulation, rather it may have caused it to decrease; and (c) these data imply that when G-CSF and ara-C are used in combination, administration of fludarabine prior to ara-C may maintain the ara-CTP AUC.	fludarabine	206-217	colony stimulating factor 3	Homo sapiens	188-193
9815970-14	1995	Based on these data it could be concluded that (a) infusion of G-CSF before fludarabine augmented the rate of F-ara-ATP synthesis in circulating AML blasts during therapy, suggesting that G-CSF may benefit fludarabine therapy by biological modulation; (b) G-CSF did not increase ara-CTP accumulation, rather it may have caused it to decrease; and (c) these data imply that when G-CSF and ara-C are used in combination, administration of fludarabine prior to ara-C may maintain the ara-CTP AUC.	ara-ctp	279-286	colony stimulating factor 3	Homo sapiens	63-68
9815970-14	1995	Based on these data it could be concluded that (a) infusion of G-CSF before fludarabine augmented the rate of F-ara-ATP synthesis in circulating AML blasts during therapy, suggesting that G-CSF may benefit fludarabine therapy by biological modulation; (b) G-CSF did not increase ara-CTP accumulation, rather it may have caused it to decrease; and (c) these data imply that when G-CSF and ara-C are used in combination, administration of fludarabine prior to ara-C may maintain the ara-CTP AUC.	ara-ctp	279-286	colony stimulating factor 3	Homo sapiens	188-193
9815970-14	1995	Based on these data it could be concluded that (a) infusion of G-CSF before fludarabine augmented the rate of F-ara-ATP synthesis in circulating AML blasts during therapy, suggesting that G-CSF may benefit fludarabine therapy by biological modulation; (b) G-CSF did not increase ara-CTP accumulation, rather it may have caused it to decrease; and (c) these data imply that when G-CSF and ara-C are used in combination, administration of fludarabine prior to ara-C may maintain the ara-CTP AUC.	ara-ctp	279-286	colony stimulating factor 3	Homo sapiens	188-193
9815970-14	1995	Based on these data it could be concluded that (a) infusion of G-CSF before fludarabine augmented the rate of F-ara-ATP synthesis in circulating AML blasts during therapy, suggesting that G-CSF may benefit fludarabine therapy by biological modulation; (b) G-CSF did not increase ara-CTP accumulation, rather it may have caused it to decrease; and (c) these data imply that when G-CSF and ara-C are used in combination, administration of fludarabine prior to ara-C may maintain the ara-CTP AUC.	ara-ctp	279-286	colony stimulating factor 3	Homo sapiens	188-193
9815970-14	1995	Based on these data it could be concluded that (a) infusion of G-CSF before fludarabine augmented the rate of F-ara-ATP synthesis in circulating AML blasts during therapy, suggesting that G-CSF may benefit fludarabine therapy by biological modulation; (b) G-CSF did not increase ara-CTP accumulation, rather it may have caused it to decrease; and (c) these data imply that when G-CSF and ara-C are used in combination, administration of fludarabine prior to ara-C may maintain the ara-CTP AUC.	Cytarabine	279-284	colony stimulating factor 3	Homo sapiens	63-68
9815970-14	1995	Based on these data it could be concluded that (a) infusion of G-CSF before fludarabine augmented the rate of F-ara-ATP synthesis in circulating AML blasts during therapy, suggesting that G-CSF may benefit fludarabine therapy by biological modulation; (b) G-CSF did not increase ara-CTP accumulation, rather it may have caused it to decrease; and (c) these data imply that when G-CSF and ara-C are used in combination, administration of fludarabine prior to ara-C may maintain the ara-CTP AUC.	Cytarabine	279-284	colony stimulating factor 3	Homo sapiens	188-193
9815970-14	1995	Based on these data it could be concluded that (a) infusion of G-CSF before fludarabine augmented the rate of F-ara-ATP synthesis in circulating AML blasts during therapy, suggesting that G-CSF may benefit fludarabine therapy by biological modulation; (b) G-CSF did not increase ara-CTP accumulation, rather it may have caused it to decrease; and (c) these data imply that when G-CSF and ara-C are used in combination, administration of fludarabine prior to ara-C may maintain the ara-CTP AUC.	Cytarabine	279-284	colony stimulating factor 3	Homo sapiens	188-193
9815970-14	1995	Based on these data it could be concluded that (a) infusion of G-CSF before fludarabine augmented the rate of F-ara-ATP synthesis in circulating AML blasts during therapy, suggesting that G-CSF may benefit fludarabine therapy by biological modulation; (b) G-CSF did not increase ara-CTP accumulation, rather it may have caused it to decrease; and (c) these data imply that when G-CSF and ara-C are used in combination, administration of fludarabine prior to ara-C may maintain the ara-CTP AUC.	Cytarabine	279-284	colony stimulating factor 3	Homo sapiens	188-193
7537550-3	1995	Culture of G-CSF receptor-expressing cells (GR-K562) in the presence of G-CSF enhanced DNA synthesis and a stimulation index of 4.61 was obtained in a 3H-thymidine uptake assay.	Tritium	151-153	colony stimulating factor 3	Homo sapiens	11-16
7537550-3	1995	Culture of G-CSF receptor-expressing cells (GR-K562) in the presence of G-CSF enhanced DNA synthesis and a stimulation index of 4.61 was obtained in a 3H-thymidine uptake assay.	Thymidine	154-163	colony stimulating factor 3	Homo sapiens	11-16
9815970-14	1995	Based on these data it could be concluded that (a) infusion of G-CSF before fludarabine augmented the rate of F-ara-ATP synthesis in circulating AML blasts during therapy, suggesting that G-CSF may benefit fludarabine therapy by biological modulation; (b) G-CSF did not increase ara-CTP accumulation, rather it may have caused it to decrease; and (c) these data imply that when G-CSF and ara-C are used in combination, administration of fludarabine prior to ara-C may maintain the ara-CTP AUC.	fludarabine	206-217	colony stimulating factor 3	Homo sapiens	63-68
9815970-14	1995	Based on these data it could be concluded that (a) infusion of G-CSF before fludarabine augmented the rate of F-ara-ATP synthesis in circulating AML blasts during therapy, suggesting that G-CSF may benefit fludarabine therapy by biological modulation; (b) G-CSF did not increase ara-CTP accumulation, rather it may have caused it to decrease; and (c) these data imply that when G-CSF and ara-C are used in combination, administration of fludarabine prior to ara-C may maintain the ara-CTP AUC.	fludarabine	206-217	colony stimulating factor 3	Homo sapiens	188-193
9815970-14	1995	Based on these data it could be concluded that (a) infusion of G-CSF before fludarabine augmented the rate of F-ara-ATP synthesis in circulating AML blasts during therapy, suggesting that G-CSF may benefit fludarabine therapy by biological modulation; (b) G-CSF did not increase ara-CTP accumulation, rather it may have caused it to decrease; and (c) these data imply that when G-CSF and ara-C are used in combination, administration of fludarabine prior to ara-C may maintain the ara-CTP AUC.	fludarabine	206-217	colony stimulating factor 3	Homo sapiens	188-193
9815970-14	1995	Based on these data it could be concluded that (a) infusion of G-CSF before fludarabine augmented the rate of F-ara-ATP synthesis in circulating AML blasts during therapy, suggesting that G-CSF may benefit fludarabine therapy by biological modulation; (b) G-CSF did not increase ara-CTP accumulation, rather it may have caused it to decrease; and (c) these data imply that when G-CSF and ara-C are used in combination, administration of fludarabine prior to ara-C may maintain the ara-CTP AUC.	fludarabine	206-217	colony stimulating factor 3	Homo sapiens	188-193
9815970-14	1995	Based on these data it could be concluded that (a) infusion of G-CSF before fludarabine augmented the rate of F-ara-ATP synthesis in circulating AML blasts during therapy, suggesting that G-CSF may benefit fludarabine therapy by biological modulation; (b) G-CSF did not increase ara-CTP accumulation, rather it may have caused it to decrease; and (c) these data imply that when G-CSF and ara-C are used in combination, administration of fludarabine prior to ara-C may maintain the ara-CTP AUC.	Cytarabine	388-393	colony stimulating factor 3	Homo sapiens	63-68
9815970-14	1995	Based on these data it could be concluded that (a) infusion of G-CSF before fludarabine augmented the rate of F-ara-ATP synthesis in circulating AML blasts during therapy, suggesting that G-CSF may benefit fludarabine therapy by biological modulation; (b) G-CSF did not increase ara-CTP accumulation, rather it may have caused it to decrease; and (c) these data imply that when G-CSF and ara-C are used in combination, administration of fludarabine prior to ara-C may maintain the ara-CTP AUC.	Cytarabine	388-393	colony stimulating factor 3	Homo sapiens	188-193
9815970-14	1995	Based on these data it could be concluded that (a) infusion of G-CSF before fludarabine augmented the rate of F-ara-ATP synthesis in circulating AML blasts during therapy, suggesting that G-CSF may benefit fludarabine therapy by biological modulation; (b) G-CSF did not increase ara-CTP accumulation, rather it may have caused it to decrease; and (c) these data imply that when G-CSF and ara-C are used in combination, administration of fludarabine prior to ara-C may maintain the ara-CTP AUC.	Cytarabine	388-393	colony stimulating factor 3	Homo sapiens	188-193
9815970-14	1995	Based on these data it could be concluded that (a) infusion of G-CSF before fludarabine augmented the rate of F-ara-ATP synthesis in circulating AML blasts during therapy, suggesting that G-CSF may benefit fludarabine therapy by biological modulation; (b) G-CSF did not increase ara-CTP accumulation, rather it may have caused it to decrease; and (c) these data imply that when G-CSF and ara-C are used in combination, administration of fludarabine prior to ara-C may maintain the ara-CTP AUC.	Cytarabine	388-393	colony stimulating factor 3	Homo sapiens	188-193
9815970-14	1995	Based on these data it could be concluded that (a) infusion of G-CSF before fludarabine augmented the rate of F-ara-ATP synthesis in circulating AML blasts during therapy, suggesting that G-CSF may benefit fludarabine therapy by biological modulation; (b) G-CSF did not increase ara-CTP accumulation, rather it may have caused it to decrease; and (c) these data imply that when G-CSF and ara-C are used in combination, administration of fludarabine prior to ara-C may maintain the ara-CTP AUC.	ara-ctp	481-488	colony stimulating factor 3	Homo sapiens	63-68
9815970-14	1995	Based on these data it could be concluded that (a) infusion of G-CSF before fludarabine augmented the rate of F-ara-ATP synthesis in circulating AML blasts during therapy, suggesting that G-CSF may benefit fludarabine therapy by biological modulation; (b) G-CSF did not increase ara-CTP accumulation, rather it may have caused it to decrease; and (c) these data imply that when G-CSF and ara-C are used in combination, administration of fludarabine prior to ara-C may maintain the ara-CTP AUC.	ara-ctp	481-488	colony stimulating factor 3	Homo sapiens	188-193
9815970-14	1995	Based on these data it could be concluded that (a) infusion of G-CSF before fludarabine augmented the rate of F-ara-ATP synthesis in circulating AML blasts during therapy, suggesting that G-CSF may benefit fludarabine therapy by biological modulation; (b) G-CSF did not increase ara-CTP accumulation, rather it may have caused it to decrease; and (c) these data imply that when G-CSF and ara-C are used in combination, administration of fludarabine prior to ara-C may maintain the ara-CTP AUC.	ara-ctp	481-488	colony stimulating factor 3	Homo sapiens	188-193
9815970-14	1995	Based on these data it could be concluded that (a) infusion of G-CSF before fludarabine augmented the rate of F-ara-ATP synthesis in circulating AML blasts during therapy, suggesting that G-CSF may benefit fludarabine therapy by biological modulation; (b) G-CSF did not increase ara-CTP accumulation, rather it may have caused it to decrease; and (c) these data imply that when G-CSF and ara-C are used in combination, administration of fludarabine prior to ara-C may maintain the ara-CTP AUC.	ara-ctp	481-488	colony stimulating factor 3	Homo sapiens	188-193
7869761-6	1995	Using a 3H-thymidine incorporation assay, DNA synthesis of leukemic blasts could be stimulated by IL-3, IL-6 and G-CSF in vitro.	3h-thymidine	8-20	colony stimulating factor 3	Homo sapiens	113-118
7538179-1	1995	The clinical effectiveness of a combination treatment using imipenem/cilastatin sodium (IPM/CS) with G-CSF was studied in neutropenic patients (&lt; 500/mm3) with hematological malignancies and secondary infections.	Cesium	92-94	colony stimulating factor 3	Homo sapiens	101-106
7538179-5	1995	According to the order of the administration, the efficacy rates were 60.0% in 5 cases in whom G-CSF treatment was started before IPM/CS, 66.7% in 21 cases given both G-CSF and IPM/CS simultaneously, and 75.0% in 4 cases in whom IPM/CS was started before G-CSF.	isophosphamide mustard	130-133	colony stimulating factor 3	Homo sapiens	95-100
7538179-5	1995	According to the order of the administration, the efficacy rates were 60.0% in 5 cases in whom G-CSF treatment was started before IPM/CS, 66.7% in 21 cases given both G-CSF and IPM/CS simultaneously, and 75.0% in 4 cases in whom IPM/CS was started before G-CSF.	Cesium	134-136	colony stimulating factor 3	Homo sapiens	95-100
7538179-5	1995	According to the order of the administration, the efficacy rates were 60.0% in 5 cases in whom G-CSF treatment was started before IPM/CS, 66.7% in 21 cases given both G-CSF and IPM/CS simultaneously, and 75.0% in 4 cases in whom IPM/CS was started before G-CSF.	Cesium	134-136	colony stimulating factor 3	Homo sapiens	95-100
7544522-9	1995	After stimulation with lipopolysaccharide or phorbol myristate acetate, the MNCs expressed high levels of G-CSF and GM-CSF mRNA.	Tetradecanoylphorbol Acetate	45-70	colony stimulating factor 3	Homo sapiens	106-111
7536277-1	1995	We report a case of acute myelogenous leukemia (AML), which developed from severe aplastic anemia (SAA) and was successfully treated by low-dose Ara-C and aclarubicin with concomitant use of G-CSF (CAG therapy).	saa	99-102	colony stimulating factor 3	Homo sapiens	191-196
7735426-6	1995	Chemotherapy was discontinued and the patient was given intravenous amphotericin B (1.0 mg/kg/day) and heparin associated with G.CSF.	Heparin	103-110	colony stimulating factor 3	Homo sapiens	127-132
8695545-5	1995	Taxol produces response rates of about 25% in previously untreated patients and is currently undergoing trials at higher doses in combination with cisplatin and granulocyte colony-stimulating factor.	Paclitaxel	0-5	colony stimulating factor 3	Homo sapiens	161-198
8750138-7	1995	BPC in apheresis product or whole blood from patients primed with chemotherapy and filgrastim (G-CSF) were found to be viable for 48 hours when stored at 4 degrees C. Patients receiving multicyclic ifosfamide, carboplatin and etoposide (ICE) chemotherapy received BPC in apheresis product or whole blood, which had been stored at 4 degrees C, on day 3 of each treatment cycle.	bpc	0-3	colony stimulating factor 3	Homo sapiens	95-100
7530477-3	1995	These results suggest a link between SAA/CN and MDS/AML in relation to G-CSF administration; however, large studies are necessary to determine if such a risk is significant in patients with SAA/CN who are treated with G-CSF.	saa	37-40	colony stimulating factor 3	Homo sapiens	71-76
7530477-3	1995	These results suggest a link between SAA/CN and MDS/AML in relation to G-CSF administration; however, large studies are necessary to determine if such a risk is significant in patients with SAA/CN who are treated with G-CSF.	saa	37-40	colony stimulating factor 3	Homo sapiens	218-223
8673471-0	1995	Expression of granulocyte colony stimulating factor (G-CSF) and granulocyte/macrophage colony stimulating factor (GM-CSF) mRNA upon stimulation with phorbol ester.	Phorbol Esters	149-162	colony stimulating factor 3	Homo sapiens	14-51
7530477-3	1995	These results suggest a link between SAA/CN and MDS/AML in relation to G-CSF administration; however, large studies are necessary to determine if such a risk is significant in patients with SAA/CN who are treated with G-CSF.	saa	190-193	colony stimulating factor 3	Homo sapiens	71-76
8673471-0	1995	Expression of granulocyte colony stimulating factor (G-CSF) and granulocyte/macrophage colony stimulating factor (GM-CSF) mRNA upon stimulation with phorbol ester.	Phorbol Esters	149-162	colony stimulating factor 3	Homo sapiens	53-58
7530477-3	1995	These results suggest a link between SAA/CN and MDS/AML in relation to G-CSF administration; however, large studies are necessary to determine if such a risk is significant in patients with SAA/CN who are treated with G-CSF.	saa	190-193	colony stimulating factor 3	Homo sapiens	218-223
7530173-10	1995	The addition of GCSF during weeks 1, 3, and 4 allowed for escalation of cisplatin to 100 mg/m2 during weeks 1 and 2, with a decreased dose of IFN at 2.5 MU/m2 per day to avoid renal toxicity.	Cisplatin	72-81	colony stimulating factor 3	Homo sapiens	16-20
8673471-1	1995	Stimulated human peripheral blood mononuclear cells (MNC) have been shown to express both G-CSF and GM-CSF, Furthermore, G-CSF is expressed by monocytes but not lymphocytes, whereas GM-CSF is expressed largely by T lymphocytes and at low levels in monocytes/macrophages, Here we present the effect of TPA (120-O-tetradecanoyl phorbol-13-acetate) on G-CSF and GM-CSF expression in stimulated human MNCs and T lymphocytes.	Tetradecanoylphorbol Acetate	301-304	colony stimulating factor 3	Homo sapiens	121-126
8673471-1	1995	Stimulated human peripheral blood mononuclear cells (MNC) have been shown to express both G-CSF and GM-CSF, Furthermore, G-CSF is expressed by monocytes but not lymphocytes, whereas GM-CSF is expressed largely by T lymphocytes and at low levels in monocytes/macrophages, Here we present the effect of TPA (120-O-tetradecanoyl phorbol-13-acetate) on G-CSF and GM-CSF expression in stimulated human MNCs and T lymphocytes.	Tetradecanoylphorbol Acetate	301-304	colony stimulating factor 3	Homo sapiens	121-126
8673471-1	1995	Stimulated human peripheral blood mononuclear cells (MNC) have been shown to express both G-CSF and GM-CSF, Furthermore, G-CSF is expressed by monocytes but not lymphocytes, whereas GM-CSF is expressed largely by T lymphocytes and at low levels in monocytes/macrophages, Here we present the effect of TPA (120-O-tetradecanoyl phorbol-13-acetate) on G-CSF and GM-CSF expression in stimulated human MNCs and T lymphocytes.	120-o-tetradecanoyl phorbol-13-acetate	306-344	colony stimulating factor 3	Homo sapiens	121-126
8673471-1	1995	Stimulated human peripheral blood mononuclear cells (MNC) have been shown to express both G-CSF and GM-CSF, Furthermore, G-CSF is expressed by monocytes but not lymphocytes, whereas GM-CSF is expressed largely by T lymphocytes and at low levels in monocytes/macrophages, Here we present the effect of TPA (120-O-tetradecanoyl phorbol-13-acetate) on G-CSF and GM-CSF expression in stimulated human MNCs and T lymphocytes.	120-o-tetradecanoyl phorbol-13-acetate	306-344	colony stimulating factor 3	Homo sapiens	121-126
8673471-2	1995	We observed that TPA (30nM) decreased G-CSF mRNA levels in MNCs, while ionomycin increased G-CSF in a dose-dependent manner.	Tetradecanoylphorbol Acetate	17-20	colony stimulating factor 3	Homo sapiens	38-43
8673471-2	1995	We observed that TPA (30nM) decreased G-CSF mRNA levels in MNCs, while ionomycin increased G-CSF in a dose-dependent manner.	Ionomycin	71-80	colony stimulating factor 3	Homo sapiens	91-96
8673471-7	1995	It would also appear these signals act on MNCs in an opposing manner to decrease G-CSF mRNA levels, indicating that activation of PKC and the calcium signaling pathway lead to a cell-type specific modulation of individual cytokines and precise regulation of granulocyte production.	Calcium	142-149	colony stimulating factor 3	Homo sapiens	81-86
7530173-21	1995	(2) GCSF can be safely administered and provides effective support of neutrophils when administered simultaneously with IFN, cisplatin, and chest radiotherapy.	Cisplatin	125-134	colony stimulating factor 3	Homo sapiens	4-8
8580054-0	1995	Increasing and planned dose intensity of doxorubicin, cyclophosphamide and etoposide (ACE) by adding recombinant human methionyl granulocyte colony-stimulating factor (G-CSF; filgrastim) in the treatment of small cell lung cancer (SCLC).	Etoposide	75-84	colony stimulating factor 3	Homo sapiens	168-173
7536433-0	1995	The feasibility of using glycosylated recombinant human granulocyte colony-stimulating factor (G-CSF) to increase the planned dose intensity of doxorubicin, cyclophosphamide and etoposide (ACE) in the treatment of small cell lung cancer.	Doxorubicin	144-155	colony stimulating factor 3	Homo sapiens	56-93
8580054-0	1995	Increasing and planned dose intensity of doxorubicin, cyclophosphamide and etoposide (ACE) by adding recombinant human methionyl granulocyte colony-stimulating factor (G-CSF; filgrastim) in the treatment of small cell lung cancer (SCLC).	Doxorubicin	41-52	colony stimulating factor 3	Homo sapiens	168-173
7536433-0	1995	The feasibility of using glycosylated recombinant human granulocyte colony-stimulating factor (G-CSF) to increase the planned dose intensity of doxorubicin, cyclophosphamide and etoposide (ACE) in the treatment of small cell lung cancer.	Doxorubicin	144-155	colony stimulating factor 3	Homo sapiens	95-100
7536433-0	1995	The feasibility of using glycosylated recombinant human granulocyte colony-stimulating factor (G-CSF) to increase the planned dose intensity of doxorubicin, cyclophosphamide and etoposide (ACE) in the treatment of small cell lung cancer.	Cyclophosphamide	157-173	colony stimulating factor 3	Homo sapiens	56-93
7536433-0	1995	The feasibility of using glycosylated recombinant human granulocyte colony-stimulating factor (G-CSF) to increase the planned dose intensity of doxorubicin, cyclophosphamide and etoposide (ACE) in the treatment of small cell lung cancer.	Cyclophosphamide	157-173	colony stimulating factor 3	Homo sapiens	95-100
7536433-0	1995	The feasibility of using glycosylated recombinant human granulocyte colony-stimulating factor (G-CSF) to increase the planned dose intensity of doxorubicin, cyclophosphamide and etoposide (ACE) in the treatment of small cell lung cancer.	Etoposide	178-187	colony stimulating factor 3	Homo sapiens	56-93
7536433-0	1995	The feasibility of using glycosylated recombinant human granulocyte colony-stimulating factor (G-CSF) to increase the planned dose intensity of doxorubicin, cyclophosphamide and etoposide (ACE) in the treatment of small cell lung cancer.	Etoposide	178-187	colony stimulating factor 3	Homo sapiens	95-100
7556279-1	1995	This study was undertaken to determine if there was an association between the use of granulocyte colony-stimulating factor (G-CSF) and the clinical response to paclitaxel in patients with advanced ovarian cancer.	Paclitaxel	161-171	colony stimulating factor 3	Homo sapiens	86-123
8835629-0	1995	Glycosylation improves the priming effect exerted by recombinant human granulocyte colony-stimulating factor (lenograstim) on human neutrophil superoxide production.	Superoxides	143-153	colony stimulating factor 3	Homo sapiens	71-108
7556279-1	1995	This study was undertaken to determine if there was an association between the use of granulocyte colony-stimulating factor (G-CSF) and the clinical response to paclitaxel in patients with advanced ovarian cancer.	Paclitaxel	161-171	colony stimulating factor 3	Homo sapiens	125-130
8586313-3	1995	We present a case of agranulocytosis after prolonged intravenous infusion of ritodrine hydrochloride and additional administration of indomethacin suppositories, effectively treated using recombinant human granulocyte colony stimulating factor without any infection in a mother with twin-to-twin transfusion syndrome.	Ritodrine	77-100	colony stimulating factor 3	Homo sapiens	206-243
8586313-3	1995	We present a case of agranulocytosis after prolonged intravenous infusion of ritodrine hydrochloride and additional administration of indomethacin suppositories, effectively treated using recombinant human granulocyte colony stimulating factor without any infection in a mother with twin-to-twin transfusion syndrome.	indomethacin suppositories	134-160	colony stimulating factor 3	Homo sapiens	206-243
7538966-0	1995	Superoxide production by neutrophils in children with malignant tumors treated with recombinant human granulocyte colony-stimulating factor.	Superoxides	0-10	colony stimulating factor 3	Homo sapiens	102-139
7538966-1	1995	BACKGROUND: Human recombinant granulocyte colony-stimulating factor (rhG-CSF), widely used to combat chemotherapy-induced neutropenia, stimulates both in vivo and in vitro intra- and extra-cellular O2- production in human polymorphonuclear cells (PMNs).	Superoxides	198-200	colony stimulating factor 3	Homo sapiens	30-67
7526143-15	1995	The present study shows that the prophylactic use of r-met-hu G-CSF allows the administration of high-dose epirubicin every 4 weeks with minimal morbidity and an improved quality of life.	Epirubicin	107-117	colony stimulating factor 3	Homo sapiens	62-67
7528271-2	1995	PATIENTS AND METHODS: Twenty-five patients with small-cell lung cancer (SCLC) were treated with six cycles of ifosfamide, carboplatin, and etoposide (ICE) with granulocyte colony-stimulating factor (G-CSF) 300 micrograms/d subcutaneously (SC) on days 4 to 15.	Water	150-153	colony stimulating factor 3	Homo sapiens	160-197
7526143-2	1995	Concurrent administration of G-CSF probably allows the administration of epirubicin on schedule with minimal morbidity.	Epirubicin	73-83	colony stimulating factor 3	Homo sapiens	29-34
7535420-0	1995	Chronic neutropenia and defect in superoxide generation of granulocytes in two patients: enhancement of bactericidal capacity and respiratory burst activity by treatment with recombinant human granulocyte colony-stimulating factor.	Superoxides	34-44	colony stimulating factor 3	Homo sapiens	193-230
7535420-7	1995	These data suggested that recombinant human granulocyte colony-stimulating factor treatment enhanced resistance to bacterial infection by stimulation of superoxide generation and increasing the bactericidal capacity of peripheral blood granulocytes.	Superoxides	153-163	colony stimulating factor 3	Homo sapiens	44-81
7536275-0	1995	[Continuation of complete remission by oral administration of cytarabine ocfosfate in a patient with M0, who achieved remission by small doses of cytosine arabinoside with G-CSF].	1-arabinofuranosylcytosine-5'-stearylphosphate	62-82	colony stimulating factor 3	Homo sapiens	172-177
8524930-13	1995	Synthetic LPS partial structure SDZ-MRL 953 (I) induces a cytokine pattern, which is profoundedly different from that of LPS, (II) with an inverse TNF to G-CSF relation, (III) is (without any ibuprofen treatment) remarkably low toxic, (IV) and downregulates the TNF-response to LPS markedly.	Sulfadiazine	32-35	colony stimulating factor 3	Homo sapiens	154-159
7536275-0	1995	[Continuation of complete remission by oral administration of cytarabine ocfosfate in a patient with M0, who achieved remission by small doses of cytosine arabinoside with G-CSF].	Cytarabine	146-166	colony stimulating factor 3	Homo sapiens	172-177
7530677-1	1994	The purpose of this study was to review the clinical outcomes and cost of administration of a prophylactic antibiotic compared to G-CSF for the prevention of neutropenic morbidity associated with taxol.	Paclitaxel	196-201	colony stimulating factor 3	Homo sapiens	130-135
7549267-6	1995	G-CSF enhanced PMN superoxide anion (O2-) production and luminol-dependent chemiluminescence (CL) induced by opsonized zymosan in a dose-dependent manner.	Superoxides	19-35	colony stimulating factor 3	Homo sapiens	0-5
7549267-6	1995	G-CSF enhanced PMN superoxide anion (O2-) production and luminol-dependent chemiluminescence (CL) induced by opsonized zymosan in a dose-dependent manner.	Superoxides	37-40	colony stimulating factor 3	Homo sapiens	0-5
7549267-6	1995	G-CSF enhanced PMN superoxide anion (O2-) production and luminol-dependent chemiluminescence (CL) induced by opsonized zymosan in a dose-dependent manner.	Luminol	57-64	colony stimulating factor 3	Homo sapiens	0-5
7549267-6	1995	G-CSF enhanced PMN superoxide anion (O2-) production and luminol-dependent chemiluminescence (CL) induced by opsonized zymosan in a dose-dependent manner.	Zymosan	119-126	colony stimulating factor 3	Homo sapiens	0-5
7529537-0	1994	Protective effect of granulocyte-colony stimulating factor against amphotericin B-induced myelosuppression in vitro.	Amphotericin B	67-81	colony stimulating factor 3	Homo sapiens	21-58
7529537-3	1994	The present study defines the role of G-CSF in preventing amphotericin B-induced myelosuppression.	Amphotericin B	58-72	colony stimulating factor 3	Homo sapiens	38-43
7529537-7	1994	These data suggest that G-CSF prevents the amphotericin B-induced myelosuppression by antagonizing the suppressive effects of TNF and IFN and by enhancing the proliferative activity of BM.	Amphotericin B	43-57	colony stimulating factor 3	Homo sapiens	24-29
7538704-0	1995	Intensive weekly chemotherapy for elderly gastric cancer patients, using 5-fluorouracil, cisplatin, epi-doxorubicin, 6S-leucovorin and glutathione with the support of G-CSF.	Fluorouracil	73-87	colony stimulating factor 3	Homo sapiens	167-172
7538704-0	1995	Intensive weekly chemotherapy for elderly gastric cancer patients, using 5-fluorouracil, cisplatin, epi-doxorubicin, 6S-leucovorin and glutathione with the support of G-CSF.	Epirubicin	100-115	colony stimulating factor 3	Homo sapiens	167-172
7538704-0	1995	Intensive weekly chemotherapy for elderly gastric cancer patients, using 5-fluorouracil, cisplatin, epi-doxorubicin, 6S-leucovorin and glutathione with the support of G-CSF.	Levoleucovorin	117-130	colony stimulating factor 3	Homo sapiens	167-172
7538704-0	1995	Intensive weekly chemotherapy for elderly gastric cancer patients, using 5-fluorouracil, cisplatin, epi-doxorubicin, 6S-leucovorin and glutathione with the support of G-CSF.	Glutathione	135-146	colony stimulating factor 3	Homo sapiens	167-172
7541924-4	1995	In addition, a role of granulocyte colony-stimulating factor (G-CSF) on dose intensity of PVB regimen was analyzed.	PVB protocol	90-93	colony stimulating factor 3	Homo sapiens	62-67
7541924-10	1995	The RDI of PVB regimen with administration of G-CSF was 0.98, whereas in the PVB-alone group it was 0.87 (p &lt; 0.01).	PVB protocol	11-14	colony stimulating factor 3	Homo sapiens	46-51
7890801-7	1994	Cytokines such as IFN alpha, IFN gamma, G-CSF, TNF alpha, IL-1, and IL-4 markedly potentiate the differentiation-inducing effect of retinoids.	Retinoids	132-141	colony stimulating factor 3	Homo sapiens	40-45
7527856-11	1994	To clarify the mechanism of the saturable clearance of NTG, the in vitro metabolic activities in rat bone marrow, spleen cells and peripheral leukocytes, which possess the G-CSF receptor, were determined.	Nitroglycerin	55-58	colony stimulating factor 3	Homo sapiens	172-177
7528855-6	1994	These effects appeared to be related to an increased incorporation of [3H]Ara-C into cellular DNA in the presence of fludarabine + G-CSF.	[3h]ara-c	70-79	colony stimulating factor 3	Homo sapiens	131-136
7525886-17	1994	CONCLUSION: The addition of cisplatin to 5-FU, HU, and concomitant radiotherapy is feasible using G-CSF.	Cisplatin	28-37	colony stimulating factor 3	Homo sapiens	98-103
7538659-3	1994	Delaying the administration of G-CSF after ABMT is an interesting possibility which merits further exploration in prospective randomized studies.	abmt	43-47	colony stimulating factor 3	Homo sapiens	31-36
7524599-4	1994	Granulocyte colony-stimulating factor, by augmenting white cell production, pulmonary sequestration and margination and production of toxic oxygen species, may exacerbate underlying subclinical bleomycin pulmonary toxicity.	Oxygen	140-146	colony stimulating factor 3	Homo sapiens	0-37
7524599-4	1994	Granulocyte colony-stimulating factor, by augmenting white cell production, pulmonary sequestration and margination and production of toxic oxygen species, may exacerbate underlying subclinical bleomycin pulmonary toxicity.	Bleomycin	194-203	colony stimulating factor 3	Homo sapiens	0-37
7524607-0	1994	Phase I study of mitozantrone, methotrexate and mitomycin with granulocyte colony-stimulating factor (filgrastim) in patients with advanced breast cancer.	Mitoxantrone	17-29	colony stimulating factor 3	Homo sapiens	63-100
7524607-0	1994	Phase I study of mitozantrone, methotrexate and mitomycin with granulocyte colony-stimulating factor (filgrastim) in patients with advanced breast cancer.	Mitomycin	48-57	colony stimulating factor 3	Homo sapiens	63-100
7524761-0	1994	All-trans retinoic acid directly inhibits granulocyte colony-stimulating factor-induced proliferation of CD34+ human hematopoietic progenitor cells.	2-octenal	4-9	colony stimulating factor 3	Homo sapiens	42-79
7524761-0	1994	All-trans retinoic acid directly inhibits granulocyte colony-stimulating factor-induced proliferation of CD34+ human hematopoietic progenitor cells.	Tretinoin	10-23	colony stimulating factor 3	Homo sapiens	42-79
7524761-6	1994	Retinoids also significantly inhibited G-CSF-induced colony formation in semisolid medium, with 88% inhibition observed at a concentration of retinoic acid of 1 mumol/L.	Retinoids	0-9	colony stimulating factor 3	Homo sapiens	39-44
7524761-6	1994	Retinoids also significantly inhibited G-CSF-induced colony formation in semisolid medium, with 88% inhibition observed at a concentration of retinoic acid of 1 mumol/L.	Tretinoin	142-155	colony stimulating factor 3	Homo sapiens	39-44
7529531-0	1994	Changes in light-scatter profile, membrane depolarization and calcium mobilization of neutrophils induced by G-CSF in vivo.	Calcium	62-69	colony stimulating factor 3	Homo sapiens	109-114
7530630-2	1994	Filgrastim, a recombinant human granulocyte colony-stimulating factor (G-CSF), has identical biological activity to that of endogenous human G-CSF, but differs in that it contains an N-terminal methionine residue and is not glycosylated.	Methionine	194-204	colony stimulating factor 3	Homo sapiens	0-10
7530630-4	1994	Two comparative studies have demonstrated that prophylactic administration of filgrastim 230 micrograms/m2/day significantly reduces the incidence, duration and severity of neutropenia in patients with previously untreated small-cell lung cancer receiving standard-dose chemotherapy with CDE (cyclophosphamide, doxorubicin plus etoposide).	Cyclophosphamide	293-309	colony stimulating factor 3	Homo sapiens	78-88
7530630-4	1994	Two comparative studies have demonstrated that prophylactic administration of filgrastim 230 micrograms/m2/day significantly reduces the incidence, duration and severity of neutropenia in patients with previously untreated small-cell lung cancer receiving standard-dose chemotherapy with CDE (cyclophosphamide, doxorubicin plus etoposide).	Doxorubicin	311-322	colony stimulating factor 3	Homo sapiens	78-88
7530630-4	1994	Two comparative studies have demonstrated that prophylactic administration of filgrastim 230 micrograms/m2/day significantly reduces the incidence, duration and severity of neutropenia in patients with previously untreated small-cell lung cancer receiving standard-dose chemotherapy with CDE (cyclophosphamide, doxorubicin plus etoposide).	Etoposide	328-337	colony stimulating factor 3	Homo sapiens	78-88
7534745-0	1994	Cyclophosphamide (3.6 g/m2) therapy with G-CSF support for resistant myeloma.	Cyclophosphamide	0-16	colony stimulating factor 3	Homo sapiens	41-46
7524599-0	1994	Serious pulmonary complications in patients receiving recombinant granulocyte colony-stimulating factor during BACOP chemotherapy for aggressive non-Hodgkin"s lymphoma.	CHOP-B protocol	111-116	colony stimulating factor 3	Homo sapiens	66-103
7525886-17	1994	CONCLUSION: The addition of cisplatin to 5-FU, HU, and concomitant radiotherapy is feasible using G-CSF.	Fluorouracil	41-45	colony stimulating factor 3	Homo sapiens	98-103
7525817-5	1994	For example, treatments of neutrophils with interleukin-8 (IL-8) or granulocyte colony-stimulating factor (G-CSF) potentiated the P-selectin-induced O2- production.	Superoxides	149-151	colony stimulating factor 3	Homo sapiens	68-105
7522643-9	1994	Hence, we predict that allogeneic transplantation using G-CSF-primed PBSC grafts will result in a more rapid hematologic reconstitution after myeloablative conditioning than BM grafting.	pbsc	69-73	colony stimulating factor 3	Homo sapiens	56-61
7525817-5	1994	For example, treatments of neutrophils with interleukin-8 (IL-8) or granulocyte colony-stimulating factor (G-CSF) potentiated the P-selectin-induced O2- production.	Superoxides	149-151	colony stimulating factor 3	Homo sapiens	107-112
7522948-3	1994	The authors report these results in terms of the number of PBPC released and the time of maximum mobilization induced by standard dose cyclophosphamide, epidoxorubicin, 5-fluorouracil (CEF) (cyclophosphamide 600 mg/m2, epidoxorubicin 60 mg/m2, 5-fluorouracil 600 mg/m2) plus granulocyte colony stimulating factor (G-CSF) in patients with breast cancer.	cef	185-188	colony stimulating factor 3	Homo sapiens	275-312
7525175-0	1994	[Treatment of clozapine-induced agranulocytosis using granulocyte colony-stimulating factor].	Clozapine	14-23	colony stimulating factor 3	Homo sapiens	54-91
7541325-1	1994	The authors have studied the efficacy and safety of recombinant human granulocyte colony-stimulating factor (rhG-CSF, Granulocyte Injection) on leucopenia and neutropenia induced by chemotherapy with regimen CE (Carboplatin and Etoposide) in lung cancer patients in a randomized, matched and cross-over clinical trial.	Carboplatin	212-223	colony stimulating factor 3	Homo sapiens	70-107
7522948-3	1994	The authors report these results in terms of the number of PBPC released and the time of maximum mobilization induced by standard dose cyclophosphamide, epidoxorubicin, 5-fluorouracil (CEF) (cyclophosphamide 600 mg/m2, epidoxorubicin 60 mg/m2, 5-fluorouracil 600 mg/m2) plus granulocyte colony stimulating factor (G-CSF) in patients with breast cancer.	cef	185-188	colony stimulating factor 3	Homo sapiens	314-319
7522393-0	1994	The efficacy of recombinant human granulocyte colony-stimulating factor and recombinant human granulocyte macrophage colony-stimulating factor in permitting the administration of higher doses of cyclophosphamide in a doxorubicin-cyclophosphamide combination.	Cyclophosphamide	195-211	colony stimulating factor 3	Homo sapiens	34-71
7522393-4	1994	This study evaluates the efficacy of granulocyte macrophage colony-stimulating factor (GM-CSF) and granulocyte colony-stimulating factor (G-CSF) in allowing administration of high-dose cyclophosphamide in combination with doxorubicin.	Cyclophosphamide	185-201	colony stimulating factor 3	Homo sapiens	99-136
7522393-4	1994	This study evaluates the efficacy of granulocyte macrophage colony-stimulating factor (GM-CSF) and granulocyte colony-stimulating factor (G-CSF) in allowing administration of high-dose cyclophosphamide in combination with doxorubicin.	Cyclophosphamide	185-201	colony stimulating factor 3	Homo sapiens	138-143
7522393-4	1994	This study evaluates the efficacy of granulocyte macrophage colony-stimulating factor (GM-CSF) and granulocyte colony-stimulating factor (G-CSF) in allowing administration of high-dose cyclophosphamide in combination with doxorubicin.	Doxorubicin	222-233	colony stimulating factor 3	Homo sapiens	99-136
7522393-4	1994	This study evaluates the efficacy of granulocyte macrophage colony-stimulating factor (GM-CSF) and granulocyte colony-stimulating factor (G-CSF) in allowing administration of high-dose cyclophosphamide in combination with doxorubicin.	Doxorubicin	222-233	colony stimulating factor 3	Homo sapiens	138-143
7523800-0	1994	Modulation of IL-8, IL-1 beta, and G-CSF secretion by all-trans retinoic acid in acute promyelocytic leukemia.	Tretinoin	64-77	colony stimulating factor 3	Homo sapiens	35-40
7521788-0	1994	Dose escalation of biweekly cyclophosphamide, doxorubicin, vincristine, and prednisolone using recombinant human granulocyte colony stimulating factor in non-Hodgkin"s lymphoma.	Prednisolone	76-88	colony stimulating factor 3	Homo sapiens	113-150
7523800-9	1994	Interestingly, the increase of IL-1 beta and G-CSF production in the presence of ATRA was highly correlated to an increase in APL cell count in vitro and in vivo hyperleukocytosis, resulting in fatal outcome.	Tretinoin	81-85	colony stimulating factor 3	Homo sapiens	45-50
7524159-18	1994	The maximum tolerated dose of paclitaxel administered as a 3-hour infusion was 210 mg/m2 without G-CSF and 250 mg/m2 with G-CSF.	Paclitaxel	30-40	colony stimulating factor 3	Homo sapiens	97-102
7524159-18	1994	The maximum tolerated dose of paclitaxel administered as a 3-hour infusion was 210 mg/m2 without G-CSF and 250 mg/m2 with G-CSF.	Paclitaxel	30-40	colony stimulating factor 3	Homo sapiens	122-127
7527590-2	1994	Recombinant human granulocyte colony-stimulating factor was administered at a dose of 5 micrograms/kg/d for days 1 through 12 after carboplatin treatment.	Carboplatin	132-143	colony stimulating factor 3	Homo sapiens	18-55
7526467-0	1994	Vinorelbine (Navelbine)/carboplatin combination therapy: dose intensification with granulocyte colony-stimulating factor.	Vinorelbine	0-11	colony stimulating factor 3	Homo sapiens	83-120
7526467-0	1994	Vinorelbine (Navelbine)/carboplatin combination therapy: dose intensification with granulocyte colony-stimulating factor.	Vinorelbine	13-22	colony stimulating factor 3	Homo sapiens	83-120
7526467-3	1994	Because the dose-limiting toxicity of both agents is myelosuppression, an additional study goal was to assess the ability of granulocyte colony-stimulating factor to alleviate hematologic toxicity and allow on-time, full-dose vinorelbine therapy.	Vinorelbine	226-237	colony stimulating factor 3	Homo sapiens	125-162
7521688-3	1994	We report here that JAK1 and JAK2 tyrosine kinases are tyrosine phosphorylated in response to G-CSF induction.	Tyrosine	34-42	colony stimulating factor 3	Homo sapiens	94-99
7939763-4	1994	In a recently completed phase II trial in patients with recurrent head and neck cancer, the complete and partial response rate to high-dose paclitaxel (250 mg/m2) given as a 24-hour infusion with granulocyte colony-stimulating factor support was 40% (12 of 30 patients).	Paclitaxel	140-150	colony stimulating factor 3	Homo sapiens	196-233
7522448-0	1994	G-CSF induces tyrosine phosphorylation of the JAK2 protein in the human myeloid G-CSF responsive and proliferative cells, but not in mature neutrophils.	Tyrosine	14-22	colony stimulating factor 3	Homo sapiens	0-5
7522448-0	1994	G-CSF induces tyrosine phosphorylation of the JAK2 protein in the human myeloid G-CSF responsive and proliferative cells, but not in mature neutrophils.	Tyrosine	14-22	colony stimulating factor 3	Homo sapiens	80-85
7522448-1	1994	Granulocyte colony-stimulating factor (G-CSF) stimulates a rapid phosphorylation on tyrosines of several proteins of Mr. 130, 100, 90, 70, 44 kd in human myeloid leukemia cell line cells, Kasumi-1, which respond to G-CSF to proliferate in vitro.	Tyrosine	84-93	colony stimulating factor 3	Homo sapiens	0-37
7530522-0	1994	Methimazole-induced agranulocytosis treated with recombinant human granulocyte colony-stimulating factor (G-CSF).	Methimazole	0-11	colony stimulating factor 3	Homo sapiens	67-104
7530522-0	1994	Methimazole-induced agranulocytosis treated with recombinant human granulocyte colony-stimulating factor (G-CSF).	Methimazole	0-11	colony stimulating factor 3	Homo sapiens	106-111
7530522-2	1994	Because of a recent report of use of recombinant human granulocyte colony-stimulating factor (G-CSF) in patients with propylthiouracil-induced agranulocytosis, 5 micrograms/kg/day G-CSF was administered and her granulocyte count returned to normal after three doses, on the sixth day after the last dose of methimazole.	Propylthiouracil	118-134	colony stimulating factor 3	Homo sapiens	55-92
7530522-2	1994	Because of a recent report of use of recombinant human granulocyte colony-stimulating factor (G-CSF) in patients with propylthiouracil-induced agranulocytosis, 5 micrograms/kg/day G-CSF was administered and her granulocyte count returned to normal after three doses, on the sixth day after the last dose of methimazole.	Propylthiouracil	118-134	colony stimulating factor 3	Homo sapiens	94-99
7522448-1	1994	Granulocyte colony-stimulating factor (G-CSF) stimulates a rapid phosphorylation on tyrosines of several proteins of Mr. 130, 100, 90, 70, 44 kd in human myeloid leukemia cell line cells, Kasumi-1, which respond to G-CSF to proliferate in vitro.	Tyrosine	84-93	colony stimulating factor 3	Homo sapiens	215-220
7522448-1	1994	Granulocyte colony-stimulating factor (G-CSF) stimulates a rapid phosphorylation on tyrosines of several proteins of Mr. 130, 100, 90, 70, 44 kd in human myeloid leukemia cell line cells, Kasumi-1, which respond to G-CSF to proliferate in vitro.	Tyrosine	84-93	colony stimulating factor 3	Homo sapiens	39-44
7521688-4	1994	We also demonstrate that the DNA-binding protein STAT3 (also called the acute-phase response factor [APRF], activated by interleukin-6) is an early target of G-CSF-induced tyrosine phosphorylation.	Tyrosine	172-180	colony stimulating factor 3	Homo sapiens	158-163
7521688-5	1994	G-CSF induces two DNA-binding complexes; the major complex contains tyrosine phosphorylated STAT3 protein and the minor complex appears to be a heterodimer of the STAT1 (previously p91, a component of DNA-binding complexes activated by interferons) and STAT3 proteins.	Tyrosine	68-76	colony stimulating factor 3	Homo sapiens	0-5
7521905-0	1994	Phase I and pharmacologic study of irinotecan and etoposide with recombinant human granulocyte colony-stimulating factor support for advanced lung cancer.	Irinotecan	35-45	colony stimulating factor 3	Homo sapiens	83-120
7520915-3	1994	The purified BN domain specifically and stoichiometrically bound G-CSF, with an apparent dissociation constant (Kd) of 3-8 x 10(-8) M. The CD spectrum of the mBN domain was similar to that of the extracellular region of the human growth hormone (GH) receptor, which is composed of turns and beta-sheets held together by disulfide bonds.	Disulfides	320-329	colony stimulating factor 3	Homo sapiens	65-70
7520915-8	1994	However, the third disulfide bond varied considerably between the G-CSF and GH receptors.	Disulfides	19-28	colony stimulating factor 3	Homo sapiens	66-71
7520915-9	1994	Disruption of these disulfide bonds in the BN domain of the G-CSF receptor suggested that all of them are critical for maintaining a stably folded protein.	Disulfides	20-29	colony stimulating factor 3	Homo sapiens	60-65
7522184-9	1994	Thus, subcutaneous administration of 2 micrograms/kg/d G-CSF for 5 days will lead to a successful PBPC harvest for transplantation, and the most suitable period for this is 24 to 30 hours after the final G-CSF administration.	PbPc	98-102	colony stimulating factor 3	Homo sapiens	55-60
7521905-0	1994	Phase I and pharmacologic study of irinotecan and etoposide with recombinant human granulocyte colony-stimulating factor support for advanced lung cancer.	Etoposide	50-59	colony stimulating factor 3	Homo sapiens	83-120
7521906-1	1994	PURPOSE: This report describes the toxicity and feasibility of administering doxorubicin (DOX) and cisplatin (CDDP) at 2-week intervals with granulocyte colony-stimulating factor (G-CSF) to patients with osteosarcoma and the compatibility of this regimen with endoprosthetic surgery performed after three cycles.	Doxorubicin	77-88	colony stimulating factor 3	Homo sapiens	141-178
7521906-1	1994	PURPOSE: This report describes the toxicity and feasibility of administering doxorubicin (DOX) and cisplatin (CDDP) at 2-week intervals with granulocyte colony-stimulating factor (G-CSF) to patients with osteosarcoma and the compatibility of this regimen with endoprosthetic surgery performed after three cycles.	Doxorubicin	77-88	colony stimulating factor 3	Homo sapiens	180-185
7521906-1	1994	PURPOSE: This report describes the toxicity and feasibility of administering doxorubicin (DOX) and cisplatin (CDDP) at 2-week intervals with granulocyte colony-stimulating factor (G-CSF) to patients with osteosarcoma and the compatibility of this regimen with endoprosthetic surgery performed after three cycles.	Doxorubicin	90-93	colony stimulating factor 3	Homo sapiens	141-178
7521906-1	1994	PURPOSE: This report describes the toxicity and feasibility of administering doxorubicin (DOX) and cisplatin (CDDP) at 2-week intervals with granulocyte colony-stimulating factor (G-CSF) to patients with osteosarcoma and the compatibility of this regimen with endoprosthetic surgery performed after three cycles.	Doxorubicin	90-93	colony stimulating factor 3	Homo sapiens	180-185
7521906-1	1994	PURPOSE: This report describes the toxicity and feasibility of administering doxorubicin (DOX) and cisplatin (CDDP) at 2-week intervals with granulocyte colony-stimulating factor (G-CSF) to patients with osteosarcoma and the compatibility of this regimen with endoprosthetic surgery performed after three cycles.	Cisplatin	99-108	colony stimulating factor 3	Homo sapiens	141-178
7521906-1	1994	PURPOSE: This report describes the toxicity and feasibility of administering doxorubicin (DOX) and cisplatin (CDDP) at 2-week intervals with granulocyte colony-stimulating factor (G-CSF) to patients with osteosarcoma and the compatibility of this regimen with endoprosthetic surgery performed after three cycles.	Cisplatin	99-108	colony stimulating factor 3	Homo sapiens	180-185
7523362-0	1994	Treatment of clozapine-induced agranulocytosis with recombinant granulocyte colony-stimulating factor.	Clozapine	13-22	colony stimulating factor 3	Homo sapiens	64-101
7523362-1	1994	BACKGROUND: Is clozapine-induced agranulocytosis amenable to treatment with recombinant granulocyte colony-stimulating factor (rG-CSF)?	Clozapine	15-24	colony stimulating factor 3	Homo sapiens	88-125
7518861-4	1994	RESULTS: When G-CSF (10 micrograms/kg/d) was administered from the day after the cyclophosphamide, neutropenia developed on day 8 followed by an abrupt increase in the WBC count.	Cyclophosphamide	81-97	colony stimulating factor 3	Homo sapiens	14-19
7522289-8	1994	Addition of either HGF enhanced the Ara-C cytotoxicity for the relapsed samples significantly (for G-CSF p = 0.036, IL-3 p = 0.036, and for GM-CSF p = 0.036).	Cytarabine	36-41	colony stimulating factor 3	Homo sapiens	99-104
7526508-4	1994	The aim of this study was to evaluate tolerability and effectiveness of an intensified mitoxantrone, methotrexate and mitomycin-C (3M) regimen, given with G-CSF support in patients with advanced breast cancer (ABC).	Mitoxantrone	87-99	colony stimulating factor 3	Homo sapiens	155-160
7526508-4	1994	The aim of this study was to evaluate tolerability and effectiveness of an intensified mitoxantrone, methotrexate and mitomycin-C (3M) regimen, given with G-CSF support in patients with advanced breast cancer (ABC).	Mitomycin	118-129	colony stimulating factor 3	Homo sapiens	155-160
8039151-5	1994	In addition, NCIC CTG is preparing a pilot of CEF with G-CSF to examine whether a substantially more intensive dosage can be given without added toxicity.	ctg	18-21	colony stimulating factor 3	Homo sapiens	55-60
7516314-0	1994	G(AnH)MTetra, a naturally occurring 1,6-anhydro muramyl dipeptide, induces granulocyte colony-stimulating factor expression in human monocytes: a molecular analysis.	mtetra	6-12	colony stimulating factor 3	Homo sapiens	75-112
7524688-0	1994	Site-specific religation of G-CSF fragments through a thioether bond.	Sulfides	54-63	colony stimulating factor 3	Homo sapiens	28-33
7520101-4	1994	In contrast, cells induced by G-CSF or GM-CSF alone showed increased DNA syntheses, the levels of which were not significantly affected by the combination of ATRA with CSFs.	Tretinoin	158-162	colony stimulating factor 3	Homo sapiens	30-35
7520101-5	1994	Interestingly, G-CSF or GM-CSF potentiated the capability of ATRA-induced cells to reduce nitroblue tetrazolium (NBT), while G-CSF or GM-CSF alone induced no NBT reduction.	Tretinoin	61-65	colony stimulating factor 3	Homo sapiens	15-20
7520101-5	1994	Interestingly, G-CSF or GM-CSF potentiated the capability of ATRA-induced cells to reduce nitroblue tetrazolium (NBT), while G-CSF or GM-CSF alone induced no NBT reduction.	Nitroblue Tetrazolium	90-111	colony stimulating factor 3	Homo sapiens	15-20
7520101-5	1994	Interestingly, G-CSF or GM-CSF potentiated the capability of ATRA-induced cells to reduce nitroblue tetrazolium (NBT), while G-CSF or GM-CSF alone induced no NBT reduction.	Nitroblue Tetrazolium	113-116	colony stimulating factor 3	Homo sapiens	15-20
7520101-6	1994	Furthermore, in several patients examined, APL cells induced by ATRA with G-CSF showed an increased activity of chemotaxis and CD11a expression.	Tretinoin	64-68	colony stimulating factor 3	Homo sapiens	74-79
7520101-7	1994	These findings suggest that G-CSF or GM-CSF can potentiate differentiation of ATRA-induced APL cells while stimulating their proliferating activity as well, and that G-CSF, rather than GM-CSF, may be a useful adjunct to promote ATRA-induced differentiation of APL.	Tretinoin	78-82	colony stimulating factor 3	Homo sapiens	28-33
7520101-7	1994	These findings suggest that G-CSF or GM-CSF can potentiate differentiation of ATRA-induced APL cells while stimulating their proliferating activity as well, and that G-CSF, rather than GM-CSF, may be a useful adjunct to promote ATRA-induced differentiation of APL.	Tretinoin	228-232	colony stimulating factor 3	Homo sapiens	166-171
7518249-2	1994	Recombinant 15N- and 13C-labeled human granulocyte colony-stimulating factor (rh-metG-CSF) has been studied by 2D and 3D NMR using uniformly labeled protein, as well as residue-specific 15N-labeled samples.	15n	12-15	colony stimulating factor 3	Homo sapiens	39-76
7518249-2	1994	Recombinant 15N- and 13C-labeled human granulocyte colony-stimulating factor (rh-metG-CSF) has been studied by 2D and 3D NMR using uniformly labeled protein, as well as residue-specific 15N-labeled samples.	13c	21-24	colony stimulating factor 3	Homo sapiens	39-76
7516314-1	1994	N-Acetylglucosaminyl-1,6-anhydro-N-acetylmuramyl-L-alanyl-D-isoglutam yl-m- diaminopimelyl-D-alanine [G (Anh)MTetra], a naturally occurring breakdown product of peptidoglycan from bacterial cell walls, was studied for its ability to induce granulocyte colony-stimulating factor (G-CSF) mRNA and protein expression in human adherent monocytes.	disaccharide tetrapeptide	102-115	colony stimulating factor 3	Homo sapiens	240-277
7516314-1	1994	N-Acetylglucosaminyl-1,6-anhydro-N-acetylmuramyl-L-alanyl-D-isoglutam yl-m- diaminopimelyl-D-alanine [G (Anh)MTetra], a naturally occurring breakdown product of peptidoglycan from bacterial cell walls, was studied for its ability to induce granulocyte colony-stimulating factor (G-CSF) mRNA and protein expression in human adherent monocytes.	disaccharide tetrapeptide	102-115	colony stimulating factor 3	Homo sapiens	279-284
7516314-6	1994	Experiments with the protein synthesis inhibitor cycloheximide revealed that G(Anh)MTetra-induced G-CSF mRNA expression was independent of new protein synthesis.	Cycloheximide	49-62	colony stimulating factor 3	Homo sapiens	98-103
7516314-6	1994	Experiments with the protein synthesis inhibitor cycloheximide revealed that G(Anh)MTetra-induced G-CSF mRNA expression was independent of new protein synthesis.	mtetra	83-89	colony stimulating factor 3	Homo sapiens	98-103
7516925-3	1994	In addition to restoring the leukocyte count, GM-CSF--to a greater extent than G-CSF--also induced neopterin, a sensitive marker of macrophages activated by interferons.	Neopterin	99-108	colony stimulating factor 3	Homo sapiens	79-84
7524888-6	1994	Post-transplant G-CSF (+/- PBPC) resulted in a trend (p = 0.07) towards a reduction in post-transplant stomatitis, but did not impact on the already low incidence of other organ toxicities.	PbPc	27-31	colony stimulating factor 3	Homo sapiens	16-21
7515712-3	1994	In this study, we showed that hematopoietic cytokines, such as IL-3, IL-6, and G-CSF, all induced tyrosine-phosphorylation of Stat family proteins and Stat-associated 150-kD and 72-kD molecules in hematopoietic lineage cell lines.	Tyrosine	98-106	colony stimulating factor 3	Homo sapiens	79-84
7514494-2	1994	In this study, we show that administration of recombinant human (rh) G-CSF decreased the in vitro and in vivo cytotoxic effects of Adriamycin or etoposide on L1210 murine leukemic cells with receptors for rhG-CSF.	Doxorubicin	131-141	colony stimulating factor 3	Homo sapiens	69-74
7514494-2	1994	In this study, we show that administration of recombinant human (rh) G-CSF decreased the in vitro and in vivo cytotoxic effects of Adriamycin or etoposide on L1210 murine leukemic cells with receptors for rhG-CSF.	Etoposide	145-154	colony stimulating factor 3	Homo sapiens	69-74
7513653-0	1994	Local anesthetic lidocaine inhibits the effect of granulocyte colony-stimulating factor on human neutrophil functions.	Lidocaine	17-26	colony stimulating factor 3	Homo sapiens	50-87
7524638-9	1994	G-CSF production in KMST-6/RAS cells was significantly stimulated by butyrate, but not by dexamethasone or 5-azacytidine.	Butyrates	69-77	colony stimulating factor 3	Homo sapiens	0-5
7524638-9	1994	G-CSF production in KMST-6/RAS cells was significantly stimulated by butyrate, but not by dexamethasone or 5-azacytidine.	Dexamethasone	90-103	colony stimulating factor 3	Homo sapiens	0-5
7521152-2	1994	Interleukin-1 beta (IL-1), interleukin-3 (IL-3), granulocyte-macrophage colony-stimulating factor (GM-CSF) and granulocyte colony-stimulating factor (G-CSF) augmented uptake of 3H-thymidine into the DNA of APL cells in a dose-dependent manner in all cases.	3h-thymidine	177-189	colony stimulating factor 3	Homo sapiens	111-148
7514443-1	1994	We have analysed the levels of soluble inositol metabolites in HL60 cells as they differentiate towards neutrophils in response to a combination of all-trans-retinoic acid and granulocyte colony-stimulating factor and towards monocytes in response to 1 alpha-25-dihydroxyvitamin D3.	Inositol	39-47	colony stimulating factor 3	Homo sapiens	176-213
7513778-0	1994	Possible toxicity with the association of G-CSF and bleomycin.	Bleomycin	52-61	colony stimulating factor 3	Homo sapiens	42-47
7517190-0	1994	In vitro response of blasts to IL-3, GM-CSF, and G-CSF is different for individual AML patients: factors that stimulate leukemic clonogenic cells also enhance Ara-C cytotoxicity.	Cytarabine	159-164	colony stimulating factor 3	Homo sapiens	49-54
7522068-6	1994	Since agranulocytosis is considered to be a severe and fatal complication of methimazole therapy, treatment with granulocyte colony stimulating factor seems to be useful for this life-threatening condition.	Methimazole	77-88	colony stimulating factor 3	Homo sapiens	113-150
7523237-0	1994	Pharmacological effects of recombinant human granulocyte colony-stimulating factor modified by polyethylene glycol on anticancer drug-induced neutropenia in mice.	Polyethylene Glycols	95-114	colony stimulating factor 3	Homo sapiens	45-82
7523237-2	1994	To clarify the pharmacological effects of recombinant human granulocyte colony-stimulating factor (rhG-CSF) conjugated to polyethylene glycol (PEG), its effects on the number of circulating neutrophils in mice made neutropenic by cyclophosphamide (CPA) or 5-fluorouracil (5-FU) were compared with rhG-CSF lacking PEG.	Polyethylene Glycols	122-141	colony stimulating factor 3	Homo sapiens	60-97
7523237-2	1994	To clarify the pharmacological effects of recombinant human granulocyte colony-stimulating factor (rhG-CSF) conjugated to polyethylene glycol (PEG), its effects on the number of circulating neutrophils in mice made neutropenic by cyclophosphamide (CPA) or 5-fluorouracil (5-FU) were compared with rhG-CSF lacking PEG.	Polyethylene Glycols	143-146	colony stimulating factor 3	Homo sapiens	60-97
7513312-8	1994	NaF-induced histamine release was enhanced up to 60 and 30% by GM-CSF and G-CSF priming, respectively.	Histamine	12-21	colony stimulating factor 3	Homo sapiens	74-79
7512826-0	1994	Interaction of recombinant granulocyte colony stimulating factor with lipid membranes: enhanced stability of a water-soluble protein after membrane insertion.	Water	111-116	colony stimulating factor 3	Homo sapiens	27-64
7514201-5	1994	In contrast, G-CSF (50 ng/ml) only slightly increased O2- production (by 15%), and MPO secretion and CD11b expression remained unchanged.	Oxygen	54-56	colony stimulating factor 3	Homo sapiens	13-18
7517568-0	1994	[The efficacy and rapidity of action of granulocyte colony-stimulating factor in a case of agranulocytosis due to noramidopyrine].	noramidopyrine	114-128	colony stimulating factor 3	Homo sapiens	40-77
7513312-5	1994	G-CSF priming induced an increase in the chemiluminescence response by up to 50% +/- 5% from human PMN and an increase in histamine release from human LMB by 20% +/- 5%.	Histamine	122-131	colony stimulating factor 3	Homo sapiens	0-5
7513312-5	1994	G-CSF priming induced an increase in the chemiluminescence response by up to 50% +/- 5% from human PMN and an increase in histamine release from human LMB by 20% +/- 5%.	leptomycin B	151-154	colony stimulating factor 3	Homo sapiens	0-5
7513312-7	1994	GM-CSF and G-CSF pretreatment increased the fluoride (NaF)-induced chemiluminescence response by up to 10-fold; the serine/threonine phosphatase inhibitor okadaic acid inhibited GM-CSF- and G-CSF-induced priming.	Fluorides	44-52	colony stimulating factor 3	Homo sapiens	11-16
7513312-7	1994	GM-CSF and G-CSF pretreatment increased the fluoride (NaF)-induced chemiluminescence response by up to 10-fold; the serine/threonine phosphatase inhibitor okadaic acid inhibited GM-CSF- and G-CSF-induced priming.	Fluorides	44-52	colony stimulating factor 3	Homo sapiens	190-195
7513312-7	1994	GM-CSF and G-CSF pretreatment increased the fluoride (NaF)-induced chemiluminescence response by up to 10-fold; the serine/threonine phosphatase inhibitor okadaic acid inhibited GM-CSF- and G-CSF-induced priming.	Okadaic Acid	155-167	colony stimulating factor 3	Homo sapiens	11-16
7513312-7	1994	GM-CSF and G-CSF pretreatment increased the fluoride (NaF)-induced chemiluminescence response by up to 10-fold; the serine/threonine phosphatase inhibitor okadaic acid inhibited GM-CSF- and G-CSF-induced priming.	Okadaic Acid	155-167	colony stimulating factor 3	Homo sapiens	190-195
7525544-0	1994	Modification of recombinant human granulocyte colony-stimulating factor (rhG-CSF) and its derivative ND 28 with polyethylene glycol.	Polyethylene Glycols	112-131	colony stimulating factor 3	Homo sapiens	34-71
7522524-0	1994	Granulocyte colony-stimulating factor inhibits the endogenous leukotriene production in tumour patients.	Leukotrienes	62-73	colony stimulating factor 3	Homo sapiens	0-37
7512720-3	1994	We detected tyrosine phosphorylation of both the G-CSF receptor and the protein tyrosine kinase JAK1 following G-CSF binding to the human G-CSF receptor.	Tyrosine	12-20	colony stimulating factor 3	Homo sapiens	49-54
7522524-4	1994	Here we report that, in contrast to GM-CSF or IL-3, G-CSF has the potential to inhibit the leukotriene production in vivo.	Leukotrienes	91-102	colony stimulating factor 3	Homo sapiens	52-57
7511442-7	1994	The synergism between G-CSF and ATRA is evident at concentrations of the retinoid between 10(-7) and 10(-5) mol/L and at concentrations of the cytokine between 1 and 10 ng/mL.	Retinoids	73-81	colony stimulating factor 3	Homo sapiens	22-27
7522524-6	1994	The differential effects of G-CSF and other haemopoietins on endogenous leukotrienes may be of major clinical significance.	Leukotrienes	72-84	colony stimulating factor 3	Homo sapiens	28-33
7511442-13	1994	In NB4 cells, ATRA induces G-CSF, alpha, and beta retinoic acid receptor transcripts, whereas G-CSF has minor effects on the expression of these mRNAs.	Tretinoin	14-18	colony stimulating factor 3	Homo sapiens	27-32
7509652-11	1994	With flexible G-CSF dosing, taxol dose intensity could be maintained at the target level in 34 of 42 patients (81% of the cohort).	Paclitaxel	28-33	colony stimulating factor 3	Homo sapiens	14-19
21566987-4	1994	The stimulation of t-RA on LPS-mediated G-CSF secretion was dose-dependent and was observed at t-RA concentration of as low as 10(-10) M. Some other retinoids were also as effective as t-RA, whereas other steroids were either less or not effective or inhibitory on LPS-mediated G-CSF secretion.	Tretinoin	19-23	colony stimulating factor 3	Homo sapiens	40-45
21566987-4	1994	The stimulation of t-RA on LPS-mediated G-CSF secretion was dose-dependent and was observed at t-RA concentration of as low as 10(-10) M. Some other retinoids were also as effective as t-RA, whereas other steroids were either less or not effective or inhibitory on LPS-mediated G-CSF secretion.	Tretinoin	19-23	colony stimulating factor 3	Homo sapiens	278-283
21566987-4	1994	The stimulation of t-RA on LPS-mediated G-CSF secretion was dose-dependent and was observed at t-RA concentration of as low as 10(-10) M. Some other retinoids were also as effective as t-RA, whereas other steroids were either less or not effective or inhibitory on LPS-mediated G-CSF secretion.	Tretinoin	95-99	colony stimulating factor 3	Homo sapiens	40-45
8200851-4	1994	For the samples in group C, RA inhibited the colonies formed by granulocyte colony-stimulating factor (G-CSF) but stimulated those by granulocyte macrophage CSF (GM-CSF).	Tretinoin	28-30	colony stimulating factor 3	Homo sapiens	64-101
8200851-4	1994	For the samples in group C, RA inhibited the colonies formed by granulocyte colony-stimulating factor (G-CSF) but stimulated those by granulocyte macrophage CSF (GM-CSF).	Tretinoin	28-30	colony stimulating factor 3	Homo sapiens	103-108
7509652-0	1994	Flexible granulocyte colony-stimulating factor dosing in ovarian cancer patients who receive dose-intense taxol therapy.	Paclitaxel	106-111	colony stimulating factor 3	Homo sapiens	9-46
7509652-2	1994	Granulocyte colony-stimulating factor (G-CSF) effectively protects the bone marrow from taxol-induced neutropenia and allows for higher taxol dose administration.	Paclitaxel	88-93	colony stimulating factor 3	Homo sapiens	0-37
7509652-2	1994	Granulocyte colony-stimulating factor (G-CSF) effectively protects the bone marrow from taxol-induced neutropenia and allows for higher taxol dose administration.	Paclitaxel	88-93	colony stimulating factor 3	Homo sapiens	39-44
7509652-2	1994	Granulocyte colony-stimulating factor (G-CSF) effectively protects the bone marrow from taxol-induced neutropenia and allows for higher taxol dose administration.	Paclitaxel	136-141	colony stimulating factor 3	Homo sapiens	0-37
7509652-2	1994	Granulocyte colony-stimulating factor (G-CSF) effectively protects the bone marrow from taxol-induced neutropenia and allows for higher taxol dose administration.	Paclitaxel	136-141	colony stimulating factor 3	Homo sapiens	39-44
7509652-3	1994	This report addresses the optimal use of G-CSF as a supportive agent for dose-intense taxol therapy.	Paclitaxel	86-91	colony stimulating factor 3	Homo sapiens	41-46
21566987-4	1994	The stimulation of t-RA on LPS-mediated G-CSF secretion was dose-dependent and was observed at t-RA concentration of as low as 10(-10) M. Some other retinoids were also as effective as t-RA, whereas other steroids were either less or not effective or inhibitory on LPS-mediated G-CSF secretion.	Steroids	205-213	colony stimulating factor 3	Homo sapiens	40-45
21566987-5	1994	Further experiments indicated that interleukin 1 (IL-1), one of the mediators of LPS activity, also synergized with t-RA to stimulate G-CSF secretion.	Tretinoin	116-120	colony stimulating factor 3	Homo sapiens	134-139
7512172-0	1994	Indomethacin potentiates the induction of HL60 differentiation to neutrophils, by retinoic acid and granulocyte colony-stimulating factor, and to monocytes, by vitamin D3.	Indomethacin	0-12	colony stimulating factor 3	Homo sapiens	100-137
7512172-3	1994	In the presence of 30 microM indomethacin (an inhibitor of the enzyme cyclooxygenase that catalyses the first step of prostanoid synthesis), the onset of differentiation provoked by RA plus G-CSF was more rapid, but the final proportion of mature cells was unchanged.	Indomethacin	29-41	colony stimulating factor 3	Homo sapiens	190-195
7512172-3	1994	In the presence of 30 microM indomethacin (an inhibitor of the enzyme cyclooxygenase that catalyses the first step of prostanoid synthesis), the onset of differentiation provoked by RA plus G-CSF was more rapid, but the final proportion of mature cells was unchanged.	Prostaglandins	118-128	colony stimulating factor 3	Homo sapiens	190-195
7512172-6	1994	Indomethacin shifted the G-CSF dose-response curve of cells treated with 10 nM RA to lower G-CSF concentrations.	Indomethacin	0-12	colony stimulating factor 3	Homo sapiens	25-30
7512172-6	1994	Indomethacin shifted the G-CSF dose-response curve of cells treated with 10 nM RA to lower G-CSF concentrations.	Indomethacin	0-12	colony stimulating factor 3	Homo sapiens	91-96
7512172-6	1994	Indomethacin shifted the G-CSF dose-response curve of cells treated with 10 nM RA to lower G-CSF concentrations.	Tretinoin	79-81	colony stimulating factor 3	Homo sapiens	25-30
7512172-6	1994	Indomethacin shifted the G-CSF dose-response curve of cells treated with 10 nM RA to lower G-CSF concentrations.	Tretinoin	79-81	colony stimulating factor 3	Homo sapiens	91-96
7510283-1	1994	Site-specific incorporation of synthetic peptides that mimic the 64-74 disulfide loop of granulocyte colony-stimulating factor.	Peptides	41-49	colony stimulating factor 3	Homo sapiens	89-126
7510283-1	1994	Site-specific incorporation of synthetic peptides that mimic the 64-74 disulfide loop of granulocyte colony-stimulating factor.	Disulfides	71-80	colony stimulating factor 3	Homo sapiens	89-126
7510283-9	1994	We illustrate the particularity of this concept by the engineered modifications of the 64-74 disulfide loop region of human granulocyte colony-stimulating factor.	Disulfides	93-102	colony stimulating factor 3	Homo sapiens	124-161
7907208-9	1994	Peripheral neuropathy is likely to become the major dose-limiting toxicity of taxol-cisplatin combination chemotherapy when higher doses of these agents are administered with granulocyte-colony stimulating factor.	Paclitaxel	78-83	colony stimulating factor 3	Homo sapiens	175-212
7907208-9	1994	Peripheral neuropathy is likely to become the major dose-limiting toxicity of taxol-cisplatin combination chemotherapy when higher doses of these agents are administered with granulocyte-colony stimulating factor.	Cisplatin	84-93	colony stimulating factor 3	Homo sapiens	175-212
7509652-14	1994	These data suggest that flexible G-CSF dosing may have merit and may allow the administration of more dose-intense taxol.	Paclitaxel	115-120	colony stimulating factor 3	Homo sapiens	33-38
7510354-1	1994	Since all-trans retinoic acid (ATRA) and granulocyte colony-stimulating factor (G-CSF) not only enhance proliferation and differentiation of normal myeloid cells but also synergistically promote the differentiation of myeloid leukemic blast cells in vitro, we have started a pilot study of combined treatment with ATRA and G-CSF in patients with myelodysplastic syndrome, to analyze the effect of these drugs on hematopoietic differentiation.	Tretinoin	16-29	colony stimulating factor 3	Homo sapiens	323-328
8124835-11	1994	Marked inhibition of G-CSF and other cytokines by vesnarinone was observed in one patient who had developed neutropenia as a result of vesnarinone therapy.	vesnarinone	50-61	colony stimulating factor 3	Homo sapiens	21-26
7510354-1	1994	Since all-trans retinoic acid (ATRA) and granulocyte colony-stimulating factor (G-CSF) not only enhance proliferation and differentiation of normal myeloid cells but also synergistically promote the differentiation of myeloid leukemic blast cells in vitro, we have started a pilot study of combined treatment with ATRA and G-CSF in patients with myelodysplastic syndrome, to analyze the effect of these drugs on hematopoietic differentiation.	Tretinoin	31-35	colony stimulating factor 3	Homo sapiens	323-328
7510354-1	1994	Since all-trans retinoic acid (ATRA) and granulocyte colony-stimulating factor (G-CSF) not only enhance proliferation and differentiation of normal myeloid cells but also synergistically promote the differentiation of myeloid leukemic blast cells in vitro, we have started a pilot study of combined treatment with ATRA and G-CSF in patients with myelodysplastic syndrome, to analyze the effect of these drugs on hematopoietic differentiation.	Tretinoin	314-318	colony stimulating factor 3	Homo sapiens	41-78
7510354-1	1994	Since all-trans retinoic acid (ATRA) and granulocyte colony-stimulating factor (G-CSF) not only enhance proliferation and differentiation of normal myeloid cells but also synergistically promote the differentiation of myeloid leukemic blast cells in vitro, we have started a pilot study of combined treatment with ATRA and G-CSF in patients with myelodysplastic syndrome, to analyze the effect of these drugs on hematopoietic differentiation.	Tretinoin	314-318	colony stimulating factor 3	Homo sapiens	80-85
7513844-1	1994	Recombinant human granulocyte colony-stimulating factor (rG-CSF) was used for the amelioration of neutropenia caused by cisplatin-based chemotherapy in head and neck cancer patients.	Cisplatin	120-129	colony stimulating factor 3	Homo sapiens	18-55
7505830-6	1994	If a patient showed fever and neutropenia, G-CSF dosage was increased to 20 micrograms/kg per day so that paclitaxel dose intensity could be maintained.	Paclitaxel	106-116	colony stimulating factor 3	Homo sapiens	43-48
7509208-6	1994	mRNA of NAP is known to be induced by in vitro treatment of the cells with granulocyte colony-stimulating factor (G-CSF), which is enhanced by a simultaneous addition of retinoic acid.	N-(4-aminophenethyl)spiroperidol	8-11	colony stimulating factor 3	Homo sapiens	75-112
7509208-6	1994	mRNA of NAP is known to be induced by in vitro treatment of the cells with granulocyte colony-stimulating factor (G-CSF), which is enhanced by a simultaneous addition of retinoic acid.	N-(4-aminophenethyl)spiroperidol	8-11	colony stimulating factor 3	Homo sapiens	114-119
7509208-6	1994	mRNA of NAP is known to be induced by in vitro treatment of the cells with granulocyte colony-stimulating factor (G-CSF), which is enhanced by a simultaneous addition of retinoic acid.	Tretinoin	170-183	colony stimulating factor 3	Homo sapiens	75-112
7509208-6	1994	mRNA of NAP is known to be induced by in vitro treatment of the cells with granulocyte colony-stimulating factor (G-CSF), which is enhanced by a simultaneous addition of retinoic acid.	Tretinoin	170-183	colony stimulating factor 3	Homo sapiens	114-119
7515265-9	1994	Factors associated with G-CSF elevation were fever, neutropenia, pathogen type and raised bilirubin and creatinine.	Bilirubin	90-99	colony stimulating factor 3	Homo sapiens	24-29
7515265-9	1994	Factors associated with G-CSF elevation were fever, neutropenia, pathogen type and raised bilirubin and creatinine.	Creatinine	104-114	colony stimulating factor 3	Homo sapiens	24-29
7515268-1	1994	The adenine nucleoside analogue fludarabine phosphate in combination with cytosine-arabinoside (Ara-C) and granulocyte-colony stimulating factor (G-CSF) has recently proved effective in the treatment of poor-prognosis acute non-lymphoid leukaemia.	Adenosine	4-22	colony stimulating factor 3	Homo sapiens	107-144
7515268-1	1994	The adenine nucleoside analogue fludarabine phosphate in combination with cytosine-arabinoside (Ara-C) and granulocyte-colony stimulating factor (G-CSF) has recently proved effective in the treatment of poor-prognosis acute non-lymphoid leukaemia.	Adenosine	4-22	colony stimulating factor 3	Homo sapiens	146-151
7515268-1	1994	The adenine nucleoside analogue fludarabine phosphate in combination with cytosine-arabinoside (Ara-C) and granulocyte-colony stimulating factor (G-CSF) has recently proved effective in the treatment of poor-prognosis acute non-lymphoid leukaemia.	fludarabine phosphate	32-53	colony stimulating factor 3	Homo sapiens	146-151
7509380-1	1994	PURPOSE: We conducted a phase I trial of a 3-hour infusion of Taxol (paclitaxel; Bristol-Myers Squibb Co, Princeton, NJ) to identify the maximum-tolerated dose of Taxol as a 3-hour infusion with and without granulocyte colony-stimulating factor (G-CSF) support.	Paclitaxel	163-168	colony stimulating factor 3	Homo sapiens	207-244
7509380-1	1994	PURPOSE: We conducted a phase I trial of a 3-hour infusion of Taxol (paclitaxel; Bristol-Myers Squibb Co, Princeton, NJ) to identify the maximum-tolerated dose of Taxol as a 3-hour infusion with and without granulocyte colony-stimulating factor (G-CSF) support.	Paclitaxel	163-168	colony stimulating factor 3	Homo sapiens	246-251
7509380-7	1994	The dose-limiting toxicity for Taxol with G-CSF was peripheral neuropathy at the 300-mg/m2 dose level.	Paclitaxel	31-36	colony stimulating factor 3	Homo sapiens	42-47
7509380-13	1994	CONCLUSION: The maximum dose of Taxol recommended for phase II and III studies, when administered as a 3-hour infusion alone and with G-CSF support, is 210 mg/m2 and 250 mg/m2, respectively.	Paclitaxel	32-37	colony stimulating factor 3	Homo sapiens	134-139
7508937-0	1994	rel Is rapidly tyrosine-phosphorylated following granulocyte-colony stimulating factor treatment of human neutrophils.	Tyrosine	15-23	colony stimulating factor 3	Homo sapiens	49-86
7508937-4	1994	Antiphosphotyrosine immunoblots of whole cell lysates prepared from neutrophils show that the G-CSF rapidly induces prominent tyrosine phosphorylation of a protein of a relative molecular mass of 80 kDa.	Tyrosine	11-19	colony stimulating factor 3	Homo sapiens	94-99
7508937-7	1994	The consequences of p80c-rel tyrosine phosphorylation are not yet known; however, tyrosine-phosphorylated p80c-rel is capable of binding to DNA, and G-CSF stimulation results in an increase in the amount of p80c-rel which binds to DNA.	Tyrosine	29-37	colony stimulating factor 3	Homo sapiens	149-154
7508937-7	1994	The consequences of p80c-rel tyrosine phosphorylation are not yet known; however, tyrosine-phosphorylated p80c-rel is capable of binding to DNA, and G-CSF stimulation results in an increase in the amount of p80c-rel which binds to DNA.	Tyrosine	82-90	colony stimulating factor 3	Homo sapiens	149-154
7508937-8	1994	These results demonstrate that one of the first biochemical events which occurs in neutrophils following G-CSF stimulation, activation of a tyrosine kinase, leads directly to the tyrosine phosphorylation of p80c-rel.	Tyrosine	140-148	colony stimulating factor 3	Homo sapiens	105-110
7512280-0	1994	Effect of recombinant human granulocyte colony-stimulating factor in patients receiving methotrexate/vinblastine/doxorubicin/cisplatin therapy for the treatment of transitional cell carcinoma of the urinary tract.	Vinblastine	101-112	colony stimulating factor 3	Homo sapiens	28-65
7512280-0	1994	Effect of recombinant human granulocyte colony-stimulating factor in patients receiving methotrexate/vinblastine/doxorubicin/cisplatin therapy for the treatment of transitional cell carcinoma of the urinary tract.	Doxorubicin	113-124	colony stimulating factor 3	Homo sapiens	28-65
7512280-0	1994	Effect of recombinant human granulocyte colony-stimulating factor in patients receiving methotrexate/vinblastine/doxorubicin/cisplatin therapy for the treatment of transitional cell carcinoma of the urinary tract.	Cisplatin	125-134	colony stimulating factor 3	Homo sapiens	28-65
7508889-1	1994	The human osteosarcoma cell line, MG63, responds both to GM-CSF and to G-CSF in vitro.	mg63	34-38	colony stimulating factor 3	Homo sapiens	71-76
7507600-4	1994	A similar response was obtained by 2 further G-CSF cycles which were given for relapsing SAA after G-CSF withdrawal.	saa	89-92	colony stimulating factor 3	Homo sapiens	45-50
7510935-0	1994	Peptide map analysis of recombinant human granulocyte colony stimulating factor: elimination of methionine modification and nonspecific cleavages.	Methionine	96-106	colony stimulating factor 3	Homo sapiens	42-79
7535152-0	1994	Ph-negative blood progenitor cells (BPCs) can be recruited after chemotherapy and G-CSF during early hemopoietic recovery in patients at diagnosis of CML or pretreated only with hydroxyurea.	Hydroxyurea	178-189	colony stimulating factor 3	Homo sapiens	82-87
7527732-0	1994	M-VEC (methotrexate, vinblastine, epirubicin, and cisplatin) with granulocyte colony-stimulating factor for the treatment of urothelial cancer: an effective and safe chemotherapy regimen.	Cisplatin	50-59	colony stimulating factor 3	Homo sapiens	66-103
7527735-4	1994	In addition, the role of granulocyte colony-stimulating factor (G-CSF) in the dose intensity of M-VAC therapy was analyzed.	M-VAC protocol	96-101	colony stimulating factor 3	Homo sapiens	25-62
7527735-4	1994	In addition, the role of granulocyte colony-stimulating factor (G-CSF) in the dose intensity of M-VAC therapy was analyzed.	M-VAC protocol	96-101	colony stimulating factor 3	Homo sapiens	64-69
7527735-10	1994	When we calculated the RDI for all 29 patients who underwent M-VAC therapy, G-CSF increased the RDI of Adriamycin significantly.	Doxorubicin	103-113	colony stimulating factor 3	Homo sapiens	76-81
7527735-11	1994	The results of this retrospective study indicate that a dose intensity for M-VAC therapy in the range of 0.61-1.00 is unlikely to correlate with the chemotherapeutic effect, although G-CSF contributes to increasing the RDI of Adriamycin.	Doxorubicin	226-236	colony stimulating factor 3	Homo sapiens	183-188
7535073-1	1994	Lenograstim, glycosylated recombinant human granulocyte colony stimulating factor (rHuG-CSF), is a glycoprotein that contains 4% O-glycosides with an approximate molecular weight of 20 kDa.	o-glycosides	129-141	colony stimulating factor 3	Homo sapiens	44-81
7517606-0	1994	Granulocyte colony-stimulating factor for neutropenia secondary to ticlopidine.	Ticlopidine	67-78	colony stimulating factor 3	Homo sapiens	0-37
7909688-10	1994	Addition of granulocyte-colony stimulating factor (G-CSF), aimed at modulating myelosuppressive toxicity, showed in Phase I studies that the taxol dose could be increased to 250 mg/m2, with peripheral neuropathy as the dose limiting toxicity.	Paclitaxel	141-146	colony stimulating factor 3	Homo sapiens	12-49
7909688-10	1994	Addition of granulocyte-colony stimulating factor (G-CSF), aimed at modulating myelosuppressive toxicity, showed in Phase I studies that the taxol dose could be increased to 250 mg/m2, with peripheral neuropathy as the dose limiting toxicity.	Paclitaxel	141-146	colony stimulating factor 3	Homo sapiens	51-56
7540079-4	1994	It was found that rh G-CSF 25 micrograms administered into the subcutaneous tissue of rabbits increased extravascular lung water to 3.45 +/- 0.26 vs 2.98 +/- 0.20 in control experiments (P &lt; 0.05); however, rhG-CSF 0.75 microgram/kg administered into the alveolar spaces did not affect liquid clearance from the alveolar spaces.	Water	123-128	colony stimulating factor 3	Homo sapiens	21-26
7512356-0	1994	A study of dose escalation of teniposide (VM-26) plus cisplatin (CDDP) with recombinant human granulocyte colony-stimulating factor (rhG-CSF) in patients with advanced small cell lung cancer.	Teniposide	30-40	colony stimulating factor 3	Homo sapiens	94-131
7512356-0	1994	A study of dose escalation of teniposide (VM-26) plus cisplatin (CDDP) with recombinant human granulocyte colony-stimulating factor (rhG-CSF) in patients with advanced small cell lung cancer.	Cisplatin	65-69	colony stimulating factor 3	Homo sapiens	94-131
7517149-0	1994	The costs of peripheral blood progenitor cell reinfusion mobilised by granulocyte colony-stimulating factor following high dose melphalan as compared with conventional therapy in multiple myeloma.	Melphalan	128-137	colony stimulating factor 3	Homo sapiens	70-107
7510873-3	1994	Short-term pretreatment (15 min) of GSD 1b neutrophils with G-CSF increased the rate of O2- production (p &lt; 0.01); however, this rate was still significantly below the rate of O2- production in control neutrophils.	Superoxides	88-90	colony stimulating factor 3	Homo sapiens	60-65
7510873-3	1994	Short-term pretreatment (15 min) of GSD 1b neutrophils with G-CSF increased the rate of O2- production (p &lt; 0.01); however, this rate was still significantly below the rate of O2- production in control neutrophils.	Superoxides	179-181	colony stimulating factor 3	Homo sapiens	60-65
7510873-7	1994	In vivo, G-CSF therapy increased f-Met-Leu-Phe-stimulated O2- production to 52% of control after 1 mo, and by mo 4, O2- production reached control levels.	f-met	33-38	colony stimulating factor 3	Homo sapiens	9-14
7510873-7	1994	In vivo, G-CSF therapy increased f-Met-Leu-Phe-stimulated O2- production to 52% of control after 1 mo, and by mo 4, O2- production reached control levels.	Leucine	39-42	colony stimulating factor 3	Homo sapiens	9-14
7510873-7	1994	In vivo, G-CSF therapy increased f-Met-Leu-Phe-stimulated O2- production to 52% of control after 1 mo, and by mo 4, O2- production reached control levels.	Phenylalanine	43-46	colony stimulating factor 3	Homo sapiens	9-14
7510873-7	1994	In vivo, G-CSF therapy increased f-Met-Leu-Phe-stimulated O2- production to 52% of control after 1 mo, and by mo 4, O2- production reached control levels.	Superoxides	58-60	colony stimulating factor 3	Homo sapiens	9-14
7510873-7	1994	In vivo, G-CSF therapy increased f-Met-Leu-Phe-stimulated O2- production to 52% of control after 1 mo, and by mo 4, O2- production reached control levels.	Superoxides	116-118	colony stimulating factor 3	Homo sapiens	9-14
7510873-9	1994	In vivo administration of G-CSF increased f-Met-Leu-Phe-triggered Ca2+ mobilization by neutrophils to 43% of control by mo 1 of G-CSF therapy and to 93% of control by mo 4, thus paralleling the improvements in O2- generation.	N-Formylmethionine Leucyl-Phenylalanine	42-55	colony stimulating factor 3	Homo sapiens	26-31
7510873-9	1994	In vivo administration of G-CSF increased f-Met-Leu-Phe-triggered Ca2+ mobilization by neutrophils to 43% of control by mo 1 of G-CSF therapy and to 93% of control by mo 4, thus paralleling the improvements in O2- generation.	N-Formylmethionine Leucyl-Phenylalanine	42-55	colony stimulating factor 3	Homo sapiens	128-133
7510873-9	1994	In vivo administration of G-CSF increased f-Met-Leu-Phe-triggered Ca2+ mobilization by neutrophils to 43% of control by mo 1 of G-CSF therapy and to 93% of control by mo 4, thus paralleling the improvements in O2- generation.	Superoxides	210-212	colony stimulating factor 3	Homo sapiens	26-31
7510873-11	1994	In summary, G-CSF therapy produced a rapid increase in circulating neutrophils and a gradual correction of O2- production.	Superoxides	107-109	colony stimulating factor 3	Homo sapiens	12-17
7530472-0	1994	Escalating doses of mitoxantrone with granulocyte colony-stimulating factor (G-CSF) rescue plus 5-fluorouracil and high-dose levofolinic acid in metastatic breast cancer.	Mitoxantrone	20-32	colony stimulating factor 3	Homo sapiens	77-82
7505809-12	1994	Nonhematologic toxicities such as increased creatinine concentration also prevented an increase in the RDI in the G-CSF arm.	Creatinine	44-54	colony stimulating factor 3	Homo sapiens	114-119
7505810-0	1994	Phase I study of irinotecan and cisplatin with granulocyte colony-stimulating factor support for advanced non-small-cell lung cancer.	Irinotecan	17-27	colony stimulating factor 3	Homo sapiens	47-84
7535466-0	1994	4-Hydroperoxycyclophosphamide purged autologous bone marrow transplantation of relapsed, responding non-Hodgkin"s lymphoma with granulocyte colony stimulating factor support results in reliable hematopoietic recovery.	perfosfamide	0-29	colony stimulating factor 3	Homo sapiens	128-165
7511543-5	1993	These results suggest that combined therapy with granulocyte colony-stimulating factor and erythropoietin may improve leukopenia and anaemia, which is not zidovudine-related, in children who have AIDS.	Zidovudine	155-165	colony stimulating factor 3	Homo sapiens	49-86
7507264-12	1993	The CR rate for de novo AML patients treated with a single course of high-dose cytarabine, idarubicin, and granulocyte colony-stimulating factor is at least comparable to CR rates achieved with standard-dose cytarabine and anthracycline regimens.	Chromium	4-6	colony stimulating factor 3	Homo sapiens	107-144
7505617-0	1993	A thermodynamic model for denaturation of granulocyte colony-stimulating factor: O-linked sugar chain suppresses not the triggering deprotonation but the succeeding denaturation.	Sugars	90-95	colony stimulating factor 3	Homo sapiens	42-79
7505617-1	1993	We have previously reported that the O-linked sugar chain of human granulocyte colony-stimulating factor (G-CSF) protects it against denaturation (Oh-eda et al.	Sugars	46-51	colony stimulating factor 3	Homo sapiens	67-104
7505617-1	1993	We have previously reported that the O-linked sugar chain of human granulocyte colony-stimulating factor (G-CSF) protects it against denaturation (Oh-eda et al.	Sugars	46-51	colony stimulating factor 3	Homo sapiens	106-111
7505617-8	1993	A sugar chain of human G-CSF, by standing close by Cys-17, may prevent free radicals from attacking the deprotonated sulfhydryl group.	Sugars	2-7	colony stimulating factor 3	Homo sapiens	23-28
7505617-8	1993	A sugar chain of human G-CSF, by standing close by Cys-17, may prevent free radicals from attacking the deprotonated sulfhydryl group.	Cysteine	51-54	colony stimulating factor 3	Homo sapiens	23-28
7504151-4	1993	G-CSF markedly enhanced RA-induced granulocytic differentiation in APL cells obtained from all four cases.	Tretinoin	24-26	colony stimulating factor 3	Homo sapiens	0-5
7693341-0	1993	Administration of human recombinant granulocyte colony-stimulating factor (filgrastim) accelerates granulocyte recovery following high-dose chemotherapy and autologous marrow transplantation with 4-hydroperoxycyclophosphamide-purged marrow in women with metastatic breast cancer.	perfosfamide	196-225	colony stimulating factor 3	Homo sapiens	36-73
7693341-12	1993	G-CSF accelerates myelopoiesis following the infusion of 4-hydroperoxycyclophosphamide-purged autologous marrow and shortens hospitalization.	perfosfamide	57-86	colony stimulating factor 3	Homo sapiens	0-5
7521347-0	1993	Treatment of methimazole-induced agranulocytosis using recombinant human granulocyte colony-stimulating factor (rhG-CSF).	Methimazole	13-24	colony stimulating factor 3	Homo sapiens	73-110
7693847-0	1993	Recombinant human granulocyte colony-stimulating factor (rhG-CSF; filgrastim) treatment of clozapine-induced agranulocytosis.	Clozapine	91-100	colony stimulating factor 3	Homo sapiens	18-55
7507240-0	1993	First use of G-CSF in chlorpromazine-induced agranulocytosis: a report of two cases.	Chlorpromazine	22-36	colony stimulating factor 3	Homo sapiens	13-18
7507533-11	1993	Dyspnea with suppressed PaO2 recovered reversibly after cessation of G-CSF.	pao2	24-28	colony stimulating factor 3	Homo sapiens	69-74
7514282-0	1993	Cell kinetic effects of granulocyte colony-stimulating factor on the sensitivity of nonlymphocytic leukemia cells to cytosine arabinoside.	Cytarabine	117-137	colony stimulating factor 3	Homo sapiens	24-61
7514282-5	1993	The number of clonogenic leukemic cells in methylcellulose was also smaller after culture with G-CSF followed by Ara-C than Ara-C alone.	Cytarabine	124-129	colony stimulating factor 3	Homo sapiens	95-100
7507240-2	1993	We describe two patients with chlorpromazine-induced granulocytosis in whom granulocyte colony stimulating factor (G-CSF) administration enhanced the speed of neutrophil recovery.	Chlorpromazine	30-44	colony stimulating factor 3	Homo sapiens	76-113
7507240-2	1993	We describe two patients with chlorpromazine-induced granulocytosis in whom granulocyte colony stimulating factor (G-CSF) administration enhanced the speed of neutrophil recovery.	Chlorpromazine	30-44	colony stimulating factor 3	Homo sapiens	115-120
7692001-0	1993	Phase I and pharmacologic study of paclitaxel and cisplatin with granulocyte colony-stimulating factor: neuromuscular toxicity is dose-limiting.	Cisplatin	50-59	colony stimulating factor 3	Homo sapiens	65-102
7511003-0	1993	[Tenoxicam-induced agranulocytosis, with good response to colony stimulating factor (G-CSF)].	tenoxicam	1-10	colony stimulating factor 3	Homo sapiens	85-90
7694480-3	1993	In particular, we assessed whether dexamethasone was capable of inhibiting the tumor necrosis factor-alpha (TNF-alpha)-mediated secretion of interleukin-6 (IL-6), interleukin-8 (IL-8), and granulocyte colony-stimulating factor (G-CSF) by a human bronchial epithelial cell line (BEAS-2B).	Dexamethasone	35-48	colony stimulating factor 3	Homo sapiens	189-226
7694480-3	1993	In particular, we assessed whether dexamethasone was capable of inhibiting the tumor necrosis factor-alpha (TNF-alpha)-mediated secretion of interleukin-6 (IL-6), interleukin-8 (IL-8), and granulocyte colony-stimulating factor (G-CSF) by a human bronchial epithelial cell line (BEAS-2B).	Dexamethasone	35-48	colony stimulating factor 3	Homo sapiens	228-233
7692001-5	1993	RESULTS: The development of a severe peripheral neuropathy and/or severe myalgias precluded the chronic administration of Taxol and cisplatin with G-CSF at doses greater than 250 mg/m2 and 75 mg/m2, respectively.	Cisplatin	132-141	colony stimulating factor 3	Homo sapiens	147-152
7505148-5	1993	At high concentrations, DAB486-G-CSF is cytotoxic towards G-CSF-dependent OCI/AML1 cells, but not factor independent OCI/AML3 cells; colony formation by G-CSF-responsive leukemic blasts from a patient with acute myeloblastic leukemia (AML) was also inhibited.	dab486	24-30	colony stimulating factor 3	Homo sapiens	31-36
7692001-11	1993	CONCLUSION: Taxol and cisplatin doses of 250 mg/m2 and 75 mg/m2, respectively, can be administered repetitively with G-CSF to untreated and minimally pretreated patients.	Paclitaxel	12-17	colony stimulating factor 3	Homo sapiens	117-122
7692001-11	1993	CONCLUSION: Taxol and cisplatin doses of 250 mg/m2 and 75 mg/m2, respectively, can be administered repetitively with G-CSF to untreated and minimally pretreated patients.	Cisplatin	22-31	colony stimulating factor 3	Homo sapiens	117-122
7511386-0	1993	Cysteine 17 of recombinant human granulocyte-colony stimulating factor is partially solvent-exposed.	Cysteine	0-8	colony stimulating factor 3	Homo sapiens	33-70
7692194-12	1993	The median IC75 values of Ara-C decreased from 0.056 to 0.0168 microgram/ml with G-CSF (p = 0.01), from 0.108 to 0.0168 microgram/ml with IL-3 (p = 0.004) and from 0.12 to 0.0204 microgram/ml for GM-CSF (p = 0.02).	Cytarabine	26-31	colony stimulating factor 3	Homo sapiens	81-86
7505148-5	1993	At high concentrations, DAB486-G-CSF is cytotoxic towards G-CSF-dependent OCI/AML1 cells, but not factor independent OCI/AML3 cells; colony formation by G-CSF-responsive leukemic blasts from a patient with acute myeloblastic leukemia (AML) was also inhibited.	dab486	24-30	colony stimulating factor 3	Homo sapiens	58-63
7505148-5	1993	At high concentrations, DAB486-G-CSF is cytotoxic towards G-CSF-dependent OCI/AML1 cells, but not factor independent OCI/AML3 cells; colony formation by G-CSF-responsive leukemic blasts from a patient with acute myeloblastic leukemia (AML) was also inhibited.	dab486	24-30	colony stimulating factor 3	Homo sapiens	58-63
7505148-9	1993	Nevertheless, DAB486-G-CSF may be included with the increasing number of other toxin-hormone fusion proteins whose toxicity is directed towards specific receptor-bearing cells, and may represent a novel approach towards the study and treatment of leukemia.	dab486	14-20	colony stimulating factor 3	Homo sapiens	21-26
7691233-3	1993	However, when this dose of rrSCF-PEG was combined with an optimal dose of recombinant human granulocyte colony-stimulating factor (rhG-CSF; 200 micrograms/kg/d), a synergistic increase in PBPC was observed.	PbPc	188-192	colony stimulating factor 3	Homo sapiens	92-129
7693069-0	1993	Granulocyte-colony stimulating factor for sulfasalazine-induced agranulocytosis.	Sulfasalazine	42-55	colony stimulating factor 3	Homo sapiens	0-37
7693069-1	1993	OBJECTIVE: To report a case of sulfasalazine-induced agranulocytosis that was successfully treated with granulocyte-colony stimulating factor (G-CSF).	Sulfasalazine	31-44	colony stimulating factor 3	Homo sapiens	104-141
7693069-1	1993	OBJECTIVE: To report a case of sulfasalazine-induced agranulocytosis that was successfully treated with granulocyte-colony stimulating factor (G-CSF).	Sulfasalazine	31-44	colony stimulating factor 3	Homo sapiens	143-148
7691653-6	1993	Interestingly, human B lymphocytes are shown to express the binding to biotin-conjugated G-CSF preparation, but not to biotin-conjugated GM-CSF preparation when examined by flow cytometry.	Biotin	71-77	colony stimulating factor 3	Homo sapiens	89-94
7508003-0	1993	[Effect of G-CSF and M-CSF on busulfan-induced marrow failure in a 91-year old patient with essential thrombocythemia].	Busulfan	30-38	colony stimulating factor 3	Homo sapiens	11-16
7504538-0	1993	Isolation and characterization of three recombinant human granulocyte colony stimulating factor His--&gt;Gln isoforms produced in Escherichia coli.	Glutamine	105-108	colony stimulating factor 3	Homo sapiens	58-95
7689868-1	1993	The aim of this study was to test whether prolonged administration of granulocyte colony-stimulating factor (G-CSF) would allow the collection by leukapheresis of PBHP in patients with SAA.	21-amino-6,9,18-tris(2-aminoethyl)-15-benzyl-3-(1-hydroxyethyl)-12-(2-methylpropyl)-1,4,7,10,13,16,19-heptazacyclotricosane-2,5,8,11,14,17,20-heptone;sulfuric acid	163-167	colony stimulating factor 3	Homo sapiens	70-107
7689868-1	1993	The aim of this study was to test whether prolonged administration of granulocyte colony-stimulating factor (G-CSF) would allow the collection by leukapheresis of PBHP in patients with SAA.	21-amino-6,9,18-tris(2-aminoethyl)-15-benzyl-3-(1-hydroxyethyl)-12-(2-methylpropyl)-1,4,7,10,13,16,19-heptazacyclotricosane-2,5,8,11,14,17,20-heptone;sulfuric acid	163-167	colony stimulating factor 3	Homo sapiens	109-114
7689868-1	1993	The aim of this study was to test whether prolonged administration of granulocyte colony-stimulating factor (G-CSF) would allow the collection by leukapheresis of PBHP in patients with SAA.	saa	185-188	colony stimulating factor 3	Homo sapiens	70-107
7689868-1	1993	The aim of this study was to test whether prolonged administration of granulocyte colony-stimulating factor (G-CSF) would allow the collection by leukapheresis of PBHP in patients with SAA.	saa	185-188	colony stimulating factor 3	Homo sapiens	109-114
7689868-10	1993	In conclusion, this study suggests that circulating hematopoietic progenitors can be recovered after ALG priming and after at least 1 month of G-CSF treatment in a proportion of patients with SAA.	saa	192-195	colony stimulating factor 3	Homo sapiens	143-148
7688839-8	1993	Ara-C cytotoxicity to normal bone marrow progenitors was enhanced significantly only by G-CSF (p = 0.02 at 0.01 microM, p = 0.01 at 0.1 microM and p &lt; 0.01 at 1 microM Ara-C), and by GM-CSF at 0.1 microM Ara-C (p = 0.045).	Cytarabine	0-5	colony stimulating factor 3	Homo sapiens	88-93
7689093-0	1993	Phase I study of high-dose piroxantrone with granulocyte colony-stimulating factor.	piroxantrone	27-39	colony stimulating factor 3	Homo sapiens	45-82
7689093-6	1993	Three of six patients treated with piroxantrone and G-CSF exhibited dose-limiting thrombocytopenia at 445 mg/m2; the MTD of piroxantrone with G-CSF was thus 355 mg/m2.	piroxantrone	124-136	colony stimulating factor 3	Homo sapiens	142-147
7689093-10	1993	CONCLUSION: The use of G-CSF results in a more than twofold increase in the MTD of piroxantrone.	piroxantrone	83-95	colony stimulating factor 3	Homo sapiens	23-28
7508772-5	1993	This case supports the concept that G-CSF accelerates ATRA-induced neutrophilic differentiation of blast cells in APL.	Tretinoin	54-58	colony stimulating factor 3	Homo sapiens	36-41
7689128-1	1993	Recombinant human granulocyte colony-stimulating factor (rhG-CSF) not only enhanced the growth of HL-60 cells, but also significantly increased NBT-reducing ability and alkaline phosphatase (ALP) activity of the cells, which were enhanced by the treatment with retinoic acid (RA).	Nitroblue Tetrazolium	144-147	colony stimulating factor 3	Homo sapiens	18-55
7689128-1	1993	Recombinant human granulocyte colony-stimulating factor (rhG-CSF) not only enhanced the growth of HL-60 cells, but also significantly increased NBT-reducing ability and alkaline phosphatase (ALP) activity of the cells, which were enhanced by the treatment with retinoic acid (RA).	Tretinoin	261-274	colony stimulating factor 3	Homo sapiens	18-55
7692928-0	1993	Peripheral blood progenitor cells mobilized by chemotherapy plus granulocyte-colony stimulating factor accelerate both neutrophil and platelet recovery after high-dose VP16, ifosfamide and cisplatin.	Etoposide	168-172	colony stimulating factor 3	Homo sapiens	65-102
7692928-0	1993	Peripheral blood progenitor cells mobilized by chemotherapy plus granulocyte-colony stimulating factor accelerate both neutrophil and platelet recovery after high-dose VP16, ifosfamide and cisplatin.	Ifosfamide	174-184	colony stimulating factor 3	Homo sapiens	65-102
7692928-0	1993	Peripheral blood progenitor cells mobilized by chemotherapy plus granulocyte-colony stimulating factor accelerate both neutrophil and platelet recovery after high-dose VP16, ifosfamide and cisplatin.	Cisplatin	189-198	colony stimulating factor 3	Homo sapiens	65-102
7692930-6	1993	CD16, induced on the defective PNH PMN during the administration of G-CSF, was phosphatidylinositol-specific phospholipase C (PIPLC)-sensitive, implying that it had GPI-linkage to the membranes.	Phosphatidylinositols	79-99	colony stimulating factor 3	Homo sapiens	68-73
7686503-5	1993	Although coadministration of recombinant granulocyte colony-stimulating factor (rG-CSF) or recombinant colony-stimulating factor-1 (rCSF-1) mimicked the capacity of bryostatin 1 to increase the total number of pIXY 321-induced day-14 CFU-GM, these growth factors, unlike bryostatin 1, were not capable of inhibiting eosinophilic colony formation.	bryostatin 1	165-177	colony stimulating factor 3	Homo sapiens	41-78
7686503-5	1993	Although coadministration of recombinant granulocyte colony-stimulating factor (rG-CSF) or recombinant colony-stimulating factor-1 (rCSF-1) mimicked the capacity of bryostatin 1 to increase the total number of pIXY 321-induced day-14 CFU-GM, these growth factors, unlike bryostatin 1, were not capable of inhibiting eosinophilic colony formation.	pixy	210-214	colony stimulating factor 3	Homo sapiens	41-78
7686503-5	1993	Although coadministration of recombinant granulocyte colony-stimulating factor (rG-CSF) or recombinant colony-stimulating factor-1 (rCSF-1) mimicked the capacity of bryostatin 1 to increase the total number of pIXY 321-induced day-14 CFU-GM, these growth factors, unlike bryostatin 1, were not capable of inhibiting eosinophilic colony formation.	-gm	237-240	colony stimulating factor 3	Homo sapiens	41-78
7686503-5	1993	Although coadministration of recombinant granulocyte colony-stimulating factor (rG-CSF) or recombinant colony-stimulating factor-1 (rCSF-1) mimicked the capacity of bryostatin 1 to increase the total number of pIXY 321-induced day-14 CFU-GM, these growth factors, unlike bryostatin 1, were not capable of inhibiting eosinophilic colony formation.	bryostatin 1	271-283	colony stimulating factor 3	Homo sapiens	41-78
7684703-5	1993	In addition, it was shown that the effects of IFN-gamma on LPS-induced G-CSF protein secretion could be mimicked by the calcium ionophore A23187, suggesting that the Ca(2+)-dependent pathway might be triggered after binding of the ligand to the receptor.	Calcium	120-127	colony stimulating factor 3	Homo sapiens	71-76
7686602-2	1993	Previous studies have shown: (i) blast cells exposed to retinoic acid before cytosine arabinoside (Ara-C) usually show increased sensitivity, but after some retinoic acid exposure times, sensitivity may be decreased; (ii) factor-sensitive or responsive blasts cultured with granulocyte colony-stimulating factor (G-CSF) are regularly more Ara-C-sensitive than when cultured with granulocyte-macrophage CSF (GM-CSF).	Tretinoin	56-69	colony stimulating factor 3	Homo sapiens	274-311
7686602-2	1993	Previous studies have shown: (i) blast cells exposed to retinoic acid before cytosine arabinoside (Ara-C) usually show increased sensitivity, but after some retinoic acid exposure times, sensitivity may be decreased; (ii) factor-sensitive or responsive blasts cultured with granulocyte colony-stimulating factor (G-CSF) are regularly more Ara-C-sensitive than when cultured with granulocyte-macrophage CSF (GM-CSF).	Tretinoin	56-69	colony stimulating factor 3	Homo sapiens	313-318
7686602-2	1993	Previous studies have shown: (i) blast cells exposed to retinoic acid before cytosine arabinoside (Ara-C) usually show increased sensitivity, but after some retinoic acid exposure times, sensitivity may be decreased; (ii) factor-sensitive or responsive blasts cultured with granulocyte colony-stimulating factor (G-CSF) are regularly more Ara-C-sensitive than when cultured with granulocyte-macrophage CSF (GM-CSF).	Cytarabine	99-104	colony stimulating factor 3	Homo sapiens	274-311
7686602-2	1993	Previous studies have shown: (i) blast cells exposed to retinoic acid before cytosine arabinoside (Ara-C) usually show increased sensitivity, but after some retinoic acid exposure times, sensitivity may be decreased; (ii) factor-sensitive or responsive blasts cultured with granulocyte colony-stimulating factor (G-CSF) are regularly more Ara-C-sensitive than when cultured with granulocyte-macrophage CSF (GM-CSF).	Cytarabine	99-104	colony stimulating factor 3	Homo sapiens	313-318
7686602-11	1993	G-CSF and GM-CSF were most effective in increasing or decreasing Ara-C, respectively, when the factor under test was included in the methylcellulose cultures.	Cytarabine	65-70	colony stimulating factor 3	Homo sapiens	0-5
7688884-3	1993	Initial data from primates revealed that G-CSF could ameliorate neutropenia following nitrogen mustard exposure.	Nitrogen	86-94	colony stimulating factor 3	Homo sapiens	41-46
7689123-0	1993	[Effects of recombinant human granulocyte colony-stimulating factor on superoxide production by neutrophil in cancer patients receiving chemotherapy].	Superoxides	71-81	colony stimulating factor 3	Homo sapiens	30-67
7686754-7	1993	Both G-CSF and M-CSF were also effective in stimulating tyrosine phosphorylation.	Tyrosine	56-64	colony stimulating factor 3	Homo sapiens	5-10
7689895-4	1993	In the present study, we found that recombinant G-CSF promotes the anti-Candida albicans activity of normal human blood polymorphonuclear (PMN) cells in vitro using both a 3H-glucose uptake procedure and a Candida colony counting assay.	3h-glucose	172-182	colony stimulating factor 3	Homo sapiens	48-53
7689895-6	1993	G-CSF treatment also enhanced superoxide anion production by the PMNs in response to f-MLP as determined by the superoxide dismutase inhibitable cytochrome C reduction method.	Superoxides	30-46	colony stimulating factor 3	Homo sapiens	0-5
7690070-16	1993	The leukocyte counts also exceeded 2000/mm3 3-5 days after G-CSF administration in 5 cycles of VAMA therapy.	vama	95-99	colony stimulating factor 3	Homo sapiens	59-64
7685198-1	1993	The bromodeoxyuridine (BrdU)-Hoechst flow cytometric technique was applied to study the immediate cell kinetic response of highly purified human (h) bone marrow progenitor cells (CD(34+)-sorted fraction) to h granulocyte colony-stimulating factor (G-CSF) and/or h granulocyte-macrophage colony-stimulating factor (GM-CSF).	Bromodeoxyuridine	4-21	colony stimulating factor 3	Homo sapiens	209-246
7688178-6	1993	We conclude that cyclosporine can be an effective treatment for cyclic neutropenia associated with autoimmunity since G-CSF may cause exacerbations of autoimmune disorders.	Cyclosporine	17-29	colony stimulating factor 3	Homo sapiens	118-123
7685228-1	1993	We have successfully overcome severe neutropenia in an RA patient treated with gold salts, using granulocyte colony-stimulating factor (G-CSF), reducing the duration of neutropenia and risk of infection.	gold salts	79-89	colony stimulating factor 3	Homo sapiens	97-134
7685228-1	1993	We have successfully overcome severe neutropenia in an RA patient treated with gold salts, using granulocyte colony-stimulating factor (G-CSF), reducing the duration of neutropenia and risk of infection.	gold salts	79-89	colony stimulating factor 3	Homo sapiens	136-141
7684320-0	1993	Pharmacokinetics of piroxantrone in a phase I trial of piroxantrone and granulocyte-colony stimulating factor.	piroxantrone	20-32	colony stimulating factor 3	Homo sapiens	72-109
7684703-5	1993	In addition, it was shown that the effects of IFN-gamma on LPS-induced G-CSF protein secretion could be mimicked by the calcium ionophore A23187, suggesting that the Ca(2+)-dependent pathway might be triggered after binding of the ligand to the receptor.	Calcimycin	138-144	colony stimulating factor 3	Homo sapiens	71-76
7684770-16	1993	PBPs, harvested during the G-CSF-augmented rebound from CPA-induced cytopenia, produce rapid hematologic recovery in patients undergoing high-dose chemotherapy (HDC).	pbps	0-4	colony stimulating factor 3	Homo sapiens	27-32
7685052-2	1993	Dipyridamole and R-verapamil caused a dose-dependent inhibition of AML cell proliferation, and for both drugs the degree of inhibition was similar when testing various haematopoietic growth factors or growth factor combinations (IL3, G-CSF, GM-CSF, G-CSF + GM-CSF, TNF-alpha + GM-CSF).	Dipyridamole	0-12	colony stimulating factor 3	Homo sapiens	234-239
7685052-2	1993	Dipyridamole and R-verapamil caused a dose-dependent inhibition of AML cell proliferation, and for both drugs the degree of inhibition was similar when testing various haematopoietic growth factors or growth factor combinations (IL3, G-CSF, GM-CSF, G-CSF + GM-CSF, TNF-alpha + GM-CSF).	Dipyridamole	0-12	colony stimulating factor 3	Homo sapiens	249-254
7694217-4	1993	Recombinant human G-CSF was labeled with fluorescein isothiocyanate.	Fluorescein-5-isothiocyanate	41-67	colony stimulating factor 3	Homo sapiens	18-23
7684770-16	1993	PBPs, harvested during the G-CSF-augmented rebound from CPA-induced cytopenia, produce rapid hematologic recovery in patients undergoing high-dose chemotherapy (HDC).	Cyclophosphamide	56-59	colony stimulating factor 3	Homo sapiens	27-32
7685769-2	1993	The carbohydrate compositional analysis indicated that G-CSF molecule contains sialic acid, galactose and galactosamine.	Carbohydrates	4-16	colony stimulating factor 3	Homo sapiens	55-60
7685769-2	1993	The carbohydrate compositional analysis indicated that G-CSF molecule contains sialic acid, galactose and galactosamine.	N-Acetylneuraminic Acid	79-90	colony stimulating factor 3	Homo sapiens	55-60
7685769-2	1993	The carbohydrate compositional analysis indicated that G-CSF molecule contains sialic acid, galactose and galactosamine.	Galactose	92-101	colony stimulating factor 3	Homo sapiens	55-60
7685769-2	1993	The carbohydrate compositional analysis indicated that G-CSF molecule contains sialic acid, galactose and galactosamine.	Galactosamine	106-119	colony stimulating factor 3	Homo sapiens	55-60
7686232-3	1993	In vitro colony assay also suggests an increase in sensitivity of GM progenitors to cytokines (GM-CSF, IL-3, G-CSF and/or SCF) in a patient with juvenile chronic myelogenous leukemia.	gm	66-68	colony stimulating factor 3	Homo sapiens	109-114
7683729-0	1993	Granulocyte colony-stimulating factor: effective in ameliorating fluorouracil-based myelosuppression?	Fluorouracil	65-77	colony stimulating factor 3	Homo sapiens	0-37
7687859-4	1993	G-CSF (5 micrograms/kg) was administered during the recovery phase in 6/14 courses with Ara-C/Etop and in 4/13 courses with Ara-C/Mit.	Cytarabine	88-93	colony stimulating factor 3	Homo sapiens	0-5
7687859-4	1993	G-CSF (5 micrograms/kg) was administered during the recovery phase in 6/14 courses with Ara-C/Etop and in 4/13 courses with Ara-C/Mit.	Etoposide	94-98	colony stimulating factor 3	Homo sapiens	0-5
7687859-4	1993	G-CSF (5 micrograms/kg) was administered during the recovery phase in 6/14 courses with Ara-C/Etop and in 4/13 courses with Ara-C/Mit.	Cytarabine	124-129	colony stimulating factor 3	Homo sapiens	0-5
7685751-0	1993	Enhancement of cytosine arabinoside cytotoxicity by granulocyte/macrophage colony-stimulating factor and granulocyte colony-stimulating factor in a human myeloblastic leukemia cell line.	Cytarabine	15-35	colony stimulating factor 3	Homo sapiens	105-142
8468485-7	1993	In addition, human bone marrow neutrophils, cord blood neutrophils, and several human hematopoietic cell lines (HL-60, U-937, and AML-193) responded to dexamethasone and GM-CSF (or G-CSF) with a superadditive increase in IL-1 binding.	Dexamethasone	152-165	colony stimulating factor 3	Homo sapiens	181-186
7681858-0	1993	Recombinant granulocyte colony-stimulating factor for dapsone-induced agranulocytosis in leukocytoclastic vasculitis.	Dapsone	54-61	colony stimulating factor 3	Homo sapiens	12-49
7684324-0	1993	Granulocyte colony-stimulating factor enhances the extracellular emission of reactive oxygen from neutrophils stimulated with formylmethionylleucylphenylalanine.	reactive oxygen	77-92	colony stimulating factor 3	Homo sapiens	0-37
7684324-0	1993	Granulocyte colony-stimulating factor enhances the extracellular emission of reactive oxygen from neutrophils stimulated with formylmethionylleucylphenylalanine.	N-Formylmethionine Leucyl-Phenylalanine	126-160	colony stimulating factor 3	Homo sapiens	0-37
7684324-1	1993	Pretreatment of neutrophils with granulocyte colony-stimulating factor (G-CSF) enhanced luminol-dependent chemiluminescence emission by the stimulation of formylmethionylleucylphenylalanine (FMLP), opsonized zymosan, and zymosan.	Luminol	88-95	colony stimulating factor 3	Homo sapiens	33-70
7684324-1	1993	Pretreatment of neutrophils with granulocyte colony-stimulating factor (G-CSF) enhanced luminol-dependent chemiluminescence emission by the stimulation of formylmethionylleucylphenylalanine (FMLP), opsonized zymosan, and zymosan.	Luminol	88-95	colony stimulating factor 3	Homo sapiens	72-77
7684324-1	1993	Pretreatment of neutrophils with granulocyte colony-stimulating factor (G-CSF) enhanced luminol-dependent chemiluminescence emission by the stimulation of formylmethionylleucylphenylalanine (FMLP), opsonized zymosan, and zymosan.	N-Formylmethionine Leucyl-Phenylalanine	155-189	colony stimulating factor 3	Homo sapiens	33-70
7684324-1	1993	Pretreatment of neutrophils with granulocyte colony-stimulating factor (G-CSF) enhanced luminol-dependent chemiluminescence emission by the stimulation of formylmethionylleucylphenylalanine (FMLP), opsonized zymosan, and zymosan.	N-Formylmethionine Leucyl-Phenylalanine	155-189	colony stimulating factor 3	Homo sapiens	72-77
7684324-1	1993	Pretreatment of neutrophils with granulocyte colony-stimulating factor (G-CSF) enhanced luminol-dependent chemiluminescence emission by the stimulation of formylmethionylleucylphenylalanine (FMLP), opsonized zymosan, and zymosan.	N-Formylmethionine Leucyl-Phenylalanine	191-195	colony stimulating factor 3	Homo sapiens	33-70
7684324-1	1993	Pretreatment of neutrophils with granulocyte colony-stimulating factor (G-CSF) enhanced luminol-dependent chemiluminescence emission by the stimulation of formylmethionylleucylphenylalanine (FMLP), opsonized zymosan, and zymosan.	N-Formylmethionine Leucyl-Phenylalanine	191-195	colony stimulating factor 3	Homo sapiens	72-77
7684324-1	1993	Pretreatment of neutrophils with granulocyte colony-stimulating factor (G-CSF) enhanced luminol-dependent chemiluminescence emission by the stimulation of formylmethionylleucylphenylalanine (FMLP), opsonized zymosan, and zymosan.	Zymosan	208-215	colony stimulating factor 3	Homo sapiens	33-70
7684324-1	1993	Pretreatment of neutrophils with granulocyte colony-stimulating factor (G-CSF) enhanced luminol-dependent chemiluminescence emission by the stimulation of formylmethionylleucylphenylalanine (FMLP), opsonized zymosan, and zymosan.	Zymosan	208-215	colony stimulating factor 3	Homo sapiens	72-77
7684324-1	1993	Pretreatment of neutrophils with granulocyte colony-stimulating factor (G-CSF) enhanced luminol-dependent chemiluminescence emission by the stimulation of formylmethionylleucylphenylalanine (FMLP), opsonized zymosan, and zymosan.	Zymosan	221-228	colony stimulating factor 3	Homo sapiens	33-70
7684324-1	1993	Pretreatment of neutrophils with granulocyte colony-stimulating factor (G-CSF) enhanced luminol-dependent chemiluminescence emission by the stimulation of formylmethionylleucylphenylalanine (FMLP), opsonized zymosan, and zymosan.	Zymosan	221-228	colony stimulating factor 3	Homo sapiens	72-77
7684324-5	1993	This indicates that G-CSF mainly enhances the extracellular release of oxygen radicals in response to the stimulation with FMLP.	Reactive Oxygen Species	71-86	colony stimulating factor 3	Homo sapiens	20-25
7683933-8	1993	We conclude that taxol, when given with G-CSF support, can be safely administered in a dose-intense fashion for multiple cycles of therapy, without cumulative bone marrow toxicity.	Paclitaxel	17-22	colony stimulating factor 3	Homo sapiens	40-45
7681704-8	1993	Recombinant human granulocyte colony-stimulating factor (rhG-CSF) and interleukin-3 (rhIL-3) displayed much smaller effects on pure PMNs and mixed PMN-MNL chemiluminescence and superoxide release than rhGM-CSF.	Superoxides	177-187	colony stimulating factor 3	Homo sapiens	18-55
7682568-7	1993	Although G-CSF itself did not affect platelet aggregation in vitro, preincubation with G-CSF augmented a secondary aggregation of platelets induced by low concentrations of adenosine diphosphate (ADP).	Adenosine Diphosphate	173-194	colony stimulating factor 3	Homo sapiens	87-92
7682568-7	1993	Although G-CSF itself did not affect platelet aggregation in vitro, preincubation with G-CSF augmented a secondary aggregation of platelets induced by low concentrations of adenosine diphosphate (ADP).	Adenosine Diphosphate	196-199	colony stimulating factor 3	Homo sapiens	87-92
7682568-9	1993	Furthermore, the augmented ADP-induced secondary aggregation of platelets on G-CSF receptors was completely abrogated in the presence of anti-G-CSF polyclonal antibodies.	Adenosine Diphosphate	27-30	colony stimulating factor 3	Homo sapiens	77-82
7682568-9	1993	Furthermore, the augmented ADP-induced secondary aggregation of platelets on G-CSF receptors was completely abrogated in the presence of anti-G-CSF polyclonal antibodies.	Adenosine Diphosphate	27-30	colony stimulating factor 3	Homo sapiens	142-147
7683885-0	1993	Characterization of two fluorescent tryptophans in recombinant human granulocyte-colony stimulating factor: comparison of native sequence protein and tryptophan-deficient mutants.	Tryptophan	36-47	colony stimulating factor 3	Homo sapiens	69-106
7683885-0	1993	Characterization of two fluorescent tryptophans in recombinant human granulocyte-colony stimulating factor: comparison of native sequence protein and tryptophan-deficient mutants.	Tryptophan	36-46	colony stimulating factor 3	Homo sapiens	69-106
7683885-1	1993	In order to probe the role of the individual tryptophans of granulocyte-colony stimulating factor (G-CSF) in pH and guanidine HCl-induced fluorescence changes, site-directed mutagenesis was used to generate mutants replacing Trp118,Trp58, or both with phenylalanine.	Tryptophan	45-56	colony stimulating factor 3	Homo sapiens	60-97
7683885-1	1993	In order to probe the role of the individual tryptophans of granulocyte-colony stimulating factor (G-CSF) in pH and guanidine HCl-induced fluorescence changes, site-directed mutagenesis was used to generate mutants replacing Trp118,Trp58, or both with phenylalanine.	Tryptophan	45-56	colony stimulating factor 3	Homo sapiens	99-104
7683885-1	1993	In order to probe the role of the individual tryptophans of granulocyte-colony stimulating factor (G-CSF) in pH and guanidine HCl-induced fluorescence changes, site-directed mutagenesis was used to generate mutants replacing Trp118,Trp58, or both with phenylalanine.	Guanidine	116-129	colony stimulating factor 3	Homo sapiens	60-97
7683885-1	1993	In order to probe the role of the individual tryptophans of granulocyte-colony stimulating factor (G-CSF) in pH and guanidine HCl-induced fluorescence changes, site-directed mutagenesis was used to generate mutants replacing Trp118,Trp58, or both with phenylalanine.	Guanidine	116-129	colony stimulating factor 3	Homo sapiens	99-104
7683885-1	1993	In order to probe the role of the individual tryptophans of granulocyte-colony stimulating factor (G-CSF) in pH and guanidine HCl-induced fluorescence changes, site-directed mutagenesis was used to generate mutants replacing Trp118,Trp58, or both with phenylalanine.	Phenylalanine	252-265	colony stimulating factor 3	Homo sapiens	60-97
7683885-1	1993	In order to probe the role of the individual tryptophans of granulocyte-colony stimulating factor (G-CSF) in pH and guanidine HCl-induced fluorescence changes, site-directed mutagenesis was used to generate mutants replacing Trp118,Trp58, or both with phenylalanine.	Phenylalanine	252-265	colony stimulating factor 3	Homo sapiens	99-104
7683885-3	1993	All of the G-CSF species responded to pH and guanidine HCl in qualitatively the same manner.	Guanidine	45-58	colony stimulating factor 3	Homo sapiens	11-16
7683885-8	1993	Below neutral pH the tyrosine fluorescence is much greater in the [Phe58]G-CSF than in the [Phe118]G-CSF, indicating that Trp58 might be a more efficient recipient of energy transfer from the tyrosine(s).	Tyrosine	21-29	colony stimulating factor 3	Homo sapiens	73-78
7683885-8	1993	Below neutral pH the tyrosine fluorescence is much greater in the [Phe58]G-CSF than in the [Phe118]G-CSF, indicating that Trp58 might be a more efficient recipient of energy transfer from the tyrosine(s).	Tyrosine	21-29	colony stimulating factor 3	Homo sapiens	99-104
7683885-8	1993	Below neutral pH the tyrosine fluorescence is much greater in the [Phe58]G-CSF than in the [Phe118]G-CSF, indicating that Trp58 might be a more efficient recipient of energy transfer from the tyrosine(s).	Tyrosine	192-200	colony stimulating factor 3	Homo sapiens	73-78
7683885-8	1993	Below neutral pH the tyrosine fluorescence is much greater in the [Phe58]G-CSF than in the [Phe118]G-CSF, indicating that Trp58 might be a more efficient recipient of energy transfer from the tyrosine(s).	Tyrosine	192-200	colony stimulating factor 3	Homo sapiens	99-104
7681919-3	1993	When the cells were first incubated in liquid culture for 4 days in IL4, followed by agar culture in G-CSF, there was a significant increase in the number of CFU-G compared to cells which had been incubated in medium alone for 4 days before plating out in agar containing G-CSF.	Agar	85-89	colony stimulating factor 3	Homo sapiens	101-106
7681919-3	1993	When the cells were first incubated in liquid culture for 4 days in IL4, followed by agar culture in G-CSF, there was a significant increase in the number of CFU-G compared to cells which had been incubated in medium alone for 4 days before plating out in agar containing G-CSF.	Agar	256-260	colony stimulating factor 3	Homo sapiens	101-106
7685751-1	1993	Enhancement of the cytotoxicity of cytosine arabinoside (ara-C) by granulocyte/macrophage colony-stimulating factor (GM-CSF) and granulocyte colony-stimulating factor (G-CSF), and the mechanisms involved, were studied in the AML-193 human leukemia cell line.	Cytarabine	35-55	colony stimulating factor 3	Homo sapiens	129-166
7685751-1	1993	Enhancement of the cytotoxicity of cytosine arabinoside (ara-C) by granulocyte/macrophage colony-stimulating factor (GM-CSF) and granulocyte colony-stimulating factor (G-CSF), and the mechanisms involved, were studied in the AML-193 human leukemia cell line.	Cytarabine	35-55	colony stimulating factor 3	Homo sapiens	168-173
7685751-1	1993	Enhancement of the cytotoxicity of cytosine arabinoside (ara-C) by granulocyte/macrophage colony-stimulating factor (GM-CSF) and granulocyte colony-stimulating factor (G-CSF), and the mechanisms involved, were studied in the AML-193 human leukemia cell line.	Cytarabine	57-62	colony stimulating factor 3	Homo sapiens	129-166
7685751-1	1993	Enhancement of the cytotoxicity of cytosine arabinoside (ara-C) by granulocyte/macrophage colony-stimulating factor (GM-CSF) and granulocyte colony-stimulating factor (G-CSF), and the mechanisms involved, were studied in the AML-193 human leukemia cell line.	Cytarabine	57-62	colony stimulating factor 3	Homo sapiens	168-173
7688830-6	1993	Receptors of these cytokines on various types of leukemic cells were also analyzed by flow-cytometry using fluorescent isothianate-labelled G-CSF or M-CSF.	isothianate	119-130	colony stimulating factor 3	Homo sapiens	140-145
7684099-5	1993	On the other hand, 5-days of prophylactic administrations of G-CSF from the 9th day of M-VAC therapy were able to increase leukocytes promptly.	M-VAC protocol	87-92	colony stimulating factor 3	Homo sapiens	61-66
7685839-7	1993	We have experienced two further patients with PMFH, in whom serum levels of IL-6 and G-CSF were markedly elevated.	pmfh	46-50	colony stimulating factor 3	Homo sapiens	85-90
7685138-0	1993	[Effect of recombinant human granulocyte colony stimulating factor in patients with transitional cell carcinoma of the urothelium receiving methotrexate, etoposide and cisplatinum combination chemotherapy].	Methotrexate	140-152	colony stimulating factor 3	Homo sapiens	29-66
8351869-4	1993	Treatment with large doses of melphalane, 140 mg/m2, was associated with a high death rate and therefore it is used nowadays only in combination with autologous transplantation or treatment with leucocytic growth factors (GM-CSF and G-CSF).	melphalane	30-40	colony stimulating factor 3	Homo sapiens	233-238
7679557-0	1993	Clomipramine-induced agranulocytosis and its treatment with G-CSF.	Clomipramine	0-12	colony stimulating factor 3	Homo sapiens	60-65
7685138-0	1993	[Effect of recombinant human granulocyte colony stimulating factor in patients with transitional cell carcinoma of the urothelium receiving methotrexate, etoposide and cisplatinum combination chemotherapy].	Etoposide	154-163	colony stimulating factor 3	Homo sapiens	29-66
7685138-0	1993	[Effect of recombinant human granulocyte colony stimulating factor in patients with transitional cell carcinoma of the urothelium receiving methotrexate, etoposide and cisplatinum combination chemotherapy].	Cisplatin	168-179	colony stimulating factor 3	Homo sapiens	29-66
7685138-1	1993	We determined the effective method of administration of recombinant human granulocyte colony-stimulating factor (rhG-CSF) in patients with transitional cell carcinoma of the urothelium receiving methotrexate, etoposide and cisplatinum (MEC) therapy.	Methotrexate	195-207	colony stimulating factor 3	Homo sapiens	74-111
7685138-1	1993	We determined the effective method of administration of recombinant human granulocyte colony-stimulating factor (rhG-CSF) in patients with transitional cell carcinoma of the urothelium receiving methotrexate, etoposide and cisplatinum (MEC) therapy.	Etoposide	209-218	colony stimulating factor 3	Homo sapiens	74-111
7685138-1	1993	We determined the effective method of administration of recombinant human granulocyte colony-stimulating factor (rhG-CSF) in patients with transitional cell carcinoma of the urothelium receiving methotrexate, etoposide and cisplatinum (MEC) therapy.	Cisplatin	223-234	colony stimulating factor 3	Homo sapiens	74-111
7685138-1	1993	We determined the effective method of administration of recombinant human granulocyte colony-stimulating factor (rhG-CSF) in patients with transitional cell carcinoma of the urothelium receiving methotrexate, etoposide and cisplatinum (MEC) therapy.	mec	236-239	colony stimulating factor 3	Homo sapiens	74-111
7680656-3	1993	A high level of expression of the G-CSFR did not promote or suppress cellular proliferation or initiate differentiation; however, exposure of transfected cells to G-CSF in suspension culture caused a large percentage of the population to enter a differentiation pathway, as determined by two markers of the mature state, the ability of cells to reduce nitroblue tetrazolium (NBT) and to express the differentiation antigen Mac-1 (CD11b) on the cell surface.	Nitroblue Tetrazolium	352-373	colony stimulating factor 3	Homo sapiens	34-39
7678988-4	1993	Exposure of human neutrophils to TNF, GM-CSF and G-CSF resulted in tyrosine phosphorylation of a 42-kDa protein and intracellular alkalinization in a dose-dependent manner.	Tyrosine	67-75	colony stimulating factor 3	Homo sapiens	49-54
7680656-3	1993	A high level of expression of the G-CSFR did not promote or suppress cellular proliferation or initiate differentiation; however, exposure of transfected cells to G-CSF in suspension culture caused a large percentage of the population to enter a differentiation pathway, as determined by two markers of the mature state, the ability of cells to reduce nitroblue tetrazolium (NBT) and to express the differentiation antigen Mac-1 (CD11b) on the cell surface.	Nitroblue Tetrazolium	375-378	colony stimulating factor 3	Homo sapiens	34-39
7679006-3	1993	However, in the presence of optimal concentrations of granulocyte colony-stimulating factor (G-CSF) or interleukin-6 (IL-6), TPA or bryostatin markedly elevated the number of colonies formed from the GM-CFC.	Tetradecanoylphorbol Acetate	125-128	colony stimulating factor 3	Homo sapiens	54-91
7679006-3	1993	However, in the presence of optimal concentrations of granulocyte colony-stimulating factor (G-CSF) or interleukin-6 (IL-6), TPA or bryostatin markedly elevated the number of colonies formed from the GM-CFC.	Tetradecanoylphorbol Acetate	125-128	colony stimulating factor 3	Homo sapiens	93-99
7678988-6	1993	The potency of the maximal effect on tyrosine phosphorylation was TNF &gt; GM-CSF &gt; G-CSF, whereas that on intracellular alkalinization was GM-CSF &gt; TNF &gt; G-CSF.	Tyrosine	37-45	colony stimulating factor 3	Homo sapiens	87-92
7678988-11	1993	These findings indicate that tyrosine phosphorylation and intracellular alkalinization are early events in human neutrophils stimulated by TNF, GM-CSF and G-CSF, and that these early events may, at least in part, mediate activation or priming of human neutrophils by these cytokines.	Tyrosine	29-37	colony stimulating factor 3	Homo sapiens	155-160
7685182-3	1993	A 4-day treatment of CY-treated mice with recombinant human G-CSF (rhG-CSF) increased resistance of CY-treated mice, together with the marked restoration of APC and TNF-alpha productions.	Cyclophosphamide	21-23	colony stimulating factor 3	Homo sapiens	60-65
7507289-5	1993	These findings suggest that long-term G-CSF therapy may be beneficial in patients with SAA who are not candidates for bone marrow transplantation.	saa	87-90	colony stimulating factor 3	Homo sapiens	38-43
7689779-1	1993	Because recombinant human granulocyte colony-stimulating factor (G-CSF) has been reported to increase the sensitivity of acute myelogenous leukemia (AML) blast cells to cytosine arabinoside (Ara-C) in vitro, we treated a patient with refractory AML with an Ara-C-based regimen in combination with G-CSF (G-CSF/Ara-C therapy).	Cytarabine	169-189	colony stimulating factor 3	Homo sapiens	26-63
7689779-1	1993	Because recombinant human granulocyte colony-stimulating factor (G-CSF) has been reported to increase the sensitivity of acute myelogenous leukemia (AML) blast cells to cytosine arabinoside (Ara-C) in vitro, we treated a patient with refractory AML with an Ara-C-based regimen in combination with G-CSF (G-CSF/Ara-C therapy).	Cytarabine	169-189	colony stimulating factor 3	Homo sapiens	65-70
7689779-1	1993	Because recombinant human granulocyte colony-stimulating factor (G-CSF) has been reported to increase the sensitivity of acute myelogenous leukemia (AML) blast cells to cytosine arabinoside (Ara-C) in vitro, we treated a patient with refractory AML with an Ara-C-based regimen in combination with G-CSF (G-CSF/Ara-C therapy).	Cytarabine	191-196	colony stimulating factor 3	Homo sapiens	26-63
7689779-1	1993	Because recombinant human granulocyte colony-stimulating factor (G-CSF) has been reported to increase the sensitivity of acute myelogenous leukemia (AML) blast cells to cytosine arabinoside (Ara-C) in vitro, we treated a patient with refractory AML with an Ara-C-based regimen in combination with G-CSF (G-CSF/Ara-C therapy).	Cytarabine	191-196	colony stimulating factor 3	Homo sapiens	65-70
7689779-1	1993	Because recombinant human granulocyte colony-stimulating factor (G-CSF) has been reported to increase the sensitivity of acute myelogenous leukemia (AML) blast cells to cytosine arabinoside (Ara-C) in vitro, we treated a patient with refractory AML with an Ara-C-based regimen in combination with G-CSF (G-CSF/Ara-C therapy).	Cytarabine	191-196	colony stimulating factor 3	Homo sapiens	297-302
7689779-1	1993	Because recombinant human granulocyte colony-stimulating factor (G-CSF) has been reported to increase the sensitivity of acute myelogenous leukemia (AML) blast cells to cytosine arabinoside (Ara-C) in vitro, we treated a patient with refractory AML with an Ara-C-based regimen in combination with G-CSF (G-CSF/Ara-C therapy).	Cytarabine	191-196	colony stimulating factor 3	Homo sapiens	297-302
7689779-1	1993	Because recombinant human granulocyte colony-stimulating factor (G-CSF) has been reported to increase the sensitivity of acute myelogenous leukemia (AML) blast cells to cytosine arabinoside (Ara-C) in vitro, we treated a patient with refractory AML with an Ara-C-based regimen in combination with G-CSF (G-CSF/Ara-C therapy).	Cytarabine	257-262	colony stimulating factor 3	Homo sapiens	26-63
7689779-1	1993	Because recombinant human granulocyte colony-stimulating factor (G-CSF) has been reported to increase the sensitivity of acute myelogenous leukemia (AML) blast cells to cytosine arabinoside (Ara-C) in vitro, we treated a patient with refractory AML with an Ara-C-based regimen in combination with G-CSF (G-CSF/Ara-C therapy).	Cytarabine	257-262	colony stimulating factor 3	Homo sapiens	65-70
7689779-1	1993	Because recombinant human granulocyte colony-stimulating factor (G-CSF) has been reported to increase the sensitivity of acute myelogenous leukemia (AML) blast cells to cytosine arabinoside (Ara-C) in vitro, we treated a patient with refractory AML with an Ara-C-based regimen in combination with G-CSF (G-CSF/Ara-C therapy).	Cytarabine	257-262	colony stimulating factor 3	Homo sapiens	26-63
7689779-1	1993	Because recombinant human granulocyte colony-stimulating factor (G-CSF) has been reported to increase the sensitivity of acute myelogenous leukemia (AML) blast cells to cytosine arabinoside (Ara-C) in vitro, we treated a patient with refractory AML with an Ara-C-based regimen in combination with G-CSF (G-CSF/Ara-C therapy).	Cytarabine	257-262	colony stimulating factor 3	Homo sapiens	65-70
7689779-4	1993	In vitro studies using 3H-thymidine uptake and dual parameter flow-cytometric analysis of DNA and proliferating cell nuclear antigen showed that leukemic blast cells in S phase were increased after incubation with G-CSF.	3h-thymidine	23-35	colony stimulating factor 3	Homo sapiens	214-219
7685182-3	1993	A 4-day treatment of CY-treated mice with recombinant human G-CSF (rhG-CSF) increased resistance of CY-treated mice, together with the marked restoration of APC and TNF-alpha productions.	Cyclophosphamide	100-102	colony stimulating factor 3	Homo sapiens	60-65
7691114-9	1993	We conclude that when prophylactic G-CSF is initiated at WHO grade IV leukopenia, addition of an oral quinolone reduces the risk of infection.	Quinolones	102-111	colony stimulating factor 3	Homo sapiens	35-40
7691117-8	1993	These results would indicate the usefulness of a phase II study with epirubicin at the dose of 90 mg/m2 in association with conventional dose of vinorelbine with the support of G-CSF in advanced NSCLC.	Epirubicin	69-79	colony stimulating factor 3	Homo sapiens	177-182
7691117-8	1993	These results would indicate the usefulness of a phase II study with epirubicin at the dose of 90 mg/m2 in association with conventional dose of vinorelbine with the support of G-CSF in advanced NSCLC.	Vinorelbine	145-156	colony stimulating factor 3	Homo sapiens	177-182
7683227-0	1993	Effect of hemopoietic growth factors G-CSF and pIXY 321 on the activity of high dose Ara-C in human myeloid leukemia cells.	Cytarabine	85-90	colony stimulating factor 3	Homo sapiens	37-42
7517152-7	1993	Taxol dose escalation with granulocyte-colony stimulating factor support, and Taxol in combination with cisplatin, have been tested and shown to be feasible.	Paclitaxel	0-5	colony stimulating factor 3	Homo sapiens	27-64
7517154-9	1993	The combination of doxorubicin and Taxol by 72-hour continuous infusion with G-CSF is an active regimen in patients with metastatic breast cancer.	Doxorubicin	19-30	colony stimulating factor 3	Homo sapiens	77-82
8385969-1	1993	This study was aimed at preventing of chemotherapy-induced neutropenia and improving the therapeutic result by reducing the cycle length of cisplatin (25 mg/m2/day, 5-day continuous infusion) and vindesine (3 mg/m2, bolus, days 1 and 8) (PiV) through the use of recombinant human granulocyte colony-stimulating factor (rG-CSF) (2-5 micrograms/kg/day, subcutaneous, days 6-21) for non-small cell lung carcinoma (NSCLC).	Cisplatin	140-149	colony stimulating factor 3	Homo sapiens	280-317
7509672-0	1993	Propylthiouracil (PTU)-induced agranulocytosis treated with recombinant human granulocyte colony-stimulating factor (G-CSF).	Propylthiouracil	0-16	colony stimulating factor 3	Homo sapiens	78-115
7509672-0	1993	Propylthiouracil (PTU)-induced agranulocytosis treated with recombinant human granulocyte colony-stimulating factor (G-CSF).	Propylthiouracil	0-16	colony stimulating factor 3	Homo sapiens	117-122
7509672-0	1993	Propylthiouracil (PTU)-induced agranulocytosis treated with recombinant human granulocyte colony-stimulating factor (G-CSF).	Propylthiouracil	18-21	colony stimulating factor 3	Homo sapiens	78-115
7509672-0	1993	Propylthiouracil (PTU)-induced agranulocytosis treated with recombinant human granulocyte colony-stimulating factor (G-CSF).	Propylthiouracil	18-21	colony stimulating factor 3	Homo sapiens	117-122
7509672-8	1993	The first patient received 300 micrograms of G-CSF on days 2 and 4 after discontinuing PTU with the appearance of 4.7 x 10(9)/L granulocytes and granulocyte precursors on day 4.	Propylthiouracil	87-90	colony stimulating factor 3	Homo sapiens	45-50
1281794-1	1992	Recombinant 15N-, 13C-labeled human granulocyte colony-stimulating factor (rh-metG-CSF) has been studied by 2D and 3D NMR using uniformly labeled protein as well as residue-specific 15N-labeled samples.	15n	12-15	colony stimulating factor 3	Homo sapiens	36-73
7505076-3	1993	In two previously untreated patients the administration of G-CSF following chemotherapy according to the UVA protocol (ultralan, vincristine, adriamycin) greatly increased circulating haematopoietic stem cells from 247 to 7552 CFU-GM/ml in patient 1 and from 173 to 6361 CFU-GM/ml in patient 2, which by far exceeded the increase in progenitor cells following chemotherapy alone, namely only to 594 and 317 CFU-GM/ml in patient 1 and patient 2, respectively.	Fluocortolone	119-127	colony stimulating factor 3	Homo sapiens	59-64
7505076-3	1993	In two previously untreated patients the administration of G-CSF following chemotherapy according to the UVA protocol (ultralan, vincristine, adriamycin) greatly increased circulating haematopoietic stem cells from 247 to 7552 CFU-GM/ml in patient 1 and from 173 to 6361 CFU-GM/ml in patient 2, which by far exceeded the increase in progenitor cells following chemotherapy alone, namely only to 594 and 317 CFU-GM/ml in patient 1 and patient 2, respectively.	Vincristine	129-140	colony stimulating factor 3	Homo sapiens	59-64
7505076-3	1993	In two previously untreated patients the administration of G-CSF following chemotherapy according to the UVA protocol (ultralan, vincristine, adriamycin) greatly increased circulating haematopoietic stem cells from 247 to 7552 CFU-GM/ml in patient 1 and from 173 to 6361 CFU-GM/ml in patient 2, which by far exceeded the increase in progenitor cells following chemotherapy alone, namely only to 594 and 317 CFU-GM/ml in patient 1 and patient 2, respectively.	Doxorubicin	142-152	colony stimulating factor 3	Homo sapiens	59-64
7505076-6	1993	In both cases, however, mobilization of haematopoietic progenitor cells by G-CSF following cyclophosphamide (50 and 70 mg/kg body weight, respectively) led to much higher CFU-GM peak values (5324 in patient 3 and 2245 in patient 4), thus allowing an adequate harvest of mononuclear cells and CD 34+ cell numbers to achieve, in all probability, the prompt and complete reconstitution of haematopoiesis in case of transplantation.	Cyclophosphamide	91-107	colony stimulating factor 3	Homo sapiens	75-80
1281794-1	1992	Recombinant 15N-, 13C-labeled human granulocyte colony-stimulating factor (rh-metG-CSF) has been studied by 2D and 3D NMR using uniformly labeled protein as well as residue-specific 15N-labeled samples.	13c	18-21	colony stimulating factor 3	Homo sapiens	36-73
1280478-6	1992	Enhanced G-CSF mRNA levels were observed when SMC were treated with cycloheximide in the absence or presence of added cytokine.	Cycloheximide	68-81	colony stimulating factor 3	Homo sapiens	9-14
1280674-0	1992	Granulocyte-macrophage colony-stimulating factor or granulocyte colony-stimulating factor infusion makes high-dose etoposide a safe outpatient regimen that is effective in lymphoma and myeloma patients.	Etoposide	115-124	colony stimulating factor 3	Homo sapiens	52-89
1384952-0	1992	Acute arterial thrombosis after escalated-dose methotrexate, vinblastine, doxorubicin, and cisplatin chemotherapy with recombinant granulocyte colony-stimulating factor.	Cisplatin	91-100	colony stimulating factor 3	Homo sapiens	131-168
1284233-1	1992	Receptor-mediated superoxide (O2.-)-generation and tyrosyl phosphorylation of neutrophil proteins, such as 58, 65, 84, 108 and 115 kDa, were enhanced by priming cells with granulocyte colony stimulating factor (G-CSF) [Akimura, K. et al.	Superoxides	18-28	colony stimulating factor 3	Homo sapiens	172-209
1284233-1	1992	Receptor-mediated superoxide (O2.-)-generation and tyrosyl phosphorylation of neutrophil proteins, such as 58, 65, 84, 108 and 115 kDa, were enhanced by priming cells with granulocyte colony stimulating factor (G-CSF) [Akimura, K. et al.	Superoxides	18-28	colony stimulating factor 3	Homo sapiens	211-216
1284233-1	1992	Receptor-mediated superoxide (O2.-)-generation and tyrosyl phosphorylation of neutrophil proteins, such as 58, 65, 84, 108 and 115 kDa, were enhanced by priming cells with granulocyte colony stimulating factor (G-CSF) [Akimura, K. et al.	Superoxides	30-32	colony stimulating factor 3	Homo sapiens	172-209
1284233-1	1992	Receptor-mediated superoxide (O2.-)-generation and tyrosyl phosphorylation of neutrophil proteins, such as 58, 65, 84, 108 and 115 kDa, were enhanced by priming cells with granulocyte colony stimulating factor (G-CSF) [Akimura, K. et al.	Superoxides	30-32	colony stimulating factor 3	Homo sapiens	211-216
1284233-1	1992	Receptor-mediated superoxide (O2.-)-generation and tyrosyl phosphorylation of neutrophil proteins, such as 58, 65, 84, 108 and 115 kDa, were enhanced by priming cells with granulocyte colony stimulating factor (G-CSF) [Akimura, K. et al.	cyclo(tyrosyl-tyrosyl)	51-58	colony stimulating factor 3	Homo sapiens	172-209
1284233-7	1992	Both enhancement of formyl-methionyl-leucyl- phenylalanine (FMLP)-mediated O2.- generation and tyrosyl phosphorylation of some neutrophil proteins, i.e., 115, 108 and 84 kDa proteins, by HHPMN after treatment with G-CSF were strongly inhibited by cepharanthine in a concentration- and treatment-time-dependent manner.	N-Formylmethionine Leucyl-Phenylalanine	60-64	colony stimulating factor 3	Homo sapiens	214-219
1284233-9	1992	These results suggest that cepharanthine might inhibit the priming step of neutrophil activation concomitantly with its inhibition of the tyrosyl phosphorylation of some neutrophil proteins that might underlie the mechanism for priming of neutrophils with G-CSF.	cepharanthine	27-40	colony stimulating factor 3	Homo sapiens	256-261
1384435-0	1992	Role of tyrosyl phosphorylation in neutrophil priming by tumor necrosis factor-alpha and granulocyte colony stimulating factor.	cyclo(tyrosyl-tyrosyl)	8-15	colony stimulating factor 3	Homo sapiens	89-126
1280241-2	1992	A set of 30-mer oligodeoxyribonucleotides (oligos) scanning the GPE3 region (-104 to -51) of the G-CSF promoter was synthesized, and the tetramer of each oligo was inserted upstream from the cat gene with the simian virus 40 enhancer element.	Oligodeoxyribonucleotides	16-41	colony stimulating factor 3	Homo sapiens	97-102
1384435-6	1992	Similar inhibition by the TK inhibitors and stimulation by the PKC inhibitors were also observed with formylmethionyl-leucyl-phenylalanine (FMLP)-induced superoxide (O2.-) generation by TNF-alpha- or G-CSF-primed PMN.	N-Formylmethionine Leucyl-Phenylalanine	102-138	colony stimulating factor 3	Homo sapiens	200-205
1384435-6	1992	Similar inhibition by the TK inhibitors and stimulation by the PKC inhibitors were also observed with formylmethionyl-leucyl-phenylalanine (FMLP)-induced superoxide (O2.-) generation by TNF-alpha- or G-CSF-primed PMN.	N-Formylmethionine Leucyl-Phenylalanine	140-144	colony stimulating factor 3	Homo sapiens	200-205
1384435-6	1992	Similar inhibition by the TK inhibitors and stimulation by the PKC inhibitors were also observed with formylmethionyl-leucyl-phenylalanine (FMLP)-induced superoxide (O2.-) generation by TNF-alpha- or G-CSF-primed PMN.	Superoxides	154-164	colony stimulating factor 3	Homo sapiens	200-205
1384435-1	1992	The ability of human tumor necrosis factor-alpha (TNF-alpha) and human granulocyte colony stimulating factor (G-CSF) to induce phosphorylation of protein tyrosyl residues in human peripheral neutrophils (PMN) was investigated by Western blot analysis with antiphosphotyrosine antibody.	cyclo(tyrosyl-tyrosyl)	154-161	colony stimulating factor 3	Homo sapiens	71-108
1384435-6	1992	Similar inhibition by the TK inhibitors and stimulation by the PKC inhibitors were also observed with formylmethionyl-leucyl-phenylalanine (FMLP)-induced superoxide (O2.-) generation by TNF-alpha- or G-CSF-primed PMN.	Superoxides	166-168	colony stimulating factor 3	Homo sapiens	200-205
1384435-1	1992	The ability of human tumor necrosis factor-alpha (TNF-alpha) and human granulocyte colony stimulating factor (G-CSF) to induce phosphorylation of protein tyrosyl residues in human peripheral neutrophils (PMN) was investigated by Western blot analysis with antiphosphotyrosine antibody.	cyclo(tyrosyl-tyrosyl)	154-161	colony stimulating factor 3	Homo sapiens	110-115
1384435-9	1992	This is the first report describing that tyrosyl phosphorylation is involved in the priming of neutrophils by G-CSF and TNF-alpha.	cyclo(tyrosyl-tyrosyl)	41-48	colony stimulating factor 3	Homo sapiens	110-115
1384435-2	1992	Both TNF-alpha and G-CSF increased the tyrosyl phosphorylation of various proteins, such as species of 54-, 63-, 72-, 83-, 98-, 108-, and 115-kDa proteins.	cyclo(tyrosyl-tyrosyl)	39-46	colony stimulating factor 3	Homo sapiens	19-24
1281810-9	1992	G-CSF plays an important role in the treatment of patients with HIV-associated Kaposi sarcoma and enables combined treatment with zidovudine, interferon, and cytostatic drugs.	Zidovudine	130-140	colony stimulating factor 3	Homo sapiens	0-5
1283080-5	1992	After chemotherapy followed by ABMT, mouthrinse neutrophil levels decreased to undetectable levels during the neutropenic period, but recovered 1-2 and 3-9 d before circulating neutrophil levels reached 0.1 and 1 x 10(9)/l respectively, whether or not patients received G-CSF.	abmt	31-35	colony stimulating factor 3	Homo sapiens	270-275
1383662-0	1992	Granulocyte colony-stimulating factor for clozapine-induced agranulocytosis.	Clozapine	42-51	colony stimulating factor 3	Homo sapiens	0-37
1284910-4	1992	1) Flow cytometric method on G-CSF susceptibility of leukemia cells using FITC-labeled G-CSF, and 2) Immunohistochemical method for detecting the ratio of cells driven from dormant phase to proliferative phase by G-CSF with anti-PCNA antibody and Ki-67 antibody.	Fluorescein-5-isothiocyanate	74-78	colony stimulating factor 3	Homo sapiens	87-99
1284910-4	1992	1) Flow cytometric method on G-CSF susceptibility of leukemia cells using FITC-labeled G-CSF, and 2) Immunohistochemical method for detecting the ratio of cells driven from dormant phase to proliferative phase by G-CSF with anti-PCNA antibody and Ki-67 antibody.	Fluorescein-5-isothiocyanate	74-78	colony stimulating factor 3	Homo sapiens	87-92
1284910-6	1992	The patients treated with cytosine arabinoside following G-CSF showed hematologically good improvement.	Cytarabine	26-46	colony stimulating factor 3	Homo sapiens	57-62
1279140-0	1992	Diffuse thallium-201-chloride uptake in hypermetabolic bone marrow following treatment with granulocyte stimulating factor.	thallium chloride	8-29	colony stimulating factor 3	Homo sapiens	92-122
1279153-2	1992	We evaluated the effect of subcutaneously administered granulocyte colony-stimulating factor (G-CSF) in pediatric patients whose absolute neutrophil count was less than 0.8 x 10(9)/L during AZT therapy despite dosage reductions to 120 mg/m2 every 6 hours.	Zidovudine	190-193	colony stimulating factor 3	Homo sapiens	94-99
1279153-9	1992	With doses of G-CSF ranging from 1 to 20 micrograms/kg per day, 17 of 19 patients were able to tolerate AZT at a dose of 120 to 180 mg/m2 every 6 hours.	Zidovudine	104-107	colony stimulating factor 3	Homo sapiens	14-19
1279153-10	1992	We conclude that G-CSF therapy enables patients who have had AZT-related neutropenia to receive therapeutic doses of AZT.	Zidovudine	61-64	colony stimulating factor 3	Homo sapiens	17-22
1279153-10	1992	We conclude that G-CSF therapy enables patients who have had AZT-related neutropenia to receive therapeutic doses of AZT.	Zidovudine	117-120	colony stimulating factor 3	Homo sapiens	17-22
1281122-0	1992	[Change in serum G-CSF levels in patients with Graves" disease by treatment with methimazole].	Methimazole	81-92	colony stimulating factor 3	Homo sapiens	17-22
1281122-1	1992	We evaluated the determination of serum G-CSF in the diagnosis of granulocytopenia due to methimazole (MMI) in 54 patients with Graves" disease, while they were being treated with MMI, by way of measuring WBC counts and serum levels of G-CSF, thyroid hormones, IgE, and interleukin-2.	Methimazole	90-101	colony stimulating factor 3	Homo sapiens	40-45
1384722-5	1992	A second allo BMT, accelerating granulocyte recovery by recombinant human granulocyte colony-stimulating factor (rhG-CSF), was successfully performed and the fungal liver abscess resolved with a combination therapy of fluconazole and amphotericin B.	Fluconazole	218-229	colony stimulating factor 3	Homo sapiens	74-111
1384722-5	1992	A second allo BMT, accelerating granulocyte recovery by recombinant human granulocyte colony-stimulating factor (rhG-CSF), was successfully performed and the fungal liver abscess resolved with a combination therapy of fluconazole and amphotericin B.	Amphotericin B	234-248	colony stimulating factor 3	Homo sapiens	74-111
1382703-8	1992	Cyclosporine A decreased cell multiplication in M1 cells without inducing apoptosis, and G-CSF and IL-6 inhibited the cytostatic effect of cyclosporine A.	Cyclosporine	139-153	colony stimulating factor 3	Homo sapiens	89-94
1381569-7	1992	MACOP-B regimen with G-CSF may be used for patients under age 65.	macop-b	0-7	colony stimulating factor 3	Homo sapiens	21-26
1383642-1	1992	In vitro preincubation with recombinant granulocyte colony-stimulating factor(rhG-CSF, 100 ng/ml) enhanced the cytotoxicity of 1-beta-D-arabinofuranosylcytosine(Ara-C) in leukemic cells resistant to Ara-C from a patient with biphenotypic leukemia.	Cytarabine	127-160	colony stimulating factor 3	Homo sapiens	40-85
1383642-1	1992	In vitro preincubation with recombinant granulocyte colony-stimulating factor(rhG-CSF, 100 ng/ml) enhanced the cytotoxicity of 1-beta-D-arabinofuranosylcytosine(Ara-C) in leukemic cells resistant to Ara-C from a patient with biphenotypic leukemia.	Cytarabine	161-166	colony stimulating factor 3	Homo sapiens	40-85
1383642-1	1992	In vitro preincubation with recombinant granulocyte colony-stimulating factor(rhG-CSF, 100 ng/ml) enhanced the cytotoxicity of 1-beta-D-arabinofuranosylcytosine(Ara-C) in leukemic cells resistant to Ara-C from a patient with biphenotypic leukemia.	Cytarabine	199-204	colony stimulating factor 3	Homo sapiens	40-85
1384497-9	1992	by G-CSF was inhibited by genistein or alpha-cyano-3-ethoxy-4-hydroxy-5-phenylthiomethylcinnamamide (ST 638), inhibitors of tyrosine kinase (TK), and was stimulated by staurosporine and 1-(5-isoquinolinesulfonyl)-3-methyl-piperazine (H-7), inhibitors of PKC.	Genistein	26-35	colony stimulating factor 3	Homo sapiens	3-8
1384497-9	1992	by G-CSF was inhibited by genistein or alpha-cyano-3-ethoxy-4-hydroxy-5-phenylthiomethylcinnamamide (ST 638), inhibitors of tyrosine kinase (TK), and was stimulated by staurosporine and 1-(5-isoquinolinesulfonyl)-3-methyl-piperazine (H-7), inhibitors of PKC.	ST 638	39-99	colony stimulating factor 3	Homo sapiens	3-8
1384497-9	1992	by G-CSF was inhibited by genistein or alpha-cyano-3-ethoxy-4-hydroxy-5-phenylthiomethylcinnamamide (ST 638), inhibitors of tyrosine kinase (TK), and was stimulated by staurosporine and 1-(5-isoquinolinesulfonyl)-3-methyl-piperazine (H-7), inhibitors of PKC.	Staurosporine	168-181	colony stimulating factor 3	Homo sapiens	3-8
1384497-9	1992	by G-CSF was inhibited by genistein or alpha-cyano-3-ethoxy-4-hydroxy-5-phenylthiomethylcinnamamide (ST 638), inhibitors of tyrosine kinase (TK), and was stimulated by staurosporine and 1-(5-isoquinolinesulfonyl)-3-methyl-piperazine (H-7), inhibitors of PKC.	1-(5-isoquinolinylsulfonyl)-3-methylpiperazine	186-232	colony stimulating factor 3	Homo sapiens	3-8
1384497-9	1992	by G-CSF was inhibited by genistein or alpha-cyano-3-ethoxy-4-hydroxy-5-phenylthiomethylcinnamamide (ST 638), inhibitors of tyrosine kinase (TK), and was stimulated by staurosporine and 1-(5-isoquinolinesulfonyl)-3-methyl-piperazine (H-7), inhibitors of PKC.	1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine	234-237	colony stimulating factor 3	Homo sapiens	3-8
1384817-0	1992	Use of granulocyte colony-stimulating factor in the treatment of pancytopenia secondary to colchicine overdose.	Colchicine	91-101	colony stimulating factor 3	Homo sapiens	7-44
1384817-6	1992	The use of G-CSF appears to be beneficial in alleviating bone marrow depression in colchicine overdose situations.	Colchicine	83-93	colony stimulating factor 3	Homo sapiens	11-16
1280628-1	1992	A comparison with recombinant human granulocyte colony-stimulating factor in 5-fluorouracil-treated mice.	Fluorouracil	77-91	colony stimulating factor 3	Homo sapiens	36-73
1280628-2	1992	The effect of a novel synthetic compound, Y-25510, (+-)-3-[4-(2-dimethylamino-1-methylethoxy)phenyl]-1H-pyrazolo[3,4 -b] pyridine-1-acetic acid, on recovery from long-lasting leukopenia induced by 5-fluorouracil was compared with that of recombinant human granulocyte colony-stimulating factor (rhG-CSF).	Y 25510	42-49	colony stimulating factor 3	Homo sapiens	256-293
1384497-6	1992	FMLP-dependent luminol chemiluminescence was also enhanced by G-CSF.	Luminol	15-22	colony stimulating factor 3	Homo sapiens	62-67
1381569-9	1992	In elderly AML patients over 60, the dose-adjustment reported by Mori, or low-dose cytarabine with G-CSF, is recommended.	Cytarabine	83-93	colony stimulating factor 3	Homo sapiens	99-104
1383133-3	1992	Both IL-4 (&gt; or = 10 pM) and the glucocorticoid, dexamethasone (10(-7) M), inhibited G-CSF production in the LPS-treated monocytes; in contrast, IFN-gamma had a weak potentiating effect on the LPS action.	Dexamethasone	52-65	colony stimulating factor 3	Homo sapiens	88-93
1379083-0	1992	Specific repression of granulocyte-macrophage and granulocyte colony-stimulating factor gene expression in interleukin-1-stimulated endothelial cells with antisense oligodeoxynucleotides.	Oligodeoxyribonucleotides	165-186	colony stimulating factor 3	Homo sapiens	50-87
1391803-3	1992	On the other hand, the Ara-C- and DNR-mediated cytotoxicity of CFU-AML was not abrogated by CSF in any instance, but rather, it was significantly enhanced by all the CSF in the majority of instances.	Cytarabine	23-28	colony stimulating factor 3	Homo sapiens	166-169
1391803-5	1992	Under the same culture conditions as those for CFU-AML, all of the CSF significantly enhanced the Ara-C-mediated cytotoxicity of day 7 normal CFU-GM, although to a lesser extent than in CFU-AML.	Cytarabine	98-103	colony stimulating factor 3	Homo sapiens	67-70
1382400-0	1992	[Role of polymorphonuclear leukocytes (PMN) and active oxygen species in hyperthermia--enhancing effect of G-CSF on superoxide generation from PMN].	Superoxides	116-126	colony stimulating factor 3	Homo sapiens	107-112
1382400-1	1992	We examined in vitro the effect of G-CSF and temperature on superoxide (O2-) generation by Cypridina luciferin analog (CLA) dependent chemiluminescence.	Superoxides	60-70	colony stimulating factor 3	Homo sapiens	35-40
1382400-1	1992	We examined in vitro the effect of G-CSF and temperature on superoxide (O2-) generation by Cypridina luciferin analog (CLA) dependent chemiluminescence.	Oxygen	72-74	colony stimulating factor 3	Homo sapiens	35-40
1382400-2	1992	PMN significantly generated O2- at the concentration of G-CSF 25 ng/ml or more at 37 degrees C within the range of 0.1 from 1,000 ng/ml.	Oxygen	28-30	colony stimulating factor 3	Homo sapiens	56-61
1382400-3	1992	O2- generation from PMN was remarkably enhanced, stimulated by opsonized zymosan (OZ) and phorbol myristate acetate (PMA), at 41 degrees C as compared with 37 degrees C. O2- generation was enhanced with the addition of 25 ng/ml of G-CSF at 41 degrees C as compared to without it at 41 degrees C. A significant enhancement of O2- generation from PMN was observed at 25 ng/ml G-CSF and 41 degrees C.	Oxygen	0-2	colony stimulating factor 3	Homo sapiens	231-236
1382400-3	1992	O2- generation from PMN was remarkably enhanced, stimulated by opsonized zymosan (OZ) and phorbol myristate acetate (PMA), at 41 degrees C as compared with 37 degrees C. O2- generation was enhanced with the addition of 25 ng/ml of G-CSF at 41 degrees C as compared to without it at 41 degrees C. A significant enhancement of O2- generation from PMN was observed at 25 ng/ml G-CSF and 41 degrees C.	Oxygen	0-2	colony stimulating factor 3	Homo sapiens	374-379
1374379-10	1992	Recombinant human granulocyte colony stimulating factor lacking either disulfide bond or both has overall secondary and tertiary structures different from those of the wild type molecule and exhibits lower biological activity.	Disulfides	71-80	colony stimulating factor 3	Homo sapiens	18-55
1376773-4	1992	G-CSF was given as a daily subcutaneous injection that started 24 hours after the completion of the taxol infusion.	Paclitaxel	100-105	colony stimulating factor 3	Homo sapiens	0-5
1376773-11	1992	CONCLUSION: Taxol can be safely administered in doses up to 250 mg/m2 with G-CSF support, which may make it possible to study taxol dose intensification.	Paclitaxel	12-17	colony stimulating factor 3	Homo sapiens	75-80
1376773-11	1992	CONCLUSION: Taxol can be safely administered in doses up to 250 mg/m2 with G-CSF support, which may make it possible to study taxol dose intensification.	Paclitaxel	126-131	colony stimulating factor 3	Homo sapiens	75-80
1625212-5	1992	From these results, it is concluded that the O-linked sugar chain of hG-CSF does not contribute to the in vitro and in vivo biological activities.	Sugars	54-59	colony stimulating factor 3	Homo sapiens	69-75
1375845-6	1992	Proliferation of AA cells cultured in a liquid medium containing SCF together with Epo, IL-3, GM-CSF, and G-CSF approached 70% of the control level, as measured by 3H-thymidine incorporation.	Tritium	164-166	colony stimulating factor 3	Homo sapiens	106-111
1380256-9	1992	When erythropoietin was added to the regimen, combined G-CSF and EPO corrected both anemia and leukopenia and lessened subsequent zidovudine toxicity.	Zidovudine	130-140	colony stimulating factor 3	Homo sapiens	55-60
1379475-6	1992	However, the second phase of aggregation induced by epinephrine was significantly inhibited by 1.0 ng/ml G-CSF.	Epinephrine	52-63	colony stimulating factor 3	Homo sapiens	105-110
1378162-5	1992	However, SCF potentiated the stimulatory effect of GM-CSF, G-CSF, and IL-3 on both 3H-TdR incorporation and colony formation.	Tritium	83-85	colony stimulating factor 3	Homo sapiens	59-64
1381342-0	1992	Granulocyte-colony-stimulating factor enhances the circulating hematopoietic progenitors in lung cancer patients treated with cisplatin-containing regimens.	Cisplatin	126-135	colony stimulating factor 3	Homo sapiens	0-37
1379521-0	1992	Chemical modification of recombinant human granulocyte colony-stimulating factor by polyethylene glycol increases its biological activity in vivo.	Polyethylene Glycols	84-103	colony stimulating factor 3	Homo sapiens	43-80
1379521-1	1992	Recombinant human granulocyte colony-stimulating factor (rHuG-CSF) produced in Escherichia coli was chemically modified by polyethylene glycol (PEG) of molecular weights 4,500 or 10,000.	Polyethylene Glycols	123-142	colony stimulating factor 3	Homo sapiens	18-55
1379521-1	1992	Recombinant human granulocyte colony-stimulating factor (rHuG-CSF) produced in Escherichia coli was chemically modified by polyethylene glycol (PEG) of molecular weights 4,500 or 10,000.	Polyethylene Glycols	144-147	colony stimulating factor 3	Homo sapiens	18-55
1377475-0	1992	Ganciclovir with recombinant methionyl human granulocyte colony-stimulating factor for treatment of cytomegalovirus disease in AIDS patients.	Ganciclovir	0-11	colony stimulating factor 3	Homo sapiens	45-82
1375008-7	1992	G-CSF-treated animals showed attenuated responses in peripheral leukopenia, excess lung water, and albumin leakage in comparison with the endotoxin-alone group.	Water	88-93	colony stimulating factor 3	Homo sapiens	0-5
1381566-8	1992	Recombinant human granulocyte colony-stimulating factor preparations contain a very low to undetectable level of the formylmethionine isoform and have no detectable deamidated isoforms.	N-Formylmethionine	117-133	colony stimulating factor 3	Homo sapiens	18-55
1623058-8	1992	In vitro studies showed that famotidine, depending on the dose, inhibits the single growth factor-dependent colony growth (IL-3, GM-CSF, or G-CSF) of bone marrow progenitors from a concentration as low as 10 micrograms/ml.	Famotidine	29-39	colony stimulating factor 3	Homo sapiens	140-145
1381617-2	1992	We have used this reaction to construct analogues of human granulocyte colony stimulating factor (G-CSF) by allowing such oxidized peptides to react with others that have had a hydrazide derivative attached to the C-terminus by reversed proteolysis.	Isoniazid	177-186	colony stimulating factor 3	Homo sapiens	59-96
1381617-2	1992	We have used this reaction to construct analogues of human granulocyte colony stimulating factor (G-CSF) by allowing such oxidized peptides to react with others that have had a hydrazide derivative attached to the C-terminus by reversed proteolysis.	Isoniazid	177-186	colony stimulating factor 3	Homo sapiens	98-103
1375132-0	1992	The substitution of cysteine 17 of recombinant human G-CSF with alanine greatly enhanced its stability.	Cysteine	20-28	colony stimulating factor 3	Homo sapiens	53-58
1373969-10	1992	This study demonstrates that neutropenia due to a single dose of mechloroethamine can be equally reduced with both early and delayed initiation of G-CSF.	Mechlorethamine	65-81	colony stimulating factor 3	Homo sapiens	147-152
1385275-0	1992	Efficacy of granulocyte colony-stimulating factor (G-CSF) on neutropenia in zidovudine-treated patients with AIDS and ARC: a preliminary report.	Zidovudine	76-86	colony stimulating factor 3	Homo sapiens	12-49
1385275-0	1992	Efficacy of granulocyte colony-stimulating factor (G-CSF) on neutropenia in zidovudine-treated patients with AIDS and ARC: a preliminary report.	Zidovudine	76-86	colony stimulating factor 3	Homo sapiens	51-56
1312809-2	1992	When HPPMN were exposed to recombinant human tumor necrosis factor alpha (rHuTNF-alpha) or recombinant human granulocyte colony stimulating factor (rG-CSF), they underwent priming and the rate of superoxide anion (O.-2) generation was increased by subsequent exposure to formyl-methionyl-leucyl-phenylalanine (FMLP) or opsonized zymosan (OZ).	Superoxides	196-212	colony stimulating factor 3	Homo sapiens	109-146
1312809-2	1992	When HPPMN were exposed to recombinant human tumor necrosis factor alpha (rHuTNF-alpha) or recombinant human granulocyte colony stimulating factor (rG-CSF), they underwent priming and the rate of superoxide anion (O.-2) generation was increased by subsequent exposure to formyl-methionyl-leucyl-phenylalanine (FMLP) or opsonized zymosan (OZ).	Zymosan	329-336	colony stimulating factor 3	Homo sapiens	109-146
1374635-0	1992	Successful treatment of clozapine induced agranulocytosis with granulocyte-colony stimulating factor (G-CSF).	Clozapine	24-33	colony stimulating factor 3	Homo sapiens	63-100
1374635-0	1992	Successful treatment of clozapine induced agranulocytosis with granulocyte-colony stimulating factor (G-CSF).	Clozapine	24-33	colony stimulating factor 3	Homo sapiens	102-107
1375670-0	1992	[In-vivo enhancement of neutrophil function by administration of recombinant human granulocyte colony-stimulating factor (rhG-CSF) in cyclophosphamide (CPA) treated mice].	Cyclophosphamide	134-150	colony stimulating factor 3	Homo sapiens	83-120
1375670-0	1992	[In-vivo enhancement of neutrophil function by administration of recombinant human granulocyte colony-stimulating factor (rhG-CSF) in cyclophosphamide (CPA) treated mice].	Cyclophosphamide	152-155	colony stimulating factor 3	Homo sapiens	83-120
1373232-3	1992	MC and monocytes from adult and neonatal subjects produced mRNA for GM-CSF, G-CSF, and M-CSF, whereas T cells produced only GM-CSF mRNA.	Methylcholanthrene	0-2	colony stimulating factor 3	Homo sapiens	76-81
1373232-6	1992	Neonatal MC also accumulated similar amounts of G-CSF mRNA and somewhat more M-CSF mRNA than did adult MC; results with monocytes were similar to those with MC.	Methylcholanthrene	9-11	colony stimulating factor 3	Homo sapiens	48-53
1373689-0	1992	Retinoic acid acts to neutralize the inhibitory effect of granulocyte-macrophage colony-stimulating factor (GM-CSF) on alkaline phosphatase activity of neutrophils that is induced by granulocyte colony-stimulating factor (G-CSF).	Tretinoin	0-13	colony stimulating factor 3	Homo sapiens	183-220
1373689-0	1992	Retinoic acid acts to neutralize the inhibitory effect of granulocyte-macrophage colony-stimulating factor (GM-CSF) on alkaline phosphatase activity of neutrophils that is induced by granulocyte colony-stimulating factor (G-CSF).	Tretinoin	0-13	colony stimulating factor 3	Homo sapiens	222-227
1372153-0	1992	Benefit of G-CSF for methotrexate-induced neutropenia in rheumatoid arthritis.	Methotrexate	21-33	colony stimulating factor 3	Homo sapiens	11-16
1373684-0	1992	Dexamethasone inhibits tumor necrosis factor-induced granulocyte colony-stimulating factor production in human endothelial cells.	Dexamethasone	0-13	colony stimulating factor 3	Homo sapiens	53-90
1373684-1	1992	Dexamethasone (10(-5)-10(-7) M) is able to suppress the tumor necrosis factor (TNF)-induced production of granulocyte colony-stimulating factor (G-CSF) in human umbilical vein endothelial cells (HUVEC).	Dexamethasone	0-13	colony stimulating factor 3	Homo sapiens	106-143
1373684-1	1992	Dexamethasone (10(-5)-10(-7) M) is able to suppress the tumor necrosis factor (TNF)-induced production of granulocyte colony-stimulating factor (G-CSF) in human umbilical vein endothelial cells (HUVEC).	Dexamethasone	0-13	colony stimulating factor 3	Homo sapiens	145-150
1373684-2	1992	Using Western-blot analysis and bioassay for the evaluation of G-CSF protein and activity, a significant decrease in TNF-induced production could be found in cells cultured in the presence of dexamethasone as compared to TNF stimulation in the absence of dexamethasone.	Dexamethasone	192-205	colony stimulating factor 3	Homo sapiens	63-68
1373684-5	1992	Suppression of G-CSF production can, at least in part, explain the functional abnormalities of granulocytes found in patients treated with glucocorticosteroids.	glucocorticosteroids	139-159	colony stimulating factor 3	Homo sapiens	15-20
1373232-2	1992	Because granulocyte-macrophage colony-stimulating factor (GM-CSF) and granulocyte colony-stimulating factor (G-CSF) play critical roles in the production of neutrophils from marrow precursors, we assessed the ability of leukocytes from neonates and adults to produce GM-CSF, G-CSF, and, for comparison, macrophage colony-stimulating factor (M-CSF) after stimulation with concanavalin A +/- phorbol myristate acetate [blood mononuclear cells (MC) and T lymphocytes] or lipopolysaccharide (monocytes).	Tetradecanoylphorbol Acetate	390-415	colony stimulating factor 3	Homo sapiens	109-114
1373232-2	1992	Because granulocyte-macrophage colony-stimulating factor (GM-CSF) and granulocyte colony-stimulating factor (G-CSF) play critical roles in the production of neutrophils from marrow precursors, we assessed the ability of leukocytes from neonates and adults to produce GM-CSF, G-CSF, and, for comparison, macrophage colony-stimulating factor (M-CSF) after stimulation with concanavalin A +/- phorbol myristate acetate [blood mononuclear cells (MC) and T lymphocytes] or lipopolysaccharide (monocytes).	Methylcholanthrene	442-444	colony stimulating factor 3	Homo sapiens	109-114
1375132-0	1992	The substitution of cysteine 17 of recombinant human G-CSF with alanine greatly enhanced its stability.	Alanine	64-71	colony stimulating factor 3	Homo sapiens	53-58
1375132-1	1992	Human recombinant granulocyte-colony stimulating factor (rhG-CSF) has one free cysteine at position 17 and has two disulfide bridges (Cys36-Cys42 and Cys64-Cys74).	Cysteine	79-87	colony stimulating factor 3	Homo sapiens	18-55
1375132-1	1992	Human recombinant granulocyte-colony stimulating factor (rhG-CSF) has one free cysteine at position 17 and has two disulfide bridges (Cys36-Cys42 and Cys64-Cys74).	Disulfides	115-124	colony stimulating factor 3	Homo sapiens	18-55
1280954-4	1992	At least three distinct elements, the CK-1 sequence, a decanucleotide present in haemopoietic growth factor genes, an NF-IL-6 consensus sequence and a consensus octamer sequence, were essential in the G-CSF promoter for TNF-alpha and IL-1 beta response.	decanucleotide	55-69	colony stimulating factor 3	Homo sapiens	201-206
1372669-6	1992	The combination of retinoic acid with interferon gamma was most effective in reducing CFU-L recovering (8 responsive/15 AML cases), G-CSF and M-CSF displayed either inhibitory or stimulatory activity in different AML cases.	Tretinoin	19-32	colony stimulating factor 3	Homo sapiens	132-137
1577097-5	1992	The increased CSA activity was mainly due to granulocyte colony-stimulating factor (G-CSF) as studied by the effects of neutralizing antibodies.	Cyclosporine	14-17	colony stimulating factor 3	Homo sapiens	45-82
1577097-5	1992	The increased CSA activity was mainly due to granulocyte colony-stimulating factor (G-CSF) as studied by the effects of neutralizing antibodies.	Cyclosporine	14-17	colony stimulating factor 3	Homo sapiens	84-89
1329215-7	1992	The first studies with hemopoietic growth factor support, eg, granulocyte colony-stimulating factor, conducted with combination chemotherapy with ifosfamide-containing regimens in SCLC, demonstrated significant reduction in neutropenia, infections, and antibiotic use.	Ifosfamide	146-156	colony stimulating factor 3	Homo sapiens	62-99
1281446-0	1992	The use of granulocyte colony-stimulating factor to shorten the interval between cycles of mitomycin C, vindesine, and cisplatin chemotherapy in non-small-cell lung cancer.	Mitomycin	91-102	colony stimulating factor 3	Homo sapiens	11-48
1281446-0	1992	The use of granulocyte colony-stimulating factor to shorten the interval between cycles of mitomycin C, vindesine, and cisplatin chemotherapy in non-small-cell lung cancer.	Vindesine	104-113	colony stimulating factor 3	Homo sapiens	11-48
1281446-0	1992	The use of granulocyte colony-stimulating factor to shorten the interval between cycles of mitomycin C, vindesine, and cisplatin chemotherapy in non-small-cell lung cancer.	Cisplatin	119-128	colony stimulating factor 3	Homo sapiens	11-48
1374341-5	1992	At higher concentrations He-PC displayed suppressive effects, most pronounced in the case of G-CSF-dependent colony growth.	miltefosine	25-30	colony stimulating factor 3	Homo sapiens	93-98
1384092-1	1992	Granulocyte colony-stimulating factor (G-CSF) was linked to NHS-biotin to yield biotinylated G-CSF (b-G-CSF), which retained the ability to stimulate colony formation by normal bone marrow (BM) cells in methylcellulose.	biotinyl N-hydroxysuccinimide ester	60-70	colony stimulating factor 3	Homo sapiens	0-37
1284302-0	1992	Structure of G-CSF: significance of the sugar chain.	Sugars	40-45	colony stimulating factor 3	Homo sapiens	13-18
1370331-3	1992	At 48 hours, 3H-thymidine uptake of both cells was significantly higher with G-CSF (one ng./ml., 10 ng./ml.)	3h-thymidine	13-25	colony stimulating factor 3	Homo sapiens	77-82
1370331-5	1992	The binding of 125I-labeled KW-2228, a muteins of G-CSF, to KU-1 and NBT-2 was inhibited by unlabeled KW-2228 in a dose-dependent manner.	Iodine-125	15-19	colony stimulating factor 3	Homo sapiens	50-55
1370331-5	1992	The binding of 125I-labeled KW-2228, a muteins of G-CSF, to KU-1 and NBT-2 was inhibited by unlabeled KW-2228 in a dose-dependent manner.	Nitroblue Tetrazolium	69-72	colony stimulating factor 3	Homo sapiens	50-55
1372056-4	1992	3H-thymidine uptake was markedly increased by the addition of GM-CSF in two cases, G-CSF in one, and IL-3 in two.	Tritium	0-2	colony stimulating factor 3	Homo sapiens	83-88
1372056-4	1992	3H-thymidine uptake was markedly increased by the addition of GM-CSF in two cases, G-CSF in one, and IL-3 in two.	Thymidine	3-12	colony stimulating factor 3	Homo sapiens	83-88
1279741-0	1992	Hexadecylphosphocholine amplifies the effect of granulocyte colony-stimulating factor on differentiating hematopoietic progenitor cells.	miltefosine	0-23	colony stimulating factor 3	Homo sapiens	48-85
1384092-1	1992	Granulocyte colony-stimulating factor (G-CSF) was linked to NHS-biotin to yield biotinylated G-CSF (b-G-CSF), which retained the ability to stimulate colony formation by normal bone marrow (BM) cells in methylcellulose.	biotinyl N-hydroxysuccinimide ester	60-70	colony stimulating factor 3	Homo sapiens	39-44
1384092-1	1992	Granulocyte colony-stimulating factor (G-CSF) was linked to NHS-biotin to yield biotinylated G-CSF (b-G-CSF), which retained the ability to stimulate colony formation by normal bone marrow (BM) cells in methylcellulose.	biotinyl N-hydroxysuccinimide ester	60-70	colony stimulating factor 3	Homo sapiens	93-98
1384092-1	1992	Granulocyte colony-stimulating factor (G-CSF) was linked to NHS-biotin to yield biotinylated G-CSF (b-G-CSF), which retained the ability to stimulate colony formation by normal bone marrow (BM) cells in methylcellulose.	biotinyl N-hydroxysuccinimide ester	60-70	colony stimulating factor 3	Homo sapiens	93-98
1720802-0	1991	Recombinant human G-CSF and GM-CSF prime human neutrophils for superoxide production through different signal transduction mechanisms.	Superoxides	63-73	colony stimulating factor 3	Homo sapiens	18-23
1720802-3	1991	G-CSF and GM-CSF alone stimulated neither superoxide production nor secretion, but both agents primed neutrophils for superoxide production stimulated by either N-formylmethionyl-leucyl-phenylalanine (FMLP) or ionomycin.	Superoxides	118-128	colony stimulating factor 3	Homo sapiens	0-5
1720802-3	1991	G-CSF and GM-CSF alone stimulated neither superoxide production nor secretion, but both agents primed neutrophils for superoxide production stimulated by either N-formylmethionyl-leucyl-phenylalanine (FMLP) or ionomycin.	N-Formylmethionine Leucyl-Phenylalanine	161-199	colony stimulating factor 3	Homo sapiens	0-5
1720802-6	1991	Conversely, G-CSF priming was inhibited by staurosporine but not by ST638.	Staurosporine	43-56	colony stimulating factor 3	Homo sapiens	12-17
1659327-2	1991	These high doses of ACNU were well tolerated if bone marrow rescue was performed and granulocyte colony stimulating factor was used.	Nimustine	20-24	colony stimulating factor 3	Homo sapiens	85-122
1726709-2	1991	IL-8-induced O2- release was potentiated by tumor necrosis factor (TNF), granulocyte-macrophage colony-stimulating factor (GM-CSF), and granulocyte-CSF (G-CSF) in a dose-dependent manner, whereas it was inhibited by cyclic AMP agonists.	Cyclic AMP	216-226	colony stimulating factor 3	Homo sapiens	136-151
1726709-2	1991	IL-8-induced O2- release was potentiated by tumor necrosis factor (TNF), granulocyte-macrophage colony-stimulating factor (GM-CSF), and granulocyte-CSF (G-CSF) in a dose-dependent manner, whereas it was inhibited by cyclic AMP agonists.	Cyclic AMP	216-226	colony stimulating factor 3	Homo sapiens	153-158
1719175-5	1991	The doses of G-CSF effectively enhanced and maintained that subpopulation of neutrophils which produced normal amounts of H2O2.	Hydrogen Peroxide	122-126	colony stimulating factor 3	Homo sapiens	13-18
1719309-1	1991	The effects of the inhibitor for protein kinase A or C, or tyrosine kinase (H-8, staurosporine, or genistein, respectively) on the proliferation of leukemic and normal bone marrow cells stimulated by granulocyte colony-stimulating factor (G-CSF), granulocyte-macrophage colony-stimulating factor (GM-CSF), or interleukin-3 (IL-3) were studied using the MTT assay.	N-(2-(methylamino)ethyl)-5-isoquinolinesulfonamide	76-79	colony stimulating factor 3	Homo sapiens	200-237
1716591-4	1991	Our data indicate that following BMT, both recipients and their normal donors show GM-CSF- and G-CSF-induced increases in: 1) O2- production in response to fMet-Leu-Phe (fMLP), 2) killing of S. aureus, and 3) phagocytosis of C. albicans.	Oxygen	126-128	colony stimulating factor 3	Homo sapiens	95-100
1716591-6	1991	Our studies indicate that GM-CSF and G-CSF increase "oxygen-dependent" oxidative activities in neutrophils from BMT recipients and their normal donors and enhance the antimicrobial activity of the cells.	Oxygen	53-59	colony stimulating factor 3	Homo sapiens	37-42
1370059-5	1991	The depression of specific G-CSF productivity per cell under the batch culture conditions was overcome by using a perfusion culture system, Biofermenter (Sato, 1983) with modifications of nutrients supplementation by a dialysis membrane and/or dissolved oxygen (DO) supplementation by microsilicone fibers.	Oxygen	254-260	colony stimulating factor 3	Homo sapiens	27-32
1370059-5	1991	The depression of specific G-CSF productivity per cell under the batch culture conditions was overcome by using a perfusion culture system, Biofermenter (Sato, 1983) with modifications of nutrients supplementation by a dialysis membrane and/or dissolved oxygen (DO) supplementation by microsilicone fibers.	do	262-264	colony stimulating factor 3	Homo sapiens	27-32
1370059-5	1991	The depression of specific G-CSF productivity per cell under the batch culture conditions was overcome by using a perfusion culture system, Biofermenter (Sato, 1983) with modifications of nutrients supplementation by a dialysis membrane and/or dissolved oxygen (DO) supplementation by microsilicone fibers.	microsilicone	285-298	colony stimulating factor 3	Homo sapiens	27-32
1719309-1	1991	The effects of the inhibitor for protein kinase A or C, or tyrosine kinase (H-8, staurosporine, or genistein, respectively) on the proliferation of leukemic and normal bone marrow cells stimulated by granulocyte colony-stimulating factor (G-CSF), granulocyte-macrophage colony-stimulating factor (GM-CSF), or interleukin-3 (IL-3) were studied using the MTT assay.	Genistein	99-108	colony stimulating factor 3	Homo sapiens	200-237
1720567-5	1991	The combination of G-CSF and recombinant human erythropoietin completely reversed the zidovudine-induced neutropenia of AIDS patients but was only partially effective in reversing anemia.	Zidovudine	86-96	colony stimulating factor 3	Homo sapiens	19-24
1722258-1	1991	We evaluated the metabolic capability of murine peripheral granulocytes after administration of recombinant human granulocyte colony-stimulating factor (rhG-CSF) by quantitative flow cytometric assay for H2O2-dependent oxidative product formation.	Hydrogen Peroxide	204-208	colony stimulating factor 3	Homo sapiens	114-151
1723599-0	1991	Conformational changes of recombinant human granulocyte-colony stimulating factor induced by pH and guanidine hydrochloride.	Guanidine	100-123	colony stimulating factor 3	Homo sapiens	44-81
1716962-7	1991	In addition, it was shown that the induction of G-CSF mRNA by the calcium-ionophore A23187 or by c-AMP elevating agents could be blocked by IL-4.	Calcium	66-73	colony stimulating factor 3	Homo sapiens	48-53
1716962-7	1991	In addition, it was shown that the induction of G-CSF mRNA by the calcium-ionophore A23187 or by c-AMP elevating agents could be blocked by IL-4.	Calcimycin	84-90	colony stimulating factor 3	Homo sapiens	48-53
1716962-7	1991	In addition, it was shown that the induction of G-CSF mRNA by the calcium-ionophore A23187 or by c-AMP elevating agents could be blocked by IL-4.	c-amp	97-102	colony stimulating factor 3	Homo sapiens	48-53
1713254-3	1991	Treatment of cells with antisense oligodeoxynucleotides (oligos) to exons 1 and 2, but not 4, 5, or 6, of the CD45 gene, or with monoclonal anti-CD45, significantly decreased CFU-GM colony formation stimulated with GM-CSF, IL-3, fusion protein, and GM-CSF + MGF, but not with G-CSF or M-CSF.	Oligodeoxyribonucleotides	34-55	colony stimulating factor 3	Homo sapiens	276-281
1723599-5	1991	The guanidine hydrochloride-induced conformational changes of G-CSF at five pH values from 2.5 to 7.5 were also studied.	Guanidine	4-27	colony stimulating factor 3	Homo sapiens	62-67
1723599-8	1991	The guanidine HCl-induced denaturation of G-CSF involved more than a two-state transition, with detectable intermediate(s) present, and the structure of the intermediate(s) appeared to depend on the pH used.	Guanidine	4-17	colony stimulating factor 3	Homo sapiens	42-47
2018046-3	1991	A combination of granulocyte colony-stimulating factor and erythropoietin has also been demonstrated to alleviate both neutropenia and anemia in patients with advanced AIDS or AIDS-related complex receiving zidovudine.	Zidovudine	207-217	colony stimulating factor 3	Homo sapiens	17-54
1721002-5	1991	The results suggest that RA not only inhibits the proliferative action of G-CSF, but also retains and enhances the action of G-CSF to induce differentiation.	Tretinoin	25-27	colony stimulating factor 3	Homo sapiens	74-79
1721002-5	1991	The results suggest that RA not only inhibits the proliferative action of G-CSF, but also retains and enhances the action of G-CSF to induce differentiation.	Tretinoin	25-27	colony stimulating factor 3	Homo sapiens	125-130
1712246-0	1991	Pharmacokinetics of recombinant human granulocyte colony-stimulating factor conjugated to polyethylene glycol in rats.	Polyethylene Glycols	90-109	colony stimulating factor 3	Homo sapiens	38-75
1712246-1	1991	The pharmacokinetics of recombinant human granulocyte colony-stimulating factor conjugated to polyethylene glycol (PEG-rhG-CSF) and rhG-CSF were studied in male Sprague-Dawley rats.	Polyethylene Glycols	94-113	colony stimulating factor 3	Homo sapiens	42-79
1712246-1	1991	The pharmacokinetics of recombinant human granulocyte colony-stimulating factor conjugated to polyethylene glycol (PEG-rhG-CSF) and rhG-CSF were studied in male Sprague-Dawley rats.	Polyethylene Glycols	115-118	colony stimulating factor 3	Homo sapiens	42-79
1714756-0	1991	Effects of recombinant human granulocyte colony-stimulating factor on leucopenia in zidovudine-treated patients with AIDS and AIDS related complex, a phase I/II study.	Zidovudine	84-94	colony stimulating factor 3	Homo sapiens	29-66
1714756-13	1991	We conclude that G-CSF increases the number of circulating neutrophilic granulocytes in zidovudine-treated patients at relatively low doses and with few side-effects.	Zidovudine	88-98	colony stimulating factor 3	Homo sapiens	17-22
1709368-0	1991	Combined therapy with recombinant granulocyte colony-stimulating factor and erythropoietin decreases hematologic toxicity from zidovudine.	Zidovudine	127-137	colony stimulating factor 3	Homo sapiens	34-71
1716070-6	1991	Unlabeled rhG-CSF and human G-CSF purified from the culture supernatant of the human bladder carcinoma cell line 5637 equally competed for the binding of labeled rhG-CSFs in a dose-dependent manner, demonstrating that the sugar moiety of human G-CSF made no contribution to the binding of human G-CSF to target cells.	Sugars	222-227	colony stimulating factor 3	Homo sapiens	12-17
1716070-6	1991	Unlabeled rhG-CSF and human G-CSF purified from the culture supernatant of the human bladder carcinoma cell line 5637 equally competed for the binding of labeled rhG-CSFs in a dose-dependent manner, demonstrating that the sugar moiety of human G-CSF made no contribution to the binding of human G-CSF to target cells.	Sugars	222-227	colony stimulating factor 3	Homo sapiens	28-33
1716070-6	1991	Unlabeled rhG-CSF and human G-CSF purified from the culture supernatant of the human bladder carcinoma cell line 5637 equally competed for the binding of labeled rhG-CSFs in a dose-dependent manner, demonstrating that the sugar moiety of human G-CSF made no contribution to the binding of human G-CSF to target cells.	Sugars	222-227	colony stimulating factor 3	Homo sapiens	28-33
1710480-1	1991	The regulation of granulocyte-colony stimulating factor (G-CSF) and interleukin-6 (IL-6) mRNA was studied in human adherent monocytes in response to the protein kinase C activator, oleolyl-acetylglycerol (OAG), the calcium-ionophore A23187 and the cyclic AMP elevating agents, dibutyryl c-AMP (DBcAMP), cholera toxin and isobutyl-methylxanthine (IBMX).	oleolyl-acetylglycerol	181-203	colony stimulating factor 3	Homo sapiens	18-55
1710480-1	1991	The regulation of granulocyte-colony stimulating factor (G-CSF) and interleukin-6 (IL-6) mRNA was studied in human adherent monocytes in response to the protein kinase C activator, oleolyl-acetylglycerol (OAG), the calcium-ionophore A23187 and the cyclic AMP elevating agents, dibutyryl c-AMP (DBcAMP), cholera toxin and isobutyl-methylxanthine (IBMX).	oleolyl-acetylglycerol	181-203	colony stimulating factor 3	Homo sapiens	57-62
1710480-1	1991	The regulation of granulocyte-colony stimulating factor (G-CSF) and interleukin-6 (IL-6) mRNA was studied in human adherent monocytes in response to the protein kinase C activator, oleolyl-acetylglycerol (OAG), the calcium-ionophore A23187 and the cyclic AMP elevating agents, dibutyryl c-AMP (DBcAMP), cholera toxin and isobutyl-methylxanthine (IBMX).	1-oleoyl-2-acetylglycerol	205-208	colony stimulating factor 3	Homo sapiens	18-55
1715961-7	1991	The cells are more ara-C sensitive in MGF or G-CSF than in IL-3 or GM-CSF.	Cytarabine	19-24	colony stimulating factor 3	Homo sapiens	45-50
1896258-5	1991	IL-3/G-CSF cultures produced cells with progressive increases in oxygen metabolism, locomotion, and phagocytosis.	Oxygen	65-71	colony stimulating factor 3	Homo sapiens	5-10
1712223-3	1991	While rIL-4 by itself did not show any colony stimulatory activity in the blast colony assay, it suppressed the blast colony formation in methylcellulose stimulated with G-CSF, GM-CSF or IL-3 in 14 patients.	Methylcellulose	138-153	colony stimulating factor 3	Homo sapiens	170-175
1724550-1	1991	Prophylactic treatment with human granulocyte colony-stimulating factor (hG-CSF) affords significant protection against systemic aspergillosis or pulmonary aspergillosis in neutropenic (cyclophosphamide-treated) mice but not in cortisone-treated animals.	Cyclophosphamide	186-202	colony stimulating factor 3	Homo sapiens	34-71
1724550-1	1991	Prophylactic treatment with human granulocyte colony-stimulating factor (hG-CSF) affords significant protection against systemic aspergillosis or pulmonary aspergillosis in neutropenic (cyclophosphamide-treated) mice but not in cortisone-treated animals.	Cyclophosphamide	186-202	colony stimulating factor 3	Homo sapiens	73-79
1724550-1	1991	Prophylactic treatment with human granulocyte colony-stimulating factor (hG-CSF) affords significant protection against systemic aspergillosis or pulmonary aspergillosis in neutropenic (cyclophosphamide-treated) mice but not in cortisone-treated animals.	Cortisone	228-237	colony stimulating factor 3	Homo sapiens	73-79
2022593-2	1991	Both G-CSF and GM-CSF have demonstrated the ability to correct leukopenia related to HIV infection and ameliorate the drug-related myelosuppressive effects of zidovudine, trimethoprim/sulfamethoxazole, ganciclovir, and, in the case of GM-CSF, alpha-interferon, and cancer chemotherapies.	Zidovudine	159-169	colony stimulating factor 3	Homo sapiens	5-10
2022593-2	1991	Both G-CSF and GM-CSF have demonstrated the ability to correct leukopenia related to HIV infection and ameliorate the drug-related myelosuppressive effects of zidovudine, trimethoprim/sulfamethoxazole, ganciclovir, and, in the case of GM-CSF, alpha-interferon, and cancer chemotherapies.	Trimethoprim, Sulfamethoxazole Drug Combination	171-200	colony stimulating factor 3	Homo sapiens	5-10
2022593-2	1991	Both G-CSF and GM-CSF have demonstrated the ability to correct leukopenia related to HIV infection and ameliorate the drug-related myelosuppressive effects of zidovudine, trimethoprim/sulfamethoxazole, ganciclovir, and, in the case of GM-CSF, alpha-interferon, and cancer chemotherapies.	Ganciclovir	202-213	colony stimulating factor 3	Homo sapiens	5-10
1704851-3	1991	Treatment of neutrophils with both G-CSF and retinoic acid augmented the amount of mRNA for NAP over the amount obtained by G-CSF alone, which was most marked at 24 h. These results show that both G-CSF-mediated NAP induction and its potentiation by retinoic acid are due to the increased levels of mRNA for NAP.	Tretinoin	45-58	colony stimulating factor 3	Homo sapiens	124-129
1705835-3	1991	When stimulated in vitro with bacterial lipopolysaccharides (LPS), PBMC of those SCN patients produced G-CSF activity, as judged by proliferation induction of the murine leukemia cell line, NFS-60.	bacterial lipopolysaccharides	30-59	colony stimulating factor 3	Homo sapiens	103-108
1721105-1	1991	Prophylactic treatment with human granulocyte colony stimulating factor (hG-CSF) affords significant protection against systemic infections caused by C. albicans in cyclophosphamide-treated but not in cortisone-treated mice.	Cyclophosphamide	165-181	colony stimulating factor 3	Homo sapiens	34-71
1721105-1	1991	Prophylactic treatment with human granulocyte colony stimulating factor (hG-CSF) affords significant protection against systemic infections caused by C. albicans in cyclophosphamide-treated but not in cortisone-treated mice.	Cyclophosphamide	165-181	colony stimulating factor 3	Homo sapiens	73-79
1704851-3	1991	Treatment of neutrophils with both G-CSF and retinoic acid augmented the amount of mRNA for NAP over the amount obtained by G-CSF alone, which was most marked at 24 h. These results show that both G-CSF-mediated NAP induction and its potentiation by retinoic acid are due to the increased levels of mRNA for NAP.	Tretinoin	45-58	colony stimulating factor 3	Homo sapiens	124-129
1704851-3	1991	Treatment of neutrophils with both G-CSF and retinoic acid augmented the amount of mRNA for NAP over the amount obtained by G-CSF alone, which was most marked at 24 h. These results show that both G-CSF-mediated NAP induction and its potentiation by retinoic acid are due to the increased levels of mRNA for NAP.	N-(4-aminophenethyl)spiroperidol	92-95	colony stimulating factor 3	Homo sapiens	35-40
1704851-3	1991	Treatment of neutrophils with both G-CSF and retinoic acid augmented the amount of mRNA for NAP over the amount obtained by G-CSF alone, which was most marked at 24 h. These results show that both G-CSF-mediated NAP induction and its potentiation by retinoic acid are due to the increased levels of mRNA for NAP.	N-(4-aminophenethyl)spiroperidol	92-95	colony stimulating factor 3	Homo sapiens	124-129
1704851-3	1991	Treatment of neutrophils with both G-CSF and retinoic acid augmented the amount of mRNA for NAP over the amount obtained by G-CSF alone, which was most marked at 24 h. These results show that both G-CSF-mediated NAP induction and its potentiation by retinoic acid are due to the increased levels of mRNA for NAP.	N-(4-aminophenethyl)spiroperidol	92-95	colony stimulating factor 3	Homo sapiens	124-129
1704851-3	1991	Treatment of neutrophils with both G-CSF and retinoic acid augmented the amount of mRNA for NAP over the amount obtained by G-CSF alone, which was most marked at 24 h. These results show that both G-CSF-mediated NAP induction and its potentiation by retinoic acid are due to the increased levels of mRNA for NAP.	Tretinoin	250-263	colony stimulating factor 3	Homo sapiens	35-40
1705636-5	1991	G-CSF induced TPA- and FMLP-stimulated NBT reduction in the presence of 100 nM RA, but GM-CSF induced only TPA-stimulated NBT reduction.	Tetradecanoylphorbol Acetate	14-17	colony stimulating factor 3	Homo sapiens	0-5
1713806-11	1991	Combined G-CSF and EPO treatment corrected both anemia and leukopenia and reduced zidovudine toxicity.	Zidovudine	82-92	colony stimulating factor 3	Homo sapiens	9-14
1705306-6	1991	In short-term liquid cultures, IL-3, GM-CSF and G-CSF increased 3H-thymidine incorporation.	Tritium	64-66	colony stimulating factor 3	Homo sapiens	48-53
1705306-6	1991	In short-term liquid cultures, IL-3, GM-CSF and G-CSF increased 3H-thymidine incorporation.	Thymidine	67-76	colony stimulating factor 3	Homo sapiens	48-53
1722549-6	1991	Both GM-CSF and G-CSF induced in vitro amplification of (a) O2- production in response to fmet-leu-phe (FMLP) (b) phagocytosis and killing of C. albicans and (c) killing of S. aureus.	Superoxides	60-62	colony stimulating factor 3	Homo sapiens	16-21
1722549-6	1991	Both GM-CSF and G-CSF induced in vitro amplification of (a) O2- production in response to fmet-leu-phe (FMLP) (b) phagocytosis and killing of C. albicans and (c) killing of S. aureus.	Phenylalanine	99-102	colony stimulating factor 3	Homo sapiens	16-21
1705636-5	1991	G-CSF induced TPA- and FMLP-stimulated NBT reduction in the presence of 100 nM RA, but GM-CSF induced only TPA-stimulated NBT reduction.	Nitroblue Tetrazolium	39-42	colony stimulating factor 3	Homo sapiens	0-5
1705636-8	1991	The results suggest that G-CSF stimulates RA-induced morphological and functional differentiation of HL-60 cells, but the differentiation-enhancing effects of GM-CSF are limited, whereas the growth-stimulating effect of GM-CSF on HL-60 cells is greater than that of G-CSF.	Tretinoin	42-44	colony stimulating factor 3	Homo sapiens	25-30
1702323-0	1990	Phorbol ester-treated human acute myeloid leukemia cells secrete G-CSF, GM-CSF and erythroid differentiation factor into serum-free media in primary culture.	Phorbol Esters	0-13	colony stimulating factor 3	Homo sapiens	65-70
1709218-0	1991	[Salicylazosulfapyridine-induced agranulocytosis in a patient with ulcerative colitis, successfully treated with granulocyte colony-stimulating factor].	Sulfasalazine	1-24	colony stimulating factor 3	Homo sapiens	113-151
1717812-1	1991	Decrease in resistance to systemic Pseudomonas infection in cyclophosphamide (CPA)-induced neutropenic mice was prevented by injections of recombinant human granulocyte colony-stimulating factor (rG-CSF).	Cyclophosphamide	60-76	colony stimulating factor 3	Homo sapiens	157-194
1717812-1	1991	Decrease in resistance to systemic Pseudomonas infection in cyclophosphamide (CPA)-induced neutropenic mice was prevented by injections of recombinant human granulocyte colony-stimulating factor (rG-CSF).	Cyclophosphamide	78-81	colony stimulating factor 3	Homo sapiens	157-194
1702323-2	1990	G-CSF was identified by its stimulation of [3H]thymidine incorporation into a G-CSF-responsive cell line, NSF-60, and the inhibition of its stimulation by a G-CSF-specific monoclonal antibody (MAB).	[3h]thymidine	43-56	colony stimulating factor 3	Homo sapiens	0-5
1702900-6	1990	When a recombinant human granulocyte colony-stimulating factor (rhG-CSF) was intravenously injected, superoxide production did not change in either GF or CV neutrophils, but the myeloperoxidase activity of neutrophils in both types of rats decreased.	Superoxides	101-111	colony stimulating factor 3	Homo sapiens	25-62
1701353-7	1990	Colony-forming capacity of NKM-1 cells in semisolid agar was also enhanced with the addition of 10 ng/ml of G-CSF or M-CSF but decreased at higher concentrations.	Agar	52-56	colony stimulating factor 3	Homo sapiens	108-113
1704940-0	1990	Granulocyte-colony stimulating factor enhances the cytotoxic effects of methotrexate to bladder cancer cells in vitro.	Methotrexate	72-84	colony stimulating factor 3	Homo sapiens	0-37
1704940-3	1990	The 3H-thymidine uptake of cultured human bladder cancer cells, KU-1 and NBT-2, was significantly higher when the cells were treated with 10 ng/ml G-CSF than without G-CSF after 24- and 48-hour incubation.	Tritium	4-6	colony stimulating factor 3	Homo sapiens	147-152
1704940-3	1990	The 3H-thymidine uptake of cultured human bladder cancer cells, KU-1 and NBT-2, was significantly higher when the cells were treated with 10 ng/ml G-CSF than without G-CSF after 24- and 48-hour incubation.	Thymidine	7-16	colony stimulating factor 3	Homo sapiens	147-152
1704940-5	1990	The binding of 125I-labeled KW-2228, a muteins of G-CSF, to KU-1 and NBT-2 was inhibited by unlabeled KW-2228 in a concentration dependent manner, which demonstrated the presence of G-CSF receptors on both cells.	Iodine-125	15-19	colony stimulating factor 3	Homo sapiens	50-55
1704940-5	1990	The binding of 125I-labeled KW-2228, a muteins of G-CSF, to KU-1 and NBT-2 was inhibited by unlabeled KW-2228 in a concentration dependent manner, which demonstrated the presence of G-CSF receptors on both cells.	Iodine-125	15-19	colony stimulating factor 3	Homo sapiens	182-187
1704940-7	1990	The combination treatment with methotrexate and G-CSF resulted in a significant increase in cytotoxic effects, when compared with methotrexate treatment alone.	Methotrexate	130-142	colony stimulating factor 3	Homo sapiens	48-53
1700731-7	1990	The transcription inhibitor, actinomycin D, and protein synthesis inhibitor, cycloheximide, inhibited the increase in GM-CSF and G-CSF production induced by IL-1 and TNF.	Dactinomycin	29-42	colony stimulating factor 3	Homo sapiens	129-134
1700731-7	1990	The transcription inhibitor, actinomycin D, and protein synthesis inhibitor, cycloheximide, inhibited the increase in GM-CSF and G-CSF production induced by IL-1 and TNF.	Cycloheximide	77-90	colony stimulating factor 3	Homo sapiens	129-134
1699657-5	1990	According to in vitro cytotoxic assay, the sensitivity of G-CSF-stimulated cells to intercalating (daunorubicin) and nonintercalating (etoposide) topo II-targeting drugs increased significantly, whereas no enhancement of sensitivity was observed with an alkylating agent (4-hydroperoxycyclophosphamide).	Daunorubicin	99-111	colony stimulating factor 3	Homo sapiens	58-63
1694845-0	1990	O-linked sugar chain of human granulocyte colony-stimulating factor protects it against polymerization and denaturation allowing it to retain its biological activity.	linked	2-8	colony stimulating factor 3	Homo sapiens	30-67
1699657-5	1990	According to in vitro cytotoxic assay, the sensitivity of G-CSF-stimulated cells to intercalating (daunorubicin) and nonintercalating (etoposide) topo II-targeting drugs increased significantly, whereas no enhancement of sensitivity was observed with an alkylating agent (4-hydroperoxycyclophosphamide).	Etoposide	135-144	colony stimulating factor 3	Homo sapiens	58-63
1699657-5	1990	According to in vitro cytotoxic assay, the sensitivity of G-CSF-stimulated cells to intercalating (daunorubicin) and nonintercalating (etoposide) topo II-targeting drugs increased significantly, whereas no enhancement of sensitivity was observed with an alkylating agent (4-hydroperoxycyclophosphamide).	perfosfamide	272-301	colony stimulating factor 3	Homo sapiens	58-63
1700239-4	1990	We show that exposure of SP CML bone marrow promyelocytes/myelocytes to recombinant human (rh) interferon (IFN)-gamma but not to rh IFN-alpha, rh tumor necrosis factor (TNF)-alpha, and rh lymphotoxin (LT) leads to downregulation of G-CSF expression and interruption of the G-CSF-mediated endogenous growth stimulation.	TFF2 protein, human	25-27	colony stimulating factor 3	Homo sapiens	232-237
1700239-4	1990	We show that exposure of SP CML bone marrow promyelocytes/myelocytes to recombinant human (rh) interferon (IFN)-gamma but not to rh IFN-alpha, rh tumor necrosis factor (TNF)-alpha, and rh lymphotoxin (LT) leads to downregulation of G-CSF expression and interruption of the G-CSF-mediated endogenous growth stimulation.	TFF2 protein, human	25-27	colony stimulating factor 3	Homo sapiens	273-278
1697466-1	1990	Granulocyte colony-stimulating factor(G-CSF) and granulocyte-macrophage colony-stimulating factor (GM-CSF) increased neutrophil C3bi-receptor expression and adherence and rapidly (less than 10 min) primed neutrophils to enhanced O2- release and membrane depolarization stimulated by chemotactic peptide.	Oxygen	229-231	colony stimulating factor 3	Homo sapiens	0-43
1694845-0	1990	O-linked sugar chain of human granulocyte colony-stimulating factor protects it against polymerization and denaturation allowing it to retain its biological activity.	Sugars	9-14	colony stimulating factor 3	Homo sapiens	30-67
1694845-1	1990	Human granulocyte colony-stimulating factor (hG-CSF) is a glycoprotein carrying one O-linked sugar chain.	o-linked sugar	84-98	colony stimulating factor 3	Homo sapiens	6-43
1694845-1	1990	Human granulocyte colony-stimulating factor (hG-CSF) is a glycoprotein carrying one O-linked sugar chain.	o-linked sugar	84-98	colony stimulating factor 3	Homo sapiens	45-51
1694845-7	1990	From these results, it was concluded that the O-linked sugar chain of hG-CSF contributes to the stability of the factor by suppressing polymerization and/or its conformational changes.	Sugars	55-60	colony stimulating factor 3	Homo sapiens	70-76
1693298-5	1990	Furthermore, CFU-C growth in both patients was supported when bone marrow cells were preincubated with IL-3 in liquid culture followed by the stimulation with G-CSF in semisolid agar culture.	Agar	178-182	colony stimulating factor 3	Homo sapiens	159-164
1691103-3	1990	NAP activity induced by G-CSF in PMN from CML patients showed a greater increase than that in PMN from normal controls.	nap	0-3	colony stimulating factor 3	Homo sapiens	24-29
1692808-0	1990	Recombinant granulocyte colony-stimulating factor and lipopolysaccharide maintain the phenotype of and superoxide anion generation by neutrophils.	Superoxides	103-119	colony stimulating factor 3	Homo sapiens	12-49
1698192-1	1990	Introduction of two tyrosine residues into human granulocyte colony-stimulating factor (G-CSF) allowed us to obtain radioiodinated material efficiently.	Tyrosine	20-28	colony stimulating factor 3	Homo sapiens	49-86
1698192-1	1990	Introduction of two tyrosine residues into human granulocyte colony-stimulating factor (G-CSF) allowed us to obtain radioiodinated material efficiently.	Tyrosine	20-28	colony stimulating factor 3	Homo sapiens	88-93
1698896-3	1990	In the prior two reports, we demonstrated that G-CSF induced the polarization of neutrophils by itself, and also enhanced superoxide production from neutrophils stimulated by the chemotactic peptides.	Superoxides	122-132	colony stimulating factor 3	Homo sapiens	47-52
1698896-6	1990	However, in mice receiving recombinant human G-CSF four daily subcutaneous injection, the number of leukocytes, particulary neutrophils, increased more rapidly than in controls receiving saline.	Sodium Chloride	187-193	colony stimulating factor 3	Homo sapiens	45-50
1698896-9	1990	Carrageenan treatment decreased the protective effect of G-CSF.	Carrageenan	0-11	colony stimulating factor 3	Homo sapiens	57-62
1689190-3	1990	G-CSF also modulates multiple differentiated functions of human neutrophils, including enhanced oxidative metabolism in response to f-Met-Leu-Phe (f-MLP), increased antibody-dependent cell-mediated cytotoxicity (ADCC), and augmented arachidonic acid release in response to ionophore and chemotactic agents.	N-Formylmethionine Leucyl-Phenylalanine	132-145	colony stimulating factor 3	Homo sapiens	0-5
1698209-3	1990	In present study, we have investigated superoxide (O2-) production from human neutrophils by recombinant human granulocyte colony-stimulating factor (G-CSF) using the microtiter plate for the purpose of being close to the inflammatory site.	Superoxides	39-49	colony stimulating factor 3	Homo sapiens	111-148
1698209-3	1990	In present study, we have investigated superoxide (O2-) production from human neutrophils by recombinant human granulocyte colony-stimulating factor (G-CSF) using the microtiter plate for the purpose of being close to the inflammatory site.	Superoxides	39-49	colony stimulating factor 3	Homo sapiens	150-155
1698209-3	1990	In present study, we have investigated superoxide (O2-) production from human neutrophils by recombinant human granulocyte colony-stimulating factor (G-CSF) using the microtiter plate for the purpose of being close to the inflammatory site.	Superoxides	51-53	colony stimulating factor 3	Homo sapiens	111-148
1698209-3	1990	In present study, we have investigated superoxide (O2-) production from human neutrophils by recombinant human granulocyte colony-stimulating factor (G-CSF) using the microtiter plate for the purpose of being close to the inflammatory site.	Superoxides	51-53	colony stimulating factor 3	Homo sapiens	150-155
1698209-5	1990	However, the optimal concentration of G-CSF (50 ng/ml) was able to prime human neutrophils with enhance of O2- release stimulated by the chemotactic peptide, N-formyl-methionyl-leucyl-phenylalanine (FMLP) from 10(-6) to 10(-8) M, but not by the non chemoattractant such as phorbol myristate acetate (PMA), concanavalin A, and ionomycin.	Superoxides	107-109	colony stimulating factor 3	Homo sapiens	38-43
1698209-5	1990	However, the optimal concentration of G-CSF (50 ng/ml) was able to prime human neutrophils with enhance of O2- release stimulated by the chemotactic peptide, N-formyl-methionyl-leucyl-phenylalanine (FMLP) from 10(-6) to 10(-8) M, but not by the non chemoattractant such as phorbol myristate acetate (PMA), concanavalin A, and ionomycin.	Tetradecanoylphorbol Acetate	273-298	colony stimulating factor 3	Homo sapiens	38-43
1698209-5	1990	However, the optimal concentration of G-CSF (50 ng/ml) was able to prime human neutrophils with enhance of O2- release stimulated by the chemotactic peptide, N-formyl-methionyl-leucyl-phenylalanine (FMLP) from 10(-6) to 10(-8) M, but not by the non chemoattractant such as phorbol myristate acetate (PMA), concanavalin A, and ionomycin.	Tetradecanoylphorbol Acetate	300-303	colony stimulating factor 3	Homo sapiens	38-43
1698209-5	1990	However, the optimal concentration of G-CSF (50 ng/ml) was able to prime human neutrophils with enhance of O2- release stimulated by the chemotactic peptide, N-formyl-methionyl-leucyl-phenylalanine (FMLP) from 10(-6) to 10(-8) M, but not by the non chemoattractant such as phorbol myristate acetate (PMA), concanavalin A, and ionomycin.	Ionomycin	326-335	colony stimulating factor 3	Homo sapiens	38-43
1689609-2	1990	We have made a mutein of human G-CSF, KW-2228, in which Thr-1, Leu-3, Gly-4, Pro-5, and Cys-17 were respectively substituted with Ala, Thr, Tyr, Arg, and Ser; showed more potent G-CSF activity; and retained full biological activity and receptor binding capacity at least 2 weeks of radioiodination.	Leucine	63-66	colony stimulating factor 3	Homo sapiens	31-36
1689609-2	1990	We have made a mutein of human G-CSF, KW-2228, in which Thr-1, Leu-3, Gly-4, Pro-5, and Cys-17 were respectively substituted with Ala, Thr, Tyr, Arg, and Ser; showed more potent G-CSF activity; and retained full biological activity and receptor binding capacity at least 2 weeks of radioiodination.	Glycine	70-73	colony stimulating factor 3	Homo sapiens	31-36
1689609-2	1990	We have made a mutein of human G-CSF, KW-2228, in which Thr-1, Leu-3, Gly-4, Pro-5, and Cys-17 were respectively substituted with Ala, Thr, Tyr, Arg, and Ser; showed more potent G-CSF activity; and retained full biological activity and receptor binding capacity at least 2 weeks of radioiodination.	Proline	77-80	colony stimulating factor 3	Homo sapiens	31-36
1689609-2	1990	We have made a mutein of human G-CSF, KW-2228, in which Thr-1, Leu-3, Gly-4, Pro-5, and Cys-17 were respectively substituted with Ala, Thr, Tyr, Arg, and Ser; showed more potent G-CSF activity; and retained full biological activity and receptor binding capacity at least 2 weeks of radioiodination.	Cysteine	88-91	colony stimulating factor 3	Homo sapiens	31-36
1689609-2	1990	We have made a mutein of human G-CSF, KW-2228, in which Thr-1, Leu-3, Gly-4, Pro-5, and Cys-17 were respectively substituted with Ala, Thr, Tyr, Arg, and Ser; showed more potent G-CSF activity; and retained full biological activity and receptor binding capacity at least 2 weeks of radioiodination.	Alanine	130-133	colony stimulating factor 3	Homo sapiens	31-36
1689609-2	1990	We have made a mutein of human G-CSF, KW-2228, in which Thr-1, Leu-3, Gly-4, Pro-5, and Cys-17 were respectively substituted with Ala, Thr, Tyr, Arg, and Ser; showed more potent G-CSF activity; and retained full biological activity and receptor binding capacity at least 2 weeks of radioiodination.	Threonine	56-59	colony stimulating factor 3	Homo sapiens	31-36
1689609-2	1990	We have made a mutein of human G-CSF, KW-2228, in which Thr-1, Leu-3, Gly-4, Pro-5, and Cys-17 were respectively substituted with Ala, Thr, Tyr, Arg, and Ser; showed more potent G-CSF activity; and retained full biological activity and receptor binding capacity at least 2 weeks of radioiodination.	Tyrosine	140-143	colony stimulating factor 3	Homo sapiens	31-36
1689609-2	1990	We have made a mutein of human G-CSF, KW-2228, in which Thr-1, Leu-3, Gly-4, Pro-5, and Cys-17 were respectively substituted with Ala, Thr, Tyr, Arg, and Ser; showed more potent G-CSF activity; and retained full biological activity and receptor binding capacity at least 2 weeks of radioiodination.	Arginine	145-148	colony stimulating factor 3	Homo sapiens	31-36
1689609-2	1990	We have made a mutein of human G-CSF, KW-2228, in which Thr-1, Leu-3, Gly-4, Pro-5, and Cys-17 were respectively substituted with Ala, Thr, Tyr, Arg, and Ser; showed more potent G-CSF activity; and retained full biological activity and receptor binding capacity at least 2 weeks of radioiodination.	Serine	154-157	colony stimulating factor 3	Homo sapiens	31-36
1690032-0	1990	Quantitative in vivo assay of human granulocyte colony-stimulating factor using cyclophosphamide-induced neutropenic mice.	Cyclophosphamide	80-96	colony stimulating factor 3	Homo sapiens	36-73
1690032-1	1990	Administration of human granulocyte colony-stimulating factor (hG-CSF) to mice with cyclophosphamide (CPA)-induced neutropenia for 4 consecutive days from the day after the CPA dosing (100 mg/kg) resulted in a dose-dependent increase in the peripheral blood neutrophil count 6 hours after the final hG-CSF injection.	Cyclophosphamide	84-100	colony stimulating factor 3	Homo sapiens	24-61
1690032-1	1990	Administration of human granulocyte colony-stimulating factor (hG-CSF) to mice with cyclophosphamide (CPA)-induced neutropenia for 4 consecutive days from the day after the CPA dosing (100 mg/kg) resulted in a dose-dependent increase in the peripheral blood neutrophil count 6 hours after the final hG-CSF injection.	Cyclophosphamide	84-100	colony stimulating factor 3	Homo sapiens	63-69
1690032-1	1990	Administration of human granulocyte colony-stimulating factor (hG-CSF) to mice with cyclophosphamide (CPA)-induced neutropenia for 4 consecutive days from the day after the CPA dosing (100 mg/kg) resulted in a dose-dependent increase in the peripheral blood neutrophil count 6 hours after the final hG-CSF injection.	Cyclophosphamide	84-100	colony stimulating factor 3	Homo sapiens	299-305
1690032-1	1990	Administration of human granulocyte colony-stimulating factor (hG-CSF) to mice with cyclophosphamide (CPA)-induced neutropenia for 4 consecutive days from the day after the CPA dosing (100 mg/kg) resulted in a dose-dependent increase in the peripheral blood neutrophil count 6 hours after the final hG-CSF injection.	Cyclophosphamide	102-105	colony stimulating factor 3	Homo sapiens	24-61
1690032-4	1990	Such an association never occurred with intact mice, and 100 mg/kg of CPA induced the highest response to hG-CSF.	Cyclophosphamide	70-73	colony stimulating factor 3	Homo sapiens	106-112
1690032-6	1990	When assayed by this bioassay procedure, which we have termed CPA-mouse assay, natural hG-CSF and recombinant hG-CSF (produced by Chinese hamster ovary cells) were nearly equipotent in specific biologic activity.	Cyclophosphamide	62-65	colony stimulating factor 3	Homo sapiens	87-93
1690032-7	1990	These results confirm the CPA-mouse assay as an especially useful assay method for quantifying the in vivo activity of hG-CSF.	Cyclophosphamide	26-29	colony stimulating factor 3	Homo sapiens	119-125
1692828-4	1990	Both forms of hG-CSF have a free Cys-17 and two intramolecular disulfide linkages, between Cys-36 and Cys-42, and between Cys-64 and Cys-74.	Cysteine	33-36	colony stimulating factor 3	Homo sapiens	14-20
1692828-4	1990	Both forms of hG-CSF have a free Cys-17 and two intramolecular disulfide linkages, between Cys-36 and Cys-42, and between Cys-64 and Cys-74.	Disulfides	63-72	colony stimulating factor 3	Homo sapiens	14-20
1692828-4	1990	Both forms of hG-CSF have a free Cys-17 and two intramolecular disulfide linkages, between Cys-36 and Cys-42, and between Cys-64 and Cys-74.	Cysteine	91-94	colony stimulating factor 3	Homo sapiens	14-20
1692828-4	1990	Both forms of hG-CSF have a free Cys-17 and two intramolecular disulfide linkages, between Cys-36 and Cys-42, and between Cys-64 and Cys-74.	Cysteine	91-94	colony stimulating factor 3	Homo sapiens	14-20
1692828-4	1990	Both forms of hG-CSF have a free Cys-17 and two intramolecular disulfide linkages, between Cys-36 and Cys-42, and between Cys-64 and Cys-74.	Cysteine	91-94	colony stimulating factor 3	Homo sapiens	14-20
1692828-4	1990	Both forms of hG-CSF have a free Cys-17 and two intramolecular disulfide linkages, between Cys-36 and Cys-42, and between Cys-64 and Cys-74.	Cysteine	91-94	colony stimulating factor 3	Homo sapiens	14-20
1695446-2	1990	Also, histamine 1 microM significantly induced the differentiation of HL-60 into cells having the morphological characteristics of mature neutrophils, as did db-cAMP and granulocyte colony-stimulating factor (G-CSF).	Histamine	6-15	colony stimulating factor 3	Homo sapiens	209-214
1690319-5	1990	The antiproliferative drugs 6-thioguanine and vincristine both antagonized the neutrophil-granulocyte differentiation inducing action of G-CSF.	Thioguanine	28-41	colony stimulating factor 3	Homo sapiens	137-142
1690319-5	1990	The antiproliferative drugs 6-thioguanine and vincristine both antagonized the neutrophil-granulocyte differentiation inducing action of G-CSF.	Vincristine	46-57	colony stimulating factor 3	Homo sapiens	137-142
1689190-3	1990	G-CSF also modulates multiple differentiated functions of human neutrophils, including enhanced oxidative metabolism in response to f-Met-Leu-Phe (f-MLP), increased antibody-dependent cell-mediated cytotoxicity (ADCC), and augmented arachidonic acid release in response to ionophore and chemotactic agents.	Arachidonic Acid	233-249	colony stimulating factor 3	Homo sapiens	0-5
1688720-8	1990	With the 3H-thymidine proliferation assay, IL-4 augmented the G-CSF-induced proliferation of acute myeloid leukemic (AML) cells in 4 of the 12 cases, while the IL-3-supported proliferation was antagonized in 3 of the 12 cases.	3h-thymidine	9-21	colony stimulating factor 3	Homo sapiens	62-67
33590721-1	2021	BACKGROUND: The aim of this study was to discuss the safety and efficacy of administering reduced doses (3 mg) of pegylated recombinant human granulocyte-colony stimulating factor (PEG-rhG-CSF) at approximately 24 h or up to three days following treatment with etoposide and cisplatin (EP).	Etoposide	261-270	colony stimulating factor 3	Homo sapiens	142-179
1688498-10	1990	The reduced capacity of these stromal cells to produce G-CSF is associated with a reduced capacity of the CM to sustain GM colony formation and may be associated with the inability of these patients to sustain their neutrophil counts in vivo.	gm	120-122	colony stimulating factor 3	Homo sapiens	55-60
1688503-0	1990	Binding of G-CSF, GM-CSF, tumor necrosis factor-alpha, and gamma-interferon to cell surface receptors on human myeloid leukemia cells triggers rapid tyrosine and serine phosphorylation of a 75-Kd protein.	Tyrosine	149-157	colony stimulating factor 3	Homo sapiens	11-16
1688503-0	1990	Binding of G-CSF, GM-CSF, tumor necrosis factor-alpha, and gamma-interferon to cell surface receptors on human myeloid leukemia cells triggers rapid tyrosine and serine phosphorylation of a 75-Kd protein.	Serine	162-168	colony stimulating factor 3	Homo sapiens	11-16
1688503-6	1990	Immunoblot analysis of lysates of intact HL60 cells that had been incubated with G-CSF, GM-CSF, IFN, or TNF confirmed that tyrosine phosphorylation of a p75 also occurred in response to these cytokines in intact cells.	Tyrosine	123-131	colony stimulating factor 3	Homo sapiens	81-86
1688638-6	1990	In contrast, TNF suppressed G-CSF-induced growth (9 of 10 cases in 3H-TdR assay; 5 of 6 cases in colony assay).	Tritium	67-69	colony stimulating factor 3	Homo sapiens	28-33
1688901-0	1990	Establishment of specific monoclonal antibodies against recombinant human granulocyte colony-stimulating factor (hG-CSF) and their application for immunoperoxidase staining of paraffin-embedded sections.	Paraffin	176-184	colony stimulating factor 3	Homo sapiens	74-111
1688901-0	1990	Establishment of specific monoclonal antibodies against recombinant human granulocyte colony-stimulating factor (hG-CSF) and their application for immunoperoxidase staining of paraffin-embedded sections.	Paraffin	176-184	colony stimulating factor 3	Homo sapiens	113-119
1691246-1	1990	This manuscript summarizes our experience with recombinant human granulocyte colony-stimulating factor (rhG-CSF) with high-dose Cytoxan, carmustine and etoposide (CBV in Hodgkin"s disease).	Cyclophosphamide	128-135	colony stimulating factor 3	Homo sapiens	65-102
1691246-1	1990	This manuscript summarizes our experience with recombinant human granulocyte colony-stimulating factor (rhG-CSF) with high-dose Cytoxan, carmustine and etoposide (CBV in Hodgkin"s disease).	Carmustine	137-147	colony stimulating factor 3	Homo sapiens	65-102
1691246-1	1990	This manuscript summarizes our experience with recombinant human granulocyte colony-stimulating factor (rhG-CSF) with high-dose Cytoxan, carmustine and etoposide (CBV in Hodgkin"s disease).	Etoposide	152-161	colony stimulating factor 3	Homo sapiens	65-102
1691246-1	1990	This manuscript summarizes our experience with recombinant human granulocyte colony-stimulating factor (rhG-CSF) with high-dose Cytoxan, carmustine and etoposide (CBV in Hodgkin"s disease).	CBV protocol	163-166	colony stimulating factor 3	Homo sapiens	65-102
33590721-1	2021	BACKGROUND: The aim of this study was to discuss the safety and efficacy of administering reduced doses (3 mg) of pegylated recombinant human granulocyte-colony stimulating factor (PEG-rhG-CSF) at approximately 24 h or up to three days following treatment with etoposide and cisplatin (EP).	Cisplatin	275-284	colony stimulating factor 3	Homo sapiens	142-179
33812396-1	2021	OBJECTIVE: To study the efficacy and safety of continuous intravenous infusion of 2-Chlorodeoxyadenosine (2-CdA) combined with high-dose cytarabine (Ara-C) and granulocyte colony-stimulating factor (G-CSF) (CLAG regiem) in the treatment of relapsed/refractory acute myeloid leukemia (AML).	Cladribine	82-104	colony stimulating factor 3	Homo sapiens	199-204
33590721-1	2021	BACKGROUND: The aim of this study was to discuss the safety and efficacy of administering reduced doses (3 mg) of pegylated recombinant human granulocyte-colony stimulating factor (PEG-rhG-CSF) at approximately 24 h or up to three days following treatment with etoposide and cisplatin (EP).	VP-P protocol	286-288	colony stimulating factor 3	Homo sapiens	142-179
33590721-3	2021	The PP-Group received a reduced dose of 3 mg of PEG-rhG-CSF within a minimum of 15 h and a maximum of 72 h following EP chemotherapy, while the rest did not receive any G-CSF prophylaxis (No-PP-Group).	Polyethylene Glycols	48-51	colony stimulating factor 3	Homo sapiens	54-59
9269788-7	1997	Compared with vehicle control, pretreatment with SDZ MRL 953 markedly reduced the release of TNF-alpha, IL-1beta, IL-8, IL-6, and G-CSF, but augmented the increase in granulocyte counts to endotoxin.	Sulfadiazine	49-52	colony stimulating factor 3	Homo sapiens	130-135
32860270-0	2020	Modulation of GCSF Conformation and Receptor Binding by Methionine Oxidation.	Methionine	56-66	colony stimulating factor 3	Homo sapiens	14-18
32860270-3	2020	Here, we identified oxidation of the various methionine residues in GCSF as a key heterogeneity that adversely impacts its efficacy.	Methionine	45-55	colony stimulating factor 3	Homo sapiens	68-72
24594699-6	2014	By contrast, hexahistidine-tagged hGCSF was insoluble at both temperatures.	His-His-His-His-His-His	13-26	colony stimulating factor 3	Homo sapiens	34-39
34605552-0	2022	Pharmacokinetic and pharmacodynamic characteristics of tripegfilgrastim, a pegylated G-CSF, in pediatric patients with solid tumors.	tripegfilgrastim	55-71	colony stimulating factor 3	Homo sapiens	85-90
8618603-11	1996	Therapy with granulocyte colony stimulating factor was more frequent in the ganciclovir group (24 percent) than in the placebo group (9 percent).	Ganciclovir	76-87	colony stimulating factor 3	Homo sapiens	13-50
34467784-0	2022	Association of Time Since Administration of Pegylated G-CSF (Pegfilgrastim) and Bone Marrow Uptake on FDG PET/CT: Determination of a Minimum Interval.	Fluorodeoxyglucose F18	102-105	colony stimulating factor 3	Homo sapiens	54-59
34591162-0	2022	Long-term outcomes following the addition of granulocyte colony-stimulating factor-combined high-dose cytarabine to total body irradiation and cyclophosphamide conditioning in single-unit cord blood transplantation for myeloid malignancies.	Cyclophosphamide	143-159	colony stimulating factor 3	Homo sapiens	45-82
34591162-11	2022	These outcomes demonstrate that G-CSF-combined myeloablative conditioning could have favorable long-term remission rates for adult patients with myeloid malignancies undergoing single-unit CBT.	N,N-BIS(4-CHLOROBENZYL)-1H-1,2,3,4-TETRAAZOL-5-AMINE	189-192	colony stimulating factor 3	Homo sapiens	32-37
7527763-10	1994	In addition, coadministration of granulocyte colony-stimulating factor (G-CSF) or granulocyte-macrophage CSF (GM-CSF) has been shown to prevent ganciclovir-associated neutropenia.	Ganciclovir	144-155	colony stimulating factor 3	Homo sapiens	33-70
7527763-10	1994	In addition, coadministration of granulocyte colony-stimulating factor (G-CSF) or granulocyte-macrophage CSF (GM-CSF) has been shown to prevent ganciclovir-associated neutropenia.	Ganciclovir	144-155	colony stimulating factor 3	Homo sapiens	72-77
34967072-7	2022	G-CSF use was associated with transplant center, induction immunosuppression, steroid-free maintenance immunosuppression, hospitalization, and decreases in mycophenolate mofetil, valganciclovir, and trimethoprim-sulfamethoxazole dosing.	Steroids	78-85	colony stimulating factor 3	Homo sapiens	0-5
34159611-3	2022	Plerixafor is given with granulocyte colony-stimulating factor (G-CSF) to help harvest autologous CD34+ cells for transplantation when mobilization with G-CSF fails.	plerixafor	0-10	colony stimulating factor 3	Homo sapiens	64-69
34965730-5	2022	Here, we have combined protein engineering with biophysical analyses and HDX-MS to reveal that increased exchange in a core region of the G-CSF comprising loop AB (ABI, a small helix, ABII) and loop CD packed onto helix B and the beginning of loop BC leads to a decrease in Tm and higher aggregation rates.	Cadmium	199-201	colony stimulating factor 3	Homo sapiens	138-143
34967072-7	2022	G-CSF use was associated with transplant center, induction immunosuppression, steroid-free maintenance immunosuppression, hospitalization, and decreases in mycophenolate mofetil, valganciclovir, and trimethoprim-sulfamethoxazole dosing.	Mycophenolic Acid	156-177	colony stimulating factor 3	Homo sapiens	0-5
34967072-7	2022	G-CSF use was associated with transplant center, induction immunosuppression, steroid-free maintenance immunosuppression, hospitalization, and decreases in mycophenolate mofetil, valganciclovir, and trimethoprim-sulfamethoxazole dosing.	Valganciclovir	179-193	colony stimulating factor 3	Homo sapiens	0-5
34967072-7	2022	G-CSF use was associated with transplant center, induction immunosuppression, steroid-free maintenance immunosuppression, hospitalization, and decreases in mycophenolate mofetil, valganciclovir, and trimethoprim-sulfamethoxazole dosing.	Trimethoprim, Sulfamethoxazole Drug Combination	199-228	colony stimulating factor 3	Homo sapiens	0-5
34870568-0	2021	Underutilisation of prophylactic G-CSF in breast cancer patients receiving adjuvant docetaxel/cyclophosphamide chemotherapy.	Docetaxel	84-93	colony stimulating factor 3	Homo sapiens	33-38
34906334-3	2022	We investigated whether the novel combination of the tyrosine-kinase inhibitor ponatinib with fludarabine, cytarabine, granulocyte colony-stimulating factor, and idarubicin (FLAG-IDA) could improve response and optimise allogeneic HSCT outcomes in patients with blast-phase chronic myeloid leukaemia.	flag-ida	174-182	colony stimulating factor 3	Homo sapiens	119-172
34870568-0	2021	Underutilisation of prophylactic G-CSF in breast cancer patients receiving adjuvant docetaxel/cyclophosphamide chemotherapy.	Cyclophosphamide	94-110	colony stimulating factor 3	Homo sapiens	33-38
34870568-7	2021	Primary prophylactic G-CSF was defined as G-CSF prescribed within two days of the first cycle of TC.	Technetium	97-99	colony stimulating factor 3	Homo sapiens	21-26
34870568-10	2021	The proportion of patients who received primary prophylactic G-CSF treatment after the first cycle of TC was 55.5%.	Technetium	102-104	colony stimulating factor 3	Homo sapiens	61-66
34342052-7	2021	Correlations were observed between the neutrophil count and G-CSF, IL-6, and cortisol (G-CSF; r = 0.667, IL-6; r = 0.667, cortisol; r = 0.623).	Hydrocortisone	77-85	colony stimulating factor 3	Homo sapiens	87-92
34533681-11	2021	CONCLUSIONS: The crude FN risk associated with (neo)adjuvant TCH(P) is over 20%, the upper limit above which the international guidelines unanimously advise PP G-CSF administration.	thiocarbohydrazide	61-64	colony stimulating factor 3	Homo sapiens	160-165
34487190-0	2021	Granulocyte colony-stimulating factor (G-CSF) enhances cocaine effects in the nucleus accumbens via a dopamine release-based mechanism.	Cocaine	55-62	colony stimulating factor 3	Homo sapiens	0-37
34487190-0	2021	Granulocyte colony-stimulating factor (G-CSF) enhances cocaine effects in the nucleus accumbens via a dopamine release-based mechanism.	Cocaine	55-62	colony stimulating factor 3	Homo sapiens	39-44
34487190-0	2021	Granulocyte colony-stimulating factor (G-CSF) enhances cocaine effects in the nucleus accumbens via a dopamine release-based mechanism.	Dopamine	102-110	colony stimulating factor 3	Homo sapiens	0-37
34487190-0	2021	Granulocyte colony-stimulating factor (G-CSF) enhances cocaine effects in the nucleus accumbens via a dopamine release-based mechanism.	Dopamine	102-110	colony stimulating factor 3	Homo sapiens	39-44
34487190-3	2021	We have previously demonstrated in animal models that cocaine use upregulates the expression of granulocyte colony-stimulating factor (G-CSF)-a pleiotropic cytokine-in the serum and the nucleus accumbens (NAc).	Cocaine	54-61	colony stimulating factor 3	Homo sapiens	96-133
34487190-3	2021	We have previously demonstrated in animal models that cocaine use upregulates the expression of granulocyte colony-stimulating factor (G-CSF)-a pleiotropic cytokine-in the serum and the nucleus accumbens (NAc).	Cocaine	54-61	colony stimulating factor 3	Homo sapiens	135-140
34487190-4	2021	G-CSF signaling has been causally linked to behavioral responses to cocaine across multiple behavioral domains.	Cocaine	68-75	colony stimulating factor 3	Homo sapiens	0-5
34487190-5	2021	The goal of this study was to define whether increases in G-CSF alter the pharmacodynamic effects of cocaine on the dopamine system and whether this occurs via direct mechanisms within local NAc microcircuits.	Cocaine	101-108	colony stimulating factor 3	Homo sapiens	58-63
34487190-5	2021	The goal of this study was to define whether increases in G-CSF alter the pharmacodynamic effects of cocaine on the dopamine system and whether this occurs via direct mechanisms within local NAc microcircuits.	Dopamine	116-124	colony stimulating factor 3	Homo sapiens	58-63
34487190-6	2021	We find that systemic G-CSF injection increases cocaine effects on dopamine terminals.	Cocaine	48-55	colony stimulating factor 3	Homo sapiens	22-27
34487190-6	2021	We find that systemic G-CSF injection increases cocaine effects on dopamine terminals.	Dopamine	67-75	colony stimulating factor 3	Homo sapiens	22-27
34487190-8	2021	Critically, this effect could be recapitulated by acute bath application of G-CSF to dopamine terminals, an effect that was occluded by prior G-CSF treatment, suggesting a similar mechanistic basis for direct and systemic exposures.	Dopamine	85-93	colony stimulating factor 3	Homo sapiens	76-81
34342052-5	2021	Time-course studies with complete blood counts, biochemical markers, cytokines, and cortisol showed transient increases in neutrophils, monocytes, myoglobin, high-sensitivity C-reactive protein (hsCRP), G-CSF, IL-6, and cortisol.	Hydrocortisone	84-92	colony stimulating factor 3	Homo sapiens	203-208
34832982-5	2021	Secondary prophylaxis of G-CSF reduced the risk of recurrent SNE (p < 0.01) and the relative dose intensity (RDI) < 85% (p = 0.03) in patients who had experienced SNE during AC-based chemotherapy.	Charcoal	174-176	colony stimulating factor 3	Homo sapiens	25-30
34832982-8	2021	This study indicated the importance of active intervention of G-CSF use to prevent recurrent SNE and improve clinical outcomes in patients with breast cancer who receive AC-based chemotherapy.	Charcoal	170-172	colony stimulating factor 3	Homo sapiens	62-67
34342052-7	2021	Correlations were observed between the neutrophil count and G-CSF, IL-6, and cortisol (G-CSF; r = 0.667, IL-6; r = 0.667, cortisol; r = 0.623).	Hydrocortisone	122-130	colony stimulating factor 3	Homo sapiens	60-65
34260805-8	2021	In vivo, iloprost administration protected BM HSC potential from radiation or granulocyte colony-stimulating factor (G-CSF)-induced exhaustion, and restored HSC homing potential with increased Kitl and Cxcl12 transcription in the BM.	Iloprost	9-17	colony stimulating factor 3	Homo sapiens	78-115
34490994-2	2021	Plerixafor is a CXC chemokine receptor type 4 (CXCR4) antagonist that can be used with granulocyte colony stimulating factor (G-CSF) to amplify the mobilization of hematopoietic stem cells (HSCs).	plerixafor	0-10	colony stimulating factor 3	Homo sapiens	87-124
34490994-2	2021	Plerixafor is a CXC chemokine receptor type 4 (CXCR4) antagonist that can be used with granulocyte colony stimulating factor (G-CSF) to amplify the mobilization of hematopoietic stem cells (HSCs).	plerixafor	0-10	colony stimulating factor 3	Homo sapiens	126-131
34490994-10	2021	CONCLUSIONS: Patients at the highest risk for poor HSC mobilization can be successfully treated with more frequent G-CSF dosing or G-CSF with plerixafor in a large majority of cases.	plerixafor	142-152	colony stimulating factor 3	Homo sapiens	131-136
34260805-8	2021	In vivo, iloprost administration protected BM HSC potential from radiation or granulocyte colony-stimulating factor (G-CSF)-induced exhaustion, and restored HSC homing potential with increased Kitl and Cxcl12 transcription in the BM.	Iloprost	9-17	colony stimulating factor 3	Homo sapiens	117-122
34681817-11	2021	GCSF significantly improved the spermatogonial niche expressed by increased the expression levels of testicular GDNF, SCF and MCSF growth factors in AML-treated mice and (AML + CYT)-treated mice compared to those groups without GCSF.	Cytarabine	177-180	colony stimulating factor 3	Homo sapiens	0-4
34801430-1	2022	Addition of plerixafor (P) to granulocyte colony stimulating factor (G-CSF) during peripheral blood mobilization of hematopoietic stem cells (HSC) increases the number of patients meeting collection goals prior to autologous stem cell transplant (aSCT).	plerixafor	12-22	colony stimulating factor 3	Homo sapiens	30-67
34801430-1	2022	Addition of plerixafor (P) to granulocyte colony stimulating factor (G-CSF) during peripheral blood mobilization of hematopoietic stem cells (HSC) increases the number of patients meeting collection goals prior to autologous stem cell transplant (aSCT).	plerixafor	12-22	colony stimulating factor 3	Homo sapiens	69-74
34681817-13	2021	Our results show for the first time the capacity of post injection of GCSF into AML- and CYT-treated mice to improve the cellular and biomolecular mechanisms that lead to improve/restore spermatogenesis and male fertility.	Cytarabine	89-92	colony stimulating factor 3	Homo sapiens	70-74
34417161-0	2021	Efficacy and Safety of Azacytidine in Combination With Fludarabine and High-Dose Cytarabine With G-CSF (FLAG) in Relapsed/Refractory Acute Myeloid Leukemia: A Nonrandomized, Open-Label, Phase II Study.	Azacitidine	23-34	colony stimulating factor 3	Homo sapiens	97-102
34900145-1	2021	Background: The recombinant human granulocyte colony stimulating factor conjugated with polyethylene glycol (PEGylated GCSF) has currently been used as an efficient drug for the treatment of neutropenia caused by chemotherapy due to its long circulating half-life.	Polyethylene Glycols	88-107	colony stimulating factor 3	Homo sapiens	34-71
34900145-1	2021	Background: The recombinant human granulocyte colony stimulating factor conjugated with polyethylene glycol (PEGylated GCSF) has currently been used as an efficient drug for the treatment of neutropenia caused by chemotherapy due to its long circulating half-life.	Polyethylene Glycols	88-107	colony stimulating factor 3	Homo sapiens	119-123
34900145-4	2021	Methods: BL21 (DE3)/pET-GCSF cells were cultured in the LiFlus GX 1.5 L bioreactor and the expression of GCSF was induced by adding 0.5 mM IPTG.	Isopropyl Thiogalactoside	139-143	colony stimulating factor 3	Homo sapiens	105-109
34900145-8	2021	The dissolved GCSF was directly used for the conjugation with 5 kDa PEG.	Polyethylene Glycols	68-71	colony stimulating factor 3	Homo sapiens	14-18
34900145-9	2021	The PEGylated GCSF was purified using two purification steps, including anion exchange chromatography and gel filtration chromatography.	pegylated	4-13	colony stimulating factor 3	Homo sapiens	14-18
34900145-10	2021	Results: PEGylated GCSF was obtained with high purity (~97%) and was finally demonstrated as a form containing one GCSF molecule and one 5 kDa PEG molecule (monoPEG-GCSF).	Polyethylene Glycols	143-146	colony stimulating factor 3	Homo sapiens	19-23
34417161-0	2021	Efficacy and Safety of Azacytidine in Combination With Fludarabine and High-Dose Cytarabine With G-CSF (FLAG) in Relapsed/Refractory Acute Myeloid Leukemia: A Nonrandomized, Open-Label, Phase II Study.	Cytarabine	81-91	colony stimulating factor 3	Homo sapiens	97-102
34426617-4	2021	The DMEK group exhibited significantly lower concentrations of several pro-inflammatory cytokines, such as IL-1beta, IL-5, IL-6, IL-10, and IL-8, and granulocyte colony stimulating factor than the BK group.	dmek	4-8	colony stimulating factor 3	Homo sapiens	150-187
34213732-3	2021	Lipegfilgrastim is a novel long-acting G-CSF that is produced by the conjugation of a single 20-kDa polyethelene glycol to the natural O-glycosylation site of G-CSF.	polyethelene glycol	100-119	colony stimulating factor 3	Homo sapiens	39-44
34213732-3	2021	Lipegfilgrastim is a novel long-acting G-CSF that is produced by the conjugation of a single 20-kDa polyethelene glycol to the natural O-glycosylation site of G-CSF.	polyethelene glycol	100-119	colony stimulating factor 3	Homo sapiens	159-164
34498383-11	2021	G-CSF levels decreased during the remission phase (p < 0.05), and positively correlated with carbohydrate antigen 19-9 (p < 0.05) and gene mutation (p < 0.05).	Carbohydrates	93-105	colony stimulating factor 3	Homo sapiens	0-5
34540696-2	2021	Methods: A clinical trial was conducted in relapsed/refractory acute myeloid leukemia patients using chidamide, decitabine, cytarabine, idarubicin, and granulocyte-colony stimulating factor, termed CDIAG, a double epigenetic priming regimen.	cdiag	198-203	colony stimulating factor 3	Homo sapiens	152-189
34162806-0	2021	Can loratadine help in treating granulocyte-colony stimulating factor-induced bone pain?	Loratadine	4-14	colony stimulating factor 3	Homo sapiens	32-69
34116181-3	2021	Granulocyte colony-stimulating factor (G-CSF), which is one of the most widely used protein therapeutics, was previously shown to be conformationally stabilized by connecting its N- and C-termini with amide bonds (backbone circularization).	Amides	201-206	colony stimulating factor 3	Homo sapiens	0-37
34116181-3	2021	Granulocyte colony-stimulating factor (G-CSF), which is one of the most widely used protein therapeutics, was previously shown to be conformationally stabilized by connecting its N- and C-termini with amide bonds (backbone circularization).	Amides	201-206	colony stimulating factor 3	Homo sapiens	39-44
34116181-6	2021	Consequently, we found that the unfolded structure of circularized G-CSF was more compact than non-circularized G-CSF, and that backbone circularization improved its aggregation resistance against chemical denaturation by guanidine hydrochloride (GdnHCl).	Guanidine	222-245	colony stimulating factor 3	Homo sapiens	67-72
34116181-6	2021	Consequently, we found that the unfolded structure of circularized G-CSF was more compact than non-circularized G-CSF, and that backbone circularization improved its aggregation resistance against chemical denaturation by guanidine hydrochloride (GdnHCl).	Guanidine	222-245	colony stimulating factor 3	Homo sapiens	112-117
34116181-6	2021	Consequently, we found that the unfolded structure of circularized G-CSF was more compact than non-circularized G-CSF, and that backbone circularization improved its aggregation resistance against chemical denaturation by guanidine hydrochloride (GdnHCl).	Guanidine	247-253	colony stimulating factor 3	Homo sapiens	67-72
34415898-9	2021	Overall, IL-4 levels did not change significantly over time in either group; however, patients within the CE3b group showed a significant decrease of IL-1ra, IL-6, IL-8, G-CSF, IFN-gamma, IP-10, MCP-1, MIP-1alpha, FGF at T1 compared to T0 (p<=0.042).	ce3b	106-110	colony stimulating factor 3	Homo sapiens	170-175
34162806-6	2021	This article describes a patient whose G-CSF-induced bone pain was completely alleviated by loratadine.	Loratadine	92-102	colony stimulating factor 3	Homo sapiens	39-44
34211033-1	2021	Granulocyte colony-stimulating factor (G-CSF) has raised much interest because of its role in cocaine addiction in preclinical models.	Cocaine	94-101	colony stimulating factor 3	Homo sapiens	0-37
34211033-1	2021	Granulocyte colony-stimulating factor (G-CSF) has raised much interest because of its role in cocaine addiction in preclinical models.	Cocaine	94-101	colony stimulating factor 3	Homo sapiens	39-44
34211033-8	2021	G-CSF concentrations were lower in patients with SUD than in controls (p < 0.05), specifically in the cocaine subgroup (p < 0.05).	Cocaine	102-109	colony stimulating factor 3	Homo sapiens	0-5
34104027-8	2021	Currently, plerixafor is used in patients with mobilization failure with G-CSF and is administered subcutaneously.	plerixafor	11-21	colony stimulating factor 3	Homo sapiens	73-78
34168464-8	2021	FLAG-IDA regimen (fludarabine, cytarabine (Ara-C), granulocyte-colony stimulating factor (G-CSF) and idarubicin), which is usually applied to eliminate leukemia cells, was administered combining with sorafenib as an effective induction chemotherapy.	flag-ida	0-8	colony stimulating factor 3	Homo sapiens	51-88
34168464-8	2021	FLAG-IDA regimen (fludarabine, cytarabine (Ara-C), granulocyte-colony stimulating factor (G-CSF) and idarubicin), which is usually applied to eliminate leukemia cells, was administered combining with sorafenib as an effective induction chemotherapy.	flag-ida	0-8	colony stimulating factor 3	Homo sapiens	90-95
34111237-8	2022	Furthermore, among inpatients, G-CSF administration was associated with increased need for high levels of oxygen supplementation and death (HR: 3.56, 95% CI: 1.19-10.2, P value: 0.024).	Oxygen	106-112	colony stimulating factor 3	Homo sapiens	31-36
34104027-14	2021	In addition, the adverse events of plerixafor are mild and transient, which can overcome the adverse events due to G-CSF.	plerixafor	35-45	colony stimulating factor 3	Homo sapiens	115-120
34069696-2	2021	Haplopine (12.5 and 25 muM) inhibited the mRNA expressions of inflammatory cytokines IL-6, TSLP, GM-CSF, and G-CSF and the protein expressions of IL-6 and GM-CSF in TNF-alpha/INF-gamma-stimulated HaCaT cells.	4,8-dimethoxy-7-hydroxyfuro(2,3-b)quinoline	0-9	colony stimulating factor 3	Homo sapiens	109-114
34466208-0	2021	Comparison of Long-Acting G-CSF (PD-Lasta) with Short-Acting G-CSF (PD-Grastim) in Neutrophil Recovery Following Consolidation Chemotherapy with High-Dose Cytarabine in Acute Myeloid Leukemia: A Randomized Clinical Trial.	Cytarabine	155-165	colony stimulating factor 3	Homo sapiens	26-31
34466208-0	2021	Comparison of Long-Acting G-CSF (PD-Lasta) with Short-Acting G-CSF (PD-Grastim) in Neutrophil Recovery Following Consolidation Chemotherapy with High-Dose Cytarabine in Acute Myeloid Leukemia: A Randomized Clinical Trial.	Cytarabine	155-165	colony stimulating factor 3	Homo sapiens	61-66
34772606-3	2021	G-CSF/CSF3R signaling involves the recruitment of non-receptor protein tyrosine kinases and their dependent signaling pathways of serine/threonine kinases, tyrosine phosphatases, and lipid second messengers.	Serine	130-136	colony stimulating factor 3	Homo sapiens	0-5
34321973-0	2021	Diffuse bone marrow uptake related to granulocyte colony-stimulating factor-producing maxillary sinus carcinoma on 4-borono-2-18F-fluoro-L-phenylalanine positron emission tomography/computed tomography.	4-borono-2-18f-fluoro-l-phenylalanine	115-152	colony stimulating factor 3	Homo sapiens	38-75
34844181-0	2021	Prophylactic granulocyte-colony stimulating factor in patients with lung neuroendocrine carcinoma receiving platinum agents plus etoposide.	Etoposide	129-138	colony stimulating factor 3	Homo sapiens	13-50
34321973-4	2021	Hypermetabolic uptake of 18F-fluorodeoxyglucose (18F-FDG) but not of 4-borono-2-18F-fluoro- L-phenylalanine (18F-FBPA), in the bone marrow of patients with G-CSF-producing tumors without bone marrow involvement during positron emission tomography (PET), has been reported.	Fluorodeoxyglucose F18	25-47	colony stimulating factor 3	Homo sapiens	156-161
34321973-4	2021	Hypermetabolic uptake of 18F-fluorodeoxyglucose (18F-FDG) but not of 4-borono-2-18F-fluoro- L-phenylalanine (18F-FBPA), in the bone marrow of patients with G-CSF-producing tumors without bone marrow involvement during positron emission tomography (PET), has been reported.	Fluorodeoxyglucose F18	49-56	colony stimulating factor 3	Homo sapiens	156-161
35487423-5	2022	G-CSF-containing hyaluronic acid solutions were cast into the mold to obtain G-CSF microneedles (GMNs), which were coated with a temperature-sensitive layer of dodecanoic acid-cetylamine salt to obtain GTSMNs.	Hyaluronic Acid	17-32	colony stimulating factor 3	Homo sapiens	0-5
35487423-5	2022	G-CSF-containing hyaluronic acid solutions were cast into the mold to obtain G-CSF microneedles (GMNs), which were coated with a temperature-sensitive layer of dodecanoic acid-cetylamine salt to obtain GTSMNs.	Hyaluronic Acid	17-32	colony stimulating factor 3	Homo sapiens	77-82
35191732-2	2022	Additionally, concurrent G-CSF and methotrexate for graft-vs-host disease (GVHD) prophylaxis may potentiate myelosuppression, and prolonged G-CSF is costly.	Methotrexate	35-47	colony stimulating factor 3	Homo sapiens	140-145
35391541-5	2022	The primary objective is to demonstrate that GCSF decreases the proportion of subjects with a 3-month post-Kasai serum Total Bilirubin >= 34 umol/L by 20%, (for a = 0.05, b = 0.80, i.e., calculated sample size of 218 subjects).	Bilirubin	125-134	colony stimulating factor 3	Homo sapiens	45-49
35227600-11	2022	G-CSF plus GH and G-CSF plus EPO had advantages in terms of CTP scores.	Cytidine Triphosphate	60-63	colony stimulating factor 3	Homo sapiens	18-23
35590355-0	2022	G-CSF upregulates the expression of aquaporin-9 through CEBPB to enhance the cytotoxic activity of arsenic trioxide to acute myeloid leukemia cells.	Arsenic Trioxide	99-115	colony stimulating factor 3	Homo sapiens	0-5
35590355-4	2022	We hypothesized that the pretreatment with G-CSF may enhance the antitumor effect of ATO in non-APL AML cells.	Arsenic Trioxide	85-88	colony stimulating factor 3	Homo sapiens	43-48
35240320-4	2022	Here we evaluated polymer-based nanoparticles (NPs), which could also be used for in vivo administration, for the delivery of mRNA and nucleases to human granulocyte colony-stimulating factor (GCSF)-mobilized CD34+ cells.	Polymers	18-25	colony stimulating factor 3	Homo sapiens	154-191
35240320-4	2022	Here we evaluated polymer-based nanoparticles (NPs), which could also be used for in vivo administration, for the delivery of mRNA and nucleases to human granulocyte colony-stimulating factor (GCSF)-mobilized CD34+ cells.	Polymers	18-25	colony stimulating factor 3	Homo sapiens	193-197
35623392-7	2022	Investigation into the possible mechanisms indicated that a combination of growth factor, G-CSF, and metabolites, Kynurenine and lactic acid produced by AECs is responsible for inducing tolerance in macrophages.	Kynurenine	114-124	colony stimulating factor 3	Homo sapiens	90-95
35623392-8	2022	Interestingly, all these molecules had differential effect on macrophages with G-CSF inducing TGF-beta, Kynurenine elevating IL-10, and lactic acid upregulating CD200R.	Kynurenine	104-114	colony stimulating factor 3	Homo sapiens	79-84
35602884-10	2022	The G-CSF upregulates the release of reactive oxygen species (ROS) in CD15+CD14+ cells leading to the suppression of T-cell proliferation.	Reactive Oxygen Species	37-60	colony stimulating factor 3	Homo sapiens	4-9
35602884-10	2022	The G-CSF upregulates the release of reactive oxygen species (ROS) in CD15+CD14+ cells leading to the suppression of T-cell proliferation.	Reactive Oxygen Species	62-65	colony stimulating factor 3	Homo sapiens	4-9
35602884-11	2022	Conclusions: G-CSF induces a population of ROS+ immunosuppressive CD15+CD14+ granulocytes.	Reactive Oxygen Species	43-46	colony stimulating factor 3	Homo sapiens	13-18
35556178-6	2022	Similar dimorphic shift was also displayed by a recombinant methanol slow utilizing (Muts) strain (SMD-GCSF Muts) producing human granulocyte colony-stimulating factor in response to change in the initial inoculum level.	Methanol	60-68	colony stimulating factor 3	Homo sapiens	130-167
35543246-8	2022	The binding relationship between miR-1247-5p and circEBF1 or CSF3 was verified by dual-luciferase reporter assay, RNA immunoprecipitation (RIP) assay and RNA pull-down assay.	CHEMBL3740941	42-44	colony stimulating factor 3	Homo sapiens	61-65
35354375-8	2022	G-CSF use was observed among 63.6%, 34.9%, 33.9%, and 44.9% of patients treated with FOLFIRINOX, FOLFOX, FOLFIRI, and liposomal irinotecan-based regimens, respectively.	folfirinox	85-95	colony stimulating factor 3	Homo sapiens	0-5
35064823-1	2022	PURPOSE: This study sought to compare the efficacy of prophylactic long-acting and standard granulocyte colony-stimulating factor (G-CSF) on febrile neutropenia, early infections, and treatment delay in patients with newly diagnosed multiple myeloma (MM) receiving the therapeutic regimen of bortezomib, lenalidomide, and dexamethasone (VRd).	Bortezomib	292-302	colony stimulating factor 3	Homo sapiens	131-136
35064823-1	2022	PURPOSE: This study sought to compare the efficacy of prophylactic long-acting and standard granulocyte colony-stimulating factor (G-CSF) on febrile neutropenia, early infections, and treatment delay in patients with newly diagnosed multiple myeloma (MM) receiving the therapeutic regimen of bortezomib, lenalidomide, and dexamethasone (VRd).	Lenalidomide	304-316	colony stimulating factor 3	Homo sapiens	131-136
35064823-1	2022	PURPOSE: This study sought to compare the efficacy of prophylactic long-acting and standard granulocyte colony-stimulating factor (G-CSF) on febrile neutropenia, early infections, and treatment delay in patients with newly diagnosed multiple myeloma (MM) receiving the therapeutic regimen of bortezomib, lenalidomide, and dexamethasone (VRd).	Dexamethasone	322-335	colony stimulating factor 3	Homo sapiens	131-136
35578937-13	2022	Steroids can be used for the treatment of G-CSF-induced aortitis.	Steroids	0-8	colony stimulating factor 3	Homo sapiens	42-47
35473591-7	2022	However, the proportion of patients receiving granulocyte colony-stimulating factor was significantly lower in the oxaliplatin group than in the cisplatin group (2.3% vs.22.7%, p = 0.01).	Oxaliplatin	115-126	colony stimulating factor 3	Homo sapiens	46-83
35354375-8	2022	G-CSF use was observed among 63.6%, 34.9%, 33.9%, and 44.9% of patients treated with FOLFIRINOX, FOLFOX, FOLFIRI, and liposomal irinotecan-based regimens, respectively.	Folfox protocol	97-103	colony stimulating factor 3	Homo sapiens	0-5
35354375-8	2022	G-CSF use was observed among 63.6%, 34.9%, 33.9%, and 44.9% of patients treated with FOLFIRINOX, FOLFOX, FOLFIRI, and liposomal irinotecan-based regimens, respectively.	FOLFIRI regimen	105-112	colony stimulating factor 3	Homo sapiens	0-5
35354375-8	2022	G-CSF use was observed among 63.6%, 34.9%, 33.9%, and 44.9% of patients treated with FOLFIRINOX, FOLFOX, FOLFIRI, and liposomal irinotecan-based regimens, respectively.	Irinotecan	128-138	colony stimulating factor 3	Homo sapiens	0-5
35440409-6	2022	MEASUREMENTS AND MAIN RESULTS: Significant reductions in high mobility group box-1 protein (HMGB-1), calprotectin, serum amyloid A, and granulocyte colony-stimulating factor (G-CSF), and an increase in insulin-like growth factor (IGF-1) occurred 1 month after ivacaftor.	ivacaftor	260-269	colony stimulating factor 3	Homo sapiens	175-180
35272139-9	2022	BromAc  acted on IL-6, demonstrating a reduction in G-CSF and VEGF-D at concentrations of 125 and 250 microg.	bromac	0-6	colony stimulating factor 3	Homo sapiens	52-57
35044962-0	2022	18F-FDG PET/CT Findings of G-CSF-Producing Gallbladder Cancer.	Fluorodeoxyglucose F18	0-7	colony stimulating factor 3	Homo sapiens	27-32
35301751-3	2022	A donor who developed severe adverse reactions after G-CSF mobilization was found to have high serum proBNP levels.	probnp	101-107	colony stimulating factor 3	Homo sapiens	53-58
35301751-8	2022	The majority of donors (86.7%) had post-G-CSF elevation of serum proBNP.	probnp	65-71	colony stimulating factor 3	Homo sapiens	40-45
35386098-7	2022	The metadynamics simulations demonstrated that the orientations of Trp residues in GCSF are dependent on pH.	Tryptophan	67-70	colony stimulating factor 3	Homo sapiens	83-87
35237000-1	2022	We analyzed the treatment effects of chidamide and decitabine in combination with a HAG (homoharringtonine, cytarabine, G-CSF) priming regimen (CDHAG) in acute myeloid leukemia (AML) patients with TP53 mutation.	cdhag	144-149	colony stimulating factor 3	Homo sapiens	120-125
35372343-0	2022	Rapamycin Promotes the Expansion of Myeloid Cells by Increasing G-CSF Expression in Mesenchymal Stem Cells.	Sirolimus	0-9	colony stimulating factor 3	Homo sapiens	64-69
35372343-4	2022	Rapamycin induced bone marrow mesenchymal stem cells to produce more G-CSF in vitro and in vivo, and promoted the myeloid cells expansion.	Sirolimus	0-9	colony stimulating factor 3	Homo sapiens	69-74
35449634-7	2022	We present a case of ceftriaxone-induced agranulocytosis which was completely reversible upon stoppage of drug and granulocyte colony-stimulating factor administration.	Ceftriaxone	21-32	colony stimulating factor 3	Homo sapiens	115-152
35317326-7	2022	In comparison to non-stimulated healthy donor neutrophils, prednisone GC neutrophils exhibited enhanced phagocytosis and G-CSF GC neutrophils showed decreased chemotaxis but increased IL-8 production.	Prednisone	59-69	colony stimulating factor 3	Homo sapiens	121-126
34993933-1	2022	BACKGROUND: Eflapegrastim (Rolontis ) is a novel long-acting pegylated recombinant human granulocyte colony-stimulating factor (G-CSF).	eflapegrastim	12-25	colony stimulating factor 3	Homo sapiens	89-126
34993933-1	2022	BACKGROUND: Eflapegrastim (Rolontis ) is a novel long-acting pegylated recombinant human granulocyte colony-stimulating factor (G-CSF).	eflapegrastim	12-25	colony stimulating factor 3	Homo sapiens	128-133
34993933-1	2022	BACKGROUND: Eflapegrastim (Rolontis ) is a novel long-acting pegylated recombinant human granulocyte colony-stimulating factor (G-CSF).	rolontis	27-35	colony stimulating factor 3	Homo sapiens	89-126
34993933-1	2022	BACKGROUND: Eflapegrastim (Rolontis ) is a novel long-acting pegylated recombinant human granulocyte colony-stimulating factor (G-CSF).	rolontis	27-35	colony stimulating factor 3	Homo sapiens	128-133
35205845-1	2022	BACKGROUND: The two most noteworthy strategies for haploidentical stem cell transplantation (haplo-HSCT) are posttransplantation cyclophosphamide (PTCy) with or without thymoglobulin (ATG) and granulocyte colony stimulating factor-primed bone marrow plus peripheral blood stem cells (GIAC).	Cyclophosphamide	129-145	colony stimulating factor 3	Homo sapiens	193-230
35205845-1	2022	BACKGROUND: The two most noteworthy strategies for haploidentical stem cell transplantation (haplo-HSCT) are posttransplantation cyclophosphamide (PTCy) with or without thymoglobulin (ATG) and granulocyte colony stimulating factor-primed bone marrow plus peripheral blood stem cells (GIAC).	ptcy	147-151	colony stimulating factor 3	Homo sapiens	193-230
35433171-7	2022	EMPA is effective in the treatment of neutropenia in our GSD 1b patients, which allows for dose reduction and even withdrawal of G-CSF.	empagliflozin	0-4	colony stimulating factor 3	Homo sapiens	129-134
35519907-7	2022	She also developed methotrexate and amphotericin B-induced pancytopenia for which injection folinic acid, granulocyte-colony stimulating factor (G-CSF), and erythropoietin were given and was switched over to liposomal amphotericin B.	Amphotericin B	36-50	colony stimulating factor 3	Homo sapiens	145-150
35218068-3	2022	Cyclophosphamide/GCSF is an effective regimen, although reported associated toxicities include risk of febrile neutropenia (FN).	Cyclophosphamide	0-16	colony stimulating factor 3	Homo sapiens	17-21
34183499-0	2022	18F-FDG PET/CT Imaging of G-CSF-Producing Dedifferentiated Liposarcoma.	Fluorodeoxyglucose F18	0-7	colony stimulating factor 3	Homo sapiens	26-31
35081882-5	2022	The various conditions effect of extraction and purification of rhG-CSF and PEG-GCSF were assayed.	Polyethylene Glycols	76-79	colony stimulating factor 3	Homo sapiens	80-84
35081882-7	2022	The obtained Data of rhG-CSF PEGylation displayed that the optimized conditions of rhG-CSF PEGylation and purification enhanced hemogenisity PEG-GCSF and managed reaction toward optimal yield of PEG-GCSF (70%) and purity of 99.9%.	Polyethylene Glycols	141-144	colony stimulating factor 3	Homo sapiens	145-149
35081882-7	2022	The obtained Data of rhG-CSF PEGylation displayed that the optimized conditions of rhG-CSF PEGylation and purification enhanced hemogenisity PEG-GCSF and managed reaction toward optimal yield of PEG-GCSF (70%) and purity of 99.9%.	Polyethylene Glycols	141-144	colony stimulating factor 3	Homo sapiens	199-203
35081882-7	2022	The obtained Data of rhG-CSF PEGylation displayed that the optimized conditions of rhG-CSF PEGylation and purification enhanced hemogenisity PEG-GCSF and managed reaction toward optimal yield of PEG-GCSF (70%) and purity of 99.9%.	Polyethylene Glycols	195-198	colony stimulating factor 3	Homo sapiens	145-149
35081882-7	2022	The obtained Data of rhG-CSF PEGylation displayed that the optimized conditions of rhG-CSF PEGylation and purification enhanced hemogenisity PEG-GCSF and managed reaction toward optimal yield of PEG-GCSF (70%) and purity of 99.9%.	Polyethylene Glycols	195-198	colony stimulating factor 3	Homo sapiens	199-203
35155259-4	2022	Methods: This research retrospectively studied mobilization efficacy and safety using etoposide combined with Cytarabine (etoposide 50-100 mg/m2, qd d1-3; AraC 0.5 g/m2, q12h d1~3) plus G-CSF (5 microg/kg/day, from d5 until the day of apheresis) in 128 patients with MM.	Etoposide	86-95	colony stimulating factor 3	Homo sapiens	186-191